Clustering O 0 3.690536232170416e-06
of O 0 1.0490325941248102e-08
missense O 0 2.3433023670804687e-05
mutations O 0 4.634229117073119e-05
in O 0 4.555773358561055e-08
the O 0 1.9128261556033976e-05
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
telangiectasia I-Disease 1 1.0
gene O 0 0.00013400817988440394
in O 0 1.4478230836445505e-09
a O 0 5.87502979598753e-09
sporadic B-Disease 0 2.2320644347928464e-05
T I-Disease 1 0.5462694764137268
- I-Disease 0 0.0168320219963789
cell I-Disease 0 0.20804032683372498
leukaemia I-Disease 1 0.8024117350578308
. O 0 2.093485846899057e-07

Ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 0.06439290940761566
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 2.4791133590440495e-09
is O 0 5.970444971747924e-11
a O 0 3.561053396605729e-10
recessive B-Disease 0 8.574246749049053e-05
multi I-Disease 0 6.151811976451427e-05
- I-Disease 1 0.6086792349815369
system I-Disease 0 6.266739364946261e-05
disorder I-Disease 0 0.060318734496831894
caused O 0 6.365945548481022e-09
by O 0 2.0261950103850346e-11
mutations O 0 1.626063372839326e-08
in O 0 3.635819423308817e-11
the O 0 9.654054639041121e-11
ATM O 0 1.5188401221166714e-06
gene O 0 3.6596546237888106e-08
at O 0 4.2551695500492315e-09
11q22 O 0 1.0192274402243129e-07
- O 0 1.198543486680137e-06
q23 O 0 3.4690381767177314e-07
( O 0 1.1802213650824456e-09
ref O 0 2.3020506034754362e-07
. O 0 4.6475021053815624e-10
3 O 0 1.020714845978432e-09
) O 0 7.897242859655762e-10
. O 0 6.493595883227954e-09

The O 0 2.1171655362195452e-07
risk O 0 1.555022890897817e-06
of O 0 1.6195098595517265e-09
cancer B-Disease 0 3.5445302728476236e-06
, O 0 2.6118365248350983e-09
especially O 0 2.2311095193572328e-09
lymphoid B-Disease 0 1.378428578391322e-06
neoplasias I-Disease 0 1.853777575888671e-05
, O 0 1.402266969208199e-09
is O 0 1.5806117525940522e-10
substantially O 0 2.4268462794907464e-08
elevated O 0 1.6340791830771195e-07
in O 0 2.4972816703439094e-08
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 0.07184740900993347
and O 0 2.740780713494928e-09
has O 0 2.8782582983666316e-09
long O 0 3.330366205034352e-09
been O 0 3.877643539595965e-09
associated O 0 5.615784726131778e-09
with O 0 2.3977409568942676e-07
chromosomal O 1 1.0
instability O 1 0.9999997615814209
. O 0 4.829320801036374e-07

By O 0 2.7091408583146404e-07
analysing O 0 4.340210944064893e-05
tumour B-Disease 1 0.9999996423721313
DNA O 0 5.563515969697619e-06
from O 0 2.832683865250374e-09
patients O 0 6.614841563390428e-09
with O 0 2.636334484051872e-10
sporadic B-Disease 0 2.269092874485068e-06
T I-Disease 0 0.06180586293339729
- I-Disease 0 0.00020808495173696429
cell I-Disease 0 0.008928959257900715
prolymphocytic I-Disease 0 0.005398196168243885
leukaemia I-Disease 0 0.17714837193489075
( O 0 2.9650975008621572e-08
T B-Disease 0 0.0011324724182486534
- I-Disease 0 7.725412615400273e-06
PLL I-Disease 0 2.4859839413693408e-06
) O 0 3.0676192142031766e-10
, O 0 1.111670304421164e-11
a O 0 3.877025783749488e-11
rare O 0 2.823781763972022e-10
clonal B-Disease 0 3.543407345318883e-08
malignancy I-Disease 0 2.638163891788281e-07
with O 0 2.718810940272043e-11
similarities O 0 1.4084829969007728e-09
to O 0 3.447911678389204e-10
a O 0 4.839982636895002e-09
mature B-Disease 0 4.6709368461961276e-07
T I-Disease 0 0.0003505822387523949
- I-Disease 0 8.71991960593732e-06
cell I-Disease 0 9.22790786717087e-05
leukaemia I-Disease 0 0.0016917531611397862
seen O 0 2.6409330189380853e-07
in O 0 2.218950800880748e-09
A B-Disease 1 0.9999996423721313
- I-Disease 1 0.9999760389328003
T I-Disease 1 1.0
, O 0 6.713129607760493e-09
we O 0 2.354475781007892e-10
demonstrate O 0 4.0301081916105375e-11
a O 0 1.5217674342871135e-11
high O 0 7.730132506322818e-11
frequency O 0 2.1509842795808254e-09
of O 0 1.1482023665188024e-10
ATM O 0 2.851114004442934e-05
mutations O 0 1.8957346981096634e-07
in O 0 1.2674781224575327e-09
T B-Disease 0 0.0003592213906813413
- I-Disease 0 1.8854154404834844e-05
PLL I-Disease 0 1.9412107576499693e-05
. O 0 6.88686867533761e-08

In O 0 5.8735203367632494e-08
marked O 0 1.97688052594458e-08
contrast O 0 2.322147141242681e-09
to O 0 1.4337794840280083e-10
the O 0 3.820239263818692e-11
ATM O 0 2.137870069418568e-06
mutation O 0 6.239236682858973e-08
pattern O 0 1.6323254214967164e-07
in O 0 6.259999185687093e-09
A B-Disease 1 1.0
- I-Disease 1 0.9999995231628418
T I-Disease 1 1.0
, O 0 1.5463113012259555e-09
the O 0 1.855083274493463e-11
most O 0 1.5293268387783776e-11
frequent O 0 3.871596376825437e-10
nucleotide O 0 9.439264481159171e-09
changes O 0 5.943996406188035e-10
in O 0 6.863608986718006e-11
this O 0 6.773474003907154e-10
leukaemia B-Disease 0 2.139714706572704e-05
were O 0 2.3647261926385e-08
missense O 0 1.330928262177622e-05
mutations O 0 8.798238923191093e-06
. O 0 1.1034295965828278e-07

These O 0 3.6690828153496113e-08
clustered O 0 1.5438018863278558e-07
in O 0 1.3009180399592424e-09
the O 0 3.5795896802248706e-10
region O 0 3.300362649838462e-08
corresponding O 0 6.600121338351528e-09
to O 0 8.031235676497772e-10
the O 0 1.11089505649975e-10
kinase O 0 8.210572133293681e-08
domain O 0 9.964621128233375e-09
, O 0 2.781297137044447e-10
which O 0 1.1101177616046343e-10
is O 0 1.211743899665052e-11
highly O 0 1.0249317020094573e-11
conserved O 0 1.462005377872444e-10
in O 0 6.393439944130108e-11
ATM O 0 4.57352234661812e-06
- O 0 2.167124080187932e-08
related O 0 1.1880811889852794e-09
proteins O 0 4.576252154997462e-10
in O 0 2.172970414715536e-10
mouse O 0 3.8652922285109526e-07
, O 0 3.4374465496256335e-09
yeast O 0 2.6328405056119664e-07
and O 0 1.8238635046685658e-09
Drosophila O 0 8.955295527357521e-08
. O 0 1.4775880075035275e-08

The O 0 3.8500388654938433e-08
resulting O 0 2.3020344741553345e-08
amino O 0 4.198928849064032e-08
- O 0 4.227231045206281e-07
acid O 0 2.818985080921266e-07
substitutions O 0 2.4461042968937363e-08
are O 0 2.7742294572696835e-10
predicted O 0 1.6908995092990153e-08
to O 0 1.0976727304878864e-09
interfere O 0 1.858007436794651e-08
with O 0 4.5401196691052803e-10
ATP O 0 1.0685415873012971e-05
binding O 0 3.3071618332769503e-08
or O 0 1.1315239412112987e-08
substrate O 0 3.2907212244026596e-07
recognition O 0 3.898543354807771e-08
. O 0 6.77164564422128e-08

Two O 0 7.603045304449552e-08
of O 0 3.771237544469841e-09
seventeen O 0 9.009141876958893e-08
mutated O 0 1.8135465325030964e-06
T B-Disease 0 0.00010213298082817346
- I-Disease 0 2.523618150007678e-06
PLL I-Disease 0 4.360396360425511e-06
samples O 0 3.750402015612053e-07
had O 0 3.69469232985864e-09
a O 0 1.7516746386725401e-10
previously O 0 2.240047969337411e-08
reported O 0 2.0123876311117783e-05
A B-Disease 1 0.9999970197677612
- I-Disease 1 0.9999614953994751
T I-Disease 1 1.0
allele O 0 3.0868213798385113e-05
. O 0 8.859814926154286e-08

In O 0 1.7614905800655833e-07
contrast O 0 6.767901084003825e-08
, O 0 3.170465445734294e-09
no O 0 3.3148650491199305e-09
mutations O 0 5.404226044447569e-08
were O 0 8.989892164024127e-10
detected O 0 2.0479328455280665e-08
in O 0 2.911866928134721e-11
the O 0 1.9797151765144072e-11
p53 O 0 7.347840114135806e-10
gene O 0 8.196580303376777e-09
, O 0 1.8646693911161805e-10
suggesting O 0 3.0364710745800494e-09
that O 0 3.3227887108466803e-10
this O 0 4.475611881105124e-09
tumour B-Disease 1 1.0
suppressor O 0 6.86818884787499e-06
is O 0 2.4661076736265386e-08
not O 0 1.4879071308371294e-09
frequently O 0 1.3484189764767507e-08
altered O 0 2.209396143371123e-06
in O 0 2.130999154914548e-09
this O 0 1.1558678458811755e-08
leukaemia B-Disease 0 0.00034826743649318814
. O 0 1.217923681906541e-07

Occasional O 0 2.2726557290297933e-05
missense O 0 0.00024244310043286532
mutations O 0 2.6139912733924575e-05
in O 0 1.6835299376793955e-08
ATM O 0 6.794269575038925e-05
were O 0 4.782092588584419e-08
also O 0 2.2606450045259407e-09
found O 0 5.323757878983315e-09
in O 0 2.1961465979103423e-09
tumour B-Disease 1 1.0
DNA O 0 2.1183915066558257e-07
from O 0 2.7022428739087445e-10
patients O 0 2.77633610545891e-10
with O 0 1.0637638339638933e-11
B B-Disease 0 1.299992931080851e-07
- I-Disease 0 1.2779165672327508e-06
cell I-Disease 0 0.0024355354253202677
non I-Disease 0 0.00024051372020039707
- I-Disease 1 0.9123818874359131
Hodgkins I-Disease 1 0.9999992847442627
lymphomas I-Disease 0 0.4245220422744751
( O 0 2.1332726696243753e-09
B B-Disease 0 1.0636807701303042e-07
- I-Disease 0 3.577440281787858e-07
NHL I-Disease 0 1.4362832700953732e-07
) O 0 1.1342605327202548e-10
and O 0 4.741044015710294e-11
a O 0 7.31634530737324e-10
B B-Disease 0 1.9015305952052586e-07
- I-Disease 0 2.70107136657316e-07
NHL I-Disease 0 7.151246705916492e-08
cell O 0 8.312965178447485e-07
line O 0 4.311894372222014e-06
. O 0 2.7438000316237776e-08

The O 0 1.463680909807863e-08
evidence O 0 1.4627257183263964e-09
of O 0 1.8444565319519768e-11
a O 0 3.655785674183676e-10
significant O 0 4.342123050005142e-10
proportion O 0 6.074682534773501e-09
of O 0 1.1289036372374994e-10
loss O 0 1.7960269360628445e-07
- O 0 6.724012280301395e-08
of O 0 1.02952524283495e-09
- O 0 1.4893751085764961e-06
function O 0 1.173412300659038e-07
mutations O 0 6.335979492178012e-07
and O 0 1.675123650901611e-10
a O 0 3.4225158818124157e-10
complete O 0 9.586465843369751e-09
absence O 0 3.5108832507901866e-10
of O 0 3.07798404819426e-12
the O 0 7.922705547169784e-11
normal O 0 8.340088619718244e-09
copy O 0 1.4995839592302218e-07
of O 0 4.6796285596562015e-11
ATM O 0 2.910666125899297e-06
in O 0 2.045896785318746e-10
the O 0 1.5881303216946918e-10
majority O 0 1.3059225922873452e-09
of O 0 7.738752416663885e-10
mutated O 0 0.0044180178083479404
tumours B-Disease 1 1.0
establishes O 0 9.635395770146715e-08
somatic O 0 1.0348436774165748e-07
inactivation O 0 3.7176900491431297e-07
of O 0 2.58395180252613e-11
this O 0 2.7835619226257435e-11
gene O 0 3.626403843881576e-09
in O 0 7.598308093825779e-11
the O 0 4.0745062879210536e-10
pathogenesis O 0 1.4246997181999177e-07
of O 0 2.658765707597155e-10
sporadic B-Disease 0 3.3681458262435626e-06
T I-Disease 0 0.0015858300030231476
- I-Disease 0 6.3470019995293114e-06
PLL I-Disease 0 4.3931449908996e-06
and O 0 2.8659818962495365e-09
suggests O 0 6.68086086452746e-10
that O 0 3.031046247325975e-11
ATM O 0 1.7496488169399527e-07
acts O 0 2.3073658539374264e-09
as O 0 4.6048481694427323e-10
a O 0 4.315170798463441e-08
tumour B-Disease 1 0.9999998807907104
suppressor O 0 3.7758461985504255e-05
. O 0 1.1918067599481219e-07

As O 0 4.335110048714341e-08
constitutional O 0 8.069903856267047e-09
DNA O 0 1.628778392159802e-07
was O 0 7.033236215647776e-08
not O 0 2.410669164287782e-10
available O 0 6.683979758559389e-11
, O 0 4.0927768119036756e-11
a O 0 9.419457436266043e-10
putative O 0 1.1958535424128058e-06
hereditary O 0 0.012075444683432579
predisposition O 0 5.116940155858174e-05
to O 0 8.339629857800901e-07
T B-Disease 0 0.05296076834201813
- I-Disease 0 7.334886322496459e-05
PLL I-Disease 0 5.143838279764168e-05
will O 0 8.777413995630923e-08
require O 0 7.819869751735098e-10
further O 0 1.2699221674239425e-09
investigation O 0 2.4955186805897256e-09
. O 0 1.0498267810632456e-09
. O 0 1.2904601831564833e-08

Myotonic B-Disease 1 0.9999995231628418
dystrophy I-Disease 1 0.9999996423721313
protein O 0 0.00011084399739047512
kinase O 0 2.4352577383979224e-05
is O 0 4.616987681060891e-09
involved O 0 3.0661451155822306e-10
in O 0 2.8933534387820536e-11
the O 0 3.089042563408917e-11
modulation O 0 1.8217357622418717e-09
of O 0 1.6133604868739937e-11
the O 0 2.0251722521180682e-10
Ca2 O 0 3.7864978708057606e-08
+ O 0 1.3581531277395698e-07
homeostasis O 0 1.4370232293003937e-07
in O 0 1.9562498287939434e-09
skeletal O 0 3.482284228084609e-06
muscle O 0 8.665708151056606e-07
cells O 0 4.3124228454871627e-07
. O 0 2.5793861269107765e-08

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9997438788414001
DM B-Disease 1 1.0
) O 0 3.526639318351954e-07
, O 0 2.6519383911072225e-10
the O 0 2.3275102331576925e-11
most O 0 4.337561976264226e-10
prevalent O 0 1.486240677195383e-07
muscular B-Disease 0 1.8650306401468697e-06
disorder I-Disease 0 3.1872536055743694e-05
in O 0 5.922154988624584e-10
adults O 0 6.682485320652631e-08
, O 0 9.09315567287905e-10
is O 0 1.3751471072964705e-09
caused O 0 9.878819540176664e-09
by O 0 2.7252866630078643e-10
( O 0 4.894756600037908e-09
CTG O 0 2.3029626845527673e-06
) O 0 1.156041484762227e-09
n O 0 5.180902462598169e-07
- O 0 5.090132617624477e-07
repeat O 0 1.989964175663772e-06
expansion O 0 4.950166387907018e-10
in O 0 1.0302136747852852e-11
a O 0 4.4746258781591663e-11
gene O 0 3.445906615606731e-10
encoding O 0 6.771084248846648e-10
a O 0 4.2208697648149496e-10
protein O 0 6.964684828858481e-09
kinase O 0 9.744027238411945e-07
( O 0 3.300205264622491e-08
DM B-Disease 1 0.9999973773956299
protein O 0 1.4037474294070762e-08
kinase O 0 3.7312865686089935e-08
; O 0 1.3442095214699634e-09
DMPK O 0 4.17025205479149e-07
) O 0 6.375855399198826e-11
and O 0 2.140308937026436e-11
involves O 0 7.190326112294088e-11
changes O 0 7.06272373918182e-10
in O 0 4.700061451146098e-10
cytoarchitecture O 0 5.922860509599559e-06
and O 0 3.548933236174889e-08
ion O 0 6.502553446807724e-07
homeostasis O 0 8.556193620279373e-07
. O 0 4.8442334588116864e-08

To O 0 1.1151892920224782e-07
obtain O 0 3.1612827910976193e-08
clues O 0 5.772200211140444e-07
to O 0 2.3178503560927766e-09
the O 0 2.8519062111875826e-10
normal O 0 1.6486609411003883e-08
biological O 0 2.0094439445728085e-09
role O 0 4.2307274350505963e-10
of O 0 3.756904162766084e-11
DMPK O 0 2.837990678017377e-06
in O 0 1.1414579281776582e-09
cellular O 0 3.3171374980156543e-07
ion O 0 1.8485822295133403e-07
homeostasis O 0 2.038412958427216e-07
, O 0 3.825996408579613e-09
we O 0 1.1426647406054258e-09
have O 0 6.407857577883647e-11
compared O 0 3.1335567474144455e-10
the O 0 4.466014363879722e-11
resting O 0 7.1763168740801575e-09
[ O 0 5.476095688017324e-10
Ca2 O 0 4.0544994028834935e-09
+ O 0 4.266451725243314e-08
] O 0 2.211329963586195e-08
i O 0 1.1936513111265867e-08
, O 0 2.7817095848980955e-11
the O 0 1.2293620114955939e-11
amplitude O 0 1.7863903412074222e-10
and O 0 3.0645255777450586e-10
shape O 0 8.050687227978415e-09
of O 0 1.2949537275819267e-10
depolarization O 0 1.4191027908339038e-08
- O 0 1.8664792378331185e-07
induced O 0 1.5999094671315106e-07
Ca2 O 0 1.8820724534407418e-08
+ O 0 5.8559354698672905e-08
transients O 0 1.7258952311749454e-06
, O 0 2.877455496097525e-10
and O 0 3.54980801697824e-11
the O 0 2.7224226345490266e-11
content O 0 6.217598103042121e-10
of O 0 1.1751637857271291e-11
ATP O 0 1.5367671721833176e-06
- O 0 4.555547405971083e-08
driven O 0 2.6799485297601677e-08
ion O 0 9.962588087830682e-09
pumps O 0 1.0771838532264155e-08
in O 0 8.228118880682089e-11
cultured O 0 2.5357472566156503e-08
skeletal O 0 9.60816066708503e-08
muscle O 0 6.992450618525936e-09
cells O 0 1.1690238777006812e-09
of O 0 1.0468265143614985e-11
wild O 0 7.009048008654872e-09
- O 0 2.227811251032108e-07
type O 0 9.936933764720379e-08
and O 0 1.1908315222797228e-08
DMPK O 0 4.237812390783802e-06
[ O 0 9.426076807983463e-09
- O 0 4.563765969578526e-07
/ O 0 2.0010815205750987e-05
- O 0 2.84567681774206e-06
] O 0 3.5032783785027277e-07
knockout O 0 1.5527362847933546e-05
mice O 0 6.321190085145645e-06
. O 0 2.6230905447732766e-08

In O 0 2.0761366670285497e-07
vitro O 0 1.058399720932357e-05
- O 0 7.293121598195285e-05
differentiated O 0 1.5734591215732507e-05
DMPK O 0 2.410978231637273e-05
[ O 0 2.1267529959345666e-08
- O 0 6.046525982128514e-07
/ O 0 1.056486780726118e-05
- O 0 6.392241402863874e-07
] O 0 1.0221999247050917e-08
myotubes O 0 1.868530574711258e-08
exhibit O 0 3.4048772135086836e-10
a O 0 4.89621065913326e-10
higher O 0 2.677545962725958e-09
resting O 0 2.9672021284454786e-08
[ O 0 1.957447759437514e-09
Ca2 O 0 8.830792985747848e-09
+ O 0 3.6334540709503926e-08
] O 0 2.5479499399239103e-08
i O 0 1.163878415866293e-08
than O 0 1.3568152157361624e-10
do O 0 5.948419534718141e-10
wild O 0 2.004739041439052e-09
- O 0 1.2118894687773718e-07
type O 0 3.394861991523612e-08
myotubes O 0 6.690060558867117e-07
because O 0 1.5887453852503342e-10
of O 0 4.1139218767694e-12
an O 0 4.2691478824297135e-11
altered O 0 6.84120948335476e-07
open O 0 1.3747262528340798e-07
probability O 0 6.950560682561502e-10
of O 0 3.6963099248055187e-11
voltage O 0 2.2309069436232676e-07
- O 0 1.1821368843811797e-06
dependent O 0 2.6647293793757854e-07
l O 0 1.5148201271131256e-07
- O 0 8.712425447754413e-09
type O 0 2.091680162408238e-09
Ca2 O 0 1.2640843038980165e-08
+ O 0 2.4539737353279634e-08
and O 0 2.763768103264397e-09
Na O 0 1.0901785572059453e-06
+ O 0 1.0178307263686293e-07
channels O 0 5.921635874983622e-07
. O 0 4.793827201865497e-08

The O 0 1.774080082839191e-08
mutant O 0 1.4855010022074566e-07
myotubes O 0 5.993169907014817e-07
exhibit O 0 7.70505792502263e-09
smaller O 0 2.1912678338509295e-09
and O 0 7.761042919440797e-10
slower O 0 4.8280913489406885e-08
Ca2 O 0 1.6783552325705386e-08
+ O 0 2.985054692317135e-08
responses O 0 2.6000515074287023e-09
upon O 0 2.2297172441732016e-10
triggering O 0 4.1246921433923944e-09
by O 0 8.395990847009926e-11
acetylcholine O 0 2.584538094652089e-07
or O 0 2.117932922374166e-07
high O 0 2.0127323807628272e-08
external O 0 5.127751023792371e-07
K O 0 8.175940138244187e-07
+ O 0 3.4886187449956196e-07
. O 0 3.4016284899962557e-08

In O 0 1.4971034545396833e-07
addition O 0 4.425672273100645e-09
, O 0 4.529984387602326e-09
we O 0 2.0535133593568844e-09
observed O 0 4.899068928310157e-10
that O 0 2.807866959775307e-11
these O 0 7.241148219233606e-12
Ca2 O 0 6.480776804096422e-09
+ O 0 1.282679278347132e-07
transients O 0 4.16704961025971e-06
partially O 0 9.805935405893251e-07
result O 0 1.857421882967003e-09
from O 0 2.8771466112353927e-11
an O 0 6.658959408184506e-12
influx O 0 5.345118792021708e-11
of O 0 9.682337397121099e-12
extracellular O 0 8.319986366522869e-10
Ca2 O 0 4.109849793820786e-09
+ O 0 6.829558696352933e-09
through O 0 7.087959663643062e-10
the O 0 4.5369946688467166e-10
l O 0 5.75541321268247e-08
- O 0 1.1618555895154259e-08
type O 0 6.638844141093614e-09
Ca2 O 0 2.7765191035200587e-08
+ O 0 7.770159982101177e-08
channel O 0 5.034650257584872e-06
. O 0 1.014773687302295e-07

Neither O 0 6.668370815532398e-07
the O 0 2.8005260332975013e-09
content O 0 1.5343108117349402e-08
nor O 0 3.8345806530060145e-09
the O 0 4.404513559430612e-11
activity O 0 2.922936059857051e-10
of O 0 3.09688871769076e-11
Na O 0 3.7288037901817006e-07
+ O 0 4.219577931507956e-08
/ O 0 1.106179468024493e-07
K O 0 1.7505273675055832e-08
+ O 0 7.464280749047703e-09
ATPase O 0 3.175969141011592e-07
and O 0 4.7366919275759756e-09
sarcoplasmic O 0 8.742265436012531e-07
reticulum O 0 5.110800316288078e-07
Ca2 O 0 1.3392791231581214e-07
+ O 0 1.8539263635375391e-07
- O 0 6.951561317691812e-07
ATPase O 0 1.0032562386186328e-05
are O 0 1.1694571533382714e-08
affected O 0 3.1350406715091594e-09
by O 0 2.4656346409024366e-10
DMPK O 0 8.63611694512656e-06
absence O 0 1.2797224258065398e-07
. O 0 1.4460272090843773e-08

In O 0 1.867308867531392e-07
conclusion O 0 5.885889819978729e-08
, O 0 3.3146752009827196e-09
our O 0 2.60137600349708e-09
data O 0 1.2403512883452095e-08
suggest O 0 8.877974466692251e-10
that O 0 6.523979273476144e-11
DMPK O 0 3.651991562492185e-07
is O 0 5.243805042964844e-11
involved O 0 3.555567645863178e-11
in O 0 2.171080155932703e-11
modulating O 0 1.4625535449397375e-08
the O 0 2.7808408353813263e-10
initial O 0 2.8120821227162196e-09
events O 0 1.7545101482774328e-10
of O 0 5.312128167900276e-11
excitation O 0 4.038717449361684e-08
- O 0 2.6952170628646854e-06
contraction O 0 1.5706980320828734e-06
coupling O 0 8.818269670030077e-09
in O 0 7.910131993860148e-10
skeletal O 0 1.4505361605188227e-06
muscle O 0 1.8151888525608229e-07
. O 0 1.8133741175319074e-09
. O 0 6.878136726840012e-09

Constitutional O 0 1.9351595256011933e-05
RB1 O 0 0.0017273641424253583
- O 0 8.86218695086427e-05
gene O 0 4.750501375383465e-06
mutations O 0 8.994324161903933e-06
in O 0 9.242168141909701e-10
patients O 0 5.830358063008134e-08
with O 0 1.3109163754521092e-09
isolated O 0 1.4814161659160163e-05
unilateral B-Disease 0 0.0002346686233067885
retinoblastoma I-Disease 0 0.0007486887043341994
. O 0 5.252481969364453e-07

In O 0 4.7452491713784184e-08
most O 0 1.4576734264082347e-09
patients O 0 1.560227325114738e-08
with O 0 3.949523208479633e-10
isolated O 0 8.107550115710183e-07
unilateral B-Disease 0 2.4935463443398476e-05
retinoblastoma I-Disease 0 7.5724528869614e-05
, O 0 1.26887202966941e-08
tumor B-Disease 0 4.538245832463872e-07
development O 0 2.1703441821507852e-10
is O 0 2.520555153484594e-10
initiated O 0 5.365274335922265e-10
by O 0 7.231849147304459e-11
somatic O 0 9.164094372238196e-09
inactivation O 0 5.022494065087812e-07
of O 0 2.282361452610182e-11
both O 0 1.5561778254902237e-10
alleles O 0 5.308113060209507e-09
of O 0 1.392418264023476e-10
the O 0 7.070895424732271e-09
RB1 O 0 2.1822945200256072e-05
gene O 0 8.445018693237216e-07
. O 0 4.0567829984183845e-08

However O 0 1.1212978989760813e-07
, O 0 7.121335743320856e-10
some O 0 3.231483483578934e-11
of O 0 7.464426646230926e-12
these O 0 2.3864590859012935e-10
patients O 0 1.3673695065108404e-08
can O 0 7.840289306670911e-09
transmit O 0 6.138866592664272e-05
retinoblastoma B-Disease 0 0.00011717125016730279
predisposition O 0 0.00010589041630737484
to O 0 1.9350983393451315e-07
their O 0 5.651251058225171e-07
offspring O 0 1.2618348591786344e-05
. O 0 1.8598942119751882e-07

To O 0 4.3980821828881744e-07
determine O 0 4.5497380085635086e-08
the O 0 6.93717083777301e-10
frequency O 0 8.200727563689725e-08
and O 0 5.5535887000246476e-09
nature O 0 2.6973059341628414e-09
of O 0 2.1461801780198186e-10
constitutional O 0 6.442644195914227e-09
RB1 O 0 2.384169965807814e-05
- O 0 1.2121015515731415e-06
gene O 0 3.5364064387977123e-07
mutations O 0 4.947848992742365e-07
in O 0 1.0396675187429594e-10
patients O 0 7.88457388267716e-09
with O 0 8.114331428998867e-11
isolated O 0 5.226658004175988e-07
unilateral B-Disease 0 7.093258773238631e-06
retinoblastoma I-Disease 0 1.2197375326650217e-05
, O 0 5.828520333039933e-09
we O 0 4.989154867018897e-09
analyzed O 0 8.226196612781678e-09
DNA O 0 5.5124338871337386e-08
from O 0 2.2197252924627264e-09
peripheral O 0 1.3022887515035109e-06
blood O 0 3.1183076316665392e-06
and O 0 3.504296586243072e-08
from O 0 1.3158068412622015e-08
tumor B-Disease 0 3.10145114781335e-05
tissue O 0 1.8893157175625674e-05
. O 0 7.731780726771831e-08

The O 0 3.359095046562288e-08
analysis O 0 4.704604705807469e-08
of O 0 2.706577184596881e-09
tumors B-Disease 1 1.0
from O 0 8.693104014412256e-09
54 O 0 1.9141479512541082e-08
( O 0 6.181343770172987e-10
71 O 0 1.1271168887105887e-08
% O 0 4.20631501851787e-10
) O 0 9.815290247239261e-11
of O 0 6.041041972215666e-11
76 O 0 3.2816007689007165e-08
informative O 0 1.6062708141362236e-07
patients O 0 3.004017798957648e-07
showed O 0 4.890382498956569e-08
loss O 0 3.352828414904252e-08
of O 0 4.340533210633879e-10
constitutional O 0 4.1070780554264275e-08
heterozygosity O 0 2.0499222955550067e-05
( O 0 1.5470517382709659e-06
LOH O 1 0.9999923706054688
) O 0 1.976590269237022e-08
at O 0 4.247355178677026e-08
intragenic O 0 5.752593551733298e-06
loci O 0 9.612218718757504e-07
. O 0 6.860268797481694e-08

Three O 0 1.3141921328951867e-07
of O 0 1.6027408289431833e-09
13 O 0 4.283787546910389e-08
uninformative O 0 0.00010262324940413237
patients O 0 2.8834690510848304e-06
had O 0 9.110073051488143e-08
constitutional O 0 5.724245255578353e-08
deletions O 0 1.8385486328043044e-05
. O 0 3.8770323840253695e-07

For O 0 9.127952438348075e-08
39 O 0 1.8837484105915792e-07
randomly O 0 4.798186523657932e-07
selected O 0 1.492941578362661e-06
tumors B-Disease 1 1.0
, O 0 3.7516016959671106e-09
SSCP O 0 3.5728789953282103e-06
, O 0 9.862775041113991e-10
hetero O 0 7.226343967658977e-08
- O 0 2.99163822603532e-08
duplex O 0 6.3370166571985465e-06
analysis O 0 3.948094295935789e-09
, O 0 4.97560811996145e-11
sequencing O 0 1.4426049244065098e-09
, O 0 1.7841429722498248e-10
and O 0 2.473836135941099e-10
Southern O 0 1.4135109971391557e-08
blot O 0 0.0001531453599454835
analysis O 0 2.5822202154301976e-09
were O 0 1.1426880275333673e-10
used O 0 2.550709088389169e-10
to O 0 3.6551879301072177e-09
identify O 0 1.6106579892039008e-07
mutations O 0 4.995904419047292e-07
. O 0 1.9131187301013597e-08

Mutations O 0 0.0003822734870482236
were O 0 1.4923109858955286e-07
detected O 0 2.1105492464812414e-07
in O 0 6.402424146401131e-10
21 O 0 4.785821960950898e-09
( O 0 3.2788197157351817e-10
91 O 0 1.7919297157220626e-09
% O 0 3.668043646598562e-10
) O 0 3.7454508938772335e-10
of O 0 1.0376335346506949e-09
23 O 0 5.945517114014365e-05
tumors B-Disease 1 1.0
with O 0 5.299812528392067e-06
LOH O 1 0.9999990463256836
. O 0 1.0326782557967817e-06

In O 0 8.737941925573978e-08
6 O 0 4.34075282385038e-08
( O 0 2.163587753400975e-09
38 O 0 8.323434386170447e-09
% O 0 4.598704472780213e-10
) O 0 2.8618013514503104e-10
of O 0 5.09350672750486e-10
16 O 0 3.907892823917791e-05
tumors B-Disease 1 1.0
without O 0 6.079279955883976e-06
LOH O 1 0.9999837875366211
, O 0 2.0049149007661526e-09
one O 0 1.908386365601089e-10
mutation O 0 3.1933029553954384e-09
was O 0 2.8207041147254586e-09
detected O 0 3.993119435108383e-08
, O 0 1.8028237236400457e-10
and O 0 1.4703727124754096e-10
in O 0 3.641482948513186e-11
9 O 0 9.006836165781351e-09
( O 0 1.28386704045802e-10
56 O 0 3.819856875253436e-09
% O 0 9.207360568419531e-11
) O 0 3.1152896234898364e-11
of O 0 5.900853417006857e-11
the O 0 7.251579972944455e-06
tumors B-Disease 1 1.0
without O 0 1.6218702512560412e-05
LOH O 1 0.9999936819076538
, O 0 2.697439827059611e-09
both O 0 5.68461278049881e-10
mutations O 0 1.2446757580164558e-07
were O 0 1.49746470778922e-09
found O 0 5.4030273588523414e-09
. O 0 1.774205315996369e-08

Thus O 0 2.3486411748763203e-07
, O 0 6.908162375474092e-10
a O 0 3.299635287223879e-10
total O 0 8.301329623705556e-10
of O 0 4.609248399622956e-11
45 O 0 4.0595673489463024e-09
mutations O 0 7.786196931647282e-08
were O 0 6.433790389337446e-09
identified O 0 1.4880021126373322e-07
in O 0 1.117171350983881e-07
tumors B-Disease 1 1.0
of O 0 4.063022807088146e-09
36 O 0 5.298743417370133e-07
patients O 0 1.2256067805083148e-07
. O 0 1.4525093128270328e-08

Thirty O 0 3.2845612167875515e-06
- O 0 1.0819804856510018e-06
nine O 0 3.922830060787419e-08
of O 0 2.4073505341948298e-11
the O 0 4.520226901116864e-11
mutations O 0 4.554381316523859e-09
- O 0 3.765875611350111e-09
including O 0 7.92062040955166e-11
34 O 0 2.1373441905225832e-10
small O 0 5.59857125936869e-11
mutations O 0 6.142855557556004e-09
, O 0 4.2711351816437926e-11
2 O 0 8.603576184817996e-11
large O 0 2.1624932400321484e-10
structural O 0 5.934916913474808e-08
alterations O 0 1.6719882012239395e-07
, O 0 6.207123148804783e-10
and O 0 5.141912451378516e-10
hypermethylation O 0 2.0555097535179812e-07
in O 0 2.678010924128671e-09
3 O 0 8.483372766932007e-06
tumors O 1 1.0
- O 0 0.00011790615826612338
were O 0 3.955351530748885e-07
not O 0 2.3665520654247985e-09
detected O 0 7.669355817085943e-09
in O 0 1.2598509041561456e-11
the O 0 6.402396668381272e-11
corresponding O 0 7.985202721272344e-09
peripheral O 0 5.205299089539039e-07
blood O 0 2.520995963095629e-07
DNA O 0 1.6047060853452422e-06
. O 0 2.4086219241326035e-08

In O 0 1.4539263304413907e-07
6 O 0 3.4365964296512175e-08
( O 0 2.4323225655820124e-09
17 O 0 3.853114716179107e-09
% O 0 4.2733211413903405e-10
) O 0 3.2908724356683905e-11
of O 0 1.032308440118701e-11
the O 0 1.1410138389678082e-09
36 O 0 4.896747896054876e-08
patients O 0 9.216853391613711e-10
, O 0 5.802301347723748e-12
a O 0 3.782156254850122e-10
mutation O 0 2.34622063999268e-08
was O 0 1.3681156652012305e-08
detected O 0 2.7170576899493426e-08
in O 0 4.123287822288546e-11
constitutional O 0 6.462661655826096e-11
DNA O 0 1.4926662572634086e-08
, O 0 8.148519081707661e-10
and O 0 2.8388594253137e-10
1 O 0 4.349964832783826e-10
of O 0 8.134953648208931e-12
these O 0 1.3702033951901171e-10
mutations O 0 1.1580061354266036e-08
is O 0 7.597148604654436e-11
known O 0 2.882850069774179e-10
to O 0 5.90923932008991e-09
be O 0 1.6096153299116622e-09
associated O 0 4.178280499367304e-10
with O 0 6.981891731427936e-10
reduced O 0 4.835671347791504e-07
expressivity O 0 1.861192868091166e-05
. O 0 1.0694336793903858e-07

The O 0 1.56646535742766e-08
presence O 0 3.286083627429548e-09
of O 0 5.147552176176795e-11
a O 0 6.424565879292743e-10
constitutional O 0 1.0681830975300954e-09
mutation O 0 3.7151234977272907e-08
was O 0 3.089330036232241e-08
not O 0 2.8684576935944506e-10
associated O 0 1.7005490071664298e-10
with O 0 5.4885051364861326e-11
an O 0 1.825902207208685e-10
early O 0 1.2547688221786757e-08
age O 0 6.311576594697499e-09
at O 0 1.4126485758936269e-08
treatment O 0 4.883242610276284e-08
. O 0 7.916762356785512e-09

In O 0 1.375520923829754e-07
1 O 0 1.1352967277389325e-07
patient O 0 3.26014969687094e-07
, O 0 1.3276116872518173e-09
somatic O 0 9.279305146492334e-08
mosaicism O 0 2.2901217562321108e-06
was O 0 1.0604371603051277e-08
demonstrated O 0 5.894557064678452e-10
by O 0 7.369166041271136e-12
molecular O 0 2.8439212096387223e-10
analysis O 0 3.3351957307026225e-10
of O 0 5.771539062643383e-12
DNA O 0 4.502610906342852e-08
and O 0 1.0137107819829794e-09
RNA O 0 6.521251805224892e-08
from O 0 7.205833263412842e-09
peripheral O 0 4.968681878381176e-06
blood O 0 3.1593135645380244e-06
. O 0 1.0372960446147772e-07

In O 0 1.773847344566093e-07
2 O 0 1.419290214244029e-07
patients O 0 4.1729489197450675e-08
without O 0 5.878153519489615e-10
a O 0 1.8188957007225781e-09
detectable O 0 7.481922352781112e-07
mutation O 0 1.6164993610345846e-07
in O 0 1.175821995325066e-09
peripheral O 0 7.245289452839643e-06
blood O 0 1.2873823834524956e-05
, O 0 7.138379221061086e-09
mosaicism O 0 1.940986521731247e-06
was O 0 2.779793817353493e-08
suggested O 0 5.128848457047752e-09
because O 0 2.6512508854992234e-10
1 O 0 1.5517911955420516e-10
of O 0 5.463820802048547e-12
the O 0 4.777291895408098e-10
patients O 0 2.99865341446548e-08
showed O 0 5.410238657077571e-08
multifocal O 0 0.23825107514858246
tumors B-Disease 1 1.0
and O 0 1.1581474446131779e-08
the O 0 9.168037162776699e-11
other O 0 3.2237837399584635e-10
later O 0 1.5230096295226758e-08
developed O 0 7.2941119810820965e-09
bilateral B-Disease 0 6.829534981989127e-08
retinoblastoma I-Disease 0 2.4859151380951516e-05
. O 0 3.3910410479620623e-07

In O 0 2.458495202972699e-07
conclusion O 0 3.3447292935306905e-08
, O 0 1.9638874970695497e-09
our O 0 2.6914730444360657e-09
results O 0 6.3001865946432645e-09
emphasize O 0 1.1459451165762857e-09
that O 0 3.388323302488949e-11
the O 0 3.639649692743774e-11
manifestation O 0 1.9398380679547245e-09
and O 0 2.2851678882496174e-10
transmissibility O 0 3.405432735803515e-08
of O 0 5.557429516578338e-11
retinoblastoma B-Disease 0 9.197982109299119e-08
depend O 0 4.671927733568282e-09
on O 0 1.315731434914369e-08
the O 0 2.0922058530103982e-10
nature O 0 4.802168662720874e-10
of O 0 6.954107862472414e-12
the O 0 7.281816122306495e-11
first O 0 1.8661503453643036e-09
mutation O 0 9.254480515252794e-10
, O 0 3.063980666406785e-11
its O 0 2.0431629998984846e-10
time O 0 6.976793587298857e-10
in O 0 2.4608882639998164e-11
development O 0 3.552313998511636e-11
, O 0 4.4418391187406314e-10
and O 0 3.827206052076093e-10
the O 0 2.1760466692444247e-11
number O 0 1.6008191439098596e-09
and O 0 4.3902240176585394e-10
types O 0 2.59185090056846e-10
of O 0 1.141628718642762e-11
cells O 0 5.577696970959778e-09
that O 0 9.449472315736784e-10
are O 0 7.595326589893148e-10
affected O 0 2.2583566128275834e-09
. O 0 8.860447930914006e-10
. O 0 1.0641003633793389e-08

Hereditary B-Disease 1 0.9999992847442627
deficiency I-Disease 1 0.999981164932251
of I-Disease 0 2.1032418029420796e-09
the I-Disease 0 2.1698072227849252e-09
fifth I-Disease 0 1.6035281191761896e-07
component I-Disease 0 1.4119454938565923e-08
of I-Disease 0 9.649635951403113e-11
complement I-Disease 0 8.350149016678188e-09
in O 0 2.0413020163090323e-09
man O 0 2.0133290945523186e-06
. O 0 5.673364711356044e-08

I O 0 0.0018652217695489526
. O 0 1.0917007102762e-06

Clinical O 0 9.200599015457556e-05
, O 0 5.526688084955822e-08
immunochemical O 0 1.4225076483853627e-05
, O 0 2.4301627377099067e-08
and O 0 2.556306499812422e-09
family O 0 2.7368850297193603e-08
studies O 0 2.5263140912556992e-08
. O 0 7.880503005708306e-08

The O 0 3.561586936484673e-08
first O 0 1.6562601956593426e-08
recognized O 0 3.387466973592268e-09
human O 0 3.3780145347606094e-09
kindred O 0 0.0001360222086077556
with O 0 9.41261987463804e-07
hereditary B-Disease 1 0.9999970197677612
deficiency I-Disease 1 0.9180837273597717
of I-Disease 0 9.35744121077775e-11
the I-Disease 0 4.397641140130304e-10
fifth I-Disease 0 3.8741529806429753e-07
component I-Disease 0 1.0412959383643283e-08
of I-Disease 0 7.557288822512831e-11
complement I-Disease 0 9.023016112053028e-09
( O 0 3.971871276320371e-09
C5 O 0 4.694628046308935e-07
) O 0 8.254216199432562e-10
is O 0 2.710155710961004e-10
described O 0 2.0425222402309373e-08
. O 0 1.1315369086162264e-08

The O 0 3.390138303416279e-08
proband O 0 8.350461371264828e-07
, O 0 4.78352857324893e-10
a O 0 2.2594798254615966e-10
20 O 0 1.5900770700127964e-09
- O 0 3.732511189014076e-08
year O 0 2.378146213288801e-08
- O 0 1.1386407550162403e-07
old O 0 8.540331464246265e-08
black O 0 1.792313497617215e-08
female O 0 5.6712767815270126e-08
with O 0 4.166344638178998e-07
systemic B-Disease 1 1.0
lupus I-Disease 1 0.9979203343391418
erythematosus I-Disease 1 0.9999990463256836
since O 0 6.9626018728286e-08
age O 0 1.1760917573155893e-08
11 O 0 2.6073665448933525e-09
, O 0 5.456359253308563e-10
lacked O 0 1.9036731302435328e-08
serum O 0 9.935735789667888e-09
hemolytic O 0 3.787404693866847e-06
complement O 0 1.4431368100531472e-08
activity O 0 1.0550825990662815e-08
, O 0 8.759259428892108e-10
even O 0 5.012897208445111e-09
during O 0 5.831211513651624e-09
remission O 0 3.921323639133334e-07
. O 0 1.659415893584537e-08

C5 O 0 0.0003657046763692051
was O 0 9.864774028756074e-07
undetectable O 0 1.288398834731197e-06
in O 0 8.913656479592191e-10
her O 0 2.0254947941111823e-08
serum O 0 3.236082068980295e-09
by O 0 1.1919028264362197e-10
both O 0 9.776357501323218e-10
immunodiffusion O 0 5.0275780267838854e-06
and O 0 2.631163020794247e-08
hemolytic O 0 8.591400546720251e-05
assays O 0 2.7202577257412486e-06
. O 0 9.021230340522379e-08

Other O 0 2.0098013919778168e-08
complement O 0 5.7927476149188806e-08
components O 0 5.887720178066047e-08
were O 0 4.0264240830367726e-09
normal O 0 1.6202058361614036e-08
during O 0 3.2369338320847874e-09
remission O 0 9.629314234871345e-08
of O 0 2.651655284235943e-10
lupus O 0 8.338600309798494e-06
, O 0 2.748369865024358e-10
but O 0 3.661717595804248e-10
C1 O 0 2.008705379807907e-08
, O 0 1.7458375023426953e-10
C4 O 0 3.665571313149485e-08
, O 0 8.282603491949203e-10
C2 O 0 3.789872238257885e-08
, O 0 2.4936619436033425e-10
and O 0 7.609043950473904e-10
C3 O 0 1.1549078635653132e-06
levels O 0 2.6841023625934213e-08
fell O 0 1.5983881894499063e-05
during O 0 1.6278288939020058e-08
exacerbations O 0 2.3395557946059853e-05
. O 0 4.958628707640855e-08

A O 0 6.277697366385837e-07
younger O 0 3.641877697191376e-07
half O 0 4.1412135942664463e-07
- O 0 2.0757139282068238e-05
sister O 0 0.008726723492145538
, O 0 3.033664697227323e-08
who O 0 8.452288824400966e-08
had O 0 9.25231802284543e-08
no O 0 1.8760728082156675e-08
underlying O 0 9.185374665321433e-07
disease O 0 6.988498626014916e-06
, O 0 1.9736359213595733e-09
was O 0 1.0328343336141188e-07
also O 0 1.8833004489238192e-08
found O 0 5.616084486348427e-09
to O 0 5.1251034527410866e-09
lack O 0 3.9694327824690845e-09
immunochemically O 0 6.831829068687512e-06
detectable O 0 1.5730336144770263e-06
C5 O 0 3.6901069506711792e-06
. O 0 6.377104000421241e-08

By O 0 1.4213408405794326e-07
hemolytic O 0 0.00037898242590017617
assay O 0 1.3606928405351937e-05
, O 0 4.0310059290504796e-08
she O 0 7.037893112737947e-08
exhibited O 0 1.0583814935571922e-09
1 O 0 4.617936033568526e-10
- O 0 2.159346479402302e-08
2 O 0 6.123202833663299e-09
% O 0 8.432324977158956e-11
of O 0 5.102077180879627e-12
the O 0 3.1924424215290514e-10
normal O 0 8.964370579178649e-08
serum O 0 6.821148534896793e-09
C5 O 0 2.1425468332836317e-07
level O 0 1.4044242435673482e-09
and O 0 2.875376048372402e-10
normal O 0 1.891907963624817e-09
concentrations O 0 5.881372611149516e-10
of O 0 6.560925847748367e-12
other O 0 8.183730776378795e-11
complement O 0 3.19205462062655e-09
components O 0 9.477151508008319e-08
. O 0 3.301918027887041e-08

C5 O 0 8.744610386202112e-05
levels O 0 1.4668928827177297e-07
of O 0 1.2928708104098519e-10
other O 0 1.4271960002698592e-10
family O 0 7.814696112440345e-10
members O 0 1.7324364165460793e-10
were O 0 1.8797816081495e-10
either O 0 6.431836174769501e-10
normal O 0 8.5114137959863e-09
or O 0 1.0387309679060763e-08
approximately O 0 3.2918110459689842e-09
half O 0 2.786855191061477e-07
- O 0 5.567629159486387e-06
normal O 0 9.496505299466662e-06
, O 0 3.040556917355275e-09
consistent O 0 5.3878479455704564e-09
with O 0 1.1725045934163347e-10
autosomal O 0 1.636337401578203e-05
codominant O 0 5.468908739203471e-07
inheritance O 0 5.4765607160334184e-08
of O 0 2.1588830723118235e-10
the O 0 4.335546588407624e-09
gene O 0 5.375339605961926e-05
determining O 0 0.00021745335834566504
C5 B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 2.010616668712828e-07

Normal O 0 0.0012003947049379349
hemolytic O 1 0.7708000540733337
titers O 0 0.0009400652488693595
were O 0 2.4382606511608174e-07
restored O 0 6.385648276818756e-08
to O 0 5.0310386967566956e-09
both O 0 1.151166006962967e-08
homozygous O 0 0.00013440450129564852
C5 B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
deficient I-Disease 1 1.0
( O 0 2.617189466036507e-06
C5D B-Disease 1 1.0
) O 0 7.789818567971452e-09
sera O 0 1.518560566182714e-07
by O 0 1.3786017466488332e-11
addition O 0 4.6812977105847864e-11
of O 0 4.4675648597225504e-11
highly O 0 2.316356662035446e-09
purified O 0 7.68035235410025e-08
human O 0 7.894972675615008e-09
C5 O 0 3.2975362955767196e-06
. O 0 6.455809398175916e-08

In O 0 9.531444788990484e-08
specific O 0 2.318346759011547e-08
C5 O 0 2.2205535969987977e-06
titrations O 0 3.4941401736432454e-06
, O 0 5.735127039940835e-09
however O 0 5.691437321431181e-10
, O 0 1.2881963551425457e-10
it O 0 1.3975061108340014e-09
was O 0 6.676966091134773e-09
noted O 0 5.377363554437409e-10
that O 0 2.0886960563903934e-11
when O 0 6.956207138086867e-11
limited O 0 1.5312504736408883e-11
amounts O 0 7.390395934114835e-11
of O 0 3.884924326680306e-11
C5 O 0 3.0350111046573147e-07
were O 0 8.725425937328168e-10
assayed O 0 1.2581023334234942e-08
in O 0 7.123315826085275e-11
the O 0 3.8354253800720883e-11
presence O 0 1.4619830346340734e-10
of O 0 1.4762956482283762e-11
low O 0 2.6614106474198707e-09
dilutions O 0 1.8666644052700576e-07
of O 0 5.44175704497718e-10
either O 0 2.7522895607035025e-07
C5D B-Disease 1 1.0
serum O 0 2.180653702055224e-08
, O 0 5.081239248805325e-11
curving O 0 8.260536255022544e-09
rather O 0 3.6375624734574785e-10
than O 0 3.708809648284017e-11
linear O 0 8.888478841839742e-10
dose O 0 5.8896741705893874e-08
- O 0 1.2231289758801722e-07
response O 0 3.238619816769983e-09
plots O 0 1.4975775286529824e-07
were O 0 1.4665067737951176e-07
consistently O 0 1.052815434832155e-07
obtained O 0 1.973711194480643e-09
, O 0 1.1654767428925794e-10
suggesting O 0 1.464210752644135e-09
some O 0 1.0845260106639998e-10
inhibitory O 0 1.583664399618101e-08
effect O 0 3.397225967205486e-08
. O 0 2.2335205684953507e-08

Further O 0 1.3149258393241325e-06
studies O 0 3.504109713503567e-08
suggested O 0 4.32113367310194e-08
that O 0 1.0086654844698728e-09
low O 0 1.4172500506504093e-08
dilutions O 0 2.8644424219237408e-06
of O 0 3.04425906705319e-09
C5D B-Disease 1 1.0
serum O 0 2.8971514964837297e-08
contain O 0 2.309173963155331e-10
a O 0 1.207236810518708e-10
factor O 0 2.6644819683951937e-10
( O 0 2.6171659284202065e-10
or O 0 2.922654651626999e-08
factors O 0 2.3621509193105794e-09
) O 0 9.059415440049179e-10
interfering O 0 4.1994053390226327e-07
at O 0 2.0832205294141204e-08
some O 0 5.362191940472272e-11
step O 0 2.4375612639460087e-09
in O 0 3.456199909601665e-11
the O 0 1.9847029575359443e-10
hemolytic O 0 1.7783083876565797e-06
assay O 0 7.389814271618889e-08
of O 0 1.615387407172264e-10
C5 O 0 2.63675531186891e-07
, O 0 4.1118236593362667e-10
rather O 0 1.7246852557217807e-10
than O 0 4.3933547771990433e-11
a O 0 3.381171453931131e-10
true O 0 4.8585921952337685e-09
C5 O 0 3.001875654717878e-07
inhibitor O 0 6.153199905156725e-08
or O 0 5.748315601294962e-08
inactivator O 0 9.339181815448683e-06
. O 0 6.547799102918361e-08

Of O 0 4.712723722377632e-08
clinical O 0 3.1844490422372473e-07
interest O 0 7.324294504229556e-09
are O 0 3.0660589622755197e-09
( O 0 6.318089385004555e-10
a O 0 7.90506859971174e-09
) O 0 1.2891655520874679e-09
the O 0 2.464017323511314e-10
documentation O 0 1.2982542152428778e-08
of O 0 2.2540831423611962e-09
membranous O 0 0.0033098605927079916
glomerulonephritis B-Disease 1 1.0
, O 0 1.1026339961972553e-05
vasculitis B-Disease 1 1.0
, O 0 9.899190445139538e-07
and O 0 1.4925422874512151e-05
arthritis B-Disease 1 1.0
in O 0 3.943215753920981e-10
an O 0 2.858659420290621e-10
individual O 0 1.938077698326879e-09
lacking O 0 2.2569667024185947e-08
C5 O 0 2.94412359380658e-07
( O 0 4.002463915853127e-10
and O 0 1.647977171392867e-10
its O 0 3.240236967627652e-10
biologic O 0 1.1579198933020507e-08
functions O 0 4.4269024557230807e-10
) O 0 3.6920702606302314e-10
, O 0 2.1939389194258752e-10
and O 0 2.693758549554559e-09
( O 0 5.925748780555296e-10
b O 0 1.0451421950108397e-08
) O 0 1.4692448646602685e-11
a O 0 1.3116384367517497e-10
remarkable O 0 2.0955737145555986e-09
propensity O 0 3.967402903981565e-07
to O 0 2.265749799335026e-06
bacterial B-Disease 1 1.0
infections I-Disease 1 1.0
in O 0 6.533110163964295e-10
the O 0 6.518423023571529e-10
proband O 0 3.368807711012778e-06
, O 0 5.596396124296632e-10
even O 0 2.300873380711721e-10
during O 0 1.2562521856107622e-10
periods O 0 1.226844598134491e-10
of O 0 6.658057785657867e-12
low O 0 4.660988928151255e-09
- O 0 9.798413458383948e-08
dose O 0 8.302460940967649e-08
or O 0 2.1249353387986503e-09
alternate O 0 1.528917970006205e-08
- O 0 1.264668441081085e-07
day O 0 5.734659325185021e-08
corticosteroid O 0 8.782753297964518e-07
therapy O 0 3.224580424898704e-08
. O 0 1.6616796827406688e-09

Other O 0 3.0131758421703125e-08
observations O 0 2.236517957499018e-07
indicate O 0 6.433376142922498e-08
that O 0 4.0902659037556077e-10
the O 0 1.9090788949682747e-09
C5D B-Disease 1 1.0
state O 0 1.6277537095987782e-09
is O 0 6.69476210579667e-11
compatible O 0 2.844975144355999e-09
with O 0 6.573229460737906e-11
normal O 0 1.7365403337521457e-08
coagulation O 0 7.199609797226003e-09
function O 0 3.362389833228008e-08
and O 0 2.79710943296152e-09
the O 0 3.896324374252913e-10
capacity O 0 1.126597773404292e-10
to O 0 7.334062246400208e-10
mount O 0 8.162786890864027e-09
a O 0 1.1110640230072022e-07
neutrophilic O 0 0.0015836396487429738
leukocytosis O 0 0.00046795481466688216
during O 0 1.957147048869956e-07
pyogenic B-Disease 0 0.0019674152135849
infection I-Disease 0 0.0011635153787210584
. O 0 7.105763533132858e-09
. O 0 3.8993317019730966e-08

Susceptibility O 1 0.5480948686599731
to O 0 0.0008066288428381085
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
in O 0 3.448972347541712e-05
twins O 0 1.6029172911657952e-05
: O 0 8.328814304903176e-10
the O 0 2.8986892747218107e-11
role O 0 3.6102118516900816e-10
of O 0 1.5599839128799253e-11
genes O 0 3.920838320681241e-09
, O 0 1.5374795880873648e-09
HLA O 0 2.506676537450403e-06
, O 0 5.29913724012232e-10
and O 0 3.7050076895361883e-10
the O 0 1.9493033853734687e-09
environment O 0 1.5164332012318482e-07
. O 0 4.4134260690498195e-08

OBJECTIVE O 0 2.75408251582121e-06
To O 0 7.381753430735216e-09
determine O 0 3.5182388113952356e-09
the O 0 1.4614980059501903e-10
relative O 0 8.229566472728322e-10
effects O 0 6.002376373714924e-09
of O 0 4.293269212363171e-11
genetic O 0 1.8442030125243036e-07
and O 0 5.491693766401795e-09
environmental O 0 8.196388012748912e-10
factors O 0 2.612542682189911e-10
in O 0 3.3867095239337175e-10
susceptibility O 0 7.678120164200664e-05
to O 0 0.2571144700050354
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
( O 0 1.2404124390741345e-05
AS B-Disease 1 0.999997615814209
) O 0 2.9179590299577285e-08
. O 0 5.527710555952581e-08

METHODS O 0 2.0269924334570533e-06
Twins O 0 1.4648739124822896e-05
with O 0 4.274703258033696e-08
AS B-Disease 1 0.9999984502792358
were O 0 9.968898595502651e-09
identified O 0 5.438180128436443e-09
from O 0 6.48770828726164e-11
the O 0 1.320998171960852e-10
Royal O 0 2.2463295579200349e-07
National O 0 2.365063034304171e-09
Hospital O 0 8.428911968394459e-08
for O 0 4.567037859004586e-09
Rheumatic B-Disease 0 0.27239990234375
Diseases I-Disease 0 0.0001045485696522519
database O 0 2.8111937808716903e-06
. O 0 2.485383845396427e-07

Clinical O 0 9.288320870837197e-05
and O 0 3.950582083689369e-08
radiographic O 0 4.046940830448875e-06
examinations O 0 8.990069204628526e-07
were O 0 1.6392386115171576e-08
performed O 0 2.8771236060265437e-08
to O 0 1.9408892271144396e-09
establish O 0 2.4392832642661233e-08
diagnoses O 0 0.0048546274192631245
, O 0 1.6152412740666477e-08
and O 0 1.6949365999607835e-07
disease O 0 3.2194606319535524e-05
severity O 0 2.228118319180794e-06
was O 0 1.3796086939521501e-08
assessed O 0 2.624525707872749e-09
using O 0 9.653912114160335e-10
a O 0 1.376889935400527e-09
combination O 0 1.831341656099994e-08
of O 0 5.379537926231137e-10
validated O 0 8.501067583210897e-08
scoring O 0 3.264844039563286e-08
systems O 0 5.761739316767489e-07
. O 0 2.963412981671354e-08

HLA O 0 0.000838003761600703
typing O 0 2.7846876037074253e-05
for O 0 1.789126891083015e-08
HLA O 0 1.3512889381672721e-05
- O 0 1.1046221288779634e-06
B27 O 0 4.231736454585189e-07
, O 0 1.538295046898952e-09
HLA O 0 5.788495514025271e-07
- O 0 7.969321558221054e-08
B60 O 0 4.282733456761889e-08
, O 0 7.137735402729106e-10
and O 0 1.3188866665458931e-09
HLA O 0 1.0414059033792e-05
- O 0 1.6490625966980588e-06
DR1 O 0 0.00020512461196631193
was O 0 1.8272942270414205e-08
performed O 0 5.991941387506472e-10
by O 0 3.891581935172583e-12
polymerase O 0 1.0036738107288556e-09
chain O 0 7.88350629221668e-09
reaction O 0 2.1158831631229447e-10
with O 0 1.3209522017887387e-11
sequence O 0 1.2598233567473471e-09
- O 0 6.306654753984731e-09
specific O 0 1.004309524432756e-09
primers O 0 1.10247867723956e-07
, O 0 5.071887909657846e-10
and O 0 5.816634396360598e-10
zygosity O 0 5.74180603507557e-07
was O 0 5.647903034144974e-09
assessed O 0 4.514252083254178e-09
using O 0 6.77767708623378e-09
microsatellite O 0 2.263132500956999e-06
markers O 0 6.257123004616005e-06
. O 0 1.467623178541544e-07

Genetic O 0 0.0002362589875701815
and O 0 4.7971017380632475e-08
environmental O 0 2.5605129128081217e-09
variance O 0 8.678790131000369e-09
components O 0 2.419615725557378e-07
were O 0 4.396913499959965e-09
assessed O 0 6.4420668799414216e-09
with O 0 5.7410860787587836e-11
the O 0 1.0996378113636851e-10
program O 0 9.934272293676827e-10
Mx O 0 1.2272178828709457e-08
, O 0 4.603160214111668e-11
using O 0 3.1333594052718183e-10
data O 0 2.768444140599513e-08
from O 0 1.3771569995491006e-10
this O 0 2.0844229120520197e-10
and O 0 2.251299147104646e-09
previous O 0 2.193564618835353e-08
studies O 0 8.840322224257235e-11
of O 0 2.7168980606950832e-11
twins O 0 4.264320452307402e-08
with O 0 6.519956130546234e-09
AS B-Disease 1 0.9999995231628418
. O 0 9.366524267306886e-08

RESULTS O 0 6.043426401447505e-05
Six O 0 8.36116065272563e-09
of O 0 2.636676710299213e-10
8 O 0 2.2691823531317823e-08
monozygotic O 0 1.9588425459460268e-07
( O 0 1.68136065070712e-08
MZ O 0 0.00023718889860901982
) O 0 2.2980588543219937e-09
twin O 0 4.806673246093851e-07
pairs O 0 3.379241491074936e-07
were O 0 6.26298728434449e-08
disease O 0 5.993198328724247e-07
concordant O 0 1.6990148310469522e-07
, O 0 6.860641499351061e-10
compared O 0 1.4069123643878356e-09
with O 0 4.8094441623680595e-11
4 O 0 7.280472336113064e-10
of O 0 4.947822707102034e-11
15 O 0 4.4628678530500565e-09
B27 O 0 5.513053835670689e-08
- O 0 2.877892768538004e-07
positive O 0 2.8297476362126872e-08
dizygotic O 0 4.289870858542599e-08
( O 0 1.3631762385557522e-09
DZ O 0 1.2194025657663587e-05
) O 0 8.097869597101237e-10
twin O 0 4.859994007233581e-08
pairs O 0 9.98299753973697e-09
( O 0 6.635207383531849e-10
27 O 0 9.294498504175408e-09
% O 0 2.392794573591317e-10
) O 0 2.724884901050828e-11
and O 0 1.2367193380491415e-10
4 O 0 4.0025019409917206e-10
of O 0 2.2479497430172302e-11
32 O 0 8.649952754069545e-09
DZ O 0 1.4218077012628783e-05
twin O 0 1.3619703054246202e-07
pairs O 0 1.7261054807704568e-08
overall O 0 1.7843326816091576e-07
( O 0 3.0705224474125714e-10
12 O 0 7.737659957207654e-10
. O 0 8.893630276674003e-11
5 O 0 6.107651051578955e-10
% O 0 9.103012232891672e-10
) O 0 1.022103957026843e-09
. O 0 8.62639204513016e-09

Nonsignificant O 0 6.251721788430586e-05
increases O 0 1.4586122176751815e-07
in O 0 4.054938052000523e-10
similarity O 0 2.2243535902077838e-09
with O 0 1.4195887521051276e-10
regard O 0 1.7900680937543711e-09
to O 0 1.1550171485907867e-08
age O 0 2.726682879483633e-08
at O 0 9.518545596165495e-08
disease O 0 1.5104583326319698e-05
onset O 0 3.5522728580872354e-07
and O 0 1.0488581114742601e-09
all O 0 1.3044507141124484e-10
of O 0 1.9866563255588332e-11
the O 0 9.726719873981438e-09
disease O 0 6.270120138651691e-06
severity O 0 5.50053812276019e-07
scores O 0 8.081197933051953e-08
assessed O 0 1.8606534979426215e-07
were O 0 3.7163976340792715e-09
noted O 0 3.718439778310767e-09
in O 0 3.29601412829561e-09
disease O 0 1.5895062460913323e-05
- O 0 0.00014647052739746869
concordant O 0 0.036041323095560074
MZ O 0 0.032931502908468246
twins O 0 3.2863285923667718e-06
compared O 0 9.606402073814024e-08
with O 0 2.772887253144063e-09
concordant O 0 0.00012948432413395494
DZ O 0 0.04328322410583496
twins O 0 1.5376688679680228e-05
. O 0 1.5019485033462843e-07

HLA O 0 0.015341379679739475
- O 0 7.634133362444118e-05
B27 O 0 3.5479358757584123e-06
and O 0 9.82492753820452e-09
B60 O 0 3.895139499832112e-08
were O 0 8.229378289925648e-10
associated O 0 8.44600708815868e-11
with O 0 4.80063662433583e-11
the O 0 7.677181113052711e-10
disease O 0 5.233870865595236e-07
in O 0 2.6805593855705467e-10
probands O 0 1.8696109691518359e-06
, O 0 2.224900930158924e-09
and O 0 1.3035926504922912e-10
the O 0 6.709398314708181e-11
rate O 0 3.422427852228793e-08
of O 0 9.253240534912166e-11
disease O 0 1.9193947764506447e-07
concordance O 0 5.613621123501389e-09
was O 0 6.236295924111346e-09
significantly O 0 4.8218328885241135e-08
increased O 0 2.996582315617502e-09
among O 0 4.1474496059734633e-10
DZ O 0 1.9314313249196857e-05
twin O 0 1.4983289986503223e-07
pairs O 0 8.871935186505198e-09
in O 0 2.39284925207528e-10
which O 0 4.811006593108402e-10
the O 0 1.7633444704401313e-09
co O 0 2.8408667276380584e-06
- O 0 1.254020844498882e-06
twin O 0 1.6590936411375878e-06
was O 0 1.0274036554847044e-07
positive O 0 2.733741288896141e-10
for O 0 1.939392049732369e-11
both O 0 2.379205443769905e-10
B27 O 0 1.1294178392518006e-07
and O 0 1.7097027793511188e-08
DR1 O 0 0.00041647718171589077
. O 0 1.0299876862518431e-07

Additive O 0 1.3614330782729667e-06
genetic O 0 3.9776195990270935e-06
effects O 0 1.7938767769010155e-06
were O 0 6.1327987133097395e-09
estimated O 0 2.3934072501674564e-09
to O 0 2.3379642666299105e-09
contribute O 0 1.1205485428433803e-09
97 O 0 8.445543708823777e-10
% O 0 1.656201564781412e-10
of O 0 1.340771764446469e-11
the O 0 1.0194851629563573e-09
population O 0 2.5174429207908133e-09
variance O 0 4.288390087481275e-08
. O 0 9.807948941897848e-08

CONCLUSION O 0 7.404204893646238e-07
Susceptibility O 0 2.2652102416031994e-05
to O 0 5.510451615009515e-07
AS B-Disease 1 0.999661922454834
is O 0 5.550144233090748e-10
largely O 0 4.7826165250342e-10
genetically O 0 4.927676044985674e-08
determined O 0 2.3413525340743035e-08
, O 0 3.077452737088038e-10
and O 0 2.3146110028626765e-10
the O 0 1.7154237752503576e-10
environmental O 0 1.949065353556989e-09
trigger O 0 5.2330918265397486e-08
for O 0 3.0303423659283624e-10
the O 0 4.018100074887343e-09
disease O 0 6.464261446126329e-07
is O 0 7.941394208899055e-10
probably O 0 2.6196259383937104e-08
ubiquitous O 0 4.4783510588786157e-07
. O 0 7.001474955359299e-08

HLA O 0 0.013722042553126812
- O 0 1.87492260010913e-05
B27 O 0 1.2124044133088319e-06
accounts O 0 1.7134437868548957e-08
for O 0 7.611464236667587e-11
a O 0 2.5442081774684766e-10
minority O 0 1.394608983851242e-09
of O 0 1.0001125795577881e-11
the O 0 2.1539475758558524e-10
overall O 0 1.1554858048157257e-07
genetic O 0 7.02399987062563e-08
susceptibility O 0 3.0894040037310333e-07
to O 0 3.2861706245057576e-07
AS B-Disease 1 0.9999953508377075
. O 0 1.4402762360532506e-07

Cell O 0 0.00010282728908350691
cycle O 0 3.648511119536124e-05
- O 0 2.2111580619821325e-05
dependent O 0 2.3033799152472056e-06
colocalization O 0 2.7535152185009792e-06
of O 0 6.711884936727586e-10
BARD1 O 0 6.768030743842246e-06
and O 0 2.4359809724927572e-09
BRCA1 O 0 4.517544383020322e-08
proteins O 0 6.927479145879545e-10
in O 0 1.0303654457421985e-10
discrete O 0 8.211888058440309e-08
nuclear O 0 9.370158409183205e-07
domains O 0 6.486567372121499e-07
. O 0 7.850094618788717e-08

Germ O 0 0.0009350272011943161
- O 0 0.00014345026283990592
line O 0 1.784966661944054e-05
mutations O 0 4.2752986928462633e-07
of O 0 9.59033338854276e-11
the O 0 2.0267837408383116e-10
BRCA1 O 0 1.955044695023389e-07
gene O 0 4.791185403973941e-08
predispose O 0 1.9978030252332246e-07
women O 0 1.5007814990752877e-09
to O 0 6.313740641417098e-10
early O 0 2.943852983605666e-08
- O 0 0.16611123085021973
onset O 0 0.09401338547468185
breast B-Disease 1 0.9999978542327881
and I-Disease 1 0.9998658895492554
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
by O 0 6.435713628683004e-10
compromising O 0 4.883177666670235e-07
the O 0 7.447312211361634e-10
genes O 0 3.104427648281671e-08
presumptive O 0 5.07179493069998e-06
function O 0 1.3683922439611251e-08
as O 0 8.9204421627187e-10
a O 0 1.6362834642791313e-08
tumor B-Disease 0 7.777313840051647e-06
suppressor O 0 1.7131262211478315e-05
. O 0 6.990372298787406e-07

Although O 0 4.538193820735614e-08
the O 0 8.256199612866055e-10
biochemical O 0 9.73290070760413e-09
properties O 0 3.023463435170015e-08
of O 0 3.1299249303451404e-10
BRCA1 O 0 3.0088915536907734e-06
polypeptides O 0 8.562250286558992e-07
are O 0 3.1391036436900777e-09
not O 0 1.2018293027438176e-09
understood O 0 1.1761651652619776e-09
, O 0 9.69958766083856e-11
their O 0 7.54965701066368e-10
expression O 0 2.316860259199416e-09
pattern O 0 6.043125040378072e-07
and O 0 5.0468105250445205e-09
subcellular O 0 1.6063918337749783e-06
localization O 0 2.022384109068298e-07
suggest O 0 7.404823421097717e-09
a O 0 6.139151409456645e-10
role O 0 1.5737599001752756e-09
in O 0 7.816217117984081e-10
cell O 0 2.631502866279334e-06
- O 0 6.565488001797348e-05
cycle O 0 4.3593252485152334e-05
regulation O 0 4.677387153151358e-07
. O 0 5.228801924772597e-08

When O 0 1.864253817984718e-07
resting O 0 5.520839749806328e-07
cells O 0 1.1416396006325158e-07
are O 0 1.5974274125696297e-09
induced O 0 4.9227718790234576e-08
to O 0 2.880806704297356e-09
proliferate O 0 5.423441962193465e-07
, O 0 1.0368199354626739e-10
the O 0 8.219303709866566e-11
steady O 0 1.3361102446651785e-07
- O 0 1.2004414351451942e-08
state O 0 7.420711822803128e-10
levels O 0 3.9350789293735033e-10
of O 0 1.584625659856176e-11
BRCA1 O 0 4.0517953436847165e-08
increase O 0 1.3487218009089474e-09
in O 0 9.754299451492088e-11
late O 0 1.173877528515277e-08
G1 O 0 8.381760494557966e-07
and O 0 1.22617616060694e-09
reach O 0 7.94171228779561e-10
a O 0 4.674608478083542e-10
maximum O 0 8.595444356274129e-10
during O 0 3.177215157634805e-09
S O 0 2.7319303626427427e-05
phase O 0 9.70543041489691e-08
. O 0 3.7952180065303764e-08

Moreover O 0 2.765302042462281e-06
, O 0 8.550091301628981e-09
in O 0 1.3470712323382372e-09
S O 0 4.799899033969268e-05
phase O 0 1.6361617838356324e-08
cells O 0 2.503257157115968e-08
, O 0 3.8346445463410817e-10
BRCA1 O 0 1.649901264499931e-07
polypeptides O 0 1.1442818248497133e-07
are O 0 7.916743371971791e-10
hyperphosphorylated O 0 4.6988742496978375e-07
and O 0 3.2021403306714546e-09
accumulate O 0 3.664886349952212e-08
into O 0 1.7638456251134471e-09
discrete O 0 2.084079824271612e-07
subnuclear O 0 1.2520918062364217e-05
foci O 0 3.926044882973656e-06
termed O 0 1.362431817142351e-06
" O 0 1.5097751315806818e-07
BRCA1 O 0 6.168939762574155e-06
nuclear O 0 2.1329619812604506e-06
dots O 0 1.9620370949269272e-05
. O 0 5.785879011455108e-07

" O 0 5.3686144383391365e-06
BRCA1 O 0 3.846285108011216e-05
associates O 0 5.099072586745024e-05
in O 0 4.5867407649780034e-09
vivo O 0 1.4822894627286587e-05
with O 0 3.765492917473523e-10
a O 0 5.878728615016371e-09
structurally O 0 1.9052370134886587e-06
related O 0 1.8526213452219054e-08
protein O 0 1.715913953148629e-07
termed O 0 3.1696438327344367e-06
BARD1 O 0 0.0002646454959176481
. O 0 1.0844137676713217e-07

Here O 0 4.256941679159354e-07
we O 0 6.462471446866402e-09
show O 0 1.06448949654947e-09
that O 0 1.3657097154562425e-11
the O 0 8.51132497814433e-11
steady O 0 3.434630357901369e-08
- O 0 3.4504992196815465e-09
state O 0 2.773329899063981e-10
levels O 0 2.1096772939710462e-10
of O 0 1.5409541698208074e-11
BARD1 O 0 2.1871606747936312e-07
, O 0 4.8951159098420405e-11
unlike O 0 4.0318613031553596e-11
those O 0 3.229751882605214e-11
of O 0 2.3980931823652796e-11
BRCA1 O 0 8.68621953031834e-07
, O 0 2.9215996288911583e-09
remain O 0 2.6992565960171078e-09
relatively O 0 2.9623023478642097e-10
constant O 0 1.6569733363169803e-09
during O 0 2.1923964865777634e-09
cell O 0 3.3779633668018505e-06
cycle O 0 2.1041405489086173e-05
progression O 0 5.312723442330025e-05
. O 0 1.2228666435021296e-07

However O 0 9.017012985168549e-07
, O 0 1.3262255293966518e-08
immunostaining O 0 1.8877583443099866e-06
revealed O 0 5.357273380468541e-07
that O 0 8.811708029909937e-10
BARD1 O 0 7.125213414838072e-07
resides O 0 9.550002566527382e-09
within O 0 1.6632524246773528e-09
BRCA1 O 0 7.092752980497607e-07
nuclear O 0 1.3187796810143482e-07
dots O 0 6.299227948147745e-07
during O 0 3.677223503473215e-08
S O 0 1.6118783605634235e-05
phase O 0 9.294920388924766e-10
of O 0 3.3490632142529897e-12
the O 0 6.528560331231503e-11
cell O 0 1.263165358977858e-07
cycle O 0 3.1538633038508124e-07
, O 0 4.987164015091139e-10
but O 0 1.6760696996964697e-10
not O 0 4.673875175775777e-11
during O 0 3.6132340175409894e-11
the O 0 1.3840879831139574e-10
G1 O 0 7.29903376850416e-07
phase O 0 2.221255357426344e-08
. O 0 8.876455126483052e-09

Nevertheless O 0 8.12195230537327e-06
, O 0 1.2071343924446865e-08
BARD1 O 0 2.1609860141325044e-06
polypeptides O 0 3.653893827504362e-07
are O 0 6.554541354120147e-10
found O 0 3.922339675277442e-10
exclusively O 0 2.291658252051576e-10
in O 0 3.8974372340572216e-11
the O 0 6.916754669017422e-11
nuclear O 0 1.900871016147221e-09
fractions O 0 1.4353289667923264e-09
of O 0 1.9087275163198747e-11
both O 0 1.2909487367984696e-10
G1 O 0 3.301943820588349e-07
- O 0 2.2071544947266375e-07
and O 0 2.0603213357617278e-08
S O 0 3.8026442780392244e-05
- O 0 7.66843726296429e-08
phase O 0 1.2457594955606055e-08
cells O 0 5.484881882011905e-08
. O 0 9.645376941591621e-09

Therefore O 0 5.68710731840838e-07
, O 0 9.624610441960613e-09
progression O 0 2.8255470851945574e-07
to O 0 1.7251343464863567e-08
S O 0 0.00017493854102212936
phase O 0 2.1063382149577592e-08
is O 0 1.8026174997132216e-10
accompanied O 0 1.1386847714733861e-10
by O 0 6.914733109014692e-12
the O 0 1.6832386179332914e-11
aggregation O 0 1.9011030527593675e-09
of O 0 1.2091379286705006e-10
nuclear O 0 3.340788978789533e-08
BARD1 O 0 1.2217712992423913e-06
polypeptides O 0 4.729102798251006e-08
into O 0 1.142301275791624e-08
BRCA1 O 0 1.9776969111262588e-06
nuclear O 0 4.2363112129351066e-07
dots O 0 2.34330809689709e-06
. O 0 8.925795214054233e-08

This O 0 3.53827473986712e-08
cell O 0 8.799470947451482e-07
cycle O 0 3.1467716326005757e-06
- O 0 5.179156687518116e-06
dependent O 0 6.728669177391566e-07
colocalization O 0 8.697011821823253e-07
of O 0 3.2421595963505467e-10
BARD1 O 0 1.5529260053881444e-05
and O 0 1.3878510785048093e-08
BRCA1 O 0 2.2468694282906654e-07
indicates O 0 2.5378021906163895e-09
a O 0 1.2576091557026103e-10
role O 0 3.0597768763129807e-10
for O 0 1.8269577517493474e-10
BARD1 O 0 2.0967556793038966e-06
in O 0 2.609132909725531e-09
BRCA1 O 0 4.9457248678663746e-05
- O 0 0.0001411582197761163
mediated O 0 0.00025766913313418627
tumor B-Disease 0 0.001096389489248395
suppression O 0 1.7086013031075709e-06
. O 0 3.430244177593522e-08

Ethnic O 0 9.550700269755907e-06
differences O 0 1.2821525388062582e-06
in O 0 3.001736414987022e-09
the O 0 7.2058878863856535e-09
HFE O 0 5.9110378060722724e-05
codon O 0 1.6788388165878132e-05
282 O 0 1.297997414440033e-06
( O 0 6.432063059946813e-08
Cys O 0 0.003307338571175933
/ O 0 8.604026515968144e-05
Tyr O 0 1.1301906852168031e-05
) O 0 9.28744547934457e-09
polymorphism O 0 3.0487879598695145e-07
. O 0 7.918018951613703e-08

Recent O 0 6.375316843332257e-07
studies O 0 4.2596866478561424e-08
have O 0 5.176553408148266e-09
shown O 0 6.711263722536387e-08
that O 0 3.0360902201209683e-06
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
( O 0 0.0010574118932709098
HH B-Disease 1 0.7676348686218262
) O 0 6.8420624721454715e-09
is O 0 2.5545421333816876e-09
likely O 0 2.046039249137266e-08
to O 0 7.361450560239291e-09
be O 0 3.989136132531712e-09
caused O 0 1.5712043888171934e-09
by O 0 2.971377310867496e-11
homozygosity O 0 8.831958808741547e-08
for O 0 3.8166487331681154e-11
a O 0 5.631763944080603e-10
Cys282Tyr O 0 7.07821754986071e-07
mutation O 0 1.7786200956493303e-08
in O 0 1.2292407369773883e-10
the O 0 5.492277743712748e-10
HFE O 0 7.722008490418375e-07
gene O 0 1.0335890721080432e-07
located O 0 3.039114560010603e-08
4 O 0 5.7803315911542086e-08
. O 0 4.0514009924663696e-08

5 O 0 1.8613683323565056e-06
Mb O 0 1.527497988718096e-05
telomeric O 0 9.496713028056547e-05
to O 0 5.337944912753301e-07
HLA O 0 6.984258652664721e-05
- O 0 2.1299249510775553e-06
A O 0 7.172754408202309e-07
. O 0 9.822326063613218e-08

Population O 0 8.508803261975117e-07
studies O 0 2.301402268756192e-08
of O 0 1.196572424477793e-10
this O 0 2.4118740338252564e-10
polymorphism O 0 1.4345551413441626e-08
are O 0 2.137935384283196e-10
facilitated O 0 1.924088666171997e-09
by O 0 8.779024035510119e-11
the O 0 1.4596120145871083e-10
fact O 0 3.889849553573299e-10
that O 0 3.759025382632508e-11
the O 0 6.808143632186514e-11
Cys282Tyr O 0 7.556909054073913e-07
mutation O 0 1.344407607462017e-08
creates O 0 2.0809756140494073e-09
a O 0 7.971563409370219e-10
Rsal O 0 2.672078665000299e-07
restriction O 0 2.8332296508892796e-09
site O 0 1.7758885917373846e-07
. O 0 6.005436148370791e-08

We O 0 2.991056135215331e-06
have O 0 1.1307142999683606e-09
studied O 0 8.069284684886213e-10
the O 0 6.290889476012751e-10
codon O 0 5.493843673320953e-07
282 O 0 5.425087579169485e-08
( O 0 1.0986808796076275e-08
Cys O 0 0.0006540342583321035
/ O 0 3.681121961562894e-05
Tyr O 0 3.7126875440662843e-07
) O 0 1.398203913760554e-10
polymorphism O 0 9.520679800090193e-10
in O 0 3.8467593693747304e-11
different O 0 2.730125292504937e-10
ethnic O 0 6.767449178823881e-08
groups O 0 5.663912006070859e-09
. O 0 2.3293745599062277e-08

In O 0 7.174156735345605e-08
agreement O 0 7.859305206636691e-09
with O 0 4.211822279831523e-10
previous O 0 4.5412679838818804e-08
observations O 0 1.1916790221278006e-08
the O 0 3.308319451722497e-10
Tyr O 0 1.271096294885865e-07
allele O 0 4.9399567103591835e-08
appeared O 0 4.1921747850892643e-08
to O 0 2.349442584925754e-10
be O 0 7.674557517267644e-11
rare O 0 2.3934701443018014e-10
or O 0 3.1448823989421726e-08
absent O 0 3.074188370533193e-08
in O 0 2.2952016676125453e-10
Asiatic O 0 2.2798024801318206e-08
( O 0 9.752736812584928e-11
Indian O 0 4.4825358702649254e-11
, O 0 3.885020430360875e-11
Chinese O 0 1.057600118592461e-10
) O 0 3.518042523964482e-10
populations O 0 1.4649880419881356e-08
. O 0 3.112016244699589e-08

The O 0 2.3617330313641105e-08
highest O 0 4.474470571835809e-08
allele O 0 2.825768206093926e-07
frequency O 0 8.648059690585796e-08
( O 0 1.639119062701866e-09
7 O 0 3.7095848615109617e-09
. O 0 1.6072983222148451e-10
5 O 0 1.0784168003041827e-09
% O 0 5.645864331604855e-10
) O 0 1.3402816356755665e-10
was O 0 5.948672221478546e-09
found O 0 2.1492045920723513e-09
in O 0 8.046937005623533e-10
Swedes O 0 9.329950444225688e-06
. O 0 2.3757298350801648e-08

Saamis O 0 4.1059487557504326e-05
( O 0 3.321150998658595e-08
2 O 0 4.469717040933574e-09
% O 0 1.5113238438502208e-09
) O 0 2.703531565284578e-10
and O 0 1.1440406399998437e-09
Mordvinians O 0 1.8395552103811497e-07
( O 0 5.4803144661219605e-11
1 O 0 2.853625669096971e-10
. O 0 7.987357303340659e-11
8 O 0 1.7303205535057486e-09
% O 0 4.020428989726099e-10
) O 0 9.034269859986566e-11
had O 0 1.5968341315897305e-08
significantly O 0 4.590856761410578e-08
lower O 0 1.1666943855459522e-08
frequencies O 0 1.3114597408048212e-08
of O 0 2.9757346586833933e-10
the O 0 4.396687014462941e-09
Tyr O 0 3.9784204091120046e-06
allele O 0 1.829413122322876e-06
. O 0 4.2130317012833984e-08

Comparisons O 0 5.55319900286122e-07
with O 0 2.3714501473648397e-09
allele O 0 1.6925362444908387e-07
frequencies O 0 3.966082218198608e-08
based O 0 1.631646107114193e-08
on O 0 2.585245795216906e-07
prevalence O 0 3.423601356189465e-06
estimates O 0 5.7908755479729734e-06
of O 0 5.815439241274589e-09
HH B-Disease 0 0.1282098889350891
showed O 0 1.775684836502478e-06
some O 0 9.701641573434117e-11
disagreements O 0 2.323538250692536e-09
with O 0 3.8493645770909524e-11
the O 0 1.0929279009586068e-10
RFLP O 0 6.672220109749105e-08
data O 0 1.6370702127233017e-08
, O 0 3.942521656363773e-11
particularly O 0 2.1982060269265524e-11
in O 0 1.0665091032535656e-10
Finns O 0 8.441347176812997e-07
. O 0 1.5445698053895285e-08

The O 0 5.000027414325814e-08
newly O 0 5.5820844835352545e-08
described O 0 4.6969027778231975e-08
HFE O 0 1.2969246654392919e-06
marker O 0 2.6432099176076918e-08
provides O 0 3.1849556325624917e-10
a O 0 1.733801574532734e-10
new O 0 1.653118197886272e-10
approach O 0 1.0681382445199006e-09
to O 0 2.2441555558305737e-10
the O 0 4.1054583344024564e-11
screening O 0 2.9508673282663267e-09
of O 0 8.810561308303377e-11
HH B-Disease 0 2.7034397135139443e-05
as O 0 5.141238546002569e-09
well O 0 4.5124762260151385e-10
as O 0 2.417599176407492e-10
studies O 0 4.2934333172039985e-11
of O 0 4.33991644704923e-12
the O 0 1.7476700642227172e-10
relationship O 0 1.101851276885668e-09
between O 0 1.6416148995723745e-10
the O 0 2.0838355485608417e-09
HFE O 0 7.350884516199585e-06
Tyr O 0 1.0964419061565422e-06
allele O 0 5.493780577126017e-07
and O 0 3.4786959979271614e-09
different O 0 7.159637327447399e-09
disorders O 0 8.06144016678445e-05
including O 0 6.100449922996631e-08
cancer B-Disease 0 0.0002514270890969783

Autosomal B-Disease 1 0.9999977350234985
dominant I-Disease 1 0.9997511506080627
neurohypophyseal I-Disease 1 0.9999743700027466
diabetes I-Disease 1 0.9999986886978149
insipidus I-Disease 1 0.7043763995170593
associated O 0 4.963663400303631e-07
with O 0 8.274960716647684e-10
a O 0 1.2911372415658207e-08
missense O 0 5.719088676414685e-06
mutation O 0 4.984093493476394e-07
encoding O 0 1.207171607120472e-07
Gly23 O 0 1.3263794244267046e-05
- O 0 1.6990898075164296e-05
- O 0 4.0451286622555926e-05
> O 0 3.412201863284281e-07
Val O 0 0.0008825352415442467
in O 0 8.98222154432915e-08
neurophysin O 0 4.575918865157291e-05
II O 0 1.2575392247526906e-06
. O 0 6.16238438055916e-08

Autosomal B-Disease 1 0.9999958276748657
dominant I-Disease 1 0.9997678399085999
neurohypophyseal I-Disease 1 0.999946117401123
diabetes I-Disease 1 0.9999990463256836
insipidus I-Disease 1 0.9991652965545654
( O 0 2.2248291315918323e-06
ADNDI B-Disease 0 0.00048358735512010753
) O 0 4.2400699840072775e-08
is O 0 1.0923058013645459e-08
an O 0 8.830516549096501e-07
inherited B-Disease 1 1.0
disease I-Disease 1 1.0
caused O 0 3.149885014863685e-05
by O 0 4.022547628323991e-09
progressive O 0 1.0411864423076622e-05
degeneration O 0 0.002512003295123577
of O 0 1.9315962718202684e-10
the O 0 8.930673978113646e-10
magnocellular O 0 4.0164860592994955e-07
neurons O 0 7.184262784676321e-08
of O 0 4.771980380291474e-11
the O 0 4.3774392444184684e-10
hypothalamus O 0 1.6921552514759242e-07
leading O 0 1.0615080725528969e-07
to O 0 1.2312365349487209e-08
decreased O 0 7.236495207507687e-07
ability O 0 1.4768358091998834e-08
to O 0 5.5418749589364324e-09
produce O 0 7.307368043996121e-09
the O 0 2.545374355733543e-09
hormone O 0 1.157557871778181e-08
arginine O 0 1.8474203500318254e-08
vasopressin O 0 3.3662910681186986e-08
( O 0 5.576545336616334e-10
AVP O 0 4.042004775328678e-07
) O 0 1.6687911053026028e-09
. O 0 7.518420552798943e-09

Affected O 0 1.517014970886521e-05
individuals O 0 2.2183593628710696e-08
are O 0 3.453402674935546e-09
not O 0 5.627966093157966e-09
symptomatic O 0 8.52095283221388e-08
at O 0 2.9834211545676226e-08
birth O 0 5.821945592288102e-07
, O 0 1.1042692094065387e-08
but O 0 1.3123305109274952e-08
usually O 0 8.234866299972055e-08
develop O 0 1.8784198800858576e-06
diabetes B-Disease 0 0.00020143335859756917
insipidus I-Disease 0 1.180671461042948e-05
at O 0 1.037307981732738e-07
1 O 0 3.9790613470813696e-08
- O 0 1.3645497347170021e-05
6 O 0 4.7148006387942587e-07
yr O 0 1.7664762708591297e-05
of O 0 1.0029541641642936e-09
age O 0 2.3788222947018767e-08
. O 0 1.7198090063175187e-08

The O 0 3.7118514484291154e-08
genetic O 0 3.575008804546087e-07
locus O 0 2.2286062062448764e-07
of O 0 1.4951700988419248e-09
the O 0 1.0168581532354892e-08
disease O 0 5.909630090172868e-06
is O 0 6.214183612129887e-10
the O 0 9.853786675506626e-10
AVP O 0 4.3008305510738865e-05
- O 0 9.898587450152263e-06
neurophysin O 0 2.0155030142632313e-05
II O 0 1.9747933777125581e-07
( O 0 4.74175199105531e-10
NPII O 0 2.0197146000100474e-07
) O 0 7.779416694164709e-11
gene O 0 2.7528515023078626e-09
, O 0 1.0949330331300189e-10
and O 0 2.6672380970538256e-10
mutations O 0 3.9489545855531105e-08
that O 0 4.657156327247947e-10
cause O 0 1.0053391896747144e-08
ADNDI B-Disease 0 5.424320261226967e-05
have O 0 5.304094941038784e-09
been O 0 4.248436602516392e-10
found O 0 4.2087067164686687e-10
in O 0 1.66468210743842e-11
both O 0 2.6593274457531457e-11
the O 0 5.5775738194707714e-11
signal O 0 1.8903640874867733e-09
peptide O 0 7.379648281347073e-11
of O 0 2.603521348162885e-12
the O 0 5.3279679279594205e-11
prepro O 0 5.861421641384368e-07
- O 0 2.1065476119019877e-07
AVP O 0 1.7179505675812834e-06
- O 0 5.5349584471287017e-08
NPII O 0 2.0299471259477286e-07
precursor O 0 4.960792665542613e-09
and O 0 1.475617961155251e-10
within O 0 2.1769777647229205e-10
NPII O 0 2.710618900891859e-06
itself O 0 9.933958722285752e-08
. O 0 1.8222058528749585e-08

An O 0 1.4947865167869168e-07
affected O 0 9.511917937743419e-07
girl O 0 0.00027687501278705895
who O 0 1.0097365787942181e-07
presented O 0 4.806661291212322e-09
at O 0 7.652595002127782e-09
9 O 0 1.4325372887924459e-08
months O 0 2.510868624128193e-09
of O 0 1.1191676058119882e-11
age O 0 3.023917560796008e-09
and O 0 3.682809168736867e-09
her O 0 6.990365477577143e-07
similarly O 0 2.9029040504724435e-08
affected O 0 1.6763623378324155e-08
younger O 0 1.4168635154021558e-08
brother O 0 2.5599925379538035e-07
and O 0 6.639023553134393e-08
father O 0 2.880572651520197e-07
were O 0 1.0472673395156562e-08
all O 0 1.2727903453413347e-10
found O 0 9.48870093608889e-10
to O 0 8.242070914654676e-10
have O 0 8.391652650541204e-11
a O 0 1.2490582179669474e-10
novel O 0 5.611630271573631e-09
missense O 0 1.5886218989180634e-06
mutation O 0 4.402252784529992e-08
( O 0 9.785143806340102e-10
G1758 O 0 1.4387207158961246e-07
- O 0 3.0868702651787316e-06
- O 0 1.695305763860233e-05
> O 0 5.0491241410099974e-08
T O 0 5.453731546367635e-07
) O 0 1.3196527204328845e-11
encoding O 0 1.211388628297172e-10
the O 0 7.469297749751469e-12
amino O 0 2.1599128041671634e-10
acid O 0 3.865250897128192e-10
substitution O 0 8.733730405552365e-11
Gly23 O 0 4.240053996795723e-08
- O 0 9.554178603821128e-08
- O 0 6.23110793185333e-07
> O 0 7.813704883119499e-08
Val O 0 5.493928256328218e-05
within O 0 4.099736372609186e-08
NPII O 0 3.088379162363708e-05
. O 0 6.370588323534321e-08

The O 0 1.1037768388177938e-07
mutation O 0 3.31678143083991e-06
was O 0 7.159694348501944e-08
confirmed O 0 1.1828181989415043e-08
by O 0 1.1916233277897703e-10
restriction O 0 2.4802389031464145e-09
endonuclease O 0 1.5289084558389732e-06
analysis O 0 2.465428678988246e-07
. O 0 1.9883752599980653e-07

A O 0 6.843408755230485e-07
T1 O 0 8.024632552405819e-05
- O 0 5.514094141290116e-07
weighted O 0 9.20254521474817e-08
magnetic O 0 6.014756337435756e-08
resonance O 0 3.200389642188384e-08
imaging O 0 8.521735253452789e-06
of O 0 4.028619104978759e-10
the O 0 9.73468239351405e-09
fathers O 0 7.645411983503436e-07
pituitary O 0 2.5129736968665384e-05
gland O 0 7.597241165058222e-06
demonstrates O 0 1.16237650615858e-08
an O 0 9.680242163412345e-10
attenuated O 0 5.1303222790011205e-06
posterior O 0 0.00044766071368940175
pituitary O 0 0.020951470360159874
bright O 0 8.257203262473922e-06
spot O 0 8.917330706026405e-05
. O 0 2.1457307752825727e-07

This O 0 4.5498335765614684e-08
mutation O 0 9.353096857012133e-07
may O 0 1.1205261074564987e-07
be O 0 1.071198060809131e-10
valuable O 0 1.3800127707241927e-10
for O 0 4.40944780688568e-11
developing O 0 7.060985685036769e-10
models O 0 7.283601277663365e-09
of O 0 8.914914362279092e-10
dominantly B-Disease 0 7.916075992397964e-05
inherited I-Disease 0 0.27067092061042786
neurodegeneration I-Disease 1 1.0
, O 0 1.6527382129538637e-08
as O 0 1.8597073880854964e-10
the O 0 1.381819519918892e-10
early O 0 7.833383719457743e-09
age O 0 1.1340599570530685e-09
of O 0 3.019332700526789e-11
onset O 0 9.34309696276614e-08
of O 0 7.37401029127227e-10
symptoms O 0 3.2695136269467184e-06
suggests O 0 5.936133251616127e-10
that O 0 3.7166630884044594e-11
this O 0 9.694963581940996e-11
mutation O 0 9.090667418831799e-08
may O 0 5.956918158744884e-08
be O 0 3.08689407368945e-10
particularly O 0 2.3386498293476166e-10
deleterious O 0 1.8389306433164165e-07
to O 0 5.023310656326885e-09
the O 0 1.5140013687187093e-09
magnocellular O 0 1.5576425766994362e-06
neuron O 0 2.0196562218188774e-06
. O 0 6.860422008259093e-09
. O 0 3.473751775118217e-08

Frequent O 0 9.764471178641543e-05
inactivation O 0 0.00021308878785930574
of O 0 2.872780768825578e-08
PTEN O 0 0.000330351700540632
/ O 0 0.0009760433458723128
MMAC1 O 0 0.0005025910213589668
in O 0 8.676904599269619e-07
primary O 0 0.018536917865276337
prostate B-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
. O 0 6.081490937503986e-07

Sporadic B-Disease 1 0.9991432428359985
prostate I-Disease 1 0.9999979734420776
carcinoma I-Disease 1 1.0
is O 0 1.267884357503135e-07
the O 0 3.4161243278596487e-10
most O 0 2.954644862107614e-10
common O 0 1.8724184425167323e-09
male B-Disease 0 3.4654924263577414e-08
cancer I-Disease 0 4.116308360835319e-08
in O 0 4.493493077628585e-11
the O 0 1.9288866337507926e-10
Western O 0 1.4932329150951773e-08
world O 0 1.3023190525984774e-08
, O 0 2.9854846372856514e-10
yet O 0 9.42861969055464e-11
many O 0 1.2809623153864358e-12
of O 0 8.001835413891378e-13
the O 0 2.1630820398743644e-11
major O 0 9.596444472403931e-11
genetic O 0 2.224752382318229e-09
events O 0 2.858124847904264e-10
involved O 0 2.3618115796431027e-10
in O 0 3.2825096807354015e-11
the O 0 1.3742235127622848e-10
progression O 0 6.372155780809408e-08
of O 0 2.2062121227128806e-11
this O 0 8.081021407591038e-10
often O 0 1.1761954255007367e-07
fatal O 0 0.00043435857514850795
cancer B-Disease 0 1.7300399122177623e-05
remain O 0 2.6901400218548588e-08
to O 0 3.2390770066115238e-09
be O 0 6.100633775929509e-09
elucidated O 0 6.001474162076192e-07
. O 0 3.16608570471999e-08

Numerous O 0 5.826133246955578e-07
cytogenetic O 0 0.00046759899123571813
and O 0 4.372454043277685e-07
allelotype O 0 6.00491366640199e-05
studies O 0 9.243145626669502e-08
have O 0 3.6542907366765576e-08
reported O 0 5.302628323988756e-06
frequent O 0 1.8581479821477842e-07
loss O 0 4.752803590690746e-07
of O 0 3.7529809815417536e-10
heterozygosity O 0 1.9028436781809432e-06
on O 0 1.7479770804129657e-06
chromosomal O 0 0.05567095801234245
arm O 0 0.0003775252553168684
10q O 0 1.0825145182025153e-05
in O 0 1.295533706979768e-07
sporadic B-Disease 0 0.356280654668808
prostate I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
. O 0 6.871817959108739e-07

Deletion O 0 0.00017607030167710036
mapping O 0 1.2565943507070187e-05
studies O 0 2.675850510058808e-07
have O 0 3.298103479210113e-08
unambiguously O 0 3.218898200429976e-06
identified O 0 2.9246340460531428e-08
a O 0 1.6052524864917928e-09
region O 0 6.566985177869356e-08
of O 0 2.5497509659189177e-10
chromosome O 0 7.792979886289686e-06
10q23 O 0 1.6903197774809087e-07
to O 0 7.59120322157969e-09
be O 0 5.045190931696197e-10
the O 0 9.18098583269078e-11
minimal O 0 3.3194140769410296e-09
area O 0 2.807967369733433e-08
of O 0 3.277183191485733e-09
loss O 0 7.0958362812234554e-06
. O 0 6.77967122442169e-08

A O 0 2.0924956345425016e-07
new O 0 2.5179243579032118e-08
tumor B-Disease 0 1.033270336847636e-06
suppressor O 0 9.553829158903682e-07
gene O 0 9.94186962088861e-07
, O 0 1.5390853036478802e-08
PTEN O 0 4.470361818675883e-05
/ O 0 0.00034498010063543916
MMAC1 O 0 9.030078945215791e-05
, O 0 5.438324901518854e-09
was O 0 5.19807263898997e-09
isolated O 0 1.4272899306888576e-08
recently O 0 5.352472598474378e-08
at O 0 2.2475363792295866e-09
this O 0 6.667796176307306e-11
region O 0 1.0902514446797795e-08
of O 0 1.0187441168429956e-10
chromosome O 0 4.0473883018421475e-06
10q23 O 0 1.2355491207927116e-07
and O 0 2.091648187985129e-09
found O 0 1.6018697479580624e-09
to O 0 6.505853078486723e-10
be O 0 2.0408573442320943e-10
inactivated O 0 4.3033390739743993e-10
by O 0 6.349856404574972e-12
mutation O 0 1.9813681806368777e-09
in O 0 1.2421760287040229e-09
three O 0 6.787444726796821e-05
prostate B-Disease 1 1.0
cancer I-Disease 1 0.9999991655349731
cell O 0 4.0513321437174454e-05
lines O 0 0.00018278160132467747
. O 0 3.2074547107185936e-07

We O 0 1.324732124885486e-06
screened O 0 4.6126510824251454e-06
80 O 0 3.696682426834741e-07
prostate B-Disease 0 0.006219211500138044
tumors I-Disease 1 1.0
by O 0 2.2190351778306194e-09
microsatellite O 0 6.365232252392161e-07
analysis O 0 3.362504941151201e-08
and O 0 3.2506504155094262e-09
found O 0 7.62037632995316e-09
chromosome O 0 2.757304628175916e-06
10q23 O 0 2.599872459541075e-07
to O 0 8.663607609094015e-09
be O 0 8.312198152005124e-10
deleted O 0 4.3094425450362905e-07
in O 0 2.135311927276007e-09
23 O 0 1.2620029465892912e-08
cases O 0 3.4981046947990535e-09
. O 0 2.7957455017713073e-08

We O 0 2.5758986339496914e-06
then O 0 1.066054622356205e-08
proceeded O 0 2.9784164023993753e-09
with O 0 4.2174794906424395e-11
sequence O 0 5.906700684121802e-10
analysis O 0 5.550821469135769e-10
of O 0 2.0884729709513827e-11
the O 0 2.718215930119783e-10
entire O 0 6.430836663184891e-08
PTEN O 0 3.6105659091845155e-05
/ O 0 1.0769294931378681e-05
MMAC1 O 0 4.546694526652573e-06
coding O 0 4.161879132880131e-06
region O 0 5.837546268594451e-07
and O 0 3.888990907086054e-09
tested O 0 2.968933099367632e-09
for O 0 3.0274175527589264e-11
homozygous O 0 4.188120517056859e-09
deletion O 0 6.344223812959626e-09
with O 0 2.6004061751128127e-11
new O 0 6.908162375474092e-10
intragenic O 0 3.778609425353352e-07
markers O 0 1.5296915023554902e-07
in O 0 4.614608140052212e-10
these O 0 3.239705448354613e-10
23 O 0 2.6045137158092757e-09
cases O 0 4.9759023290629756e-11
with O 0 1.2282658223838894e-10
10q23 O 0 1.2292402118418977e-07
loss O 0 8.887300850801694e-08
of O 0 1.4680726634352936e-09
heterozygosity O 0 8.988457921077497e-06
. O 0 1.2665030624248175e-07

The O 0 5.98369842563784e-09
identification O 0 1.056046983194392e-08
of O 0 7.463148848918522e-11
the O 0 3.8936645574416673e-10
second O 0 2.208370908363122e-08
mutational O 0 1.0147137885496704e-07
event O 0 4.7143213777189885e-09
in O 0 1.6818466064272286e-10
10 O 0 4.348380544527686e-10
( O 0 9.117447768991482e-11
43 O 0 1.1077943007364865e-08
% O 0 1.0855308651969153e-08
) O 0 4.153225461323018e-07
tumors B-Disease 1 1.0
establishes O 0 7.633043423993513e-06
PTEN O 0 7.497423212043941e-05
/ O 0 1.2775017239619046e-05
MMAC1 O 0 1.432646058674436e-06
as O 0 2.485172068134034e-10
a O 0 2.2230163543301984e-10
main O 0 1.7473249513955125e-08
inactivation O 0 6.867022648293641e-07
target O 0 1.4022488947773581e-08
of O 0 1.0813430012523995e-10
10q O 0 2.671523304798029e-07
loss O 0 9.728873919812031e-07
in O 0 4.1628762659229324e-08
sporadic B-Disease 0 0.24331767857074738
prostate I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
. O 0 1.166093799298551e-08
. O 0 2.2527606446942627e-08

Risk O 0 9.60683319135569e-05
reversals O 0 5.4823212849441916e-06
in O 0 1.1019988477301013e-08
predictive O 0 3.373803792783292e-06
testing O 0 4.961448212270625e-07
for O 0 3.518764799537166e-07
Huntington B-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 1.7644295269292343e-07

The O 0 1.4977910467450783e-08
first O 0 5.459745544555972e-09
predictive O 0 1.9295626429993717e-07
testing O 0 3.929082836862108e-08
for O 0 4.0660946609705206e-08
Huntington B-Disease 1 1.0
disease I-Disease 1 1.0
( O 0 3.667809522767129e-08
HD B-Disease 0 0.0004949959111399949
) O 0 6.561761800583099e-09
was O 0 1.4171498641246671e-08
based O 0 8.911939519684609e-10
on O 0 6.889874892834769e-09
analysis O 0 4.480461002209779e-10
of O 0 1.105472918067063e-11
linked O 0 1.345343836334223e-08
polymorphic O 0 2.7413154413125085e-08
DNA O 0 3.5757516059220507e-08
markers O 0 2.3008976057781183e-08
to O 0 2.352704031594044e-09
estimate O 0 3.109382475940947e-07
the O 0 6.896142545897987e-10
likelihood O 0 3.2955362883058115e-09
of O 0 2.8743273386422352e-11
inheriting O 0 4.2458808025003236e-08
the O 0 5.63007807041771e-10
mutation O 0 3.41574342144213e-08
for O 0 2.977496027511961e-09
HD B-Disease 0 5.733125362894498e-05
. O 0 7.132597801273732e-08

Limits O 0 1.0699621100229706e-07
to O 0 1.3195792902820358e-08
accuracy O 0 3.54486076048488e-08
included O 0 2.690547784567343e-10
recombination O 0 7.916199917801237e-10
between O 0 3.3091130530182866e-11
the O 0 2.5558458127683537e-11
DNA O 0 6.971090815710568e-09
markers O 0 3.4476784094295e-08
and O 0 2.931098141978339e-10
the O 0 5.133873881568718e-11
mutation O 0 5.6329274578104105e-09
, O 0 7.555443770623782e-11
pedigree O 0 3.91293397683512e-09
structure O 0 3.815961324704631e-09
, O 0 4.0093939279728374e-10
and O 0 7.852883621151108e-11
whether O 0 7.605209517702605e-11
DNA O 0 2.4182413849160866e-09
samples O 0 8.127335249241696e-09
were O 0 1.635570567870559e-10
available O 0 8.442737481351159e-11
from O 0 8.61789736794627e-11
family O 0 2.4826150024637172e-09
members O 0 2.97410784888541e-09
. O 0 7.209503660732253e-09

With O 0 1.532634819056966e-08
direct O 0 1.1370538288701937e-08
tests O 0 2.744740879023766e-09
for O 0 2.1874444963709827e-11
the O 0 1.3726936254343514e-10
HD B-Disease 0 1.072029317583656e-05
mutation O 0 2.1451839415931317e-08
, O 0 2.645139107748662e-10
we O 0 4.975515555116772e-10
have O 0 3.515350510685522e-11
assessed O 0 8.630172687595916e-10
the O 0 2.110478042327557e-10
accuracy O 0 2.304561377286518e-07
of O 0 2.661216247368259e-10
results O 0 1.6595051022250118e-07
obtained O 0 1.0405171169125538e-09
by O 0 1.5087358445908805e-11
linkage O 0 2.8969235899012347e-09
approaches O 0 5.502650335387216e-09
when O 0 1.0163748731528699e-09
requested O 0 1.0342132705787321e-09
to O 0 1.8520588396242488e-09
do O 0 3.183280972152147e-09
so O 0 1.428078211240802e-10
by O 0 1.29982552499186e-11
the O 0 1.0191269356196742e-10
test O 0 5.793570623247035e-10
individuals O 0 1.2548441452597814e-10
. O 0 3.6758476262832573e-09

For O 0 1.60069788535111e-08
six O 0 2.642649210571335e-09
such O 0 4.067360337423054e-11
individuals O 0 1.2736621479714216e-10
, O 0 1.7793283513256597e-09
there O 0 4.298630340571208e-10
was O 0 5.1571094061841904e-09
significant O 0 4.564379429972121e-10
disparity O 0 8.870407741667918e-10
between O 0 1.9622130309482344e-10
the O 0 1.7677086461276303e-09
tests O 0 5.383883117104915e-09
. O 0 5.937597524763305e-09

Three O 0 2.393925342403236e-07
went O 0 5.020037292524648e-07
from O 0 9.865483985294077e-10
a O 0 3.0443636500621096e-09
decreased O 0 3.1219678930938244e-06
risk O 0 1.751135236816026e-08
to O 0 6.950747200029639e-10
an O 0 1.7275955666029574e-10
increased O 0 1.120034198720532e-08
risk O 0 8.668140338841113e-08
, O 0 7.603878637851835e-10
while O 0 9.392403521601977e-10
in O 0 2.1630986932197338e-11
another O 0 7.554669667619862e-10
three O 0 8.07478084396962e-10
the O 0 1.8214961761131576e-09
risk O 0 5.217464860152177e-08
was O 0 6.254929019178235e-08
decreased O 0 8.261120569841296e-07
. O 0 2.9227607001303113e-08

Knowledge O 0 9.239073506250861e-08
of O 0 8.327082912096273e-10
the O 0 3.744286825035914e-10
potential O 0 9.1572055493927e-10
reasons O 0 1.7572497623685734e-10
for O 0 2.592764197784092e-11
these O 0 1.1472604984075208e-11
changes O 0 4.751529725233183e-10
in O 0 7.068181595570877e-10
results O 0 1.5248442650772631e-06
and O 0 2.194886050688183e-09
impact O 0 2.0844863335423014e-10
of O 0 6.655734557242665e-12
these O 0 1.3874949800207759e-10
risk O 0 2.1371782121804017e-09
reversals O 0 1.5807701814196662e-08
on O 0 4.8897295101824056e-08
both O 0 8.832156339622088e-09
patients O 0 5.366842970033758e-09
and O 0 8.364965664586776e-11
the O 0 1.1412983752512318e-10
counseling O 0 3.9270109386535523e-10
team O 0 5.6434926176684996e-11
can O 0 2.4139256565858247e-11
assist O 0 2.3871498527894275e-11
in O 0 9.814723686552007e-12
the O 0 2.157737703789575e-11
development O 0 1.802193810851449e-11
of O 0 3.0232730381662964e-12
strategies O 0 2.7171431771222387e-10
for O 0 1.370432673591937e-11
the O 0 3.969587505925354e-11
prevention O 0 1.5033599920499796e-09
and O 0 1.9911878812450823e-09
, O 0 1.865323867589197e-10
where O 0 3.508172086164052e-10
necessary O 0 3.7923991724753137e-10
, O 0 1.234619351198063e-10
management O 0 2.8069310764600175e-10
of O 0 1.5977631544206172e-12
a O 0 3.150698368870053e-09
risk O 0 1.3130490472690326e-08
reversal O 0 8.929486483566507e-09
in O 0 4.44909491192913e-11
any O 0 4.251549390321685e-10
predictive O 0 2.998356052330564e-08
testing O 0 2.7589859286081264e-09
program O 0 1.2374253843816518e-09
. O 0 4.177053425369337e-10
. O 0 7.137902713338917e-09

A O 0 1.3891680339384038e-07
novel O 0 1.3739503401666298e-07
common O 0 4.11245544285066e-08
missense O 0 6.526915967697278e-06
mutation O 0 3.0423979069382767e-07
G301C O 0 7.045601790878209e-08
in O 0 5.054958118755337e-10
the O 0 3.8593503393080653e-10
N O 0 7.78232242737431e-06
- O 0 1.474175633120467e-06
acetylgalactosamine O 0 1.4599801033909898e-05
- O 0 5.142702548255329e-07
6 O 0 4.5006789406443204e-08
- O 0 6.688988491987402e-07
sulfate O 0 4.7554877369293536e-08
sulfatase O 0 1.9470977008495538e-07
gene O 0 3.5597668812670236e-08
in O 0 1.2692151774018612e-09
mucopolysaccharidosis B-Disease 0 9.628461157262791e-06
IVA I-Disease 0 0.0014698493760079145
. O 0 8.915841931411705e-08

Mucopolysaccharidosis B-Disease 1 0.705653965473175
IVA I-Disease 1 0.9999381303787231
( O 0 0.0043899971060454845
MPS B-Disease 1 0.9999998807907104
IVA I-Disease 1 1.0
) O 0 2.570683044211819e-08
is O 0 5.575066519547534e-10
an O 0 6.757050918793084e-09
autosomal B-Disease 1 0.9999911785125732
recessive I-Disease 1 0.9999955892562866
lysosomal I-Disease 1 0.9999954700469971
storage I-Disease 1 0.9976608753204346
disorder I-Disease 1 0.9998610019683838
caused O 0 6.172183475428028e-08
by O 0 1.1519358383837996e-10
a O 0 1.0888221169125245e-07
genetic B-Disease 1 1.0
defect I-Disease 1 0.9999997615814209
in O 0 2.991191516699132e-09
N O 0 2.0206914996379055e-05
- O 0 5.105906893732026e-06
acetylgalactosamine O 0 0.00018152155098505318
- O 0 7.530460152338492e-06
6 O 0 3.442064837599901e-07
- O 0 2.6664793040254153e-05
sulfate O 0 8.563654887439043e-07
sulfatase O 0 1.1494786349430797e-06
( O 0 1.0669857219980372e-09
GALNS O 0 8.681672625243664e-07
) O 0 2.081436134560022e-09
. O 0 7.473099472576905e-09

In O 0 1.944928129660184e-07
previous O 0 5.119420052324131e-07
studies O 0 1.5145449339115657e-08
, O 0 3.325935304943073e-09
we O 0 5.004795244900606e-09
have O 0 9.581264948099744e-11
found O 0 8.73169800352791e-11
two O 0 3.880754745333448e-11
common O 0 1.154795634117356e-10
mutations O 0 4.194684155578443e-09
in O 0 3.0686824609160723e-11
Caucasians O 0 7.830295345456761e-08
and O 0 8.938973450334231e-10
Japanese O 0 4.564991051836387e-09
, O 0 6.868274282645359e-10
respectively O 0 1.0100023217773924e-07
. O 0 2.862153714033866e-08

To O 0 4.7511855427728733e-07
characterize O 0 2.953870080091292e-06
the O 0 5.688921778101985e-09
mutational O 0 1.7204722553287866e-06
spectrum O 0 2.0892569452257703e-08
in O 0 3.2338404176712743e-10
various O 0 5.623710871982546e-11
ethnic O 0 5.650456103012402e-09
groups O 0 2.3412385918852863e-10
, O 0 1.904393726048781e-10
mutations O 0 2.8701665488739536e-09
in O 0 1.8151787364861782e-11
the O 0 5.954319676204634e-11
GALNS O 0 1.932885140831786e-07
gene O 0 1.0864049215797422e-08
in O 0 4.2736306160584547e-10
Colombian O 0 3.8127877814986277e-06
MPS B-Disease 1 0.9999995231628418
IVA I-Disease 1 1.0
patients O 0 2.865578835553606e-06
were O 0 2.692709111240532e-10
investigated O 0 3.568888518046265e-09
, O 0 3.7809086417261994e-10
and O 0 4.1765674252403073e-10
genetic O 0 2.0446933035600523e-08
backgrounds O 0 2.956446110147226e-08
were O 0 1.914220115750709e-09
extensively O 0 7.063913010085798e-09
analyzed O 0 9.285041357998125e-08
to O 0 3.1822366963751847e-09
identify O 0 9.470696227253939e-09
racial O 0 7.33362814919758e-10
origin O 0 1.5960538446435635e-09
, O 0 1.3682238675372105e-10
based O 0 1.4849832474794766e-10
on O 0 2.0836725678208268e-09
mitochondrial O 0 1.0145859619115072e-07
DNA O 0 8.355710292562435e-07
( O 0 6.956104581234968e-10
mtDNA O 0 4.53780408804505e-08
) O 0 2.1650943260453914e-09
lineages O 0 3.152642307213682e-07
. O 0 3.469791920451826e-08

Three O 0 1.7329280410649517e-07
novel O 0 1.848661526082651e-07
missense O 0 6.104855128796771e-05
mutations O 0 0.00010172970360144973
never O 0 5.488439569489856e-07
identified O 0 1.8604259466314943e-08
previously O 0 8.252567518240994e-09
in O 0 1.429348028825217e-10
other O 0 4.1700484731954646e-10
populations O 0 3.769655698704355e-09
and O 0 5.9196061386046495e-09
found O 0 4.079671711565425e-09
in O 0 1.9191984113042793e-10
16 O 0 7.58975104986348e-10
out O 0 4.214273374714139e-10
of O 0 2.8661153311793086e-11
19 O 0 8.742542689788024e-08
Colombian O 0 3.7407360196084483e-06
MPS B-Disease 1 0.9999806880950928
IVA I-Disease 1 0.9999982118606567
unrelated O 0 3.4213314847875154e-08
alleles O 0 2.6535198927035708e-08
account O 0 6.564543753029284e-08
for O 0 2.9772690979257277e-09
84 O 0 8.456948563662081e-08
. O 0 4.5512049240414854e-08

2 O 0 3.3907983265635266e-07
% O 0 1.4638373180275721e-08
of O 0 5.990977852698975e-11
the O 0 8.602689394177077e-11
alleles O 0 4.773915485145608e-09
in O 0 3.464669384722896e-10
this O 0 4.730839053834757e-10
study O 0 3.560579830974575e-09
. O 0 2.3142911587115123e-08

The O 0 6.264169627456795e-08
G301C O 0 8.372452953153697e-07
and O 0 1.3606157089895987e-08
S162F O 0 2.1649638881626743e-07
mutations O 0 6.57762768696557e-07
account O 0 6.090393611657419e-08
for O 0 2.321420833339971e-09
68 O 0 1.2133118332258164e-07
. O 0 2.720184433258055e-08

4 O 0 5.507535547621956e-07
% O 0 4.26259632035908e-08
and O 0 5.881790610118287e-09
10 O 0 1.1087625040318017e-08
. O 0 3.4437221074767876e-08

5 O 0 3.9617430047655944e-07
% O 0 1.0390143856398026e-08
of O 0 6.049678119568469e-11
mutations O 0 7.690071157639977e-08
, O 0 1.683021944032248e-09
respectively O 0 9.003129974871626e-08
, O 0 3.4386515856965616e-10
whereas O 0 4.807694797825945e-10
the O 0 2.1361093449634438e-10
remaining O 0 3.4218142985764644e-08
F69V O 0 4.667090252041817e-06
is O 0 3.5201833115117154e-10
limited O 0 6.414179604119497e-11
to O 0 2.8382421413120085e-10
a O 0 5.570273131638714e-10
single O 0 8.565405096305767e-08
allele O 0 2.3543177576357266e-06
. O 0 9.733052053206848e-08

The O 0 9.905672015975142e-08
skewed O 0 3.4860754567489494e-06
prevalence O 0 1.012339566841547e-06
of O 0 2.4595661618498355e-10
G301C O 0 2.3215108058138867e-08
in O 0 5.115627366159003e-10
only O 0 5.630819144286647e-10
Colombian O 0 2.895891881848911e-08
patients O 0 6.250585382616691e-09
and O 0 9.639113812687228e-11
haplotype O 0 1.7244707350982935e-07
analysis O 0 2.136880672409802e-09
by O 0 8.093603565129115e-11
restriction O 0 9.337745021653632e-10
fragment O 0 1.9071947576776438e-08
length O 0 1.314226683035713e-08
polymorphisms O 0 2.0477617113101587e-07
in O 0 5.505912947789682e-10
the O 0 2.9688182467957347e-10
GALNS O 0 1.444007693862659e-06
gene O 0 2.1396102667381456e-08
suggest O 0 1.529547266621023e-09
that O 0 3.763502010034614e-11
G301C O 0 1.4253087599058745e-09
originated O 0 3.424553418618359e-10
from O 0 4.7855705509469715e-11
a O 0 3.458146546897467e-10
common O 0 2.3076474064964714e-09
ancestor O 0 2.1881162126646814e-07
. O 0 2.4906086082410184e-07

Investigation O 0 2.913460832587589e-07
of O 0 3.1624913798822263e-10
the O 0 1.3575192359116528e-10
genetic O 0 7.94064103359915e-09
background O 0 5.491515686628645e-09
by O 0 7.947103392025312e-11
means O 0 2.1981610975885246e-10
of O 0 3.073497706340689e-11
mtDNA O 0 1.9481371182905605e-08
lineages O 0 5.730832342010217e-08
indicate O 0 5.530326063762914e-08
that O 0 2.303956331273227e-10
all O 0 1.5924375706966032e-10
our O 0 8.643191051760368e-09
patients O 0 1.890367640200452e-09
are O 0 2.0484612270332825e-11
probably O 0 5.547477477385598e-10
of O 0 4.778629575374893e-11
native O 0 2.9998890482829665e-08
American O 0 5.473939381772652e-07
descent O 0 0.00018102808098774403

Low O 0 6.446927727665752e-06
frequency O 0 7.521800853282912e-07
of O 0 5.989602147593587e-09
BRCA1 O 0 8.354838428203948e-06
germline O 0 1.260779936274048e-05
mutations O 0 3.491745246719802e-06
in O 0 1.8431641768401619e-09
45 O 0 1.0722686027975215e-07
German O 0 0.4962618052959442
breast B-Disease 1 0.9999994039535522
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 2.2454428005858063e-07
. O 0 4.2530459154477285e-08

In O 0 5.1299075209954026e-08
this O 0 7.932295931212252e-10
study O 0 6.193475732274578e-10
we O 0 1.4979245621660198e-09
investigated O 0 1.2239920188505948e-08
45 O 0 1.7371300842228266e-08
German O 0 0.0009175775339826941
breast B-Disease 1 0.9999349117279053
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 5.3583537606982645e-09
for O 0 5.670373059984968e-10
germline O 0 5.946241117271711e-07
mutations O 0 5.239963911662926e-07
in O 0 4.2392897525722617e-10
the O 0 2.395860176918063e-09
BRCA1 O 0 6.101909548306139e-06
gene O 0 2.1045827907073544e-06
. O 0 7.061490947535276e-08

We O 0 2.373350980633404e-06
identified O 0 9.476464413182839e-08
four O 0 4.9569903737278764e-09
germline O 0 7.60455179715791e-07
mutations O 0 1.172832185147854e-06
in O 0 2.77799028225445e-09
three O 0 5.6213494303847256e-08
breast B-Disease 0 0.000205163742066361
cancer I-Disease 0 1.710065953375306e-05
families O 0 2.480068594934437e-09
and O 0 6.90965462624149e-09
in O 0 4.290964916719986e-09
one O 0 0.0037155502941459417
breast B-Disease 1 1.0
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 0 6.453605294609588e-08
. O 0 1.66938227130764e-10
among O 0 2.5742952908247574e-11
these O 0 2.938463361523702e-11
were O 0 3.8662167911596157e-10
one O 0 1.6087529086661334e-09
frameshift O 0 3.120806695733336e-06
mutation O 0 4.394501118554217e-08
, O 0 2.956206390791749e-10
one O 0 1.1683194411915565e-09
nonsense O 0 7.650876199249979e-08
mutation O 0 1.3284711108951797e-08
, O 0 9.766884523365604e-11
one O 0 1.0066698863386847e-10
novel O 0 2.1037431796600004e-09
splice O 0 7.302147423615679e-05
site O 0 1.1490160432003904e-06
mutation O 0 6.008564241710701e-07
, O 0 1.031661867045841e-09
and O 0 4.2753756090974093e-10
one O 0 4.0945611345932775e-09
missense O 0 4.97956443723524e-06
mutation O 0 9.939300298356102e-07
. O 0 3.4304861173950485e-08

The O 0 1.4884648180668592e-07
missense O 0 3.8591075281146914e-05
mutation O 0 1.5374886061181314e-05
was O 0 2.3193294396151032e-07
also O 0 2.435999624239571e-09
found O 0 7.606403285009833e-10
in O 0 1.3419237943068651e-10
2 O 0 4.072894199680377e-08
. O 0 4.796644503812786e-08

8 O 0 1.2626730949705234e-06
% O 0 1.534981031170446e-08
of O 0 7.118344802492516e-11
the O 0 4.919885054910367e-10
general O 0 4.019853616643587e-10
population O 0 1.7445359046242004e-10
, O 0 5.009281878187721e-10
suggesting O 0 5.8234976840765285e-09
that O 0 4.0333478223963937e-10
it O 0 6.409171859900198e-09
is O 0 1.48760914697732e-09
not O 0 2.3891121969654705e-08
disease O 0 2.15825181726359e-07
associated O 0 7.727723350114957e-09
. O 0 5.328413266170173e-08

The O 0 2.8095799464722404e-08
average O 0 3.598758553380321e-07
age O 0 5.455896356920675e-08
of O 0 9.854557170285716e-10
disease O 0 2.290132579219062e-05
onset O 0 2.6721426138465176e-07
in O 0 7.954522041053735e-10
those O 0 3.19051451924679e-09
families O 0 1.90556836976441e-09
harbouring O 0 3.107303427896113e-06
causative O 0 2.209063268310274e-06
mutations O 0 7.326068953261711e-06
was O 0 1.0700903274596385e-08
between O 0 1.4448409135781048e-09
32 O 0 2.2992597337179177e-07
. O 0 5.748414011463865e-08

3 O 0 1.5576159739794093e-06
and O 0 6.692204834735094e-08
37 O 0 2.739063518220064e-07
. O 0 9.103332843096723e-08

4 O 0 1.0257525673296186e-06
years O 0 2.0443188475383067e-08
, O 0 2.1629140145584813e-10
whereas O 0 4.468828362913513e-10
the O 0 1.4992415642289814e-10
family O 0 1.4314120555525278e-08
harbouring O 0 3.326677870063577e-06
the O 0 1.312419950494359e-09
missense O 0 9.92277364275651e-07
mutation O 0 2.1161844188100076e-07
had O 0 2.2224122986358452e-08
an O 0 1.1593640630858104e-10
average O 0 3.808764148516275e-08
age O 0 5.36834798836594e-09
of O 0 2.1223016399840589e-10
onset O 0 1.216142067050896e-07
of O 0 8.391239925131799e-10
51 O 0 6.102045517764054e-07
. O 0 4.422046018248693e-08

2 O 0 3.309359499326092e-06
years O 0 2.4957680011539196e-07
. O 0 1.507082174612151e-07

These O 0 1.0503043057497052e-07
findings O 0 1.1950665168569685e-07
show O 0 6.049420875342548e-08
that O 0 4.3501804936063593e-10
BRCA1 O 0 6.222812203304784e-07
is O 0 1.1809465627621307e-09
implicated O 0 4.6026555899914e-09
in O 0 1.7373725721969713e-11
a O 0 3.431822534483153e-11
small O 0 7.520765260560225e-11
fraction O 0 2.651031039135887e-08
of O 0 9.763098063331199e-08
breast B-Disease 1 0.9999997615814209
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 1.1115298903519033e-08
suggesting O 0 8.378195026637059e-09
the O 0 1.48234299834904e-10
involvement O 0 1.0015931417584056e-09
of O 0 1.5858713647842748e-11
another O 0 1.9850825427880636e-09
susceptibility O 0 9.801310341117642e-08
gene O 0 3.1748061246617e-07
( O 0 4.164083478030989e-08
s O 0 0.0010284710442647338
) O 0 2.7104692890134174e-07

Paternal O 0 0.006588816177099943
transmission O 0 0.1497797816991806
of O 0 9.03490035852883e-06
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 6.148116517579183e-05

We O 0 9.085835699806921e-06
report O 0 4.6958099630955985e-08
a O 0 4.135292941409574e-10
rare O 0 8.943919493908936e-10
case O 0 3.949382154644354e-09
of O 0 3.785261437627696e-09
paternally O 0 0.4315665662288666
transmitted O 1 0.999998927116394
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.7299714088439941
DM B-Disease 1 1.0
) O 0 1.153944594989298e-06
. O 0 1.5423037780237792e-07

The O 0 4.302957634649829e-08
proband O 0 2.3775849058438325e-06
is O 0 6.533782959117218e-10
a O 0 6.492737458785314e-10
23 O 0 1.217860479130195e-08
year O 0 4.342978421334465e-09
old O 0 1.2348299378572847e-06
, O 0 1.8022088852376328e-06
mentally B-Disease 1 1.0
retarded I-Disease 1 0.9999998807907104
male O 0 6.790079351048917e-05
who O 0 6.514193955808878e-05
suffers O 1 0.9981735944747925
severe O 0 0.00035565602593123913
muscular B-Disease 0 5.83888468099758e-05
weakness I-Disease 0 0.00017470867896918207
. O 0 9.988067972699355e-08

He O 0 1.9522666150351142e-07
presented O 0 2.1530089711063738e-08
with O 0 2.6822394971759422e-08
respiratory O 0 0.07680708914995193
and O 0 1.2157141782154213e-07
feeding O 0 3.825487965514185e-06
difficulties O 0 7.204474741229205e-07
at O 0 6.763035997892075e-08
birth O 0 4.198604415250884e-07
. O 0 1.205880693078143e-07

His O 0 2.5651149826444453e-06
two O 0 6.529067491101159e-07
sibs O 1 0.7496331930160522
suffer O 0 0.036726221442222595
from O 0 1.0979773890085198e-07
childhood O 0 4.4195934606250376e-05
onset O 0 0.053442247211933136
DM B-Disease 1 1.0
. O 0 3.3296043966402067e-06

Their O 0 4.480581026200525e-07
late O 0 2.3216796307679033e-07
father O 0 8.447227628494147e-08
had O 0 6.613630088025957e-09
the O 0 6.233732280369608e-11
adult O 0 6.519741413413271e-10
type O 0 4.470970260683771e-09
of O 0 5.925457902122844e-09
DM B-Disease 1 1.0
, O 0 7.652799283164313e-09
with O 0 6.209349701080669e-10
onset O 0 6.013562625639679e-08
around O 0 2.6831592503384627e-09
30 O 0 1.4754562904784052e-08
years O 0 3.2731100052529882e-09
. O 0 6.323204182479003e-09

Only O 0 5.5869417536769106e-08
six O 0 2.8206394997454254e-09
other O 0 5.82499187773422e-11
cases O 0 2.0191862071250455e-10
of O 0 6.073576364062916e-11
paternal O 0 2.6252837415086105e-06
transmission O 0 0.021222705021500587
of O 0 3.9271085370273795e-06
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
have O 0 4.648060348699801e-05
been O 0 1.2187555853415688e-07
reported O 0 5.282691290631192e-06
recently O 0 3.3716122516125324e-07
. O 0 3.394674052970004e-08

We O 0 1.2375957112453762e-06
review O 0 4.123795527277707e-09
the O 0 1.1880965655741704e-10
sex O 0 3.0317024446446794e-09
related O 0 1.2587665354502064e-09
effects O 0 4.637164607856903e-08
on O 0 2.918681047958671e-07
transmission O 0 0.00047753166290931404
of O 0 8.672181479596475e-07
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 0 2.181953277613502e-06

Decreased O 0 0.00023856193001847714
fertility O 0 3.5045688946411246e-06
of O 0 2.0664676636528156e-09
males O 0 1.2007896010857166e-08
with O 0 2.980007351993663e-09
adult O 0 4.214698037685594e-06
onset O 0 0.0009709427249617875
DM B-Disease 1 1.0
and O 0 1.7235565508144646e-07
contraction O 0 2.992671568335936e-07
of O 0 6.762003717381004e-12
the O 0 2.9267183121461926e-10
repeat O 0 6.046780072210822e-07
upon O 0 7.871632790035221e-10
male O 0 6.771346150458157e-09
transmission O 0 8.829348274730364e-08
contribute O 0 9.311991178151402e-10
to O 0 5.176619688462836e-10
the O 0 1.389399151285886e-10
almost O 0 3.926586167324331e-09
absent O 0 1.4944637527491977e-08
occurrence O 0 4.8863237900320655e-09
of O 0 2.5596230690538846e-10
paternal O 0 1.933533667397569e-06
transmission O 0 0.001613890053704381
of O 0 1.9625051663751947e-06
congenital B-Disease 1 0.9999998807907104
DM I-Disease 1 1.0
. O 0 6.0457696235971525e-06

Also O 0 1.7364368432026822e-07
the O 0 1.0933516314537428e-09
fathers O 0 7.042536331880456e-09
of O 0 6.396318197321449e-11
the O 0 5.28944577027346e-09
reported O 0 6.76569834467955e-05
congenitally O 0 0.00043632957385852933
affected O 0 2.3127870463213185e-07
children O 0 1.8583902416935416e-08
showed O 0 2.268161125584811e-08
, O 0 9.507863246716042e-11
on O 0 4.700906774957048e-09
average O 0 7.129401780048283e-08
, O 0 2.330297954600269e-09
shorter O 0 5.538115033232316e-07
CTG O 0 9.49844343267614e-06
repeat O 0 2.4471644337609177e-06
lengths O 0 1.2317201480982476e-06
and O 0 5.98668981055539e-09
hence O 0 2.957708078454857e-09
less O 0 9.76521796758334e-09
severe O 0 1.993824298551772e-06
clinical O 0 1.4767097411549912e-07
symptoms O 0 3.4597283047332894e-06
than O 0 7.676387303590104e-11
the O 0 2.2411826561263837e-10
mothers O 0 8.335254264579817e-09
of O 0 1.6446487227650408e-10
children O 0 1.7474658875471505e-07
with O 0 8.145889296429232e-06
congenital B-Disease 1 0.9999998807907104
DM I-Disease 1 1.0
. O 0 7.913631634437479e-06

We O 0 3.9802948776923586e-06
conclude O 0 2.004060064564328e-07
that O 0 7.015397707199611e-10
paternal O 0 2.459508436913893e-07
transmission O 0 0.00013938041229266673
of O 0 5.428523195405432e-07
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
is O 0 2.512393848519423e-07
rare O 0 6.0541056612350985e-09
and O 0 7.729281659152321e-10
preferentially O 0 1.2406920824048484e-08
occurs O 0 5.217239973376309e-10
with O 0 1.0704790526228081e-10
onset O 0 1.2246719904851489e-07
of O 0 7.251608202807347e-09
DM B-Disease 1 1.0
past O 0 2.5136068870779127e-06
30 O 0 7.42874561865392e-09
years O 0 1.4077222720842997e-10
in O 0 1.683765279980598e-11
the O 0 1.7118610695643355e-10
father O 0 8.551673147394467e-09
. O 0 1.261316384670863e-09
. O 0 1.1371383834557491e-08

The O 0 2.1141107708899654e-07
RB1 O 0 2.3261585738509893e-05
gene O 0 4.6010782739358547e-07
mutation O 0 3.31941606646069e-07
in O 0 1.2109871994070431e-09
a O 0 1.7349977454728105e-08
child O 0 4.1352286643814296e-06
with O 0 3.299725904071238e-06
ectopic B-Disease 1 0.9999980926513672
intracranial I-Disease 1 0.9998342990875244
retinoblastoma I-Disease 1 0.9169170260429382
. O 0 4.857278781855712e-06

The O 0 1.4011746429787308e-07
RB1 O 0 2.561028850323055e-05
gene O 0 9.785205747903092e-07
mutation O 0 6.342332881104085e-07
was O 0 8.451445765444987e-09
investigated O 0 7.81064724009184e-09
in O 0 4.195560218689387e-11
a O 0 3.1623663687696535e-09
child O 0 3.4482678756830865e-07
with O 0 6.560262733046329e-08
ectopic B-Disease 1 0.9998745918273926
intracranial I-Disease 0 0.00036215444561094046
retinoblastoma I-Disease 0 3.0150670227158116e-06
using O 0 1.2821748995861526e-08
DNA O 0 2.68808889813954e-07
obtained O 0 5.632315058790027e-09
from O 0 2.362726403415394e-10
both O 0 1.4636598877348916e-10
the O 0 9.76066893976224e-10
pineal B-Disease 0 5.661010800395161e-05
and I-Disease 0 4.813554369320627e-06
retinal I-Disease 1 0.9982907176017761
tumours I-Disease 1 1.0
of O 0 9.040824755501831e-10
the O 0 4.851304247210919e-09
patient O 0 1.096973278436053e-06
. O 0 2.623485961805727e-08

A O 0 2.4482196749886498e-06
nonsense O 0 4.760451702168211e-06
mutation O 0 8.471291153000493e-07
in O 0 2.7350570697137755e-09
exon O 0 1.3616875094157876e-06
17 O 0 1.2334017185366974e-07
( O 0 1.608360111760021e-09
codon O 0 9.834455738655379e-08
556 O 0 5.728709506769292e-09
) O 0 9.709527626355907e-11
of O 0 1.7414601011234154e-11
the O 0 4.102219675061747e-10
RB1 O 0 6.223909849722986e-07
gene O 0 4.252121144077137e-08
was O 0 5.445539130732868e-09
found O 0 5.993815443972039e-10
to O 0 3.6263264613367596e-10
be O 0 2.0846653570050222e-10
present O 0 1.8056008077582675e-10
homozygously O 0 9.952582047390024e-08
in O 0 1.0951919926505127e-10
both O 0 1.6527429425039486e-10
the O 0 3.8930111911916754e-10
retinal B-Disease 0 1.3833782759320457e-05
and I-Disease 0 8.092673908777215e-08
the I-Disease 0 8.78329160514113e-08
pineal I-Disease 1 0.6694487929344177
tumours I-Disease 1 1.0
. O 0 3.7589526868941903e-07

The O 0 1.3924648101237835e-08
same O 0 5.133223179853985e-09
mutation O 0 2.999671622205824e-08
was O 0 5.180691875494858e-09
present O 0 3.5271732756747554e-10
heterozygously O 0 1.868637333757306e-08
in O 0 3.1886313034412694e-11
the O 0 2.541088520158219e-11
DNA O 0 1.0077909173844546e-08
from O 0 1.335759280962634e-10
the O 0 4.597324951283177e-11
constitutional O 0 7.231103910099179e-11
cells O 0 2.793685005553215e-10
of O 0 3.815322190126036e-12
the O 0 2.283047528806037e-09
patient O 0 1.2731561582768336e-07
, O 0 4.327175007201589e-10
proving O 0 4.77894435135795e-09
it O 0 3.781891244614144e-09
to O 0 9.448823945490403e-10
be O 0 4.882483306545282e-10
of O 0 1.153131687359199e-10
germline O 0 2.911444596520596e-07
origin O 0 5.770472455424169e-08
. O 0 3.6315139340104e-08

The O 0 6.77630964673881e-08
initial O 0 1.2865702103681542e-07
mutation O 0 1.9471161749606836e-07
was O 0 3.5811570597843456e-08
shown O 0 9.143348300710841e-10
to O 0 6.444300093555455e-10
have O 0 2.7977375971488527e-10
occurred O 0 9.227600905603595e-10
in O 0 5.659468033103465e-11
the O 0 3.5233604922524364e-10
paternally O 0 3.3742531968528056e-07
derived O 0 3.943520354710017e-08
RB1 O 0 1.4900293535902165e-05
allele O 0 3.659840331238229e-06
. O 0 1.1092028273651522e-07

The O 0 1.9597500511281396e-08
mutation O 0 3.024228192316514e-07
is O 0 6.019237885901418e-10
in O 0 4.9595386825140864e-11
an O 0 1.431454260680809e-10
area O 0 7.11482250892459e-09
of O 0 5.430007138373938e-11
the O 0 1.3120488029372268e-10
gene O 0 3.2960330020870288e-09
that O 0 1.64495205651205e-11
encodes O 0 3.1897520735846285e-10
the O 0 3.128741363211951e-11
protein O 0 5.49789858084182e-09
- O 0 7.064252827149176e-08
binding O 0 1.1527304444314268e-08
region O 0 7.4353083689970845e-09
known O 0 3.3251723596805505e-10
as O 0 1.6195646213024162e-10
the O 0 3.0941563200492794e-10
pocket O 0 0.0015704302350059152
region O 0 1.958427492354531e-05
and O 0 4.4866058601655823e-07
has O 0 9.867389572093543e-09
been O 0 1.0604871425456963e-09
detected O 0 5.833848071290504e-09
in O 0 1.3078206052841157e-11
other O 0 2.9978824978016405e-11
cases O 0 6.800564278375276e-11
of O 0 5.388490001423385e-11
retinoblastoma B-Disease 0 3.989808305959741e-07
. O 0 7.913290467342904e-09
. O 0 2.967553136556944e-08

Low O 0 5.134497314429609e-06
levels O 0 9.988868754362557e-08
of O 0 3.7145106435154673e-10
beta O 0 1.5123452712373364e-08
hexosaminidase O 0 7.36904013365347e-08
A O 0 6.451018386144369e-09
in O 0 4.6103676432096563e-10
healthy O 0 1.72659930797181e-08
individuals O 0 8.047746496986363e-11
with O 0 1.701997098813024e-09
apparent O 0 1.3819027117278893e-05
deficiency O 0 9.473694080952555e-05
of O 0 7.396770002054964e-11
this O 0 6.748958614188894e-10
enzyme O 0 2.6099587557837367e-07
. O 0 3.317093089094669e-08

Appreciable O 0 6.320580723695457e-05
beta O 0 2.596349304440082e-06
hexosaminidase O 0 5.564646016864572e-06
A O 0 1.0503724467980646e-07
( O 0 4.986415280683332e-09
hex O 0 6.049871785762662e-07
A O 0 6.60251586737104e-08
) O 0 6.989460121786806e-10
activity O 0 1.4424124117340398e-09
has O 0 6.449599743163503e-10
been O 0 3.4511818403082373e-10
detected O 0 1.9414231999803633e-08
in O 0 1.9628830505435957e-10
cultured O 0 4.940271992381895e-06
skin O 0 0.1641208976507187
fibroblasts O 0 1.8219473076896975e-06
and O 0 5.194299390609558e-08
melanoma B-Disease 0 0.0008790590800344944
tissue O 0 3.7400975543278037e-06
from O 0 2.946115351676326e-09
healthy O 0 1.0640277281481758e-07
individuals O 0 2.3270321780621828e-10
previously O 0 3.2019841000874294e-07
reported O 0 3.854440728900954e-05
as O 0 2.753751005002414e-08
having O 0 4.1682480400595523e-07
deficiency B-Disease 0 1.2594078953043208e-06
of I-Disease 0 2.4821294325461096e-11
hex I-Disease 0 8.273483445009333e-07
A I-Disease 0 1.0898792091040832e-08
activity O 0 1.0716073584049468e-09
indistinguishable O 0 9.123111155417973e-09
from O 0 5.2938511213573847e-11
that O 0 9.553303460807516e-12
of O 0 1.7820163747406248e-11
patients O 0 1.602182209126113e-08
with O 0 4.041681052058266e-07
Tay B-Disease 1 1.0
- I-Disease 1 1.0
Sachs I-Disease 1 1.0
disease I-Disease 1 0.9947852492332458
( O 0 9.106525311608493e-09
TSD B-Disease 0 7.1485173975816e-06
) O 0 5.547289294582924e-09
. O 0 2.084444616912151e-08

Identification O 0 3.390236997802276e-06
and O 0 7.344413432974761e-08
quantitation O 0 3.4414879337418824e-06
of O 0 1.2940556404217318e-09
hex O 0 1.1961991503994795e-06
A O 0 7.990660577661401e-08
, O 0 5.799054014765659e-10
amounting O 0 3.213441290839114e-09
to O 0 2.45426257095005e-09
3 O 0 2.1065270416897874e-08
. O 0 5.548001524857682e-08

5 O 0 9.214583087668871e-07
% O 0 2.138672385854079e-07
- O 0 3.1588590445608133e-06
6 O 0 5.382806875786628e-07
. O 0 1.0135241979014609e-07

9 O 0 1.2962742630406865e-06
% O 0 2.5566690098344225e-08
of O 0 8.696594833157434e-11
total O 0 1.97379401711828e-09
beta O 0 9.19334830484786e-09
hexosaminidase O 0 2.9131970791240747e-07
activity O 0 1.1064892113665792e-08
, O 0 5.393397950470558e-10
has O 0 5.458711815897743e-10
been O 0 1.4008841309198772e-10
obtained O 0 3.2481634049119634e-10
by O 0 9.439830861435183e-11
cellulose O 0 3.671505623970006e-07
acetate O 0 9.229580655301106e-08
gel O 0 9.154085205409501e-07
electrophoresis O 0 1.4210291965355282e-07
, O 0 5.842987760296126e-10
DEAE O 0 3.8669404034408217e-07
- O 0 7.614800523469967e-08
cellulose O 0 4.2859369386860635e-07
ion O 0 2.4274203980212405e-08
- O 0 5.148885762196187e-08
exchange O 0 1.2447594954778651e-08
chromatography O 0 8.043212318398218e-09
, O 0 3.469894094276782e-10
radial O 0 2.0945464029864524e-07
immunodiffusion O 0 1.0956307505693985e-06
, O 0 1.4207189868997716e-09
and O 0 2.6256170571059556e-09
radioimmunoassay O 0 5.1154502216377296e-06
. O 0 6.080388459395181e-08

Previous O 0 6.039298114046687e-06
family O 0 7.426155690382075e-08
studies O 0 8.190453648637686e-09
suggested O 0 2.4265824905000954e-08
that O 0 6.162109156271356e-10
these O 0 1.1142033823352548e-10
individuals O 0 7.76979244831999e-11
may O 0 9.729484773401964e-09
be O 0 1.7076412506256133e-10
compound O 0 1.0117695570244223e-09
heterozygotes O 0 1.0316447252023409e-08
for O 0 2.714484366450609e-11
the O 0 2.007905473833116e-11
common O 0 4.19690671105144e-10
mutant O 0 1.5435155376053444e-08
TSD B-Disease 0 1.859124552083813e-07
gene O 0 3.801644155032591e-08
and O 0 4.0186731720126545e-10
a O 0 1.1759027085389562e-09
rare O 0 3.1180631410165915e-09
( O 0 1.0582543730208727e-09
allelic O 0 3.220707966988812e-08
) O 0 5.057060881163977e-10
mutant O 0 3.3534039545202177e-08
gene O 0 8.749680091568734e-07
. O 0 3.677490312270493e-08

Thus O 0 8.027458306969493e-07
, O 0 2.2525661336203484e-09
the O 0 2.2175702940607778e-10
postulated O 0 1.1061600524442383e-08
rate O 0 4.821647081598712e-09
mutant O 0 3.4314462382667443e-09
gene O 0 5.336020691970589e-08
appears O 0 2.97802031923311e-08
to O 0 6.858796863795646e-10
code O 0 2.4946703036654583e-10
for O 0 3.331754316882041e-11
the O 0 4.37941627406957e-11
expression O 0 3.59907353919553e-10
of O 0 3.026898176550219e-11
low O 0 4.952652510326061e-09
amounts O 0 1.6625449905660616e-09
of O 0 2.385671660221078e-10
hex O 0 3.537961674737744e-06
A O 0 2.0875924633401155e-07
. O 0 3.4034325580023506e-08

Heterozygotes O 0 1.794209674699232e-05
for O 0 2.7827311566142043e-09
the O 0 1.4248785484838322e-10
rare O 0 6.390638573883223e-10
mutant O 0 9.511540355333636e-08
may O 0 5.774875830866222e-07
be O 0 1.020004525287277e-09
indistinguishable O 0 8.84076989393634e-09
from O 0 3.222523636825514e-10
heterozygotes O 0 3.47628343888573e-08
for O 0 1.1589020021407492e-10
the O 0 3.9234845927715867e-10
common O 0 2.8114508054954968e-08
TSD B-Disease 0 1.0918955922534224e-05
mutant O 0 3.0221719953260617e-06
. O 0 1.7948147501556377e-07

However O 0 7.782084310292703e-08
, O 0 5.355326737621624e-10
direct O 0 1.3901420015116628e-09
visualization O 0 2.549389535033697e-07
and O 0 8.970610032577042e-09
quantitation O 0 4.967304789715854e-07
of O 0 2.0154385105275452e-10
hex O 0 2.522554325423698e-07
A O 0 2.317470215729145e-09
by O 0 9.07237566322161e-12
the O 0 2.3593254086518023e-11
methods O 0 8.766066095233782e-09
described O 0 9.637252418315256e-08
may O 0 5.254235091456394e-08
prevent O 0 4.6345536297565104e-09
false O 0 5.9531927831812936e-08
- O 0 2.4034284251683857e-06
positive O 0 7.329202844630345e-08
prenatal O 0 3.7640070331690367e-06
diagnosis O 0 3.4209576824650867e-06
of O 0 1.277903477481246e-10
TSD B-Disease 0 3.343611751915887e-06
in O 0 6.391178697384703e-09
fetuses O 0 2.2226629425858846e-07
having O 0 2.2039348124280878e-09
the O 0 1.992106202219901e-10
incomplete O 0 6.831267995721646e-08
hex B-Disease 0 3.087407458224334e-05
A I-Disease 0 5.4600882322120015e-06
deficiency I-Disease 0 1.999559208343271e-05
of O 0 1.0418148982394015e-11
the O 0 2.649440944413328e-10
type O 0 4.720631352483906e-08
described O 0 3.478113796973048e-08
in O 0 1.3056206116246472e-10
the O 0 8.008718688223837e-10
four O 0 5.7632568939425255e-08
healthy O 0 2.1493578117315337e-07
individuals O 0 1.1113328035605718e-08

The O 0 1.8380680444352038e-07
tumor B-Disease 0 7.803562766639516e-06
suppressor O 0 3.671589865916758e-06
gene O 0 3.3593432817724533e-06
Smad4 O 0 0.00016061868518590927
/ O 0 0.00022837991127744317
Dpc4 O 0 5.4315396482707e-06
is O 0 8.419328012543303e-10
required O 0 1.866256316152004e-10
for O 0 4.0131713924251855e-11
gastrulation O 0 2.3225780410029984e-08
and O 0 5.998095797821179e-09
later O 0 4.138216169735642e-08
for O 0 3.105360135702284e-10
anterior O 0 7.049916348478291e-07
development O 0 6.300375221535148e-10
of O 0 5.3803357602522084e-11
the O 0 1.6145257353272768e-09
mouse O 0 4.116197487746831e-06
embryo O 0 4.123831786273513e-06
. O 0 1.8843107341126597e-07

Mutations O 0 0.00014298623136710376
in O 0 2.9007676261016968e-08
the O 0 6.03135363874685e-09
SMAD4 O 0 0.0023658964782953262
/ O 0 0.0006753741181455553
DPC4 O 0 2.4539218429708853e-05
tumor B-Disease 0 1.0914134236372774e-06
suppressor O 0 1.5266137154412718e-07
gene O 0 7.564063508880281e-08
, O 0 1.1135552896446299e-10
a O 0 1.7188264700429556e-10
key O 0 1.8863204331864836e-08
signal O 0 9.221345464993647e-08
transducer O 0 2.7869074159525553e-08
in O 0 1.606584032476377e-10
most O 0 2.58113558304629e-10
TGFbeta O 0 2.788657411656459e-06
- O 0 2.946255506230955e-07
related O 0 5.249314316557729e-09
pathways O 0 2.0149062862628853e-08
, O 0 6.233961125090559e-10
are O 0 5.168350122874976e-11
involved O 0 5.698418473198963e-11
in O 0 5.751585666069481e-11
50 O 0 6.952510789304256e-10
% O 0 1.247994374509176e-09
of O 0 5.8220757104265886e-09
pancreatic B-Disease 0 0.0645432099699974
cancers I-Disease 0 0.04847406968474388
. O 0 2.0478221074426983e-07

Homozygous O 0 0.00026562431594356894
Smad4 O 0 5.8873654779745266e-05
mutant O 0 4.304917456465773e-05
mice O 0 0.0019461771007627249
die O 0 0.010188279673457146
before O 0 4.932349284558768e-08
day O 0 1.7991636624969942e-08
7 O 0 4.107775453121576e-08
. O 0 4.6877918435939137e-08

5 O 0 1.3222444295024616e-06
of O 0 2.4110120122600165e-08
embryogenesis O 0 7.085700417519547e-06
. O 0 4.261320327714202e-07

Mutant O 0 9.433743798581418e-06
embryos O 0 4.643609372578794e-06
have O 0 2.9559949155100185e-08
reduced O 0 2.596326176274033e-08
size O 0 3.2081146628115675e-08
, O 0 3.1856757232162636e-08
fail O 0 3.704577693497413e-06
to O 0 4.998804037370519e-09
gastrulate O 0 4.77701041745604e-06
or O 0 2.7547018888185448e-08
express O 0 1.1459631465982056e-08
a O 0 1.1831243762472354e-09
mesodermal O 0 1.3356132910757879e-07
marker O 0 4.91767593757686e-07
, O 0 1.934797877467531e-09
and O 0 3.3997717974187935e-09
show O 0 6.427660537156044e-07
abnormal O 0 2.3679544938204344e-06
visceral O 0 1.5495692196054733e-07
endoderm O 0 3.0500430057145422e-06
development O 0 1.543827643502027e-08
. O 0 4.3231786150954576e-08

Growth B-Disease 1 0.9999998807907104
retardation I-Disease 1 1.0
of O 0 4.7367101352335794e-09
the O 0 4.889363136584279e-09
Smad4 O 0 0.0001296173722948879
- O 0 6.297016079770401e-05
deficient O 0 9.712355677038431e-05
embryos O 0 7.510597583859635e-07
results O 0 4.223374787670764e-07
from O 0 5.408313796806397e-10
reduced O 0 1.2087772560676058e-08
cell O 0 7.633398126927204e-07
proliferation O 0 9.048782168008529e-09
rather O 0 9.32233401584881e-10
than O 0 6.252132145334599e-10
increased O 0 4.969334721494079e-09
apoptosis O 0 5.311093076443285e-08
. O 0 4.764366678955412e-08

Aggregation O 0 7.352594820986269e-06
of O 0 5.431358918173146e-09
mutant O 0 4.2766768615365436e-07
Smad4 O 0 6.779393970646197e-06
ES O 0 5.808590799460944e-07
cells O 0 2.4103957940724285e-08
with O 0 4.961500099653904e-10
wild O 0 6.09339139145959e-08
- O 0 5.425048129836796e-06
type O 0 3.3720658620950417e-07
tetraploid O 0 5.533023340831278e-06
morulae O 0 1.761614294082392e-05
rescues O 0 4.437162260728655e-06
the O 0 1.3929561504255616e-08
gastrulation B-Disease 0 1.0443288374517579e-05
defect I-Disease 0 1.6148804206750356e-05
. O 0 6.521898399114434e-08

These O 0 2.733964095114061e-07
results O 0 1.1117822396045085e-06
indicate O 0 1.3473392179719212e-08
that O 0 5.710346084875084e-10
Smad4 O 0 6.945213044673437e-07
is O 0 4.1572703612935413e-10
initially O 0 1.1190490756263216e-09
required O 0 3.89740774375813e-11
for O 0 6.627573490014527e-12
the O 0 4.2279658940547193e-11
differentiation O 0 1.6102809363705006e-10
of O 0 1.3057868154808805e-11
the O 0 2.7385688161629673e-10
visceral O 0 1.9618742186366944e-08
endoderm O 0 5.472091402225487e-07
and O 0 4.958160548795831e-10
that O 0 2.6452538076648935e-11
the O 0 2.583943059519811e-10
gastrulation B-Disease 0 1.545858623330787e-07
defect I-Disease 0 4.84515787491091e-08
in O 0 3.4486535155364706e-11
the O 0 9.308825238418805e-11
epiblast O 0 2.3109789992759033e-07
is O 0 9.535473521893323e-10
secondary O 0 8.869837309077866e-09
and O 0 5.178044215625732e-09
non O 0 1.0765536728740699e-07
- O 0 6.603972906304989e-06
cell O 0 0.0001544820552226156
autonomous O 0 4.761521631735377e-05
. O 0 4.091691039320722e-07

Rescued O 0 0.0001579917734488845
embryos O 0 1.1276606528554112e-05
show O 0 2.2448470190283842e-05
severe O 0 9.036488336278126e-05
anterior O 0 0.00020378806220833212
truncations O 0 5.381068694987334e-05
, O 0 2.495443673922182e-08
indicating O 0 1.170657792926022e-08
a O 0 1.0472568368058432e-09
second O 0 2.3929201731220928e-08
important O 0 1.3106805918372544e-10
role O 0 8.116208816133508e-10
for O 0 4.6548917498334674e-10
Smad4 O 0 2.435463329675258e-06
in O 0 5.4413855643531406e-09
anterior O 0 2.4934632165241055e-05
patterning O 0 3.841505531454459e-05
during O 0 1.2375586777579883e-07
embryogenesis O 0 1.2328249567872263e-06
. O 0 6.42285655771957e-08

Prevalence O 0 0.00017713892157189548
of O 0 1.4574268902833865e-08
p16 O 0 7.960143193486147e-07
and O 0 1.1443577641045977e-08
CDK4 O 0 8.456095201836433e-06
germline O 0 3.316395577712683e-06
mutations O 0 1.564768467687827e-06
in O 0 1.8882020391686183e-09
48 O 0 6.680152750959678e-07
melanoma B-Disease 1 0.9732996821403503
- O 0 0.025356145575642586
prone O 0 0.030342482030391693
families O 0 3.0029632114292326e-08
in O 0 9.86680515069338e-09
France O 0 3.253094473620877e-05
. O 0 1.0716818366063308e-07

The O 0 2.7603252306107606e-07
French O 0 2.175379813706968e-05
Familial B-Disease 0 0.03522168844938278
Melanoma I-Disease 1 0.9995649456977844
Study O 0 3.917742503745103e-07
Group O 0 1.4451745755650336e-06
. O 0 1.4146390014957433e-07

Germline O 0 0.0005945593002252281
mutations O 0 0.00010369340452598408
in O 0 2.4173836266072612e-09
the O 0 4.5798670411656417e-10
p16 O 0 3.614204402424548e-08
and O 0 2.2177786274113487e-09
CDK4 O 0 2.5222659587598173e-06
genes O 0 8.505024595706345e-08
have O 0 1.018005058028848e-08
been O 0 3.2579685615985454e-09
reported O 0 8.555021224765369e-08
in O 0 1.0537697450740957e-11
a O 0 1.3880217808459605e-10
subset O 0 4.52606352396856e-09
of O 0 7.612963037750831e-10
melanoma B-Disease 0 0.0005884256097488105
pedigrees O 0 7.784161084600782e-07
, O 0 4.800339681310106e-09
but O 0 1.5479431070275496e-09
their O 0 1.5750879711617927e-08
prevalence O 0 2.8848171496065333e-07
is O 0 6.506573058118192e-10
not O 0 8.354063552040714e-10
well O 0 5.630206856288567e-10
known O 0 5.088906629424628e-09
. O 0 2.45417961508565e-08

We O 0 3.1212633189170447e-07
searched O 0 6.264516372311846e-08
for O 0 2.6029481348111005e-10
such O 0 7.335317769863181e-11
germline O 0 1.4589350882943108e-07
mutations O 0 1.0500760083687055e-07
in O 0 3.86049886502704e-10
48 O 0 3.437927276195296e-08
French O 0 5.183984740142478e-06
melanoma B-Disease 1 0.9822201728820801
- O 0 0.0002603681059554219
prone O 0 5.4490559705300257e-05
families O 0 1.6296579641306153e-09
selected O 0 1.0747124301602184e-09
according O 0 2.2068444294198741e-10
to O 0 2.6313612400130637e-10
two O 0 1.4856803287610632e-10
major O 0 5.423416160610373e-10
criteria O 0 9.288929070372376e-10
families O 0 2.3817694344563378e-11
with O 0 1.1356871693068982e-10
at O 0 6.278644093526964e-08
least O 0 1.4849217411239124e-09
three O 0 1.8036707682966835e-09
affected O 0 9.503553499712325e-10
members O 0 1.9639156620399056e-11
( O 0 1.627671261661412e-11
n O 0 3.8172807137470954e-08
= O 0 6.233336335981221e-08
20 O 0 3.4234184376202847e-09
) O 0 6.967162263782356e-11
or O 0 2.3385617886617638e-09
families O 0 4.900000891150391e-11
with O 0 2.0258328348177201e-10
two O 0 1.876731303696033e-08
affected O 0 5.062863017712971e-09
members O 0 4.4328655329772815e-11
, O 0 2.228092189915376e-11
one O 0 3.0659565164459224e-11
of O 0 4.035737022345387e-12
them O 0 5.852490714275405e-10
affected O 0 4.80788797663223e-10
before O 0 8.870204570854412e-10
the O 0 2.8213898231599366e-11
age O 0 4.909262232843936e-11
of O 0 1.913041773604629e-12
50 O 0 1.5302059619415331e-10
( O 0 8.394037548375977e-11
n O 0 1.081325962104529e-07
= O 0 1.9493401737236127e-07
28 O 0 9.489866670264746e-08
) O 0 1.3668831344570975e-10
, O 0 3.405585258242638e-10
and O 0 4.320849233963031e-10
one O 0 5.387074675233805e-10
additional O 0 3.0228970437917724e-09
minor O 0 1.0244249892821244e-08
criterion O 0 2.0130553934905038e-07
. O 0 2.5666361480602973e-08

Sixteen O 0 1.178022330350359e-06
different O 0 1.9205332435490163e-08
p16 O 0 7.225971216939797e-07
germline O 0 3.6906697005179012e-06
mutations O 0 6.187812232383294e-06
were O 0 8.974768483938078e-09
found O 0 1.819836170646738e-09
in O 0 3.5002453713239845e-10
21 O 0 9.08736996763082e-09
families O 0 1.390700887782259e-10
, O 0 2.2643721619974855e-10
while O 0 8.158176356687363e-10
one O 0 9.123802269250803e-10
germline O 0 7.034658722204767e-08
mutation O 0 2.3463101683773857e-08
, O 0 6.353678694281939e-10
Arg24His O 0 7.231554945974494e-07
, O 0 7.157462955653671e-10
was O 0 5.8288316395760376e-09
detected O 0 2.7044679384857773e-08
in O 0 1.2431378149102557e-10
the O 0 9.9369446004971e-10
CDK4 O 0 9.92657987808343e-06
gene O 0 3.7045668932478293e-07
. O 0 3.065352771614016e-08

The O 0 2.776328500431191e-08
frequency O 0 8.699161924141663e-08
of O 0 1.945877348141778e-10
p16 O 0 1.4483624077854529e-08
gene O 0 1.9607185208769806e-08
mutation O 0 2.382900099462404e-08
in O 0 2.340854454718766e-10
our O 0 1.4746648346886104e-09
sample O 0 2.9881863650160767e-09
( O 0 1.5044292200894205e-10
44 O 0 1.1944022437759827e-09
% O 0 1.247791314717972e-10
) O 0 6.111843670053574e-11
is O 0 5.7337211367691765e-11
among O 0 5.54381193729192e-12
the O 0 8.016539515542931e-11
highest O 0 3.182396213219363e-08
rates O 0 2.9060075235065597e-07
yet O 0 1.5935876618300426e-08
reported O 0 2.703896200273448e-07
and O 0 1.244708364156466e-10
the O 0 6.6640200302448e-11
CDK4 O 0 1.6877343114174437e-06
mutation O 0 6.334647917327629e-09
is O 0 2.0614659285156378e-11
the O 0 2.6749397835645894e-11
second O 0 2.580409663721639e-08
mutation O 0 8.746825486127818e-09
detected O 0 1.9359875480517985e-08
in O 0 1.8684919930733734e-11
this O 0 5.0603094631229695e-11
gene O 0 1.9623422886638764e-08
worldwide O 0 3.1414590040412804e-08
. O 0 3.193505193621604e-08

In O 0 7.026504817986279e-07
summary O 0 1.8093132894136943e-05
, O 0 3.691038941155966e-08
our O 0 3.4271835147592355e-08
results O 0 1.4945470638849656e-07
show O 0 1.6879253550428075e-08
frequent O 0 3.289407191076066e-09
involvement O 0 1.360814905204677e-09
of O 0 1.3834908045573524e-11
the O 0 3.858943026235906e-11
p16 O 0 2.5267752334912075e-09
gene O 0 7.150357195229162e-09
in O 0 1.4114512336682594e-10
familial B-Disease 0 4.24396239395719e-05
melanoma I-Disease 1 0.9999370574951172
and O 0 2.029242551770949e-07
confirm O 0 9.587106433173176e-07
the O 0 8.204111001663961e-11
role O 0 4.1515413329307194e-10
of O 0 1.4231774612960546e-11
the O 0 1.3971429568826466e-10
CDK4 O 0 2.0730701066895563e-07
gene O 0 2.012792599259683e-09
as O 0 9.296120817570142e-11
a O 0 3.743046317339349e-09
melanoma B-Disease 0 0.0002934251388069242
- O 0 1.9042868188989814e-06
predisposing O 0 1.0953309583783266e-06
gene O 0 8.904767128115054e-07
. O 0 5.252298596047922e-09
. O 0 2.656365971631658e-08

Progression O 0 0.0005324116791598499
of O 0 4.790445728986015e-08
somatic O 0 3.523025952745229e-06
CTG O 0 0.0001272598165087402
repeat O 0 1.8477096091373824e-05
length O 0 1.5220345517263922e-07
heterogeneity O 0 2.0901303798837034e-07
in O 0 6.146380071569979e-10
the O 0 8.325780620488388e-10
blood O 0 3.394134182599373e-07
cells O 0 2.2275148694461677e-06
of O 0 8.080719737790787e-08
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 0 0.0002048630703939125
. O 0 3.9487890290956784e-08

The O 0 2.2403428445727513e-08
genetic O 0 2.928863978013396e-07
basis O 0 7.781416400121088e-08
of O 0 3.3188084103130677e-07
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.05139319226145744
DM B-Disease 1 1.0
) O 0 1.0931040961281724e-08
is O 0 1.2409441529914744e-10
the O 0 1.1434876483196188e-11
expansion O 0 2.687029487802306e-10
of O 0 4.5582607133276554e-11
an O 0 2.7718294326462e-09
unstable O 0 3.1836232665227726e-05
CTG O 0 1.24132839118829e-05
repeat O 0 2.4740661501709837e-06
in O 0 1.173186964242845e-10
the O 0 8.269434442764734e-11
34 O 0 1.3314891411653207e-09
UTR O 0 3.858154329350327e-08
of O 0 1.058221565930495e-10
the O 0 2.251300124100908e-08
DM B-Disease 1 0.9999997615814209
protein O 0 1.5853325763259818e-08
kinase O 0 2.8293104747945108e-08
gene O 0 1.5140480869035855e-08
on O 0 7.471787633051008e-09
chromosome O 0 5.0722692321869545e-06
19 O 0 1.1353357365351258e-07
. O 0 1.5577088063878364e-08

One O 0 3.8059756235497844e-08
of O 0 2.484337735531028e-10
the O 0 2.501650830932789e-10
principal O 0 4.162906019899992e-09
features O 0 3.7407765773878054e-09
of O 0 2.605431426161431e-10
the O 0 2.2634510798980045e-07
DM B-Disease 1 1.0
mutation O 0 2.5323888053208066e-07
is O 0 1.248712799828411e-10
an O 0 6.602330487881503e-11
extraordinarily O 0 8.351868530098727e-09
high O 0 5.747347486817489e-09
level O 0 1.394178106295385e-09
of O 0 6.374116512386507e-11
somatic O 0 2.8932419127158937e-08
mosaicism O 0 6.644876293648849e-07
, O 0 1.2391258019661677e-09
due O 0 1.479107170077043e-09
to O 0 1.1329790439162934e-09
an O 0 3.936827808193044e-10
extremely O 0 5.127958502271213e-09
high O 0 3.4140155147355244e-09
degree O 0 4.127620023552936e-09
of O 0 2.9066465900839944e-10
somatic O 0 5.551282242777233e-07
instability O 0 1.2876357402547e-07
both O 0 1.0772633896038997e-09
within O 0 6.069710845046927e-10
and O 0 1.2636955926126348e-09
between O 0 1.8537472945556743e-10
different O 0 3.98197474993367e-09
tissues O 0 1.0320087540094391e-06
. O 0 3.8223806342330136e-08

This O 0 1.0475834244516591e-07
instability O 0 2.088946615685927e-07
appears O 0 2.9488546715583652e-08
to O 0 1.7977391797430187e-09
be O 0 7.405738244870008e-10
biased O 0 2.691104761254337e-08
towards O 0 2.5063312536488525e-10
further O 0 7.686672826023866e-11
expansion O 0 1.747536559904006e-10
and O 0 4.3866918431056945e-10
continuous O 0 1.4387661062542634e-09
throughout O 0 1.5058788938038248e-10
the O 0 7.948845748284583e-11
life O 0 1.1509980468726866e-10
of O 0 2.3081280810244298e-12
an O 0 3.830081390931994e-11
individual O 0 2.2491850396044732e-11
, O 0 6.987057460383639e-11
features O 0 6.618273928893359e-09
that O 0 1.0297181773921693e-08
could O 0 6.980086908470184e-08
be O 0 5.471856856509305e-10
associated O 0 1.7438805954839154e-10
with O 0 1.5165409206208125e-10
the O 0 1.4557813843296685e-09
progressive O 0 4.756739357958395e-08
nature O 0 2.2395727494739504e-09
of O 0 5.645430650735861e-11
the O 0 1.1822519851989455e-08
disease O 0 4.922739208268467e-06
. O 0 1.168389207606424e-08

Although O 0 1.9225018377255765e-07
increasing O 0 2.04555927751926e-08
measured O 0 7.74979298512335e-08
allele O 0 3.4068824561472866e-07
size O 0 4.6691503996498795e-08
between O 0 1.6020049287135407e-08
patients O 0 6.767416493858036e-07
clearly O 0 3.872351772571392e-09
correlates O 0 3.0206839252144846e-09
with O 0 8.028658293746105e-11
an O 0 2.914718744140288e-10
increased O 0 2.1977694331098974e-08
severity O 0 3.993267455371097e-06
of O 0 4.5063890397045725e-09
symptoms O 0 0.0001344432239420712
and O 0 7.224115056159164e-11
an O 0 1.1973601277137647e-10
earlier O 0 3.033838993360405e-07
age O 0 5.447544193515341e-09
of O 0 8.722609440292572e-11
onset O 0 3.301823525703185e-08
, O 0 1.342612410137889e-10
this O 0 3.529230727106203e-11
correlation O 0 5.932989655121901e-09
is O 0 1.7018511044852858e-09
not O 0 2.5129047731553555e-09
precise O 0 3.939465216262761e-07
and O 0 8.56958504158456e-09
measured O 0 8.384432703678613e-08
allele O 0 2.139590264960134e-07
length O 0 5.94611094584252e-07
cannot O 0 3.2399194083154725e-07
be O 0 1.4227548306156024e-10
used O 0 1.8794985012782206e-10
as O 0 2.1662581450865304e-10
an O 0 2.3659776915430086e-10
accurate O 0 1.1481179171823896e-06
predictor O 0 3.6403474950930104e-05
of O 0 1.2575666064051916e-09
age O 0 2.4941114062926317e-08
of O 0 2.2473090055541434e-09
onset O 0 1.5967784747772384e-06
. O 0 1.0886808610166554e-07

In O 0 9.906806042181415e-08
order O 0 9.706797143849144e-09
to O 0 3.034103190913129e-09
further O 0 3.785044722093289e-09
characterize O 0 1.3183571923036652e-07
the O 0 2.697846168686624e-09
dynamics O 0 8.310523753607413e-07
of O 0 2.8627979986595165e-08
DM B-Disease 1 1.0
CTG O 0 0.00016966211842373013
repeat O 0 4.748680566990515e-06
somatic O 0 2.2544375610777934e-07
instability O 0 1.2499656065756426e-07
, O 0 5.227620003545042e-10
we O 0 8.90417461985038e-10
have O 0 7.80777942299693e-11
studied O 0 5.59385593401629e-10
repeat O 0 7.026451953606738e-08
length O 0 6.232038884945723e-09
changes O 0 5.333695152209827e-10
over O 0 1.0992394494646618e-10
time O 0 1.1877006045324379e-09
in O 0 1.717860631522683e-09
111 O 0 1.4919637578714173e-06
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 0 1.5380984450530377e-06
with O 0 1.5598390634696813e-10
varying O 0 2.5788747137767132e-08
clinical O 0 6.403810175470426e-07
severity O 0 6.023836249369197e-06
and O 0 1.625464918220132e-08
CTG O 0 1.0962820852000732e-05
repeat O 0 7.352065267696162e-07
size O 0 1.3315019087301039e-09
over O 0 1.6437902150556738e-09
time O 0 1.5167181954822695e-09
intervals O 0 3.513691781975581e-09
of O 0 1.603986908571553e-11
1 O 0 4.856980151402013e-09
- O 0 1.604418429224097e-07
7 O 0 4.5366444823002894e-08
years O 0 5.1844675219570036e-09
. O 0 7.629073373038864e-09

We O 0 1.4420863408304285e-05
have O 0 3.3714233627080148e-09
found O 0 1.7725189371819994e-10
a O 0 1.2725134834745688e-10
direct O 0 5.83148951349699e-09
progression O 0 4.3381831460465037e-07
of O 0 3.076512308797241e-11
the O 0 3.3053676462557746e-10
size O 0 2.437877233418817e-09
heterogeneity O 0 6.84239154224997e-08
over O 0 2.6784654494349525e-09
time O 0 2.5903148515027397e-09
related O 0 6.575339717151962e-10
to O 0 2.0921351318037296e-09
initial O 0 1.5036217604347257e-08
CTG O 0 4.6246927354332e-07
repeat O 0 7.531628654078304e-08
size O 0 8.251036520690036e-10
and O 0 1.7584006473114755e-09
the O 0 1.927606824159156e-10
time O 0 6.1893223879394554e-09
interval O 0 1.2663528003997726e-08
and O 0 2.667605691897279e-09
always O 0 2.671847409985162e-09
biased O 0 1.8749028996012385e-08
towards O 0 3.8430725268767674e-10
further O 0 7.106071842066797e-10
expansion O 0 9.550803703461952e-09
. O 0 4.20831725023163e-08

Attempts O 0 2.0597183265635977e-06
to O 0 4.215925741846149e-08
mathematically O 0 2.873477455977991e-07
model O 0 8.173396182087345e-09
the O 0 1.2849308284046401e-09
dynamics O 0 1.4186435919327778e-06
have O 0 6.766027293991783e-09
proved O 0 5.822864412863282e-09
only O 0 1.793392240267977e-10
partially O 0 2.8733122547919265e-08
successful O 0 1.5991589163988351e-09
suggesting O 0 5.652965318070358e-10
that O 0 9.347500204426318e-12
individual O 0 5.855365237811272e-12
specific O 0 8.854868227547996e-11
genetic O 0 6.115233475156856e-08
and O 0 1.0140095696442586e-07
/ O 0 0.003171820193529129
or O 0 5.639896016873536e-07
environmental O 0 4.432650246855019e-09
factors O 0 6.937290186748157e-10
also O 0 1.2268054350172974e-09
play O 0 1.5526150365374747e-09
a O 0 2.9397370648887033e-10
role O 0 6.768992588668254e-10
in O 0 3.965821004925374e-10
somatic O 0 3.034978846017111e-08
mosaicism O 0 7.59190015742206e-07
. O 0 2.4864343917130327e-09
. O 0 1.2491357281874116e-08

Aspartylglucosaminuria B-Disease 1 0.9999979734420776
among O 0 3.5871804016096576e-07
Palestinian O 0 5.1503084250725806e-06
Arabs O 0 3.995483893959317e-06
. O 0 1.3317277591795573e-07

Aspartylglucosaminuria B-Disease 1 1.0
( O 0 0.07843738049268723
AGU B-Disease 1 1.0
) O 0 3.344792887105541e-08
is O 0 2.909719687416157e-10
a O 0 5.694760218943884e-10
rare O 0 1.2343968514016979e-08
disorder B-Disease 0 1.975660961761605e-05
of I-Disease 0 1.1691213275266676e-10
glycoprotein I-Disease 0 5.49457183751656e-07
metabolism I-Disease 0 0.0002421949611743912
caused O 0 3.851203302929207e-07
by O 0 2.979232971433987e-10
the O 0 1.0856509469192588e-08
deficiency B-Disease 0 1.5246874681906775e-05
of I-Disease 0 2.177869516672981e-11
the I-Disease 0 1.1741276839671855e-09
lysosomal I-Disease 0 3.655507725852658e-06
enzyme I-Disease 0 4.7065253738765023e-07
aspartylglucosaminidase I-Disease 0 2.0492650492087705e-06
( O 0 2.013967881353551e-09
AGA O 0 3.192251369910082e-07
) O 0 1.090708945383767e-08
. O 0 3.305862961155981e-08

AGU B-Disease 1 0.9999997615814209
is O 0 4.51583872518313e-07
inherited O 0 6.33987565379357e-06
as O 0 1.3869533299626369e-09
an O 0 1.3863925563128987e-09
autosomal O 1 0.8835552930831909
recessive O 1 0.5129960179328918
trait O 0 8.835168409859762e-05
and O 0 4.950114984580978e-08
occurs O 0 1.0425672547498266e-09
with O 0 1.5772379929890334e-11
a O 0 8.819207031329768e-10
high O 0 1.0474032308138703e-08
frequency O 0 3.2050297704699915e-07
in O 0 1.3013084831925426e-08
Finland O 0 2.6872667149291374e-05
because O 0 1.3594633196944983e-09
of O 0 9.181191397422683e-12
a O 0 7.807142710092307e-10
founder O 0 1.2208053590256895e-07
effect O 0 2.3831319140299456e-08
. O 0 1.7906801375033865e-08

While O 0 5.912692131460062e-07
very O 0 6.163546117932128e-09
few O 0 2.5981676810005183e-09
patients O 0 4.285896082478757e-08
with O 0 1.401144622548145e-08
AGU B-Disease 1 1.0
have O 0 7.296035420267799e-08
been O 0 3.3063591864390673e-09
reported O 0 1.8596637119117077e-07
from O 0 2.7907132160720494e-10
non O 0 2.064191839679097e-08
- O 0 4.6624364813396824e-07
Finnish O 0 9.631691000322462e-07
origin O 0 2.3886657984917292e-08
, O 0 7.836163717911404e-09
we O 0 6.71392612616728e-08
diagnosed O 0 1.245878138433909e-06
the O 0 1.1733010396586252e-10
disorder O 0 2.0786686150131573e-07
in O 0 8.098142989521051e-11
8 O 0 6.224234017082608e-09
patients O 0 1.1271571453974616e-09
originating O 0 4.575143597307374e-10
from O 0 4.6140974374608845e-10
3 O 0 4.3928145565530485e-09
unrelated O 0 1.6831831928243446e-08
families O 0 1.7837390453578905e-09
, O 0 4.0232903120163144e-10
all O 0 1.7093780557697613e-10
Palestinian O 0 6.307679711881065e-08
Arabs O 0 1.930655280091287e-08
from O 0 3.829075667649562e-10
the O 0 3.7124778251573787e-10
region O 0 1.7933278684267862e-07
of O 0 8.494721037699549e-10
Jerusalem O 0 0.004158985801041126
. O 0 1.590101192050497e-06

The O 0 9.680398704858817e-08
clinical O 0 1.3381267081058468e-06
diagnosis O 0 0.00035667535848915577
of O 0 1.9248091120971367e-08
AGU B-Disease 1 1.0
is O 0 6.864469526135508e-08
often O 0 4.293535749155808e-09
difficult O 0 6.683706477161877e-09
, O 0 1.160935098054594e-10
in O 0 3.707685200526889e-11
particular O 0 1.0463059585408274e-10
early O 0 2.436850055076434e-09
in O 0 9.442441273321833e-11
the O 0 1.1580644776465476e-10
course O 0 1.6625426368932494e-08
of O 0 1.5942540690372375e-11
the O 0 1.6281045400745597e-09
disease O 0 9.082639849111729e-07
, O 0 1.0695627716827971e-10
and O 0 1.6465004359922375e-10
most O 0 8.69254408036868e-12
of O 0 4.5839525751600885e-12
the O 0 7.081352171312005e-10
patients O 0 1.9419713837010022e-08
are O 0 4.320602209340052e-10
diagnosed O 0 8.990463129521231e-07
after O 0 7.650854949581287e-10
the O 0 1.9933642236846794e-10
age O 0 1.1239948971564218e-09
of O 0 3.0832503217226304e-11
5 O 0 1.4715328511272219e-08
years O 0 4.615649196182403e-09
. O 0 1.8103856191942214e-08

However O 0 3.5176910273548856e-07
, O 0 3.067240239573721e-09
since O 0 1.2623416756341044e-09
these O 0 1.1563165008832144e-10
patients O 0 1.2096529333760486e-09
excrete O 0 3.6317269191954438e-09
early O 0 1.797789694890639e-10
large O 0 4.2159432195321145e-11
amounts O 0 3.8082301201392e-10
of O 0 7.523146688948046e-11
aspartylglucosamine O 0 6.518516215692216e-07
in O 0 3.9223924108711117e-10
urine O 0 4.1611695422716366e-08
, O 0 5.6909785911551936e-11
biochemical O 0 4.247439622240279e-10
screening O 0 1.8201554707886203e-09
is O 0 2.6328120239504926e-10
easy O 0 1.484271194840403e-08
by O 0 3.04766795133915e-10
urine O 0 7.225971643265439e-08
chromatography O 0 1.4261469338805455e-08
. O 0 1.5758594429371442e-09
. O 0 7.392518153181982e-09

Detection O 0 1.2583082025230397e-06
of O 0 6.159574184039229e-09
heterozygous O 0 2.524994897612487e-07
carriers O 0 5.651289569641449e-08
of O 0 3.4114511215932453e-09
the O 0 4.945611726725474e-05
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 5.376558078751259e-07
ATM O 0 1.1508450370456558e-05
) O 0 5.708680195226634e-10
gene O 0 8.911603899264264e-09
by O 0 5.262494329194567e-10
G2 O 0 1.8552207166067092e-06
phase O 0 1.130465179244311e-07
chromosomal O 0 0.00016292350483126938
radiosensitivity O 0 2.4131339159794152e-05
of O 0 4.037405965107155e-09
peripheral O 0 5.896372385905124e-05
blood O 0 5.699089160771109e-05
lymphocytes O 0 1.5161574083322193e-05
. O 0 1.2541877936200763e-07

In O 0 0.012456180527806282
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 0.003285110229626298
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 4.979906975677295e-08
patients O 0 4.0699898562479575e-08
, O 0 3.232617645787528e-11
mutations O 0 2.4944526444414805e-09
in O 0 1.9272566181838258e-11
a O 0 1.1575655017859177e-10
single O 0 4.790808638688304e-09
gene O 0 1.4035252071664672e-08
, O 0 3.7648967277092993e-10
ATM O 0 2.370444235566538e-06
, O 0 2.477973104486608e-10
result O 0 8.075196622492342e-10
in O 0 9.097544939606905e-10
an O 0 2.353396121179685e-05
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
syndrome I-Disease 1 1.0
that O 0 8.962523878608408e-08
embraces O 0 2.1595731425350095e-08
a O 0 3.4813227300922733e-10
variety O 0 4.196506753206819e-10
of O 0 5.044341680471298e-11
clinical O 0 5.844684292100055e-09
features O 0 3.899272371654661e-08
and O 0 9.885760476890937e-08
manifests O 0 7.737475016256212e-07
extreme O 0 1.7873839297521954e-08
radiosensitivity O 0 1.1559160384422285e-06
and O 0 3.2239558245272804e-10
a O 0 8.824087016634508e-10
strong O 0 2.0367869613124867e-09
pre O 0 1.5325462072723894e-06
- O 0 2.2233965864870697e-05
disposition O 0 2.8997201297897846e-05
to O 0 2.82033511211921e-07
malignancy B-Disease 0 2.7735086405300535e-05
. O 0 5.434791816583129e-08

Heterozygotes O 0 8.68723655003123e-05
for O 0 1.327113707816352e-08
the O 0 1.1416255718543766e-09
ATM O 0 1.8328393025512923e-06
gene O 0 1.1627827944948876e-07
have O 0 1.476021194157795e-09
no O 0 3.126315317736328e-10
clinical O 0 6.271911878741321e-10
expression O 0 2.3570909113423966e-10
of O 0 3.512591051357816e-10
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
but O 0 3.1117604066821514e-06
may O 0 3.001320294515608e-07
be O 0 3.6330640718063023e-09
cancer B-Disease 0 1.4089881972267904e-07
prone O 0 1.89603426292706e-08
with O 0 3.425622979724707e-11
a O 0 1.3568390855311918e-09
moderate O 0 5.392045210328433e-08
increase O 0 2.8265960683171443e-09
in O 0 2.5487542631985605e-10
in O 0 2.051012026882404e-09
vitro O 0 8.235256814259628e-07
radiosensitivity O 0 9.335059985460248e-06
. O 0 2.8415492181466107e-08

We O 0 1.3065980510873487e-06
performed O 0 8.924042305125113e-08
a O 0 7.420120962109422e-09
blind O 0 1.6514235312570236e-07
chromosomal O 0 6.866072362754494e-05
analysis O 0 2.3327446641019378e-08
on O 0 5.668843172657034e-08
G2 O 0 6.463703357439954e-06
- O 0 8.32181683563249e-07
phase O 0 4.570081202359688e-08
lymphocytes O 0 3.817681104578696e-08
from O 0 1.9062217082588262e-10
7 O 0 1.3832863743346024e-09
unrelated O 0 2.035044310844114e-08
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 3.2668676794855855e-06
, O 0 3.48647083425746e-11
13 O 0 2.0877091722049101e-10
obligate O 0 6.029927668294022e-09
A B-Disease 1 0.9999959468841553
- I-Disease 1 0.9999983310699463
T I-Disease 1 1.0
heterozygotes O 0 4.227338195050834e-06
( O 0 3.902073109074422e-10
parents O 0 9.060983907627218e-11
of O 0 3.72495784217719e-12
the O 0 9.051763782963462e-10
patients O 0 6.805203955906336e-09
) O 0 5.071150444013739e-11
, O 0 2.2079811590192122e-10
and O 0 2.1742401212776485e-09
14 O 0 1.863966314630261e-09
normal O 0 1.0672875028205908e-08
controls O 0 1.1738129757077331e-07
following O 0 8.925037930929136e-10
X O 0 3.5740202974920976e-07
- O 0 2.564957668482748e-08
irradiation O 0 1.4990515495583168e-08
with O 0 2.742123195176305e-10
1 O 0 2.2053727732895823e-09
Gy O 0 1.6790573909020168e-07
in O 0 3.1755518353770995e-11
order O 0 2.447954616791037e-10
to O 0 5.7931948127532e-10
evaluate O 0 1.9911992055199335e-09
this O 0 8.811232993233276e-11
cytogenetic O 0 1.736755805836765e-08
method O 0 3.4758423916869674e-10
as O 0 3.043002308467102e-11
a O 0 4.565029951275612e-11
tool O 0 8.651367400247523e-10
for O 0 5.280166581744794e-11
detection O 0 1.4321813734952116e-09
of O 0 3.358534006459024e-10
ATM O 0 0.0002625335182528943
carriers O 0 9.817940735956654e-07
. O 0 7.082844177830339e-08

Both O 0 1.0963531167362817e-06
A B-Disease 1 0.9999604225158691
- I-Disease 1 0.9999914169311523
T I-Disease 1 1.0
homozygotes O 0 0.00047836219891905785
and O 0 8.771602111323773e-09
heterozygotes O 0 4.815087777387816e-07
showed O 0 3.156823780159357e-08
significantly O 0 1.275613215057092e-08
increased O 0 1.0427144703228919e-09
levels O 0 5.950915871189011e-10
of O 0 1.923515374757656e-10
radiation O 0 2.3769503059156705e-06
- O 0 5.021430479246192e-05
induced O 0 5.902544216951355e-05
chromatid O 0 0.0014490879839286208
damage O 0 4.129056469537318e-05
relative O 0 1.5376768303099198e-08
to O 0 4.796788299898935e-09
that O 0 1.891268391895906e-10
of O 0 1.719587389148458e-10
normal O 0 3.8613649167018593e-07
controls O 0 7.672775973333046e-05
. O 0 2.413593733763264e-07

These O 0 1.6555058834910596e-07
results O 0 2.9264793965921854e-07
show O 0 4.607293213609864e-09
that O 0 4.3252255943482254e-11
the O 0 7.839175836243939e-11
G2 O 0 1.905002875446371e-07
- O 0 5.836744776388514e-08
phase O 0 7.841157056986958e-09
chromosomal O 0 2.472216920068604e-06
radiosensitivity O 0 1.9267233142272744e-07
assay O 0 5.287874671466852e-08
can O 0 8.354987812708714e-10
be O 0 9.21424308381047e-12
used O 0 1.471982605250055e-11
for O 0 7.612041205695697e-12
the O 0 1.4126894966326464e-11
detection O 0 1.4396802638927397e-09
of O 0 7.138198365730375e-10
A B-Disease 1 1.0
- I-Disease 1 0.9999995231628418
T I-Disease 1 1.0
heterozygotes O 0 7.034483860479668e-05
. O 0 1.0420394147558909e-07

In O 0 1.1650621800640693e-08
combination O 0 9.782238130640053e-09
with O 0 1.9684393004482104e-10
molecular O 0 9.007179890829775e-09
genetic O 0 4.308316476908658e-07
analyses O 0 1.902094766137452e-07
, O 0 1.352542189358985e-09
this O 0 5.623778109864475e-10
test O 0 1.892813905612911e-09
may O 0 3.020418803956204e-09
be O 0 3.351601982060082e-11
of O 0 1.2539145069490054e-12
value O 0 1.077571698537838e-09
in O 0 7.360151377255875e-11
studies O 0 6.911479721871672e-11
of O 0 2.6168451086605593e-11
familial B-Disease 0 3.1998151825973764e-06
and I-Disease 0 1.9625636582532024e-07
sporadic I-Disease 0 8.454934686596971e-06
cancers I-Disease 0 2.38822049141163e-05
aimed O 0 5.443773432034504e-09
at O 0 6.753948156301703e-08
determination O 0 2.584787273107736e-09
of O 0 1.062575635119023e-11
the O 0 5.3082996331887955e-11
potential O 0 4.5381631785801346e-10
involvement O 0 3.633588985252345e-10
of O 0 4.176047702086905e-11
ATM O 0 1.5621573766111396e-05
mutations O 0 5.0673679652391e-07
in O 0 1.1632320662258167e-09
tumor B-Disease 0 1.214574422192527e-05
risk O 0 4.240539510647068e-07
or O 0 3.1597632954571964e-08
development O 0 2.0204085071640066e-09
. O 0 6.780819461482679e-09
. O 0 4.928380903379548e-08

Ataxia B-Disease 1 1.0
- I-Disease 1 0.9999997615814209
telangiectasia I-Disease 1 1.0
: O 0 6.727873937961704e-07
identification O 0 2.7523594070544277e-08
and O 0 3.3238156671444585e-10
detection O 0 2.183053737780938e-09
of O 0 8.90600440617284e-11
founder O 0 1.16157913510051e-07
- O 0 2.7320297704136465e-06
effect O 0 1.3498063822225959e-07
mutations O 0 6.923998085994754e-08
in O 0 3.068612378087643e-11
the O 0 5.557291779534346e-11
ATM O 0 7.1297677095572e-07
gene O 0 1.4029176931273923e-08
in O 0 2.0870563610664306e-10
ethnic O 0 8.00126045419347e-08
populations O 0 1.427540894383128e-07
. O 0 3.618833233076657e-08

To O 0 9.519671095858939e-08
facilitate O 0 1.2492430201405114e-08
the O 0 7.230487319986878e-10
evaluation O 0 1.4930925384959437e-09
of O 0 4.3177739161848194e-11
ATM O 0 1.2635535995286773e-06
heterozygotes O 0 6.45363016360534e-08
for O 0 1.0346211387624038e-10
susceptibility O 0 2.1018353280055635e-08
to O 0 2.8765458903734498e-09
other O 0 2.1764350321973325e-09
diseases O 0 2.476136160112219e-06
, O 0 1.7143052255530478e-10
such O 0 5.467660005309405e-11
as O 0 5.7871378800200546e-08
breast B-Disease 0 0.00013672048225998878
cancer I-Disease 0 1.2542477634269744e-05
, O 0 6.013480380318015e-09
we O 0 1.3920000263567545e-08
have O 0 1.4112683244249524e-10
attempted O 0 3.743890530927274e-08
to O 0 7.582068306533074e-10
define O 0 1.1037569747074372e-09
the O 0 2.0166640926633228e-11
most O 0 1.3683144894915955e-11
common O 0 1.1462723131794306e-10
mutations O 0 7.301600213338588e-09
and O 0 8.535287060462693e-11
their O 0 1.1268497246419429e-09
frequencies O 0 5.731558303523343e-07
in O 0 1.379868081130553e-05
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 3.3349686418659985e-05
A B-Disease 1 1.0
- I-Disease 1 0.9999997615814209
T I-Disease 1 1.0
) O 0 1.2136216476221762e-08
homozygotes O 0 5.262168656372523e-07
from O 0 3.680728777322173e-10
10 O 0 3.8031197635568503e-10
ethnic O 0 1.90520950127393e-08
populations O 0 5.071699860081935e-08
. O 0 4.5178808250057045e-08

Both O 0 4.262490449491452e-08
genomic O 0 8.744057709009212e-07
mutations O 0 2.5000013920362107e-05
and O 0 2.376282637328586e-08
their O 0 9.2061407386268e-09
effects O 0 2.621345096542882e-08
on O 0 1.4660167302338323e-08
cDNA O 0 2.3752048150527116e-07
were O 0 1.1359418294887291e-08
characterized O 0 4.644618201155026e-08
. O 0 2.599904114219953e-08

Protein O 0 5.772536496806424e-06
- O 0 4.3229742914263625e-06
truncation O 0 3.662458766484633e-06
testing O 0 1.4408128024001599e-08
of O 0 2.1261414503981335e-11
the O 0 3.4261066206298096e-11
entire O 0 2.0647854537259036e-09
ATM O 0 2.8283321285016427e-07
cDNA O 0 6.890719106422694e-08
detected O 0 1.274896135328163e-07
92 O 0 2.436357338098105e-09
( O 0 2.1113437387310086e-10
66 O 0 8.518413530111957e-09
% O 0 7.828465653503258e-10
) O 0 2.8568605814349723e-10
truncating O 0 1.2312206365550082e-07
mutations O 0 2.5897688260556606e-07
in O 0 2.050842967671329e-10
140 O 0 8.849369015351272e-10
mutant O 0 6.959561460462282e-08
alleles O 0 1.1621879139056546e-06
screened O 0 2.5745242965058424e-05
. O 0 3.6140326642453147e-07

The O 0 3.8555796777473006e-08
haplotyping O 0 2.7487742499943124e-06
of O 0 5.727799345933704e-10
patients O 0 8.261560324740458e-09
with O 0 5.942293185290382e-11
identical O 0 4.6118938712425006e-07
mutations O 0 1.4605133401346393e-05
indicates O 0 1.3241002250197198e-07
that O 0 3.5456143576695354e-10
almost O 0 7.409298730109981e-10
all O 0 3.783900623388625e-11
of O 0 4.029352806272923e-12
these O 0 2.4760108893739918e-11
represent O 0 1.5370565931149827e-10
common O 0 1.3142084087647277e-09
ancestry O 0 8.967796816250484e-07
and O 0 2.963729350824451e-08
that O 0 8.524586037061965e-10
very O 0 5.856544138538311e-10
few O 0 1.3486162186993056e-09
spontaneously O 0 4.864046587726989e-08
recurring O 0 1.6578631800712174e-07
ATM O 0 5.1691335102077574e-05
mutations O 0 1.0881865819101222e-05
exist O 0 2.1369697833506507e-07
. O 0 6.39786463807468e-08

Assays O 0 3.2892069157242076e-06
requiring O 0 1.0767343638917737e-07
minimal O 0 1.3636866746935539e-08
amounts O 0 2.3155881656578003e-09
of O 0 7.555012171422959e-11
genomic O 0 1.5440514644637915e-08
DNA O 0 3.4156300898757763e-07
were O 0 3.766780221070576e-09
designed O 0 1.0781268100501507e-09
to O 0 1.3962725420313404e-09
allow O 0 5.186077123298105e-10
rapid O 0 1.9565893349948738e-09
screening O 0 9.717054938462866e-10
for O 0 4.1864792882373436e-11
common O 0 1.981103503467807e-09
ethnic O 0 6.256366873458319e-07
mutations O 0 8.13907081465004e-06
. O 0 4.816446974587052e-08

These O 0 4.248205698331731e-08
rapid O 0 1.2410878014179616e-07
assays O 0 1.4772506062854518e-07
detected O 0 1.0754393287015773e-07
mutations O 0 9.013696455895115e-08
in O 0 1.8936831269744658e-10
76 O 0 5.4197379917297894e-09
% O 0 1.681147443477471e-10
of O 0 2.217129431436593e-11
Costa O 0 2.441308595280134e-07
Rican O 0 1.0339652689594914e-08
patients O 0 3.5160920841548204e-09
( O 0 3.3001500837626097e-11
3 O 0 6.857069911880842e-10
) O 0 1.4781673107755466e-10
, O 0 6.112695072335583e-11
50 O 0 1.0225108953987316e-10
% O 0 8.220651243062704e-11
of O 0 3.6437197009631106e-11
Norwegian O 0 0.0004539951332844794
patients O 0 3.6607922027087625e-08
( O 0 2.4378006557856935e-11
1 O 0 4.748612059124468e-10
) O 0 1.2448674036047436e-10
, O 0 1.3468805237781822e-10
25 O 0 9.13525574630647e-11
% O 0 5.822536897071018e-11
of O 0 2.1395784449707023e-11
Polish O 0 8.142627621054999e-07
patients O 0 4.8526831442075036e-09
( O 0 1.8374444327173833e-11
4 O 0 1.2194892873296226e-09
) O 0 2.2113740005824667e-10
, O 0 4.91661156232226e-10
and O 0 1.8493265807606463e-09
14 O 0 9.584341098545224e-10
% O 0 3.597095191154587e-11
of O 0 5.38773756511568e-12
Italian O 0 7.818578069418436e-07
patients O 0 2.772046148180607e-09
( O 0 1.206844867096546e-11
1 O 0 1.3475826010633796e-09
) O 0 7.352536357529971e-10
, O 0 4.3547218608885885e-10
as O 0 3.3807975863275885e-10
well O 0 4.699162586829786e-11
as O 0 1.168312252497472e-10
in O 0 5.798586957816987e-11
patients O 0 1.0998434107900579e-10
of O 0 8.278773500070002e-12
Amish O 0 3.170848401623516e-07
/ O 0 5.554541712626815e-05
Mennonite O 0 1.184633219963871e-06
and O 0 5.361320631891431e-08
Irish O 0 1.0783087134313973e-07
English O 0 4.345690030049809e-08
backgrounds O 0 1.9366567016732006e-07
. O 0 6.234525784520883e-08

Additional O 0 3.01698918292459e-07
mutations O 0 9.53509152168408e-06
were O 0 2.194100368058116e-08
observed O 0 6.9663586010904055e-09
in O 0 1.1091463164580873e-10
Japanese O 0 1.6984494921601367e-09
, O 0 7.113607619624318e-11
Utah O 0 6.034975852386992e-10
Mormon O 0 1.1376801722917662e-09
, O 0 1.9839081766281907e-10
and O 0 9.505034259671419e-11
African O 0 8.581713117905565e-11
American O 0 1.4266631209736147e-09
patients O 0 5.448385298478797e-09
. O 0 4.073497983370089e-09

These O 0 3.5034748435691654e-08
assays O 0 3.633163103700099e-08
should O 0 6.441178701521721e-10
facilitate O 0 3.5544370224904753e-10
screening O 0 4.374729023481905e-09
for O 0 1.8625482267609073e-09
A B-Disease 1 0.9999998807907104
- I-Disease 1 0.9999996423721313
T I-Disease 1 1.0
heterozygotes O 0 1.1898119964826037e-06
in O 0 2.6438931599592763e-10
the O 0 1.8244471211570357e-10
populations O 0 1.3496301853876957e-09
studied O 0 3.6092360211625873e-09
. O 0 1.2955966299799115e-09
. O 0 1.2827668705028827e-08

The O 0 2.0420216060301755e-06
von B-Disease 1 0.9988263249397278
Hippel I-Disease 1 0.999846339225769
- I-Disease 1 0.9997100234031677
Lindau I-Disease 1 0.9991602897644043
tumor I-Disease 0 0.0007855278090573847
suppressor O 0 2.350907607251429e-06
gene O 0 9.774199725143262e-07
is O 0 2.0226178509830106e-09
required O 0 6.677510766550654e-10
for O 0 3.849866259120205e-10
cell O 0 8.674853120282933e-07
cycle O 0 1.04571499832673e-05
exit O 0 8.33012836665148e-06
upon O 0 5.587173390608768e-09
serum O 0 1.0657826265969561e-07
withdrawal O 0 9.199208648169588e-07
. O 0 3.5002486242774467e-08

The O 0 3.4550250660458914e-08
inactivation O 0 1.3611371514343773e-06
of O 0 2.2801739663069753e-10
the O 0 5.461016083785353e-09
von B-Disease 1 0.9979501366615295
Hippel I-Disease 1 0.9999158382415771
- I-Disease 1 0.9997385144233704
Lindau I-Disease 1 0.9997065663337708
( I-Disease 0 1.9666347839120135e-07
VHL I-Disease 0 6.304922862909734e-05
) I-Disease 0 2.4891308569863213e-08
tumor I-Disease 0 2.1470912088261684e-06
suppressor O 0 1.8172030422647367e-06
gene O 0 2.5744423055584775e-06
predisposes O 0 8.630691809230484e-06
affected O 0 2.8875589919152844e-07
individuals O 0 2.6260178476178453e-09
to O 0 3.3825924283803488e-09
the O 0 6.341852820668237e-09
human O 0 1.8590462786960416e-06
VHL B-Disease 1 0.9999709129333496
cancer I-Disease 1 0.9999972581863403
syndrome I-Disease 1 0.999997615814209
and O 0 1.1568602964473484e-08
is O 0 9.808034384661823e-10
associated O 0 3.211996713048393e-08
with O 0 2.253474491453744e-07
sporadic B-Disease 1 0.8516923785209656
renal I-Disease 1 0.9999995231628418
cell I-Disease 1 0.999996542930603
carcinomas I-Disease 1 1.0
( O 0 6.54685718473047e-05
RCC B-Disease 0 0.3718920052051544
) O 0 2.3825690220746765e-07
and O 0 3.0962470987105917e-07
brain B-Disease 0 0.0030651879496872425
hemangioblastomas I-Disease 0 0.0005803439416922629
. O 0 1.996448872887413e-07

VHL O 0 0.02608686499297619
- O 0 0.0005284239887259901
negative O 0 2.2285719751380384e-05
786 O 0 3.26866279465321e-06
- O 0 2.492025032552192e-06
0 O 0 7.223394504762837e-08
RCC B-Disease 0 3.1010836210043635e-06
cells O 0 2.84579158460474e-07
are O 0 9.090693198210431e-10
tumorigenic O 0 5.528173687707749e-07
in O 0 3.6713772022523017e-09
nude O 0 0.00010279759590048343
mice O 0 2.7759006115957163e-05
which O 0 7.644950450469423e-09
is O 0 3.290836214642212e-10
suppressed O 0 2.053547609737194e-10
by O 0 1.617864913219802e-12
the O 0 1.9883546198418145e-11
reintroduction O 0 1.5018418508816467e-08
of O 0 6.255556073142543e-10
VHL B-Disease 0 6.083757398300804e-06
. O 0 3.830364647683382e-08

Remarkably O 0 6.830630445620045e-05
, O 0 6.5246457126022506e-09
this O 0 6.173567212997e-10
occurs O 0 9.42204425591342e-10
without O 0 3.5857056213117744e-10
affecting O 0 7.855404104972763e-10
the O 0 1.3644606278173654e-10
growth O 0 8.90673135245379e-08
rate O 0 5.2326029731375456e-08
and O 0 1.7290634479749656e-09
cell O 0 2.862023791294632e-07
cycle O 0 6.670323386970267e-07
profile O 0 3.4899422018952464e-08
of O 0 9.05324495925619e-11
these O 0 9.303535025706466e-11
cells O 0 1.5422141341758788e-09
in O 0 1.6830949134405415e-10
culture O 0 5.7213526361010736e-08
. O 0 8.218108149549153e-08

The O 0 8.924246230890276e-08
786 O 0 5.345056024452788e-07
- O 0 1.6717184507797356e-06
0 O 0 3.211874144426474e-08
cell O 0 2.3493632852478186e-06
line O 0 3.351656914674095e-06
, O 0 4.14129175396738e-10
like O 0 2.0762014329989142e-10
many O 0 5.5910050894558694e-11
cancer B-Disease 0 1.1159038137975585e-08
cells O 0 3.933729786353979e-09
, O 0 1.6557918369741742e-09
fails O 0 2.504962992588844e-07
to O 0 4.0790024691261806e-09
exit O 0 2.5745774223651097e-07
the O 0 5.707667671828176e-10
cell O 0 3.1088367791198834e-07
cycle O 0 1.4238534618016274e-07
upon O 0 4.673968767576753e-09
serum O 0 7.810650259898466e-08
withdrawal O 0 3.914168758001324e-07
. O 0 2.001836030274262e-08

Here O 0 2.0896609385090414e-06
, O 0 3.6850433815516226e-09
it O 0 3.1294830615813396e-10
is O 0 3.464079717518942e-11
shown O 0 9.94338500426295e-11
that O 0 9.951917762096585e-12
reintroduction O 0 5.008756187585561e-10
of O 0 8.39030407651098e-12
the O 0 5.7606652087427435e-11
wild O 0 1.903655011403771e-08
- O 0 4.6532633746210195e-07
type O 0 2.5560105143540568e-08
VHL B-Disease 0 4.6027898292777536e-07
gene O 0 5.243142808808443e-08
restores O 0 1.1617031248079002e-07
the O 0 1.295126644818012e-10
ability O 0 2.99506242029679e-09
of O 0 1.7449787448331477e-10
VHL O 0 0.0001234472874784842
- O 0 0.00017780870257411152
negative O 0 3.085782373091206e-05
RCC B-Disease 0 6.642558582825586e-05
cancer I-Disease 0 1.0972023574140621e-06
cells O 0 5.067143149517506e-09
to O 0 7.983219085794246e-10
exit O 0 2.9551563329732744e-07
the O 0 5.930067548121087e-10
cell O 0 4.311896759645606e-07
cycle O 0 1.5913421975710662e-06
and O 0 2.1733042032678895e-08
enter O 0 1.7321862344488181e-07
G0 O 0 9.19220838113688e-06
/ O 0 7.164863291109214e-06
quiescence O 0 7.168821980485518e-07
in O 0 2.49805220953192e-09
low O 0 2.2964570689509856e-07
serum O 0 2.2013065859027847e-07
. O 0 5.715135387163173e-08

Both O 0 9.084303087547596e-07
VHL O 0 0.0004856027371715754
- O 0 5.4282798373606056e-05
positive O 0 5.381241408031201e-07
and O 0 5.928781465769362e-09
VHL O 0 3.968927194364369e-05
- O 0 6.014279279042967e-06
negative O 0 1.3357271200220566e-06
RCC B-Disease 0 3.114557102890103e-06
cells O 0 4.452887836237096e-08
exit O 0 1.6039562922287587e-07
the O 0 3.030088124855723e-10
cell O 0 9.927290989253379e-08
cycle O 0 1.0846433440292458e-07
by O 0 4.0864917005833945e-10
contact O 0 2.0553724766614323e-07
inhibition O 0 1.975034535917075e-07
. O 0 5.0271854235006685e-08

The O 0 9.901309283577575e-08
cyclin O 0 5.49365222468623e-06
- O 0 1.981646619242383e-06
dependent O 0 2.557625293775345e-07
kinase O 0 6.40673647467338e-07
inhibitor O 0 1.3402656406924507e-07
, O 0 8.037870924404444e-10
p27 O 0 6.930974905117182e-08
, O 0 2.2178239800219046e-10
accumulates O 0 3.754729860361294e-09
upon O 0 5.164232930177093e-10
serum O 0 3.7233789385027194e-09
withdrawal O 0 5.006783965200157e-08
, O 0 1.0411677769939232e-10
only O 0 1.2902539280046366e-11
in O 0 7.445515558257565e-12
the O 0 6.412308184433613e-11
presence O 0 5.201402641930031e-10
of O 0 5.039773806614356e-11
VHL B-Disease 0 3.052791157642787e-07
, O 0 3.014954952362814e-10
as O 0 4.38699111759977e-11
a O 0 1.4661549752048586e-10
result O 0 3.162183848104405e-10
of O 0 4.8425976770238854e-12
the O 0 9.653170623957763e-11
stabilization O 0 5.257959068138973e-10
of O 0 7.199530468321447e-12
the O 0 2.5992419327991456e-10
protein O 0 2.7467793373148197e-08
. O 0 2.277959332275259e-08

We O 0 3.0863296274219465e-07
propose O 0 8.328424172532323e-08
that O 0 2.6834393040964244e-10
the O 0 1.198136867497368e-10
loss O 0 7.268307733454549e-09
of O 0 2.2887393369419584e-11
wild O 0 4.9323681139412656e-08
- O 0 6.914561254234286e-06
type O 0 1.8704957938098232e-07
VHL B-Disease 0 2.8250128707441036e-06
gene O 0 4.50161081744227e-07
results O 0 2.7674781577502472e-08
in O 0 5.485247239062074e-12
a O 0 4.5910338031251996e-11
specific O 0 6.446783107350029e-10
cellular O 0 9.79007836576784e-07
defect O 0 4.495694554407237e-07
in O 0 1.374692720768067e-10
serum O 0 1.634056800980943e-08
- O 0 2.4839955585775897e-06
dependent O 0 3.242669208702864e-06
growth O 0 3.709633347170893e-06
control O 0 1.8440728410951124e-07
, O 0 1.4494782041296617e-09
which O 0 7.063360563108745e-09
may O 0 1.2497415013967839e-07
initiate O 0 3.521187608157561e-08
tumor B-Disease 0 1.0871220865737996e-06
formation O 0 4.497032080053032e-08
. O 0 4.1766750058513935e-08

This O 0 2.138406607343768e-08
is O 0 2.9601856521566106e-09
corrected O 0 7.679047371311754e-07
by O 0 2.8489417422394858e-11
the O 0 3.076183752170891e-11
reintroduction O 0 4.29044932914735e-09
of O 0 7.007797814262418e-11
wild O 0 5.0079872693231664e-08
- O 0 8.851401616993826e-06
type O 0 7.399468699986755e-07
VHL B-Disease 0 3.8378620956791565e-05
, O 0 3.5418175059476198e-09
implicating O 0 1.7656347495176306e-07
VHL B-Disease 0 7.513491482313839e-07
as O 0 4.030233369256564e-10
the O 0 4.5559486738788735e-11
first O 0 2.886020311620996e-09
tumor B-Disease 0 2.6689200183227513e-08
suppressor O 0 3.168732121139328e-08
involved O 0 1.7241039707016625e-09
in O 0 4.3033535068737194e-11
the O 0 7.383168382224525e-11
regulation O 0 5.14443376786744e-10
of O 0 2.3287847344954926e-11
cell O 0 3.270772026553459e-07
cycle O 0 6.383015261235414e-06
exit O 0 6.664804823230952e-05
, O 0 1.6350846232526806e-09
which O 0 9.424705460503446e-10
is O 0 6.3319866017153e-10
consistent O 0 3.461764874757023e-09
with O 0 2.2383619263655063e-11
its O 0 2.277467325839666e-09
gatekeeper O 0 5.207612474578127e-08
function O 0 4.134955933210449e-09
in O 0 2.672840004880328e-10
the O 0 3.413436200361275e-09
kidney O 0 1.8488693967810832e-05
. O 0 3.0763629421670657e-09
. O 0 1.5825440513594913e-08

Piebaldism B-Disease 1 1.0
with O 0 0.008063788525760174
deafness B-Disease 1 1.0
: O 0 2.2021710677222472e-08
molecular O 0 1.868687427020177e-08
evidence O 0 2.0016328594607558e-09
for O 0 4.559836952466867e-10
an O 0 3.965089145907541e-09
expanded O 0 4.692973379860632e-05
syndrome O 1 0.9991570711135864
. O 0 1.3371784746141202e-07

In O 0 2.4601130022006146e-08
a O 0 6.2148028945330225e-09
South O 0 6.4333121052584374e-09
African O 0 3.171679585634024e-10
girl O 0 4.2054047355577495e-08
of O 0 4.6349823284996816e-11
Xhosa O 0 5.0685844144027214e-06
stock O 0 4.379542133392533e-06
with O 0 8.54623871671123e-10
severe O 0 7.994599400262814e-07
piebaldism B-Disease 0 3.9705439121462405e-05
and O 0 1.7379859684751864e-07
profound O 0 2.193704403907759e-06
congenital O 1 0.9999998807907104
sensorineural B-Disease 1 1.0
deafness I-Disease 1 1.0
we O 0 2.6113351850654e-05
identified O 0 3.0425308494841374e-08
a O 0 4.895762129031311e-10
novel O 0 4.934068265072256e-09
missense O 0 2.76851352509766e-07
substitution O 0 2.525532227792837e-09
at O 0 1.5121831564712807e-09
a O 0 2.545494370842505e-10
highly O 0 3.3418307010535386e-10
conserved O 0 1.9156007891041327e-09
residue O 0 1.6399235747144303e-08
in O 0 4.9062011397982275e-11
the O 0 3.24362377235321e-11
intracellular O 0 1.1735455940353745e-09
kinase O 0 4.618214077822813e-08
domain O 0 4.594568281390821e-09
of O 0 6.246741318660654e-11
the O 0 1.4136342096904286e-09
KIT O 0 7.817981781954586e-07
proto O 0 6.924366857674613e-07
- O 0 2.89954073195986e-07
oncogene O 0 1.9408369666962244e-07
, O 0 1.3394466646943215e-09
R796G O 0 1.5530666530594317e-07
. O 0 1.2478379218805458e-08

Though O 0 2.6064390112878755e-06
auditory B-Disease 0 9.762404079083353e-05
anomalies I-Disease 0 0.1317116618156433
have O 0 3.365963507917513e-08
been O 0 1.9975670006999735e-09
observed O 0 3.8434189164604504e-09
in O 0 2.2878980654450487e-10
mice O 0 3.571055628981412e-08
with O 0 3.708931772816726e-10
dominant O 0 6.327097139546822e-07
white O 0 1.7990647904753132e-07
spotting O 0 1.3010228940402158e-05
( O 0 2.3651500313803808e-08
W O 0 0.00029262559837661684
) O 0 9.183669935630689e-10
due O 0 4.676884657328628e-09
to O 0 3.273284976401669e-09
KIT O 0 7.001987796684261e-06
mutations O 0 2.554694401624147e-05
, O 0 2.2200148919182539e-07
deafness B-Disease 1 1.0
is O 0 1.5972757339000054e-08
not O 0 6.044375555624981e-10
typical O 0 4.458112101701772e-09
in O 0 2.581511004962067e-09
human O 0 1.1506611663492095e-08
piebaldism B-Disease 0 4.4682736188406125e-05
. O 0 8.23538499616916e-08

Thus O 0 2.2279388645074505e-07
, O 0 1.2004706118062813e-09
the O 0 1.7280998854118934e-10
occurrence O 0 2.3408907168231963e-07
of O 0 4.2736186145475585e-08
sensorineural B-Disease 1 0.9999998807907104
deafness I-Disease 1 1.0
in O 0 1.3094430073579133e-07
this O 0 4.679650889016784e-09
patient O 0 1.1678481826038478e-07
extends O 0 5.792479829125341e-09
considerably O 0 1.2801223192582256e-08
the O 0 2.010984295752749e-10
phenotypic O 0 3.868101572379601e-08
range O 0 6.577826283660215e-09
of O 0 4.106556483751689e-10
piebaldism B-Disease 0 4.502947376749944e-06
due O 0 8.746041224583223e-09
to O 0 6.726135204360162e-10
KIT O 0 2.7715085337831624e-08
gene O 0 5.061289609642472e-09
mutation O 0 2.8455993117404432e-09
in O 0 3.4314821817371666e-11
humans O 0 8.333628787049463e-10
and O 0 2.3232236134873574e-09
tightens O 0 9.4997567430255e-06
the O 0 2.311782709707444e-10
clinical O 0 8.010551666437493e-10
similarity O 0 7.360941300937895e-10
between O 0 2.575116508918285e-10
piebaldism B-Disease 0 4.8694355427869596e-06
and O 0 3.66712021859783e-10
the O 0 9.109134453677559e-12
various O 0 2.0887359550303408e-11
forms O 0 1.3109344720874105e-08
of O 0 3.115787450269636e-08
Waardenburg B-Disease 1 0.9999538660049438
syndrome I-Disease 1 0.9997497200965881
. O 0 9.764975494874761e-09
. O 0 3.2691250595462407e-08

Cycloheximide O 0 5.2918105211574584e-05
facilitates O 0 2.741467710620782e-07
the O 0 1.8988490779747735e-09
identification O 0 7.904254140100875e-09
of O 0 2.595348103096029e-10
aberrant O 0 2.2733981097644573e-07
transcripts O 0 2.949705049104523e-07
resulting O 0 5.2758433177757524e-09
from O 0 2.3069288146437827e-10
a O 0 3.976174389741516e-10
novel O 0 7.620143627207199e-09
splice O 0 0.00022780383005738258
- O 0 4.160942353337305e-06
site O 0 2.2861125614781486e-07
mutation O 0 1.5261798580468167e-07
in O 0 4.818260790351303e-10
COL17A1 O 0 1.9997446543129627e-06
in O 0 1.4350051702471944e-10
a O 0 2.194429749025062e-09
patient O 0 8.935709416846294e-08
with O 0 3.5704477152620484e-09
generalized O 0 2.129357380908914e-05
atrophic B-Disease 1 0.995110809803009
benign I-Disease 1 0.9107751250267029
epidermolysis I-Disease 1 0.9697209596633911
bullosa I-Disease 1 0.7839933633804321
. O 0 1.0376426871516742e-05

Patients O 0 0.0006312632467597723
with O 0 1.641518707629075e-07
generalized O 0 0.00013262381253298372
atrophic B-Disease 1 0.9992672801017761
benign I-Disease 1 0.9960874319076538
epidermolysis I-Disease 1 0.9739974737167358
bullosa I-Disease 0 0.4239782691001892
often O 0 4.791592800756916e-06
show O 0 2.6189894697381533e-07
decreased O 0 5.797201652057993e-07
expression O 0 7.2123507166566014e-09
of O 0 7.067089691226158e-10
type O 0 3.208739371984848e-07
XVII O 0 4.510300641413778e-06
collagen O 0 1.3635341247208999e-06
, O 0 2.778847429940612e-10
a O 0 6.24436224949676e-10
transmembrane O 0 1.534957583260166e-08
hemidesmosomal O 0 5.3483905304574364e-08
protein O 0 3.1661808730376606e-09
encoded O 0 1.1190818050010876e-08
by O 0 2.0739385764301232e-09
COL17A1 O 0 3.2952775654848665e-05
. O 0 1.46337455930734e-07

This O 0 1.729299441421972e-07
report O 0 1.2588829179094319e-07
documents O 0 2.368277129960461e-09
a O 0 5.061374097614646e-10
novel O 0 5.03114438998864e-09
splice O 0 0.0001721956505207345
- O 0 7.419072062475607e-06
site O 0 1.5987639301329182e-07
mutation O 0 1.1578673309031728e-07
in O 0 2.4575591561770693e-10
COL17A1 O 0 1.1933801715713344e-06
in O 0 7.464487361552585e-11
a O 0 2.8517770367386674e-09
patient O 0 9.432788061758401e-08
with O 0 1.999896470650242e-09
generalized O 0 1.211761718877824e-05
atrophic B-Disease 1 0.9690091013908386
benign I-Disease 0 0.3548242747783661
epidermolysis I-Disease 0 0.040524642914533615
bullosa I-Disease 0 0.003951276186853647
, O 0 9.078087259695167e-08
and O 0 5.720255380481376e-10
applies O 0 2.5925728230902223e-10
a O 0 1.9192936129286409e-10
new O 0 9.554406155132256e-10
methodology O 0 1.0380794002173843e-08
to O 0 6.0159011106009075e-09
define O 0 1.302001635394845e-07
and O 0 3.5097951212037515e-08
characterize O 0 4.5025939243714674e-07
the O 0 1.7085608483569104e-09
resulting O 0 6.542416386423611e-09
mRNA O 0 1.7200918023263512e-07
splice O 0 0.0001454138837289065
variants O 0 2.3014827092993073e-06
. O 0 8.586080468830914e-08

Mutational O 0 0.00015918411372695118
analysis O 0 2.588045617812895e-07
of O 0 2.662781550810678e-09
COL17A1 O 0 6.75856790621765e-06
identified O 0 7.722275086052832e-08
a O 0 3.6409308901141912e-09
maternally O 0 3.5746884918808064e-07
inherited O 0 8.669559861118614e-07
G O 0 8.3756922322209e-06
- O 0 2.842097330812976e-07
to O 0 1.7168501642572664e-07
- O 0 2.3710410914645763e-06
T O 0 1.3061398021818604e-05
transversion O 0 4.289854516059677e-08
at O 0 6.663273821594373e-10
the O 0 3.6207536968646536e-11
- O 0 7.711143723554414e-09
1 O 0 1.3608771887163584e-09
position O 0 3.687251393102997e-09
of O 0 6.525112394850652e-11
exon O 0 1.728474927631396e-07
32 O 0 1.6592576201901466e-08
. O 0 1.4390550973075733e-08

This O 0 1.3558153710846454e-08
acceptor O 0 8.350215807695349e-08
splice O 0 1.0249946171825286e-05
- O 0 1.436472643945308e-06
site O 0 8.484220614946025e-08
mutation O 0 9.690818103536003e-08
led O 0 5.475426778644987e-10
to O 0 2.1068061184514875e-10
the O 0 7.449552780203206e-11
formation O 0 3.366608936072879e-10
of O 0 1.6403683966714766e-11
aberrant O 0 1.5964870314633117e-08
transcripts O 0 4.48203856251439e-08
present O 0 9.809250078873788e-10
at O 0 4.485978699619864e-09
extremely O 0 4.041335266435908e-09
low O 0 5.450518969496443e-08
levels O 0 3.362588429922653e-08
. O 0 3.163128070582388e-08

Based O 0 1.1342377774781198e-06
on O 0 1.2245249081388465e-07
our O 0 1.0005186901196339e-08
recent O 0 3.516460900243601e-09
finding O 0 4.0140024637480565e-09
that O 0 7.577832805694129e-10
cycloheximide O 0 5.552510629058816e-07
stabilized O 0 1.3542151009460213e-06
mutant O 0 1.6428765547971125e-07
COL17A1 O 0 2.3624168079550145e-06
transcripts O 0 7.509667199201431e-08
in O 0 3.616262844730045e-10
keratinocytes O 0 1.9782919480348937e-07
homozygous O 0 5.079066411894928e-08
for O 0 1.1240650771293659e-10
a O 0 2.1428028240677577e-09
frameshift O 0 1.5598914615111426e-05
mutation O 0 2.2124527276901063e-07
, O 0 2.0205807860218528e-10
the O 0 6.048513079282003e-11
effects O 0 5.296977523272517e-09
of O 0 2.5310947782131166e-11
the O 0 4.33358432472275e-10
splice O 0 0.00012852433428633958
- O 0 3.4450596331225825e-07
site O 0 3.5707287793229625e-08
mutation O 0 1.3943544097116956e-08
on O 0 3.2249397596828544e-10
splicing O 0 1.4733751996232058e-08
of O 0 9.637882159019284e-11
COL17A1 O 0 1.4588781596103217e-06
transcripts O 0 4.2053244442286086e-08
were O 0 1.6513375389326512e-10
determined O 0 1.499178697850212e-10
using O 0 2.1458855525846587e-10
reverse O 0 8.000542806030353e-08
transcriptase O 0 1.6726835383451544e-07
polymerase O 0 2.2639815355773862e-08
chain O 0 2.0686580626261275e-07
reaction O 0 4.7444836948074e-10
of O 0 8.50899906090774e-12
total O 0 1.992432885344897e-10
RNA O 0 2.91456601075879e-08
from O 0 3.7542289277325835e-09
keratinocytes O 0 1.2786439640422032e-07
incubated O 0 1.0371967285038863e-08
for O 0 1.4922149627061287e-10
2 O 0 2.5821118576629942e-09
. O 0 1.3445665913991434e-08

5 O 0 5.147550155015779e-07
h O 0 2.9897385047661373e-06
in O 0 1.4170573603422554e-09
the O 0 2.602451587563337e-10
presence O 0 8.73028704884149e-10
or O 0 7.687677161527517e-09
absence O 0 5.463680619044453e-10
of O 0 1.2687079685436142e-11
10 O 0 1.8147962022041497e-09
microg O 0 4.714171097930375e-07
cycloheximide O 0 6.861759516141319e-07
per O 0 5.866555952138697e-08
ml O 0 4.122561676922487e-06
. O 0 2.80560659149387e-08

Using O 0 1.0046169762745194e-07
this O 0 4.048788415644822e-09
approach O 0 2.581985114602503e-08
, O 0 1.8780124122486086e-09
an O 0 1.1842666847172723e-09
abnormally O 0 2.4175269572879188e-06
spliced O 0 0.23472283780574799
transcript O 0 0.2816429138183594
was O 0 4.0725760186433035e-07
identified O 0 9.98993066048115e-09
that O 0 6.3554057849746215e-12
contains O 0 5.5138840542034995e-12
an O 0 1.0378600756588696e-11
extra O 0 2.9714014582182813e-10
264 O 0 3.219623734285193e-10
bases O 0 2.5131863257144005e-10
upstream O 0 2.448007130340102e-09
from O 0 3.235308687621341e-10
exon O 0 6.81922642797872e-08
32 O 0 4.700171807314746e-09
, O 0 6.892522663726197e-11
resulting O 0 2.559901179921553e-10
in O 0 1.558916884469852e-10
a O 0 3.929090297560833e-08
premature O 0 8.440019314548408e-07
termination O 0 4.8737327063008706e-08
codon O 0 4.499958095038892e-07
27 O 0 7.222431008813146e-08
bp O 0 2.0949726149410708e-06
downstream O 0 2.189243275552144e-07
from O 0 1.1674997635324758e-09
the O 0 6.177596212353365e-10
cryptic O 0 7.806195299053797e-07
splice O 0 4.358439764473587e-05
site O 0 5.644093334922218e-07
. O 0 5.158804228244662e-08

Three O 0 3.362966793929445e-08
other O 0 4.3996881138319566e-10
splice O 0 1.2132023812227999e-06
variants O 0 4.8707033073469574e-08
, O 0 8.475102564187154e-11
including O 0 7.879616230332953e-12
one O 0 2.6460510865744524e-11
derived O 0 7.807094554168614e-11
from O 0 3.424852068611983e-11
the O 0 2.4063636500093466e-11
skipping O 0 1.3260332387687868e-08
of O 0 2.956576997115157e-11
exon O 0 5.0362068293452467e-08
32 O 0 8.76456152099081e-09
, O 0 3.2660366078296477e-10
were O 0 1.3930935294226288e-09
also O 0 1.1533198396307398e-08
identified O 0 2.140992449994883e-07
. O 0 2.2157797374688926e-08

These O 0 4.509026894083945e-07
results O 0 7.648453106412489e-07
indicate O 0 4.8400008445526055e-09
the O 0 3.4737063919765276e-11
usefulness O 0 7.759992093347989e-10
of O 0 2.6183829410220127e-11
cycloheximide O 0 3.951234646137891e-07
treatment O 0 5.3756123996606675e-09
in O 0 3.456351524433465e-11
evaluating O 0 1.5724936908156906e-09
the O 0 2.536407195385948e-10
abnormal O 0 5.224933730119119e-08
processing O 0 2.6590003532334094e-09
of O 0 1.6861498308706757e-11
mRNA O 0 7.334961082960945e-09
due O 0 1.6810274061640484e-08
to O 0 1.626887624617268e-09
splice O 0 5.0451901188353077e-05
- O 0 8.683477403792494e-07
site O 0 4.1006640572049946e-07
mutations O 0 2.8435174499463756e-06
, O 0 6.209692759995278e-10
because O 0 4.899498584620687e-10
( O 0 6.609603420137944e-10
i O 0 5.708163186568527e-08
) O 0 1.9693255359776174e-10
aberrant O 0 1.1632924845628168e-08
splicing O 0 1.4902259692917141e-07
often O 0 3.522603320149642e-09
generates O 0 7.079788755248728e-09
a O 0 3.959240046924606e-09
premature O 0 2.536156387122901e-07
termination O 0 1.887536882350105e-08
codon O 0 1.9940246431815467e-07
, O 0 2.1979735809196654e-09
( O 0 6.119871831522516e-10
ii O 0 4.006095721820202e-08
) O 0 3.4523948144737915e-09
transcripts O 0 8.426066955280476e-08
with O 0 1.881701683359438e-09
premature O 0 4.802274133908213e-08
termination O 0 5.044952899879718e-09
codons O 0 4.3154425810598696e-08
can O 0 1.0981423770317633e-08
occur O 0 2.933364884327716e-09
at O 0 6.123004769875706e-09
low O 0 1.613003632883192e-07
or O 0 7.734080327281845e-07
undetectable O 0 9.133950129580626e-07
levels O 0 2.385354580525245e-09
due O 0 1.1338263661286874e-09
to O 0 1.2960910122927771e-09
nonsense O 0 7.005241542401563e-08
- O 0 1.754592204861183e-08
mediated O 0 1.1945600952856239e-08
mRNA O 0 2.861584746938206e-09
decay O 0 8.780272509056886e-09
, O 0 1.5546916531938848e-10
and O 0 2.928667308665922e-10
( O 0 1.2581755082230472e-10
iii O 0 1.9036439979913666e-08
) O 0 5.275820336159143e-10
the O 0 1.5883303006170024e-10
levels O 0 2.1850897480302223e-10
of O 0 5.206906520532906e-12
these O 0 5.122772345211857e-11
transcripts O 0 3.307578211320106e-08
can O 0 2.7377606848233427e-09
be O 0 2.1295150365308047e-10
increased O 0 1.78177264609225e-10
by O 0 4.557002830640755e-10
cycloheximide O 0 5.1733072723436635e-06
. O 0 2.7885558750995187e-08

A O 0 3.2084642498375615e-07
deletion O 0 6.84779752191389e-06
mutation O 0 4.614159365701198e-07
in O 0 1.5935504027453362e-09
COL17A1 O 0 7.0650798988936e-06
in O 0 9.321533545048055e-10
five O 0 3.2185198950429594e-09
Austrian O 0 3.243616788495274e-07
families O 0 8.353744362921134e-10
with O 0 3.2110822889563906e-09
generalized O 0 7.020683369773906e-06
atrophic B-Disease 1 0.982466459274292
benign I-Disease 1 0.5072813630104065
epidermolysis I-Disease 0 0.04681548848748207
bullosa I-Disease 0 0.002553066937252879
represents O 0 1.3222604877682897e-07
propagation O 0 4.889346882919199e-08
of O 0 2.7093391419263924e-10
an O 0 9.939598033525954e-10
ancestral O 0 3.129915512545267e-06
allele O 0 0.0002892948978114873
. O 0 5.535147806767782e-07

Patients O 0 0.0005682324408553541
with O 0 1.2272957405912166e-07
generalized O 0 0.00024489176576025784
atrophic B-Disease 1 0.9998019337654114
benign I-Disease 1 0.998839795589447
epidermolysis I-Disease 1 0.9584635496139526
bullosa I-Disease 0 0.322109192609787
, O 0 3.036350904039864e-08
a O 0 2.252673381164527e-09
usually O 0 3.910994195166495e-09
nonlethal O 0 9.258443611770417e-08
form O 0 1.362095858326029e-08
of O 0 8.623513458871912e-09
junctional B-Disease 0 0.009442371316254139
epidermolysis I-Disease 0 0.16579148173332214
bullosa I-Disease 0 0.0034771300852298737
, O 0 5.2319041543569256e-08
have O 0 2.0711001802453666e-09
generalized O 0 5.952216497462359e-08
blistering B-Disease 0 5.060208422946744e-05
, O 0 3.3375915364786124e-08
nail B-Disease 1 0.9999790191650391
dystrophy I-Disease 1 0.7276459336280823
, O 0 2.687981464077893e-07
patchy B-Disease 0 0.3554406464099884
alopecia I-Disease 1 0.9999927282333374
, O 0 1.5435838918165246e-07
and O 0 1.026024989414509e-07
dental B-Disease 0 0.0003871864464599639
abnormalities I-Disease 1 0.7012830376625061
. O 0 2.1884250145376427e-07

Skin B-Disease 1 0.9999716281890869
fragility I-Disease 0 0.003967679105699062
in O 0 4.488109883737934e-09
most O 0 3.7268374497578804e-10
cases O 0 8.169667720103746e-10
is O 0 3.766807421534679e-10
due O 0 8.424922093297482e-09
to O 0 6.8384222728923305e-09
mutations O 0 2.7460460572115153e-08
in O 0 4.514522783383157e-11
the O 0 9.628860903054814e-11
gene O 0 1.7738667423827792e-08
encoding O 0 6.752621573014039e-08
type O 0 3.9771046544956334e-07
XVII O 0 6.708301953040063e-06
collagen O 0 5.396096184995258e-06
( O 0 8.181959998410093e-09
COL17A1 O 0 1.3412936823442578e-05
) O 0 1.3590180536482421e-08
. O 0 1.999706711330873e-08

Recently O 0 2.9862969313398935e-05
, O 0 5.729028984546858e-08
we O 0 2.9348660390837722e-08
reported O 0 1.0091935109812766e-07
five O 0 8.390887984432993e-10
Austrian O 0 2.250010879834008e-07
families O 0 8.427007980316148e-10
with O 0 2.0234975917077236e-09
generalized O 0 4.373402589408215e-06
atrophic B-Disease 1 0.7770166993141174
benign I-Disease 0 0.12980051338672638
epidermolysis I-Disease 0 0.035294800996780396
bullosa I-Disease 0 0.020440170541405678
who O 0 1.6231080735451542e-05
share O 0 4.606829691056191e-07
the O 0 7.45694894721538e-10
same O 0 7.486495867681242e-09
COL17A1 O 0 3.4182750823674724e-05
mutation O 0 7.798977890161041e-07
. O 0 3.956524352588531e-08

Affected O 0 1.9890947442036122e-05
individuals O 0 4.289541166713207e-09
in O 0 4.4923126329976526e-10
three O 0 9.965832603597846e-10
families O 0 4.5469056297875454e-10
are O 0 1.4964902927960821e-10
homozygous O 0 7.071070839970162e-09
for O 0 1.7552667652687148e-10
4003delTC O 0 1.3786230113055353e-07
, O 0 1.0261844707315504e-09
whereas O 0 1.1220562257108213e-09
those O 0 1.582355219076348e-10
in O 0 5.279381445899567e-11
two O 0 2.1064936461812067e-09
others O 0 9.401997402846973e-09
are O 0 1.4450939056498413e-10
compound O 0 6.162679255794501e-08
heterozygotes O 0 1.5375353541458026e-06
. O 0 3.900388279021172e-08

To O 0 2.551953457441414e-07
determine O 0 4.266386710582992e-08
if O 0 1.3144666466402555e-09
the O 0 6.310101746676011e-11
occurrence O 0 3.387324865045116e-09
of O 0 5.908860900571966e-11
4003delTC O 0 4.3434113194962265e-08
in O 0 1.1649321784990008e-10
these O 0 2.515285375814802e-11
unrelated O 0 1.1568905833314602e-09
families O 0 1.4748723076163373e-10
signifies O 0 1.5811312259472743e-09
propagation O 0 2.0400605649228964e-09
of O 0 3.253363897726125e-11
an O 0 7.085577263810094e-11
ancestral O 0 6.265543817107755e-08
allele O 0 6.902530458319234e-06
or O 0 1.0446902365401911e-07
a O 0 1.2104568014592587e-08
mutational O 0 1.989569682336878e-06
hot O 0 9.954753750207601e-07
spot O 0 1.4975737940403633e-05
, O 0 2.2010779865411223e-09
haplotypes O 0 3.651845474905713e-07
were O 0 2.8355491288323265e-09
determined O 0 1.623363332647898e-09
for O 0 7.076838420827514e-11
polymorphisms O 0 7.464625895181598e-08
both O 0 1.8821684211189904e-09
within O 0 2.098925699911547e-09
and O 0 3.709147833319548e-08
flanking O 0 9.953046173905022e-06
COL17A1 O 0 0.000516234606038779
. O 0 8.103022253180825e-08

Five O 0 1.0867012179005542e-06
intragenic O 0 1.1964994882873725e-05
polymorphisms O 0 1.0373240911576431e-05
were O 0 6.580175693216006e-08
chosen O 0 1.1311269254576928e-08
based O 0 3.7146117293218595e-09
on O 0 8.253987715534095e-08
their O 0 1.8105278343227837e-07
informativeness O 0 2.9265700504765846e-05
. O 0 2.827017908657581e-08

One O 0 5.2930516858396004e-08
of O 0 5.16748477341622e-10
these O 0 3.581392682416862e-10
, O 0 6.08886663311381e-10
not O 0 2.1389237048197174e-09
previously O 0 8.442282961595993e-08
reported O 0 2.868909632525174e-06
, O 0 6.171189115278253e-10
was O 0 1.1799378141219563e-09
2988 O 0 2.7667270696696278e-09
A O 0 4.868833780591331e-09
or O 0 9.796035982390094e-09
C O 0 2.027602050702626e-07
that O 0 8.599310152845874e-11
introduces O 0 5.348722020848129e-10
a O 0 6.713340994224382e-11
new O 0 8.228950160171777e-11
restriction O 0 1.304318736350396e-10
site O 0 4.094529604259378e-09
for O 0 7.96505861266894e-10
Eco0109 O 0 2.5806713210840826e-07
I O 0 3.118456334050279e-06
. O 0 1.2919674219347144e-08

All O 0 2.4194791947707017e-08
the O 0 1.1471390504169676e-09
4003delTC O 0 8.504764537065057e-08
alleles O 0 2.6872580605186158e-08
showed O 0 9.09246633540306e-09
the O 0 2.949255076267754e-11
same O 0 5.124602409090073e-10
haplotype O 0 1.747845885802235e-07
for O 0 2.1187707144321166e-10
these O 0 4.42835247638218e-11
five O 0 5.797948232633132e-10
polymorphic O 0 2.7789596401817107e-07
markers O 0 1.5745630435048952e-06
. O 0 9.873868833665256e-08

Fourteen O 0 6.737029707437614e-06
microsatellite O 0 2.7146312277182005e-05
polymorphisms O 0 4.91527134727221e-05
were O 0 1.443649466636998e-07
selected O 0 7.325785533751628e-10
based O 0 4.2830639035429385e-10
on O 0 2.2541531308206686e-08
their O 0 1.1115914411163885e-08
high O 0 1.1692430135212817e-08
heterozygosity O 0 1.1618649153888327e-07
and O 0 2.2246291475624957e-09
their O 0 6.655842543779045e-10
location O 0 1.778725078338539e-08
within O 0 1.230996415912955e-09
10q23 O 0 1.483796268075821e-07
- O 0 5.5790820852053e-07
q25 O 0 4.774200306201237e-07
near O 0 2.3216352929011919e-07
COL17A1 O 0 9.581416816217825e-05
. O 0 8.955483821182497e-08

Three O 0 3.832879542642331e-07
families O 0 1.1497287566442083e-08
shared O 0 6.038916477990597e-09
microsatellite O 0 1.0785036010929616e-06
polymorphisms O 0 2.3845199393690564e-05
covering O 0 1.3764411050942726e-06
at O 0 4.832098170481913e-07
most O 0 2.118698994024726e-09
19 O 0 9.008640944330182e-09
cM O 0 1.0724666488215462e-08
, O 0 4.911081541436602e-10
whereas O 0 7.443264893325363e-10
the O 0 2.6307941936032364e-10
others O 0 3.7278984343913635e-09
shared O 0 4.0310171867119493e-10
smaller O 0 6.425255438813338e-09
regions O 0 2.4964157319118385e-07
consistent O 0 9.674694467776135e-08
with O 0 2.996386194720202e-10
cross O 0 1.2926485624120687e-06
- O 0 3.6725737118104007e-06
over O 0 8.837704967845639e-08
events O 0 2.357721573531535e-09
during O 0 8.862358069627874e-10
passage O 0 5.070650010985389e-10
of O 0 3.8056268206188015e-12
this O 0 3.877070192670473e-11
mutation O 0 7.361025677887767e-10
through O 0 1.8959238345939156e-10
several O 0 6.424504261914876e-10
generations O 0 5.030702965314049e-09
. O 0 1.1046841663642226e-08

These O 0 2.510770116259664e-07
results O 0 9.857823215497774e-07
indicate O 0 1.2719930886362363e-08
that O 0 1.505930657952348e-10
4003delTC O 0 3.0654231153448563e-08
occurs O 0 2.5468541164919145e-10
on O 0 1.1407281369502087e-10
a O 0 1.8815249358539177e-10
single O 0 1.8083968766902103e-09
ancestral O 0 2.430273937648053e-08
allele O 0 1.1434771067797556e-06
. O 0 5.480278453262599e-09
. O 0 2.401470489132862e-08

The O 0 2.2259935406054865e-07
haptoglobin O 0 2.3567399694002233e-05
- O 0 1.237323976965854e-05
gene O 0 5.727811185352039e-06
deletion O 0 3.144956281175837e-05
responsible O 0 5.089753472020675e-07
for O 0 6.844633748670503e-09
anhaptoglobinemia B-Disease 0 5.15984465891961e-05
. O 0 1.1597261817541948e-07

We O 0 5.914625035075005e-06
have O 0 4.1640340064930115e-09
found O 0 4.19690671105144e-10
an O 0 9.89683890395554e-11
allelic O 0 2.763089668178509e-08
deletion O 0 2.816778987835278e-07
of O 0 2.1249911552612133e-10
the O 0 2.5088531252492885e-09
haptoglobin O 0 1.0281735285389004e-06
( O 0 1.5883432347152393e-09
Hp O 0 3.3532504772892935e-08
) O 0 5.6582911966973626e-11
gene O 0 1.2065652921222636e-09
from O 0 7.293186193857437e-11
an O 0 7.556322928481407e-11
individual O 0 5.431377014808447e-10
with O 0 1.8748279373426158e-08
anhaptoglobinemia B-Disease 0 7.103464304236695e-05
. O 0 7.162235249325022e-08

The O 0 1.1721999015890106e-07
Hp O 0 4.818587626687076e-07
gene O 0 5.8767923860614246e-08
cluster O 0 1.7093505277898657e-08
consists O 0 1.4857538810364446e-10
of O 0 2.909407437190481e-11
coding O 0 1.4007379149916233e-06
regions O 0 3.449665939569968e-07
of O 0 6.701839777578655e-11
the O 0 2.949307187360972e-10
alpha O 0 4.391432550931995e-09
chain O 0 2.391022917436203e-07
and O 0 6.756815107422653e-10
beta O 0 6.210414960072796e-10
chain O 0 6.9694152671218035e-09
of O 0 9.458677764639933e-12
the O 0 2.2034880864385542e-10
haptoglobin O 0 3.3496196039095594e-08
gene O 0 1.2482568756411183e-08
( O 0 4.626364569215724e-10
Hp O 0 4.0333901552003226e-08
) O 0 6.859499773748112e-11
and O 0 4.437958334158054e-11
of O 0 2.3988560703819273e-12
the O 0 2.2795261511721066e-10
alpha O 0 2.349537897572418e-09
chain O 0 6.555209353109603e-08
and O 0 3.6130498592967797e-10
beta O 0 3.8861561191261274e-10
chain O 0 2.0637105357934615e-09
of O 0 7.375914982954423e-12
the O 0 5.336971975467009e-10
haptoglobin O 0 2.894159081279213e-07
- O 0 1.132958331595546e-07
related O 0 6.732120194641311e-09
gene O 0 9.723366645175702e-08
( O 0 1.2836302021312918e-09
Hpr O 0 1.7457714420743287e-06
) O 0 5.741964681504896e-10
, O 0 1.2364032020428795e-10
in O 0 1.0430461355737108e-10
tandem O 0 5.775185130119098e-08
from O 0 1.2609724375778342e-09
the O 0 8.15977896362341e-10
5 O 0 2.0142453038829444e-08
side O 0 1.4073832232952554e-07
. O 0 3.03138598667374e-08

Southern O 0 1.2089732081221882e-05
blot O 0 0.002394456183537841
and O 0 2.1295376129160104e-08
PCR O 0 2.477602549788571e-07
analyses O 0 4.528276420501243e-08
have O 0 8.531661488397901e-10
indicated O 0 5.105823319695446e-09
that O 0 1.142181921959251e-11
the O 0 6.565632586219561e-12
individual O 0 2.1531453703316217e-11
with O 0 6.85439899283935e-11
anhaptoglobinemia B-Disease 0 3.333590541387821e-07
was O 0 2.261757892085825e-09
homozygous O 0 1.1152606615993932e-09
for O 0 8.94838109860574e-12
the O 0 2.7900201246544576e-11
gene O 0 1.1354869933200007e-08
deletion O 0 1.8738077756097482e-07
and O 0 7.431901760668325e-10
that O 0 2.8283835343256847e-11
the O 0 3.926829347800087e-11
gene O 0 6.0554565806114624e-09
deletion O 0 7.14297172521583e-08
was O 0 4.2123464716326e-09
included O 0 1.0652303344960146e-10
at O 0 2.1484094503421147e-09
least O 0 1.5392305485750768e-10
from O 0 6.793304807573008e-11
the O 0 1.7499182658475831e-10
promoter O 0 3.44138527452742e-07
region O 0 1.3995934011745703e-07
of O 0 1.6158434312796288e-10
Hp O 0 1.1142218880877408e-07
to O 0 2.0126391664376797e-09
Hpr O 0 1.5236174988331186e-07
alpha O 0 5.3007371825231075e-09
but O 0 8.951565044768017e-10
not O 0 3.034147932901021e-10
to O 0 6.098687665989644e-10
Hpr O 0 9.159919045487186e-07
beta O 0 1.4867760356196413e-08
( O 0 7.315173466970748e-10
Hpdel O 0 4.571153624510771e-07
) O 0 3.5953293675561326e-09
. O 0 1.1879301098360884e-08

In O 0 3.3946804478546255e-08
addition O 0 2.342557259282785e-09
, O 0 2.3155259931684213e-09
we O 0 4.751441462502726e-09
found O 0 3.51919660079858e-10
seven O 0 1.2398061743912336e-10
individuals O 0 1.3424140271611762e-12
with O 0 1.921109105129659e-11
hypohaptoglobinemia B-Disease 0 1.745720226153935e-07
in O 0 1.1817659351098797e-10
three O 0 2.1245016856852317e-09
families O 0 1.0305069991778382e-10
, O 0 3.2371602620706597e-10
and O 0 6.702443600126173e-10
the O 0 3.8974246052703165e-10
genotypes O 0 1.0960456542363772e-08
of O 0 8.455335390178398e-12
six O 0 7.38896221985641e-10
of O 0 9.267966602499733e-12
the O 0 7.296639958909168e-10
seven O 0 1.1898666940624025e-08
individuals O 0 2.2156920395643986e-11
were O 0 4.383446661204715e-10
found O 0 3.9914554994524565e-10
to O 0 2.0579324910841024e-09
be O 0 3.955760607965431e-09
Hp2 O 0 1.7467908037360758e-05
/ O 0 2.1808027668157592e-05
Hpdel O 0 1.5905070540611632e-05
. O 0 9.520796595552383e-08

The O 0 6.781326078453276e-08
phenotypes O 0 2.9061950499453815e-06
and O 0 5.6119542790611376e-08
genotypes O 0 5.021651077186107e-07
in O 0 3.6910208223162044e-10
one O 0 4.708172740564009e-10
of O 0 1.6382889836408232e-11
these O 0 8.363242737230436e-11
three O 0 7.302013993459866e-10
families O 0 1.628454593394224e-10
showed O 0 2.1366453495375026e-08
the O 0 1.1359211488093379e-10
father O 0 3.2737843547181456e-09
to O 0 2.9623656860877645e-09
be O 0 1.9626293923380445e-09
hypohaptoglobinemic B-Disease 0 1.0362361990701174e-07
( O 0 1.1226958945842469e-10
Hp2 O 0 1.3767440520950913e-07
) O 0 2.1880508516147756e-10
and O 0 8.061193379482745e-10
Hp2 O 0 4.19031903220457e-06
/ O 0 2.613727247080533e-06
Hpdel O 0 4.327600606757187e-07
, O 0 1.6021012294586967e-10
the O 0 5.866983981972496e-11
mother O 0 3.006356052992487e-08
to O 0 6.367205651613972e-10
be O 0 2.9546617930087393e-10
Hp2 O 0 7.928174028393187e-08
- O 0 1.7535082719177808e-08
1 O 0 4.0439878112863425e-09
and O 0 3.1892002372302386e-09
Hp1 O 0 1.364417357763159e-06
/ O 0 6.70732163143839e-07
Hp2 O 0 1.945152519056137e-07
, O 0 1.1096710356151007e-10
one O 0 2.3616799488257456e-11
of O 0 1.022018515824119e-12
the O 0 1.2305778618326713e-10
two O 0 4.522913599203093e-09
children O 0 2.2933472898500895e-09
to O 0 1.3257771547259267e-09
be O 0 4.1346170931433335e-09
hypohaptoglobinemic B-Disease 0 5.764278512288001e-07
( O 0 2.698688772451163e-10
Hp2 O 0 8.658820860318883e-08
) O 0 1.2739972965469804e-10
and O 0 4.3124678827943796e-10
Hp2 O 0 2.1864816517336294e-06
/ O 0 3.5873624710802687e-06
Hpdel O 0 7.741873560007662e-07
, O 0 4.3998138465894954e-10
and O 0 5.8740602659757e-11
the O 0 3.1450755194617486e-11
other O 0 6.978080613340154e-11
child O 0 1.587907028088864e-09
to O 0 3.515929214437108e-10
be O 0 4.538907860673902e-10
Hp1 O 0 2.4766174533397134e-07
and O 0 1.751311429210034e-09
Hp1 O 0 2.7015064461011207e-06
/ O 0 2.641749460963183e-06
Hpdel O 0 1.2069833701389143e-06
, O 0 4.702994105265645e-10
showing O 0 5.1635957731832605e-09
an O 0 3.4150866162763194e-11
anomalous O 0 2.6169340472392832e-08
inheritance O 0 1.1118399356746522e-07
of O 0 2.175550850580521e-09
Hp O 0 2.382885440965765e-06
phenotypes O 0 3.664522907342871e-08
in O 0 1.6185577877969592e-10
the O 0 9.67950386510097e-10
child O 0 2.470217452810175e-08
with O 0 3.098640455334589e-09
Hp1 O 0 9.371666965307668e-05
. O 0 8.816945040734936e-08

The O 0 2.393441320691636e-07
Hp2 O 0 0.0001935670297825709
/ O 0 0.001511935843154788
Hpdel O 0 8.571777289034799e-05
individuals O 0 2.3982751784501488e-08
had O 0 4.082507132352475e-08
an O 0 2.3161698947671283e-10
extremely O 0 2.477808402900905e-09
low O 0 1.291903384270654e-08
level O 0 1.794207560301686e-09
of O 0 9.72368643936683e-11
Hp O 0 5.961759796946353e-08
( O 0 1.5272609565908368e-10
mean O 0 1.3872787363311545e-09
+ O 0 1.6088979037931495e-08
/ O 0 2.9930225764474017e-07
- O 0 6.13413462247081e-08
SD O 0 6.922802526787564e-07
= O 0 6.122117035545216e-09
0 O 0 3.346563859363272e-10
. O 0 5.1743959811334506e-11
049 O 0 2.006205157556451e-08
+ O 0 4.908378148371639e-09
/ O 0 2.614778615850355e-08
- O 0 1.0214534107433337e-08
0 O 0 6.58613386050888e-10
. O 0 1.305867219913992e-10
043 O 0 2.4396555886596616e-08
mg O 0 2.641763607869052e-08
/ O 0 2.436772206237947e-08
ml O 0 8.241744176018528e-09
; O 0 6.098010291166744e-11
n O 0 6.928301488073885e-09
= O 0 7.269139956633808e-09
6 O 0 9.265872513708473e-10
) O 0 3.499128764516968e-11
, O 0 3.505508036627525e-11
compared O 0 4.87642426438839e-10
with O 0 3.625093281112157e-11
the O 0 3.382771285309616e-10
level O 0 2.82540879581461e-10
( O 0 1.1642962635671772e-11
1 O 0 2.6114055362569388e-11
. O 0 1.1880346532933128e-11
64 O 0 8.335945822501856e-11
+ O 0 1.1291583223993484e-09
/ O 0 3.0565136199811604e-08
- O 0 2.7727813378675137e-09
1 O 0 1.87946014307272e-09
. O 0 4.877661607949335e-10
07 O 0 7.1827530589985145e-09
mg O 0 1.946562377952432e-08
/ O 0 1.1032675217848009e-07
ml O 0 1.4902113321113575e-08
) O 0 2.0173911152721047e-11
obtained O 0 2.9081881347536864e-10
from O 0 9.292083769096848e-10
52 O 0 2.02935801496551e-08
healthy O 0 4.133339448486595e-09
volunteers O 0 2.706637691751723e-10
having O 0 1.4725120012215598e-09
phenotype O 0 9.901422970415297e-08
Hp2 O 0 4.936650270792597e-07
, O 0 3.1494051810909696e-10
whereas O 0 2.7737531715921193e-10
the O 0 1.4221523958468651e-10
serum O 0 1.5575625234021118e-09
Hp O 0 1.3705236057148795e-08
level O 0 5.7485804311196986e-11
of O 0 3.3645447539143447e-12
an O 0 4.741441961275683e-11
individual O 0 6.90092843980139e-11
with O 0 2.070231319706295e-09
Hp1 O 0 6.707554712193087e-05
/ O 0 2.301994027220644e-05
Hpdel O 0 2.7426574433775386e-06
was O 0 2.4166656231727757e-08
0 O 0 3.856496899601325e-09
. O 0 1.1647467879072337e-08

50 O 0 2.9037405511189718e-06
mg O 0 1.1346899555064738e-05
/ O 0 0.00017799308989197016
ml O 0 5.419293302111328e-06
, O 0 1.8990626848847114e-09
which O 0 3.794179137539544e-10
was O 0 1.7615393588243933e-09
approximately O 0 1.2282376504746395e-10
half O 0 1.8038669447051348e-09
the O 0 7.10293768246828e-11
level O 0 4.209973342161888e-11
of O 0 8.486550871766863e-12
Hp O 0 2.3925414538439327e-08
in O 0 9.756085522782953e-11
control O 0 5.834640859347928e-08
sera O 0 1.1775438224503887e-06
from O 0 1.3520487507356904e-10
the O 0 1.689157147488629e-10
Hp1 O 0 3.015424283603352e-07
phenotype O 0 2.1586423315511638e-08
( O 0 4.5122329483948675e-11
1 O 0 8.927757144672199e-11
. O 0 3.1613985734813e-11
26 O 0 2.131563120455482e-10
+ O 0 2.5322270946759318e-09
/ O 0 4.3146197725718594e-08
- O 0 4.932017461101168e-09
0 O 0 5.514279033391745e-10
. O 0 2.027560758177671e-10
33 O 0 1.9083181701518015e-09
mg O 0 1.1952666412184954e-08
/ O 0 2.0313253301651457e-08
ml O 0 5.549723347542113e-09
; O 0 6.540874786242767e-11
n O 0 1.1302621949482727e-08
= O 0 1.470205823750348e-08
9 O 0 7.53504458828047e-09
) O 0 7.156189529844426e-11
, O 0 7.291934417397172e-11
showing O 0 3.3364571105920504e-09
a O 0 4.761645522322056e-10
gene O 0 7.136721080769348e-08
- O 0 2.1503246898646466e-06
dosage O 0 1.1673392691591289e-05
effect O 0 3.177929386311007e-07
. O 0 2.719935388029171e-08

The O 0 2.840411283955291e-08
other O 0 1.5488113014328064e-09
allele O 0 3.883270949245343e-07
( O 0 5.337972286412196e-09
Hp2 O 0 1.0258464726575767e-06
) O 0 2.7041505146208067e-10
of O 0 7.257879193478534e-12
individuals O 0 1.893429510402278e-11
with O 0 9.16108466864074e-10
Hp2 O 0 0.00011561907012946904
/ O 0 3.556781666702591e-05
Hpdel O 0 4.699556484411005e-06
was O 0 2.31727703692286e-08
found O 0 1.3672279974841217e-09
to O 0 1.3761337624984549e-09
have O 0 6.829060095192574e-10
, O 0 1.1564090657278925e-10
in O 0 3.0064548073305275e-11
all O 0 2.951372479742531e-10
exons O 0 7.72399815218705e-08
, O 0 3.6492370236729244e-10
no O 0 1.8743397112164217e-10
mutation O 0 4.770144834687073e-10
, O 0 1.0797533873951881e-11
by O 0 1.1825793816422348e-11
DNA O 0 8.186345823446572e-09
sequencing O 0 7.278813285438446e-08
. O 0 2.9496478148871574e-08

On O 0 1.9270598272669304e-07
the O 0 5.066241870466115e-10
basis O 0 8.568256659735596e-10
of O 0 2.9011397451039755e-11
the O 0 8.064668377549822e-10
present O 0 1.2989518349826312e-09
study O 0 1.756023382259997e-10
, O 0 3.5945784543356396e-11
the O 0 6.4195857830962044e-12
mechanism O 0 7.900326920440293e-11
of O 0 2.971496312897948e-11
anhaptoglobinemia B-Disease 0 2.3210939161799615e-06
and O 0 3.855259722573834e-10
the O 0 4.337890810446332e-11
mechanism O 0 1.3211619298569843e-10
of O 0 2.2062079593765382e-11
anomalous O 0 2.905020046739537e-08
inheritance O 0 1.3959821387743432e-07
of O 0 3.1758033980366918e-09
Hp O 0 2.8868532808701275e-06
phenotypes O 0 2.8598682888514304e-07
were O 0 1.0302014352703281e-08
well O 0 3.117825109200112e-09
explained O 0 3.1776596642885124e-07
. O 0 2.2340062244552428e-08

However O 0 3.006666133842373e-07
, O 0 9.881038209869075e-10
the O 0 1.8607114460333918e-10
mechanism O 0 2.3950330607647174e-09
of O 0 4.4335188298383343e-10
hypohaptoglobinemia B-Disease 0 1.550101296743378e-05
remains O 0 2.5306985662609804e-07
unknown O 0 9.277399044549384e-07

ATM O 0 0.0010203939164057374
mutations O 0 0.00030455837259069085
and O 0 5.487351373290039e-08
phenotypes O 0 2.671480797289405e-05
in O 0 5.007916479371488e-05
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
families O 0 2.173484244849533e-05
in O 0 5.666332292264542e-09
the O 0 1.777910263456306e-09
British O 0 2.3715199404250598e-07
Isles O 0 2.0525415038719075e-06
: O 0 1.8540582957804475e-10
expression O 0 5.678519807150728e-11
of O 0 4.815499995286521e-12
mutant O 0 1.932621840339266e-09
ATM O 0 1.1796422541010543e-06
and O 0 1.5644938677894515e-09
the O 0 9.507306053535558e-10
risk O 0 1.761466350558294e-08
of O 0 3.680560300978186e-10
leukemia B-Disease 0 0.0006212699227035046
, O 0 8.71987776918104e-06
lymphoma B-Disease 1 1.0
, O 0 7.697025239394861e-07
and O 0 1.6962800373221398e-06
breast B-Disease 0 0.010007956065237522
cancer I-Disease 0 0.00011192897363798693
. O 0 1.4729205588537297e-07

We O 0 1.0047967407444958e-05
report O 0 3.1389735255515916e-08
the O 0 1.0727519567099719e-10
spectrum O 0 6.388981010907457e-10
of O 0 6.304819860636357e-11
59 O 0 1.3553525413101397e-08
ATM O 0 4.922123935102718e-06
mutations O 0 1.863343527475081e-06
observed O 0 2.467124318172864e-07
in O 0 2.3608290575793944e-06
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 0.00014573175576515496
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 6.588049217270964e-08
patients O 0 3.118177716032733e-08
in O 0 3.4859188452474044e-11
the O 0 9.519718346950867e-10
British O 0 5.977096861897735e-07
Isles O 0 1.3203619346313644e-05
. O 0 7.854542616314575e-08

Of O 0 2.850919322838763e-08
51 O 0 6.384552762028761e-07
ATM O 0 9.420770766155329e-06
mutations O 0 1.084690438801772e-06
identified O 0 4.878112846995464e-08
in O 0 2.56041410295893e-10
families O 0 1.5826118193729144e-10
native O 0 6.644642613906626e-10
to O 0 3.0656084337721268e-09
the O 0 1.2141442295998672e-09
British O 0 1.9470826373435557e-07
Isles O 0 2.947993834823137e-06
, O 0 2.3278146077387873e-09
11 O 0 5.794886237531216e-10
were O 0 1.4694614969279485e-10
founder O 0 1.2682568328870047e-09
mutations O 0 7.343388119807059e-09
, O 0 1.0960738566767603e-10
and O 0 1.0273237815994207e-10
2 O 0 7.463750728575747e-10
of O 0 3.410731766462227e-11
these O 0 1.445077252304472e-10
11 O 0 7.690415526617755e-10
conferred O 0 5.072139375172924e-10
a O 0 1.2722932707376344e-09
milder O 0 1.286471274397627e-06
clinical O 0 4.3278705064153655e-09
phenotype O 0 2.0750553275661332e-08
with O 0 9.218818763923053e-11
respect O 0 7.073657215528328e-10
to O 0 6.571731603344233e-09
both O 0 4.582615886761232e-08
cerebellar B-Disease 0 0.07873841375112534
degeneration I-Disease 1 0.6869545578956604
and O 0 1.5324740587630004e-08
cellular O 0 3.145374876112328e-07
features O 0 2.4400517872891214e-07
. O 0 1.4028351813522022e-07

We O 0 1.1938290299440268e-05
report O 0 6.621937842510306e-08
, O 0 1.5215330384510395e-10
in O 0 3.1329456390283283e-11
two O 0 1.0964680718927866e-08
A B-Disease 1 1.0
- I-Disease 1 0.9999983310699463
T I-Disease 1 1.0
families O 0 3.821657212910168e-09
, O 0 3.2607690853003746e-11
an O 0 3.2110484410319273e-11
ATM O 0 3.884651505359216e-06
mutation O 0 1.919797121274769e-08
( O 0 1.9251487903826359e-10
7271T O 0 1.5945301967690284e-08
- O 0 1.8066434392949304e-07
- O 0 1.321348236160702e-06
> O 0 2.2932917786988583e-08
G O 0 1.5094742593646515e-06
) O 0 1.4226625433266804e-10
that O 0 5.116661538906442e-10
may O 0 1.9613580093391647e-08
be O 0 1.3327360048887016e-10
associated O 0 7.174639354845525e-11
with O 0 1.8934943890602796e-11
an O 0 1.1495698143404454e-10
increased O 0 2.7058508322852504e-08
risk O 0 1.8001357204866508e-07
of O 0 7.272894508858485e-10
breast B-Disease 0 0.00016197891090996563
cancer I-Disease 0 4.249289759172825e-06
in O 0 6.893775550409487e-10
both O 0 7.0294250420488424e-09
homozygotes O 0 1.020823219732847e-05
and O 0 6.4785896647379104e-09
heterozygotes O 0 1.3955309441371355e-07
( O 0 2.569660872975277e-10
relative O 0 3.9800536200118586e-09
risk O 0 3.3893815754026946e-08
12 O 0 1.507494795660591e-09
. O 0 1.2325251930178638e-10
7 O 0 2.664478415681515e-09
; O 0 3.5276190857302936e-09
P O 0 0.0004391194088384509
= O 0 1.8218902653188707e-07
. O 0 7.271909741035643e-10
0025 O 0 1.2162053586450838e-08
) O 0 8.198822870619793e-11
, O 0 4.696850894325699e-11
although O 0 4.9824550735211304e-11
there O 0 3.746947630639541e-12
is O 0 7.063807438284497e-12
a O 0 7.367768062316316e-10
less O 0 5.010385351056357e-08
severe O 0 8.056024853431154e-06
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
phenotype O 0 0.0001557050709379837
in O 0 1.4419392346809445e-09
terms O 0 2.0830566160867647e-09
of O 0 1.2682168683275652e-11
the O 0 4.6002221476548755e-10
degree O 0 2.9020958081105164e-08
of O 0 1.836557217416157e-08
cerebellar B-Disease 1 0.9846203327178955
degeneration I-Disease 1 0.9952417612075806
. O 0 5.186211637919769e-07

This O 0 5.1476877871436955e-08
mutation O 0 8.510847919751541e-07
( O 0 9.182255844564224e-09
7271T O 0 2.476709539678268e-07
- O 0 1.0649773685145192e-06
- O 0 2.9573370738944504e-06
> O 0 3.628862188520543e-08
G O 0 8.559996445001161e-07
) O 0 1.1975084812654302e-10
also O 0 8.268614265505292e-11
allows O 0 3.870073359002468e-11
expression O 0 8.974160303765188e-11
of O 0 6.6567502378378496e-12
full O 0 2.2904959873226716e-10
- O 0 2.4851636304390468e-09
length O 0 1.3304660706481286e-09
ATM O 0 4.5343956145416087e-08
protein O 0 1.1522945930764195e-09
at O 0 3.5280950383409504e-10
a O 0 9.077451290639971e-11
level O 0 1.1281567346976829e-10
comparable O 0 4.6297718436782986e-10
with O 0 1.0751342177650614e-10
that O 0 7.231162890697362e-10
in O 0 1.332235988193986e-09
unaffected O 0 2.223757974206819e-06
individuals O 0 3.4740545995504135e-09
. O 0 2.835420431779312e-08

In O 0 4.25719335339636e-08
addition O 0 3.5924982988433385e-09
, O 0 2.7402424773725897e-09
we O 0 1.3136821630510553e-09
have O 0 6.819710768324327e-11
studied O 0 1.624676615463727e-09
18 O 0 6.412793851495735e-08
A B-Disease 1 0.9999998807907104
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 6.077001671656035e-06
, O 0 3.196346312628329e-11
in O 0 1.9682205518178897e-11
15 O 0 9.625485963837832e-10
families O 0 7.325977324779132e-11
, O 0 6.041931954747781e-10
who O 0 5.53037864392536e-08
developed O 0 2.19268045498211e-07
leukemia B-Disease 0 0.0004277792468201369
, O 0 2.8348474643280497e-06
lymphoma B-Disease 1 1.0
, O 0 1.8182895189511328e-08
preleukemic O 0 1.0962131455016788e-05
T O 0 0.00018021966388914734
- O 0 4.251279733580304e-06
cell O 0 6.0848666180390865e-05
proliferation O 0 1.1941964430661756e-06
, O 0 1.9597200306975537e-08
or O 0 0.3922146260738373
Hodgkin B-Disease 1 1.0
lymphoma I-Disease 1 1.0
, O 0 9.938617040461395e-09
mostly O 0 1.5882575810088895e-10
in O 0 5.004630598826054e-10
childhood O 0 9.672295675500209e-08
. O 0 5.810807834905063e-08

A O 0 2.0046431359332928e-07
wide O 0 3.989061880815825e-08
variety O 0 4.1071075429499615e-09
of O 0 2.0020439472911988e-10
ATM O 0 5.0770795496646315e-06
mutation O 0 6.149621611939438e-08
types O 0 1.6811835257257712e-09
, O 0 6.573229460737906e-11
including O 0 4.7071287839761666e-11
missense O 0 8.323166298396245e-07
mutations O 0 9.403800049767597e-07
and O 0 1.2785599246001311e-09
in O 0 2.1172719133488727e-10
- O 0 1.3692196034753579e-06
frame O 0 5.015792339690961e-05
deletions O 0 5.06632641190663e-05
, O 0 1.5673261799520333e-08
were O 0 1.747104239058217e-09
seen O 0 1.4273116910601402e-08
in O 0 3.7624056647977966e-10
these O 0 1.3478191895899272e-09
patients O 0 1.043088992958019e-08
. O 0 5.719559936778751e-09

We O 0 3.0053411137487274e-06
also O 0 3.1103588593595077e-09
show O 0 4.072790993348008e-09
that O 0 4.57727120095619e-11
25 O 0 1.1052479070849941e-10
% O 0 4.510150933279e-11
of O 0 9.159712051343138e-12
all O 0 4.93275154056505e-09
A B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
patients O 0 8.865085874276701e-07
carried O 0 9.072713136326627e-10
in O 0 7.382802008626399e-11
- O 0 7.876430885289665e-08
frame O 0 1.2726843579002889e-06
deletions O 0 4.631861884263344e-06
or O 0 1.2601681476098747e-07
missense O 0 3.2057253065431723e-06
mutations O 0 1.45779745253094e-06
, O 0 2.9220328934265183e-10
many O 0 9.719751045689229e-12
of O 0 2.570482889041603e-11
which O 0 1.8616434616092192e-08
were O 0 1.0674728656567822e-08
also O 0 6.9578733885578e-09
associated O 0 4.909152528931315e-10
with O 0 7.323015110971554e-11
expression O 0 4.2627543161977144e-10
of O 0 3.6703511757663065e-11
mutant O 0 8.638576076691606e-09
ATM O 0 2.0254890387150226e-06
protein O 0 1.8783183008963533e-07
. O 0 2.4267629683549785e-08

The O 0 4.4918113673020343e-08
DMPK O 0 8.115896889648866e-06
gene O 0 1.3503384934665519e-06
of O 0 2.7147681436190396e-08
severely O 1 0.8414815664291382
affected O 0 0.0032629724591970444
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 0 0.06899512559175491
is O 0 4.8719828171783774e-09
hypermethylated O 0 2.5638726128818234e-06
proximal O 0 1.9542761947377585e-05
to O 0 6.451266898466201e-08
the O 0 2.106582019933967e-09
largely O 0 3.658063363332076e-08
expanded O 0 4.7667117542005144e-07
CTG O 0 0.00017803262744564563
repeat O 0 5.0496899348217994e-05
. O 0 8.275141993863144e-08

Using O 0 1.1289051826679497e-07
methylation O 0 2.0286324797780253e-06
- O 0 5.566790605371352e-06
sensitive O 0 3.572459661427274e-07
restriction O 0 3.711396523442545e-09
enzymes O 0 8.343493895779375e-09
, O 0 2.396612908128759e-10
we O 0 2.9134736290181706e-10
characterized O 0 1.0301492991970918e-10
the O 0 1.6141022546323214e-11
methylation O 0 1.013485118050994e-08
pattern O 0 2.4904329620767385e-07
on O 0 6.894807569324257e-08
the O 0 3.4282393590601146e-10
5 O 0 7.353588293845803e-10
side O 0 4.466203795683299e-10
of O 0 1.1313195172335533e-11
the O 0 4.605296421988925e-10
CTG O 0 1.8636917502590222e-06
repeat O 0 1.6958095727659384e-07
in O 0 2.778294781735635e-11
the O 0 2.7148156986345207e-11
DMPK O 0 4.584783752648036e-08
gene O 0 3.4982581276210567e-09
of O 0 2.969281071019125e-11
normal O 0 1.8004270074811757e-08
individuals O 0 1.4546926163649943e-10
and O 0 6.261727802936434e-10
of O 0 1.2742890076467006e-10
patients O 0 4.463585412395332e-08
affected O 0 1.353983147822646e-08
with O 0 4.7647441192566475e-07
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
, O 0 3.5735747694332076e-09
showing O 0 6.85163437097458e-09
expansions O 0 6.168697996855599e-09
of O 0 3.050614968969079e-11
the O 0 8.030806575298755e-10
repetitive O 0 3.516615151966107e-06
sequence O 0 1.9013874918982765e-07
. O 0 7.079535180309904e-08

The O 0 1.9677468543477517e-08
gene O 0 1.0040652398402017e-07
segment O 0 1.5341504422394792e-07
analyzed O 0 3.783884139352267e-08
corresponds O 0 7.96430299487838e-09
to O 0 5.260095692349864e-10
the O 0 3.482431842893874e-10
genomic O 0 1.0198186828347389e-07
SacI O 0 6.789856342948042e-06
- O 0 4.0707044490773114e-07
HindIII O 0 7.85442807682557e-07
fragment O 0 6.481867131924446e-08
carrying O 0 9.196364558761161e-09
exons O 0 3.207338181709929e-07
11 O 0 6.549258468879771e-09
- O 0 7.872976226508399e-08
15 O 0 1.7808773122851562e-08
. O 0 1.8084598707446276e-08

There O 0 7.091860965147134e-08
is O 0 1.1366889651753809e-09
constitutive O 0 7.50317852293847e-09
methylation O 0 3.493538969223664e-08
in O 0 1.897476842316337e-09
intron O 0 7.08730249243672e-06
12 O 0 5.782170298118672e-09
at O 0 3.47439077508227e-10
restriction O 0 6.805144642241245e-11
sites O 0 6.928126405902901e-10
of O 0 6.67284699717996e-11
SacII O 0 1.088664816961682e-06
and O 0 2.109034502595364e-09
HhaI O 0 1.0365504721221441e-07
, O 0 7.95022589428207e-11
localized O 0 9.368286146838045e-10
1 O 0 3.1038205339228853e-10
, O 0 4.447355678172116e-11
159 O 0 4.090765504116689e-10
- O 0 5.728927554571328e-09
1 O 0 5.39305089475306e-09
, O 0 2.447805291794225e-10
232 O 0 5.735747432566995e-10
bp O 0 3.4662594572409944e-08
upstream O 0 1.9951567065135123e-09
of O 0 4.3394881438230115e-11
the O 0 5.175967987547381e-10
CTG O 0 1.1483172102089156e-06
repeat O 0 3.99114412630297e-07
, O 0 4.587768706598716e-11
whereas O 0 3.1358391577862577e-11
most O 0 2.4493032602102005e-11
, O 0 9.652765392553775e-11
if O 0 5.231001187766537e-10
not O 0 1.8122910117046587e-10
all O 0 1.5056714555705675e-11
, O 0 5.405998565466419e-12
of O 0 3.609944374677321e-13
the O 0 8.241040662382293e-12
other O 0 5.6171044378328094e-12
sites O 0 5.978401662609656e-10
of O 0 2.5622838920047464e-11
SacII O 0 1.6794993484836596e-07
, O 0 2.481472805015983e-10
HhaI O 0 2.9062281470260132e-08
, O 0 7.980870131429896e-11
and O 0 5.933968594273864e-11
HpaII O 0 2.7938424906892578e-08
in O 0 2.3970048168564517e-11
this O 0 5.153593871098927e-11
region O 0 2.609343141557474e-08
are O 0 3.6631217503746427e-10
unmethylated O 0 1.6478223585636442e-07
, O 0 3.035699192022179e-10
in O 0 5.627788512985177e-11
normal O 0 3.471989629133532e-08
individuals O 0 1.6507392675002563e-10
and O 0 3.6341157860775297e-10
most O 0 7.909946309059279e-11
of O 0 2.631761475413441e-11
the O 0 7.298954773915511e-09
patients O 0 6.902558169485928e-08
. O 0 6.2381273480127675e-09

In O 0 1.2132605142767261e-08
a O 0 1.4026734218575143e-09
number O 0 5.779873801792235e-10
of O 0 1.0925881033241325e-10
young O 0 1.0875390366038573e-08
and O 0 1.6937504199177056e-07
severely O 0 0.00014716279110871255
affected O 0 2.6191469260083977e-07
patients O 0 3.374191237526247e-08
, O 0 1.2881005984066718e-10
however O 0 5.649602452528768e-10
, O 0 6.32491073404573e-11
complete O 0 4.688010535325304e-10
methylation O 0 5.954711390643297e-09
of O 0 6.372973676560534e-11
these O 0 7.30295823814231e-11
restriction O 0 1.8869410201016734e-10
sites O 0 2.226171069708016e-08
was O 0 9.012080681713996e-08
found O 0 9.525293886980535e-10
in O 0 4.8619244047420906e-11
the O 0 2.0232689135202264e-10
mutated O 0 2.4181923663491034e-07
allele O 0 9.153692417385173e-07
. O 0 6.462079227276263e-08

In O 0 3.425040162596815e-08
most O 0 2.34404440302427e-10
of O 0 2.331873930061512e-11
these O 0 2.0170728975976715e-10
patients O 0 3.467394815714897e-09
, O 0 3.615067620255097e-11
the O 0 2.0637526410016704e-10
onset O 0 4.358615157684653e-08
of O 0 1.3004386456572092e-10
the O 0 4.018079380330164e-08
disease O 0 0.0005610909429378808
was O 0 4.304322374082403e-06
congenital O 1 0.9987357258796692
. O 0 2.7642053623821994e-07

Preliminary O 0 5.833222076034872e-06
in O 0 4.0047051896863195e-08
vivo O 0 4.583889676723629e-05
footprinting O 0 4.019798507215455e-05
data O 0 2.1557956131346145e-07
gave O 0 3.0140134832379317e-09
evidence O 0 1.746866817864401e-10
for O 0 1.839769482592235e-11
protein O 0 1.206981847801103e-09
- O 0 2.8203075430610625e-08
DNA O 0 5.233162028162042e-07
contact O 0 7.003691848694871e-08
in O 0 2.879497751351323e-10
normal O 0 1.2640361646276688e-08
genes O 0 3.921900582071203e-09
at O 0 3.5523719521535213e-09
an O 0 2.2412038891417296e-10
Sp1 O 0 2.5646647827670677e-07
consensus O 0 2.372604113176635e-09
binding O 0 7.378131994251191e-10
site O 0 4.345207305078702e-09
upstream O 0 1.1393725074526628e-08
of O 0 3.290501898733922e-11
the O 0 1.0294113339526234e-09
CTG O 0 4.12452800446772e-06
repeat O 0 1.6043647974584019e-06
and O 0 6.160954385547868e-11
for O 0 3.726620574628914e-12
a O 0 4.513102738745722e-11
significant O 0 2.838317914033439e-10
reduction O 0 8.140021989788693e-10
of O 0 2.824285076641342e-12
this O 0 3.331976708431661e-11
interaction O 0 3.2309904751670615e-11
in O 0 4.485341265070275e-11
cells O 0 4.713581747139983e-10
with O 0 7.187309081224669e-11
a O 0 7.17388060067492e-09
hypermethylated O 0 2.392930809946847e-06
DMPK O 0 6.398731215995213e-07
gene O 0 2.256743059092514e-08
. O 0 8.445060761808065e-10
. O 0 8.394398065547648e-09

The O 0 1.624389710741525e-06
hemochromatosis B-Disease 1 0.9999955892562866
gene O 0 2.481973524481873e-06
product O 0 3.718328045465569e-08
complexes O 0 1.9986303723129595e-09
with O 0 1.3360447470578407e-10
the O 0 1.8679335855864565e-10
transferrin O 0 7.664047174671396e-09
receptor O 0 1.919038261632977e-09
and O 0 1.856752418483154e-09
lowers O 0 1.0101410197194127e-07
its O 0 1.7448988087753747e-10
affinity O 0 1.6793495760669686e-10
for O 0 4.55580087543872e-11
ligand O 0 7.096878196222178e-09
binding O 0 7.312055316788246e-08
. O 0 4.390630792272532e-08

We O 0 1.3156723980500828e-05
recently O 0 3.2912484471125936e-07
reported O 0 2.2655544285044016e-07
the O 0 9.113396148840991e-11
positional O 0 1.4069398091010044e-08
cloning O 0 8.67592275799467e-10
of O 0 1.0430953843731938e-11
a O 0 1.0269991523870203e-09
candidate O 0 6.855493950297387e-08
gene O 0 1.7845450202003121e-06
for O 0 8.445215826213825e-06
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
called O 0 0.0006492800894193351
HFE O 0 0.006947705522179604
. O 0 6.446051656894269e-07

The O 0 9.159132119407332e-09
gene O 0 6.058335344505394e-08
product O 0 5.902685984437994e-08
, O 0 1.4157273964254813e-10
a O 0 1.789046549793838e-10
member O 0 1.170611940715105e-10
of O 0 6.388560687409228e-12
the O 0 1.2437496865747022e-10
major O 0 3.32491895127518e-10
histocompatibility O 0 5.1138933088168415e-09
complex O 0 5.322445262301301e-10
class O 0 2.050972947031937e-09
I O 0 9.77192598838883e-07
- O 0 4.115295837436861e-08
like O 0 2.1908623804023364e-09
family O 0 3.633980938388959e-08
, O 0 3.4948699489945056e-09
was O 0 6.783833494949931e-09
found O 0 4.474389192488104e-10
to O 0 3.6866448782646444e-10
have O 0 3.0343203644145333e-11
a O 0 7.785294631190709e-11
mutation O 0 3.3004050603580026e-09
, O 0 1.6940678027044243e-10
Cys O 0 8.890452249943337e-07
- O 0 3.858860608829673e-08
282 O 0 6.279206843373686e-08
- O 0 7.097706316017138e-07
- O 0 2.860410404537106e-06
> O 0 2.131366194646489e-08
Tyr O 0 2.9504141707548115e-07
( O 0 3.5839620160516006e-10
C282Y O 0 4.382144869197191e-09
) O 0 3.946704768553744e-11
, O 0 1.3222479534891196e-11
in O 0 1.6682929343536657e-11
85 O 0 6.427580689916113e-10
% O 0 4.699218791870408e-10
of O 0 1.051593881418178e-10
patient O 0 9.269062672956352e-08
chromosomes O 0 8.571907414989255e-07
. O 0 1.5040555467749073e-07

This O 0 2.1930835814032434e-08
mutation O 0 1.1521088794097523e-07
eliminates O 0 8.73892531672027e-08
the O 0 1.0724456878108413e-09
ability O 0 4.015380472566221e-09
of O 0 2.0583003357277363e-10
HFE O 0 1.7904501419252483e-06
to O 0 2.4216120664277696e-08
associate O 0 6.329671897731259e-09
with O 0 2.2296323121118178e-10
beta2 O 0 2.7016561944037676e-05
- O 0 3.9220463804667816e-05
microglobulin O 0 5.190888623474166e-05
( O 0 1.6582031303613576e-09
beta2m O 0 7.107317401278124e-07
) O 0 3.4191360853697006e-10
and O 0 3.647295521158611e-10
prevents O 0 4.9154889047997585e-09
cell O 0 1.4498156133413431e-06
- O 0 1.496548702561995e-05
surface O 0 4.013145007775165e-05
expression O 0 5.218315664023976e-07
. O 0 5.4541278160513684e-08

A O 0 4.940239364259469e-07
second O 0 4.061087963691534e-07
mutation O 0 2.7384263034946343e-07
that O 0 6.552653419866772e-10
has O 0 6.266566709989263e-10
no O 0 4.495646910296358e-10
effect O 0 9.088301222703876e-10
on O 0 8.705004717057818e-08
beta2m O 0 8.702656487002969e-06
association O 0 1.7396217799614533e-10
, O 0 8.961503067395071e-11
H63D O 0 6.319276053545764e-07
, O 0 6.547806186141258e-10
was O 0 4.813303533524049e-09
found O 0 5.806170544353506e-10
in O 0 5.871136909973984e-11
eight O 0 1.4405482362533917e-09
out O 0 1.4286402061358672e-09
of O 0 1.770642660270383e-11
nine O 0 1.9915837867756636e-08
patients O 0 6.906475946699686e-10
heterozygous O 0 8.124588224411866e-10
for O 0 4.11168044056609e-11
the O 0 7.400047796757292e-10
C282Y O 0 2.847404232397821e-07
mutant O 0 6.867572892588214e-07
. O 0 1.0347390855258709e-07

In O 0 8.584639488162793e-08
this O 0 5.56889512282055e-09
report O 0 2.994498800035217e-07
, O 0 7.438396565362382e-10
we O 0 3.518216828979348e-10
demonstrate O 0 1.094352525266018e-10
in O 0 3.574355048052702e-11
cultured O 0 4.197439551489879e-08
293 O 0 5.510695899602069e-09
cells O 0 1.7368483540280977e-08
overexpressing O 0 6.243820394047361e-07
wild O 0 2.442356006326918e-08
- O 0 1.4385766178293125e-07
type O 0 4.204161641041537e-08
or O 0 6.565592514107266e-09
mutant O 0 2.0572270997831765e-08
HFE O 0 2.5564011707501777e-07
proteins O 0 2.0358312813328894e-09
that O 0 5.8205825576029824e-11
both O 0 1.649753250676511e-11
the O 0 4.8990103640456084e-11
wild O 0 1.830950502323958e-08
- O 0 9.576114052833873e-07
type O 0 1.330332821680713e-07
and O 0 9.387178145914277e-09
H63D O 0 2.522150452932692e-06
HFE O 0 1.88754810892533e-07
proteins O 0 1.5457833901777462e-09
form O 0 1.7634689264411918e-09
stable O 0 1.4625562982928386e-08
complexes O 0 3.607361909185869e-10
with O 0 1.2877517108211833e-10
the O 0 7.355692166477468e-10
transferrin O 0 4.1314418552929055e-08
receptor O 0 3.772194556717068e-09
( O 0 1.2041651009653265e-09
TfR O 0 2.781407033580763e-07
) O 0 3.468413556362293e-09
. O 0 1.1545193245865448e-08

The O 0 5.9375548033813175e-08
C282Y O 0 1.0234815590592916e-06
mutation O 0 1.2135078577557579e-06
nearly O 0 3.3850312775030034e-07
completely O 0 7.123400109776412e-07
prevents O 0 9.087265162577296e-09
the O 0 2.1488100188093995e-10
association O 0 8.204658480392979e-11
of O 0 8.555428067380522e-12
the O 0 2.0849039161774385e-10
mutant O 0 2.1607144518043242e-08
HFE O 0 4.936509299113823e-07
protein O 0 1.858188092285218e-08
with O 0 2.0976440029407684e-10
the O 0 3.7138536690406454e-09
TfR O 0 5.054557277617278e-06
. O 0 4.146195919929596e-08

Studies O 0 5.904340696361032e-07
on O 0 6.163290322547255e-08
cell O 0 7.918975484244584e-07
- O 0 1.2642743740798323e-06
associated O 0 1.4434677098051907e-07
transferrin O 0 1.3542342003347585e-07
at O 0 4.103554473999793e-08
37 O 0 1.3356510564221935e-08
degrees O 0 7.843778604410545e-08
C O 0 4.1638975289970404e-07
suggest O 0 2.820682354354176e-09
that O 0 8.654003208485861e-11
the O 0 1.3724475722565188e-10
overexpressed O 0 2.18982378896726e-07
wild O 0 3.051195562875364e-08
- O 0 1.510593250486636e-07
type O 0 1.6644877476323927e-08
HFE O 0 2.717856659728568e-07
protein O 0 2.3375816837756247e-08
decreases O 0 9.448216431451328e-09
the O 0 1.6262003896261312e-11
affinity O 0 2.485674444052677e-10
of O 0 3.148388494356169e-11
the O 0 7.613892849533954e-10
TfR O 0 1.6874818697942828e-07
for O 0 8.413950092212019e-10
transferrin O 0 1.6139331648901134e-07
. O 0 4.1147071527802836e-08

The O 0 2.65451802761163e-07
overexpressed O 0 3.291655957582407e-05
H63D O 0 4.4167668420413975e-06
protein O 0 1.3519682795504195e-07
does O 0 1.3960574918314705e-08
not O 0 5.365100586018912e-10
have O 0 4.006074291740269e-11
this O 0 2.2571312874308802e-11
effect O 0 6.365821203502264e-10
, O 0 6.170774308200677e-11
providing O 0 3.684196697717468e-11
the O 0 5.2297513541965657e-11
first O 0 1.610545918850903e-09
direct O 0 1.555543582831831e-09
evidence O 0 3.615600596695856e-10
for O 0 4.41105450776913e-11
a O 0 5.839221883796597e-10
functional O 0 5.914008838203699e-09
consequence O 0 2.4898940687023696e-09
of O 0 3.6272443382223685e-11
the O 0 5.274223724427429e-09
H63D O 0 0.000135166133986786
mutation O 0 1.6239947626672802e-06
. O 0 4.466412661940922e-08

Addition O 0 5.779405398698145e-08
of O 0 1.0910142789199995e-09
soluble O 0 5.37229425390251e-08
wild O 0 9.54650971607407e-08
- O 0 7.3116066232614685e-06
type O 0 1.781970240699593e-06
HFE O 0 0.0002448779996484518
/ O 0 3.770186594920233e-05
beta2m O 0 3.1034919629746582e-06
heterodimers O 0 3.9409118812727684e-07
to O 0 6.614853997888304e-09
cultured O 0 1.9154505537244404e-07
cells O 0 1.3269597332055127e-07
also O 0 3.325656416919287e-09
decreased O 0 4.19906491799793e-08
the O 0 6.5017560779701e-11
apparent O 0 5.610492626040298e-10
affinity O 0 2.9012128810457227e-10
of O 0 1.1636303032247497e-11
the O 0 1.1048432307925182e-10
TfR O 0 1.4179177831863399e-08
for O 0 2.995082307166719e-11
its O 0 8.099286519236415e-11
ligand O 0 3.68879704559788e-10
under O 0 1.0422248480912444e-10
steady O 0 1.0358606772342682e-07
- O 0 4.865373526286021e-08
state O 0 7.616802299992287e-09
conditions O 0 1.866212357981567e-07
, O 0 8.950092056370096e-11
both O 0 5.4970646090612973e-11
in O 0 7.103181237644307e-11
293 O 0 8.168141163444886e-10
cells O 0 3.821350791355371e-09
and O 0 5.360886179417435e-10
in O 0 7.799120793627878e-10
HeLa O 0 4.482483745960053e-06
cells O 0 7.500175911445695e-07
. O 0 3.892495570312349e-08

Furthermore O 0 7.01201884112379e-07
, O 0 6.4711671576844765e-09
at O 0 5.948830761326462e-09
4 O 0 8.934103234992108e-09
degrees O 0 7.170921207944048e-07
C O 0 4.770845862367423e-06
, O 0 7.513800692748873e-10
the O 0 2.808859256298035e-10
added O 0 2.2059376547645115e-08
soluble O 0 1.2421571549126043e-09
complex O 0 2.1940937955378104e-10
of O 0 9.022491087584683e-11
HFE O 0 1.5907406123005785e-05
/ O 0 1.3635285540658515e-05
beta2m O 0 7.015209462224448e-07
inhibited O 0 2.8157547404816796e-08
binding O 0 2.7449607031826417e-09
of O 0 7.419349162818278e-11
transferrin O 0 1.663681459262989e-08
to O 0 3.258994185628694e-09
HeLa O 0 6.970826689212117e-07
cell O 0 4.635670052266505e-07
TfR O 0 3.2182001064029464e-07
in O 0 1.436322311088034e-10
a O 0 9.41784095154219e-10
concentration O 0 5.223209953442165e-08
- O 0 2.3550724108645227e-06
dependent O 0 7.367675038949528e-07
manner O 0 2.5137699140032055e-06
. O 0 7.89560843372783e-08

Scatchard O 0 0.00019780737056862563
plots O 0 1.0200914402958006e-05
of O 0 5.857005103138135e-09
these O 0 1.6915696621211396e-09
data O 0 6.378953543162424e-08
indicate O 0 1.621522827122135e-08
that O 0 1.6009800429817034e-10
the O 0 1.395071280718696e-10
added O 0 1.608502131489331e-08
heterodimer O 0 1.2299455676156867e-08
substantially O 0 2.1203414135584353e-08
reduced O 0 1.6510549594173085e-09
the O 0 6.239668504104401e-11
affinity O 0 6.49331977076173e-10
of O 0 9.243149995397104e-11
TfR O 0 1.1504586439059494e-07
for O 0 1.0573061315355403e-09
transferrin O 0 1.449566582323314e-07
. O 0 5.029391303423836e-08

These O 0 1.8315903105303732e-07
results O 0 2.0058766381225723e-07
establish O 0 2.5299002892609224e-09
a O 0 8.340911850091004e-10
molecular O 0 6.760376702885651e-09
link O 0 1.1248338296354632e-06
between O 0 1.192358922708081e-08
HFE O 0 8.263777999673039e-05
and O 0 4.30037117027382e-09
a O 0 4.777702122815697e-10
key O 0 5.10741093862066e-09
protein O 0 2.7763800147795337e-09
involved O 0 2.479206839822723e-10
in O 0 1.7892956560849882e-10
iron O 0 8.071945103438338e-07
transport O 0 2.271126398056822e-08
, O 0 2.987563807455018e-10
the O 0 1.0902336672335977e-10
TfR O 0 4.1788908333728614e-08
, O 0 3.2301045171934106e-10
and O 0 2.9083213615166414e-10
raise O 0 3.9826947295651394e-10
the O 0 8.016631108942462e-11
possibility O 0 2.660429654355312e-10
that O 0 4.227208513785108e-11
alterations O 0 6.6828906852833825e-09
in O 0 7.937407675573382e-11
this O 0 1.100907490170222e-10
regulatory O 0 1.7625273462940072e-09
mechanism O 0 7.935034851414002e-10
may O 0 6.200218649610179e-08
play O 0 6.547181685689907e-10
a O 0 1.233997765082151e-10
role O 0 3.3551406097842573e-10
in O 0 3.043838098237828e-11
the O 0 5.468684949327951e-10
pathogenesis O 0 9.337873052572832e-06
of O 0 3.3066453397623263e-07
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 0 8.310943826472794e-07
. O 0 5.121275492570021e-08

Genomic O 0 7.120443569874624e-06
organization O 0 2.470825144484934e-08
of O 0 6.789215301061802e-10
the O 0 4.783321294610232e-09
UBE3A O 0 3.08028502331581e-05
/ O 0 2.7876609237864614e-05
E6 O 0 4.045964487886522e-06
- O 0 7.412254944938468e-06
AP O 0 1.3241713531897403e-05
gene O 0 1.3766548079274799e-07
and O 0 1.1397283117275947e-09
related O 0 8.481466196030851e-09
pseudogenes O 0 2.26631595978688e-06
. O 0 8.447808141909263e-08

The O 0 3.610077570215253e-08
UBE3A O 0 4.670514044846641e-06
gene O 0 1.5588716451020446e-07
encodes O 0 3.972221662706943e-08
the O 0 2.0848174298038202e-09
E6 O 0 3.680564475416759e-07
- O 0 4.866872700404201e-07
AP O 0 1.5152304513321724e-06
ubiquitin O 0 2.7708423999683873e-08
- O 0 2.7797831592124567e-08
protein O 0 4.0088607988764124e-09
ligase O 0 2.025628997870399e-09
and O 0 1.3403845811055248e-09
has O 0 2.3449345243342634e-10
recently O 0 2.57674925840945e-09
been O 0 7.064538537493448e-11
shown O 0 1.089919751673385e-10
to O 0 1.368082869213083e-10
be O 0 3.883777743851624e-10
mutated O 0 5.199248334974982e-06
in O 0 2.0045717974426225e-06
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 0 0.0007476125028915703
who O 0 4.029558908769104e-09
lack O 0 1.460949583531601e-09
15q11 O 0 6.43342445982853e-08
- O 0 6.713868287988589e-07
q13 O 0 7.22632933047862e-07
deletions O 0 5.313399924489204e-06
or O 0 3.9568118381794193e-07
chromosome O 0 0.0002268581447424367
15 O 0 4.6089920147096564e-07
paternal O 0 9.042260899150278e-06
uniparental B-Disease 0 0.005805646535009146
disomy I-Disease 0 0.03769070282578468
. O 0 1.770086782926228e-06

Previous O 0 5.2505861276586074e-06
UBE3A O 0 2.79632458841661e-05
cDNA O 0 2.0204884094709996e-06
analysis O 0 5.924308155158542e-08
has O 0 9.183057092521096e-10
shown O 0 1.539397914696039e-10
a O 0 2.6702004496392817e-10
coding O 0 9.254026736016385e-07
region O 0 2.157383249823397e-07
of O 0 3.21981385997816e-10
approximately O 0 2.75930167603633e-09
2 O 0 2.3568777152149778e-08
. O 0 1.409174288369286e-08

6 O 0 1.4937661489966558e-06
kb O 0 1.0982808817061596e-05
and O 0 3.2775582248234514e-09
a O 0 1.8685795133421834e-09
3 O 0 2.0978126258341945e-07
- O 0 0.0035932576283812523
untranslated O 0 0.17213620245456696
region O 0 5.367958146962337e-05
( O 0 7.453810013657858e-09
UTR O 0 3.1665149435866624e-07
) O 0 1.2052765729908543e-10
of O 0 1.3427372928809245e-11
< O 0 1.9977157705852733e-09
50 O 0 6.391211448963929e-10
bp O 0 6.035614887878182e-07
, O 0 2.749843130978036e-10
whereas O 0 2.1455417997806592e-10
Northern O 0 2.4090800465614848e-09
analysis O 0 1.6897669929960557e-09
has O 0 7.6743267296564e-10
indicated O 0 4.72449079857995e-10
mRNA O 0 4.2454875726072316e-10
sizes O 0 8.044496735415407e-10
of O 0 4.354520216631741e-11
5 O 0 5.7226263727727655e-09
- O 0 4.743258159578545e-07
8 O 0 1.1171628244710519e-07
kb O 0 3.4179770409537014e-06
. O 0 2.4451527025348696e-08

We O 0 1.4073982583795441e-06
have O 0 2.0300847669574296e-09
analyzed O 0 5.479609210823355e-09
additional O 0 4.4032896773238406e-10
cDNA O 0 2.7578035854958216e-08
clones O 0 3.272268259024713e-06
and O 0 4.075588311280853e-09
provide O 0 1.7958225184688814e-10
evidence O 0 2.1873330924293555e-10
for O 0 3.6065209846336543e-11
an O 0 4.614614593223543e-11
additional O 0 1.1968148694307956e-09
0 O 0 9.143596990668357e-09
. O 0 3.086467259549863e-08

5 O 0 2.838291663920245e-07
kb O 0 1.3575371440310846e-06
of O 0 6.905474525531474e-10
5 O 0 1.0629461755229386e-08
- O 0 8.838764529173204e-07
UTR O 0 1.6945822380876052e-06
and O 0 3.829552230882882e-09
> O 0 4.0100975318146936e-10
2 O 0 4.658889385389386e-10
kb O 0 3.716654362051486e-08
of O 0 1.9591193251011774e-11
3 O 0 6.294709198328974e-09
- O 0 6.695850970572792e-06
UTR O 0 2.715045411605388e-05
. O 0 1.23957846653866e-07

We O 0 8.330302080139518e-06
have O 0 2.7598332508205203e-09
established O 0 1.2667621118733763e-10
the O 0 8.356959568800448e-11
genomic O 0 1.045070430194528e-08
organization O 0 4.836842593114454e-10
of O 0 5.388068810563418e-11
UBE3A O 0 2.4767641093603743e-07
and O 0 2.5685042981393735e-10
the O 0 1.7158450008047943e-11
sequence O 0 7.86760934179398e-10
of O 0 2.148564104409445e-10
intron O 0 1.753722972352989e-05
- O 0 1.7382457144776708e-06
exon O 0 2.8101242151024053e-06
borders O 0 3.258975993958302e-06
. O 0 1.6228106858307e-07

We O 0 1.1557835023268126e-05
have O 0 1.2905907453841792e-08
also O 0 6.047500833439301e-10
mapped O 0 5.1413881152484464e-08
two O 0 1.816658490305656e-10
highly O 0 1.0024737290281749e-10
homologous O 0 1.2627534573539378e-09
processed O 0 6.79696938732377e-08
pseudogenes O 0 4.587617752349615e-08
, O 0 9.744040019299405e-10
UBE3AP1 O 0 1.6834164853207767e-06
and O 0 2.6855349055665556e-09
UBE3AP2 O 0 1.082083713299653e-06
, O 0 2.942238952474696e-10
to O 0 2.166076346066248e-10
chromosomes O 0 2.2827819634585467e-09
2 O 0 1.4692807859262302e-08
and O 0 9.743561513175791e-09
21 O 0 1.090024781547072e-08
, O 0 3.3815328315256465e-10
respectively O 0 8.546834351363941e-08
, O 0 1.5506202988291307e-09
and O 0 3.533275449996154e-09
determined O 0 1.1346902084596877e-08
their O 0 3.3387106412874346e-09
genomic O 0 4.366145134326871e-08
organization O 0 9.158084068872085e-09
. O 0 3.025552075541782e-08

These O 0 3.1542271017315215e-07
results O 0 1.542665700071666e-06
will O 0 2.4761690475827436e-09
form O 0 7.558456638356859e-11
the O 0 3.5035967183016936e-11
basis O 0 3.8552963599336465e-10
for O 0 5.074479031419443e-11
studies O 0 2.5209050125152288e-11
of O 0 1.3559710645982825e-11
mutation O 0 1.3060428294409121e-08
and O 0 1.4864235398093228e-09
imprinting O 0 1.4251074276216968e-07
of O 0 3.0942879369888487e-09
UBE3A O 0 3.2422482036054134e-05
. O 0 8.378150795351758e-08

Mutation O 0 4.9127924285130575e-05
spectrum O 0 2.0852696707152063e-06
and O 0 5.224844201734413e-08
genotype O 0 8.36533508845605e-05
- O 0 0.00010967547859763727
phenotype O 0 0.0005362965748645365
analyses O 0 7.55216888137511e-07
in O 0 2.476778560023263e-09
Cowden B-Disease 0 0.027474652975797653
disease I-Disease 0 0.00920629408210516
and O 0 3.5225781402914436e-08
Bannayan B-Disease 1 0.6400355696678162
- I-Disease 1 0.9999898672103882
Zonana I-Disease 1 0.9999971389770508
syndrome I-Disease 1 0.9999995231628418
, O 0 2.0937478417693e-09
two O 0 7.85972442685079e-09
hamartoma B-Disease 0 0.00302949664182961
syndromes I-Disease 0 0.001109618810005486
with O 0 1.041764718934246e-08
germline O 0 7.692953658988699e-05
PTEN O 0 0.00034237303771078587
mutation O 0 6.083711559767835e-05
. O 0 1.3359549200231413e-07

The O 0 4.677905053540599e-06
tumour B-Disease 1 0.9999984502792358
suppressor O 0 3.6612786061596125e-05
gene O 0 6.1432833717844915e-06
PTEN O 0 2.0826757463510148e-05
, O 0 3.8199372554004185e-09
which O 0 4.5306564055991316e-10
maps O 0 3.2103955049933575e-07
to O 0 6.786023476479386e-08
10q23 O 0 2.6361421987530775e-06
. O 0 8.303965159939253e-08

3 O 0 1.9022326114281896e-07
and O 0 1.6032514205122084e-09
encodes O 0 6.448791722846181e-09
a O 0 2.943934263033299e-10
403 O 0 7.353616049421419e-10
amino O 0 1.7233872107169645e-09
acid O 0 1.0686747486943204e-08
dual O 0 1.1272544675478002e-08
specificity O 0 4.114226292983858e-09
phosphatase O 0 1.9304627130622976e-05
( O 0 7.212375141563143e-10
protein O 0 8.400949269571356e-09
tyrosine O 0 6.120846762769361e-08
phosphatase O 0 1.0123530046257656e-05
; O 0 5.2766280234095575e-09
PTPase O 0 3.710450471317017e-07
) O 0 2.567867585234751e-10
, O 0 1.303261942808831e-10
was O 0 1.2589802533824468e-09
shown O 0 3.42440964473667e-10
recently O 0 7.147534564211355e-09
to O 0 5.943055492174665e-10
play O 0 1.052286591196605e-09
a O 0 2.4480295568451993e-10
broad O 0 9.543223988828231e-10
role O 0 2.2046493519667365e-09
in O 0 9.48844669501625e-10
human O 0 1.376893266069601e-08
malignancy B-Disease 0 2.764403870969545e-05
. O 0 5.7267349973244563e-08

Somatic O 0 0.00022552812879439443
PTEN O 0 0.0008387669804506004
deletions O 0 0.0008701949845999479
and O 0 6.684639402010362e-07
mutations O 0 1.0027961252490059e-05
were O 0 1.0988505216857902e-08
observed O 0 1.5299388422818083e-08
in O 0 3.732345099649592e-09
sporadic B-Disease 0 4.527058990788646e-05
breast I-Disease 0 0.14740712940692902
, I-Disease 0 9.29147745409864e-07
brain I-Disease 0 0.09015996009111404
, I-Disease 0 2.686387574613036e-07
prostate I-Disease 0 0.08198130130767822
and I-Disease 0 1.2446762411855161e-06
kidney I-Disease 0 0.03620133548974991
cancer I-Disease 0 4.358780643087812e-05
cell O 0 1.1197862477274612e-05
lines O 0 0.0013183954870328307
and O 0 4.822237897883497e-08
in O 0 8.234025683506729e-10
several O 0 7.993706141462553e-09
primary O 0 2.769745151454117e-05
tumours B-Disease 1 1.0
such O 0 1.910579694452963e-09
as O 0 9.639575182518456e-07
endometrial B-Disease 1 0.9953290224075317
carcinomas I-Disease 1 1.0
, O 1 0.5746546983718872
malignant B-Disease 1 1.0
melanoma I-Disease 1 1.0
and O 1 0.5989509224891663
thyroid B-Disease 1 0.9999982118606567
tumours I-Disease 1 1.0
. O 0 1.5465207070519682e-06

In O 0 2.0513574838787463e-08
addition O 0 6.676775132774537e-09
, O 0 2.4742052850967866e-09
PTEN O 0 3.834883045783499e-06
was O 0 4.2925389465153785e-08
identified O 0 2.4288178135378757e-09
as O 0 5.89645415827178e-11
the O 0 3.220764280276178e-11
susceptibility O 0 5.162158256410976e-09
gene O 0 1.0801320726727681e-08
for O 0 6.913540295805376e-10
two O 0 2.332487412104456e-07
hamartoma B-Disease 1 0.9908733367919922
syndromes I-Disease 1 0.9920607805252075
Cowden B-Disease 1 0.8334163427352905
disease I-Disease 1 0.9408053159713745
( O 0 7.001765833791751e-09
CD B-Disease 0 6.859986569907051e-06
; O 0 6.008552588809835e-08
MIM O 0 0.0003914636909030378
158350 O 0 2.1888718038098887e-07
) O 0 1.0552371199068489e-09
and O 0 1.880750888361149e-09
Bannayan B-Disease 0 6.134540308266878e-05
- I-Disease 0 0.0001514382311142981
Zonana I-Disease 0 0.0006027716444805264
( I-Disease 0 6.954330888930826e-09
BZS I-Disease 0 8.647413665130443e-07
) I-Disease 0 4.1389860983009896e-10
or I-Disease 0 4.898398575647889e-09
Ruvalcaba I-Disease 0 8.743076250539161e-06
- I-Disease 0 7.5820698839379475e-06
Riley I-Disease 0 0.00010062108776764944
- I-Disease 0 0.08726881444454193
Smith I-Disease 0 0.2500048875808716
syndrome I-Disease 1 0.9764955043792725
( O 0 2.773675289446942e-09
MIM O 0 5.292602872941643e-05
153480 O 0 2.898611910495674e-07
) O 0 3.0078859403204206e-09
. O 0 1.163445606522373e-08

Constitutive O 0 2.818500661305734e-06
DNA O 0 1.213999894389417e-06
from O 0 6.536628571751635e-09
37 O 0 7.455672523803969e-09
CD B-Disease 0 1.5319368174004921e-07
families O 0 1.548911776616535e-09
and O 0 9.142493984093392e-10
seven O 0 4.092164385127717e-09
BZS B-Disease 0 1.0631721352183376e-06
families O 0 8.040125787367458e-10
was O 0 3.124439151847014e-09
screened O 0 4.2371436137500496e-08
for O 0 2.7460342888474543e-09
germline O 0 2.293459374413942e-06
PTEN O 0 5.609057916444726e-05
mutations O 0 2.3182945369626395e-05
. O 0 5.724823637365262e-08

PTEN O 0 0.0005901968688704073
mutations O 0 0.00047884168452583253
were O 0 8.357130809599767e-08
identified O 0 5.572061034797571e-09
in O 0 1.8925855327367458e-10
30 O 0 6.611217684415749e-10
of O 0 5.5912292157289656e-11
37 O 0 9.601984096718752e-09
( O 0 3.519686764263952e-10
81 O 0 1.7429105936273004e-09
% O 0 2.5477578380339594e-10
) O 0 7.25868601336721e-11
CD B-Disease 0 7.538195632150746e-07
families O 0 4.736201986155208e-10
, O 0 5.249869636236859e-11
including O 0 8.065771661680543e-11
missense O 0 5.805478622278315e-07
and O 0 1.50024419554029e-08
nonsense O 0 1.263853448563168e-07
point O 0 2.104647478518018e-08
mutations O 0 3.2410621741973955e-08
, O 0 2.082153893745442e-10
deletions O 0 4.972807587932948e-08
, O 0 5.673467251554598e-10
insertions O 0 1.2788342473868397e-07
, O 0 3.1534863609294916e-10
a O 0 9.09522013259334e-10
deletion O 0 5.2958662308810744e-06
/ O 0 3.155708691338077e-05
insertion O 0 3.4424095929352916e-07
and O 0 1.7558107856530114e-08
splice O 0 0.00020603567827492952
site O 0 4.043279659526888e-06
mutations O 0 1.7037578800227493e-05
. O 0 5.15764320141443e-08

These O 0 4.1338381606692565e-08
mutations O 0 1.9804299427050864e-06
were O 0 1.1712608660729984e-08
scattered O 0 7.1644459254116555e-09
over O 0 1.95236560251999e-09
the O 0 4.021387389752107e-10
entire O 0 4.611389936570731e-09
length O 0 6.8510073170102714e-09
of O 0 8.874329743280285e-11
PTEN O 0 2.2451943948453845e-07
, O 0 8.762429670738925e-11
with O 0 4.078506195964726e-12
the O 0 3.3951414596389284e-11
exception O 0 5.907914435443473e-11
of O 0 3.3132290314097368e-12
the O 0 1.4292281247385574e-10
first O 0 4.2847517534028157e-08
, O 0 1.5819396903538063e-09
fourth O 0 1.1342053767293692e-06
and O 0 1.7525787043837227e-08
last O 0 6.55773533253523e-08
exons O 0 1.8563799812909565e-06
. O 0 3.21062465502564e-08

A O 0 3.5836515621667786e-07
hot O 0 1.468033588025719e-06
spot O 0 1.5994487512216438e-06
for O 0 1.288017692502308e-09
PTEN O 0 9.494816595179145e-07
mutation O 0 6.152906451006857e-08
in O 0 5.046605910941082e-10
CD B-Disease 0 9.512689871371549e-07
was O 0 2.2768736229750175e-08
identified O 0 2.4941053666793778e-09
in O 0 5.377596631883641e-11
exon O 0 2.072665949981456e-08
5 O 0 1.0138809791726544e-09
that O 0 1.9797908104579598e-11
contains O 0 1.6796947513442184e-11
the O 0 1.2736281473912925e-10
PTPase O 0 1.6745796926898038e-07
core O 0 7.195944284887901e-09
motif O 0 1.3393316455889703e-09
, O 0 2.4895354874820974e-11
with O 0 4.009160191331684e-12
13 O 0 1.3287460021160769e-10
of O 0 9.253041041712429e-12
30 O 0 8.046215915769039e-10
( O 0 7.172176741399028e-11
43 O 0 3.2023785845325392e-09
% O 0 3.3201913440805697e-10
) O 0 1.9742861512295207e-10
CD B-Disease 0 1.9132119177811546e-06
mutations O 0 3.3195522064488614e-07
identified O 0 1.7883456493450467e-08
in O 0 1.5111530082823066e-10
this O 0 7.84478870752281e-10
exon O 0 1.65151152486942e-06
. O 0 6.883599468210377e-08

Seven O 0 3.5349765425962687e-07
of O 0 1.949399974776611e-09
30 O 0 7.298147419732004e-09
( O 0 8.78670136650328e-10
23 O 0 8.867655054700663e-09
% O 0 9.045412752151094e-10
) O 0 2.3606003263232367e-10
were O 0 6.937193874900771e-11
within O 0 7.330166855445963e-12
the O 0 6.797141322012479e-11
core O 0 6.825495724172015e-09
motif O 0 5.964897020760418e-09
, O 0 2.563952106182654e-10
the O 0 9.311346832463485e-11
majority O 0 2.418387712310732e-10
( O 0 1.1364650887024652e-10
five O 0 4.261437591690509e-10
of O 0 1.1833578388020793e-11
seven O 0 5.188464324845654e-09
) O 0 5.7645669487849105e-11
of O 0 3.77387964628495e-12
which O 0 3.4625837752599864e-09
were O 0 2.387061215358699e-09
missense O 0 1.0581725007341447e-07
mutations O 0 2.659072784183536e-08
, O 0 7.36333910511533e-11
possibly O 0 2.095993378858907e-09
pointing O 0 1.0653842252850154e-07
to O 0 1.2111051050922583e-09
the O 0 1.2272448335348685e-10
functional O 0 1.078673927956686e-09
significance O 0 7.670361013012439e-10
of O 0 7.815095098839819e-11
this O 0 2.842794666335635e-09
region O 0 2.5174356323987013e-06
. O 0 1.7421378117887798e-07

Germline O 0 0.0016594635089859366
PTEN O 0 0.0003758722741622478
mutations O 0 0.0003966071817558259
were O 0 1.9384785332476895e-07
identified O 0 3.797339687139356e-08
in O 0 2.7065241714474553e-10
four O 0 5.985110740347466e-10
of O 0 3.3486692585515954e-11
seven O 0 4.628167182829657e-09
( O 0 2.811206545327849e-10
57 O 0 7.463356155312795e-09
% O 0 5.314218509688828e-10
) O 0 5.50027634549366e-10
BZS B-Disease 0 6.206667535479937e-07
families O 0 2.0773947007057814e-09
studied O 0 2.5036438699999053e-08
. O 0 5.7887934445943756e-08

Interestingly O 0 1.5606741726514883e-05
, O 0 1.7809588470640847e-08
none O 0 4.183753343767194e-09
of O 0 4.57473156578736e-11
these O 0 1.3116184527373065e-10
mutations O 0 7.578518790296584e-08
was O 0 8.339324786277302e-09
observed O 0 2.7111755063202736e-09
in O 0 7.69845437398331e-11
the O 0 4.837802380919243e-10
PTPase O 0 3.778241534746485e-06
core O 0 2.9755199193459703e-07
motif O 0 6.629229574173223e-07
. O 0 5.725981111481815e-08

It O 0 4.324044766690349e-07
is O 0 1.9178161281274697e-09
also O 0 2.464346504638115e-10
worthy O 0 3.5997602121362604e-10
of O 0 3.756803548804477e-11
note O 0 1.3798983289348143e-08
that O 0 3.368668885506132e-11
a O 0 2.1074370026852307e-10
single O 0 2.805825971563536e-08
nonsense O 0 6.456806289634187e-08
point O 0 9.289217395291871e-09
mutation O 0 1.8072211505071323e-09
, O 0 6.346904252163554e-11
R233X O 0 1.9495265402014184e-09
, O 0 1.4277104498638948e-10
was O 0 8.883868640729986e-10
observed O 0 5.320811014009053e-10
in O 0 3.7504960942458254e-11
the O 0 6.380720951604246e-11
germline O 0 8.72910899119006e-09
DNA O 0 1.2328933429728295e-08
from O 0 9.273452838964857e-11
two O 0 9.487791108320209e-11
unrelated O 0 2.6064568281469747e-09
CD B-Disease 0 2.0129950826230925e-06
families O 0 1.9643295878779554e-09
and O 0 2.5923760915702587e-09
one O 0 1.4631869049708257e-08
BZS B-Disease 0 6.651903277088422e-06
family O 0 5.029496819020096e-08
. O 0 6.191284285250731e-08

Genotype O 0 0.06101406738162041
- O 0 0.0008003440452739596
phenotype O 0 0.00043855051626451313
studies O 0 1.645664582383688e-07
were O 0 1.9345222312949772e-08
not O 0 5.49939538352362e-10
performed O 0 6.2394365230034055e-09
on O 0 3.203747045432692e-09
this O 0 7.561527792798728e-11
small O 0 1.4672713044561192e-10
group O 0 3.6070971987101075e-08
of O 0 2.599276627268665e-10
BZS B-Disease 0 2.3865447928983485e-06
families O 0 1.1504351249413958e-08
. O 0 4.541250575584854e-08

However O 0 3.703344759742322e-07
, O 0 1.1208975081444805e-08
genotype O 0 5.127421900397167e-06
- O 0 6.749834028596524e-06
phenotype O 0 8.841388080327306e-06
analysis O 0 1.7083433334619258e-08
inthe O 0 8.757418754612445e-07
group O 0 3.0286813057500694e-08
of O 0 7.957461772845065e-11
CD B-Disease 0 7.920614848444529e-07
families O 0 1.6231899158114516e-09
revealed O 0 2.628340212140756e-07
two O 0 7.266169887998331e-10
possible O 0 5.52396350883555e-10
associations O 0 1.2031261403810944e-11
worthy O 0 1.417937989245388e-10
of O 0 1.3692543626708797e-11
follow O 0 1.7341143632165767e-08
- O 0 2.4712264234949544e-07
up O 0 1.606204932613764e-06
in O 0 5.026799421159467e-09
independent O 0 4.2773621089509106e-08
analyses O 0 9.979004289561999e-08
. O 0 1.7476750713285583e-08

The O 0 6.349190329046905e-08
first O 0 9.057212224661271e-08
was O 0 4.296274269677269e-08
an O 0 2.2021560963647602e-10
association O 0 9.015850566118644e-11
noted O 0 6.768449689609213e-10
in O 0 5.223202079185363e-11
the O 0 3.5473868287283494e-10
group O 0 1.5358478933080733e-08
of O 0 1.7489728415531758e-11
CD B-Disease 0 1.6742488924137433e-06
families O 0 4.499054462314689e-09
with O 0 6.324557233483574e-08
breast B-Disease 0 0.08155828714370728
disease I-Disease 0 0.00020801553910132498
. O 0 6.039368116717014e-08

A O 0 2.561741041517962e-07
correlation O 0 4.7543491632495716e-07
was O 0 6.199627478054026e-08
observed O 0 4.648603724177747e-09
between O 0 2.927353498494156e-11
the O 0 7.093460541174323e-11
presence O 0 8.79075812143526e-10
/ O 0 2.151818080164958e-06
absence O 0 4.4862674686285686e-10
of O 0 5.252681536255244e-12
a O 0 3.4961553097012654e-10
PTEN O 0 4.1005350226441806e-07
mutation O 0 2.406481947048178e-08
and O 0 1.6071695363439886e-10
the O 0 9.007686263551307e-11
type O 0 3.424034034082979e-08
of O 0 1.7484110825805033e-09
breast O 0 0.000502934621181339
involvement O 0 3.6866171626570576e-07
( O 0 1.7712601163566433e-08
unaffected O 0 9.502122338744812e-06
versus O 0 2.1315424874046585e-06
benign O 0 0.0004701299185398966
versus O 0 4.325919235270703e-06
malignant O 0 0.012217416428029537
) O 0 3.638683310214219e-08
. O 0 8.549947949632042e-08

Specifically O 0 1.4658314739790512e-07
and O 0 8.50581560740693e-09
more O 0 2.978437496636843e-10
directly O 0 2.4551898292202168e-09
, O 0 2.835311097015847e-09
an O 0 1.0312704024073582e-09
association O 0 1.4647190127448084e-09
was O 0 6.523826812099287e-08
also O 0 6.046258160807838e-09
observed O 0 1.3290026856793702e-09
between O 0 1.7578655545080757e-11
the O 0 3.7536522501380176e-11
presence O 0 1.0193718785744821e-10
of O 0 1.2218255053542126e-11
a O 0 2.6590205592924576e-09
PTEN O 0 2.976533505716361e-05
mutation O 0 1.834397880884353e-05
and O 0 6.456079404415505e-07
malignant B-Disease 1 0.999755322933197
breast I-Disease 1 0.9924483299255371
disease I-Disease 0 0.1966409683227539
. O 0 1.8330423756651726e-07

Secondly O 0 0.0020452351309359074
, O 0 8.790263450464408e-08
there O 0 2.938959520193407e-09
appeared O 0 5.440610451046268e-08
to O 0 2.1463983923553087e-09
be O 0 1.0426468577406922e-09
an O 0 9.936034217616907e-10
interdependent O 0 6.7800406213791575e-06
association O 0 5.228557031777825e-10
between O 0 3.7158215393517935e-10
mutations O 0 2.4105344209601753e-07
upstream O 0 8.16079790411095e-08
and O 0 2.4303563606054013e-09
within O 0 1.50875104076853e-10
the O 0 1.9992546507197062e-10
PTPase O 0 2.8777827765225084e-07
core O 0 1.8909240395714733e-08
motif O 0 6.2400080658164825e-09
, O 0 4.2187506960056353e-11
the O 0 8.774818545387308e-12
core O 0 1.2291921924756366e-09
motif O 0 3.78767184283646e-10
containing O 0 4.1084351198872326e-11
the O 0 1.8469347579097573e-11
majority O 0 6.22865717336829e-11
of O 0 1.5569727798703248e-11
missense O 0 6.002058228204987e-08
mutations O 0 7.281590796992532e-08
, O 0 4.331039415994553e-10
and O 0 3.426421923968803e-10
the O 0 2.1285609386190174e-10
involvement O 0 2.4231170403510305e-09
of O 0 3.1954258683519754e-11
all O 0 2.942339982769937e-10
major O 0 1.8484802577489745e-09
organ O 0 2.60021749909356e-07
systems O 0 4.752322979584278e-07
( O 0 1.3586570757340155e-09
central O 0 4.8864663426684274e-08
nervous O 0 2.445857944621821e-06
system O 0 5.1919490928753476e-09
, O 0 4.519748575404492e-09
thyroid O 0 1.9582987079047598e-05
, O 0 2.161885070961489e-08
breast O 0 0.0006649806746281683
, O 0 3.245072548452299e-06
skin O 1 0.9999994039535522
and O 0 0.004723121412098408
gastrointestinal O 0 0.41553953289985657
tract O 0 0.000553100137040019
) O 0 1.6353763498955232e-07
. O 0 2.0175795611976355e-07

However O 0 4.142624163705477e-07
, O 0 1.8246951727363125e-09
these O 0 5.6791914920806263e-11
observations O 0 4.9197095286501735e-09
would O 0 5.344441778021292e-09
need O 0 3.4065467113819636e-10
to O 0 4.670348552338055e-10
be O 0 8.677097373954723e-10
confirmed O 0 2.131369303270958e-09
by O 0 2.286072589910426e-12
studying O 0 2.4547282609366228e-11
a O 0 8.367279091814339e-11
larger O 0 4.341195736223824e-10
number O 0 8.335886425570038e-10
of O 0 7.539177615534243e-11
CD B-Disease 0 1.028800215863157e-05
families O 0 1.640164271066169e-08
. O 0 2.981288105274871e-08

Molecular O 0 0.0005148450145497918
defects O 1 0.9997715353965759
leading O 0 3.620241955104575e-07
to O 0 4.1853178700534954e-09
human O 0 3.0232429892862456e-09
complement B-Disease 0 9.301167551711842e-07
component I-Disease 0 0.0015838824911043048
C6 I-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 6.073046510124414e-10
an O 0 5.288462029406915e-11
African O 0 3.861301556273844e-10
- O 0 4.608420312024464e-08
American O 0 1.8036647730923505e-08
family O 0 3.403043180583154e-08
. O 0 3.8315924655307754e-08

Complement B-Disease 0 0.00010344797919970006
component I-Disease 0 0.035287998616695404
C6 I-Disease 1 1.0
deficiency I-Disease 1 1.0
( O 0 3.666592931494961e-07
C6D B-Disease 0 0.00014850462321192026
) O 0 1.34103990134804e-08
was O 0 7.503882670789608e-08
diagnosed O 0 2.9034858926024754e-06
in O 0 1.3000660444018042e-11
a O 0 3.967689510275818e-10
16 O 0 2.9313342864156766e-09
- O 0 1.6244202427628807e-08
year O 0 2.3370736457195562e-08
- O 0 1.890895084954991e-08
old O 0 2.5599479869242714e-08
African O 0 3.032232798183543e-10
- O 0 1.6450761863850971e-09
American O 0 1.175463171243507e-09
male O 0 1.1635898466977324e-08
with O 0 4.847080248282509e-08
meningococcal B-Disease 1 0.9999994039535522
meningitis I-Disease 1 0.9999959468841553
. O 0 1.8982855465310422e-07

The O 0 1.7475025515523157e-07
patients O 0 5.165912170923548e-06
father O 0 8.290150077527869e-08
and O 0 1.680033712148088e-08
two O 0 2.2337335536803948e-08
brothers O 0 6.022147317708004e-06
also O 0 5.4191513498835775e-08
had O 0 5.6139779047725824e-08
C6D B-Disease 0 4.719538083008956e-06
, O 0 1.1002257993553144e-09
but O 0 2.0576096382285414e-10
gave O 0 3.890237465498103e-09
no O 0 3.32491895127518e-10
history O 0 7.700995396930921e-11
of O 0 1.122923420915356e-09
meningitis B-Disease 1 0.999998927116394
or O 0 5.372735145670049e-08
other O 0 5.338338660010322e-09
neisserial B-Disease 0 0.0013526169350370765
infection I-Disease 0 0.0001471933937864378
. O 0 5.860438179183802e-08

By O 0 5.759769994284625e-09
using O 0 8.670368423224772e-09
exon O 0 4.0079839891404845e-07
- O 0 8.678082963342604e-08
specific O 0 1.5053139845733199e-09
polymerase O 0 4.9080433939252543e-08
chain O 0 2.3132126614200388e-07
reaction O 0 2.8405506835582628e-09
( O 0 9.692172064923454e-11
PCR O 0 4.382035623251568e-09
) O 0 3.020611538673279e-11
/ O 0 4.121585739369493e-09
single O 0 1.260287096904733e-09
- O 0 1.746648514711069e-08
strand O 0 3.092200358878472e-06
conformation O 0 1.4244289303633195e-08
polymorphism O 0 8.920646443755231e-10
as O 0 1.3420152142340491e-11
a O 0 2.458322087561804e-11
screening O 0 3.228269040977949e-10
step O 0 1.0517067217108433e-09
and O 0 1.4955193333721084e-11
nucleotide O 0 1.0066204536585133e-09
sequencing O 0 1.4686691862664247e-09
of O 0 3.3671336552298925e-11
target O 0 5.7721127433296715e-08
exons O 0 3.1685601697972743e-07
, O 0 2.2473263250333275e-09
we O 0 1.7989775225046856e-09
determined O 0 1.2408878369285503e-09
that O 0 6.154670523228489e-11
the O 0 1.099486751643397e-10
proband O 0 1.4904733802723058e-07
was O 0 5.73300240613861e-10
a O 0 6.373800098824489e-11
compound O 0 8.049270694421296e-10
heterozygote O 0 1.4751353916153676e-08
for O 0 2.4059745862281545e-10
two O 0 1.7951796715820478e-09
C6 O 0 3.392669441382168e-06
gene O 0 8.81479024883447e-07
mutations O 0 1.6667645468260162e-06
. O 0 2.0893446972536367e-08

The O 0 2.2988139392055018e-08
first O 0 6.0755169783988094e-09
, O 0 3.453690666788134e-10
1195delC O 0 6.766878613007066e-09
located O 0 5.751895626460168e-10
in O 0 2.2030173518761131e-10
exon O 0 5.5131064158331355e-08
7 O 0 2.2658349863036165e-08
, O 0 7.289820136424652e-11
is O 0 1.1240923122879387e-11
a O 0 9.690359625835754e-11
novel O 0 1.571809904454824e-09
mutation O 0 1.3195540660149163e-08
, O 0 1.438046626223155e-10
while O 0 1.3941933718619737e-10
the O 0 7.100851850960765e-11
second O 0 1.875944022344811e-08
, O 0 1.8266581303105767e-10
1936delG O 0 3.4620886157910036e-09
in O 0 4.984689050413493e-11
exon O 0 4.475375092738432e-08
12 O 0 9.040864057396902e-09
, O 0 2.538289856079956e-10
has O 0 7.149221215030366e-10
been O 0 9.070775797148656e-10
described O 0 5.943296521593311e-09
before O 0 6.237818261922712e-09
to O 0 2.540039290011009e-09
cause O 0 1.4831922356961513e-09
C6D B-Disease 0 5.532493787541171e-07
in O 0 8.119672989526094e-11
an O 0 5.0476043483849153e-11
unrelated O 0 2.8262132634182535e-09
African O 0 6.27898566474272e-10
- O 0 3.880190746485823e-08
American O 0 5.939976066571262e-09
individual O 0 8.597892175998822e-09
. O 0 2.7394857937679262e-08

Both O 0 2.741031153163931e-07
mutations O 0 1.5354255083366297e-05
result O 0 1.147415886748604e-07
in O 0 1.1342682348924882e-08
premature O 0 1.3342630609258777e-06
termination O 0 5.214261591390823e-07
codons O 0 5.867635991307907e-06
and O 0 7.906292864845454e-08
C6 O 0 4.624022767529823e-05
null O 0 0.00019986247934866697
alleles O 0 1.963171598617919e-06
. O 0 2.14112532148647e-07

Allele O 0 4.087415072717704e-05
- O 0 1.2588664048962528e-06
specific O 0 1.1975348712667255e-08
PCR O 0 2.0181472848435078e-07
indicated O 0 1.1042207148648231e-08
that O 0 4.057117489186801e-11
the O 0 3.56363341613708e-11
probands O 0 2.3599460519108106e-07
two O 0 3.6624385746364396e-09
brothers O 0 1.5561356292437267e-07
also O 0 1.3167550383386128e-09
inherited O 0 7.529786572035846e-09
the O 0 7.147540892482596e-11
1195delC O 0 1.9475800527857245e-08
mutation O 0 2.51589726829593e-09
from O 0 6.970059945876628e-11
their O 0 7.947121294371584e-10
heterozygous O 0 1.8973439708247497e-08
mother O 0 6.364030014083255e-08
and O 0 2.2442453451176902e-10
the O 0 1.6715777373388363e-10
1936delG O 0 6.744756575471911e-08
mutation O 0 5.721709328554425e-09
from O 0 2.3727883546875717e-10
their O 0 2.780709662530967e-09
homozygous O 0 1.1712679537367876e-07
father O 0 3.648023039204418e-08
. O 0 4.635870798352926e-09
. O 0 2.2422579348813088e-08

PAX6 O 0 0.019745467230677605
mutations O 0 0.016507355496287346
reviewed O 0 3.844044840661809e-05
. O 0 5.6241799484269e-07

Mutations O 0 0.0005933449720032513
in O 0 7.864196760465347e-08
PAX6 O 0 2.6272267859894782e-05
are O 0 1.3515525587592947e-08
responsible O 0 2.1216763457232446e-08
for O 0 2.097773066367381e-09
human O 0 4.089435634568872e-08
aniridia B-Disease 1 1.0
and O 0 1.282756670661911e-06
have O 0 1.0349044288204823e-08
also O 0 4.313687629320384e-09
been O 0 3.2850541731299643e-10
found O 0 4.775060347128601e-10
in O 0 2.932747933392932e-10
patients O 0 2.9441771243199355e-09
with O 0 1.81523940323558e-09
Peters B-Disease 1 1.0
anomaly I-Disease 1 0.9999998807907104
, O 0 2.017051770053513e-08
with O 0 2.592005046153645e-07
congenital B-Disease 1 0.9999998807907104
cataracts I-Disease 1 0.9999984502792358
, O 0 4.952060095320121e-08
with O 0 6.34152925726994e-08
autosomal B-Disease 1 0.999846339225769
dominant I-Disease 0 0.10002411901950836
keratitis I-Disease 1 0.9693040251731873
, O 0 1.8125415834902014e-08
and O 0 4.684920007491655e-09
with O 0 6.955102804795388e-08
isolated B-Disease 0 0.20432528853416443
foveal I-Disease 1 1.0
hypoplasia I-Disease 1 1.0
. O 0 2.4206622128986055e-06

No O 0 3.5059019865002483e-07
locus O 0 1.9035010723200685e-07
other O 0 2.7627087284542995e-09
than O 0 5.619084753050174e-09
chromosome O 0 6.207736441865563e-05
11p13 O 0 1.9219717160012806e-06
has O 0 3.8052135664656817e-08
been O 0 4.601830472239499e-09
implicated O 0 8.010849938955289e-08
in O 0 1.2851276487424457e-08
aniridia B-Disease 1 1.0
, O 0 1.4818441584907305e-08
and O 0 1.5129245634071253e-09
PAX6 O 0 3.970502859829139e-07
is O 0 7.127042844778941e-10
clearly O 0 9.28735310878892e-10
the O 0 7.050996592150582e-11
major O 0 2.32823627044354e-09
, O 0 2.039473034898265e-09
if O 0 4.470936509903822e-09
not O 0 3.7821273890514817e-10
only O 0 7.462465367868987e-11
, O 0 2.2394476550946507e-10
gene O 0 1.7965232856909097e-08
responsible O 0 1.3952420374607755e-07
. O 0 4.314833645935323e-08

Twenty O 0 1.9094752587989205e-06
- O 0 5.0564999583002646e-06
eight O 0 1.2829900697397534e-07
percent O 0 6.128411200734263e-07
of O 0 6.191228779650615e-11
identified O 0 6.111406936071262e-09
PAX6 O 0 5.090676040708786e-07
mutations O 0 2.7170531780029705e-07
are O 0 7.731050799542061e-10
C O 0 2.7759904241975164e-07
- O 0 2.9272600841068197e-06
T O 0 2.3539954781881534e-05
changes O 0 6.682355113696303e-09
at O 0 1.7765204862740802e-09
CpG O 0 6.38859702917216e-08
dinucleotides O 0 8.699677067625089e-08
, O 0 5.0884647190274634e-11
20 O 0 6.924952972164888e-11
% O 0 5.670802716295498e-11
are O 0 2.948388755363851e-11
splicing O 0 1.7437035637613008e-07
errors O 0 9.833752301346976e-06
, O 0 3.535768067219891e-10
and O 0 1.4880909005032805e-10
more O 0 4.110245477306762e-11
than O 0 1.315725167705395e-10
30 O 0 6.276124064896749e-10
% O 0 2.7904792365696096e-10
are O 0 1.4463236164274917e-10
deletion O 0 1.016515227547643e-07
or O 0 5.7401308595217415e-08
insertion O 0 4.2840531477850163e-07
events O 0 8.079271651695308e-08
. O 0 1.4380046309270256e-07

There O 0 5.449614803865188e-08
is O 0 2.592336345585977e-09
a O 0 6.887220571627495e-09
noticeably O 0 3.6910571452608565e-06
elevated O 0 2.237025711337992e-07
level O 0 9.387854937870088e-10
of O 0 1.6961491239309012e-11
mutation O 0 1.8487376074460826e-09
in O 0 2.4054182257149392e-11
the O 0 4.1569116204787093e-11
paired O 0 8.677284668578977e-09
domain O 0 3.4225307032897945e-09
compared O 0 4.099546924152264e-09
with O 0 2.992072908880594e-11
the O 0 2.0453388982488718e-10
rest O 0 2.020107858768938e-09
of O 0 9.314628061918295e-12
the O 0 2.0286322621743125e-10
gene O 0 4.240150985879154e-08
. O 0 8.20969159320839e-09

Increased O 0 6.683236506432877e-07
mutation O 0 3.7039910694147693e-07
in O 0 8.551831465197779e-10
the O 0 3.766929546067388e-10
homeodomain O 0 1.728969465375485e-07
is O 0 3.174949192441545e-09
accounted O 0 7.503023624622074e-08
for O 0 5.554303197929933e-11
by O 0 1.840197612346106e-11
the O 0 1.2564566054251713e-09
hypermutable O 0 9.092363143281545e-06
CpG O 0 1.1105678368039662e-06
dinucleotide O 0 1.441187151840495e-07
in O 0 1.2388965409115826e-09
codon O 0 3.198059346232185e-07
240 O 0 2.5548748894266282e-08
. O 0 2.1502840397147338e-08

Very O 0 5.271490977065696e-07
nearly O 0 5.977358341624495e-08
all O 0 1.5030474642685476e-09
mutations O 0 1.577951280751222e-07
appear O 0 2.0633579822515458e-07
to O 0 2.244037666798704e-08
cause O 0 1.0127840965878931e-07
loss O 0 1.34594756673323e-07
of O 0 1.4043130373841972e-11
function O 0 3.43512496225884e-10
of O 0 7.243026924758089e-12
the O 0 3.7972541777619995e-11
mutant O 0 2.6375330808292574e-09
allele O 0 6.56836363077673e-08
, O 0 7.392076950551996e-10
and O 0 1.8998841389006316e-10
more O 0 3.8188330969690654e-11
than O 0 4.2157263790976174e-11
80 O 0 1.1470334404517502e-10
% O 0 1.396223969774013e-10
of O 0 1.9339694776188132e-11
exonic O 0 1.8015387013292639e-06
substitutions O 0 8.555184649594594e-08
result O 0 5.273911529712905e-09
in O 0 1.1755955098280424e-09
nonsense O 0 1.511493906036776e-06
codons O 0 4.493149845075095e-06
. O 0 7.110945432486915e-08

In O 0 1.1988352532910085e-08
a O 0 8.920493788089345e-10
gene O 0 1.0908151715227632e-08
with O 0 2.006260435560847e-10
such O 0 4.443912945961692e-11
extraordinarily O 0 4.945525322597177e-09
high O 0 1.1331713345441585e-09
sequence O 0 1.6374567257670947e-09
conservation O 0 2.2083349038304334e-10
throughout O 0 2.392940567919055e-10
evolution O 0 5.082017029423014e-10
, O 0 1.2325956921799275e-10
there O 0 4.1589735128022554e-11
are O 0 1.0321396515244885e-10
presumed O 0 2.790370956518018e-07
undiscovered O 0 7.626362048540614e-07
missense O 0 2.267526724608615e-06
mutations O 0 1.8872885902965209e-06
, O 0 4.4201356463879904e-10
these O 0 1.985364650458621e-11
are O 0 1.0406477068958253e-10
hypothesized O 0 4.9110373545602215e-09
to O 0 1.8714551686116465e-08
exist O 0 1.4510576074044934e-09
in O 0 7.851850419848816e-11
as O 0 2.063859971812576e-09
- O 0 1.2493725307649584e-06
yet O 0 8.485061897545165e-08
unidentified O 0 5.715755833080038e-07
phenotypes O 0 1.0185861754052894e-07
. O 0 1.1971255098330857e-09
. O 0 1.0659610971686106e-08

Genetic O 0 0.00026309280656278133
heterogeneity O 0 5.836913987877779e-05
and O 0 1.0285074125704341e-07
penetrance O 0 4.739143605547724e-06
analysis O 0 1.4848630769392912e-08
of O 0 1.0643631809248433e-10
the O 0 1.3527253761580482e-09
BRCA1 O 0 1.1405309123801999e-05
and O 0 8.408310492313831e-08
BRCA2 O 0 3.6192319385008886e-05
genes O 0 1.3575836419477127e-06
in O 0 3.5128490338820484e-08
breast B-Disease 0 0.033647846430540085
cancer I-Disease 0 0.00038244263851083815
families O 0 1.4918528279395105e-07
. O 0 1.1616101147637892e-07

The O 0 0.0008223573095165193
Breast B-Disease 1 1.0
Cancer I-Disease 1 0.9999998807907104
Linkage O 0 0.0003870198270305991
Consortium O 0 4.418641765369102e-06
. O 0 1.667192179866106e-07

The O 0 1.6175842887378167e-08
contribution O 0 1.1673778388399114e-08
of O 0 3.6870947961453737e-10
BRCA1 O 0 5.726544259232469e-06
and O 0 4.3854709019797156e-07
BRCA2 O 0 0.2542888820171356
to O 0 0.013383110985159874
inherited B-Disease 1 1.0
breast I-Disease 1 1.0
cancer I-Disease 1 1.0
was O 0 1.2344955848675454e-06
assessed O 0 1.2800934712231538e-07
by O 0 2.507679897068016e-10
linkage O 0 1.1318287818085082e-07
and O 0 2.4059116920938095e-09
mutation O 0 3.895568312373143e-09
analysis O 0 3.430070671939234e-10
in O 0 7.014805403215973e-11
237 O 0 4.004800380208451e-10
families O 0 7.615951619355243e-11
, O 0 4.072219991768655e-11
each O 0 4.930152952553613e-10
with O 0 3.2432621033251507e-09
at O 0 1.2714988883999467e-07
least O 0 1.0932535987606684e-09
four O 0 2.3338739829625865e-09
cases O 0 4.1659226068802013e-10
of O 0 4.358402527770977e-10
breast B-Disease 0 0.0005361560033634305
cancer I-Disease 0 5.011866051063407e-06
, O 0 1.0372867842445288e-10
collected O 0 1.4351455579486583e-09
by O 0 7.82683862166067e-10
the O 0 4.529534635366872e-06
Breast B-Disease 1 1.0
Cancer I-Disease 1 0.9999998807907104
Linkage O 0 3.6262927096686326e-06
Consortium O 0 1.6922585643897037e-07
. O 0 1.760008672135882e-08

Families O 0 9.605647619537194e-07
were O 0 2.248622266165512e-08
included O 0 3.327393083285557e-10
without O 0 6.461629564746829e-10
regard O 0 3.4347055755112876e-10
to O 0 3.068994502974931e-10
the O 0 4.393884978082241e-10
occurrence O 0 1.1852711878646005e-07
of O 0 7.4262094251764665e-09
ovarian B-Disease 0 0.00019678739772643894
or I-Disease 0 4.2629866925381066e-07
other I-Disease 0 9.767866515630885e-08
cancers I-Disease 0 0.0005769619019702077
. O 0 1.0381234005762963e-07

Overall O 0 0.0007160313543863595
, O 0 3.8364524357348273e-07
disease O 0 3.2905354601098225e-05
was O 0 1.916950331803946e-08
linked O 0 4.507319673052734e-08
to O 0 3.355891120548904e-09
BRCA1 O 0 1.2827770490275725e-07
in O 0 3.7398972807523023e-10
an O 0 8.925220285060931e-11
estimated O 0 5.339673148085922e-09
52 O 0 6.103042959892946e-09
% O 0 7.158045683963721e-11
of O 0 4.047577811111536e-12
families O 0 1.169855323723823e-10
, O 0 3.182805685675305e-10
to O 0 2.2843673619377114e-09
BRCA2 O 0 6.172855364638963e-07
in O 0 2.387360586997289e-10
32 O 0 8.791697370114093e-10
% O 0 5.796430696536348e-11
of O 0 8.643441865019419e-12
families O 0 2.0795543065332822e-10
, O 0 1.0757522650450824e-09
and O 0 2.608585569774391e-09
to O 0 1.4165790762632469e-09
neither O 0 5.736797703548291e-10
gene O 0 1.9337131895724724e-09
in O 0 4.3274207134347265e-11
16 O 0 9.21154597044449e-10
% O 0 1.950812567041993e-10
( O 0 4.532365108222969e-11
95 O 0 1.790416370717196e-09
% O 0 2.580447633349081e-09
confidence O 0 2.439692892153289e-08
interval O 0 3.4046907515516978e-09
[ O 0 2.8788071926300063e-09
CI O 0 4.407555934449192e-06
] O 0 1.7272769881060412e-09
6 O 0 1.5759396565506734e-10
% O 0 1.167347746244829e-10
- O 0 4.7593076146768e-08
28 O 0 7.778626809340494e-08
% O 0 5.886276466249285e-10
) O 0 7.320278411215853e-11
, O 0 1.0633079833288761e-10
suggesting O 0 1.942848548708298e-09
other O 0 2.5181909335536545e-10
predisposition O 0 6.524374640548558e-08
genes O 0 1.0739982059249087e-07
. O 0 5.616162823685045e-08

The O 0 3.048444341402501e-08
majority O 0 6.279372133377592e-09
( O 0 1.7088085391137042e-09
81 O 0 4.6836872158451115e-09
% O 0 4.1898282066021864e-10
) O 0 4.0473787515926674e-11
of O 0 5.541488448668197e-11
the O 0 3.0035159852559445e-06
breast B-Disease 1 0.9999998807907104
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 1.3494661388335771e-08
were O 0 3.106505275241034e-09
due O 0 1.5722206869739352e-09
to O 0 2.6274207254317616e-09
BRCA1 O 0 1.8925373979072901e-07
, O 0 3.0385435834112684e-10
with O 0 4.4657926662194924e-11
most O 0 3.467869602591378e-10
others O 0 7.414971303632001e-09
( O 0 1.6140569436551289e-10
14 O 0 4.1146659413016096e-09
% O 0 7.337672136564777e-10
) O 0 2.59013588355117e-10
due O 0 7.110983357705436e-09
to O 0 1.0157923213682807e-07
BRCA2 O 0 0.0005220090388320386
. O 0 1.5814916309864202e-07

Conversely O 0 6.26974997430807e-06
, O 0 3.670201031980014e-09
the O 0 1.160341892014749e-10
majority O 0 1.3038362056683184e-10
of O 0 9.709892612175253e-12
families O 0 7.551352598778038e-11
with O 0 7.524413869752777e-10
male B-Disease 0 2.108026677660746e-07
and I-Disease 0 6.151545761667876e-08
female I-Disease 0 4.244634226324706e-07
breast I-Disease 0 5.791250441689044e-05
cancer I-Disease 0 1.7101263438235037e-05
were O 0 1.0504122016641304e-08
due O 0 9.225053609895895e-09
to O 0 2.1101461911143815e-08
BRCA2 O 0 1.71826559380861e-05
( O 0 3.53196827340696e-09
76 O 0 2.391482922803334e-08
% O 0 3.2487599277430945e-09
) O 0 3.5221867644708027e-09
. O 0 3.591397046420752e-08

The O 0 1.4216060328919866e-08
largest O 0 3.272324988756736e-08
proportion O 0 2.012893496328161e-08
( O 0 3.3222580242409094e-09
67 O 0 2.8213619884809304e-08
% O 0 5.471303965443042e-10
) O 0 6.627032950179412e-11
of O 0 1.3866107047288967e-11
families O 0 4.5440787244110936e-10
due O 0 1.208021149778915e-08
to O 0 7.599446405492927e-09
other O 0 1.637968094492237e-10
genes O 0 4.6537134146262815e-09
was O 0 6.659848850176786e-08
found O 0 2.8498521320585724e-09
in O 0 9.507392095819966e-11
families O 0 5.506088640583329e-11
with O 0 2.0495914687668204e-10
four O 0 1.681700645406181e-08
or O 0 3.336547749199781e-08
five O 0 3.2396823002045494e-09
cases O 0 2.242978719424471e-10
of O 0 1.6156154192259464e-10
female O 0 1.844811549744918e-06
breast B-Disease 0 0.0005318144685588777
cancer I-Disease 0 7.85862448537955e-06
only O 0 9.569074421733603e-09
. O 0 3.86332388302435e-08

These O 0 1.7565083965109807e-07
estimates O 0 7.591243956994731e-06
were O 0 2.4749335025830987e-08
not O 0 4.6459445179891645e-09
substantially O 0 1.2193228826617997e-07
affected O 0 2.830788048413524e-09
either O 0 1.0124779903364356e-09
by O 0 1.4302015127753975e-10
changing O 0 1.408798144808543e-08
the O 0 9.542350243307851e-10
assumed O 0 5.962237281664784e-08
penetrance O 0 8.475340962377231e-08
model O 0 1.8525782019551684e-09
for O 0 6.987643796918519e-11
BRCA1 O 0 7.735690132903983e-08
or O 0 8.132111872782843e-09
by O 0 6.878732999870962e-11
including O 0 1.2005639538070767e-10
or O 0 1.7795913720419776e-07
excluding O 0 9.236727237293962e-06
BRCA1 O 0 3.635324173956178e-05
mutation O 0 8.703923413122538e-07
data O 0 5.052606866229326e-07
. O 0 2.4186302738371523e-08

Among O 0 5.6190128105981785e-08
those O 0 3.92546306571262e-09
families O 0 5.319146789695139e-10
with O 0 3.717248509005344e-09
disease O 0 1.5569206880172715e-05
due O 0 2.6204054037748392e-08
to O 0 1.842184538247693e-08
BRCA1 O 0 3.0387147944566095e-06
that O 0 2.2501096541560628e-09
were O 0 5.828917903905051e-10
tested O 0 2.529272069562438e-10
by O 0 2.4972337565876135e-12
one O 0 1.1215480801018973e-11
of O 0 7.786683082176837e-13
the O 0 9.265033185101856e-12
standard O 0 6.455593837273454e-10
screening O 0 4.410905252161257e-10
methods O 0 6.622488113450231e-10
, O 0 2.422173295268948e-10
mutations O 0 1.399974625115874e-08
were O 0 3.7186645429621024e-10
detected O 0 4.3749457390163116e-09
in O 0 6.700979181262223e-12
the O 0 2.9152954356126415e-11
coding O 0 3.3754403716557135e-08
sequence O 0 4.729479030629591e-09
or O 0 3.0115712146283613e-09
splice O 0 1.1187285053892992e-06
sites O 0 6.486997605748002e-09
in O 0 8.255282568647715e-11
an O 0 9.616655388677842e-11
estimated O 0 5.582539319703983e-09
63 O 0 7.546565150562401e-09
% O 0 1.4068068932004962e-10
( O 0 5.385027493365335e-11
95 O 0 2.1842656572346186e-09
% O 0 1.336606159085818e-09
CI O 0 0.00010192817717324942
51 O 0 1.196685985860313e-07
% O 0 2.5563455796628887e-09
- O 0 1.8181063410338538e-07
77 O 0 7.212367592046576e-08
% O 0 2.4776951601523933e-09
) O 0 1.6090720977857131e-09
. O 0 2.9931335632227274e-08

The O 0 3.137985871148885e-08
estimated O 0 5.843874006927763e-08
sensitivity O 0 4.238483342078325e-09
was O 0 6.836492261186322e-09
identical O 0 4.085893401395424e-09
for O 0 2.6260804295019646e-11
direct O 0 3.902140277567412e-10
sequencing O 0 2.0147602697306866e-08
and O 0 2.566370671530649e-09
other O 0 2.9603702822456057e-10
techniques O 0 3.413939353436035e-08
. O 0 3.1646731457612987e-08

The O 0 9.77907035348835e-08
penetrance O 0 1.6932648577494547e-05
of O 0 9.780278809046195e-09
BRCA2 O 0 2.468323327775579e-05
was O 0 2.162536638650181e-08
estimated O 0 1.895447576671927e-09
by O 0 9.843317827495923e-11
maximizing O 0 2.364847873081999e-08
the O 0 4.837176881267169e-09
LOD O 0 0.000261302397120744
score O 0 1.4913463530774607e-07
in O 0 7.692396164493687e-10
BRCA2 O 0 0.0001136066421167925
- O 0 2.882685521399253e-06
mutation O 0 3.291769417046453e-07
families O 0 1.1114190678895852e-09
, O 0 9.785344756707559e-11
over O 0 7.301471094400824e-10
all O 0 1.1572922620217696e-09
possible O 0 1.1539007083172237e-08
penetrance O 0 1.4685797395941336e-06
functions O 0 2.6291663957067613e-08
. O 0 3.8310588479362195e-08

The O 0 1.5373514017369416e-08
estimated O 0 6.26051530616678e-08
cumulative O 0 7.741113563497493e-07
risk O 0 3.0010113505340996e-07
of O 0 1.5546833820323513e-09
breast B-Disease 0 0.0007421105983667076
cancer I-Disease 0 0.00016041604976635426
reached O 0 5.283459358906839e-07
28 O 0 1.320203590893243e-08
% O 0 3.289763184088912e-10
( O 0 6.663333079748313e-11
95 O 0 1.3247180019604343e-09
% O 0 1.7187619105740737e-09
CI O 0 2.8020400350214913e-05
9 O 0 6.497052229548217e-09
% O 0 2.7846625005878423e-10
- O 0 2.998247694563361e-08
44 O 0 5.113727663541567e-09
% O 0 7.028760212746121e-11
) O 0 5.644189976505842e-12
by O 0 1.4446960988623303e-11
age O 0 5.419817927787562e-10
50 O 0 1.8826665226789885e-10
years O 0 1.3296433398757301e-10
and O 0 2.980949653785814e-10
84 O 0 2.3242861801886505e-10
% O 0 2.4485464003576318e-11
( O 0 1.7463362353420386e-11
95 O 0 8.944209262118363e-10
% O 0 5.808962200148926e-10
CI O 0 1.5669840649934486e-05
43 O 0 6.267657504110957e-09
% O 0 2.876824334308026e-10
- O 0 9.679545165397485e-09
95 O 0 1.6288538517983397e-08
% O 0 1.2143410721421333e-09
) O 0 1.0888579621282091e-10
by O 0 1.9131131401284307e-10
age O 0 4.437302525417408e-09
70 O 0 2.0607957562646106e-09
years O 0 2.7014763759325433e-09
. O 0 6.1358877978534565e-09

The O 0 2.7115574994240887e-06
corresponding O 1 0.7997019290924072
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
risks O 0 0.0005183969042263925
were O 0 2.0339035344818512e-08
0 O 0 2.8477453284381227e-08
. O 0 4.9565578308374825e-08

4 O 0 4.820453796128277e-07
% O 0 2.108400032341251e-08
( O 0 9.231597153380733e-10
95 O 0 3.3689102618694733e-09
% O 0 2.9159656911303955e-09
CI O 0 9.218721061188262e-06
0 O 0 2.190987613559514e-09
% O 0 3.4425692851947076e-10
- O 0 4.284765875439689e-09
1 O 0 2.4474191562262604e-09
% O 0 1.4302889428385868e-10
) O 0 1.3683693067534364e-11
by O 0 2.1713368950071477e-11
age O 0 3.981426299759505e-10
50 O 0 8.290470393523819e-11
years O 0 1.1502584995604082e-10
and O 0 1.7312472289088277e-10
27 O 0 8.981768107041432e-10
% O 0 3.426583669585703e-11
( O 0 1.181082662227162e-11
95 O 0 3.7168779165597243e-10
% O 0 6.604449209746122e-10
CI O 0 1.9386186522751814e-06
0 O 0 7.128620471696934e-10
% O 0 2.5563834382680284e-10
- O 0 1.895687162800641e-08
47 O 0 5.0567571463489e-08
% O 0 4.661147023909962e-10
) O 0 4.5889413796684764e-11
by O 0 1.2150425110490914e-10
age O 0 2.4617545779648253e-09
70 O 0 1.8506886023672564e-09
years O 0 2.5268573899950297e-09
. O 0 7.0503176630154485e-09

The O 0 7.405561319728804e-08
lifetime O 0 9.079071787709836e-07
risk O 0 1.1577519671845948e-06
of O 0 4.793111685330587e-09
breast B-Disease 0 0.005377588327974081
cancer I-Disease 0 3.361852213856764e-05
appears O 0 3.372183954297725e-08
similar O 0 6.573696587075517e-10
to O 0 2.3554427297511893e-09
the O 0 3.4294164730219734e-10
risk O 0 1.3489797723309493e-08
in O 0 8.329938128159853e-11
BRCA1 O 0 3.2566475738349254e-07
carriers O 0 2.286862077482965e-08
, O 0 1.2980676533658198e-09
but O 0 1.531783477837223e-09
there O 0 1.1138655275910736e-10
was O 0 1.0504557224066957e-09
some O 0 6.4134175400965e-12
suggestion O 0 1.1545885775232634e-10
of O 0 2.578653002932585e-12
a O 0 1.435189411758131e-09
lower O 0 6.977437578825629e-07
risk O 0 3.466973552690433e-08
in O 0 7.413412106416217e-10
BRCA2 O 0 4.764425739267608e-06
carriers O 0 3.145746063637489e-08
< O 0 1.2493954315573319e-08
50 O 0 2.9201066009676424e-09
years O 0 6.202046654024684e-10
of O 0 1.127251209043223e-10
age O 0 2.6371369088451502e-08
. O 0 2.9300334603021838e-08

Eye B-Disease 1 0.9998570680618286
movement I-Disease 0 0.00010420180478831753
abnormalities I-Disease 1 0.9065278172492981
correlate O 0 2.806307975333766e-06
with O 0 3.3017211187313933e-09
genotype O 0 9.128544479608536e-05
in O 0 6.904690508235944e-08
autosomal O 1 0.9999971389770508
dominant O 1 0.9995915293693542
cerebellar B-Disease 1 0.9999839067459106
ataxia I-Disease 1 0.999998927116394
type I-Disease 0 0.0009772558696568012
I I-Disease 0 0.0005977542605251074
. O 0 3.3665614296296553e-07

We O 0 1.9180679373675957e-06
compared O 0 2.707080000163842e-07
horizontal O 0 1.715860162221361e-05
eye O 1 0.977200984954834
movements O 0 5.357209010981023e-05
( O 0 5.521503965155716e-08
visually O 0 5.433827254819334e-07
guided O 0 5.187681040297321e-07
saccades O 0 9.871891052171122e-06
, O 0 4.183234647570089e-09
antisaccades O 0 2.535805947445624e-07
, O 0 7.362991327752866e-10
and O 0 8.508699300691092e-10
smooth O 0 8.292285258448828e-08
pursuit O 0 5.545821935015738e-08
) O 0 4.909658235519032e-10
in O 0 1.5249700113795228e-10
control O 0 9.932158917536071e-08
subjects O 0 1.1304238434206582e-08
( O 0 2.0048078752665788e-09
n O 0 8.12976281849842e-07
= O 0 9.425519351680123e-07
14 O 0 7.784518629705417e-08
) O 0 1.2527928694439083e-09
and O 0 5.602711183883002e-09
patients O 0 6.045712819258142e-10
with O 0 5.8299680187612335e-12
three O 0 9.912903831121866e-10
forms O 0 1.877662114679879e-08
of O 0 4.1441778897421955e-09
autosomal O 1 0.9943718910217285
dominant O 0 0.002655048854649067
cerebellar B-Disease 0 0.002422011224552989
ataxias I-Disease 0 0.00028521838248707354
type I-Disease 0 5.083164523966843e-06
I I-Disease 0 2.3468337531085126e-05
spinocerebellar B-Disease 0 0.0029276839923113585
ataxias I-Disease 0 1.5815647202543914e-05
1 I-Disease 0 1.6514588807581276e-08
and I-Disease 0 1.117897219238273e-09
2 I-Disease 0 3.1180331649949267e-09
( O 0 3.0241467663394417e-10
SCA1 B-Disease 0 7.333047165047901e-07
, O 0 2.338547411273595e-10
n O 0 2.2566524648937047e-08
= O 0 3.4680184057833685e-08
11 O 0 2.4960995492762095e-09
; O 0 2.520521569238099e-10
SCA2 B-Disease 0 2.6324892132834066e-07
, O 0 4.676329323771711e-10
n O 0 2.100580864805579e-08
= O 0 1.7379187866595203e-08
10 O 0 1.4634596867679761e-09
) O 0 3.2903532676265e-10
and O 0 2.594638104369551e-08
SCA3 B-Disease 1 1.0
/ O 0 0.00014143306179903448
Machado B-Disease 0 1.1723669786078972e-06
- I-Disease 0 3.987475793110207e-06
Joseph I-Disease 0 2.724499427131377e-05
disease I-Disease 0 0.00021663036022800952
( O 0 1.8532894330292038e-08
MJD B-Disease 1 1.0
) O 0 2.6641633343871263e-09
( O 0 2.0698000258168037e-10
n O 0 2.0673999756581907e-07
= O 0 2.96142474098815e-07
16 O 0 1.5698992328339045e-08
) O 0 2.3619572964150848e-09
. O 0 1.344081912435513e-08

In O 0 3.8240730759753205e-07
SCA1 B-Disease 0 2.141890763596166e-05
, O 0 5.934426727804976e-09
saccade O 0 1.1443269158917246e-06
amplitude O 0 6.362791538094825e-08
was O 0 5.618852227939897e-08
significantly O 0 8.228005299315555e-08
increased O 0 4.622662252984355e-09
, O 0 4.73696082359254e-10
resulting O 0 2.437868129590015e-09
in O 0 1.8715828886683994e-09
hypermetria B-Disease 0 2.6305584469810128e-05
. O 0 5.4163198370815735e-08

The O 0 9.234334896746077e-08
smooth O 0 2.123955709976144e-06
pursuit O 0 1.0553401352808578e-06
gain O 0 2.307972863491159e-05
was O 0 2.1814820172494365e-07
decreased O 0 1.5412833818118088e-06
. O 0 4.0920024702018054e-08

In O 0 1.2357165246612567e-07
SCA2 B-Disease 0 9.214633791998494e-06
, O 0 3.791345459802642e-09
saccade O 0 1.2927557691000402e-06
velocity O 0 7.074108339111262e-07
was O 0 1.404433618290568e-07
markedly O 0 5.239531674305908e-06
decreased O 0 3.8655830394418444e-06
. O 0 6.354290604804191e-08

The O 0 1.9991727384649494e-08
percentage O 0 1.1532070232078695e-07
of O 0 8.613793567313621e-10
errors O 0 3.7007782793807564e-06
in O 0 2.0064527816998634e-09
antisaccades O 0 8.399570106121246e-06
was O 0 1.1045371195450571e-07
greatly O 0 1.5173836631632298e-09
increased O 0 3.6383622781244185e-09
and O 0 3.43576878059082e-09
was O 0 2.5005752135598414e-08
significantly O 0 2.774560314833252e-08
correlated O 0 1.5510087436609865e-08
with O 0 7.829286663429968e-10
age O 0 3.4506587809346456e-08
at O 0 1.855833318131772e-07
disease O 0 1.1990421626251191e-05
onset O 0 5.074235218671674e-07
. O 0 4.97838783530824e-08

In O 0 2.2890221273996758e-08
addition O 0 1.7041735800304991e-09
, O 0 2.2373002062092695e-10
a O 0 3.043508500777392e-10
correlation O 0 7.25361415376824e-09
between O 0 9.277650869776721e-10
smooth O 0 1.892748173304426e-06
pursuit O 0 4.6009640186639444e-07
gain O 0 7.541757440776564e-06
and O 0 1.3414485078300231e-09
the O 0 8.998773948221128e-11
number O 0 7.063074014546089e-10
of O 0 5.945265946216693e-10
trinucleotide O 0 2.864850830519572e-05
repeats O 0 1.988400617847219e-05
was O 0 1.2138229976699222e-08
found O 0 1.0770339287091701e-08
. O 0 1.3242186014394974e-08

In O 0 4.524651558313053e-06
SCA3 B-Disease 1 0.9999996423721313
, O 0 7.888847335379978e-07
gaze B-Disease 0 0.00027626060182228684
- I-Disease 0 7.096673652995378e-05
evoked I-Disease 0 1.143640702139237e-06
nystagmus I-Disease 0 2.6813482691068202e-05
was O 0 2.2540026733963714e-08
often O 0 4.0795375411128987e-10
present O 0 1.2516458702815925e-10
as O 0 9.931614558533752e-11
was O 0 1.2992814601986424e-09
saccade O 0 2.392208955370734e-07
hypometria O 0 1.5995448165995185e-06
and O 0 1.0583518061935138e-08
smooth O 0 1.645488794110861e-07
pursuit O 0 2.184073792932395e-07
gain O 0 6.269731784414034e-06
was O 0 1.2340854027570458e-07
markedly O 0 2.257777850900311e-06
decreased O 0 2.4548642159061274e-06
. O 0 3.647563673325749e-08

Three O 0 1.9140719587085187e-07
major O 0 2.664739007229855e-08
criteria O 0 2.3257962666889398e-08
, O 0 5.978766925984758e-10
saccade O 0 3.3838693980214885e-07
amplitude O 0 1.455834919283916e-08
, O 0 1.409592997880793e-09
saccade O 0 2.853357159438019e-07
velocity O 0 7.863206263891698e-08
, O 0 7.285750891483644e-10
and O 0 1.1492058693551854e-10
presence O 0 3.401599280028478e-10
of O 0 2.827203748889673e-10
gaze B-Disease 0 5.3175488574197516e-05
- I-Disease 0 6.125453182903584e-06
evoked I-Disease 0 7.790281841835167e-08
nystagmus I-Disease 0 1.792440542658369e-07
, O 0 7.645890864882432e-11
permitted O 0 5.432337565891565e-11
the O 0 9.794232785909074e-11
correct O 0 4.2457554627617355e-07
assignment O 0 2.8486455416754097e-09
of O 0 7.317762715230991e-12
90 O 0 1.405465882564627e-10
% O 0 3.3219441086806967e-11
of O 0 5.11247164394768e-12
the O 0 1.6059560625780733e-10
SCA1 B-Disease 0 7.749193287054368e-07
, O 0 1.239922053919429e-10
90 O 0 6.886320680354885e-11
% O 0 1.643387335936719e-11
of O 0 1.978947821584809e-12
the O 0 1.994961695839237e-10
SCA2 B-Disease 0 3.1869449230725877e-06
, O 0 8.62322935279991e-10
and O 0 1.725929121842995e-10
93 O 0 9.441469828175286e-11
% O 0 2.5592410135555355e-11
of O 0 9.259515897086512e-13
the O 0 2.442591129359073e-10
patients O 0 2.4157058575724477e-09
with O 0 2.648465891041951e-10
SCA3 B-Disease 1 1.0
to O 0 6.996948798132507e-08
their O 0 5.8534537217269644e-09
genetically O 0 7.247406870192208e-07
confirmed O 0 2.384146910117124e-06
patient O 0 2.4272674536973682e-08
group O 0 6.764504512091207e-09
and O 0 4.709396428381751e-09
, O 0 9.384953925106743e-10
therefore O 0 1.5809050735171581e-09
, O 0 2.172805713129833e-09
may O 0 1.488506740088269e-08
help O 0 5.709703820855339e-10
orient O 0 0.001798871555365622
diagnoses O 0 4.717427509604022e-05
of O 0 1.2849081520993622e-10
SCA1 B-Disease 0 8.272194463643245e-06
, O 0 1.6234747990395704e-09
SCA2 B-Disease 0 2.766066927506472e-06
, O 0 3.3266713828083994e-09
and O 0 1.230264778939727e-08
SCA3 B-Disease 1 1.0
at O 0 2.589955805376576e-08
early O 0 4.035866307816605e-09
clinical O 0 7.063343243629561e-10
stages O 0 8.024299558151426e-10
of O 0 3.386500802005088e-11
the O 0 2.662501996653077e-09
diseases O 0 2.7857759050675668e-06
. O 0 1.5782899431826536e-09
. O 0 1.6119328094532648e-08

Genetic O 0 1.9129793145111762e-05
basis O 0 1.0797822369568166e-07
and O 0 3.230845813106953e-09
molecular O 0 6.645903027902023e-08
mechanism O 0 8.625751775070967e-07
for O 0 1.4138004189589992e-05
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 0.9999995231628418
fibrillation I-Disease 1 1.0
. O 0 0.00021535845007747412

Ventricular B-Disease 1 0.9997993111610413
fibrillation I-Disease 1 0.9999688863754272
causes O 0 6.039393338141963e-05
more O 0 7.425997150534158e-09
than O 0 5.293783189586065e-10
300 O 0 2.5555740856830766e-10
, O 0 1.3174127067028252e-10
000 O 0 7.13163916810089e-10
sudden O 0 1.0700555996834282e-08
deaths O 0 1.486549106033408e-08
each O 0 1.3428513856439395e-09
year O 0 3.2457685428255445e-09
in O 0 1.6505188882298683e-10
the O 0 1.5596552938035302e-09
USA O 0 1.348222758679185e-05
alone O 0 2.1114429671342805e-07
. O 0 1.3614049443333442e-08

In O 0 6.458259349528817e-08
approximately O 0 7.1075252350283336e-09
5 O 0 4.291963673352939e-09
- O 0 5.74203653513905e-08
12 O 0 9.819868473925908e-09
% O 0 4.657823016174234e-10
of O 0 2.9743356215472527e-12
these O 0 2.605748429529431e-11
cases O 0 1.1342107808509638e-10
, O 0 4.1730799371642036e-10
there O 0 1.4532727798943768e-10
are O 0 3.3039179725413703e-10
no O 0 7.086516706777957e-09
demonstrable O 0 4.058930699102348e-06
cardiac O 0 8.379223800147884e-06
or O 0 6.803376209063572e-07
non O 0 8.327999239554629e-06
- O 0 0.0783575177192688
cardiac O 1 0.9593023657798767
causes O 0 3.6309225492914265e-07
to O 0 1.141125416381783e-08
account O 0 2.2389246012721742e-08
for O 0 1.868746130062604e-10
the O 0 3.5408162513128616e-10
episode O 0 2.822045416905894e-06
, O 0 4.175876533452083e-09
which O 0 4.481888471463691e-10
is O 0 4.383112484074303e-10
therefore O 0 2.8358193571165202e-09
classified O 0 5.531524948310107e-06
as O 0 3.0296774639282376e-05
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 0.9999992847442627
fibrillation I-Disease 1 1.0
( O 0 0.0003041243471670896
IVF B-Disease 1 1.0
) O 0 5.130779072715086e-07
. O 0 1.8647854460596136e-07

A O 0 1.4623910260525008e-07
distinct O 0 6.965962739968745e-08
group O 0 1.7936410756647092e-07
of O 0 2.575511137692388e-09
IVF B-Disease 1 1.0
patients O 0 3.813094735960476e-05
has O 0 1.8931243239705964e-09
been O 0 1.6979699868358011e-09
found O 0 2.3265316340115305e-09
to O 0 4.3711068098417627e-10
present O 0 9.663449901387011e-11
with O 0 1.117216128637688e-11
a O 0 1.3486934902218195e-09
characteristic O 0 2.0877935469343356e-07
electrocardiographic O 0 9.529806993668899e-05
pattern O 0 1.3586621207650751e-05
. O 0 7.735690132903983e-08

Because O 0 4.7739906250399144e-08
of O 0 1.4652297430917116e-10
the O 0 3.320284672203577e-11
small O 0 1.4108994528250207e-10
size O 0 1.151758466377828e-09
of O 0 3.949310323214661e-11
most O 0 1.6633752708550276e-10
pedigrees O 0 1.9332714984443555e-08
and O 0 5.658888357906733e-10
the O 0 1.1375472092067795e-10
high O 0 5.4177120567544534e-09
incidence O 0 8.69843006512383e-07
of O 0 1.6839917238442581e-09
sudden B-Disease 0 1.6792636188256438e-06
death I-Disease 0 6.449679545994513e-08
, O 0 2.0865627281541066e-10
however O 0 5.702974203991573e-11
, O 0 1.0131433886284569e-11
molecular O 0 1.362032014950998e-10
genetic O 0 1.1776204011937352e-08
studies O 0 1.1347091044555668e-09
of O 0 6.3599623345567124e-09
IVF B-Disease 1 1.0
have O 0 1.1862215387736796e-06
not O 0 1.2165904728078658e-08
yet O 0 5.278963932653369e-09
been O 0 2.4312833968309633e-09
done O 0 1.3256615361001423e-08
. O 0 1.7729771428776075e-08

Because O 0 7.631635526195168e-05
IVF B-Disease 1 1.0
causes O 0 0.0005695308209396899
cardiac O 1 0.9952600598335266
rhythm O 1 0.7409160137176514
disturbance O 0 0.0001681604189798236
, O 0 6.275719943715785e-09
we O 0 2.115085218079571e-09
investigated O 0 7.401322221767259e-09
whether O 0 2.374582530606517e-09
malfunction O 0 1.3725008329856792e-06
of O 0 1.1149474399285708e-10
ion O 0 9.062672745585587e-08
channels O 0 1.5439903791047982e-06
could O 0 1.0531624639043002e-06
cause O 0 1.9409640117373783e-08
the O 0 7.450778882756026e-10
disorder O 0 7.170093567765434e-07
by O 0 1.7100848515028133e-11
studying O 0 6.00431981911953e-10
mutations O 0 4.986418034036433e-08
in O 0 1.6735268726364438e-10
the O 0 2.165875034876308e-09
cardiac O 0 5.201723070058506e-06
sodium O 0 9.489976093846053e-08
channel O 0 2.645937001943821e-06
gene O 0 1.6805500990813016e-06
SCN5A O 0 4.5771281293127686e-05
. O 0 1.25141127682582e-07

We O 0 1.4889752492308617e-05
have O 0 1.0638872893764528e-08
now O 0 1.3425235367847677e-09
identified O 0 2.2003392441405367e-09
a O 0 6.003793018294346e-10
missense O 0 5.035193453295506e-07
mutation O 0 5.897026156276297e-08
, O 0 8.261661493813577e-11
a O 0 2.5397328684562126e-10
splice O 0 0.0001484472886659205
- O 0 8.050249562074896e-06
donor O 0 8.702713927277728e-08
mutation O 0 2.9517593702621525e-07
, O 0 2.8342928004576606e-10
and O 0 1.7704274157814837e-10
a O 0 3.5363025840950968e-09
frameshift O 0 1.1185768926225137e-05
mutation O 0 3.614955801367614e-08
in O 0 3.542895143926472e-11
the O 0 3.3298180879270944e-10
coding O 0 3.173321601934731e-06
region O 0 4.741440022826282e-07
of O 0 5.408685166408134e-10
SCN5A O 0 1.0902505891863257e-05
in O 0 2.4296471501372707e-09
three O 0 8.265992335054761e-08
IVF B-Disease 1 0.9999998807907104
families O 0 6.51258815764777e-08
. O 0 3.2442226682860564e-08

We O 0 1.5801031167939072e-06
show O 0 2.4785471453014907e-08
that O 0 7.920031297459218e-11
sodium O 0 4.400938780069197e-10
channels O 0 1.2155831896620839e-09
with O 0 3.690202657335995e-11
the O 0 2.019016759335912e-10
missense O 0 4.5097880274624913e-07
mutation O 0 6.66012809347194e-08
recover O 0 6.670546213172202e-07
from O 0 8.569514542422496e-10
inactivation O 0 2.0419696511453367e-07
more O 0 8.88474571691944e-11
rapidly O 0 5.986506845800932e-09
than O 0 2.6639332406652727e-10
normal O 0 3.1521306453896614e-08
and O 0 1.2602944243766956e-09
that O 0 8.20636475440395e-11
the O 0 1.9054656463790565e-10
frameshift O 0 9.499892257736064e-06
mutation O 0 3.083783894908265e-08
causes O 0 1.3679427590673754e-09
the O 0 5.883333403788882e-11
sodium O 0 3.676085880144342e-09
channel O 0 3.116421112281387e-07
to O 0 7.195930518122395e-09
be O 0 6.839723787344099e-10
non O 0 4.212659998614754e-09
- O 0 1.714461319579641e-07
functional O 0 1.9553037589048472e-07
. O 0 4.457119828771283e-08

Our O 0 2.3081687686499208e-05
results O 0 2.9476200325007085e-06
indicate O 0 1.2458925446878766e-08
that O 0 1.383602399318562e-10
mutations O 0 1.0018668561428967e-08
in O 0 1.5268880604324409e-10
cardiac O 0 3.690039704906667e-07
ion O 0 9.195720451771194e-08
- O 0 9.272126817450044e-07
channel O 0 8.89744933374459e-06
genes O 0 6.848815559123977e-08
contribute O 0 8.76340777722362e-09
to O 0 9.774194786871249e-10
the O 0 2.40932690465101e-10
risk O 0 3.00637736927456e-09
of O 0 5.840399691647846e-11
developing O 0 1.1174909531064259e-07
IVF B-Disease 1 1.0
. O 0 1.1930777255031444e-08
. O 0 2.1781595194170222e-08

Molecular O 0 3.2870368613657774e-06
heterogeneity O 0 7.608130545122549e-06
in O 0 3.5068779880020884e-08
mucopolysaccharidosis B-Disease 0 5.902786142542027e-05
IVA I-Disease 0 0.062000662088394165
in O 0 6.746454772610377e-08
Australia O 0 8.556914110613434e-08
and O 0 1.4887558963394554e-09
Northern O 0 4.943906262155906e-08
Ireland O 0 3.603597633627942e-07
: O 0 2.2193134829873173e-10
nine O 0 5.091670973733642e-10
novel O 0 9.460616734457972e-10
mutations O 0 9.512733711858345e-09
including O 0 2.844272387059199e-11
T312S O 0 9.341418305552907e-09
, O 0 6.568216109892333e-11
a O 0 1.9594564859559682e-10
common O 0 6.392515961017864e-10
allele O 0 1.0019398644089961e-07
that O 0 1.751769174163087e-09
confers O 0 3.911220147756467e-08
a O 0 7.865486395530752e-08
mild O 0 7.004866802162724e-06
phenotype O 0 1.9008679373655468e-05
. O 0 1.6542938396924e-07

Mucopolysaccharidosis B-Disease 1 0.5642983913421631
IVA I-Disease 1 0.99991774559021
( O 0 0.004845253191888332
MPS B-Disease 1 0.9999998807907104
IVA I-Disease 1 1.0
) O 0 3.919554458775565e-08
is O 0 9.101797648902732e-10
an O 0 4.022885580212687e-09
autosomal B-Disease 1 0.9999878406524658
recessive I-Disease 1 0.9999963045120239
lysosomal I-Disease 1 0.999994158744812
storage I-Disease 1 0.9982810020446777
disorder I-Disease 1 0.9999521970748901
caused O 0 1.244513185838514e-07
by O 0 3.1704211478356115e-10
a O 0 2.2959446255299554e-07
genetic B-Disease 1 1.0
defect I-Disease 1 0.9999998807907104
in O 0 1.4142006454775924e-09
N O 0 2.4326534912688658e-05
- O 0 1.471086943638511e-05
acetylgalactosamine O 0 0.00029544177232310176
- O 0 8.245942808571272e-06
6 O 0 8.555801969123422e-07
- O 0 4.7541532694594935e-05
sulfate O 0 1.296432515118795e-06
sulfatase O 0 2.318052111149882e-06
( O 0 1.797338167186524e-09
GALNS O 0 2.0318116185080726e-06
) O 0 4.232747041754692e-09
. O 0 1.2041840413701266e-08

Previous O 0 1.3536057394958334e-06
studies O 0 1.1786832843085904e-08
of O 0 1.0945132994377715e-10
patients O 0 3.8000691482409366e-09
from O 0 7.69033794978391e-11
a O 0 1.0934725347411245e-09
British O 0 4.0970442682919384e-07
- O 0 9.964251148630865e-06
Irish O 0 3.3383098525519017e-06
population O 0 8.126029849009342e-10
showed O 0 2.240888807847341e-09
that O 0 4.7125970660533145e-12
the O 0 6.2678152598638626e-12
I113F O 0 1.0746981082832008e-09
mutation O 0 1.25175148024681e-09
is O 0 7.658059082704671e-12
the O 0 2.88631336713141e-12
most O 0 3.281462558277215e-12
common O 0 4.521598373496971e-11
single O 0 9.159097480448963e-09
mutation O 0 1.9246665772243432e-07
among O 0 7.825949666084853e-08
MPS B-Disease 1 0.9999998807907104
IVA I-Disease 1 1.0
patients O 0 3.53669747710228e-05
and O 0 3.828067585143202e-10
produces O 0 3.322069375144565e-08
a O 0 1.63916126894037e-07
severe O 0 3.068987643928267e-05
clinical O 0 3.359089078003308e-07
phenotype O 0 1.5543646441074088e-05
. O 0 1.4712388463067327e-07

We O 0 7.662785037609865e-07
studied O 0 2.9401549639374025e-08
mutations O 0 1.1060445359589721e-07
in O 0 2.272506627321036e-10
the O 0 1.4162486461355428e-10
GALNS O 0 4.204233903237764e-07
gene O 0 1.8223241582404626e-08
from O 0 4.816120280359826e-10
23 O 0 5.638828959320108e-09
additional O 0 4.355216276508145e-08
MPS B-Disease 1 0.9999998807907104
IVA I-Disease 1 1.0
patients O 0 3.9864536915956705e-07
( O 0 4.8170092914467944e-11
15 O 0 1.1996620363774468e-10
from O 0 1.2742962240963607e-10
Australia O 0 1.3171244095389056e-09
, O 0 6.060604101909561e-11
8 O 0 3.6483671639331305e-10
from O 0 7.999829271243541e-11
Northern O 0 2.8512726402141197e-08
Ireland O 0 2.455051060223923e-07
) O 0 1.0674228861917712e-10
, O 0 8.900583395310413e-12
with O 0 5.585513388611796e-12
various O 0 4.9809635582764855e-11
clinical O 0 5.228848909410999e-09
phenotypes O 0 1.0472218292534308e-07
( O 0 1.7033229937624128e-08
severe O 0 3.3861492738651577e-06
, O 0 7.761161713304432e-10
16 O 0 1.9775208137673417e-09
cases O 0 1.4678618043273417e-10
; O 0 1.4933994318955257e-10
intermediate O 0 7.071354168886046e-09
, O 0 4.219726512655342e-10
4 O 0 2.328742532142769e-09
cases O 0 7.743063412668505e-10
; O 0 6.8851453427498654e-09
mild O 0 2.7833175408886746e-07
, O 0 4.796941177609426e-10
3 O 0 7.212763719621762e-09
cases O 0 1.6234561472927567e-09
) O 0 1.781277569889994e-09
. O 0 2.2360055140779878e-08

We O 0 4.396085842017783e-07
found O 0 2.1525152771317835e-09
two O 0 1.0992729643222177e-10
common O 0 2.7629076804203123e-10
mutations O 0 2.0043577464434748e-08
that O 0 1.2758527567768851e-10
together O 0 1.706860541794697e-09
accounted O 0 2.1681995576727786e-07
for O 0 2.2560822654504875e-10
32 O 0 2.8452897815611777e-09
% O 0 1.4791345925857513e-10
of O 0 6.1043141028060965e-12
the O 0 4.691678157087154e-10
44 O 0 2.9012423574670265e-09
unrelated O 0 1.7577702626780933e-09
alleles O 0 9.10600395087613e-09
in O 0 8.058856360015909e-10
these O 0 2.423625522496309e-09
patients O 0 1.0162690955439757e-07
. O 0 1.4649014445922148e-08

One O 0 1.4461713249147579e-07
is O 0 1.4043251006512492e-09
the O 0 2.0049827076373816e-10
T312S O 0 2.4796678488314683e-08
mutation O 0 1.6610085751267434e-08
, O 0 7.792395895211968e-11
a O 0 1.0909513570300788e-10
novel O 0 3.6839684636191805e-09
mutation O 0 5.2364271141414065e-08
found O 0 2.5860349417428097e-09
exclusively O 0 7.689432979240962e-10
in O 0 2.2657817844162764e-09
milder O 0 3.789336915360764e-05
patients O 0 1.1935417205677368e-06
. O 0 1.4631561739975041e-08

The O 0 7.320024053569796e-08
other O 0 2.6169477695958676e-09
is O 0 3.190086805826553e-10
the O 0 7.041078137204337e-11
previously O 0 1.5301374389764533e-08
described O 0 5.060517338506543e-09
I113F O 0 2.073504390409653e-08
that O 0 1.1642059538630178e-10
produces O 0 1.2263427606740152e-08
a O 0 2.458968317853305e-08
severe O 0 2.87911097984761e-06
phenotype O 0 4.051188625453506e-06
. O 0 9.243833432037718e-08

The O 0 2.762309847526012e-08
I113F O 0 6.175287126097828e-07
and O 0 3.980501706024597e-09
T312S O 0 1.1249159825865718e-07
mutations O 0 2.7687300985235197e-07
accounted O 0 1.260216180298812e-07
for O 0 1.6879074526965354e-10
8 O 0 1.7514750760838638e-09
( O 0 3.9353262315522386e-10
18 O 0 1.799787541223452e-09
% O 0 2.0053270155528935e-10
) O 0 1.2297732276955742e-10
and O 0 2.4042143831337626e-09
6 O 0 5.029542116119501e-09
( O 0 1.7336627966546558e-10
14 O 0 2.386560504774593e-09
% O 0 1.1390453857895722e-10
) O 0 3.218345034916581e-11
of O 0 2.554427502854395e-11
44 O 0 2.6837632116638588e-09
unrelated O 0 6.016325659885524e-09
alleles O 0 4.5646189050785324e-08
, O 0 7.215364306034644e-09
respectively O 0 9.742317388372612e-07
. O 0 1.0802828853684332e-07

The O 0 2.763237461067547e-08
relatively O 0 1.1628466189961273e-08
high O 0 7.392940926109759e-09
residual O 0 9.44512095202299e-08
GALNS O 0 5.611115284409607e-06
activity O 0 2.3633823786894936e-08
seen O 0 9.21011000798444e-09
when O 0 1.0305148401279496e-10
the O 0 2.7416248091216566e-11
T312S O 0 3.5724025959638084e-09
mutant O 0 2.9584923399994523e-09
cDNA O 0 2.7127700974460822e-08
is O 0 9.765622754898118e-10
overexpressed O 0 8.178936639069434e-08
in O 0 1.1166499669368335e-10
mutant O 0 6.476649883069285e-09
cells O 0 1.0191279820048749e-08
provides O 0 1.216737821607694e-10
an O 0 3.0489864105698317e-11
explanation O 0 6.45074382799038e-10
for O 0 6.41200217921245e-11
the O 0 1.2683487593534437e-09
mild O 0 3.6029308603247046e-07
phenotype O 0 3.7885214965172054e-07
in O 0 8.905143289439366e-10
patients O 0 5.456476603882265e-09
with O 0 2.4206803228565832e-11
this O 0 1.0619526369382015e-09
mutation O 0 3.8799618096163613e-07
. O 0 3.428504058433646e-08

The O 0 1.2286793804605622e-08
distribution O 0 3.460043629388565e-08
and O 0 6.314390676998016e-10
relative O 0 3.982003338176554e-10
frequencies O 0 2.2701682755865704e-09
of O 0 2.6156276797251188e-11
the O 0 1.491489293181658e-10
I113F O 0 1.6383259193730737e-08
and O 0 6.650348050030175e-10
T312S O 0 4.545650522658207e-09
mutations O 0 1.0616028944809841e-08
in O 0 4.8732511082061336e-11
Australia O 0 6.972283306261318e-10
corresponded O 0 2.5556730065545707e-09
to O 0 6.359001103461992e-10
those O 0 9.921750226959958e-11
observed O 0 2.0108779086314144e-09
in O 0 1.6729491403300045e-10
Northern O 0 1.4726298047662567e-07
Ireland O 0 1.5197543916656286e-06
and O 0 7.23715143369219e-10
are O 0 9.933144584639564e-12
unique O 0 6.349060166499498e-11
to O 0 1.3838616919059632e-09
these O 0 1.067200494642151e-11
two O 0 1.2599982168737256e-10
populations O 0 2.8298635657009186e-10
, O 0 1.207499378264032e-10
suggesting O 0 6.46723952169026e-10
that O 0 2.057424022816612e-11
both O 0 7.434747956169829e-11
mutations O 0 5.739142494576299e-09
were O 0 3.3387154152464404e-10
probably O 0 3.3062125259775144e-10
introduced O 0 2.7715849060250264e-10
to O 0 3.565402972860454e-10
Australia O 0 2.795102760355661e-10
by O 0 5.987571116000678e-12
Irish O 0 6.534132679369975e-10
migrants O 0 8.008840812756546e-10
during O 0 7.925350653525953e-11
the O 0 1.0291732049916291e-10
19th O 0 6.376627226245546e-09
century O 0 2.9952865077120805e-08
. O 0 1.1019384515975617e-07

Haplotype O 0 0.0002212275139754638
analysis O 0 8.265646300742446e-08
using O 0 1.143142647208606e-08
6 O 0 1.1747645523030315e-08
RFLPs O 0 1.3346661376090196e-07
provides O 0 3.4891936562253534e-10
additional O 0 2.796836096052857e-10
data O 0 5.205076814007725e-09
that O 0 7.803342694234772e-11
the O 0 9.554803476197193e-11
I113F O 0 3.064423381715642e-08
mutation O 0 3.782641311289581e-09
originated O 0 3.9592831790891125e-10
from O 0 9.074301032807597e-11
a O 0 3.052176289486397e-10
common O 0 3.101431333973892e-09
ancestor O 0 1.730794139120917e-07
. O 0 2.4023140099416196e-07

The O 0 3.328716502437601e-08
other O 0 1.2189055320632747e-09
9 O 0 3.3057225845567473e-09
novel O 0 2.009371113942393e-09
mutations O 0 1.706289367575664e-07
identified O 0 4.5283364613624144e-08
in O 0 5.388626767022231e-10
these O 0 6.731320500996674e-10
23 O 0 3.327872377667518e-08
patients O 0 3.182825558667446e-09
were O 0 7.553455777520313e-11
each O 0 3.083528155034543e-10
limited O 0 8.154225072942722e-10
to O 0 1.4444689888648554e-09
a O 0 1.6080750064872973e-09
single O 0 8.923242234004647e-08
family O 0 1.207549331638802e-07
. O 0 8.774568271974204e-08

These O 0 9.154489788443243e-08
data O 0 8.22778503106747e-08
provide O 0 8.774676540923565e-10
further O 0 5.764306254540941e-10
evidence O 0 2.6702107192022595e-10
for O 0 4.948502024815227e-11
extensive O 0 2.8425775067120185e-09
allelic O 0 2.003150569862555e-07
heterogeneity O 0 6.805673251619737e-07
in O 0 2.5116128199442755e-07
MPS B-Disease 1 0.9999997615814209
IVA I-Disease 1 1.0
in O 0 2.3170900753655133e-09
British O 0 4.9082682807011224e-08
- O 0 3.0266655812738463e-06
Irish O 0 4.2846190808631945e-06
patients O 0 1.4893991817643837e-07
and O 0 5.713840511845092e-11
provide O 0 4.19108150961911e-11
evidence O 0 8.697922243561251e-11
for O 0 3.405245876941798e-11
their O 0 1.1913512398820103e-09
transmission O 0 7.031439253069038e-08
to O 0 4.935292174934602e-09
Australia O 0 8.934746276167971e-10
by O 0 1.167013187475252e-11
British O 0 2.6830058175164595e-09
- O 0 5.319598983533069e-08
Irish O 0 4.140884968251157e-08
migrants O 0 9.508126730395361e-09
. O 0 4.790769447815535e-10
. O 0 4.4466901272244286e-09

Identification O 0 4.913447924081993e-07
of O 0 5.175615047647852e-09
constitutional O 0 6.415424280703519e-08
WT1 O 0 2.0943471099599265e-05
mutations O 0 1.8821887351805344e-05
, O 0 9.449652171866774e-10
in O 0 1.7389847895010746e-10
patients O 0 1.543762806477389e-08
with O 0 1.3285668121199024e-09
isolated O 0 0.00023140007397159934
diffuse B-Disease 1 0.9995810389518738
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
, O 0 4.513135110073563e-08
and O 0 1.3854832836557307e-09
analysis O 0 2.105192242751741e-09
of O 0 1.1955213485848049e-09
genotype O 0 0.0002080865524476394
/ O 0 0.003430642420426011
phenotype O 0 1.4799602467974182e-05
correlations O 0 1.1358187634868955e-07
by O 0 3.5784070151478886e-11
use O 0 4.2378345277427343e-10
of O 0 2.780097159427175e-11
a O 0 3.860758379659046e-09
computerized O 0 3.1480951292905957e-05
mutation O 0 9.539171514916234e-07
database O 0 8.386925856029848e-07
. O 0 8.487393188261194e-08

Constitutional O 0 5.261197657091543e-06
mutations O 0 5.04193894812488e-06
of O 0 1.6983490169764082e-09
the O 0 1.4483562127409755e-09
WT1 O 0 1.0415203632874181e-06
gene O 0 4.894665650567731e-08
, O 0 1.0879839390520729e-10
encoding O 0 2.2407904420873592e-09
a O 0 3.55216855929541e-09
zinc O 0 1.3944301826995797e-05
- O 0 6.761166332580615e-06
finger O 0 3.989829565398395e-05
transcription O 0 1.6904036215237284e-07
factor O 0 5.184725093698717e-09
involved O 0 1.1704071045670617e-09
in O 0 2.997405434967959e-09
renal O 0 0.03447309508919716
and O 0 1.0460499311193416e-07
gonadal O 0 1.753326432663016e-05
development O 0 3.739913267963857e-09
, O 0 3.9994646483521024e-10
are O 0 7.031710630434063e-11
found O 0 3.51851853208629e-10
in O 0 2.939864671147596e-11
most O 0 2.930528042455194e-10
patients O 0 1.4627424826940683e-09
with O 0 1.8106610655266309e-09
Denys B-Disease 1 0.9999948740005493
- I-Disease 1 0.9999997615814209
Drash I-Disease 1 0.9999997615814209
syndrome I-Disease 1 1.0
( O 0 6.496788387266861e-07
DDS B-Disease 1 1.0
) O 0 1.826416351491389e-08
, O 0 3.759860867091902e-09
or O 0 2.854961530829314e-05
diffuse B-Disease 1 0.9999459981918335
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
( O 0 1.8200943259216729e-06
DMS B-Disease 0 0.0034661926329135895
) O 0 3.749298205235618e-09
associated O 0 1.5195219305041974e-08
with O 0 3.788412072935898e-08
pseudohermaphroditism B-Disease 1 1.0
and O 0 3.0416717891057488e-06
/ O 0 0.0005031417822465301
or O 0 4.594904567056801e-06
Wilms B-Disease 0 0.002742895158007741
tumor I-Disease 0 0.001102970913052559
( O 0 4.0101099330058787e-07
WT B-Disease 1 0.9999985694885254
) O 0 1.4826923688815441e-08
. O 0 2.3896225442854302e-08

Most O 0 4.0524068367631116e-07
mutations O 0 5.246257205726579e-05
in O 0 3.767232215068361e-07
DDS B-Disease 1 1.0
patients O 0 0.0013067995896562934
lie O 0 3.2335236710423487e-07
in O 0 3.248919189235977e-10
exon O 0 1.3851726521352248e-07
8 O 0 1.0805894845589137e-08
or O 0 2.5001209991160067e-09
exon O 0 4.8515843786844925e-08
9 O 0 7.84180098634124e-09
, O 0 7.319482520085074e-11
encoding O 0 5.921492185478883e-09
zinc O 0 4.837788310396718e-06
finger O 0 7.41243566153571e-05
2 O 0 1.1145895939534967e-07
or O 0 2.709254545152362e-07
zinc O 0 8.290675395983271e-06
finger O 0 2.8520007617771626e-05
3 O 0 8.87246009995124e-09
, O 0 3.8283451408993585e-10
respectively O 0 1.0116020909833878e-08
, O 0 4.842775486180173e-11
with O 0 1.3534594452135895e-11
a O 0 2.052726211232425e-09
hot O 0 9.207327593685477e-07
spot O 0 9.740341738506686e-06
( O 0 6.21820261947903e-10
R394W O 0 3.967707051799607e-09
) O 0 4.5810532450785146e-11
in O 0 8.621284242060767e-11
exon O 0 2.631435052080633e-07
9 O 0 8.042556487453112e-08
. O 0 2.55344758670617e-08

We O 0 1.6243169511653832e-06
analyzed O 0 4.101230288711122e-08
a O 0 8.529595363349074e-10
series O 0 7.029609117026325e-10
of O 0 5.47587357402346e-11
24 O 0 3.0607314016606324e-08
patients O 0 1.353662182346227e-09
, O 0 2.7674895361484708e-11
10 O 0 3.815799065609582e-10
with O 0 4.964853417277482e-09
isolated B-Disease 0 4.2745752580231056e-05
DMS I-Disease 0 0.4433780014514923
( O 0 7.895303966165557e-09
IDMS B-Disease 0 4.906742105958983e-06
) O 0 3.58860663407512e-10
, O 0 1.6223161702910716e-10
10 O 0 6.981545341844253e-10
with O 0 1.9228130199167026e-08
DDS B-Disease 1 1.0
, O 0 1.170974872621855e-08
and O 0 7.025909298796762e-10
4 O 0 2.0276391676787853e-09
with O 0 5.65333513335986e-09
urogenital B-Disease 0 0.0005759059567935765
abnormalities I-Disease 1 0.9049833416938782
and O 0 1.213684583944996e-07
/ O 0 0.021870525553822517
or O 0 0.0023391330614686012
WT B-Disease 1 0.9999997615814209
. O 0 2.0379114573643164e-07

We O 0 5.502618932951009e-06
report O 0 2.269291172751764e-07
WT1 O 0 4.5879382923885714e-06
heterozygous O 0 1.172776251223695e-06
mutations O 0 1.775569671735866e-06
in O 0 2.4230983886042168e-09
16 O 0 3.141638771353428e-08
patients O 0 9.03059227397307e-09
, O 0 1.106258140648464e-10
4 O 0 2.466012061219658e-09
of O 0 3.1842875558574235e-10
whom O 0 1.2199882348795654e-07
presented O 0 2.166520651769588e-08
with O 0 1.722461462350111e-08
IDMS B-Disease 0 0.001087171956896782
. O 0 1.4728546204878512e-07

One O 0 3.2074424893835385e-07
male O 0 2.449550606797857e-07
and O 0 1.3084814121100408e-08
two O 0 9.62435375839732e-09
female O 0 1.543092480460473e-07
IDMS B-Disease 0 0.0004770267114508897
patients O 0 1.0859304211408016e-06
with O 0 2.001892429603913e-09
WT1 O 0 0.00028521730564534664
mutations O 0 0.0005360382492654026
underwent O 0 6.078463411540724e-05
normal O 0 1.1063626516261138e-05
puberty O 0 3.089510209974833e-05
. O 0 1.8978258253810054e-07

Two O 0 5.710623440791096e-07
mutations O 0 1.1547169378900435e-05
associated O 0 7.930412238010831e-08
with O 0 6.54422604995375e-09
IDMS B-Disease 0 0.0009349977481178939
are O 0 2.2463577664666445e-09
different O 0 1.2470895149885308e-10
from O 0 5.025914684431143e-10
those O 0 1.5736456582260416e-09
described O 0 9.736653794334416e-08
in O 0 1.5547649923064455e-07
DDS B-Disease 1 1.0
patients O 0 5.961283022770658e-05
. O 0 2.602881110647104e-08

No O 0 1.4067245501792058e-06
WT1 O 0 3.364366784808226e-05
mutations O 0 5.1947507017757744e-05
were O 0 1.5744271664175358e-08
detected O 0 6.397815610625912e-08
in O 0 1.0789840548808272e-10
the O 0 8.885152336102209e-11
six O 0 1.827791806796597e-09
other O 0 1.2471567112370963e-09
IDMS B-Disease 0 0.00012929493095725775
patients O 0 7.982936978123689e-08
, O 0 8.093958836496995e-11
suggesting O 0 2.8941455898490176e-09
genetic O 0 4.655597862779359e-08
heterogeneity O 0 9.82084600309463e-08
of O 0 3.9008232755044503e-10
this O 0 3.05985032866829e-08
disease O 0 3.681311500258744e-05
. O 0 2.1707894148903506e-08

We O 0 2.6130842343263794e-06
analyzed O 0 2.4475309601257322e-06
genotype O 0 7.654266664758325e-05
/ O 0 0.0003475557896308601
phenotype O 0 9.748444426804781e-06
correlations O 0 1.4417083775697392e-06
, O 0 1.9648243032577284e-09
on O 0 4.054251601104397e-09
the O 0 1.94077337534182e-10
basis O 0 1.252350889657805e-09
of O 0 1.0609453419963e-11
the O 0 5.27290322516194e-10
constitution O 0 8.328592260298251e-10
of O 0 8.922951787171396e-12
a O 0 6.28673890723519e-10
WT1 O 0 1.6156485571627854e-07
mutation O 0 6.365727056589776e-09
database O 0 2.930450992977285e-09
of O 0 9.593809080499227e-11
84 O 0 5.379469314448215e-09
germ O 0 1.4290203580458183e-06
- O 0 5.8309524320065975e-06
line O 0 0.0004045254609081894
mutations O 0 1.382966047458467e-06
, O 0 9.715789284214793e-11
to O 0 1.8832770065646542e-10
compare O 0 2.5128665814833084e-09
the O 0 5.417995566081579e-11
distribution O 0 6.139376562686039e-09
and O 0 4.855995605623775e-10
type O 0 1.0320359011828373e-09
of O 0 2.9136724283285176e-11
mutations O 0 1.0012941231707373e-07
, O 0 1.0586071602647351e-10
according O 0 1.473308974819787e-10
to O 0 2.5100341249917335e-10
the O 0 3.4572628093698654e-10
different O 0 4.911667517148999e-08
symptoms O 0 8.07926153356675e-06
. O 0 1.1076548567245936e-08

This O 0 5.325375340703431e-08
demonstrated O 0 1.962491857909754e-08
( O 0 1.3371059814915043e-09
1 O 0 2.3766666412683435e-09
) O 0 2.8596405798886337e-10
the O 0 1.4839526829568683e-10
association O 0 3.836691034320161e-11
between O 0 2.2935375820765103e-11
mutations O 0 4.120053187506301e-09
in O 0 4.763523256401392e-11
exons O 0 5.332947949909794e-08
8 O 0 6.529202511984522e-09
and O 0 1.2070348054393776e-09
9 O 0 1.2809599603258448e-08
and O 0 4.881172355197805e-09
DMS B-Disease 0 6.227262019820046e-06
; O 0 2.9566121773072496e-10
( O 0 5.648112533229721e-11
2 O 0 2.606168392205177e-09
) O 0 4.2773493080794367e-10
among O 0 1.113880376824028e-10
patients O 0 1.2340430899371313e-09
with O 0 1.077616398892367e-10
DMS B-Disease 0 3.347395613673143e-05
, O 0 3.4810421906117384e-11
a O 0 1.560815227064083e-10
higher O 0 1.4225384203925273e-09
frequency O 0 2.931155540508712e-09
of O 0 1.095041557430676e-10
exon O 0 9.844458048746674e-08
8 O 0 4.597321190402681e-09
mutations O 0 2.5502302491986484e-08
among O 0 9.553545454732415e-11
46 O 0 6.131044560930832e-09
, O 0 2.390870612600793e-09
XY O 0 2.6629663807398174e-06
patients O 0 9.638021047919665e-09
with O 0 7.520779832237423e-11
female O 0 9.128227951293866e-09
phenotype O 0 1.3045806213085598e-07
than O 0 1.8762795761517737e-09
among O 0 3.1706451353308296e-10
46 O 0 3.367228629258534e-08
, O 0 5.2401607497643e-09
XY O 0 6.407227374438662e-06
patients O 0 2.254320818906308e-08
with O 0 1.9735972578427408e-10
sexual O 0 8.920276961532636e-09
ambiguity O 0 2.2633857454934514e-08
or O 0 1.8534066725806042e-07
male O 0 7.97053729684194e-08
phenotype O 0 1.6588104472248233e-06
; O 0 1.427505047502109e-08
and O 0 1.159559825936185e-08
( O 0 1.1536295252412287e-09
3 O 0 1.652719383571366e-08
) O 0 1.0798637539721767e-09
statistically O 0 1.8566582582479896e-07
significant O 0 2.988566616402011e-10
evidence O 0 5.654323675940987e-10
that O 0 2.254254144462564e-10
mutations O 0 6.286358100737743e-09
in O 0 7.348789632377617e-11
exons O 0 1.3155514011486957e-07
8 O 0 6.543314778895137e-09
and O 0 5.279404136082633e-10
9 O 0 1.938772919984899e-09
preferentially O 0 8.440523835417935e-09
affect O 0 2.9122304567863466e-09
amino O 0 1.7132337770675576e-09
acids O 0 1.0820884188689206e-09
with O 0 4.0621095896697934e-12
different O 0 2.018468898967729e-11
functions O 0 4.2703554581358105e-10
. O 0 9.433048786533504e-10
. O 0 1.344712785567026e-08

The O 0 6.327356771862469e-08
185delAG O 0 5.040468295192113e-06
BRCA1 O 0 7.617946721438784e-06
mutation O 0 4.115885019473353e-07
originated O 0 1.3149864308559245e-08
before O 0 2.7012858616615176e-09
the O 0 3.4363550199811854e-11
dispersion O 0 7.249713718238127e-09
of O 0 2.275797605921781e-11
Jews O 0 3.882903720775488e-10
in O 0 1.876661326338791e-10
the O 0 3.8376155031549786e-10
diaspora O 0 4.521559127113051e-09
and O 0 1.0502198222184234e-08
is O 0 6.959715026511049e-10
not O 0 7.064003826329213e-10
limited O 0 5.836928163027721e-10
to O 0 1.2147262751227572e-08
Ashkenazim O 0 1.8779577430905192e-06
. O 0 3.26143307916027e-08

The O 0 3.624055011641758e-08
185delAG O 0 5.106848561808874e-07
mutation O 0 1.1711115632806468e-07
in O 0 7.06827596452797e-10
BRCA1 O 0 7.316296546377998e-07
is O 0 1.1411944722539147e-09
detected O 0 5.041646389258858e-08
in O 0 7.026065840243234e-11
Ashkenazi O 0 1.0900043889705557e-07
Jews O 0 1.3803581611071536e-09
both O 0 5.253137369543026e-10
in O 0 2.563503631591857e-09
familial B-Disease 0 0.4342981278896332
breast I-Disease 1 0.9999998807907104
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 6.367743221602495e-09
in O 0 1.4410339588266652e-10
the O 0 5.649850032263259e-10
general O 0 1.688323703064043e-09
population O 0 2.6809647835079886e-09
. O 0 1.2926254733258702e-08

All O 0 2.2840990254735516e-07
tested O 0 2.689768621166877e-07
Ashkenazi O 0 2.8477484192990232e-06
mutation O 0 1.7246746608634567e-07
carriers O 0 1.8616434616092192e-08
share O 0 2.578043378775874e-08
the O 0 1.7454579448461516e-10
same O 0 2.80559442344952e-09
allelic O 0 1.4490551336621138e-07
pattern O 0 8.574908179070917e-07
at O 0 2.521350950246415e-08
the O 0 3.8369143418037766e-09
BRCA1 O 0 2.9539432944147848e-06
locus O 0 2.3349430193775333e-06
. O 0 1.6547292602808739e-07

Our O 0 8.922746133066539e-07
previous O 0 1.2605215715666418e-07
study O 0 4.0435557124851584e-09
showed O 0 1.382153058671065e-08
that O 0 4.184307761390116e-11
this O 0 5.1744063894743064e-11
Ashkenazi O 0 4.863615572503477e-07
mutation O 0 3.0804216066826484e-08
also O 0 1.1417757850296084e-09
occurs O 0 1.6525916746168434e-10
in O 0 3.262305703355395e-11
Iraqi O 0 1.3660316211527856e-09
Jews O 0 3.360398903584638e-10
with O 0 2.2175521835476886e-11
a O 0 4.5503759094067675e-10
similar O 0 1.3869850823411412e-09
allelic O 0 7.092326654856151e-07
pattern O 0 8.341121429111809e-06
. O 0 1.3163796097614977e-07

We O 0 4.560328932257107e-07
extended O 0 6.872182822803552e-09
our O 0 7.219173592254435e-10
analysis O 0 1.402608446054998e-10
to O 0 1.212408090589534e-10
other O 0 1.1743600536462395e-10
non O 0 3.7083185411290742e-09
- O 0 7.572363358576695e-08
Ashkenazi O 0 6.074668021938123e-07
subsets O 0 1.4832580497170511e-08
354 O 0 1.965424045735631e-09
of O 0 1.979620807557314e-11
Moroccan O 0 1.4996349051443758e-08
origin O 0 5.295997418386378e-09
, O 0 2.715676850062465e-10
200 O 0 1.772742092009949e-10
Yemenites O 0 4.7830777560875504e-08
and O 0 2.2581012060207684e-10
150 O 0 1.1583584091923171e-10
Iranian O 0 3.3092553142211045e-09
Jews O 0 2.902040741048495e-08
. O 0 3.708659690460081e-08

Heteroduplex O 0 2.2283000362222083e-05
analysis O 0 6.583665168591324e-08
complemented O 0 9.651706989188824e-09
by O 0 3.639788123677157e-11
direct O 0 9.48258471744623e-10
DNA O 0 2.047128333515502e-08
sequencing O 0 1.9509185378296934e-08
of O 0 3.0528632399828837e-10
abnormally O 0 8.786206961985954e-08
migrating O 0 1.0129092231636605e-08
bands O 0 2.1728068233528575e-08
were O 0 6.311167144446017e-09
employed O 0 2.552011224565831e-08
. O 0 1.785945791255017e-08

Four O 0 1.4105006584941293e-07
of O 0 2.9528704481585066e-10
Moroccan O 0 2.878138971595945e-08
origin O 0 3.0347919732776063e-09
( O 0 9.421931984610055e-11
1 O 0 7.043307603815663e-11
. O 0 1.8062371043292558e-11
1 O 0 2.475955551695108e-10
% O 0 1.6725121287919364e-10
) O 0 8.419259733827289e-11
and O 0 6.782303052510485e-10
none O 0 1.8187351624732173e-10
of O 0 3.0281148682281822e-12
the O 0 1.930027526686473e-10
Yemenites O 0 2.2027722934581107e-07
or O 0 3.89637833109191e-09
Iranians O 0 2.4094983785971635e-09
was O 0 2.0175731918481432e-10
a O 0 6.776351701986982e-11
carrier O 0 2.2925952247732084e-09
of O 0 1.8752076280659224e-11
the O 0 5.145483483737223e-10
185delAG O 0 9.069509019354882e-07
mutation O 0 3.375280073214526e-07
. O 0 2.5739604225805124e-08

BRCA1 O 0 0.0007444878574460745
allelic O 0 3.388671393622644e-05
patterns O 0 0.0003349935286678374
were O 0 1.9867280798280262e-07
determined O 0 1.4410272086706755e-08
for O 0 9.85744749715245e-11
four O 0 2.645956509450542e-10
of O 0 1.3774557883206029e-11
these O 0 1.1139207611865487e-10
individuals O 0 2.4133363710210354e-11
and O 0 1.684443834415461e-10
for O 0 4.571940048769818e-11
12 O 0 1.94362206884513e-10
additional O 0 1.5557090338180757e-10
non O 0 1.1525325582795176e-08
- O 0 2.9978301085975545e-07
Ashkenazi O 0 5.130659701535478e-06
185delAG O 0 7.403570378983204e-08
mutation O 0 4.865587044378117e-08
carriers O 0 2.978633872885439e-08
who O 0 9.024913083521824e-08
had O 0 7.611981709487736e-05
breast B-Disease 1 0.9999915361404419
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 4.977908929504338e-07

Six O 0 3.6546398405334912e-06
non O 0 2.1890396055823658e-06
- O 0 6.172059511300176e-05
Ashkenazi O 0 0.00018415364320389926
individuals O 0 3.008115312397308e-09
shared O 0 6.357339099594128e-10
the O 0 1.6596167495830372e-10
common O 0 2.290016620776214e-09
Ashkenazi O 0 4.408245786180487e-06
haplotype O 0 6.816898803663207e-06
, O 0 1.798826643195639e-09
four O 0 8.287976971388389e-10
had O 0 2.5145157067640866e-09
a O 0 1.296369817049836e-10
closely O 0 1.817193062692013e-09
related O 0 3.7207807945804916e-09
pattern O 0 3.5087359719909728e-06
, O 0 3.11617220916105e-09
and O 0 3.9591852019071894e-10
the O 0 2.117732378348336e-10
rest O 0 9.094495823092075e-09
( O 0 1.5521108009952655e-10
n O 0 2.0282982404751237e-07
= O 0 1.4109606638612604e-07
6 O 0 5.5582831670619726e-09
) O 0 4.040283038686532e-11
displayed O 0 4.411309095786464e-10
a O 0 1.0290834850934516e-09
distinct O 0 2.5813058357471164e-08
BRCA1 O 0 8.533606887795031e-06
allelic O 0 3.86260535378824e-06
pattern O 0 2.6207006158074364e-05
. O 0 1.3643051488543279e-07

We O 0 3.8042812775529455e-06
conclude O 0 1.4428290739942895e-07
that O 0 1.0949204737320528e-10
the O 0 2.5708556811165906e-11
185delAG O 0 5.361423305316748e-08
BRCA1 O 0 3.0169459819262556e-07
mutation O 0 1.9634990522376938e-08
occurs O 0 4.3541734107144237e-10
in O 0 1.2106466003303229e-11
some O 0 1.684195664874988e-11
non O 0 1.1907770769425952e-08
- O 0 8.666022495162906e-07
Ashkenazi O 0 1.060815884557087e-05
populations O 0 1.6825413950982693e-08
at O 0 7.03233515864099e-09
rates O 0 2.5532660430371834e-09
comparable O 0 6.730755397477139e-10
with O 0 1.2061643350769202e-10
that O 0 1.1661682730590428e-10
of O 0 2.0634653707940487e-10
Ashkenazim O 0 3.3823539524746593e-06
. O 0 3.715130603154648e-08

The O 0 3.621567401523862e-08
majority O 0 6.701717847334976e-09
of O 0 1.0775259157158601e-10
Jewish O 0 6.2641438702826235e-09
185delAG O 0 9.6880239652819e-07
mutation O 0 2.693385283691896e-07
carriers O 0 5.827953231118954e-09
have O 0 1.4852778729146365e-10
a O 0 2.208351973509437e-10
common O 0 3.1964959568142604e-09
allelic O 0 2.61794326661402e-07
pattern O 0 9.125251381192356e-06
, O 0 1.4715852980629052e-09
supporting O 0 2.4914081908633534e-10
the O 0 8.688504082865478e-11
founder O 0 9.499824038528004e-09
effect O 0 1.3191406855739274e-09
notion O 0 4.6295511868521544e-10
, O 0 2.757895578575642e-10
but O 0 9.844425968852377e-11
dating O 0 3.679858084915111e-10
the O 0 4.735133465882946e-11
mutations O 0 2.858518977078006e-09
origin O 0 3.715304175422318e-10
to O 0 9.810334766768847e-10
an O 0 1.1008675221413355e-10
earlier O 0 4.911386142225638e-08
date O 0 1.428050211416121e-07
than O 0 2.1412136508303092e-09
currently O 0 3.0765037184465882e-09
estimated O 0 2.2320257642149954e-08
. O 0 3.043633611810037e-08

However O 0 1.0346838053010288e-07
, O 0 3.92183868713758e-10
the O 0 6.547977438042807e-11
different O 0 1.7097954996270204e-10
allelic O 0 6.747895753278499e-08
pattern O 0 3.951554958803172e-07
at O 0 1.145749006781216e-08
the O 0 3.1670488453983126e-10
BRCA1 O 0 2.804837038183905e-07
locus O 0 8.046085042678897e-08
even O 0 5.202079655930447e-09
in O 0 1.344936488567594e-11
some O 0 9.647201440476927e-12
Jewish O 0 3.42319506074773e-10
mutation O 0 6.074636349495677e-09
carriers O 0 1.0866447741619822e-09
, O 0 3.7060893243179294e-10
might O 0 2.552399180899556e-09
suggest O 0 1.3944919663444466e-09
that O 0 5.65128048524155e-11
the O 0 1.1544080968928228e-10
mutation O 0 1.7154386355855422e-08
arose O 0 3.2676208405746365e-09
independently O 0 2.9396728606911893e-08
. O 0 1.8023398329347629e-09
. O 0 1.32089370552535e-08

Crystal O 0 0.00043989025289192796
structure O 0 3.310810541279352e-07
of O 0 1.4913535961724733e-09
the O 0 2.3584874497828423e-08
hemochromatosis B-Disease 1 0.9999998807907104
protein O 0 9.149747484116233e-07
HFE O 0 7.702540642640088e-06
and O 0 4.055078939302348e-09
characterization O 0 5.502223388020866e-08
of O 0 7.124471151920275e-11
its O 0 1.5828149901864208e-09
interaction O 0 4.73156958058496e-10
with O 0 4.3832626417383835e-10
transferrin O 0 7.786879763216348e-08
receptor O 0 2.264219212122498e-08
. O 0 2.5374113477028004e-08

HFE O 0 0.00044560435344465077
is O 0 4.517647766988375e-08
an O 0 2.4447688318218752e-09
MHC O 0 1.9210575885608705e-07
- O 0 5.756169798587507e-07
related O 0 1.964630413908708e-08
protein O 0 1.714221831150553e-08
that O 0 5.0740335544308124e-11
is O 0 2.0539698414312468e-11
mutated O 0 5.703970185066964e-09
in O 0 2.5762355790326374e-11
the O 0 1.3467990056525991e-09
iron B-Disease 1 0.8549492359161377
- I-Disease 1 0.9999977350234985
overload I-Disease 1 0.9999598264694214
disease I-Disease 1 0.9999974966049194
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 0 1.2456544027372729e-05

HFE O 0 0.00011528418690431863
binds O 0 7.312054890462605e-07
to O 0 3.480376875586444e-08
transferrin O 0 3.311426439722709e-07
receptor O 0 2.162503776048652e-08
( O 0 2.4634547735047363e-09
TfR O 0 1.9634697423498437e-07
) O 0 6.715098477272363e-10
and O 0 1.708159169666601e-10
reduces O 0 1.176562292037886e-09
its O 0 1.2713514963014205e-10
affinity O 0 1.1876614969263954e-10
for O 0 7.321102057922246e-11
iron O 0 1.1626641338580157e-07
- O 0 9.182819837860734e-08
loaded O 0 3.475951970699498e-08
transferrin O 0 2.1695601759574856e-08
, O 0 1.367355784154256e-09
implicating O 0 1.862885454784191e-07
HFE O 0 1.023089339469152e-06
in O 0 2.54400545074418e-09
iron O 0 1.1580319551285356e-05
metabolism O 0 1.4489872228296008e-05
. O 0 6.466135715754717e-08

The O 0 2.520731356980832e-07
2 O 0 4.948703349327843e-07
. O 0 2.2252632447816723e-07

6 O 0 1.1688883887472912e-06
A O 0 5.238584677158542e-08
crystal O 0 2.1350102542783134e-05
structure O 0 5.292072557949723e-08
of O 0 1.4650795021609042e-09
HFE O 0 4.2370043047412764e-06
reveals O 0 2.8359028192426194e-07
the O 0 1.2222037271136799e-10
locations O 0 1.1972584701425149e-08
of O 0 2.2692114853839485e-09
hemochromatosis B-Disease 1 1.0
mutations O 0 0.00010684628796298057
and O 0 1.0180356557754067e-09
a O 0 1.886135914119791e-09
patch O 0 0.00018532713875174522
of O 0 5.161220339999772e-10
histidines O 0 9.54131428443361e-06
that O 0 3.0421869468000295e-09
could O 0 9.891489405333687e-09
be O 0 2.9164981540930057e-10
involved O 0 1.268672389365122e-10
in O 0 3.8960940029753033e-10
pH O 0 1.4563453305527219e-06
- O 0 4.417285254021408e-06
dependent O 0 1.2729805121125537e-06
interactions O 0 3.389892455629706e-08
. O 0 3.563339845413793e-08

We O 0 3.9254905459529255e-06
also O 0 7.668843338137776e-09
demonstrate O 0 3.818524163534676e-09
that O 0 3.394366177023045e-10
soluble O 0 3.751724975131765e-08
TfR O 0 1.0284442168995156e-06
and O 0 3.3037559354909263e-09
HFE O 0 7.137489888009441e-07
bind O 0 5.1926747346442426e-08
tightly O 0 4.9683514191656286e-08
at O 0 6.403197083670875e-09
the O 0 6.496524845855944e-11
basic O 0 2.7238382660499383e-09
pH O 0 1.2876450128374017e-08
of O 0 1.4495209720022384e-11
the O 0 3.1898678143349457e-10
cell O 0 6.26301073225477e-07
surface O 0 2.0294373825890943e-06
, O 0 6.184932122010878e-09
but O 0 1.2977384722390184e-09
not O 0 2.393401588030031e-10
at O 0 7.624457731836287e-10
the O 0 6.985088618627344e-10
acidic O 0 1.1484398783068173e-06
pH O 0 4.470384240562453e-08
of O 0 1.550936046257334e-10
intracellular O 0 2.764723916470757e-08
vesicles O 0 1.5097522521045903e-07
. O 0 5.561329174952334e-08

TfR O 0 0.012126297689974308
HFE O 0 0.0008750444394536316
stoichiometry O 0 8.162943231582176e-06
( O 0 5.342936049146374e-08
2 O 0 1.0429854313542819e-08
1 O 0 1.7433894328178212e-09
) O 0 3.432059914043606e-10
differs O 0 6.535207486280115e-09
from O 0 1.3648621122186455e-09
TfR O 0 3.588720289826597e-07
transferrin O 0 1.1488080708943471e-08
stoichiometry O 0 1.163356877498245e-08
( O 0 1.9768824077726066e-10
2 O 0 6.914911421240788e-10
2 O 0 9.469481865309604e-10
) O 0 7.906628129994431e-11
, O 0 6.390586670956822e-11
implying O 0 1.3623567551857008e-10
a O 0 1.905868171614422e-11
different O 0 1.3372115914567217e-11
mode O 0 1.7556728293399715e-09
of O 0 1.0536009564798832e-11
binding O 0 3.4357161560194527e-09
for O 0 9.244053855717027e-10
HFE O 0 1.3124551969667664e-06
and O 0 4.577590306809043e-09
transferrin O 0 1.778725078338539e-08
to O 0 1.2912234836903735e-08
TfR O 0 4.47728751851173e-07
, O 0 1.2185290554356243e-09
consistent O 0 2.4044162216796394e-09
with O 0 7.334324120256142e-11
our O 0 7.968766202459676e-10
demonstration O 0 6.98911317709161e-10
that O 0 7.47859552063801e-11
HFE O 0 9.643614617971252e-08
, O 0 3.9719752487066273e-10
transferrin O 0 5.7543565468165525e-09
, O 0 6.571051480719348e-10
and O 0 7.784838329527588e-10
TfR O 0 5.473772546338296e-08
form O 0 5.054929252956697e-10
a O 0 1.421049611316505e-09
ternary O 0 5.3610754946475936e-08
complex O 0 7.073839469740051e-08
. O 0 1.318986022624813e-07

Identification O 0 5.182790232538537e-07
of O 0 7.366278698128781e-10
three O 0 1.926218295977833e-09
novel O 0 7.912731803116912e-09
mutations O 0 5.175915021027322e-07
and O 0 8.604580936655282e-10
a O 0 5.346661446914425e-10
high O 0 1.9863097833194843e-09
frequency O 0 6.782798323001771e-09
of O 0 6.005027031186216e-11
the O 0 6.275549524481505e-10
Arg778Leu O 0 1.0565122465777677e-06
mutation O 0 2.5217405053012953e-08
in O 0 1.4987040775071847e-10
Korean O 0 4.154571442427368e-08
patients O 0 4.8075778913414524e-09
with O 0 3.006719873077657e-10
Wilson B-Disease 0 4.767898644786328e-06
disease I-Disease 0 2.077242788800504e-05
. O 0 3.390254477153576e-08

Four O 0 2.045704405873039e-07
mutations O 0 4.97994915349409e-06
- O 0 1.3570970622822642e-06
- O 0 3.0761702873860486e-06
R778L O 0 2.6870125680034107e-07
, O 0 3.7815070519364724e-10
A874V O 0 2.2401878130295927e-09
, O 0 4.0754989660829466e-11
L1083F O 0 7.906843513261208e-10
, O 0 3.0964456693149955e-11
and O 0 4.215549437303068e-11
2304delC O 0 9.581128779245773e-09
- O 0 5.180543549698768e-09
- O 0 1.8440371007955036e-08
in O 0 2.5712784679221556e-10
the O 0 1.683624767379044e-10
copper O 0 3.4541951521305236e-08
- O 0 1.020101780824234e-09
transporting O 0 6.403303443036634e-10
enzyme O 0 8.495272263431275e-10
, O 0 5.390299318008829e-11
P O 0 2.030211817327654e-06
- O 0 2.4929414976782027e-08
type O 0 6.7510987911134634e-09
ATPase O 0 3.7083492543388274e-07
( O 0 1.4459327069005212e-09
ATP7B O 0 6.982670015531767e-07
) O 0 9.857691746217867e-11
, O 0 3.5946880888593213e-11
were O 0 2.1870076583052622e-10
identified O 0 2.4570026013748247e-09
in O 0 1.2619391642765265e-10
Korean O 0 3.2006095551651015e-08
Patients O 0 4.626137251051432e-09
with O 0 1.923508019530118e-10
Wilson B-Disease 0 1.972987320186803e-06
disease I-Disease 0 4.002776222478133e-06
. O 0 1.8698854020726685e-08

Arg778Leu O 0 9.09687951207161e-05
, O 0 1.4969113948382073e-08
the O 0 3.209053855979249e-10
most O 0 2.4333096648732067e-10
frequently O 0 2.3884423328013327e-08
reported O 0 1.195495116235179e-07
mutation O 0 1.6462659013782854e-09
of O 0 3.40883116005386e-12
this O 0 1.3083346905862214e-11
enzyme O 0 1.78477010948086e-09
, O 0 2.5633703493177507e-10
was O 0 3.229539524696179e-09
found O 0 1.014681894062619e-09
in O 0 7.082915504108556e-11
six O 0 3.471986032010932e-10
of O 0 5.928682024480825e-12
eight O 0 2.3497752632550828e-09
unrelated O 0 1.1677586009284369e-08
patients O 0 3.6602878505931358e-09
studied O 0 4.1851719312369084e-10
, O 0 1.1437738950403897e-10
an O 0 7.995756140521948e-11
allele O 0 5.352084642140653e-08
frequency O 0 9.479772700160538e-08
of O 0 1.8010305469218224e-09
37 O 0 3.429547916766751e-07
. O 0 6.346792957856451e-08

5 O 0 9.082310157282336e-07
% O 0 1.1444673475580203e-07
, O 0 1.2587425546328745e-09
which O 0 2.0596276073536757e-10
is O 0 3.2148861350833613e-10
considerably O 0 1.2271243576833513e-08
higher O 0 6.3241447634254655e-09
than O 0 6.513240502492579e-10
those O 0 9.988587734710563e-11
in O 0 1.9138458179357443e-11
other O 0 1.5505249861824666e-10
Asian O 0 5.394964475158304e-09
populations O 0 1.1356299012277304e-08
. O 0 3.0155330676961967e-08

The O 0 7.781516764282514e-09
novel O 0 9.347621343636092e-09
single O 0 6.4000831301314065e-09
nucleotide O 0 7.555253489499592e-08
deletion O 0 8.956480428423674e-07
, O 0 2.3731243636859745e-09
2304delC O 0 2.656789774846402e-07
, O 0 1.967561891191849e-09
was O 0 9.582297622046099e-09
found O 0 2.233928375616756e-09
in O 0 2.205476773431414e-10
one O 0 1.3865335546370261e-08
patient O 0 7.838573878871102e-08
. O 0 1.0048676557516956e-08

Since O 0 1.2582250974446652e-07
a O 0 7.570540638823786e-09
mutation O 0 1.058408756193785e-07
at O 0 5.156106208659139e-09
cDNA O 0 3.3151926004393317e-07
nucleotide O 0 2.0502875486272387e-06
2302 O 0 1.1420153896324337e-05
( O 0 4.9231454468667835e-09
2302insC O 0 2.990238101574505e-07
) O 0 1.8544872304460114e-09
had O 0 4.2162714208870966e-08
been O 0 3.267047743449325e-09
previously O 0 1.5303212919093312e-08
described O 0 9.1415746084067e-09
, O 0 8.233409093394428e-11
this O 0 1.676030321473565e-11
region O 0 4.169589118419026e-09
of O 0 2.6879561076942338e-11
the O 0 5.576013539787539e-10
ATP7B O 0 3.636786232164013e-06
gene O 0 1.4984917129368114e-07
may O 0 4.954365095954927e-08
be O 0 1.1148905132429832e-09
susceptible O 0 9.636369924237442e-08
to O 0 2.5542790105248514e-09
gene O 0 1.8714410998654785e-06
rearrangements O 0 0.00014997062680777162
causing O 0 0.00015830679330974817
Wilson B-Disease 0 1.8793170966091566e-05
disease I-Disease 0 0.00013119907816872
. O 0 1.147573414073122e-07

Disruption O 0 1.1831398296635598e-05
of O 0 1.705292129727809e-09
splicing O 0 9.630269914850942e-08
regulated O 0 1.1310406833331399e-08
by O 0 1.227212081955642e-10
a O 0 2.394740628020031e-09
CUG O 0 5.9476587921381e-06
- O 0 5.302732688505785e-07
binding O 0 1.3845757962371863e-07
protein O 0 4.390710159896116e-07
in O 0 1.2633184098831407e-07
myotonic B-Disease 1 0.9999998807907104
dystrophy I-Disease 1 0.9999998807907104
. O 0 4.851288508689322e-07

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9998992681503296
DM B-Disease 1 1.0
) O 0 8.280460974674497e-07
is O 0 3.014628768838179e-09
caused O 0 3.5478215920647926e-09
by O 0 3.1267429617676257e-11
a O 0 1.0020344554106941e-09
CTG O 0 4.536471749361226e-07
expansion O 0 8.873369261586106e-10
in O 0 1.8194881712396693e-10
the O 0 3.584584018501147e-10
3 O 0 7.956407976905666e-09
untranslated O 0 1.622987474547699e-05
region O 0 2.4645186158522847e-07
of O 0 3.2478475464614576e-10
the O 0 9.184991967003953e-08
DM B-Disease 1 1.0
gene O 0 1.9442711618467e-06
. O 0 2.031685575332176e-08

One O 0 8.745461599346527e-08
model O 0 8.950360808057667e-08
of O 0 2.2896161411267713e-08
DM B-Disease 1 1.0
pathogenesis O 0 2.7748948923544958e-05
suggests O 0 1.5620704729712998e-08
that O 0 7.516004485452754e-11
RNAs O 0 1.0108441195200157e-08
from O 0 1.2229592338819373e-10
the O 0 3.0045972654324515e-11
expanded O 0 2.3197953280540418e-10
allele O 0 1.9173040932685126e-09
create O 0 2.3491736333980384e-10
a O 0 6.374447636403602e-10
gain O 0 2.378641426048489e-07
- O 0 2.1165876162854147e-08
of O 0 1.8336746010483296e-10
- O 0 7.417152403377258e-08
function O 0 3.249317703790666e-09
mutation O 0 5.502419408998094e-09
by O 0 2.8132435617167495e-11
the O 0 6.12813896849751e-11
inappropriate O 0 3.185923302950755e-09
binding O 0 3.2377656111748365e-10
of O 0 2.574082873935124e-12
proteins O 0 7.540817276163736e-11
to O 0 5.679779424561104e-10
the O 0 1.4111828372520563e-09
CUG O 0 9.798796236282215e-05
repeats O 0 2.723691977735143e-05
. O 0 3.6632091138244505e-08

Data O 0 6.324922651401721e-06
presented O 0 7.41825658678863e-08
here O 0 2.5704560702166646e-09
indicate O 0 5.624478660593013e-09
that O 0 3.946230495155412e-11
the O 0 7.765037224327642e-11
conserved O 0 6.401060126393077e-09
heterogeneous O 0 3.321163433156471e-08
nuclear O 0 1.3559835032594947e-08
ribonucleoprotein O 0 1.6923449308592353e-08
, O 0 1.463964227621517e-10
CUG O 0 4.655366936390237e-08
- O 0 3.985211716184267e-09
binding O 0 2.8867856993741725e-09
protein O 0 9.121301047798624e-09
( O 0 4.0930128730742865e-10
CUG O 0 1.5626881122443592e-06
- O 0 5.811560868096421e-07
BP O 0 2.8416572604328394e-05
) O 0 1.458137222076772e-10
, O 0 9.976135889600002e-11
may O 0 5.276457049063765e-09
mediate O 0 3.533816439471593e-08
the O 0 2.0929401267633096e-10
trans O 0 2.1848839537597087e-07
- O 0 3.2832915053404577e-07
dominant O 0 7.793997269800457e-08
effect O 0 2.063694770626512e-09
of O 0 9.526228764156208e-12
the O 0 1.4162514216931044e-10
RNA O 0 1.3153368172424962e-07
. O 0 1.9808927831377332e-08

CUG O 0 0.0018203789368271828
- O 0 0.0002664501953404397
BP O 0 0.0006314023048616946
was O 0 6.273149466551331e-08
found O 0 5.012684156646685e-10
to O 0 9.56815252028953e-11
bind O 0 1.1580650882692112e-09
to O 0 4.044170831551952e-10
the O 0 3.0409380569196287e-10
human O 0 5.192048124769144e-09
cardiac O 0 8.150170287990477e-06
troponin O 0 6.624122761422768e-07
T O 0 1.1800725587818306e-05
( O 0 4.727753744049323e-10
cTNT O 0 2.189672976271595e-08
) O 0 3.99676486351197e-10
pre O 0 5.957497606345896e-08
- O 0 8.2709128434999e-08
messenger O 0 1.4442733231589955e-07
RNA O 0 5.026600646829138e-08
and O 0 2.502739127052678e-10
regulate O 0 1.2678020855361183e-09
its O 0 1.6984331718816748e-09
alternative O 0 6.480121772511893e-09
splicing O 0 5.512579832611664e-07
. O 0 1.8325330586321797e-08

Splicing O 0 2.7270471036899835e-05
of O 0 4.2022296753430055e-08
cTNT O 0 8.933917342801578e-06
was O 0 2.5299650019405817e-07
disrupted O 0 4.503059244598262e-05
in O 0 1.6844171568664024e-07
DM B-Disease 1 1.0
striated O 0 0.00010872197890421376
muscle O 0 2.8482227207859978e-05
and O 0 1.6888358489453026e-09
in O 0 1.2880661814929084e-10
normal O 0 6.627485049648385e-08
cells O 0 7.213152031226855e-08
expressing O 0 1.5999643832032007e-09
transcripts O 0 1.3946416466126266e-08
that O 0 2.56330179304598e-10
contain O 0 3.879729870703841e-09
CUG O 0 7.246866880450398e-05
repeats O 0 2.6137446184293367e-05
. O 0 3.5624566407932434e-08

Altered O 0 2.4255858079413883e-05
expression O 0 4.720883239883733e-08
of O 0 3.170070872471342e-10
genes O 0 1.1502201857638283e-08
regulated O 0 1.074987743265865e-08
posttranscriptionally O 0 3.9084687841750565e-07
by O 0 9.603371431410324e-10
CUG O 0 1.3808238691126462e-05
- O 0 2.7125972337671556e-05
BP O 0 0.0008111630450002849
therefore O 0 4.3359204227044756e-08
may O 0 2.566127221825809e-08
contribute O 0 1.0671451278199129e-08
to O 0 3.4806231496986584e-07
DM B-Disease 1 1.0
pathogenesis O 0 6.697671778965741e-06
. O 0 1.3653281838443831e-09
. O 0 3.895338274162441e-09

Identification O 0 5.767786319665902e-07
of O 0 7.241183208606117e-10
a O 0 1.9933994455101356e-09
novel O 0 7.60887743922467e-08
nonsense O 0 3.947342975152424e-06
mutation O 0 1.446157398277137e-07
and O 0 3.5384398189286514e-10
a O 0 6.11000472439116e-10
missense O 0 6.489425885547462e-08
substitution O 0 3.7545774822511646e-10
in O 0 7.04426170172745e-11
the O 0 4.1686487595171684e-10
vasopressin O 0 5.191298413365075e-08
- O 0 7.568023647763766e-07
neurophysin O 0 4.080724011146231e-06
II O 0 2.2309531999553656e-08
gene O 0 1.1026233259769924e-08
in O 0 1.2389905768017684e-10
two O 0 1.180962216906778e-09
Spanish O 0 3.4941120219400545e-08
kindreds O 0 4.948707555740839e-06
with O 0 1.386086712074075e-08
familial B-Disease 0 0.015308775939047337
neurohypophyseal I-Disease 1 0.9993519186973572
diabetes I-Disease 1 0.9995930790901184
insipidus I-Disease 0 0.01841769553720951
. O 0 9.08076913219702e-07

Familial B-Disease 1 0.9999817609786987
neurohypophyseal I-Disease 1 0.9999830722808838
diabetes I-Disease 1 0.9999998807907104
insipidus I-Disease 1 0.9999796152114868
( O 0 0.0047158729285001755
FNDI B-Disease 1 1.0
) O 0 1.1520111087293117e-07
is O 0 1.1861114312949894e-09
an O 0 3.747332222303612e-09
autosomal B-Disease 1 0.9999984502792358
dominant I-Disease 1 0.9998983144760132
disease I-Disease 1 0.9999139308929443
caused O 0 3.72370823242818e-06
by O 0 9.402050693552155e-09
deficiency O 0 0.0006929562659934163
in O 0 4.87024309769879e-10
the O 0 1.100847679680328e-08
antidiuretic O 0 4.238295878167264e-05
hormone O 0 1.9370223469650227e-07
arginine O 0 9.448976356907224e-08
vasopressin O 0 9.368722686531328e-08
( O 0 7.83137776849685e-10
AVP O 0 3.4356133937762934e-08
) O 0 1.9046106705666865e-11
encoded O 0 7.883904640237915e-11
by O 0 1.4644440174405027e-11
the O 0 1.357022133552377e-10
AVP O 0 7.506955171265872e-06
- O 0 1.0807914350152714e-06
neurophysin O 0 2.2261938283918425e-06
II O 0 6.095518756410456e-08
( O 0 6.983370548496737e-10
AVP O 0 9.647640126786428e-07
- O 0 1.7474658875471505e-07
NPII O 0 6.995654757702141e-07
) O 0 9.366708103586419e-11
gene O 0 3.92987509201248e-09
on O 0 6.963661647318986e-09
chromosome O 0 8.967926078184973e-06
20p13 O 0 2.074487383652013e-06
. O 0 7.123053791247003e-08

In O 0 1.1088072682241545e-07
this O 0 8.588528777053739e-10
study O 0 1.206296063038792e-09
, O 0 1.7722966427768938e-09
we O 0 3.311143137452177e-09
analyzed O 0 1.9768986447843417e-09
two O 0 6.7970892803082e-11
families O 0 3.7887245424306215e-11
with O 0 2.682006838838902e-10
FNDI B-Disease 1 0.9999998807907104
using O 0 2.4770336892743217e-09
direct O 0 1.3940824050706624e-09
automated O 0 1.1543480837872266e-07
fluorescent O 0 8.344066770860081e-09
, O 0 2.537196008844944e-10
solid O 0 5.027604998986135e-09
phase O 0 7.953793734749581e-10
, O 0 5.13798829870904e-11
single O 0 1.1269766231336575e-09
- O 0 8.804858175892605e-09
stranded O 0 6.276869246590877e-09
DNA O 0 1.3374170659830042e-09
sequencing O 0 3.4089386868885185e-10
of O 0 6.865543723810763e-12
PCR O 0 2.0684167267859266e-08
- O 0 4.594167535287852e-08
amplified O 0 3.283730052316969e-07
AVP O 0 9.241203429155576e-07
- O 0 1.431205163271443e-07
NPII O 0 9.333867865279899e-07
DNA O 0 3.264483439124888e-07
. O 0 1.1794433874001697e-08

In O 0 7.321922623759747e-08
one O 0 1.5223001748054799e-09
of O 0 1.702680357817954e-11
the O 0 5.002654956953734e-10
families O 0 9.207962725632513e-10
, O 0 2.3415922534297806e-09
affected O 0 2.3557977790744644e-09
individuals O 0 1.8475795546257778e-11
presented O 0 4.1937300854222315e-10
a O 0 6.79726108732126e-10
novel O 0 1.3019961997429164e-08
nonsense O 0 1.5786135065809503e-07
mutation O 0 5.512335921054046e-09
in O 0 5.523381058081256e-11
exon O 0 1.5675114539703827e-08
3 O 0 8.618296631901501e-10
of O 0 7.930185154381153e-12
the O 0 3.7583228196247376e-11
gene O 0 3.2921250170403482e-09
, O 0 2.6825526175389136e-11
consisting O 0 7.1106198186454694e-12
in O 0 1.0361966493177555e-11
a O 0 4.61114146865782e-10
G O 0 3.6638070923800115e-06
to O 0 1.5810234899049647e-08
T O 0 5.029371095588431e-06
transition O 0 3.798018344269849e-09
at O 0 8.816364860386727e-10
nucleotide O 0 1.665583226895251e-08
2101 O 0 4.151466370672097e-08
, O 0 3.2281152750890385e-10
which O 0 8.119874217449308e-11
produces O 0 4.2845019199155843e-10
a O 0 2.985837410651726e-10
stop O 0 8.514162885830956e-08
signal O 0 9.481309604097987e-08
in O 0 1.0815580653300572e-09
codon O 0 5.074554678685672e-07
82 O 0 1.410752847874619e-08
( O 0 1.7424685028188946e-09
Glu O 0 3.846028448606376e-06
) O 0 3.0560326491624323e-10
of O 0 1.9331074241346613e-10
NPII O 0 3.4109383705072105e-05
. O 0 5.3523500298524596e-08

The O 0 1.2519363679075468e-07
premature O 0 1.3161264860173105e-06
termination O 0 4.510501483423468e-08
eliminates O 0 2.7388274759232445e-08
part O 0 6.787687079068405e-10
of O 0 3.2236775748817337e-11
the O 0 7.6364509160598e-10
C O 0 1.7153932958535734e-06
- O 0 3.0254946636887325e-07
terminal O 0 3.68966681207894e-07
domain O 0 3.660678649097804e-09
of O 0 9.376897175394916e-11
NPII O 0 1.1938741408812348e-06
, O 0 2.1376367689840414e-11
including O 0 1.531611751488804e-12
a O 0 1.3228128661890715e-11
cysteine O 0 1.585315767549389e-10
residue O 0 1.3516910923883074e-09
in O 0 1.9316211824493834e-11
position O 0 7.443098581916274e-09
85 O 0 4.365274808293407e-10
, O 0 8.83290593445274e-11
which O 0 4.929531782771335e-10
could O 0 2.2045496095302042e-08
be O 0 7.771308041526481e-10
involved O 0 9.129193928592017e-11
in O 0 9.889083996128534e-11
the O 0 2.548478539310395e-09
correct O 0 2.4409027901128866e-05
folding O 0 7.110023148015898e-08
of O 0 2.1209500822294558e-10
the O 0 4.7629105104363134e-09
prohormone O 0 1.892453474283684e-05
. O 0 1.224625378881683e-07

In O 0 3.712361262842023e-08
the O 0 8.61412219332891e-10
second O 0 5.582201723086655e-08
family O 0 1.3334690018851347e-09
, O 0 3.3699928264629975e-11
a O 0 3.901319545196458e-11
G279A O 0 9.768007513955013e-10
substitution O 0 9.370693804244823e-11
at O 0 1.2515269931512307e-09
position O 0 7.334611140663583e-09
- O 0 1.2682139782782542e-08
1 O 0 7.897423270897264e-10
of O 0 6.7175640050542995e-12
the O 0 9.073816698013104e-11
signal O 0 1.062435384113769e-08
peptide O 0 2.629795825548342e-10
was O 0 1.2540288807372235e-09
observed O 0 4.954776033905262e-10
in O 0 5.4308873370656485e-11
all O 0 2.772198304246132e-10
affected O 0 2.3495245748961224e-09
individuals O 0 3.0006871987176e-10
. O 0 9.374117482252586e-09

This O 0 9.136662271203022e-08
missense O 0 2.699675678741187e-05
mutation O 0 4.686433840106474e-06
, O 0 6.901857307894943e-09
which O 0 2.4695518963113727e-09
replaces O 0 1.0221003776678117e-06
Ala O 0 2.0488671736984543e-07
with O 0 5.685513171371781e-10
Thr O 0 3.735357677214779e-05
, O 0 5.64995827900816e-10
is O 0 1.0684107765168704e-10
frequent O 0 1.677619287931975e-08
among O 0 1.0987625920222399e-08
FNDI B-Disease 1 1.0
patients O 0 1.7592117728781886e-05
and O 0 1.5795569019427802e-10
is O 0 1.206730271263723e-10
thought O 0 1.84829340721393e-09
to O 0 6.379969330616575e-10
reduce O 0 3.034982931637842e-09
the O 0 9.708009396369732e-11
efficiency O 0 9.97100402244655e-10
of O 0 2.9698816322865085e-11
cleavage O 0 1.0648540182955912e-07
by O 0 1.1743808148168e-09
signal O 0 3.5004364917767816e-07
peptidases O 0 9.563948424329283e-07
. O 0 3.584162078240638e-09
. O 0 1.7608684288461518e-08

Genetic O 0 3.7401230656541884e-05
heterogeneity O 0 7.305096914933529e-06
of O 0 2.206834004425673e-08
Saethre B-Disease 0 0.27204015851020813
- I-Disease 1 0.999645471572876
Chotzen I-Disease 1 0.999940037727356
syndrome I-Disease 1 0.9999990463256836
, O 0 9.901187647542997e-10
due O 0 3.6509864020928262e-09
to O 0 2.9084226138564873e-09
TWIST O 0 9.874574061541352e-06
and O 0 7.614800523469967e-08
FGFR O 0 8.429244189755991e-05
mutations O 0 3.3347014323226176e-06
. O 0 2.7062688090495612e-08

Thirty O 0 9.032987691171002e-06
- O 0 6.6918678385263775e-06
two O 0 1.4272953485772177e-08
unrelated O 0 4.345590554066803e-08
patients O 0 8.308239429766218e-09
with O 0 6.3818134804494164e-12
features O 0 4.143703602466076e-09
of O 0 2.759448891609395e-09
Saethre B-Disease 1 0.9838736653327942
- I-Disease 1 0.9995961785316467
Chotzen I-Disease 1 0.9997934699058533
syndrome I-Disease 1 0.9999457597732544
, O 0 8.040044324753026e-11
a O 0 4.169022349564955e-10
common O 0 5.7873364767146995e-08
autosomal B-Disease 1 0.8350424766540527
dominant I-Disease 0 0.000401250523282215
condition I-Disease 0 4.3933134293183684e-05
of O 0 1.9693415787003232e-09
craniosynostosis B-Disease 0 0.02820451557636261
and O 0 1.351715673081344e-05
limb B-Disease 1 0.9993773102760315
anomalies I-Disease 1 0.9968605041503906
, O 0 1.9712329546450746e-08
were O 0 2.8913980099076753e-09
screened O 0 4.5984457130998635e-08
for O 0 2.6076935055741046e-10
mutations O 0 1.3364843454155562e-08
in O 0 1.1776618569214747e-10
TWIST O 0 2.8133633804827696e-06
, O 0 1.1621503759329244e-08
FGFR2 O 0 6.6510656324680895e-06
, O 0 1.4243195511909335e-09
and O 0 2.5048367824354045e-09
FGFR3 O 0 3.701535388245247e-05
. O 0 4.548766341372357e-08

Nine O 0 1.4073257261770777e-06
novel O 0 7.172159399715383e-08
and O 0 5.5039839352843956e-09
three O 0 1.0570425423850338e-08
recurrent O 0 2.2470916519523598e-05
TWIST O 0 5.3351690439740196e-05
mutations O 0 7.141424430301413e-05
were O 0 9.76491953963432e-09
found O 0 1.070269428637971e-09
in O 0 1.8536834567317584e-10
12 O 0 3.785001645439934e-09
families O 0 2.5172846029875018e-09
. O 0 2.3187183728623495e-08

Seven O 0 7.83235520884773e-07
families O 0 1.1809246025507036e-08
were O 0 4.021941890641756e-09
found O 0 1.37390454568731e-09
to O 0 1.1705544311624294e-09
have O 0 1.9945470275395394e-10
the O 0 9.782508136879642e-11
FGFR3 O 0 3.6715545093102264e-07
P250R O 0 6.096493088136867e-09
mutation O 0 3.6823806226493616e-09
, O 0 1.7186430056881363e-10
and O 0 2.3239760116311459e-10
one O 0 6.691254217372489e-10
individual O 0 6.973583516201032e-11
was O 0 3.977801910082235e-08
found O 0 5.2056035038106074e-09
to O 0 8.624544967084091e-10
have O 0 1.7775024507837855e-10
an O 0 6.790739498496734e-11
FGFR2 O 0 1.147834382209112e-06
VV269 O 0 3.808262860616196e-08
- O 0 8.723021949208487e-08
270 O 0 4.599919734005198e-08
deletion O 0 1.3075505194137804e-05
. O 0 5.42956968274666e-08

To O 0 2.3630403234164987e-07
date O 0 5.786905887816829e-08
, O 0 3.6466554775849147e-10
our O 0 2.17150353254425e-10
detection O 0 8.054953370972839e-10
rate O 0 3.531011927293548e-09
for O 0 4.496185021518606e-11
TWIST O 0 3.3547766520314326e-07
or O 0 1.2038285035487206e-07
FGFR O 0 6.723885235260241e-06
mutations O 0 8.956422448136436e-08
is O 0 1.6498925836661016e-10
68 O 0 1.5107186612794976e-09
% O 0 1.0925589599697361e-10
in O 0 1.0050218990365067e-10
our O 0 1.6278761449939338e-07
Saethre B-Disease 0 0.08319243788719177
- I-Disease 1 0.9905989766120911
Chotzen I-Disease 1 0.9994800686836243
syndrome I-Disease 1 0.9999957084655762
patients O 0 4.110246663913131e-06
, O 0 8.849752874962036e-11
including O 0 7.431529003287807e-11
our O 0 3.887939570290655e-08
five O 0 4.5112933833024726e-08
patients O 0 2.680111022002052e-09
elsewhere O 0 1.0605599731761117e-09
reported O 0 7.690877623645065e-08
with O 0 8.770744686081855e-10
TWIST O 0 5.06031938130036e-05
mutations O 0 3.340937473694794e-05
. O 0 2.4807984999597466e-08

More O 0 1.4894554034583507e-08
than O 0 1.4532928194199712e-09
35 O 0 1.0528045102375927e-09
different O 0 1.2832304663312755e-10
TWIST O 0 4.070514307841222e-07
mutations O 0 1.8825464849214768e-06
are O 0 3.08777142743466e-10
now O 0 3.772789858302872e-10
known O 0 1.0562232338751087e-10
in O 0 8.011739882629598e-11
the O 0 3.869529419109341e-10
literature O 0 5.50325918169392e-09
. O 0 3.151018646008197e-08

The O 0 1.0533272032375862e-08
most O 0 2.1686144546784192e-10
common O 0 1.9756687952288132e-10
phenotypic O 0 1.7235096905210412e-08
features O 0 9.219301766449917e-09
, O 0 5.97462912477198e-10
present O 0 1.431235824300714e-10
in O 0 3.753931193672955e-11
more O 0 2.6055048743534037e-11
than O 0 4.2926145277233374e-11
a O 0 1.3802343712399079e-09
third O 0 2.2232819674172788e-07
of O 0 1.1969285285129416e-10
our O 0 3.6861067087556876e-08
patients O 0 8.230163772715571e-10
with O 0 2.8178836000702923e-11
TWIST O 0 2.4632670374558074e-06
mutations O 0 4.579907908919267e-06
, O 0 6.61758869924256e-10
are O 0 3.384513780346765e-10
coronal B-Disease 0 5.3876838137512095e-06
synostosis I-Disease 0 4.207295933156274e-05
, O 0 3.473484833094176e-09
brachycephaly B-Disease 0 3.693060534715187e-06
, O 0 4.1608498868583865e-09
low B-Disease 0 2.9603986604342936e-06
frontal I-Disease 1 0.984641969203949
hairline I-Disease 1 0.9999995231628418
, O 0 2.7373423563403776e-06
facial B-Disease 1 0.564096212387085
asymmetry I-Disease 0 4.205471122986637e-05
, O 0 8.202792400879844e-08
ptosis B-Disease 0 0.004617577884346247
, O 0 2.9073646601318615e-08
hypertelorism B-Disease 0 5.294899892760441e-05
, O 0 7.042401772849871e-09
broad B-Disease 0 2.7563521243223477e-08
great I-Disease 0 9.300779879595211e-08
toes I-Disease 1 0.6295605897903442
, O 0 3.758091793315543e-08
and O 0 2.0567327396747714e-08
clinodactyly B-Disease 0 1.927094672282692e-05
. O 0 8.024353093105674e-08

Significant O 0 1.0236026355414651e-06
intra O 0 1.0730092071753461e-05
- O 0 8.608614734839648e-05
and O 0 1.7434740584576502e-07
interfamilial O 0 3.721993834915338e-06
phenotypic O 0 6.044946871952561e-07
variability O 0 4.7246399503819703e-07
is O 0 6.211339220740797e-10
present O 0 1.9196119693809521e-10
for O 0 7.339921725968424e-11
either O 0 6.095818516627105e-09
TWIST O 0 1.8101676687365398e-05
mutations O 0 1.154855726781534e-05
or O 0 1.2306581709253805e-07
FGFR O 0 0.00020811591821257025
mutations O 0 1.5699366485932842e-05
. O 0 4.6227352612504546e-08

The O 0 2.4410892862647415e-08
overlap O 0 2.55718646258174e-07
in O 0 3.1281359724744107e-09
clinical O 0 7.356678377590242e-09
features O 0 9.014724966505128e-09
and O 0 5.462516217136226e-09
the O 0 9.266627742920974e-11
presence O 0 4.972555700533121e-10
, O 0 9.384770044418289e-11
in O 0 7.2594577918416725e-12
the O 0 1.6256855236984613e-11
same O 0 1.4389713032247897e-10
genes O 0 5.717266660099085e-10
, O 0 3.820363123074877e-11
of O 0 1.8053579464716307e-12
mutations O 0 3.5300220524447923e-09
for O 0 1.9324649519480985e-11
more O 0 3.673684967342439e-11
than O 0 9.355548974410155e-11
one O 0 3.710702856096759e-09
craniosynostotic B-Disease 0 6.210235824255506e-06
condition I-Disease 0 5.077196973957143e-08
- O 0 3.6269505176989014e-09
such O 0 6.434029004021014e-11
as O 0 2.156678169384918e-09
Saethre B-Disease 0 3.0308049190352904e-06
- I-Disease 0 3.796050975779508e-07
Chotzen I-Disease 0 1.0580358775769128e-06
, I-Disease 0 2.8933491713623027e-10
Crouzon I-Disease 0 5.7882637349848665e-08
, I-Disease 0 2.5854765550725745e-10
and I-Disease 0 6.739031555014208e-09
Pfeiffer I-Disease 0 0.24721361696720123
syndromes I-Disease 0 4.924716267851181e-05
- O 0 6.30587564387497e-08
support O 0 1.3032842860472016e-10
the O 0 2.537398069435426e-11
hypothesis O 0 2.2392639131840752e-10
that O 0 2.607418794764449e-11
TWIST O 0 5.5517379138336764e-08
and O 0 1.315944242463729e-09
FGFRs O 0 5.944274050762033e-08
are O 0 2.1241714984188143e-11
components O 0 3.040990237401786e-10
of O 0 5.56656110095588e-12
the O 0 3.404583212573975e-11
same O 0 1.4998050024139786e-10
molecular O 0 4.844154521954636e-10
pathway O 0 2.764963813461918e-10
involved O 0 1.365306756540008e-10
in O 0 2.0320273241836162e-11
the O 0 9.033856301909893e-11
modulation O 0 2.449792901870751e-08
of O 0 1.3555224720462888e-09
craniofacial O 0 0.0005074800574220717
and O 0 8.781119618106459e-07
limb O 0 6.393983494490385e-05
development O 0 1.2395229287420761e-09
in O 0 1.5928325325376136e-10
humans O 0 1.6287754478483407e-09
. O 0 1.423048678894645e-09
. O 0 1.3883091121158486e-08

Mutation O 0 4.026251190225594e-05
analysis O 0 3.6539006487146253e-07
of O 0 3.4882123856050384e-08
UBE3A O 0 0.03447931259870529
in O 0 0.0009176487801596522
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 0 0.04171032831072807
. O 0 2.3042186114707874e-07

Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.012034272775053978
AS B-Disease 1 0.9999998807907104
) O 0 1.8637786425301783e-08
is O 0 1.2352369127555107e-09
caused O 0 4.002946418779629e-09
by O 0 1.5828321986433025e-10
chromosome O 0 1.3822124856233131e-05
15q11 O 0 8.381001634916174e-07
- O 0 3.188907555795595e-07
q13 O 0 8.727415234943692e-08
deletions O 0 1.8187238026712294e-07
of O 0 7.05062050410099e-11
maternal O 0 9.744639761777307e-09
origin O 0 1.1562008239707211e-08
, O 0 7.90690402041605e-10
by O 0 9.63004120890787e-10
paternal O 0 1.4547850923918304e-06
uniparental B-Disease 0 0.0023272475227713585
disomy I-Disease 1 0.8305311799049377
( O 0 3.7445943235070445e-06
UPD B-Disease 1 1.0
) O 0 1.5357072058463928e-08
15 O 0 1.1912921760171002e-09
, O 0 2.9400162859793966e-11
by O 0 9.53583184637452e-11
imprinting O 0 6.98766962159425e-05
defects O 1 0.9842037558555603
, O 0 3.1880507123105417e-09
and O 0 7.98279276015279e-10
by O 0 1.1811440714382115e-10
mutations O 0 6.706452637672555e-08
in O 0 2.097431950343065e-10
the O 0 1.9718786603561966e-09
UBE3A O 0 5.750503532908624e-06
gene O 0 1.6951754560068366e-06
. O 0 8.841244891755196e-08

UBE3A O 0 0.0001945792173501104
encodes O 0 2.212339722973411e-06
a O 0 3.1549998169566607e-08
ubiquitin O 0 1.2652692760184436e-07
- O 0 1.6018957182950544e-07
protein O 0 2.5412280280079358e-08
ligase O 0 1.1138092226303797e-08
and O 0 3.568180417801159e-09
shows O 0 1.7042653510657146e-08
brain O 0 2.421645831418573e-06
- O 0 2.9888693120483367e-07
specific O 0 3.680430538111068e-08
imprinting O 0 6.8244835347286426e-06
. O 0 5.956668047701896e-08

Here O 0 5.911750236009539e-07
we O 0 2.7705199912020362e-08
describe O 0 4.11736067462698e-08
UBE3A O 0 1.1913871276192367e-05
coding O 0 4.0389604691881686e-05
- O 0 6.50868023512885e-05
region O 0 5.960559519735398e-06
mutations O 0 6.0752809076802805e-06
detected O 0 1.639523929952702e-07
by O 0 6.042228523073234e-11
SSCP O 0 1.5473305836621876e-07
analysis O 0 1.7092224302572845e-09
in O 0 9.307231652044834e-10
13 O 0 7.941341095829557e-08
AS B-Disease 1 0.9999959468841553
individuals O 0 2.8939398100114033e-10
or O 0 1.3888335814726815e-08
families O 0 3.5086691330121766e-09
. O 0 5.5179665281457346e-08

Two O 0 1.1606168470734701e-07
identical O 0 4.365716392840113e-07
de O 0 6.423021545742813e-07
novo O 0 5.034924015490105e-06
5 O 0 3.0962024055725124e-08
- O 0 4.5452367203324684e-07
bp O 0 3.2727646157582058e-06
duplications O 0 4.675041225254972e-07
in O 0 6.244743611105719e-10
exon O 0 1.821219512976313e-07
16 O 0 8.898236814047777e-09
were O 0 1.2667628057627667e-09
found O 0 3.439597939802752e-09
. O 0 1.4664417236076588e-08

Among O 0 1.4091017241923964e-08
the O 0 3.4222810696427075e-10
other O 0 1.2352528722114897e-10
11 O 0 1.1960248069708967e-10
unique O 0 8.589278593928995e-11
mutations O 0 2.0478234219467595e-08
, O 0 1.5147688658956326e-10
8 O 0 1.0515300852276255e-09
were O 0 7.242353938785584e-11
small O 0 3.891346619933067e-11
deletions O 0 3.975390541199886e-07
or O 0 1.6652045076170907e-07
insertions O 0 1.5324045307352208e-05
predicted O 0 8.656863064970821e-05
to O 0 8.216258606807969e-08
cause O 0 4.6438032086371095e-08
frameshifts O 0 3.0226906346797477e-06
, O 0 3.0577876342086086e-10
1 O 0 1.0580485376721072e-09
was O 0 2.3799238135779888e-09
a O 0 1.3561993195132516e-10
mutation O 0 1.586835218780891e-09
to O 0 1.3870081472244777e-10
a O 0 3.683706673029974e-10
stop O 0 1.0097249258933516e-07
codon O 0 5.962942140058658e-08
, O 0 2.079705019308875e-10
1 O 0 1.491927553720629e-10
was O 0 3.275568982719079e-10
a O 0 1.9131753126178097e-10
missense O 0 6.598537538593519e-08
mutation O 0 1.5150275700648308e-08
, O 0 4.852912516284391e-10
and O 0 3.9761594017306834e-10
1 O 0 8.606079404671618e-09
was O 0 2.0015312429677579e-07
predicted O 0 5.541993459701189e-07
to O 0 1.538441707360505e-09
cause O 0 7.029863913210477e-10
insertion O 0 5.769401845157063e-09
of O 0 9.342906309717236e-11
an O 0 4.002580045181503e-09
isoleucine O 0 0.005011489614844322
in O 0 2.5638655642978847e-09
the O 0 5.568839278602411e-10
hect O 0 8.607347012912214e-08
domain O 0 1.1562509838469737e-09
of O 0 1.3808123047742704e-11
the O 0 2.0082666085663448e-10
UBE3A O 0 1.1019278645107988e-07
protein O 0 7.964242598745841e-09
, O 0 9.879865675577193e-11
which O 0 1.7844517530285486e-11
functions O 0 3.992298158728147e-11
in O 0 7.126985113181661e-11
E2 O 0 3.965136485817311e-08
binding O 0 9.516182508662041e-09
and O 0 4.5792206138095537e-10
ubiquitin O 0 9.657876276492061e-09
transfer O 0 5.509132705583397e-08
. O 0 4.401178088642155e-08

Eight O 0 2.2931611454168888e-07
of O 0 1.4531284509011755e-10
the O 0 2.243761704212588e-10
cases O 0 1.9035089060537302e-09
were O 0 2.546748589793424e-09
familial O 0 3.412878584185819e-07
, O 0 4.5592937425453783e-08
and O 0 8.351804581252509e-09
five O 0 1.6672583313948053e-08
were O 0 1.4588703578510831e-08
sporadic O 0 7.857806849642657e-07
. O 0 6.589959866687423e-08

In O 0 6.14192074976927e-08
two O 0 5.548834280943993e-09
familial O 0 2.319203304068651e-05
cases O 0 7.124269245650794e-07
and O 0 1.7644623540036264e-08
one O 0 1.570294472230671e-08
sporadic O 0 7.745964580863074e-07
case O 0 1.2409358873810561e-08
, O 0 7.329838958014534e-10
mosaicism O 0 3.6310439099906944e-07
for O 0 1.0228703439807418e-09
UBE3A O 0 3.7017098293290474e-06
mutations O 0 2.5642098080425058e-06
was O 0 1.3280074817600962e-08
detected O 0 7.781060418210473e-08
in O 0 7.725416140136332e-11
the O 0 2.82068118862e-10
mother O 0 1.7559423781676742e-07
of O 0 5.272981010162603e-11
three O 0 4.0917299770626414e-07
AS B-Disease 1 1.0
sons O 0 5.948289185653266e-07
, O 0 2.2604369764867016e-10
in O 0 2.0925042948372052e-11
the O 0 1.4928840108563435e-10
maternal O 0 2.7357145437889585e-09
grandfather O 0 4.077858939410817e-09
of O 0 5.6486725019677664e-11
two O 0 5.81466608196024e-08
AS B-Disease 1 1.0
first O 0 2.540492118896509e-07
cousins O 0 9.634051139073563e-07
, O 0 2.9111200117171165e-09
and O 0 6.452552936409006e-10
in O 0 8.301832138402077e-11
the O 0 1.0168402786447928e-09
mother O 0 1.5995416902114812e-07
of O 0 7.992767558917535e-11
an O 0 1.2228579038264797e-08
AS B-Disease 1 1.0
daughter O 0 0.00013744884927291423
. O 0 1.342340283372323e-07

The O 0 1.3299112033848814e-08
frequencies O 0 2.7336346519746257e-08
with O 0 3.10076714304941e-10
which O 0 5.723922447131713e-10
we O 0 1.614165467955786e-09
detected O 0 4.9959352210748875e-09
mutations O 0 5.456799456737826e-09
were O 0 2.200019333375991e-10
5 O 0 1.3061934867053537e-10
( O 0 8.255959110803346e-11
14 O 0 1.309059860510331e-09
% O 0 6.459013879300812e-11
) O 0 1.5768681499439552e-11
of O 0 6.848567286193985e-12
35 O 0 1.4978075446592243e-09
in O 0 1.5578260903481578e-10
sporadic O 0 2.0388563370943302e-07
cases O 0 3.222537348079868e-09
and O 0 5.488981713597241e-09
8 O 0 4.749556303806912e-09
( O 0 8.367119497254549e-11
80 O 0 1.6688284087962302e-10
% O 0 2.6865634716877196e-10
) O 0 4.7678503506398684e-11
of O 0 2.3349761360536014e-11
10 O 0 2.9292606118502817e-09
in O 0 6.0110000310587e-10
familial O 0 2.902444748542621e-06
cases O 0 1.8396283607557962e-08
. O 0 4.297829203636638e-09
. O 0 4.104164830209811e-08

The O 0 9.237855351784674e-07
hemochromatosis B-Disease 1 0.9999971389770508
845 O 0 1.8783141513267765e-06
G O 0 5.408068773249397e-06
- O 0 2.7189301476937544e-07
- O 0 2.3614633448687528e-07
> O 0 1.6438465033630223e-09
A O 0 1.916002689839047e-09
and O 0 1.582463882154883e-10
187 O 0 2.560433531861861e-10
C O 0 8.107455151673548e-09
- O 0 2.6011441889295384e-08
- O 0 3.2270295946545957e-07
> O 0 1.3419635180866862e-08
G O 0 7.280242471097154e-07
mutations O 0 1.6082022114005667e-07
: O 0 1.5654721963187512e-10
prevalence O 0 8.988541466692368e-09
in O 0 1.1935635813031809e-10
non O 0 1.3053285385922209e-07
- O 0 1.2250298823346384e-05
Caucasian O 0 3.5089215089101344e-05
populations O 0 9.363002959617006e-07
. O 0 4.006752618579412e-08

Hemochromatosis B-Disease 1 0.8610256910324097
, O 0 2.2031138087186264e-06
the O 0 1.8233168930237298e-06
inherited B-Disease 1 1.0
disorder I-Disease 1 1.0
of I-Disease 0 1.6493930665717471e-09
iron I-Disease 0 6.1022754380246624e-05
metabolism I-Disease 0 5.579987555393018e-05
, O 0 7.939611634810717e-09
leads O 0 5.501069111346624e-08
, O 0 1.0900076397035718e-09
if O 0 6.676545538653045e-09
untreated O 0 1.427596885150706e-06
, O 0 8.848909105463321e-11
to O 0 1.378755776215712e-09
progressive O 0 4.682399037392315e-07
iron B-Disease 0 0.06399047374725342
overload I-Disease 0 0.03146376088261604
and O 0 1.9048609374294756e-06
premature B-Disease 0 4.681569407694042e-06
death I-Disease 0 2.906439817706996e-07
. O 0 4.0694771996641066e-08

The O 0 2.0783802483492764e-06
hemochromatosis B-Disease 1 0.9999990463256836
gene O 0 1.4191350601322483e-05
, O 0 8.725596245540146e-09
HFE O 0 1.0326849405828398e-05
, O 0 1.5401100839085302e-08
recently O 0 5.8439521666286964e-08
has O 0 5.27522958648774e-09
been O 0 2.0235864095496936e-09
identified O 0 1.4025298256115093e-08
, O 0 2.0141088796776785e-10
and O 0 1.0100260211531875e-10
characterization O 0 2.9205855511804657e-09
of O 0 7.88018695435655e-12
this O 0 6.409238417770524e-11
gene O 0 8.234784409921758e-09
has O 0 2.3460493547844408e-09
shown O 0 6.781992745175103e-10
that O 0 2.8194425960581526e-11
it O 0 1.1058277904485436e-10
contains O 0 3.145387422742729e-11
two O 0 1.0459213495295216e-09
mutations O 0 1.0900579994199688e-08
that O 0 3.248626367913232e-11
result O 0 5.759116100678696e-11
in O 0 1.343862000846574e-11
amino O 0 5.72072444970928e-10
acid O 0 2.2054316151098874e-09
substitutions O 0 1.5125609653665606e-09
- O 0 4.852116486375735e-10
cDNA O 0 8.834178721883745e-09
nucleotides O 0 7.2856023436429496e-09
845 O 0 1.3804695164765235e-08
G O 0 2.819360744865662e-08
- O 0 2.2872153948583218e-08
- O 0 6.322254364476976e-08
> O 0 1.310696218226326e-09
A O 0 1.9388874950010404e-09
( O 0 5.435260574948586e-11
C282Y O 0 5.693966964592789e-10
) O 0 1.2533891459443058e-11
and O 0 1.2299460928899553e-11
187 O 0 9.738274769910404e-11
C O 0 7.744780816665298e-09
- O 0 1.0006106521132097e-07
- O 0 1.185132646241982e-06
> O 0 2.8383857042513227e-08
G O 0 8.737255825508328e-07
( O 0 6.988807310648326e-10
H63D O 0 1.0899582321144408e-06
) O 0 1.7346029057563328e-09
. O 0 8.925144179272593e-09

Although O 0 1.0625128197716549e-05
hemochromatosis B-Disease 1 0.9999997615814209
is O 0 1.0420409424227728e-08
common O 0 1.787614833936857e-09
in O 0 6.67575272839116e-10
Caucasians O 0 1.6691425344106392e-06
, O 0 2.993525871630709e-09
affecting O 0 4.082162163854264e-09
> O 0 3.0206490642115114e-09
= O 0 8.562596320871307e-08
1 O 0 2.589975700573177e-08
/ O 0 8.955190651249723e-07
300 O 0 1.8415642621949502e-10
individuals O 0 1.6339356950778594e-11
of O 0 6.327018770013737e-12
northern O 0 5.423452975605869e-08
European O 0 2.972272028500811e-08
origin O 0 2.863927317520165e-09
, O 0 3.733249709370057e-09
it O 0 1.054251885790336e-08
has O 0 3.8154590598082905e-09
not O 0 6.807705510425421e-10
been O 0 1.2698876672434523e-10
recognized O 0 4.974147135849982e-11
in O 0 2.7425454268703575e-11
other O 0 2.424382639087952e-10
populations O 0 1.1272458522171291e-08
. O 0 2.0807267020472864e-08

The O 0 3.479494026237262e-08
present O 0 4.66879246374674e-09
study O 0 3.085398880831036e-10
used O 0 2.5526705749179257e-10
PCR O 0 2.3050223063592057e-08
and O 0 5.544015246883305e-11
restriction O 0 1.2074785615823203e-10
- O 0 1.795580351071635e-09
enzyme O 0 5.190463614468399e-09
digestion O 0 8.637159432112185e-09
to O 0 1.5718818469068196e-09
analyze O 0 6.8064758274033466e-09
the O 0 4.467411510167274e-11
frequency O 0 3.865398279234711e-10
of O 0 5.201288184875086e-12
the O 0 7.097141624390346e-11
845 O 0 8.256892947144934e-10
G O 0 2.13839452811726e-08
- O 0 3.870099796188242e-09
- O 0 4.562275446318154e-09
> O 0 1.540569893876409e-10
A O 0 4.0674091872361373e-10
and O 0 7.688080033707578e-11
187 O 0 7.646226013457991e-11
C O 0 2.334711091123154e-09
- O 0 6.888758008471996e-09
- O 0 8.968132192421763e-08
> O 0 2.6241602224530425e-09
G O 0 4.082935234350771e-08
mutations O 0 4.494920435860195e-09
in O 0 6.153649811935225e-11
HLA O 0 1.60089697942567e-07
- O 0 5.213960374561566e-09
typed O 0 1.291935802782973e-07
samples O 0 2.2529658139092135e-09
from O 0 1.1627546148140766e-10
non O 0 2.8925175588057073e-09
- O 0 1.6196534602386237e-07
Caucasian O 0 1.1998815807601204e-06
populations O 0 1.5791730589853614e-08
, O 0 1.3656270558826122e-10
comprising O 0 1.3605824800144717e-11
Australian O 0 4.412720536195458e-11
Aboriginal O 0 5.844098815988019e-11
, O 0 1.6806304611871603e-11
Chinese O 0 2.552406550004882e-11
, O 0 7.235601701127692e-11
and O 0 3.4362060419290685e-10
Pacific O 0 2.1584900977700272e-08
Islanders O 0 1.164014307164507e-07
. O 0 8.208345114724125e-09

Results O 0 0.0001554248738102615
showed O 0 5.224435639661351e-08
that O 0 7.410919794503812e-11
the O 0 5.825513682555794e-11
845 O 0 4.326162095225072e-09
G O 0 1.747532678564312e-07
- O 0 6.011888586954228e-08
- O 0 1.4443311613376864e-07
> O 0 2.346206118275518e-09
A O 0 7.052644690475063e-09
mutation O 0 1.738621691060871e-08
was O 0 3.789783598051599e-09
present O 0 1.3846135349382394e-10
in O 0 4.792594793245897e-11
these O 0 3.8928905238266864e-11
populations O 0 3.409003634935459e-10
( O 0 3.8173041116973394e-11
allele O 0 2.4926167796479604e-09
frequency O 0 2.7971200911025562e-09
0 O 0 3.8903241739163263e-10
. O 0 7.065051321752946e-11
32 O 0 7.919552236224092e-10
% O 0 9.635749836922614e-11
) O 0 4.456262789331866e-11
, O 0 4.3286446649304366e-10
and O 0 4.4566923484978815e-09
, O 0 6.687707054808811e-10
furthermore O 0 1.8385961642053417e-09
, O 0 9.376347476219848e-10
it O 0 1.2615144484584562e-08
was O 0 6.074407110645552e-08
always O 0 9.848318827110347e-10
seen O 0 6.429861643120205e-10
in O 0 9.898911551564638e-12
conjunction O 0 2.627870421267886e-10
with O 0 1.0122732652106947e-09
HLA O 0 4.1889725252985954e-06
haplotypes O 0 5.504385569565784e-08
common O 0 3.5404261744531595e-09
in O 0 2.6253654805685755e-10
Caucasians O 0 1.7818499031818646e-07
, O 0 1.3725182101964606e-10
suggesting O 0 6.811303188136719e-10
that O 0 3.5132660669567883e-11
845 O 0 1.7319746747901377e-09
G O 0 5.528954147848708e-07
- O 0 1.743800055464817e-07
- O 0 5.45965917808644e-07
> O 0 2.5808908343805115e-09
A O 0 1.9408406615184504e-07
may O 0 4.785062515111349e-07
have O 0 2.481222172168174e-10
been O 0 4.3054056847458e-11
introduced O 0 4.6746682913489934e-11
into O 0 8.659634120888882e-11
these O 0 2.1218270196410316e-11
populations O 0 2.030281359699515e-10
by O 0 3.940501536181529e-10
Caucasian O 0 7.818362064426765e-07
admixture O 0 1.5398655932585825e-06
. O 0 1.2658269099574682e-07

187 O 0 1.9640349364635767e-06
C O 0 3.3219669148820685e-06
- O 0 2.0690422388724983e-06
- O 0 2.5662820917204954e-06
> O 0 4.421303856361192e-08
G O 0 2.3118020635592984e-06
was O 0 9.650381826986631e-09
present O 0 9.79518549604208e-11
at O 0 1.4516243762585646e-10
an O 0 2.55206081961612e-11
allele O 0 1.4118808344676381e-08
frequency O 0 2.7011376246832697e-08
of O 0 4.4931011689008926e-10
2 O 0 6.721806755649595e-08
. O 0 5.5848424551641074e-08

68 O 0 1.1811174772446975e-05
% O 0 4.735727898719233e-08
in O 0 3.643693680110971e-10
the O 0 1.8713534888359362e-10
two O 0 4.530641195543694e-09
populations O 0 1.0895341517880297e-08
analyzed O 0 1.379701473069872e-07
( O 0 5.200023189821934e-10
Australian O 0 8.265433337761863e-10
Aboriginal O 0 1.9859601463334542e-10
and O 0 2.0811653789198914e-10
Chinese O 0 3.3975661173357707e-10
) O 0 1.0535236016906424e-09
. O 0 9.972911385602856e-09

In O 0 4.644564910449844e-08
the O 0 7.333782470198003e-10
Australian O 0 1.1976324376661296e-09
Aboriginal O 0 6.169188493387878e-10
samples O 0 8.587218158773169e-10
, O 0 4.277820458975512e-11
187 O 0 1.1224925156039234e-10
C O 0 4.549293386446607e-09
- O 0 2.3556372852340246e-08
- O 0 4.776021569341538e-07
> O 0 8.460187217451676e-09
G O 0 9.101976843339799e-07
was O 0 4.187993063453632e-09
found O 0 4.025907662796868e-10
to O 0 6.25649865249045e-10
be O 0 1.9794556271879316e-10
associated O 0 1.7272332175632954e-10
with O 0 5.241697631497289e-10
HLA O 0 3.993221525888657e-06
haplotypes O 0 3.4226758316435735e-08
common O 0 8.113392180320034e-10
in O 0 1.3395481945899235e-10
Caucasians O 0 1.4307438789273874e-07
, O 0 1.3485236260990519e-09
suggesting O 0 9.283071200627546e-09
that O 0 2.2819840461707486e-10
it O 0 2.0404846701183033e-09
was O 0 6.676682540174284e-10
introduced O 0 9.725745209188119e-11
by O 0 5.175620348962795e-11
recent O 0 2.5495576760903305e-09
admixture O 0 3.0796260830356914e-07
. O 0 1.2411528871325572e-07

In O 0 1.7418745557051807e-08
the O 0 4.702985223481448e-10
Chinese O 0 3.94053900620861e-10
samples O 0 2.7232303079216535e-09
analyzed O 0 4.130667807800137e-09
, O 0 8.203124984840215e-11
187 O 0 2.496717277367111e-10
C O 0 1.075100453107325e-08
- O 0 5.5552121125401754e-08
- O 0 5.864362719876226e-07
> O 0 1.5942564601800768e-08
G O 0 1.9008956542165834e-06
was O 0 1.5314103762875675e-08
present O 0 2.928013664860174e-10
in O 0 7.80971606828551e-11
association O 0 1.1508459983600172e-11
with O 0 4.621297268470048e-12
a O 0 2.6746452275183685e-10
wide O 0 5.465013996897028e-10
variety O 0 9.284466528924895e-10
of O 0 9.879959350644896e-11
HLA O 0 2.3583738766319584e-06
haplotypes O 0 1.0140134065750317e-07
, O 0 4.600178293845403e-10
showing O 0 5.669813063491347e-09
this O 0 3.452641644807741e-11
mutation O 0 1.8521401079496513e-09
to O 0 1.0407453787664167e-09
be O 0 8.24946277955263e-10
widespread O 0 3.870857800958305e-10
and O 0 1.6199671604155697e-09
likely O 0 6.0219162989483266e-09
to O 0 5.140470826781041e-10
predate O 0 1.7291105436356702e-08
the O 0 1.1352194184688358e-10
more O 0 7.703786220059072e-11
genetically O 0 2.427821943484787e-09
restricted O 0 4.6004941522959086e-10
845 O 0 2.382662511735134e-09
G O 0 2.191380161775669e-07
- O 0 1.1509382602525875e-07
- O 0 7.060809821268776e-07
> O 0 6.729359736112883e-09
A O 0 1.7850467770585965e-08
mutation O 0 2.5054143293345987e-07
. O 0 1.634306023845511e-08

Genotype O 0 0.08954766392707825
- O 0 0.0019431824330240488
phenotype O 0 0.007963975891470909
correlations O 0 0.00042699332698248327
in O 0 4.077899120602524e-06
attenuated B-Disease 1 0.9993833303451538
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 0.9999991655349731
coli I-Disease 1 0.9999998807907104
. O 0 1.1935842849197797e-05

Germ O 0 0.0020843844395130873
- O 0 0.00032896947232075036
line O 0 3.302667391835712e-05
mutations O 0 6.006501962474431e-07
of O 0 8.75441108494357e-11
the O 0 1.2154023343313725e-09
tumor B-Disease 0 2.2976539639785187e-06
suppressor O 0 3.188927166775102e-06
APC O 0 5.862792022526264e-06
are O 0 6.928170037667769e-09
implicated O 0 3.4231507015647367e-06
in O 0 2.87120911934835e-07
attenuated B-Disease 1 0.9998505115509033
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
( O 0 0.0008895317441783845
AAPC B-Disease 1 1.0
) O 0 9.177619375577706e-08
, O 0 4.0824252311999487e-10
a O 0 3.501221979007596e-09
variant O 0 0.0003250342851970345
of O 0 6.941729679965647e-06
familial B-Disease 1 1.0
adenomatous I-Disease 1 0.9999998807907104
polyposis I-Disease 1 1.0
( O 0 2.074267467833124e-05
FAP B-Disease 0 1.3720671631745063e-05
) O 0 1.316329445444353e-07
. O 0 7.727328465989558e-08

AAPC B-Disease 1 0.9999985694885254
is O 0 2.6112655859833467e-07
recognized O 0 1.6691220627862435e-09
by O 0 6.491595455626609e-11
the O 0 6.757069903606805e-11
occurrence O 0 1.8688405489797333e-08
of O 0 3.270231585528194e-10
< O 0 6.130789387270852e-08
100 O 0 5.704612338064408e-09
colonic B-Disease 0 1.255474671779666e-06
adenomas I-Disease 0 0.00043010659283027053
and O 0 5.693252980165653e-09
a O 0 5.218029563991422e-09
later O 0 3.2682152095731e-07
onset O 0 2.6917292416328564e-05
of O 0 9.517247963231057e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 7.897340026374877e-08
age O 0 2.765757578515604e-08
> O 0 1.0048408327634206e-08
40 O 0 1.6527540225297344e-08
years O 0 4.791905094947424e-09
) O 0 2.51777909632267e-09
. O 0 1.1281664491491483e-08

The O 0 4.240053996795723e-08
aim O 0 7.034967097752087e-08
of O 0 8.678748691925975e-11
this O 0 1.0578320858156687e-10
study O 0 3.1019564694645396e-10
was O 0 5.4074402733306215e-09
to O 0 3.489694533342913e-09
assess O 0 7.099723831061056e-08
genotype O 0 5.0728499445540365e-06
- O 0 1.7317235688096844e-05
phenotype O 0 4.17878181906417e-05
correlations O 0 3.849833319691243e-06
in O 0 9.854358751226755e-08
AAPC B-Disease 1 0.9999997615814209
families O 0 6.86735006638628e-07
. O 0 1.148707795550763e-07

By O 0 5.993864515829728e-09
protein O 0 4.7661117719144386e-08
- O 0 5.800541771350254e-07
truncation O 0 1.4738404388481285e-05
test O 0 4.2161829583164945e-08
( O 0 1.791433390518904e-10
PTT O 0 1.7308303768004407e-07
) O 0 7.455238509868067e-11
assay O 0 1.2795210446725491e-09
, O 0 1.3909469930017959e-11
the O 0 8.401096658616769e-12
entire O 0 8.418750141458986e-10
coding O 0 1.2102210575903882e-06
region O 0 1.1385821352405401e-07
of O 0 2.7957787127053102e-11
the O 0 1.4200572662215194e-10
APC B-Disease 0 4.926583141440233e-09
gene O 0 1.8707477789092763e-09
was O 0 1.5002233899608086e-09
screened O 0 1.2545150696041674e-08
in O 0 4.278467302665234e-10
affected O 0 5.900690602800296e-09
individuals O 0 1.7670774565825553e-10
from O 0 4.078177795463489e-09
11 O 0 2.5907223744070507e-07
AAPC B-Disease 1 0.9999994039535522
kindreds O 0 9.769627467903774e-06
, O 0 2.717947866770487e-09
and O 0 4.978173429037724e-10
their O 0 3.926968084044802e-09
phenotypic O 0 3.0281560725597956e-07
differences O 0 2.455636547438189e-07
were O 0 4.752975613087074e-08
examined O 0 4.220833886847686e-07
. O 0 7.137415281022186e-08

Five O 0 2.9360202802308777e-07
novel O 0 5.083651331005967e-07
germ O 0 5.963762305327691e-05
- O 0 0.00011510073090903461
line O 0 0.0001566520513733849
APC B-Disease 0 1.1269834203631035e-06
mutations O 0 5.054905614088057e-07
were O 0 1.5677739106934041e-09
identified O 0 4.291448085780303e-09
in O 0 6.113432537979691e-10
seven O 0 5.303247974097758e-08
kindreds O 0 2.080285776173696e-05
. O 0 1.1472560856873315e-07

Mutations O 0 0.0008369770948775113
were O 0 4.394903641014025e-08
located O 0 1.834207341566696e-09
in O 0 2.5300536665717743e-10
three O 0 5.833600269511408e-10
different O 0 2.7112465050826984e-10
regions O 0 1.9995693989471874e-08
of O 0 3.017950819805826e-11
the O 0 6.520424755684928e-10
APC B-Disease 0 1.2964428641737413e-08
gene O 0 1.3127328113426984e-09
( O 0 4.510159259951685e-11
1 O 0 2.293341766490542e-10
) O 0 1.1071784461469392e-10
at O 0 2.677750243762489e-09
the O 0 3.1657684806951636e-10
5 O 0 5.804114522334203e-09
end O 0 1.395280246896391e-08
spanning O 0 1.3896648276556789e-09
exons O 0 1.9285025132376177e-08
4 O 0 1.1810162847680772e-09
and O 0 1.7410357877611915e-10
5 O 0 4.691678157087154e-10
, O 0 9.492044650283304e-11
( O 0 1.7538233018643545e-11
2 O 0 2.318906039411317e-10
) O 0 3.1058385030480196e-11
within O 0 4.734898931268994e-11
exon O 0 7.220416708975108e-09
9 O 0 6.591000190070417e-09
, O 0 1.692662815466761e-10
and O 0 3.7627431725972826e-10
( O 0 6.562293763945348e-11
3 O 0 8.860279732125775e-10
) O 0 2.243145530433921e-10
at O 0 3.561462680323757e-09
the O 0 3.9491693248905335e-10
3 O 0 1.4810670911913348e-08
distal O 0 2.7355833935871487e-06
end O 0 1.9285727148599108e-07
of O 0 8.790435046535094e-11
the O 0 8.523626804368689e-10
gene O 0 2.9757612196590344e-07
. O 0 5.264788427439271e-08

Variability O 0 6.146368832560256e-05
in O 0 5.02285057990548e-09
the O 0 1.0060657862354105e-09
number O 0 2.939655985301215e-08
of O 0 5.7908755479729734e-06
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
was O 0 9.57764405029593e-06
most O 0 7.055479533946141e-10
apparent O 0 9.933575739751177e-09
in O 0 1.668694765699641e-10
individuals O 0 1.543154146133041e-11
with O 0 1.1939232935631594e-10
mutations O 0 1.4271026316237112e-07
in O 0 5.942613623410864e-10
region O 0 1.1288449286439572e-07
1 O 0 1.0316136922483565e-07
, O 0 2.411075339381341e-09
and O 0 9.294002900617215e-09
upper O 0 6.005172508594114e-06
- O 1 0.9986385703086853
gastrointestinal O 1 0.6572713255882263
manifestations O 0 1.8623876485435176e-06
were O 0 8.4915674491981e-09
more O 0 6.517776873771197e-10
severe O 0 4.042509260671068e-08
in O 0 2.471275406534801e-10
them O 0 1.3783252761356835e-08
. O 0 3.20233759509847e-08

In O 0 3.9018612341124026e-08
individuals O 0 8.493247216634359e-10
with O 0 2.515464225805175e-10
mutations O 0 5.897081933881054e-08
in O 0 7.870071261351086e-10
either O 0 1.318163000973982e-08
region O 0 5.477850208990276e-07
2 O 0 4.612228110545402e-07
or O 0 1.7416560638139345e-07
region O 0 8.567219111910163e-08
3 O 0 1.190697584974032e-08
, O 0 4.316588406161337e-11
the O 0 2.3050672481872425e-11
average O 0 2.2435744373439093e-09
number O 0 4.393558017401489e-10
of O 0 1.1158984153381013e-10
adenomas B-Disease 0 3.213834861526266e-05
tended O 0 5.981960953249654e-07
to O 0 1.6733178398453674e-08
be O 0 3.1281122137016837e-09
lower O 0 5.326990404341814e-08
than O 0 9.112480214845675e-10
those O 0 1.1585549880566148e-10
in O 0 2.5613896420528803e-11
individuals O 0 6.493573474070091e-12
with O 0 8.250623101391241e-11
mutations O 0 2.9103331300461832e-08
in O 0 5.724621332525714e-10
region O 0 2.0576162285124155e-07
1 O 0 6.982656941545429e-08
, O 0 1.7085771686353723e-09
although O 0 6.411687292207091e-10
age O 0 1.629486989784823e-09
at O 0 6.162206300786011e-09
diagnosis O 0 4.338386077051837e-07
was O 0 2.335637461214901e-09
similar O 0 3.2023663720792683e-09
. O 0 3.8076311881241054e-08

In O 0 2.325576133443974e-06
all O 0 5.528289648282225e-07
AAPC B-Disease 1 0.9999978542327881
kindreds O 0 7.010282570263371e-05
, O 0 9.025800662421091e-10
a O 0 2.644442720356466e-10
predominance O 0 1.9887293589704313e-08
of O 0 9.938461165148738e-10
right O 0 0.001001609256491065
- O 1 0.9999996423721313
sided O 1 1.0
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and O 0 0.00035906321136280894
rectal B-Disease 1 0.9999152421951294
polyp I-Disease 0 0.019647149369120598
sparing O 0 9.792873242986389e-06
was O 0 3.1091687446860305e-07
observed O 0 2.417588120806613e-07
. O 0 4.0847815796496434e-08

No O 0 0.00011098328832304105
desmoid B-Disease 1 0.9366520643234253
tumors I-Disease 1 1.0
were O 0 3.8752543218834035e-07
found O 0 7.042401772849871e-09
in O 0 8.715562715977399e-10
these O 0 4.253376317819857e-09
kindreds O 0 5.007042636862025e-05
. O 0 1.3033707091381075e-07

Our O 0 2.72397255685064e-06
data O 0 2.3285713268705877e-07
suggest O 0 4.874557646417088e-09
that O 0 2.78739364922842e-10
, O 0 3.0757510427470436e-10
in O 0 2.49748999259225e-09
AAPC B-Disease 1 1.0
families O 0 8.452638589062644e-09
, O 0 6.271477781538692e-11
the O 0 1.3880158307444379e-11
location O 0 3.3157692147511852e-09
of O 0 4.328559732869053e-11
the O 0 2.382212871410161e-09
APC B-Disease 0 1.2997340945730684e-06
mutation O 0 2.557488869570079e-07
may O 0 5.705703287617325e-08
partially O 0 2.7806615321424033e-07
predict O 0 1.993442211301044e-08
specific O 0 1.0109092452026402e-09
phenotypic O 0 3.3402255894543487e-07
expression O 0 9.872795203591522e-08
. O 0 4.571267098185672e-08

This O 0 7.762397302712998e-08
should O 0 6.1693445907451405e-09
help O 0 2.668550935780445e-10
in O 0 3.266022521875023e-11
the O 0 5.1053217209329205e-11
design O 0 4.129982578149338e-09
of O 0 1.304095026410934e-10
tailored O 0 4.908539494863362e-07
clinical O 0 8.989968591777142e-08
- O 0 1.5310707794924383e-06
management O 0 3.919868163393403e-08
protocols O 0 9.217293039931462e-10
in O 0 1.3013163463471145e-11
this O 0 1.9702524334253013e-11
subset O 0 9.72949942834589e-10
of O 0 2.049564268302717e-10
FAP B-Disease 0 8.159226183579449e-08
patients O 0 3.814689719661146e-08
. O 0 5.935975044835118e-10
. O 0 9.516581300772486e-09

Wilms B-Disease 0 0.0016324034659191966
' I-Disease 0 1.2675517609750386e-05
tumor I-Disease 0 9.470207260164898e-06
1 O 0 1.7008069619350863e-08
and O 0 4.1322358868001174e-09
Dax O 0 0.0008428616565652192
- O 0 1.634568604913511e-07
1 O 0 1.9038790544101403e-09
modulate O 0 2.075973704052103e-08
the O 0 1.2803798299376723e-10
orphan O 0 8.072814416948404e-09
nuclear O 0 6.131348762039579e-09
receptor O 0 1.4080263621707445e-09
SF O 0 4.409203938848805e-06
- O 0 1.406647420765239e-08
1 O 0 8.558995179264173e-10
in O 0 9.792328059532451e-11
sex O 0 9.048466420580326e-10
- O 0 3.893251054876146e-09
specific O 0 3.3295768919749946e-10
gene O 0 2.955374789337384e-08
expression O 0 2.080627403699964e-08
. O 0 1.1749571982022644e-08

Products O 0 8.200357797250035e-07
of O 0 1.4920762403392018e-09
steroidogenic O 0 4.832978675040067e-07
factor O 0 5.5017688183056634e-09
1 O 0 8.65891536250274e-09
( O 0 7.262404899677222e-09
SF O 0 0.0008136813994497061
- O 0 1.1649776752165053e-06
1 O 0 1.2664831849917846e-08
) O 0 4.382476881392705e-10
and O 0 1.4656021951608977e-09
Wilms B-Disease 0 2.0826344098168192e-06
tumor I-Disease 0 4.412634950767824e-07
1 O 0 3.5449940760656773e-09
( O 0 4.4176495794800985e-10
WT1 O 0 1.8596672646253865e-07
) O 0 2.96924318465841e-10
genes O 0 2.876408666807606e-09
are O 0 9.135481954247737e-11
essential O 0 2.2488344519899783e-10
for O 0 8.601147571951628e-11
mammalian O 0 1.532637661227909e-08
gonadogenesis O 0 1.6331084680132335e-06
prior O 0 1.2185529030261932e-08
to O 0 2.830539580500613e-09
sexual O 0 8.636895643121534e-09
differentiation O 0 2.5782254553519124e-08
. O 0 4.0711388038516816e-08

In O 0 1.8182970507041318e-07
males O 0 1.851170310374073e-07
, O 0 2.211059779710922e-08
SF O 0 0.2982596158981323
- O 0 1.7694352209218778e-05
1 O 0 4.1349341728391664e-08
participates O 0 8.682167873530489e-09
in O 0 1.9216599145277513e-10
sexual O 0 9.492099467545145e-11
development O 0 1.4508541937297004e-11
by O 0 1.4193253343453005e-11
regulating O 0 1.0323508714549234e-09
expression O 0 1.4175223217449684e-09
of O 0 2.97839079788087e-11
the O 0 5.759294707807783e-10
polypeptide O 0 2.634528470935038e-07
hormone O 0 1.0816246565070742e-08
Mullerian O 0 6.303241661953507e-08
inhibiting O 0 6.046813894045044e-08
substance O 0 8.038232124363276e-08
( O 0 8.081348923383302e-09
MIS O 0 0.00266371201723814
) O 0 2.765636430979157e-08
. O 0 2.2153024303861457e-08

Here O 0 2.358565097893006e-06
, O 0 1.0332752431452263e-08
we O 0 3.7623859583391095e-09
show O 0 1.0005225092868386e-08
that O 0 3.7543840258891237e-10
WT1 O 0 1.760635200298566e-06
- O 0 9.301247700932436e-07
KTS O 0 3.7845597944397014e-06
isoforms O 0 4.4547910249548295e-08
associate O 0 3.3065688853639585e-08
and O 0 3.345542731736373e-10
synergize O 0 3.4185924846497073e-07
with O 0 8.557074160364664e-09
SF O 0 0.030222775414586067
- O 0 2.2461676962848287e-06
1 O 0 1.0648028236914797e-08
to O 0 5.722571749799954e-09
promote O 0 1.4147948590448323e-08
MIS O 0 0.0009639178751967847
expression O 0 6.938884666851663e-08
. O 0 1.4571628348392096e-08

In O 0 9.35202919549738e-08
contrast O 0 1.6530951540971728e-07
, O 0 1.4625897826192613e-08
WT1 O 0 2.7977623176411726e-05
missense O 0 2.4275594114442356e-05
mutations O 0 6.96426195645472e-06
, O 0 1.0797525096251093e-09
associated O 0 3.5570635326109823e-09
with O 0 1.324874654429209e-09
male B-Disease 0 1.3534946674553794e-06
pseudohermaphroditism I-Disease 1 1.0
in O 0 3.9203624169203977e-07
Denys B-Disease 1 0.9999792575836182
- I-Disease 1 0.9999711513519287
Drash I-Disease 1 0.9999600648880005
syndrome I-Disease 1 0.9999982118606567
, O 0 8.532268225280859e-09
fail O 0 4.830342845707492e-07
to O 0 1.3908899587633528e-09
synergize O 0 1.988194298974122e-06
with O 0 3.682249172243246e-08
SF O 1 0.9513131380081177
- O 0 3.927054422092624e-05
1 O 0 2.35993709907234e-07
. O 0 4.920800833474459e-08

Additionally O 0 5.177544153411873e-07
, O 0 3.371269041707592e-09
the O 0 3.368657852664825e-10
X O 0 3.910286250174977e-05
- O 0 9.894190043269191e-06
linked O 0 1.8504870240576565e-05
, O 0 1.5079146820085043e-09
candidate O 0 4.256419661174959e-09
dosage O 0 4.8391360252253435e-08
- O 0 2.459418624312093e-08
sensitive O 0 5.0972147391803446e-08
sex O 0 7.581870242745481e-09
- O 0 1.3483751892806595e-08
reversal O 0 2.4399440690103802e-08
gene O 0 5.553662418833483e-09
, O 0 8.422664649065936e-11
Dax O 0 0.00012622048961929977
- O 0 6.508216898737373e-08
1 O 0 2.794890985313714e-09
, O 0 2.918022767861572e-10
antagonizes O 0 6.292622600767572e-08
synergy O 0 1.1457839121931102e-08
between O 0 1.5142959108871423e-09
SF O 0 0.0005920876865275204
- O 0 9.51309800711897e-07
1 O 0 6.201446023368362e-09
and O 0 5.387301160730829e-10
WT1 O 0 4.269642772669613e-08
, O 0 7.546140101677423e-11
most O 0 1.6544515757388467e-11
likely O 0 9.313122495413495e-11
through O 0 1.9777941437371105e-11
a O 0 1.2335835131160877e-10
direct O 0 2.9639708465367676e-09
interaction O 0 7.647061317506143e-10
with O 0 7.049901107336609e-09
SF O 1 0.8089069724082947
- O 0 1.0059924534289166e-05
1 O 0 1.1750517359132573e-07
. O 0 3.7809773090202725e-08

We O 0 1.0259363989462145e-06
propose O 0 1.52341982584403e-07
that O 0 1.603667310057233e-09
WT1 O 0 6.990078986746084e-07
and O 0 1.1578912051390944e-08
Dax O 0 0.048170026391744614
- O 0 9.515711099084001e-07
1 O 0 5.374464429053205e-09
functionally O 0 5.8887195564238937e-08
oppose O 0 1.1481963158033182e-09
each O 0 3.622752098308979e-10
other O 0 8.098112458387874e-11
in O 0 1.473820648856261e-10
testis O 0 1.5539822584287322e-07
development O 0 2.315904829019999e-10
by O 0 1.6979076478129684e-10
modulating O 0 4.6660525754305127e-07
SF O 0 0.026090314611792564
- O 0 4.136096322326921e-06
1 O 0 1.8401694035219407e-07
- O 0 4.479278686631005e-06
mediated O 0 1.3893974255552166e-06
transactivation O 0 3.2694140372768743e-06
. O 0 3.6296425864890125e-09
. O 0 9.679729906508783e-09

A O 0 1.8897239328907744e-07
mouse O 0 1.1774359336413909e-06
model O 0 1.7283727515859937e-07
for O 0 6.81839310345822e-07
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
imprinting O 0 0.0019419972086325288
- O 0 0.0001449183328077197
centre O 0 4.853676273341989e-06
mutations O 0 4.333308243076317e-05
. O 0 6.75102427294405e-08

Imprinting O 0 3.8080619560787454e-05
in O 0 2.5438176010084135e-08
the O 0 2.6806630248898955e-09
15q11 O 0 1.3500398381438572e-06
- O 0 3.6000635645905277e-06
q13 O 0 5.120210744280485e-07
region O 0 2.1737518451914184e-08
involves O 0 5.111472356489344e-10
an O 0 2.520372521797043e-10
imprinting O 0 2.801554046527599e-07
centre O 0 3.275026472238096e-07
( O 0 3.198063369680426e-09
IC O 0 3.921469442502712e-07
) O 0 2.197327042541275e-10
, O 0 3.097698139664651e-11
mapping O 0 1.960063000794321e-09
in O 0 1.5774193062867425e-10
part O 0 3.9404940421761125e-10
to O 0 1.878893707285556e-09
the O 0 1.8236920307224125e-10
promoter O 0 1.0486089507821816e-07
and O 0 6.507888117290861e-10
first O 0 8.455795508233166e-10
exon O 0 8.050000133152935e-08
of O 0 6.128761942392202e-10
SNRPN O 0 1.958194116014056e-05
. O 0 4.8119201068175244e-08

Deletion O 0 6.31343646091409e-05
of O 0 5.311039608102419e-09
this O 0 4.617603632794953e-09
IC O 0 7.060627467581071e-06
abolishes O 0 2.2594017536903266e-06
local O 0 4.225487071352063e-09
paternally O 0 1.2634015433832246e-07
derived O 0 2.05026884358972e-09
gene O 0 2.4392832642661233e-08
expression O 0 5.4402131688391364e-09
and O 0 6.4455085713177596e-09
results O 0 5.585573489952367e-06
in O 0 2.196245759478188e-06
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 2.4730729819566477e-06
PWS B-Disease 1 0.9999997615814209
) O 0 5.166544525536665e-08
. O 0 3.6688867055545415e-08

We O 0 1.899956941997516e-06
have O 0 1.2751260047849655e-09
created O 0 1.432322732641822e-10
two O 0 4.370940276388069e-10
deletion O 0 2.9561144287981733e-07
mutations O 0 2.1813448825014348e-07
in O 0 7.049910655254621e-10
mice O 0 1.1748448969228775e-06
to O 0 2.745779852375563e-07
understand O 0 1.8012808595813112e-06
PWS B-Disease 1 1.0
and O 0 4.286368149308828e-09
the O 0 3.7778932759913175e-11
mechanism O 0 2.601766579957143e-10
of O 0 5.598165334075311e-11
this O 0 2.0733372796399863e-09
IC O 0 2.3315151338465512e-05
. O 0 3.97678547869873e-08

Mice O 0 0.0016068975673988461
harbouring O 0 0.0002041828993242234
an O 0 9.619526508686249e-09
intragenic O 0 4.907593392999843e-06
deletion O 0 1.0676604688342195e-05
in O 0 5.0351380842528215e-09
Snrpn O 0 4.6229601139202714e-05
are O 0 8.430773412726467e-09
phenotypically O 0 2.1944179025013e-06
normal O 0 4.631480976513558e-07
, O 0 1.1520879805715367e-09
suggesting O 0 5.011797643561522e-09
that O 0 1.9076075441493145e-10
mutations O 0 1.0068340827729116e-08
of O 0 5.127444649422053e-11
SNRPN O 0 2.9298013032530434e-05
are O 0 1.4698854355899016e-09
not O 0 5.473171915681974e-10
sufficient O 0 1.0725438315262181e-09
to O 0 3.089630240538099e-08
induce O 0 1.3579812048192252e-06
PWS B-Disease 1 0.9999916553497314
. O 0 3.9964496068023436e-07

Mice O 0 2.3718921511317603e-05
with O 0 1.1987659753742719e-09
a O 0 8.377231131007079e-10
larger O 0 1.8056052208947904e-09
deletion O 0 1.1194899229849398e-07
involving O 0 5.564549376835259e-10
both O 0 4.1868167266478906e-10
Snrpn O 0 9.79954052127141e-07
and O 0 1.0981732190273874e-09
the O 0 1.916020897496651e-09
putative O 0 2.229702840850223e-05
PWS O 1 1.0
- O 0 8.002982940524817e-05
IC O 0 3.856385319522815e-06
lack O 0 1.470014443505363e-09
expression O 0 2.681827537820425e-10
of O 0 7.698758297536301e-12
the O 0 1.0330358096721781e-10
imprinted O 0 1.7550182462855446e-07
genes O 0 2.9595492279099744e-08
Zfp127 O 0 6.150337981125631e-07
( O 0 5.687378346053151e-10
mouse O 0 4.045941892627525e-08
homologue O 0 4.2481653395043395e-07
of O 0 1.5230320338233128e-09
ZNF127 O 0 1.5007533875177614e-05
) O 0 2.102183094265797e-09
, O 0 8.649981286801278e-10
Ndn O 0 1.1046873851228156e-06
and O 0 1.394305781943217e-09
Ipw O 0 1.0067173406014263e-07
, O 0 7.174957850075714e-10
and O 0 6.429543009112137e-10
manifest O 0 5.741006958714934e-08
several O 0 2.719388048078031e-10
phenotypes O 0 1.229200279340148e-07
common O 0 1.3622704386762052e-07
to O 0 1.6675639926688746e-05
PWS B-Disease 1 1.0
infants O 0 0.007873093709349632
. O 0 9.771145670356418e-08

These O 0 4.3319523967966234e-08
data O 0 3.4735926135454065e-08
demonstrate O 0 1.69575942177147e-09
that O 0 4.100582720600876e-11
both O 0 2.230388269908179e-11
the O 0 5.805946348691471e-11
position O 0 8.644048143935379e-09
of O 0 1.1187727827488558e-11
the O 0 1.9250238902923655e-10
IC O 0 4.792104277839826e-07
and O 0 3.5965622147138276e-10
its O 0 3.4505431845133216e-10
role O 0 1.4478609977608414e-10
in O 0 1.8833443485299917e-11
the O 0 5.078071296793496e-11
coordinate O 0 7.607451557589684e-09
expression O 0 4.962834587729503e-10
of O 0 5.7556212400278195e-12
genes O 0 2.555086697775266e-10
is O 0 2.711596745752498e-11
conserved O 0 3.8278924474610676e-10
between O 0 1.9625609470885763e-10
mouse O 0 3.081086106249131e-07
and O 0 2.4450129032516088e-08
human O 0 1.167381746824958e-09
, O 0 1.6321247686690299e-09
and O 0 1.7106314142978363e-09
indicate O 0 1.8169505899834348e-09
that O 0 2.21830522700861e-11
the O 0 1.6390205165306426e-11
mouse O 0 8.76106742708771e-09
is O 0 7.428652831764637e-11
a O 0 9.585322813254749e-11
suitable O 0 9.336070805332497e-10
model O 0 1.3866332526646374e-09
system O 0 5.212565379331124e-10
in O 0 6.570095856250902e-11
which O 0 9.10461039893562e-10
to O 0 6.721249112828787e-10
investigate O 0 1.5475466741410315e-10
the O 0 8.437228346536152e-12
molecular O 0 1.977387698026689e-10
mechanisms O 0 1.7515611183682722e-10
of O 0 3.1038369791014375e-11
imprinting O 0 1.7652541828283574e-07
in O 0 2.26665930469494e-09
this O 0 6.384059392239294e-10
region O 0 6.854605061334951e-08
of O 0 3.259935724142515e-11
the O 0 6.420642489901596e-11
genome O 0 3.2324607435185726e-09
. O 0 1.1752434581069338e-09
. O 0 1.005799532549645e-08

Mutations O 0 4.8109064664458856e-05
of O 0 2.6275308595558045e-09
the O 0 9.544425250140876e-10
ATM O 0 1.6484463003507699e-06
gene O 0 2.153436611251891e-07
detected O 0 6.574197186637321e-07
in O 0 2.8267737040010843e-09
Japanese O 0 9.11629613256082e-05
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
patients O 1 0.9989425539970398
: O 0 4.9712473026986e-10
possible O 0 6.693092191589756e-10
preponderance O 0 5.1738582307336856e-09
of O 0 2.4920534386074777e-11
the O 0 1.343972988454567e-10
two O 0 2.8352460379466038e-09
founder O 0 1.2050713849021122e-07
mutations O 0 1.1780094411051323e-07
4612del165 O 0 4.2598490068712636e-08
and O 0 1.3860542713572954e-09
7883del5 O 0 1.655676413747642e-07
. O 0 2.2939785182529704e-08

The O 0 3.0320162380803595e-08
ATM O 0 5.22047484992072e-05
( O 0 2.65234945118209e-07
A O 1 0.9999997615814209
- O 1 0.9999988079071045
T O 1 1.0
, O 0 1.1101463748275364e-08
mutated O 0 5.5388451158933094e-08
) O 0 1.1568657143357086e-10
gene O 0 4.947072973493505e-09
on O 0 3.884639276918733e-09
human O 0 3.795961767139033e-09
chromosome O 0 2.9518811061279848e-05
11q22 O 0 6.24552149020019e-06
. O 0 1.0165715025323152e-07

3 O 0 2.1037983515270753e-06
has O 0 2.9780542476487426e-08
recently O 0 1.760159840102915e-08
been O 0 5.404003911024802e-10
identified O 0 1.0383680582037869e-09
as O 0 2.1764201552088025e-11
the O 0 1.2400916231392056e-11
gene O 0 1.928291526454018e-09
responsible O 0 1.687290307472722e-09
for O 0 2.4640867471448225e-11
the O 0 3.017791294634975e-10
human O 0 1.9419385921537469e-07
recessive B-Disease 1 0.9999996423721313
disease I-Disease 1 1.0
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 0.0017611143412068486
A B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
) O 0 1.0473696221424689e-07
. O 0 4.140790110795933e-08

In O 0 5.509847511575572e-08
order O 0 2.630805351344634e-09
to O 0 2.0663730726511176e-09
define O 0 6.49695319765442e-09
the O 0 1.1042765313273861e-10
types O 0 1.7314923939082405e-09
of O 0 3.872962506257238e-10
disease O 0 3.223177918698639e-05
- O 0 2.301147105754353e-06
causing O 0 6.198550181579776e-06
ATM O 0 9.814171789912507e-06
mutations O 0 2.0900108665955486e-07
in O 0 1.1844378255965182e-10
Japanese O 0 3.5759626371145714e-08
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 6.986752850934863e-06
as O 0 4.07583307382442e-11
well O 0 4.319133245500595e-11
as O 0 1.372471164495792e-10
to O 0 4.5595413555865605e-10
look O 0 3.904598866455444e-09
for O 0 8.351526414873689e-11
possible O 0 1.0615942569458525e-09
mutational O 0 1.0053836518864046e-07
hotspots O 0 6.345074154978647e-08
, O 0 4.480691651043145e-10
reverse O 0 8.230883281612478e-07
- O 0 4.1357358782079245e-07
transcribed O 0 7.14077771135635e-07
RNA O 0 2.4007697163597186e-08
derived O 0 1.2802436888392776e-09
from O 0 4.019102273211672e-10
ten O 0 1.0260435834297255e-09
patients O 0 2.6939780961576787e-10
belonging O 0 1.1812972822156098e-10
to O 0 3.0770067049878946e-10
eight O 0 7.014313574416065e-10
unrelated O 0 3.5370850692828526e-09
Japanese O 0 5.0657927630481936e-08
A B-Disease 1 0.9999959468841553
- I-Disease 1 0.9999557733535767
T I-Disease 1 1.0
families O 0 9.053844252093768e-08
was O 0 1.2408317040524253e-08
analyzed O 0 5.5268647436435e-09
for O 0 2.782823971259063e-11
mutations O 0 1.714325570389974e-09
by O 0 5.946666336437145e-12
the O 0 2.5420870269909912e-11
restriction O 0 1.214051525977311e-09
endonuclease O 0 1.0276544770704277e-07
fingerprinting O 0 1.8327276052332309e-07
method O 0 5.0973216758620765e-08
. O 0 4.107681306209088e-08

As O 0 2.937249803380837e-07
has O 0 1.2867365839497324e-08
been O 0 1.547810213331502e-09
reported O 0 8.404511220305722e-08
by O 0 6.118678480548922e-11
others O 0 3.1993625526638425e-09
, O 0 1.649637648704072e-10
mutations O 0 2.0241963660794227e-09
that O 0 2.8865349346873792e-11
lead O 0 1.193090737316993e-09
to O 0 4.731389724454971e-10
exon O 0 2.3876984300841286e-07
skipping O 0 2.331351879547583e-06
or O 0 4.5474345711227215e-07
premature O 0 1.5861014901474846e-07
protein O 0 1.0192289678911948e-08
truncation O 0 3.0878684356139274e-06
were O 0 1.5013034371236245e-08
also O 0 5.718815421218437e-10
predominant O 0 2.2856760040212976e-08
in O 0 6.090980497752696e-10
our O 0 2.2645041397595378e-08
mutants O 0 2.521597082250082e-07
. O 0 1.1873886762714392e-08

Six O 0 1.378634806314949e-07
different O 0 2.3465953624679514e-09
mutations O 0 7.968333193275612e-08
were O 0 1.5997935198797109e-09
identified O 0 4.834511457829649e-09
on O 0 1.4677262072382291e-08
12 O 0 2.5886801591212816e-09
of O 0 1.121372699558476e-11
the O 0 1.080840528189242e-09
16 O 0 1.0223422108879276e-08
alleles O 0 4.743547776797641e-08
examined O 0 2.367840892247841e-07
. O 0 4.6172889511808535e-08

Four O 0 1.2608774113687105e-07
were O 0 3.5044021018393323e-09
deletions O 0 4.368452621861252e-08
involving O 0 4.049605095701736e-10
a O 0 6.399522245459366e-09
loss O 0 5.259599333840015e-08
of O 0 8.235085356689265e-12
a O 0 3.868960984920733e-10
single O 0 1.643979175014465e-08
exon O 0 1.9830065411952091e-07
exon O 0 2.9576540327980183e-07
7 O 0 1.7062818713498018e-08
, O 0 4.945674425549385e-10
exon O 0 7.27351192608694e-08
16 O 0 4.200648717755939e-09
, O 0 2.8173152699650927e-10
exon O 0 8.110923488402477e-08
33 O 0 2.2033431079648835e-08
or O 0 1.938966143200105e-08
exon O 0 1.4106258277024608e-06
35 O 0 3.3603387805669627e-07
. O 0 5.6743814980109164e-08

The O 0 7.83278935045928e-08
others O 0 3.769549650201043e-08
were O 0 1.408875238695373e-09
minute O 0 4.725412505734994e-09
deletions O 0 6.476923886111763e-08
, O 0 4.820338572741889e-10
4649delA O 0 1.794283654987794e-08
in O 0 1.6027247584649018e-10
exon O 0 7.126451606609407e-08
33 O 0 1.2458877485244102e-08
and O 0 3.5834768485898394e-10
7883del5 O 0 7.422484848973454e-09
in O 0 4.4171183377628154e-10
exon O 0 6.489741508630686e-07
55 O 0 1.1319431791889656e-07
. O 0 5.07036510555281e-08

The O 0 1.2077958899681107e-07
mutations O 0 1.1839262015200802e-06
4612del165 O 0 3.106676160768984e-07
and O 0 4.3565764329400736e-09
7883del5 O 0 4.4401325283160986e-08
were O 0 1.636985103026234e-09
found O 0 1.5886938986575672e-10
in O 0 7.668071039246271e-12
more O 0 1.877895755564296e-11
than O 0 2.2294438864478572e-11
two O 0 6.878103642193878e-11
unrelated O 0 6.528351748080752e-10
families O 0 5.769318703330306e-11
; O 0 1.8260311318574196e-10
44 O 0 2.492902106965289e-09
% O 0 2.13335696330752e-10
( O 0 6.200281260637652e-11
7 O 0 2.7066442420675685e-09
of O 0 3.770759052224015e-11
16 O 0 3.067059051176102e-09
) O 0 2.574693062917799e-11
of O 0 1.4235133254450472e-12
the O 0 4.84805286193879e-11
mutant O 0 9.011098534017492e-09
alleles O 0 1.6850400186285697e-08
had O 0 9.682263168997451e-08
one O 0 2.601627802079065e-10
of O 0 1.1723810290631409e-11
the O 0 2.0746457329856582e-10
two O 0 6.8257692831252825e-09
mutations O 0 4.7514484435851045e-07
. O 0 1.8440230675764724e-08

The O 0 1.83169088785462e-08
4612del165 O 0 2.3144770011640503e-07
mutations O 0 4.2707100078587246e-07
in O 0 1.934047921814397e-10
three O 0 1.5911927331302422e-10
different O 0 1.7684261000017187e-10
families O 0 1.920604647542845e-10
were O 0 1.4994653296795946e-09
all O 0 9.5785240850077e-11
ascribed O 0 1.5645983397760688e-09
to O 0 4.953736865154212e-10
the O 0 5.7551848703374375e-11
same O 0 1.0050569265729337e-09
T O 0 2.4354260403924854e-06
- O 0 1.1016416223696979e-08
- O 0 7.789194178542402e-09
> O 0 2.2387515452582107e-10
A O 0 1.7643259075939e-10
substitution O 0 4.961118668656006e-11
at O 0 7.36872021733781e-11
the O 0 2.423724589084575e-11
splice O 0 3.5745586046687094e-07
donor O 0 2.317523284389722e-09
site O 0 8.547270446968014e-09
in O 0 8.95055751737317e-10
intron O 0 1.2377548046060838e-05
33 O 0 2.568505124145304e-07
. O 0 2.8984118216612842e-08

Microsatellite O 0 8.000372326932847e-05
genotyping O 0 1.7743304852047004e-05
around O 0 1.0468484390457888e-07
the O 0 4.028851918747023e-09
ATM O 0 7.480698059225688e-06
locus O 0 5.758037104897085e-07
also O 0 9.578646853469763e-08
indicated O 0 3.689434180387252e-08
that O 0 2.2285171971669904e-11
a O 0 1.3444625968084267e-10
common O 0 1.247304259877069e-09
haplotype O 0 3.1399729323311476e-06
was O 0 2.5168537476361053e-08
shared O 0 1.723941961406794e-10
by O 0 1.0194996756529573e-11
the O 0 3.5917477325675407e-11
mutant O 0 9.465821015908205e-09
alleles O 0 9.574368853293436e-09
in O 0 1.2258090098526964e-09
both O 0 5.640162559217288e-09
mutations O 0 2.6255793272866867e-06
. O 0 7.038281779614408e-08

This O 0 2.78041945023233e-08
suggests O 0 2.2813161137946736e-08
that O 0 3.317482122344728e-10
these O 0 4.5622533528799636e-11
two O 0 5.287132953668561e-10
founder O 0 7.075971097947331e-08
mutations O 0 1.1017245924449526e-06
may O 0 2.6762554838910546e-08
be O 0 1.3240655794000133e-10
predominant O 0 3.692191663517974e-09
among O 0 6.955132997310542e-11
Japanese O 0 1.928335713330398e-09
ATM O 0 2.4508730689376534e-07
mutant O 0 1.3347577976219327e-07
alleles O 0 5.074186901765643e-07
. O 0 8.038354337713827e-08

W474C O 0 4.947504294250393e-06
amino O 0 2.7769223720497394e-07
acid O 0 6.602868296567976e-08
substitution O 0 1.699629104123801e-09
affects O 0 1.17496556928387e-09
early O 0 1.860399334585594e-10
processing O 0 9.217275276363068e-10
of O 0 4.81344348060575e-12
the O 0 2.4188847105865996e-11
alpha O 0 1.762264223437171e-10
- O 0 1.7922707762352275e-10
subunit O 0 1.97141511448784e-10
of O 0 9.413772712740798e-12
beta O 0 6.926474949153771e-10
- O 0 5.716974893488214e-09
hexosaminidase O 0 3.038981688519016e-08
A O 0 4.3064534160919266e-09
and O 0 1.4189065200564954e-10
is O 0 3.6936669001175204e-11
associated O 0 2.764953266343184e-10
with O 0 1.4441742246518174e-09
subacute O 0 1.1479676686576568e-05
G B-Disease 0 9.504786248726305e-06
( I-Disease 0 1.4680193727301116e-09
M2 I-Disease 0 5.15498641107115e-06
) I-Disease 0 2.1567450048110004e-08
gangliosidosis I-Disease 0 8.47779301693663e-06
. O 0 5.8812887004933145e-08

Mutations O 0 0.0001157137012341991
in O 0 6.644646166620305e-09
the O 0 5.151886139920236e-10
HEXA O 0 2.1192270196479512e-06
gene O 0 4.342094328535495e-08
, O 0 8.414507285392503e-11
encoding O 0 1.6056743434855747e-10
the O 0 5.017808737961538e-11
alpha O 0 8.559452036038806e-10
- O 0 8.06642252992873e-10
subunit O 0 4.2174577719045203e-10
of O 0 3.989984037611194e-11
beta O 0 2.517678288072034e-09
- O 0 2.3880188493308196e-08
hexosaminidase O 0 1.2107527425087028e-07
A O 0 4.153768884407327e-09
( O 0 9.981235976619374e-11
Hex O 0 2.8018524389494814e-08
A O 0 5.255746060583988e-09
) O 0 3.698898132231676e-11
, O 0 1.2859936206199851e-11
that O 0 1.9168194809182637e-11
abolish O 0 1.2451483177855494e-09
Hex O 0 1.2365813262249503e-08
A O 0 3.0680288864992633e-10
enzyme O 0 6.383844119994819e-09
activity O 0 2.2713951608466232e-08
cause O 0 0.00010027452663052827
Tay B-Disease 1 1.0
- I-Disease 1 1.0
Sachs I-Disease 1 1.0
disease I-Disease 1 0.9835416674613953
( O 0 5.287831950084865e-09
TSD B-Disease 0 1.366420065096463e-06
) O 0 5.436818217852135e-10
, O 0 1.1375364539212285e-10
the O 0 4.824376453882451e-10
fatal O 0 3.641673902166076e-05
infantile B-Disease 0 6.026565188221866e-06
form I-Disease 0 4.17049594858554e-09
of I-Disease 0 2.119890374352451e-10
G I-Disease 0 6.909538569743745e-06
( I-Disease 0 8.576758747658175e-10
M2 I-Disease 0 2.8537156140373554e-06
) I-Disease 0 1.484448786115422e-09
gangliosidosis I-Disease 0 1.8732379203356686e-07
, I-Disease 0 9.520111782235219e-11
Type I-Disease 0 2.4030180068024265e-09
1 I-Disease 0 1.5032261657665913e-08
. O 0 3.574190188260218e-08

Less O 0 1.3930850400356576e-05
severe O 0 0.0006102161714807153
, O 0 3.85324199214665e-08
subacute O 0 0.00044276195694692433
( O 0 3.97129070961455e-07
juvenile O 0 0.018933987244963646
- O 1 0.9902584552764893
onset O 1 0.9065153002738953
) O 0 4.664304071866354e-07
and O 0 2.1346245375752915e-06
chronic O 0 0.04699508845806122
( O 0 8.320355071589347e-09
adult O 0 3.0375758797163144e-06
- O 0 0.024515612050890923
onset O 0 0.0008180317818187177
) O 0 2.6215338788659892e-09
variants O 0 6.829483112369417e-08
are O 0 2.3960189388105846e-10
characterized O 0 4.0619824170917695e-10
by O 0 1.606013412536189e-11
a O 0 6.073034852782655e-10
broad O 0 3.754500710329012e-09
spectrum O 0 4.6076094051272776e-09
of O 0 1.5317272450410258e-10
clinical O 0 1.0325482691087018e-08
manifestations O 0 2.4364423367728705e-08
and O 0 3.17801518434635e-09
are O 0 2.510306962300035e-10
associated O 0 6.325456269884455e-10
with O 0 4.839407763412851e-10
residual O 0 5.158868816579343e-07
levels O 0 7.19256920689304e-09
of O 0 2.5631392841507505e-11
Hex O 0 1.397501989686134e-07
A O 0 4.812247933472236e-09
enzyme O 0 2.950182320660133e-08
activity O 0 2.4485595773171553e-08
. O 0 1.396124105212948e-08

We O 0 5.798053166472528e-07
identified O 0 2.7197645025012207e-08
a O 0 6.507271166356077e-09
1422 O 0 5.668318294738128e-07
G O 0 5.3449152801476885e-06
- O 0 1.3230113609097316e-06
- O 0 2.913624030043138e-06
> O 0 1.625588730291838e-08
C O 0 4.912117290700735e-08
( O 0 1.1487324980130609e-10
amino O 0 1.12853171252425e-09
acid O 0 7.087189168863972e-10
W474C O 0 3.4870578646817307e-10
) O 0 2.2537015656465265e-12
substitution O 0 3.660394036486547e-12
in O 0 2.725252749163909e-12
the O 0 2.8995021661426534e-11
first O 0 5.222061449927651e-09
position O 0 2.6227591209959655e-09
of O 0 1.9159788339218053e-11
exon O 0 1.6686326986814493e-08
13 O 0 3.13242126681601e-10
of O 0 1.7534352442227785e-11
HEXA O 0 5.975170438432542e-07
of O 0 2.1113669840255866e-11
a O 0 1.982282782364564e-09
non O 0 4.296585487395532e-08
- O 0 2.5025272520906583e-07
Jewish O 0 1.2478609789923212e-07
proband O 0 0.00011883078695973381
who O 0 6.864090096314612e-08
manifested O 0 6.4483609563126265e-09
a O 0 1.2853476061280844e-09
subacute O 0 8.348852134076878e-07
variant O 0 1.261584543499339e-07
of O 0 4.1971148778685574e-10
G B-Disease 0 1.4850088518869597e-05
( I-Disease 0 1.8335846174721837e-09
M2 I-Disease 0 1.372610313410405e-05
) I-Disease 0 1.4975455542298732e-08
gangliosidosis I-Disease 0 5.998670076223789e-06
. O 0 5.450456797007064e-08

On O 0 2.1289309870553552e-07
the O 0 9.862873184829368e-09
second O 0 2.746756706528686e-07
maternally O 0 2.99262546832324e-06
inherited O 0 2.0602742552000564e-06
allele O 0 3.210332806702354e-06
, O 0 5.27576249353956e-09
we O 0 1.8167495285936752e-09
identified O 0 1.2882462874230782e-09
the O 0 1.0691976470855735e-10
common O 0 3.123321050679806e-07
infantile O 0 0.07211443781852722
disease O 0 0.022779414430260658
- O 0 4.099591023987159e-06
causing O 0 4.770384111907333e-05
4 O 0 3.648176161163974e-08
- O 0 1.3285188060763176e-06
bp O 0 5.591894478129689e-06
insertion O 0 5.114949530593549e-08
, O 0 7.595066242593873e-10
+ O 0 1.1301565017163284e-08
TATC O 0 5.81230892748863e-07
1278 O 0 3.4584932251391365e-08
, O 0 2.1901759572617863e-10
in O 0 1.3515048802315022e-10
exon O 0 6.021844569659152e-07
11 O 0 3.7196759450353056e-08
. O 0 3.042292817667658e-08

Pulse O 0 0.0014108306495472789
- O 0 5.573845101025654e-06
chase O 0 2.928913090727292e-06
analysis O 0 1.4036618090074171e-08
using O 0 1.5298134314889467e-08
proband O 0 2.1025784917583223e-06
fibroblasts O 0 1.4317949137421238e-07
revealed O 0 1.2256909087682288e-07
that O 0 3.0649625198941877e-11
the O 0 3.037470275302212e-11
W474C O 0 3.283852967328471e-09
- O 0 6.503991789585939e-10
containing O 0 7.39796904292156e-11
alpha O 0 8.265433337761863e-10
- O 0 1.5676175635359613e-10
subunit O 0 9.458339667034465e-11
precursor O 0 1.6105090594464855e-09
was O 0 7.03850366878811e-10
normally O 0 1.1018969070519802e-10
synthesized O 0 8.827655828547165e-10
, O 0 1.8186197339731258e-11
but O 0 2.7286662512837623e-11
not O 0 2.0626025193370978e-11
phosphorylated O 0 2.977460777930929e-10
or O 0 3.6713543316579944e-10
secreted O 0 5.169081829237143e-10
, O 0 1.0395089650172551e-10
and O 0 1.1619054329781164e-10
the O 0 8.97034460600743e-11
mature O 0 2.5881567999874733e-09
lysosomal O 0 1.2829038276152005e-08
alpha O 0 2.428947265542547e-09
- O 0 5.4025326434725685e-09
subunit O 0 3.4557747774499603e-09
was O 0 7.533510881785332e-08
not O 0 5.511326950369266e-09
detected O 0 9.184098104242366e-08
. O 0 9.110070031681516e-09

When O 0 7.947645030981221e-08
the O 0 1.6492105459064987e-09
W474C O 0 3.5606767312401644e-08
- O 0 4.946469012168109e-09
containing O 0 2.97800589743602e-10
alpha O 0 2.0412982415507486e-09
- O 0 1.727784360028295e-09
subunit O 0 1.3599664727692584e-09
was O 0 1.7749803404853992e-08
transiently O 0 4.761377425666069e-08
co O 0 2.6168242683866083e-08
- O 0 2.3619166622523835e-09
expressed O 0 4.333590777894081e-11
with O 0 3.12173594266274e-12
the O 0 5.9847166285209585e-12
beta O 0 1.9612700352666934e-10
- O 0 2.704088619687184e-10
subunit O 0 4.3628772816717287e-10
to O 0 5.815070092118901e-10
produce O 0 8.497508807714382e-10
Hex O 0 2.9583414828948662e-08
A O 0 5.057689822507427e-09
( O 0 1.0018563062486052e-10
alphabeta O 0 1.613756950291645e-08
) O 0 4.820244203784796e-11
in O 0 1.5693436827834972e-10
COS O 0 0.00039542815648019314
- O 0 7.781876121271125e-08
7 O 0 3.1270621647649932e-09
cells O 0 1.6531978008771375e-09
, O 0 2.6135331746002244e-11
the O 0 2.756205853826632e-11
mature O 0 4.862817926110097e-10
alpha O 0 1.0489275420466626e-10
- O 0 1.1978877612062178e-10
subunit O 0 2.544106036950211e-10
was O 0 2.5085518107204052e-09
present O 0 8.828072300959278e-11
, O 0 3.2989919823700475e-11
but O 0 4.4308199470544096e-11
its O 0 2.859329994997495e-10
level O 0 8.808510865154773e-11
was O 0 1.6689183368612248e-09
much O 0 1.9282025975897454e-10
lower O 0 9.660068300831881e-09
than O 0 1.9644522120110253e-10
that O 0 6.336260682804351e-11
from O 0 4.2203282535346887e-11
normal O 0 1.957862316714909e-09
alpha O 0 9.661870192800848e-10
- O 0 9.69136437767304e-10
subunit O 0 8.021804887015094e-10
transfections O 0 1.186524301033387e-07
, O 0 1.0288297991323248e-10
although O 0 3.858185299021599e-11
higher O 0 1.581842296038971e-10
than O 0 4.963551444858716e-11
in O 0 4.8013513304079325e-11
those O 0 1.6317815154653914e-10
cells O 0 9.126256417246736e-10
transfected O 0 1.5736194569626605e-08
with O 0 7.102640003919802e-11
an O 0 5.7785148194211544e-11
alpha O 0 2.4803241682747057e-09
- O 0 1.0051437016045384e-08
subunit O 0 8.286273001090194e-09
associated O 0 5.464874064387004e-08
with O 0 2.6482110726533392e-08
infantile O 0 0.00013856739678885788
TSD B-Disease 0 6.794044020352885e-05
. O 0 1.1764533525138177e-07

Furthermore O 0 6.161298529150372e-07
, O 0 2.3515058789058685e-09
the O 0 1.2583482866812545e-10
precursor O 0 5.0115587235666226e-09
level O 0 2.0564716596283006e-10
of O 0 5.671665394280101e-12
the O 0 3.856323940731876e-11
W474C O 0 1.447154951428331e-09
alpha O 0 4.695885902350483e-10
- O 0 4.760855043528522e-10
subunit O 0 3.262052017394268e-10
was O 0 1.5375383188853675e-09
found O 0 2.880497507184998e-10
to O 0 1.485085249219864e-10
accumulate O 0 2.3273483140684448e-09
in O 0 1.859766854406253e-11
comparison O 0 5.116407852945315e-10
to O 0 1.0622038804086742e-09
the O 0 1.6250352452562566e-10
normal O 0 5.091858046313291e-09
alpha O 0 1.783718506231935e-09
- O 0 3.150458116607524e-09
subunit O 0 4.092304717318029e-09
precursor O 0 4.145547549683215e-08
levels O 0 1.8220598363427598e-08
. O 0 7.616685948619306e-09

We O 0 2.2635815639659995e-06
conclude O 0 1.0572809117093129e-07
that O 0 1.8004664426030104e-10
the O 0 1.5331273750529562e-10
1422 O 0 3.698445283362162e-08
G O 0 1.5348265378634096e-06
- O 0 4.7563401039951714e-07
- O 0 6.779121122235665e-07
> O 0 1.9281603869103492e-08
C O 0 2.2049518122457812e-07
mutation O 0 9.718986504481109e-09
is O 0 7.49770592833876e-11
the O 0 4.585721385952368e-11
cause O 0 1.0991602072962792e-09
of O 0 3.170957940668018e-11
Hex B-Disease 0 1.5775776773807593e-05
A I-Disease 0 2.0516434233286418e-05
enzyme I-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 2.57317223084641e-10
the O 0 1.4287790950362478e-09
proband O 0 1.4326775271911174e-05
. O 0 5.399568792086029e-08

The O 0 4.6781451601418667e-08
resulting O 0 5.914992939892727e-08
W474C O 0 1.5727155755485e-07
substitution O 0 1.7995240852997085e-08
clearly O 0 4.778087259182939e-09
interferes O 0 1.376685787590759e-08
with O 0 7.726226602944308e-11
alpha O 0 1.5273432518725372e-09
- O 0 1.2680996253067178e-09
subunit O 0 9.608648321446367e-10
processing O 0 1.3651127339642244e-08
, O 0 1.2380881042606262e-10
but O 0 2.7947496747393608e-11
because O 0 4.314298484436874e-12
the O 0 3.401595628435561e-12
base O 0 8.094869219377188e-11
substitution O 0 1.4963333350159758e-10
falls O 0 5.464561070311902e-08
at O 0 5.42226819000291e-10
the O 0 4.199298894724812e-11
first O 0 3.6196732278170884e-09
position O 0 1.6397444513316373e-09
of O 0 5.1102099982158755e-12
exon O 0 9.864886685306828e-09
13 O 0 3.6306863071544626e-10
, O 0 5.344639661397643e-11
aberrant O 0 3.2925266957306576e-09
splicing O 0 1.870442218887547e-07
may O 0 6.81477899888705e-07
also O 0 9.788932997523148e-10
contribute O 0 4.592945468395726e-10
to O 0 1.5015889642810976e-09
Hex B-Disease 0 9.698242138256319e-06
A I-Disease 0 2.4752057470323052e-06
deficiency I-Disease 0 1.9535420960892225e-06
in O 0 6.814379616137956e-11
this O 0 3.246646007593057e-10
proband O 0 1.1210299817321356e-06
. O 0 1.9282659913244515e-09
. O 0 1.0106570691448269e-08

Two O 0 3.5580060853135365e-07
frequent O 0 3.829601610050304e-06
missense O 0 0.001328740268945694
mutations O 0 0.005905570928007364
in O 0 3.985760849900544e-05
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 7.712140359217301e-06

Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
is O 0 9.628718544263393e-06
an O 0 0.00010326525807613507
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 0 0.0015614914009347558
by O 0 4.0701294778955344e-08
early O 0 1.1429939149820711e-05
childhood O 1 0.9587172269821167
deafness B-Disease 1 1.0
and O 1 0.685823917388916
goiter B-Disease 1 1.0
. O 0 5.603863883152371e-06

A O 0 2.5474867015873315e-07
century O 0 2.2432804058780675e-08
after O 0 8.515424809729666e-09
its O 0 5.093457877691776e-10
recognition O 0 3.242239809964076e-10
as O 0 5.842697992086698e-10
a O 0 2.5061570596562888e-08
syndrome O 0 0.00015700241783633828
by O 0 2.605411719702744e-10
Vaughan O 0 4.999045586373541e-07
Pendred O 0 2.8344155111881264e-07
, O 0 1.8955118030739015e-10
the O 0 2.6930380148115773e-10
disease O 0 1.2683911165822792e-07
gene O 0 3.585018504281834e-08
( O 0 3.570004736275223e-09
PDS O 0 2.0975772713427432e-05
) O 0 8.066160517294918e-10
was O 0 5.822186732729051e-09
mapped O 0 2.9780497357023705e-07
to O 0 1.419584716444433e-08
chromosome O 0 2.3149739718064666e-05
7q22 O 0 2.7306441552354954e-06
- O 0 5.844860424986109e-06
q31 O 0 3.144542915833881e-06
. O 0 5.058879537500616e-08

1 O 0 1.1178932481925585e-06
and O 0 3.4417258376606696e-08
, O 0 1.831871765389792e-09
recently O 0 4.771696637817513e-08
, O 0 1.8894259767865407e-10
found O 0 1.6745806130646912e-10
to O 0 1.0433565122980326e-10
encode O 0 2.8581264022164987e-09
a O 0 1.9826684738433187e-09
putative O 0 3.317083780984831e-07
sulfate O 0 6.935139253982925e-07
transporter O 0 7.5109510362381116e-06
. O 0 3.7162433130788486e-08

We O 0 1.8363333538218285e-06
performed O 0 7.656336009631559e-08
mutation O 0 3.486463029389597e-08
analysis O 0 1.1823325651860728e-09
of O 0 2.6532475869145422e-11
the O 0 3.594696762476701e-10
PDS B-Disease 0 1.7954515669771354e-06
gene O 0 1.2252019843117523e-08
in O 0 1.05700517782914e-10
patients O 0 4.443891921113163e-09
from O 0 2.1282239859310437e-10
14 O 0 1.4102061740572935e-09
Pendred B-Disease 0 1.0318812826426438e-07
families O 0 5.773435549083494e-11
originating O 0 9.91749904422079e-10
from O 0 1.6204738662040086e-09
seven O 0 1.5746493886581447e-08
countries O 0 3.819221328082989e-10
and O 0 1.1131013888387997e-09
identified O 0 4.748653381625445e-08
all O 0 2.9324751515957814e-09
mutations O 0 2.2759752482670592e-07
. O 0 1.2754477474175019e-08

The O 0 9.335007433719511e-09
mutations O 0 1.1177446879173658e-07
include O 0 2.149482120072932e-10
three O 0 7.860724848818279e-10
single O 0 9.457952643288081e-09
base O 0 5.033332861614781e-09
deletions O 0 1.4575887519185926e-07
, O 0 7.510977950708764e-10
one O 0 2.9712315940955136e-10
splice O 0 8.762207471590955e-06
site O 0 1.2620154166143038e-07
mutation O 0 1.4916081170213147e-07
and O 0 9.964634672954276e-10
10 O 0 3.1699514124738926e-09
missense O 0 4.652882580558071e-06
mutations O 0 4.47587990493048e-06
. O 0 7.262782020234226e-08

One O 0 5.841444590259925e-07
missense O 0 5.3921688959235325e-05
mutation O 0 4.960964361089282e-06
( O 0 3.3542484345616685e-08
L236P O 0 3.280437113062362e-07
) O 0 4.15044310031476e-09
was O 0 5.152842152966741e-09
found O 0 6.636979854590663e-10
in O 0 1.1923797019197657e-11
a O 0 4.117427232497306e-10
homozygous O 0 6.863027035564073e-09
state O 0 9.773406389745887e-11
in O 0 1.0705750175254991e-10
two O 0 1.908769586833614e-09
consanguineous O 0 2.423303726573067e-07
families O 0 1.507926117305658e-09
and O 0 5.365857758121706e-10
in O 0 3.134182843811395e-11
a O 0 5.935318347916052e-10
heterozygous O 0 6.15566353445729e-09
state O 0 8.921901412106692e-11
in O 0 7.357722764389507e-11
five O 0 4.5718115404547177e-10
additional O 0 1.474063204831566e-09
non O 0 1.4616338717132749e-07
- O 0 6.598344953090418e-06
consanguineous O 0 1.1385486686776858e-05
families O 0 1.595583540847656e-07
. O 0 6.361663196230438e-08

Another O 0 1.5089401586010354e-06
missense O 0 0.0001259706332348287
mutation O 0 1.2920489098178223e-05
( O 0 6.034520083630923e-08
T416P O 0 3.667061605483468e-07
) O 0 4.836992584245081e-09
was O 0 2.6199094005363577e-09
found O 0 4.1964423602713907e-10
in O 0 1.9956989186220575e-11
a O 0 3.059642816882757e-10
homozygous O 0 1.3857323288846146e-08
state O 0 3.704195283837919e-10
in O 0 2.647309316206048e-10
one O 0 2.58681942533201e-09
family O 0 1.3679799515387003e-08
and O 0 2.8225015658023267e-09
in O 0 2.2265371837915104e-11
a O 0 5.725254714761263e-10
heterozygous O 0 3.6809271186655224e-09
state O 0 1.7708766397728226e-10
in O 0 2.1152174456418038e-10
four O 0 7.47767625597362e-09
families O 0 3.772993029116378e-09
. O 0 2.673209742454219e-08

Pendred B-Disease 0 0.0019324731547385454
patients O 0 6.51855007163249e-05
in O 0 2.2243746844452517e-09
three O 0 8.567264231373883e-09
non O 0 1.310347528260536e-07
- O 0 3.1961612876330037e-06
consanguineous O 0 1.1518463907123078e-05
families O 0 1.1141857214624906e-07
were O 0 4.697061850578166e-09
shown O 0 1.1543580535899878e-09
to O 0 4.1262007699494063e-10
be O 0 3.023218342335099e-10
compound O 0 6.3594169930070166e-09
heterozygotes O 0 6.779580274951513e-08
for O 0 4.201087255850666e-10
L236P O 0 4.277566034716074e-08
and O 0 2.7691979820332335e-09
T416P O 0 4.5054116526443977e-07
. O 0 1.7934556950649494e-08

In O 0 9.236607212415038e-08
total O 0 3.7524337415106856e-08
, O 0 1.2018384065726195e-09
one O 0 5.107885781008292e-10
or O 0 3.50461615283848e-09
both O 0 1.6665031854490309e-10
of O 0 1.5787791213250912e-11
these O 0 1.0574528752638201e-10
mutations O 0 1.8874251495049066e-08
were O 0 6.943789987445825e-10
found O 0 4.2261460997394806e-10
in O 0 2.730582079890631e-11
nine O 0 1.026493778866211e-09
of O 0 4.397309339571054e-12
the O 0 5.221043042347162e-10
14 O 0 3.360227429638485e-09
families O 0 3.4745961663418257e-10
analyzed O 0 6.590914836124284e-08
. O 0 3.1248994503130234e-08

The O 0 1.3599178672052403e-08
identification O 0 1.2373009283805914e-08
of O 0 1.727813170315784e-10
two O 0 2.5410813453419223e-09
frequent O 0 5.477422178046254e-07
PDS B-Disease 0 0.0002998781274072826
mutations O 0 2.5011820525833173e-06
will O 0 7.646274169381684e-10
facilitate O 0 2.2957401257794885e-10
the O 0 1.1236684499538185e-10
molecular O 0 7.950313118954e-08
diagnosis O 0 0.0025126677937805653
of O 0 4.041307306579256e-07
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 5.284648523229407e-07

Insertional O 0 5.3111631132196635e-05
mutation O 0 1.3919795947003877e-06
by O 0 1.4932435288272927e-09
transposable O 0 8.943771376834775e-07
element O 0 2.4240197404878927e-08
, O 0 3.0930840111409452e-09
L1 O 0 4.149389098984102e-07
, O 0 5.622169396701793e-10
in O 0 8.489922653787119e-11
the O 0 7.695335035862172e-09
DMD B-Disease 1 1.0
gene O 0 2.953205239464296e-06
results O 0 1.1396641497185556e-07
in O 0 1.5166371492014719e-09
X B-Disease 1 0.9888896942138672
- I-Disease 1 0.9999117851257324
linked I-Disease 1 0.9999899864196777
dilated I-Disease 1 0.9999818801879883
cardiomyopathy I-Disease 1 1.0
. O 0 1.989823658732348e-06

X B-Disease 1 0.9998070597648621
- I-Disease 1 0.9999836683273315
linked I-Disease 1 0.9999845027923584
dilated I-Disease 1 0.9999980926513672
cardiomyopathy I-Disease 1 1.0
( O 0 8.907602932595182e-06
XLDCM B-Disease 0 0.00033215017174370587
) O 0 3.4941236570773526e-09
is O 0 1.9990029076488725e-10
a O 0 1.5971104438960992e-09
clinical O 0 1.6971485550243415e-08
phenotype O 0 2.8606976343326096e-07
of O 0 2.635298923525653e-10
dystrophinopathy B-Disease 0 2.4546872737118974e-05
which O 0 4.659095775849664e-09
is O 0 1.188611015168206e-10
characterized O 0 6.187170775717732e-10
by O 0 3.219341182525426e-10
preferential O 0 2.1284388367348583e-06
myocardial B-Disease 0 0.0001357739238301292
involvement I-Disease 0 3.1781262066488125e-08
without O 0 5.148725890080641e-09
any O 0 2.286424605202342e-09
overt O 0 1.2654793124511343e-07
clinical O 0 8.747613122750408e-08
signs O 0 3.767189014070027e-07
of O 0 1.4832275496701186e-07
skeletal B-Disease 1 1.0
myopathy I-Disease 1 1.0
. O 0 6.075599685573252e-06

To O 0 4.387139824757469e-07
date O 0 2.0625120100703498e-07
, O 0 3.279257143606884e-10
several O 0 4.5465041453862653e-11
mutations O 0 1.2024580442471233e-08
in O 0 1.0590938542831552e-10
the O 0 6.716677436457985e-09
Duchenne B-Disease 0 0.016186773777008057
muscular I-Disease 0 4.008754785900237e-06
dystrophy I-Disease 0 3.857429874187801e-06
gene O 0 6.527959612867562e-07
, O 0 4.123891628182719e-08
DMD O 1 1.0
, O 0 5.2158132035629023e-08
have O 0 1.8566426174260187e-09
been O 0 1.4258634273289772e-09
identified O 0 1.1332562444010819e-08
in O 0 3.0341132384315017e-10
patients O 0 2.8856625977624617e-09
with O 0 4.864521632730323e-11
XLDCM B-Disease 0 3.1626470445189625e-05
, O 0 7.964025550144527e-10
but O 0 2.487171926746079e-11
a O 0 2.490922398901141e-11
pathogenic O 0 5.664557156670469e-10
correlation O 0 6.579102818093929e-10
of O 0 2.810830040944623e-11
these O 0 4.2551676071589384e-10
cardiospecific O 0 1.8494317828299245e-06
mutations O 0 4.6157396127455286e-07
in O 0 3.3990521508542315e-09
DMD O 1 1.0
with O 0 1.869249643959847e-09
the O 0 2.32001773348145e-09
XLDCM B-Disease 0 0.00020646715711336583
phenotype O 0 8.97130485100206e-06
has O 0 2.011086053244071e-08
remained O 0 1.8688227854113393e-08
to O 0 2.0196764261015687e-09
be O 0 3.632683043264251e-09
elucidated O 0 4.1222412505703687e-07
. O 0 2.1212272827142442e-08

We O 0 2.436830436636228e-05
report O 0 2.1726332022353745e-07
here O 0 2.0339635531385625e-10
the O 0 9.971431666477848e-12
identification O 0 4.977850909249071e-10
of O 0 1.2556287606879657e-11
a O 0 2.58040699918638e-10
unique O 0 1.1457375048706808e-09
de O 0 1.5740795333840651e-07
novo O 0 8.160344577845535e-07
L1 O 0 1.1277581535296122e-07
insertion O 0 1.208841737820876e-08
in O 0 1.5504185435499807e-10
the O 0 1.1196336219265746e-10
muscle O 0 6.044240219438279e-09
exon O 0 2.6041922396302652e-08
1 O 0 4.827314992184029e-09
in O 0 3.1861238092290023e-09
DMD O 1 1.0
in O 0 6.9980146122361475e-09
three O 0 1.279780459384483e-08
XLDCM B-Disease 0 8.845098636811599e-05
patients O 0 7.49446726899805e-09
from O 0 1.6203703309680684e-11
two O 0 1.0088226781723719e-10
unrelated O 0 7.894205289460388e-09
Japanese O 0 1.3234458862143583e-08
families O 0 3.7580258904768016e-09
. O 0 2.352431316410275e-08

The O 0 2.1048883525054407e-08
insertion O 0 2.0937534372933442e-07
was O 0 2.2110556940901915e-08
a O 0 1.0342665612839141e-09
5 O 0 2.8423283726652926e-09
- O 0 7.598536200248418e-08
truncated O 0 1.4441809526033467e-07
form O 0 5.3944910760606035e-09
of O 0 4.499058764428909e-11
human O 0 2.6231630756434754e-10
L1 O 0 1.1101383989853275e-07
inversely O 0 8.407072371596769e-09
integrated O 0 1.8241845367583664e-08
in O 0 1.654793246874675e-10
the O 0 2.028814199972473e-10
5 O 0 2.6258890173380678e-08
- O 0 9.598134056432173e-06
untranslated O 0 8.70231888256967e-05
region O 0 4.0920892274698417e-07
in O 0 5.130694757937704e-10
the O 0 1.206808541986959e-10
muscle O 0 3.898854128436824e-09
exon O 0 6.440223909720544e-09
1 O 0 8.640318460706453e-10
, O 0 8.873364543138251e-11
which O 0 1.0319723547924653e-10
affected O 0 1.0986231369081167e-10
the O 0 1.8422765049597167e-11
transcription O 0 4.392806118858061e-09
or O 0 8.554740027477692e-09
the O 0 3.6144973125651347e-10
stability O 0 5.999709173920564e-09
of O 0 2.0719238824629116e-11
the O 0 1.3473301641031554e-10
muscle O 0 5.112381629146512e-09
form O 0 3.0810767825961705e-10
of O 0 3.350700619741964e-11
dystrophin O 0 3.420287697508684e-08
transcripts O 0 1.3923722974595876e-07
but O 0 1.3033147894248032e-09
not O 0 1.4980523765917297e-10
that O 0 1.2618374227446605e-11
of O 0 6.6508487085725765e-12
the O 0 8.856461120032577e-10
brain O 0 3.865973667416256e-06
or O 0 1.1648361208926872e-07
Purkinje O 0 2.972261791001074e-05
cell O 0 4.747013917949516e-06
form O 0 5.337486541634462e-08
, O 0 5.207251962957571e-09
probably O 0 2.995000869532305e-08
due O 0 5.253711687913665e-09
to O 0 7.758275133440407e-10
its O 0 2.388900188776688e-10
unique O 0 1.9505930204388733e-10
site O 0 4.899036909478127e-08
of O 0 5.789803636524482e-10
integration O 0 4.830292610336073e-08
. O 0 3.428124983884118e-08

We O 0 1.4903454257364501e-06
speculate O 0 1.236818860661515e-07
that O 0 1.2195212895083074e-10
this O 0 2.4812679688679395e-11
insertion O 0 9.018779612013361e-10
of O 0 2.6038355499524712e-11
an O 0 2.4340568449687794e-10
L1 O 0 5.613484859168238e-07
sequence O 0 9.169605874603803e-08
in O 0 7.055728445948262e-08
DMD O 1 1.0
is O 0 1.3796245923458628e-08
responsible O 0 8.443679533343129e-09
for O 0 4.855882015930568e-11
some O 0 1.3836148372858847e-11
of O 0 8.318819591512927e-12
the O 0 9.282477564376279e-11
population O 0 1.0569628505763262e-10
of O 0 7.375352932548207e-12
Japanese O 0 4.696506294976643e-09
patients O 0 3.4616443045365486e-10
with O 0 2.667038118131515e-11
XLDCM B-Disease 0 8.52331595524447e-07
. O 0 2.3657173997548853e-09
. O 0 2.0235873421370343e-08

Severe O 0 0.031879521906375885
early O 0 7.241311323014088e-06
- O 1 0.9962510466575623
onset O 1 0.9998658895492554
obesity B-Disease 1 1.0
, O 0 5.051563857705332e-05
adrenal B-Disease 1 1.0
insufficiency I-Disease 1 1.0
and O 0 2.3245951297212741e-07
red O 0 4.174547484581126e-06
hair O 1 0.9982436895370483
pigmentation O 0 0.03330191224813461
caused O 0 4.672580757869582e-07
by O 0 1.0829059871042546e-09
POMC O 0 1.2612369573616888e-05
mutations O 0 9.896888286675676e-07
in O 0 1.1174153824455857e-09
humans O 0 5.2285926699369156e-08
. O 0 4.4861863557343895e-08

Sequential O 0 3.2608713809167966e-05
cleavage O 0 4.371421709947754e-06
of O 0 4.332733338774375e-10
the O 0 1.0319349541543232e-10
precursor O 0 8.638510351488549e-09
protein O 0 2.217784000890788e-08
pre O 0 3.66363252624069e-07
- O 0 3.393513907212764e-06
pro O 0 7.540726301158429e-07
- O 0 4.93451352667762e-06
opiomelanocortin O 0 5.974724899715511e-06
( O 0 1.1138235889163184e-09
POMC O 0 3.2271648819914844e-07
) O 0 2.0878486439723787e-10
generates O 0 3.1838578440357423e-09
the O 0 4.197835135055783e-10
melanocortin O 0 1.6513430978193355e-07
peptides O 0 2.452864578117442e-08
adrenocorticotrophin O 0 1.1241079391766107e-06
( O 0 2.7477422559485376e-09
ACTH O 0 3.64854884082888e-07
) O 0 1.5046386359074404e-10
, O 0 1.7271639674021344e-10
melanocyte O 0 6.014446967128606e-07
- O 0 6.566392130480381e-06
stimulating O 0 5.884407983103301e-07
hormones O 0 9.729487970844275e-08
( O 0 3.250574254209937e-10
MSH O 0 1.9184506072633667e-07
) O 0 3.799420500438799e-11
alpha O 0 1.1360533347382074e-10
, O 0 1.0867845685880173e-11
beta O 0 1.2463928500405785e-10
and O 0 1.769160686004856e-11
gamma O 0 3.112113899916835e-10
as O 0 5.5634219453537526e-11
well O 0 1.658018167205455e-11
as O 0 9.397984994385933e-12
the O 0 9.959324163977268e-12
opioid O 0 2.2256381460028507e-10
- O 0 2.572524415711541e-10
receptor O 0 2.1156895679830257e-10
ligand O 0 2.454833669673917e-09
beta O 0 2.8292943099472723e-08
- O 0 5.563837817135209e-07
endorphin O 0 1.7795040548662655e-05
. O 0 9.368007169996417e-08

While O 0 6.6932898334926e-08
a O 0 1.2642572544407926e-09
few O 0 7.289795989073866e-10
cases O 0 7.55127016471846e-10
of O 0 1.229860546736461e-09
isolated O 0 0.0007780355517752469
ACTH B-Disease 1 0.9997851252555847
deficiency I-Disease 1 0.5776631236076355
have O 0 1.6881797293422096e-08
been O 0 1.9506581239170373e-08
reported O 0 4.856482064496959e-06
( O 0 5.368041122721934e-09
OMIM O 0 2.8510597985587083e-05
201400 O 0 8.501342563249636e-08
) O 0 2.7485375087010766e-10
, O 0 1.1029650803795477e-10
an O 0 8.309851695642578e-10
inherited O 0 0.00030913957743905485
POMC O 0 0.3904266953468323
defect O 0 0.0639045387506485
has O 0 1.841580221650929e-08
not O 0 1.9859573985314682e-09
been O 0 1.0795137006525124e-09
described O 0 1.2060504595012844e-08
so O 0 3.765645573139409e-09
far O 0 3.5341920501252844e-09
. O 0 1.1129788646258021e-08

Recent O 0 6.188952852426155e-07
studies O 0 1.859694975792081e-08
in O 0 3.522977742864697e-10
animal O 0 4.966596467426143e-09
models O 0 8.661508843488264e-09
elucidated O 0 6.644696792790228e-09
a O 0 1.8884856178846832e-10
central O 0 5.32075050685421e-10
role O 0 2.320777875430835e-10
of O 0 2.1581243736523703e-11
alpha O 0 6.156825715919467e-09
- O 0 3.017360370449751e-07
MSH O 0 2.19056028072373e-06
in O 0 9.86856499296529e-11
the O 0 2.4970588097250612e-11
regulation O 0 1.4167134132492265e-10
of O 0 8.13324668030857e-12
food O 0 9.256104216426309e-10
intake O 0 4.24834722956291e-10
by O 0 2.0968430117229708e-11
activation O 0 3.8495209797595464e-10
of O 0 3.701438808234592e-11
the O 0 7.242426658393697e-10
brain O 0 6.70890187848272e-07
melanocortin O 0 1.192865397570131e-07
- O 0 2.9042777072163517e-08
4 O 0 3.773453549626993e-09
- O 0 8.508249216276909e-09
receptor O 0 8.014708896553202e-10
( O 0 2.380676211721777e-10
MC4 O 0 1.8301339821391593e-07
- O 0 1.9736820178195558e-08
R O 0 3.968359862938087e-08
; O 0 1.7163630239291905e-10
refs O 0 1.0146824713785918e-08
3 O 0 3.9298206355731224e-10
- O 0 9.476116780149368e-09
5 O 0 2.0049952809131355e-09
) O 0 2.21839838165927e-11
and O 0 1.2017408769493532e-11
the O 0 2.2237064620234115e-11
linkage O 0 1.617559597377749e-08
of O 0 1.620674011659773e-10
human O 0 2.515409214254305e-08
obesity B-Disease 1 0.9999995231628418
to O 0 3.449132179866865e-08
chromosome O 0 1.542492100270465e-06
2 O 0 1.210124356276765e-08
in O 0 5.10995190605712e-10
close O 0 3.4772117629700006e-08
proximity O 0 7.960141878982085e-09
to O 0 1.8176239180434095e-08
the O 0 1.2589393971751406e-09
POMC O 0 4.415228147536254e-07
locus O 0 1.808346006271222e-08
, O 0 3.245970991994085e-10
led O 0 1.578725622453092e-10
to O 0 1.58123292237633e-10
the O 0 4.57677368226328e-11
proposal O 0 1.5861755242596587e-09
of O 0 1.8230791876128194e-11
an O 0 3.001614512498918e-10
association O 0 1.2161531504073508e-10
of O 0 6.26088833555194e-11
POMC O 0 3.6632900446420535e-06
with O 0 8.77759287476465e-09
human O 0 4.448550612323743e-07
obesity B-Disease 1 0.9999978542327881
. O 0 1.6190820417705254e-07

The O 0 2.011227984155539e-08
dual O 0 7.22116340057255e-08
role O 0 1.0490325941248102e-08
of O 0 4.038667178463129e-10
alpha O 0 6.861485246645316e-08
- O 0 6.822791419835994e-06
MSH O 0 2.3785625671735033e-05
in O 0 4.697758293481513e-10
regulating O 0 7.613142116724703e-09
food O 0 1.1394984511525763e-08
intake O 0 4.450578572345876e-08
and O 0 6.712963074306799e-09
influencing O 0 5.597297558779246e-07
hair O 0 0.2613513171672821
pigmentation O 0 0.00027526833582669497
predicts O 0 7.139850822568405e-06
that O 0 1.1862012760932572e-10
the O 0 1.4319348484725936e-10
phenotype O 0 1.0312693632386072e-07
associated O 0 2.4893100913914168e-09
with O 0 1.6517974488206022e-10
a O 0 1.6635196331549196e-08
defect O 0 4.5397737835628504e-07
in O 0 3.079942689776516e-10
POMC O 0 6.374769441208628e-07
function O 0 1.5146026655088463e-08
would O 0 1.7238679816955482e-08
include O 0 6.100878469084137e-09
obesity B-Disease 1 1.0
, O 0 2.839694701606277e-09
alteration O 0 8.178107577805349e-07
in O 0 2.1610770062352458e-08
pigmentation O 1 0.7067957520484924
and O 0 0.00021330609160941094
ACTH B-Disease 1 0.970416784286499
deficiency I-Disease 0 0.001207216177135706
. O 0 2.1537235994628645e-08

The O 0 3.902367495811632e-08
observation O 0 1.5880131343237736e-07
of O 0 8.739567403104331e-10
these O 0 3.1865734495539755e-09
symptoms O 0 3.432070911912888e-07
in O 0 1.8679646371366765e-11
two O 0 1.9629878278415447e-10
probands O 0 3.422461531954468e-07
prompted O 0 2.178125235730022e-09
us O 0 3.621309918599991e-09
to O 0 1.5683652987430463e-10
search O 0 4.415789955913851e-09
for O 0 7.021796477602038e-10
mutations O 0 2.8988319300538024e-08
within O 0 5.779785539061777e-10
their O 0 1.8655677891388223e-08
POMC O 0 9.682808013167232e-06
genes O 0 3.7844372968720563e-07
. O 0 6.323797663299047e-08

Patient O 0 0.006884383037686348
1 O 0 3.254433806887391e-07
was O 0 4.919064622299629e-08
found O 0 5.075064812842811e-09
to O 0 5.319369944523089e-10
be O 0 1.105471408857639e-10
a O 0 9.652599552989471e-11
compound O 0 1.2335630295012834e-09
heterozygote O 0 8.403561402303694e-09
for O 0 7.678319785542342e-11
two O 0 1.6232942767757663e-10
mutations O 0 6.785981998547186e-09
in O 0 1.0274335549009805e-10
exon O 0 3.8032833771239893e-08
3 O 0 4.927626306994171e-09
( O 0 3.789716596092063e-10
G7013T O 0 1.2903175417022794e-08
, O 0 8.54881443412836e-10
C7133delta O 0 4.514568558988685e-07
) O 0 2.741709914655388e-10
which O 0 1.9750055757494778e-10
interfere O 0 4.714285406492991e-09
with O 0 3.664768835620613e-11
appropriate O 0 3.5194183678477486e-10
synthesis O 0 6.0562883597015116e-09
of O 0 3.7357406057481057e-10
ACTH O 0 2.215263748439611e-06
and O 0 1.879338240584616e-09
alpha O 0 6.830850907135755e-08
- O 0 6.881977242301218e-06
MSH O 0 0.00013106341066304594
. O 0 7.891242148616584e-08

Patient O 0 0.0012579652247950435
2 O 0 1.597029779532022e-07
was O 0 2.107085528280095e-08
homozygous O 0 4.545696086211137e-08
for O 0 6.903259214263713e-11
a O 0 4.1672018613603257e-10
mutation O 0 1.4690312966081365e-08
in O 0 3.2041122532966426e-10
exon O 0 1.488376852876172e-07
2 O 0 2.562629930480398e-08
( O 0 1.308283592571513e-09
C3804A O 0 2.877765581388303e-08
) O 0 1.109758396289351e-09
which O 0 5.650445444871366e-09
abolishes O 0 3.3573283872101456e-05
POMC O 0 5.108261029818095e-05
translation O 0 2.8686524728982477e-06
. O 0 1.1306678970868234e-07

These O 0 1.120553889677467e-07
findings O 0 2.436070545286384e-08
represent O 0 6.285683640250284e-10
the O 0 4.406252793187626e-11
first O 0 2.7616434139510204e-10
examples O 0 4.01668628913221e-11
of O 0 2.6458087457048585e-11
a O 0 1.4380815116510348e-07
genetic B-Disease 1 0.9999998807907104
defect I-Disease 1 0.9999988079071045
within O 0 1.3243794949602261e-09
the O 0 3.588982999680468e-10
POMC O 0 5.405874503594532e-07
gene O 0 3.739094722732261e-08
and O 0 3.04848757348708e-10
define O 0 2.7771214217153783e-09
a O 0 4.010711318613858e-09
new O 0 1.2361242340830358e-07
monogenic B-Disease 0 0.25197336077690125
endocrine I-Disease 1 0.9726018309593201
disorder I-Disease 0 0.019704585894942284
resulting O 0 1.2389091530451424e-08
in O 0 5.698758687167071e-10
early O 0 7.76157435211644e-07
- O 1 0.9999418258666992
onset O 1 0.9999891519546509
obesity B-Disease 1 1.0
, O 0 7.68200188758783e-05
adrenal B-Disease 1 1.0
insufficiency I-Disease 1 1.0
and O 0 1.2297067542021978e-07
red O 0 6.202335498528555e-07
hair O 0 0.2994349002838135
pigmentation O 0 0.0002039739047177136
. O 0 1.216936329484497e-08
. O 0 1.2337636690062936e-08

A O 0 1.0610359595375485e-06
European O 0 4.826286499337584e-07
multicenter O 0 9.230967407347634e-06
study O 0 1.8113603061920003e-07
of O 0 2.523030673273752e-07
phenylalanine B-Disease 1 1.0
hydroxylase I-Disease 1 1.0
deficiency I-Disease 1 1.0
: O 0 4.2351235407522836e-08
classification O 0 2.6903245853304725e-08
of O 0 3.0919190818767817e-11
105 O 0 1.093170221011519e-09
mutations O 0 7.096745946455485e-08
and O 0 2.69131272823131e-10
a O 0 4.258130792411663e-10
general O 0 1.4813565651916605e-10
system O 0 3.9273928553740234e-10
for O 0 1.8307320936994387e-10
genotype O 0 4.063846574808849e-07
- O 0 1.3122612472216133e-06
based O 0 4.3497456658769806e-07
prediction O 0 2.4373732685489813e-06
of O 0 1.719270170674747e-09
metabolic O 0 2.575572580099106e-05
phenotype O 0 1.8566755898064002e-05
. O 0 1.0517838688883785e-07

Phenylketonuria B-Disease 1 0.9291550517082214
( O 0 3.6250619359634584e-06
PKU B-Disease 0 0.00016422239423263818
) O 0 8.716602195590895e-08
and O 0 1.8509373944652907e-07
mild B-Disease 0 0.013915752992033958
hyperphenylalaninemia I-Disease 1 1.0
( O 0 9.354863141197711e-05
MHP B-Disease 1 1.0
) O 0 2.1665661265046765e-08
are O 0 3.943668946959633e-09
allelic B-Disease 0 2.5190060114255175e-05
disorders I-Disease 1 0.5861867666244507
caused O 0 3.5489264860188996e-08
by O 0 1.2575947228032902e-10
mutations O 0 6.62004353557677e-08
in O 0 8.197181822211519e-11
the O 0 4.086780081014041e-10
gene O 0 4.5796579684065364e-07
encoding O 0 1.779375338628597e-06
phenylalanine O 0 0.0015737825306132436
hydroxylase O 0 0.01291526760905981
( O 0 2.0107414400172274e-07
PAH O 0 0.00010400156315881759
) O 0 8.018416508548398e-08
. O 0 6.579397648920349e-08

Previous O 0 1.4351087884278968e-05
studies O 0 7.353062159154433e-08
have O 0 2.768453244428315e-09
suggested O 0 3.184252639343299e-09
that O 0 6.982341094197153e-11
the O 0 8.612474622360367e-11
highly O 0 1.8308413674006374e-09
variable O 0 1.9731820088964014e-07
metabolic O 0 1.7186705008498393e-05
phenotypes O 0 4.907106813334394e-06
of O 0 4.494785343922558e-08
PAH B-Disease 1 0.9997984766960144
deficiency I-Disease 1 0.9921197891235352
correlate O 0 1.260089993593283e-05
with O 0 7.23870456909026e-08
PAH O 0 0.006526990793645382
genotypes O 0 0.000330441165715456
. O 0 2.5296031935795327e-07

We O 0 2.940223282621446e-07
identified O 0 3.2150246909168345e-08
both O 0 3.2158184448682903e-10
causative O 0 1.0933797511825105e-07
mutations O 0 8.231220931520511e-07
in O 0 1.9124317685026426e-09
686 O 0 1.9002851558980183e-07
patients O 0 5.615690952254226e-07
from O 0 1.4816144977558565e-09
seven O 0 9.724753446960221e-09
European O 0 2.3953267813681123e-08
centers O 0 9.877010320735735e-09
. O 0 2.3929977999159746e-08

On O 0 2.7639549671221175e-07
the O 0 5.457992946489298e-10
basis O 0 5.983535888987035e-10
of O 0 8.961224991221872e-12
the O 0 5.5724379971477944e-11
phenotypic O 0 1.889366529894687e-08
characteristics O 0 1.2191543330430932e-09
of O 0 9.052553845423361e-11
297 O 0 3.471115661568547e-08
functionally O 0 1.4304071100923466e-06
hemizygous O 0 1.3210118595452514e-05
patients O 0 3.042371758965601e-07
, O 0 2.053374310861944e-11
105 O 0 7.955125447267619e-11
of O 0 7.995508768954274e-12
the O 0 8.541023999164565e-10
mutations O 0 3.203492724423995e-07
were O 0 2.5340294307341082e-09
assigned O 0 1.0211900214329717e-09
to O 0 6.607978053629893e-10
one O 0 2.49344767055959e-10
of O 0 1.1323772648730301e-11
four O 0 1.8246917310449362e-09
arbitrary O 0 1.4368573886258673e-07
phenotype O 0 1.8333865909880842e-06
categories O 0 5.454429015117057e-07
. O 0 5.471517994237729e-08

We O 0 8.706862786311831e-07
proposed O 0 8.205778279091192e-09
and O 0 2.3763948586719152e-09
tested O 0 1.4145297155820913e-09
a O 0 8.919383981398354e-11
simple O 0 2.894188222413163e-10
model O 0 1.4143625159945827e-09
for O 0 4.4603192667080904e-11
correlation O 0 3.191159336779492e-09
between O 0 1.7312182798434606e-09
genotype O 0 2.455456524330657e-06
and O 0 1.0691804774864977e-08
phenotypic O 0 4.297208420211973e-07
outcome O 0 3.4457991660019616e-07
. O 0 4.7973212957685973e-08

The O 0 4.579216650313356e-08
observed O 0 4.5246329705150856e-07
phenotype O 0 3.22738515023957e-06
matched O 0 9.517607963971386e-07
the O 0 5.442974071456774e-09
predicted O 0 7.691675705245871e-07
phenotype O 0 2.5203036102539045e-07
in O 0 7.94762200495569e-10
79 O 0 7.598808693387582e-09
% O 0 1.273195715523201e-10
of O 0 3.644329629737264e-12
the O 0 6.138272667932654e-10
cases O 0 2.460271320003926e-09
, O 0 1.6027316140920789e-09
and O 0 3.5780831630916055e-09
in O 0 1.0466113392615384e-10
only O 0 1.27152122164631e-10
5 O 0 1.2294025519832275e-10
of O 0 3.4148313517168294e-12
184 O 0 2.991030201293654e-10
patients O 0 1.4618610766348183e-09
was O 0 4.5956705108096685e-10
the O 0 2.0330404026935867e-10
observed O 0 1.5679779252764092e-08
phenotype O 0 8.807347740003024e-08
more O 0 2.4618518335017825e-10
than O 0 1.5002599162983188e-10
one O 0 3.9657904737921967e-10
category O 0 1.1679858857860381e-08
away O 0 4.498782502082577e-08
from O 0 7.449414973770274e-10
that O 0 1.4098940903650714e-09
expected O 0 1.8253196287787432e-07
. O 0 8.384908767311572e-09

Among O 0 3.5609549087212145e-08
the O 0 1.1745756589576217e-09
seven O 0 2.699590995192125e-09
contributing O 0 2.136016918896644e-09
centers O 0 4.786038787507607e-10
, O 0 1.0158451857478212e-10
the O 0 1.554798373382127e-10
proportion O 0 7.43632933009053e-09
of O 0 4.10112471760371e-10
patients O 0 6.619082171255286e-09
for O 0 6.308741723470845e-11
whom O 0 5.191532981285718e-09
the O 0 4.810841169877733e-10
observed O 0 6.799095331189164e-08
phenotype O 0 6.071563802834135e-07
did O 0 1.8793467404520925e-07
not O 0 6.948652209182171e-10
match O 0 4.47603865083579e-09
the O 0 2.554458033987572e-10
predicted O 0 1.4962370187276974e-07
phenotype O 0 1.1570368663171848e-08
was O 0 6.159923682247381e-10
4 O 0 5.565631844284269e-10
% O 0 1.6682301373638353e-10
- O 0 2.3375594793151322e-08
23 O 0 2.404050469806407e-08
% O 0 7.296779291898758e-10
( O 0 4.792689023425112e-10
P O 0 4.817076478502713e-05
< O 0 2.8284619091323293e-09
. O 0 1.3547205024444509e-10
0001 O 0 6.0816152114284705e-09
) O 0 4.272846312880496e-11
, O 0 2.5535070585780417e-11
suggesting O 0 5.516140322292529e-10
that O 0 2.4699261733096556e-11
differences O 0 1.9661128281001083e-10
in O 0 1.0876141133542294e-11
methods O 0 1.331132981619021e-10
used O 0 1.0480855766603625e-10
for O 0 1.7774472865772495e-11
mutation O 0 9.841596426696242e-10
detection O 0 5.730840246798152e-09
or O 0 1.2300458251957025e-07
phenotype O 0 9.533509910397697e-06
classification O 0 8.483551027893554e-06
may O 0 6.883853984618327e-07
account O 0 5.045376116896705e-09
for O 0 1.9154233754647976e-11
a O 0 9.98666357943101e-11
considerable O 0 1.1499469432241227e-10
proportion O 0 4.431246924951893e-09
of O 0 1.1822220979951226e-09
genotype O 0 0.00024495270918123424
- O 0 0.010821480304002762
phenotype O 0 0.016106145456433296
inconsistencies O 0 0.0003598715993575752
. O 0 1.398662021756536e-07

Our O 0 1.2383854937070282e-06
data O 0 2.2348677930494887e-07
indicate O 0 1.631885737651828e-08
that O 0 1.6640289146607756e-10
the O 0 6.439409561131981e-10
PAH O 0 1.308995433646487e-05
- O 0 3.483104592305608e-06
mutation O 0 2.2535476773555274e-07
genotype O 0 1.6028829463721195e-07
is O 0 5.419112034110718e-11
the O 0 1.00617413706372e-11
main O 0 2.0754660212674025e-09
determinant O 0 1.9084756885945353e-08
of O 0 9.077988361028133e-11
metabolic O 0 2.613358446978964e-06
phenotype O 0 1.5214757240755716e-06
in O 0 7.886014063984703e-10
most O 0 4.170432443828531e-09
patients O 0 1.5822006105281616e-07
with O 0 2.3984354058370627e-08
PAH B-Disease 1 0.9949216246604919
deficiency I-Disease 1 0.8448577523231506
. O 0 1.3228293482825393e-07

In O 0 7.211817631969097e-08
the O 0 1.8816550539924037e-09
present O 0 2.310743596467546e-09
study O 0 3.6428599026194775e-10
, O 0 1.3758706673971943e-10
the O 0 1.404343169530975e-10
classification O 0 7.750381669779927e-09
of O 0 4.095994030062222e-11
105 O 0 2.057853887293959e-09
PAH O 0 1.7797250393414288e-06
mutations O 0 3.3444855489506153e-06
may O 0 2.9002533707966904e-08
allow O 0 1.3632692197340646e-10
the O 0 2.0351355323189324e-10
prediction O 0 6.909301930591027e-08
of O 0 1.1320705657624774e-11
the O 0 2.4244656282590427e-10
biochemical O 0 7.232325405226447e-09
phenotype O 0 3.4397046988488e-08
in O 0 2.4096025175168734e-10
> O 0 1.5114968165974574e-09
10 O 0 2.1619745993461947e-09
, O 0 1.2312728614460866e-10
000 O 0 2.8274571572950435e-10
genotypes O 0 1.619733147606439e-08
, O 0 5.525870871991856e-10
which O 0 4.7905528433034306e-09
may O 0 4.3032283514321534e-08
be O 0 6.83797185541124e-11
useful O 0 5.7113019175103474e-11
for O 0 1.9407909307433968e-11
the O 0 3.377658708281217e-10
management O 0 1.6766147581392943e-08
of O 0 6.912775352141409e-10
hyperphenylalaninemia B-Disease 1 1.0
in O 0 3.9850768018823146e-08
newborns O 0 1.0240518122373032e-06
. O 0 1.5416501852882902e-08

Somatic O 0 0.00013530050637200475
instability O 0 7.714236744504888e-06
of O 0 2.87966939183093e-09
the O 0 7.614622710150343e-09
CTG O 0 3.406358155189082e-05
repeat O 0 3.4237482395838015e-06
in O 0 4.704887035522631e-10
mice O 0 3.9070297219723216e-08
transgenic O 0 4.857649571476941e-08
for O 0 1.5732586344796573e-09
the O 0 6.972343413735871e-08
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
region O 0 3.748035305761732e-05
is O 0 1.7409544028623714e-08
age O 0 7.155609882403269e-09
dependent O 0 7.577214411469413e-09
but O 0 5.715655948534959e-09
not O 0 4.908244366497172e-10
correlated O 0 3.644335055952297e-09
to O 0 2.9901517373254194e-10
the O 0 1.2588330378093815e-10
relative O 0 1.2316845321436176e-09
intertissue O 0 5.53942015812936e-07
transcription O 0 1.0711750775271867e-07
levels O 0 4.091612026968505e-08
and O 0 1.4648790624960384e-08
proliferative O 0 4.346958303358406e-05
capacities O 0 7.705875759711489e-07
. O 0 5.3287891432773904e-08

A O 0 2.0963539100193884e-06
( O 0 1.7705650634525227e-07
CTG O 0 1.0106840818480123e-05
) O 0 3.882068888572121e-09
nexpansion O 0 1.0647057990809117e-07
in O 0 2.106155250203301e-10
the O 0 2.117926251044011e-10
3 O 0 9.686677771014729e-08
- O 0 0.00014741897757630795
untranslated O 0 0.020968303084373474
region O 0 1.3963970559416339e-05
( O 0 3.1359379537576615e-09
UTR O 0 1.7478959080108325e-07
) O 0 1.1237327735003078e-10
of O 0 2.8618928407664335e-11
the O 0 1.5398839536828746e-08
DM O 1 1.0
protein O 0 4.957455956855483e-08
kinase O 0 7.989868322511029e-08
gene O 0 3.530340109136887e-08
( O 0 3.7662181706643594e-10
DMPK O 0 9.365547839479405e-07
) O 0 2.2300405966291237e-10
is O 0 1.8615314845149555e-10
responsible O 0 8.014364993869094e-08
for O 0 8.381778826560549e-08
causing O 1 0.9823139905929565
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.00023675868578720838
DM B-Disease 1 1.0
) O 0 9.297356484694319e-08
. O 0 5.42159099836681e-08

Major O 0 2.2798863028583582e-06
instability O 0 5.792449542241229e-07
, O 0 9.104089704337071e-10
with O 0 1.1088057555452835e-10
very O 0 2.4466662029709596e-10
large O 0 1.1189589532722977e-10
expansions O 0 1.3772741169759684e-08
between O 0 4.258073893481651e-10
generations O 0 1.291826201565982e-09
and O 0 7.567158566423871e-10
high O 0 1.4530073810803401e-09
levels O 0 4.704043821135429e-10
of O 0 2.7085162238038585e-11
somatic O 0 1.0334802347244931e-08
mosaicism O 0 3.762406777241267e-07
, O 0 5.910949507637042e-10
is O 0 2.0228406449884773e-10
observed O 0 1.1378000763784257e-08
in O 0 4.9365533882905765e-09
patients O 0 7.004119595421798e-08
. O 0 1.1228897811577099e-08

There O 0 1.1398717703059447e-07
is O 0 6.560194054650026e-10
a O 0 1.1574665670366358e-09
good O 0 2.718948621804884e-09
correlation O 0 9.085532326480461e-09
between O 0 1.7226543524984095e-09
repeat O 0 4.48310811407282e-06
size O 0 1.6299321003998557e-08
( O 0 2.1594155352744338e-09
at O 0 6.8036594136344775e-09
least O 0 3.2927072179944616e-10
in O 0 1.69802741312175e-10
leucocytes O 0 1.089385591512837e-06
) O 0 5.757505028292087e-10
, O 0 2.294002487968072e-10
clinical O 0 2.172909185915728e-09
severity O 0 2.39241870758633e-07
and O 0 1.832529683554185e-08
age O 0 9.717763482797181e-09
of O 0 1.9996140299127774e-09
onset O 0 1.7948694903680007e-06
. O 0 9.499520103872783e-08

The O 0 1.4603062936657807e-06
trinucleotide O 0 0.0011030880268663168
repeat O 0 0.0001003585202852264
instability O 0 1.9805762008218153e-07
mechanisms O 0 9.715002136090334e-09
involved O 0 4.522672014672935e-09
in O 0 4.8352887915825704e-08
DM B-Disease 1 1.0
and O 0 4.1583295029568035e-08
other O 0 5.95453797380685e-10
human O 0 1.6834047045222178e-08
genetic B-Disease 1 1.0
diseases I-Disease 1 1.0
are O 0 5.191503671397868e-09
unknown O 0 6.477850433839194e-08
. O 0 7.630444542883197e-08

We O 0 6.858723509139963e-07
studied O 0 5.939605074445353e-08
somatic O 0 3.301987874237966e-07
instability O 0 1.0184792387235575e-07
by O 0 2.5122134927890727e-10
measuring O 0 1.5468081926428567e-07
the O 0 4.764873384743851e-09
CTG O 0 1.0722011211328208e-05
repeat O 0 1.1945917322009336e-06
length O 0 1.07990132391933e-08
at O 0 5.998324947853462e-09
several O 0 1.5583639934035887e-10
ages O 0 1.2920290615170416e-08
in O 0 4.533143652118987e-11
various O 0 3.103789447678196e-11
tissues O 0 6.297374621766494e-09
of O 0 2.4241270449310015e-11
transgenic O 0 6.161997134768171e-08
mice O 0 1.0391060101255789e-07
carrying O 0 3.3976843560878933e-09
a O 0 4.924760599323008e-09
( O 0 3.355334454724357e-09
CTG O 0 1.5787684333190555e-06
) O 0 4.0489561703438426e-10
55expansion O 0 3.012940297253408e-08
surrounded O 0 1.5629458838262167e-09
by O 0 5.7100164874146486e-11
45 O 0 1.8799357903720448e-10
kb O 0 2.17201119312449e-08
of O 0 2.5040221632299797e-11
the O 0 3.9860781342326845e-09
human O 0 5.631360977531585e-07
DM B-Disease 1 1.0
region O 0 1.0241592462989502e-06
, O 0 8.237351772910628e-11
using O 0 2.7681879011254296e-10
small O 0 6.38678776532231e-10
- O 0 4.770377017848659e-07
pool O 0 4.798584640752779e-08
PCR O 0 1.7321615075616137e-07
. O 0 2.795349285378279e-09

These O 0 9.085258767527193e-08
mice O 0 2.0828647393500432e-06
have O 0 2.080269290161141e-09
been O 0 2.7240601441214096e-10
shown O 0 4.15265044573232e-10
to O 0 1.20487264609892e-09
reproduce O 0 2.7336329821991967e-07
the O 0 2.0173269998924326e-10
intergenerational O 0 2.3750908795250325e-08
and O 0 1.8511617794203516e-09
somatic O 0 1.453421116792697e-08
instability O 0 6.070049796136345e-09
of O 0 2.462465648056522e-11
the O 0 8.068453682952281e-10
55 O 0 3.831314643321093e-08
CTG O 0 4.034282028442249e-06
repeat O 0 1.3162607501726598e-06
suggesting O 0 3.587150798622929e-09
that O 0 1.2110183515712247e-11
surrounding O 0 9.978647769193216e-11
sequences O 0 6.914173122929412e-10
and O 0 1.7271871433077735e-10
the O 0 5.400559513479841e-11
chromatin O 0 3.6605041220383328e-09
environment O 0 3.12926395906743e-09
are O 0 5.843430600505073e-11
involved O 0 2.2521740028480508e-10
in O 0 5.601842323343931e-10
instability O 0 2.9239592080898547e-08
mechanisms O 0 2.5765785949261044e-08
. O 0 5.795178736889284e-08

As O 0 3.72436090856354e-08
observed O 0 1.685522121874783e-08
in O 0 1.723570453027179e-10
some O 0 1.383654388981137e-11
of O 0 4.356154326146111e-12
the O 0 3.483454913411066e-10
tissues O 0 3.24783286487218e-07
of O 0 2.10922053156537e-08
DM B-Disease 1 1.0
patients O 0 2.4692839360795915e-05
, O 0 5.907418304529344e-11
there O 0 1.013663371990381e-11
is O 0 3.681330587590459e-11
a O 0 1.505098712328845e-09
tendency O 0 3.969926609670438e-08
for O 0 5.337644215508419e-10
repeat O 0 9.930962505677599e-07
length O 0 3.2525129256555374e-08
and O 0 3.48121842463911e-09
somatic O 0 7.544738167553078e-09
mosaicism O 0 7.274275048985146e-08
to O 0 9.091248309722744e-10
increase O 0 3.9401332196931094e-10
with O 0 2.6042390466329834e-10
the O 0 2.1295203378457472e-09
age O 0 1.5181971235733727e-09
of O 0 2.5734655725861977e-11
the O 0 1.1697754986883524e-09
mouse O 0 5.448106890071358e-07
. O 0 1.1421568757441491e-07

Furthermore O 0 1.0677806130843237e-05
, O 0 8.28344823844418e-08
we O 0 1.360875323541677e-08
observed O 0 5.750845577523478e-09
no O 0 3.464167286360009e-10
correlation O 0 2.1913180159316425e-09
between O 0 6.537195784694916e-11
the O 0 1.2439632657290645e-10
somatic O 0 2.4491573213936135e-08
mutation O 0 1.3593634662356635e-07
rate O 0 1.4269747339312744e-07
and O 0 7.439762583771881e-09
tissue O 0 2.8750612273142906e-06
proliferation O 0 1.258515567315044e-07
capacity O 0 1.0872756028845743e-08
. O 0 1.8156592673790328e-08

The O 0 2.155774581069636e-08
somatic O 0 3.259350478401757e-07
mutation O 0 4.5987707153472e-07
rates O 0 8.473902823880053e-08
in O 0 1.7182726075315458e-10
different O 0 3.8700828652871166e-10
tissues O 0 5.352243306333548e-07
were O 0 4.5834260831156826e-09
also O 0 3.119318137123628e-09
not O 0 4.6085388283323425e-10
correlated O 0 2.4651281016474513e-09
to O 0 6.080603243141525e-10
the O 0 1.5696520472285869e-10
relative O 0 2.8196498469412745e-09
inter O 0 9.680053381089238e-07
- O 0 3.3900139442266664e-06
tissue O 0 4.767557584273163e-06
difference O 0 2.1231165714397093e-09
in O 0 2.8504689927877358e-11
transcriptional O 0 1.085961098823418e-09
levels O 0 2.371327023631409e-10
of O 0 1.9533350631428803e-12
the O 0 1.54506563793122e-11
three O 0 3.2840016817026196e-10
genes O 0 1.4127340408620626e-09
( O 0 3.8991046502623306e-10
DMAHP O 0 1.708130412225728e-06
, O 0 9.55123646839695e-10
DMPK O 0 1.964098601092701e-06
and O 0 3.952502325432761e-09
59 O 0 3.0824360841563703e-09
) O 0 2.608493282485469e-11
surrounding O 0 2.890503114638676e-10
the O 0 2.6402611208453663e-09
repeat O 0 8.174635695468169e-06
. O 0 2.2568278357226745e-09
. O 0 1.0884499523911018e-08

A O 0 2.9162853820707824e-07
novel O 0 1.364475537002363e-07
missense O 0 1.2814636647817679e-05
mutation O 0 2.764835244306596e-06
in O 0 4.833045519347934e-09
patients O 0 7.909581256626552e-08
from O 0 1.7862643308941273e-10
a O 0 5.354410248514796e-09
retinoblastoma B-Disease 0 3.088237644988112e-05
pedigree O 0 9.656024485593662e-05
showing O 0 1.4637315871368628e-05
only O 0 4.242357576345057e-09
mild O 0 2.5577467255288866e-08
expression O 0 4.1013434315395614e-10
of O 0 4.282955934353794e-11
the O 0 2.5429527372722305e-09
tumor B-Disease 0 2.677941438378184e-06
phenotype O 0 3.1914585179038113e-06
. O 0 4.912154594194362e-08

We O 0 9.80319555310416e-07
have O 0 7.850790573193933e-10
used O 0 2.713000102350094e-10
single O 0 2.4066277859446927e-09
strand O 0 1.006461729957664e-06
conformation O 0 7.174691063482896e-08
polymorphism O 0 2.0600383621172114e-08
analysis O 0 3.6169127692886605e-09
to O 0 1.51996748520844e-09
study O 0 2.2818795464285557e-10
the O 0 1.996160597927954e-10
27 O 0 7.326250273109736e-09
exons O 0 1.7025305609763564e-08
of O 0 1.749349970436853e-11
the O 0 3.3974625890387244e-10
RB1 O 0 2.0451854254588397e-07
gene O 0 6.363905846740181e-09
in O 0 4.8686898262984e-11
individuals O 0 2.304451768297966e-11
from O 0 8.263962431032112e-11
a O 0 5.39500533136561e-09
family O 0 1.6296812077598588e-07
showing O 0 1.2444160347513389e-05
mild O 0 1.5688102905642154e-07
expression O 0 8.308568277826112e-10
of O 0 4.645851411910762e-11
the O 0 2.5690789495769195e-09
retinoblastoma B-Disease 0 1.4286661098594777e-05
phenotype O 0 2.272005622216966e-05
. O 0 9.005706402831493e-08

In O 0 2.8435009014060597e-08
this O 0 1.0052563226281563e-09
family O 0 4.091734950861792e-09
affected O 0 9.934296052449554e-09
individuals O 0 2.292480233423433e-10
developed O 0 7.157796488854729e-08
unilateral B-Disease 1 0.9654123783111572
tumors I-Disease 1 1.0
and O 0 5.83263783937582e-07
, O 0 4.849646240145944e-10
as O 0 6.424954318573484e-11
a O 0 2.9887775587766896e-10
result O 0 6.860026435795419e-10
of O 0 1.2760200882033779e-11
linkage O 0 1.902493274030803e-08
analysis O 0 4.130825459469634e-09
, O 0 3.3610206284784283e-10
unaffected O 0 5.4619146538925634e-08
mutation O 0 2.098010298823283e-08
carriers O 0 1.5149868914932085e-08
were O 0 2.216341110639064e-09
also O 0 1.2102667756863639e-09
identified O 0 9.807870071654179e-09
within O 0 2.949374633409718e-10
the O 0 1.822771600323847e-09
pedigree O 0 1.1757248330468428e-06
. O 0 8.951965924097749e-08

A O 0 1.6881627118436882e-07
single O 0 6.957571230259418e-08
band O 0 4.636457262563454e-08
shift O 0 2.4177355228971464e-08
using O 0 3.4752607458443663e-09
SSCP O 0 2.055150389423943e-06
was O 0 6.1376321802697476e-09
identified O 0 1.512552416649271e-09
in O 0 1.2034526153392733e-10
exon O 0 1.3269091425627266e-07
21 O 0 2.33635155666434e-08
which O 0 3.4377400925933443e-10
resulted O 0 1.2525341874791707e-10
in O 0 2.1578280828826735e-11
a O 0 4.5937953441210766e-10
missense O 0 1.3142697241619317e-07
mutation O 0 7.688703007602271e-09
converting O 0 1.1265751886924136e-08
a O 0 1.0816907369814999e-08
cys O 0 6.177065370138735e-05
- O 0 1.8138457562599797e-06
- O 0 3.7041113500890788e-06
> O 0 2.3678223826095746e-08
arg O 0 1.0316860254988569e-08
at O 0 4.769061812126552e-10
nucleotide O 0 6.6711738355706984e-09
position O 0 1.0406526307349395e-08
28 O 0 6.093385795935546e-10
in O 0 2.205378935027369e-11
the O 0 4.541124420942566e-10
exon O 0 1.4004307331560994e-06
. O 0 7.371148313950471e-08

The O 0 4.233548622778471e-08
mutation O 0 5.076374804957595e-07
destroyed O 0 2.9572905191344034e-07
an O 0 5.823183601982862e-10
NdeI O 0 4.5062668618811585e-07
restriction O 0 9.10798458875206e-09
enzyme O 0 3.8834038207369304e-08
site O 0 1.3077332994271273e-07
. O 0 5.94081726035256e-08

Analysis O 0 4.320417303915747e-07
of O 0 1.2958982775757022e-09
all O 0 6.100689398103043e-10
family O 0 7.8890977084356e-10
members O 0 1.5367047911940546e-10
demonstrated O 0 1.0590413962452416e-10
that O 0 1.0096691711869443e-11
the O 0 4.6177311974204827e-11
missense O 0 3.5655162378134264e-07
mutation O 0 1.5356610560957051e-07
co O 0 1.537088252234753e-07
- O 0 1.3082473060421762e-07
segregated O 0 3.670748682793601e-08
with O 0 1.3861969350159598e-09
patients O 0 1.33702030780114e-07
with O 0 4.238404471834656e-08
tumors B-Disease 1 1.0
or O 0 2.837443389580585e-05
who O 0 5.989004421280697e-07
, O 0 2.621732553276246e-10
as O 0 5.136763236990305e-11
a O 0 5.266922453728284e-10
result O 0 9.714237192426367e-10
of O 0 2.7067036112438103e-11
linkage O 0 2.5094149691540224e-07
analysis O 0 6.65114043840731e-08
had O 0 5.06160176882986e-07
been O 0 1.2637564772433052e-08
predicted O 0 1.3034775747655658e-07
to O 0 2.24640805956966e-10
carry O 0 4.392253227791798e-09
the O 0 8.893634162454589e-10
predisposing O 0 6.036576110091119e-07
mutation O 0 5.479673745867331e-07
. O 0 3.216791100157934e-08

These O 0 6.602263624699845e-08
observations O 0 1.4566521144843136e-07
point O 0 9.956417557077657e-08
to O 0 1.0758137714006466e-09
another O 0 2.3705142293550807e-09
region O 0 4.5959819061636153e-08
of O 0 1.741819743994455e-10
the O 0 1.8085969388792478e-09
RB1 O 0 4.14102828472096e-07
gene O 0 8.839067255905775e-09
where O 0 2.373376772890623e-10
mutations O 0 6.8498313687825885e-09
only O 0 1.1037711022954255e-10
modify O 0 1.1955881618064268e-08
the O 0 8.710041021764425e-11
function O 0 5.752016640769853e-10
of O 0 1.6075550612892897e-11
the O 0 2.4109311769215935e-10
gene O 0 7.035074389705187e-08
and O 0 2.8168545274098733e-09
raise O 0 5.753322263046812e-10
important O 0 7.496661624806222e-11
questions O 0 1.7250438577587346e-10
for O 0 1.061969782945038e-11
genetic O 0 2.6162489952241685e-09
counseling O 0 3.9311104371719807e-10
in O 0 1.5964785049504826e-11
families O 0 6.469814961551634e-11
with O 0 1.7601479995743574e-10
these O 0 6.188693446596005e-10
distinctive O 0 2.839550745648012e-07
phenotypes O 0 7.949203677526384e-07
. O 0 5.737292863017274e-09
. O 0 1.5543877296408937e-08

Maternal B-Disease 0 0.008357287384569645
disomy I-Disease 1 0.9220980405807495
and O 0 0.3178078234195709
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
consistent O 0 5.274744694361289e-07
with O 0 2.6750535120356744e-10
gamete O 0 2.0568862169056956e-07
complementation O 0 1.4183783605403733e-06
in O 0 3.2456984322415394e-10
a O 0 5.525217505741864e-10
case O 0 1.4012428994902848e-09
of O 0 6.911757277627828e-11
familial O 0 2.017818303556851e-07
translocation O 0 1.8218256627733354e-06
( O 0 5.424670934672804e-09
3 O 0 7.615058805754416e-09
; O 0 2.0054811145087115e-09
15 O 0 4.221886396038599e-09
) O 0 2.3575719154678154e-10
( O 0 5.87555074038626e-11
p25 O 0 1.745165900679524e-09
; O 0 1.1813965083984357e-10
q11 O 0 3.1459665983391005e-09
. O 0 1.0460605298634462e-10
2 O 0 1.4993566388454838e-09
) O 0 1.3607603932541679e-09
. O 0 1.4570572304251073e-08

Maternal B-Disease 0 0.027316929772496223
uniparental I-Disease 1 0.5459195971488953
disomy I-Disease 1 0.9431200623512268
( I-Disease 0 0.00022375531261786819
UPD I-Disease 1 0.9999997615814209
) I-Disease 0 1.4775464762806223e-07
for I-Disease 0 1.9776982274066768e-09
chromosome I-Disease 0 2.96652451652335e-05
15 I-Disease 0 1.4897486266818305e-07
is O 0 7.720470374117383e-10
responsible O 0 6.955975795364111e-09
for O 0 1.7020806986067782e-10
an O 0 1.3553615174632938e-10
estimated O 0 7.889764397361887e-09
30 O 0 2.7448874284630165e-09
% O 0 9.706398879094635e-11
of O 0 2.2153497786225884e-11
cases O 0 6.177869771306632e-09
of O 0 4.7544855874548375e-07
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 9.812317330215592e-06
PWS B-Disease 1 0.9999994039535522
) O 0 2.786180175462505e-07
. O 0 1.1771536634341828e-07

We O 0 2.5387935238541104e-05
report O 0 1.1267412247661923e-07
on O 0 5.583995488223081e-10
an O 0 4.2344870665456114e-11
unusual O 0 1.441017444259174e-10
case O 0 1.1443899161633908e-09
of O 0 3.133399789634339e-11
maternal B-Disease 0 1.5000066966308623e-08
disomy I-Disease 0 1.2658291780098807e-05
15 I-Disease 0 8.761990955008514e-08
in O 0 9.227482777873774e-09
PWS B-Disease 1 1.0
that O 0 3.0186910748852824e-09
is O 0 1.2154018069754358e-10
most O 0 3.545382390446328e-11
consistent O 0 7.829496495581623e-10
with O 0 8.077622772051374e-12
adjacent O 0 2.973228552249907e-09
- O 0 2.8939325602550525e-07
1 O 0 9.05574015774846e-09
segregation O 0 3.038132245780645e-10
of O 0 1.8262069374080925e-12
a O 0 3.9656997130599336e-10
paternal O 0 1.0976084041658396e-08
t O 0 8.951622021413641e-07
( O 0 1.0568418362666421e-10
3 O 0 1.1408375355514977e-09
; O 0 6.26189489150164e-10
15 O 0 8.457666789141172e-10
) O 0 8.499190240485177e-11
( O 0 3.5629402206360794e-11
p25 O 0 1.5794131558166669e-09
; O 0 8.586690386502838e-11
q11 O 0 1.8745480723225683e-09
. O 0 4.205863782247299e-11
2 O 0 3.1467931038697827e-10
) O 0 4.0339072360229267e-11
with O 0 8.916151844617914e-11
simultaneous O 0 2.3100183454971557e-07
maternal O 0 2.3183585540209606e-07
meiotic O 0 2.0678505734395003e-06
nondisjunction O 0 1.659807276155334e-05
for O 0 8.739321266659772e-09
chromosome O 0 1.676506144576706e-05
15 O 0 3.4294467354811786e-07
. O 0 6.918532591271287e-08

The O 0 1.3293815470660775e-07
patient O 0 1.0575173519100645e-06
( O 0 3.616043686704984e-09
J O 0 7.203765562735498e-06
. O 0 8.168389853402402e-10
B O 0 2.1422113860580794e-08
. O 0 3.547831473049712e-11
) O 0 1.5229985675380142e-11
, O 0 7.114608381597609e-12
a O 0 1.0847556880522191e-10
17 O 0 2.1692443397114403e-09
- O 0 4.0928764377667903e-08
year O 0 4.572391532065012e-08
- O 0 1.0158834129470051e-07
old O 0 7.63141940751666e-08
white O 0 2.972627477504375e-09
male O 0 3.319344576979688e-09
with O 0 3.3740223948086623e-09
PWS B-Disease 1 0.9999992847442627
, O 0 2.0240109588343103e-09
was O 0 1.4471190912246357e-09
found O 0 3.2947175543363016e-10
to O 0 6.133825669607518e-10
have O 0 1.9930790351452288e-10
47 O 0 7.268692314710279e-10
chromosomes O 0 8.822639840921909e-10
with O 0 4.87029652718185e-11
a O 0 1.2846491648232927e-09
supernumerary O 0 6.944683264009655e-07
, O 0 1.534530191804606e-08
paternal O 0 3.3723003411978425e-07
der O 1 0.7770795822143555
( O 0 5.202020147976327e-09
15 O 0 1.023807261191223e-09
) O 0 3.462963249489803e-11
consisting O 0 1.320906838769842e-11
of O 0 1.698758668455813e-11
the O 0 3.2367548641332178e-09
short O 0 1.2181227475593914e-06
arm O 0 0.00017679501615930349
and O 0 1.522562342870515e-08
the O 0 8.586923949671643e-10
proximal O 0 4.6056093196966685e-06
long O 0 1.9887809799001843e-07
arm O 0 1.5424773209815612e-06
of O 0 7.15415574004119e-11
chromosome O 0 4.683726274379296e-06
15 O 0 4.224877159231255e-08
, O 0 1.1525496113051759e-09
and O 0 1.557087969672466e-08
distal O 0 0.0003151155833620578
chromosome O 0 0.39432820677757263
arm O 0 0.16381311416625977
3p O 0 0.0009711133898235857
. O 0 6.039346089892206e-07

The O 0 5.5280167998716934e-08
t O 0 1.2561405355882016e-06
( O 0 7.607868224290826e-10
3 O 0 6.809341979163719e-10
; O 0 6.729137802530261e-10
15 O 0 1.7449028888449902e-09
) O 0 1.410853794903133e-10
was O 0 5.999789554067547e-09
present O 0 8.200919804357554e-11
in O 0 7.029950406522989e-12
the O 0 6.386297740634816e-11
balanced O 0 9.14607323210248e-09
state O 0 4.737837344670481e-10
in O 0 1.2815305761026963e-10
the O 0 2.5022963701104572e-09
patients O 0 3.1881253192977965e-08
father O 0 1.8745553997945308e-09
and O 0 1.51697565620168e-09
a O 0 1.7201729818339118e-08
sister O 0 4.7423032810911536e-05
. O 0 1.0948843964797561e-07

Fluorescent O 0 1.4445270153373713e-06
in O 0 8.86772344443898e-09
situ O 0 7.72611983279603e-08
hybridization O 0 6.143804132108244e-09
analysis O 0 1.7512780114969928e-09
demonstrated O 0 1.0584199072738443e-09
that O 0 1.5284819243621683e-10
the O 0 2.8278901442746474e-09
PWS B-Disease 1 1.0
critical O 0 3.633176959283446e-08
region O 0 1.845001129652246e-08
resided O 0 1.4130042913507168e-08
on O 0 2.4681956478644906e-09
the O 0 4.538247555530006e-11
derivative O 0 3.927649760981922e-09
chromosome O 0 2.654305149007996e-07
3 O 0 1.9431459108432136e-08
and O 0 2.9653224320469462e-09
that O 0 6.119545425953277e-10
there O 0 1.7217238745814711e-10
was O 0 3.864287112520515e-09
no O 0 3.594374520243804e-10
deletion O 0 2.1284776607899403e-08
of O 0 1.1666577426350244e-10
the O 0 4.840982370524216e-08
PWS B-Disease 1 1.0
region O 0 2.0143720576015767e-06
on O 0 6.083126180556064e-08
the O 0 9.630775066327146e-10
normal O 0 2.3773662150006203e-08
pair O 0 1.4116788626949983e-08
of O 0 6.035606042731345e-11
15s O 0 1.3284781053002348e-09
present O 0 5.097287592015221e-10
in O 0 7.096658261041e-10
J O 0 0.000188251375220716
. O 0 1.0438914443966496e-07

B O 0 0.00021980998280923814
. O 0 2.0669674540840788e-06

Methylation O 0 8.425571650150232e-06
analysis O 0 1.6460616336644307e-07
at O 0 8.829579734026538e-09
exon O 0 5.6182305030461066e-08
alpha O 0 5.578930650784741e-09
of O 0 3.489697419922777e-11
the O 0 4.747522860948372e-11
small O 0 5.178001916128494e-10
nuclear O 0 2.8609314028926747e-08
ribonucleoprotein O 0 2.8200654256238522e-08
- O 0 7.449406780324352e-08
associated O 0 1.059757792631899e-08
polypeptide O 0 5.7095679295571244e-08
N O 0 1.5165242075454444e-06
( O 0 2.3190920017679417e-10
SNRPN O 0 1.1982756120687554e-07
) O 0 7.149313085985654e-11
gene O 0 2.4020554434400765e-09
showed O 0 1.90424964685576e-09
a O 0 7.373570504176641e-11
pattern O 0 8.927258932089899e-08
characteristic O 0 6.585044509677118e-09
of O 0 2.553838043817258e-11
only O 0 2.2711804659181212e-10
the O 0 2.1676882511201256e-10
maternal O 0 1.1806655209056771e-08
chromosome O 0 7.300165634660516e-06
15 O 0 4.782430096383905e-08
in O 0 1.876429678304703e-09
J O 0 0.00027543242322281003
. O 0 5.7060081104509663e-08

B O 0 0.00016924783994909376
. O 0 7.54509983380558e-07

Maternal B-Disease 0 0.0034778621047735214
disomy I-Disease 0 0.003533425508067012
was O 0 1.178415573122038e-06
confirmed O 0 5.24888648101296e-08
by O 0 4.5330569159451883e-11
polymerase O 0 2.5917842094713706e-08
chain O 0 2.16748844650283e-07
reaction O 0 3.1855404980518642e-09
analysis O 0 4.983988222129199e-10
of O 0 3.782514926276015e-11
microsatellite O 0 4.9798881462947975e-08
repeats O 0 7.554402259302151e-07
at O 0 5.568668859368131e-10
the O 0 6.9328952301273e-11
gamma O 0 2.2427029122695785e-08
- O 0 5.959577151770645e-07
aminobutyric O 0 7.372722166110179e-07
acid O 0 1.3058635062179746e-08
receptor O 0 4.003761766568914e-10
beta3 O 0 1.097447288600506e-08
subunit O 0 2.6689135346202875e-09
( O 0 8.8066343106874e-10
GABRB3 O 0 4.373963804482628e-07
) O 0 1.2390218850910628e-09
locus O 0 2.987698337619804e-07
. O 0 9.716283955185645e-08

A O 0 2.2385502234101295e-06
niece O 0 8.223183976951987e-05
( O 0 5.975568484473115e-08
B O 0 4.879955781689205e-07
. O 0 1.7294286835944916e-10
B O 0 6.538748653639459e-09
. O 0 2.1100341959789937e-11
) O 0 1.2074573112197395e-11
with O 0 2.1814572717659964e-11
45 O 0 1.3690852618264415e-10
chromosomes O 0 1.4158173522460515e-09
and O 0 2.0038549986001186e-10
the O 0 1.6902939117824367e-11
derivative O 0 6.25288376632227e-10
3 O 0 4.994998858975919e-10
but O 0 4.186776758619004e-10
without O 0 4.1232584013783935e-10
the O 0 8.297624809472381e-10
der O 0 0.0018301766831427813
( O 0 3.680911409009724e-10
15 O 0 3.5316968793885906e-10
) O 0 4.410700971124726e-11
demonstrated O 0 2.3900395551557096e-10
a O 0 9.258894206887192e-10
phenotype O 0 3.983633689585986e-07
consistent O 0 1.7749293590441084e-08
with O 0 1.329612947520431e-10
that O 0 2.0951980150840654e-09
reported O 0 9.036106689563894e-07
for O 0 1.3680123700510194e-10
haploinsufficiency O 0 2.404436543201882e-07
of O 0 1.7773127414244527e-10
distal O 0 6.94533264322672e-06
3 O 0 9.197260624205228e-07
p O 0 0.00036973319947719574
. O 0 1.758928931394621e-07

Uniparental B-Disease 1 0.9999929666519165
disomy I-Disease 1 0.9999980926513672
associated O 0 4.524585892795585e-05
with O 0 2.6597474445111402e-08
unbalanced O 0 0.0001043439915520139
segregation O 0 1.4987604401994759e-07
of O 0 4.572631162602647e-10
non O 0 8.167571508010951e-08
- O 0 3.7436052480188664e-06
Robertsonian O 0 4.985686973668635e-05
translocations O 0 0.00013507672701962292
has O 0 8.717299948557411e-08
been O 0 2.0404700151743782e-08
reported O 0 2.4363318971154513e-06
previously O 0 1.4232860223728494e-07
but O 0 5.9443165945083365e-09
has O 0 1.7425216825017742e-09
not O 0 8.206086921092037e-10
, O 0 1.3063355952525058e-10
to O 0 6.827679532861453e-10
our O 0 1.5620190696452596e-09
knowledge O 0 2.4024299216662826e-10
, O 0 1.4822101879197191e-10
been O 0 1.8699690407242286e-10
observed O 0 5.471021413683275e-10
in O 0 5.700582020318201e-11
a O 0 1.1250629317061112e-09
case O 0 6.20601392498088e-09
of O 0 7.287575876091523e-09
PWS B-Disease 1 0.9999995231628418
. O 0 1.8737773643806577e-07

Furthermore O 0 5.007485015084967e-06
, O 0 3.2944257100098184e-08
our O 0 1.6255734536230193e-08
findings O 0 1.4931673675278034e-08
are O 0 1.3140272203671088e-10
best O 0 1.222069112571944e-09
interpreted O 0 2.3049155917220787e-09
as O 0 2.7313021289110395e-10
true O 0 4.027722155797164e-09
gamete O 0 3.1381716780742863e-07
complementation O 0 2.058375002889079e-06
resulting O 0 6.781585426551828e-08
in O 0 1.2404909099927863e-08
maternal B-Disease 0 3.987999298260547e-05
UPD I-Disease 1 1.0
15 I-Disease 0 0.00015368017193395644
and O 0 1.2273872926016338e-05
PWS B-Disease 1 0.9999974966049194

Schwartz B-Disease 1 0.9980030655860901
- I-Disease 1 0.999363124370575
Jampel I-Disease 1 0.9988909363746643
syndrome I-Disease 1 0.9999794960021973
type I-Disease 0 9.343667528582955e-08
2 I-Disease 0 2.299094781221811e-08
and O 0 1.6736050767462984e-08
Stuve B-Disease 1 0.9344633221626282
- I-Disease 1 0.9999959468841553
Wiedemann I-Disease 1 0.9999992847442627
syndrome I-Disease 1 0.9999959468841553
: O 0 3.6627023636270906e-10
a O 0 3.740232290549983e-10
case O 0 1.3705699908328484e-09
for O 0 2.681981026153579e-10
" O 0 3.947448945496035e-08
lumping O 0 1.7562337006893358e-07
" O 0 1.6077115105872508e-07
. O 0 1.9630197911624236e-08

Recent O 0 3.388419429484202e-07
studies O 0 2.1589098508911775e-08
demonstrated O 0 3.4756917344225258e-09
the O 0 1.321814879773342e-10
existence O 0 5.606898278998074e-10
of O 0 6.423063903665538e-12
a O 0 4.1336528644464465e-10
genetically O 0 3.088263511585865e-08
distinct O 0 3.385748792439358e-09
, O 0 1.4836300243903366e-10
usually O 0 1.744812211379454e-10
lethal O 0 1.2581807817824142e-09
form O 0 1.3556046563056867e-10
of O 0 1.6168970676244676e-11
the O 0 8.694945208276295e-09
Schwartz B-Disease 1 0.9984837174415588
- I-Disease 1 0.9998735189437866
Jampel I-Disease 1 0.9999957084655762
syndrome I-Disease 1 0.9999994039535522
( O 0 4.36204956599795e-08
SJS B-Disease 0 0.15514403581619263
) O 0 1.7110948213883148e-09
of O 0 9.44064493246799e-10
myotonia B-Disease 1 0.879035234451294
and O 0 3.563133077477687e-07
skeletal B-Disease 0 0.00018446784815751016
dysplasia I-Disease 1 0.5388620495796204
, O 0 3.5995972869073967e-09
which O 0 2.0870296602026883e-09
we O 0 1.2143186012281149e-08
called O 0 3.3724671055779254e-08
SJS B-Disease 0 0.004298695828765631
type I-Disease 0 2.2315786551985184e-08
2 I-Disease 0 1.739888766394415e-08
. O 0 3.3346648109500165e-08

This O 0 6.951667614885082e-07
disorder O 0 0.00020458063227124512
is O 0 8.975569176783438e-10
reminiscent O 0 8.478247437437858e-09
of O 0 7.20173157220394e-11
another O 0 2.6057112023636364e-09
rare O 0 5.00685759519115e-09
condition O 0 3.700040451803943e-07
, O 0 1.1295132190669577e-10
the O 0 2.830091716532479e-09
Stuve B-Disease 1 0.9704681038856506
- I-Disease 1 0.999998927116394
Wiedemann I-Disease 1 0.9999997615814209
syndrome I-Disease 1 0.9999997615814209
( O 0 1.3684685029602406e-07
SWS B-Disease 0 0.03214208036661148
) O 0 1.5424141963649163e-09
, O 0 9.21574136447667e-11
which O 0 1.641567992649584e-10
comprises O 0 4.883172199932062e-10
campomelia B-Disease 0 1.6474075437145075e-07
at O 0 4.310981349675558e-09
birth O 0 1.5049788970600275e-08
with O 0 4.97937246990432e-09
skeletal B-Disease 0 0.00018384137365501374
dysplasia I-Disease 1 0.6193361878395081
, O 0 1.3810883991993705e-08
contractures B-Disease 0 4.667523899115622e-05
, O 0 4.831303357377692e-09
and O 0 1.8763044451475253e-09
early B-Disease 0 4.670735975764728e-08
death I-Disease 0 3.0149470831020153e-07
. O 0 3.756357713768921e-08

To O 0 5.952215360593982e-07
test O 0 1.0642545511529988e-08
for O 0 2.397344545101987e-10
possible O 0 2.9035340798344578e-09
nosologic O 0 2.929073161794804e-07
identity O 0 5.632876565186962e-08
between O 0 1.7304986332788985e-09
these O 0 9.386748267559142e-09
disorders O 0 1.950771729752887e-05
, O 0 2.5484299115419162e-09
we O 0 1.0915144343925931e-08
reviewed O 0 5.0647948057758185e-09
the O 0 1.1648411402109815e-10
literature O 0 3.5015740307287047e-10
and O 0 4.487610838488365e-10
obtained O 0 7.285042569193934e-10
a O 0 3.6017175353286746e-10
follow O 0 2.3506359081437722e-09
- O 0 1.1066581429020061e-08
up O 0 6.007635988680704e-08
of O 0 1.627720874752825e-11
the O 0 2.696754208830754e-10
only O 0 4.2144018830292396e-10
two O 0 8.923913830116703e-10
surviving O 0 2.985994385085178e-08
patients O 0 1.0741735279040654e-09
, O 0 8.592698601261883e-12
one O 0 7.321619005518087e-11
with O 0 1.0592257071451172e-09
SJS B-Disease 0 0.0002666545333340764
type I-Disease 0 4.682356280483191e-09
2 I-Disease 0 3.0906073256176114e-09
at O 0 2.2588961812175512e-08
age O 0 1.5123965413366136e-09
10 O 0 5.862501040176937e-10
years O 0 2.0607358874880077e-10
and O 0 1.258276122184654e-10
another O 0 9.5380559006486e-10
with O 0 7.31785654295436e-09
SWS B-Disease 0 0.00041564408456906676
at O 0 3.131641790332651e-08
age O 0 3.565431949681397e-09
7 O 0 8.49524450785566e-09
years O 0 5.762879951021205e-09
. O 0 8.253212335773696e-09

Patients O 0 0.04515368491411209
reported O 0 1.425920709152706e-05
as O 0 4.656847796269403e-09
having O 0 6.717078093743112e-08
either O 0 1.964158627743018e-06
neonatal O 1 0.9972461462020874
SJS B-Disease 1 0.9999940395355225
or O 0 7.933774031698704e-05
SWS B-Disease 0 0.0022240153048187494
presented O 0 2.403297560960027e-09
a O 0 2.2555186884876122e-10
combination O 0 1.3751392247129957e-09
of O 0 5.947282250007291e-11
a O 0 2.9772818876949714e-08
severe O 0 4.470666681299917e-06
, O 0 3.566139383792688e-09
prenatal O 0 0.0020500540267676115
- O 1 0.9984930753707886
onset O 1 0.9231092929840088
neuromuscular B-Disease 1 0.9998927116394043
disorder I-Disease 1 0.997456967830658
( O 0 6.07797412399691e-09
with O 0 8.772593673711526e-08
congenital B-Disease 1 0.9999998807907104
joint I-Disease 0 0.006571159232407808
contractures I-Disease 1 0.999988317489624
, O 0 3.4921113183372654e-06
respiratory O 1 0.9990144968032837
and O 0 4.9391744028071116e-08
feeding O 0 5.343931661627721e-06
difficulties O 0 1.0782321169244824e-06
, O 0 2.624155337471734e-09
tendency O 0 6.938818586377238e-08
to O 0 4.504775574787345e-08
hyperthermia B-Disease 0 0.000134750094730407
, O 0 1.2689810091615072e-08
and O 0 8.265469197965558e-09
frequent O 0 2.27720420298283e-07
death O 0 1.927535322465701e-06
in O 0 6.627345783272176e-08
infancy O 0 1.3477924767357763e-06
) O 0 6.954801318181936e-11
with O 0 3.801602435626883e-11
a O 0 4.50177539690344e-09
distinct O 0 5.091249022370903e-07
campomelic B-Disease 0 0.0028057440649718046
- I-Disease 0 0.04672480747103691
metaphyseal I-Disease 0 0.12439005076885223
skeletal I-Disease 0 0.0729733407497406
dysplasia I-Disease 1 0.7738184332847595
. O 0 4.059577918269497e-07

The O 0 1.8732444928559744e-08
similarity O 0 1.514363034971211e-08
of O 0 1.1732004256970185e-10
the O 0 2.414585198451391e-10
clinical O 0 7.565084558791568e-09
and O 0 2.0475217077375873e-09
radiographic O 0 9.46648924582405e-07
findings O 0 8.367466364234133e-08
is O 0 4.1313194532044406e-10
so O 0 2.873150328763785e-10
extensive O 0 2.315636571381674e-09
that O 0 1.022824047680615e-08
these O 0 6.7508292289630845e-09
disorders O 0 5.434803824755363e-06
appear O 0 7.82874209903639e-08
to O 0 4.585323676309372e-09
be O 0 8.217990732362068e-10
a O 0 7.879804586607975e-10
single O 0 1.3823539291024645e-07
entity O 0 3.5131592994730454e-06
. O 0 2.5233362066501286e-07

The O 0 1.858655984676716e-08
follow O 0 5.515020617963273e-08
- O 0 3.456775914401078e-07
up O 0 5.660469355461828e-07
observation O 0 1.0648312454009101e-08
of O 0 6.7789337511448e-12
an O 0 5.1157515723598834e-11
identical O 0 2.314617830734278e-08
and O 0 3.413356264303502e-10
unique O 0 1.3140580845671934e-09
pattern O 0 2.80617405223893e-06
of O 0 1.3224761286068087e-09
progressive O 0 5.162646630196832e-06
bone B-Disease 0 0.025057004764676094
dysplasia I-Disease 0 0.09417175501585007
in O 0 1.3219038086376145e-09
the O 0 1.0806261441231868e-09
two O 0 1.219962513232531e-07
patients O 0 1.553338613291544e-08
( O 0 1.544921135465671e-11
one O 0 5.268168123961914e-10
with O 0 6.4689458234568065e-09
SJS B-Disease 0 0.10675205290317535
type I-Disease 0 2.2675296307284043e-08
2 I-Disease 0 4.968917721726029e-09
, O 0 1.4520397384476524e-10
one O 0 8.711574239761433e-10
with O 0 8.139156904007905e-09
SWS B-Disease 0 0.0005102110444568098
) O 0 5.100253552825507e-10
surviving O 0 8.83454909228476e-09
beyond O 0 4.935548858497896e-08
infancy O 0 1.2126969295422896e-06
adds O 0 8.957619002103456e-08
to O 0 8.683123664532388e-10
the O 0 4.2682031520246966e-11
evidence O 0 3.756346900196661e-10
in O 0 3.337535803282776e-11
favor O 0 3.296546924325128e-10
of O 0 5.94424301447738e-11
identity O 0 8.575668744015275e-07
. O 0 4.9513513289412003e-08

The O 0 8.549312013883537e-08
hypothesis O 0 2.2126762644347764e-07
that O 0 9.003555234698979e-09
SWS B-Disease 0 0.002706186380237341
and O 0 2.3730169829150327e-08
SJS B-Disease 0 0.0005000850651413202
type I-Disease 0 9.383634314019673e-09
2 I-Disease 0 1.7315453515465151e-09
are O 0 4.708924916663193e-11
the O 0 3.593433536841495e-11
same O 0 7.568955595615989e-08
disorder O 0 5.856521966052242e-06
should O 0 6.259888718496143e-10
be O 0 3.3663821730200993e-11
testable O 0 6.460286194887033e-10
by O 0 9.117669293179365e-12
molecular O 0 4.6218134874820294e-10
methods O 0 1.002073268807635e-08
. O 0 3.159563055632475e-09
. O 0 2.3682874328301295e-08

A O 0 2.644184178279829e-07
mouse O 0 1.8211255792266456e-06
model O 0 4.805930871043529e-07
of O 0 7.079656683117719e-08
severe O 1 0.9970483183860779
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
: O 0 0.0005867623258382082
defects O 1 0.9998623132705688
in O 0 1.3314090097082953e-07
hemostasis O 0 0.1929125040769577
and O 0 1.8127882867702283e-05
thrombosis B-Disease 0 0.02559329755604267
. O 0 2.779805186037265e-07

von B-Disease 1 0.9826734066009521
Willebrand I-Disease 1 0.7035234570503235
factor I-Disease 0 2.270104050694499e-05
( I-Disease 0 1.4634222225140547e-06
vWf I-Disease 0 0.002605777932330966
) I-Disease 0 0.0003438938583713025
deficiency I-Disease 1 0.9999638795852661
causes O 0 0.028774654492735863
severe O 1 0.9999936819076538
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
in O 0 4.82329085116362e-07
humans O 0 1.799769961507991e-06
. O 0 2.279837758578651e-07

We O 0 1.3472445914430864e-07
generated O 0 1.6563540539138444e-09
a O 0 4.044510282241731e-10
mouse O 0 1.904875190916755e-08
model O 0 2.6828317345461983e-09
for O 0 8.388419819871373e-11
this O 0 1.2000968274694657e-10
disease O 0 5.975213213105235e-09
by O 0 4.406561920911045e-12
using O 0 3.0794506944431532e-09
gene O 0 1.8150988978504756e-07
targeting O 0 7.150052283577679e-07
. O 0 7.798666956659872e-08

vWf B-Disease 0 0.014493742026388645
- I-Disease 1 0.7741949558258057
deficient I-Disease 1 0.781334638595581
mice O 0 0.0003618452465161681
appeared O 0 7.471148819604423e-07
normal O 0 1.57136184952833e-07
at O 0 3.591301123151425e-08
birth O 0 9.05201389400645e-08
; O 0 8.627642600345098e-09
they O 0 1.8252949374186755e-08
were O 0 3.5350413707391226e-09
viable O 0 3.927853953200611e-08
and O 0 4.104522943748634e-09
fertile O 0 1.404776526214846e-07
. O 0 1.7323249323908385e-07

Neither O 0 3.130694312858395e-05
vWf O 0 0.0003591275308281183
nor O 0 2.2372214516508393e-05
vWf O 0 0.00014365068636834621
propolypeptide O 0 0.000644295068923384
( O 0 5.140799999026058e-07
von B-Disease 0 0.205597385764122
Willebrand I-Disease 0 0.40963971614837646
antigen O 0 2.9862885639886372e-05
II O 0 7.424621799145825e-06
) O 0 1.0264766814316317e-08
were O 0 3.3902141094444005e-09
detectable O 0 1.517630465741604e-08
in O 0 7.640569427147526e-11
plasma O 0 4.3771851920837435e-08
, O 0 1.8317634076225886e-09
platelets O 0 1.7977716026962298e-07
, O 0 1.105254776589959e-09
or O 0 1.107245051201744e-08
endothelial O 0 5.391685320432771e-08
cells O 0 2.375018581801669e-08
of O 0 7.872559548705027e-11
the O 0 1.69022795759588e-09
homozygous O 0 1.0117643114426755e-06
mutant O 0 1.1055441291318857e-06
mice O 0 2.0294593923608772e-05
. O 0 9.774315401500644e-08

The O 0 3.5822981914179763e-08
mutant O 0 1.2629067214220413e-06
mice O 0 7.669302431168035e-05
exhibited O 0 1.1818813618447166e-05
defects O 0 0.4353601038455963
in O 0 2.241081098475206e-09
hemostasis O 0 5.319991487340303e-06
with O 0 8.533712625435896e-10
a O 0 1.129156768087114e-08
highly O 0 1.5250363105678844e-07
prolonged O 0 7.659704351681285e-06
bleeding O 0 0.00892761629074812
time O 0 3.047863117444649e-08
and O 0 1.2927044323873815e-08
spontaneous O 0 7.649796174291623e-08
bleeding O 0 8.82863241713494e-05
events O 0 7.536967161492214e-10
in O 0 6.969743671092488e-10
approximately O 0 2.647138952482919e-09
10 O 0 2.2857227222061738e-09
% O 0 9.690993563182815e-10
of O 0 5.561694993438948e-10
neonates O 0 1.537375510451966e-06
. O 0 7.996652584552066e-08

As O 0 3.23462110429773e-08
in O 0 7.662566692268058e-10
the O 0 5.185870066704013e-10
human O 0 2.8529087980899703e-09
disease O 0 1.2533381550383638e-06
, O 0 1.2446846331393147e-10
the O 0 1.2386927594754127e-10
factor O 0 1.3479656280068752e-09
VIII O 0 1.6287999642372597e-06
level O 0 1.680155392591587e-08
in O 0 4.2801243105294873e-10
these O 0 3.7368022565154035e-10
mice O 0 1.2324200326929713e-07
was O 0 4.187315738590769e-08
reduced O 0 4.5954275940118805e-09
strongly O 0 9.602675321573884e-10
as O 0 3.796413877710236e-11
a O 0 3.1315611215276817e-10
result O 0 3.691908168068636e-10
of O 0 6.0354299682985335e-12
the O 0 2.0258754396262901e-10
lack O 0 1.8834854509375276e-10
of O 0 1.5604214101405667e-11
protection O 0 2.991246972339212e-10
provided O 0 2.0123079591538584e-10
by O 0 7.17283732409868e-10
vWf O 0 1.9279289062978933e-06
. O 0 1.3805201604100148e-07

Defective O 1 0.5573570728302002
thrombosis B-Disease 0 0.1546308547258377
in O 0 8.235713977455816e-08
mutant O 0 1.6824856174935121e-06
mice O 0 0.0001733076642267406
was O 0 2.9950498969810724e-07
also O 0 2.9783426835905402e-09
evident O 0 4.961073774012448e-10
in O 0 2.3059422427085252e-11
an O 0 5.062163188629398e-11
in O 0 3.2879940436991717e-10
vivo O 0 1.556297434035514e-06
model O 0 7.118962752628022e-09
of O 0 2.1115702519836077e-09
vascular B-Disease 0 0.0030611108522862196
injury I-Disease 0 0.0001436749444110319
. O 0 6.489908344065043e-08

In O 0 2.950351074559876e-08
this O 0 5.602483477140652e-10
model O 0 2.8503521765088635e-09
, O 0 3.0622057667351044e-10
the O 0 2.719637015591303e-10
exteriorized O 0 4.6926987806727993e-07
mesentery O 0 9.304175137003767e-07
was O 0 5.050190488020689e-09
superfused O 0 3.5560681510560244e-08
with O 0 1.3797336884113776e-10
ferric O 0 3.1919281440195846e-08
chloride O 0 8.049827471268145e-09
and O 0 2.1517546078264616e-10
the O 0 1.382433750807266e-10
accumulation O 0 1.0156932184202105e-08
of O 0 1.633730928318755e-10
fluorescently O 0 1.3523102779799956e-06
labeled O 0 5.392877255872008e-07
platelets O 0 1.0632766134222038e-06
was O 0 1.2018917416867225e-08
observed O 0 1.6970246319303328e-09
by O 0 2.37363045885175e-10
intravital O 0 9.825583902056678e-07
microscopy O 0 1.0610060741100824e-07
. O 0 3.392596070739273e-08

We O 0 1.2979062375961803e-05
conclude O 0 3.832111872270616e-07
that O 0 2.3959001449469497e-10
these O 0 4.0252225164127964e-11
mice O 0 2.457439762793001e-08
very O 0 7.630975851213861e-10
closely O 0 8.392064643203412e-08
mimic O 0 0.00010919408668996766
severe O 0 0.00027878585387952626
human O 0 1.0370154996053316e-05
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
and O 0 2.129381573467981e-05
will O 0 1.0020849003922194e-06
be O 0 6.359635040809053e-09
very O 0 3.380487834103718e-10
useful O 0 2.0734627903529201e-10
for O 0 4.369354184019514e-11
investigating O 0 7.662815937337086e-10
the O 0 1.3819302646655984e-10
role O 0 6.823409615108744e-10
of O 0 5.257916324552525e-11
vWf O 0 8.768963510874528e-08
in O 0 3.1083424723021835e-09
normal O 0 7.082518891365908e-07
physiology O 0 1.1263244203973954e-07
and O 0 9.189895067152065e-09
in O 0 7.361685705475907e-10
disease O 0 2.70501033128312e-07
models O 0 1.0776133763101825e-08
. O 0 2.8731790280289715e-09
. O 0 2.8452046052507285e-08

Oral O 0 0.00023731218243483454
contraceptives O 0 0.004560869187116623
and O 0 2.574598667592909e-08
the O 0 5.6116942204198494e-09
risk O 0 1.951123522303533e-06
of O 0 4.2242203335263184e-07
hereditary B-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 7.638087708983221e-07

Hereditary B-Disease 1 0.9999995231628418
Ovarian I-Disease 1 0.999998927116394
Cancer I-Disease 1 0.9816266298294067
Clinical O 0 3.9290203858399764e-05
Study O 0 2.0692500868335628e-07
Group O 0 3.362561528774677e-06
. O 0 1.6653933698762557e-07

BACKGROUND O 0 2.2583921236218885e-05
Women O 0 1.2276305483283068e-07
with O 0 5.801344404865461e-10
mutations O 0 3.825699224080381e-08
in O 0 1.2452308628674302e-10
either O 0 6.194857959940236e-10
the O 0 4.788375806974443e-10
BRCA1 O 0 1.7253274791073636e-06
or O 0 3.628924361009922e-08
the O 0 8.080003888188969e-10
BRCA2 O 0 1.6866642909008078e-06
gene O 0 2.234530249722866e-08
have O 0 1.6281626047387476e-10
a O 0 1.4251556879063543e-10
high O 0 1.793400983274296e-08
lifetime O 0 2.6558322474556917e-07
risk O 0 2.0321474949014373e-05
of O 0 5.973807674308773e-06
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
. O 0 2.017194873360495e-07

Oral O 0 0.00015640385390724987
contraceptives O 0 0.005442112684249878
protect O 0 7.730974175501615e-05
against O 0 0.000785681651905179
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 1.1913177111466666e-08
general O 0 1.3654662955886465e-09
, O 0 1.6104537703398591e-09
but O 0 1.4530849856697614e-09
it O 0 2.0078538831569404e-09
is O 0 1.319623299522732e-10
not O 0 1.4920072122226458e-10
known O 0 5.7960327509709586e-11
whether O 0 7.313081251680842e-10
they O 0 3.6894249877406082e-09
also O 0 3.037461393518015e-09
protect O 0 1.99431982039755e-09
against O 0 1.1575372882433044e-09
hereditary B-Disease 0 1.3643961210618727e-05
forms I-Disease 0 5.943395080976188e-06
of I-Disease 0 6.393490184564143e-05
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999997615814209
. O 0 6.953192865921665e-08

METHODS O 0 1.0837794661711087e-06
We O 0 2.5926050639668574e-08
enrolled O 0 7.671828505806388e-09
207 O 0 3.793705261045943e-08
women O 0 3.5556002586645263e-08
with O 0 1.1415321523600142e-06
hereditary B-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 1.101078694887292e-08
161 O 0 6.119404982740662e-10
of O 0 4.466559413995874e-11
their O 0 9.072150675137891e-08
sisters O 0 2.1551923055085354e-06
as O 0 3.2612326172909434e-09
controls O 0 4.504634034674382e-07
in O 0 1.7019377573923578e-10
a O 0 8.169936727142613e-09
case O 0 7.374706001428422e-08
- O 0 1.2826494639739394e-05
control O 0 1.5803616406628862e-05
study O 0 3.60409195820921e-08
. O 0 4.250499330282764e-08

All O 0 4.232506967127847e-08
the O 0 1.3834393630673958e-09
patients O 0 3.882061339055554e-09
carried O 0 3.1673752509675523e-10
a O 0 1.2611714450549982e-10
pathogenic O 0 4.180435109191194e-09
mutation O 0 1.240592695239684e-08
in O 0 2.525492592830858e-10
either O 0 5.332884356334944e-09
BRCA1 O 0 9.453750067223154e-07
( O 0 3.7790286455674504e-09
179 O 0 5.549808168581194e-09
women O 0 4.788433205504816e-09
) O 0 1.3041950852610285e-09
or O 0 8.454858289042022e-07
BRCA2 O 0 0.0005884917918592691
( O 0 2.3046220931632888e-08
28 O 0 1.31194056507411e-07
women O 0 4.991182578351072e-09
) O 0 1.3330569981206963e-09
. O 0 8.49385095591515e-09

The O 0 1.9268134110461688e-07
control O 0 1.0508558716537664e-06
women O 0 5.227764887649755e-08
were O 0 1.8957984071477085e-09
enrolled O 0 2.4048243396634916e-09
regardless O 0 1.919316483522948e-09
of O 0 3.225325909128607e-11
whether O 0 4.1128296324188796e-09
or O 0 1.7723728262808436e-07
not O 0 4.4347157057700315e-08
they O 0 9.46713818450462e-09
had O 0 1.839554641946961e-08
either O 0 8.816050112159246e-09
mutation O 0 1.4157996020003338e-07
. O 0 2.0666421463033657e-08

Lifetime O 0 5.244025942374719e-06
histories O 0 1.1826667787318002e-06
of O 0 2.329826775948618e-09
oral O 0 1.2467488375023095e-07
- O 0 8.148811616592866e-07
contraceptive O 0 8.282577255158685e-07
use O 0 2.04587036201076e-09
were O 0 3.481057109233632e-10
obtained O 0 2.9469565676620846e-10
by O 0 6.313472661334529e-11
interview O 0 3.3511858532619954e-07
or O 0 1.7923467154901118e-09
by O 0 8.017517899583382e-11
written O 0 1.7870115387452756e-09
questionnaire O 0 3.0378901616501253e-09
and O 0 3.4577246621481095e-10
were O 0 5.048569895471644e-10
compared O 0 1.2439210772541287e-09
between O 0 1.3155343481230375e-10
patients O 0 8.734671652632642e-09
and O 0 1.1674196054300978e-09
control O 0 5.023591143071826e-07
women O 0 1.2300488627658979e-08
, O 0 3.421987138096938e-10
after O 0 2.245132746381273e-09
adjustment O 0 8.83891015934779e-10
for O 0 9.670745974854622e-12
year O 0 2.808527022057916e-10
of O 0 1.7149124134641092e-11
birth O 0 6.171183031256078e-08
and O 0 1.0224475488485041e-08
parity O 0 3.112022284312843e-08
. O 0 2.0056120320077753e-08

RESULTS O 0 6.0625956393778324e-05
The O 0 3.6461009766952657e-09
adjusted O 0 0.00011829457071144134
odds O 0 1.0357582141296007e-05
ratio O 0 1.0858208952413406e-05
for O 0 0.0011158845154568553
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
associated O 0 2.056109060788458e-08
with O 0 2.169326246415082e-10
any O 0 9.45931777351916e-10
past O 0 4.414055343460177e-09
use O 0 2.37555197735162e-09
of O 0 2.2293174251064585e-10
oral O 0 9.7596725368021e-08
contraceptives O 0 1.1145678399770986e-05
was O 0 1.2464320242600024e-08
0 O 0 6.524197626589512e-09
. O 0 1.2620847478217456e-08

5 O 0 4.6836586875542707e-07
( O 0 1.9243540094748823e-08
95 O 0 1.4259026670515595e-07
percent O 0 2.086898712150287e-05
confidence O 0 3.445272866997584e-08
interval O 0 2.526717501893927e-09
, O 0 5.5942910026640646e-11
0 O 0 4.1653562543597644e-11
. O 0 8.80434093686322e-12
3 O 0 1.1247148351545277e-10
to O 0 3.468345888268942e-10
0 O 0 2.7905322497190355e-10
. O 0 7.61383109337821e-11
8 O 0 2.3850041941386735e-09
) O 0 6.493902082738146e-10
. O 0 8.264223083642719e-09

The O 0 2.4158967448784097e-07
risk O 0 2.8723588911816478e-06
decreased O 0 3.819750133970956e-07
with O 0 2.464214943209697e-10
increasing O 0 6.278351172284147e-10
duration O 0 3.1487279450459482e-09
of O 0 3.218197583421123e-11
use O 0 9.746237594754348e-09
( O 0 3.3654998787824297e-09
P O 0 3.09352544718422e-05
for O 0 6.182392930931258e-10
trend O 0 8.077329738398475e-08
, O 0 1.881230726752392e-10
< O 0 3.028169937024927e-10
0 O 0 1.4350352850467374e-10
. O 0 3.352746552609531e-11
001 O 0 1.3892295647188746e-10
) O 0 7.807224484956965e-12
; O 0 6.592235004404534e-12
use O 0 2.641191432228851e-10
for O 0 5.073203523942027e-10
six O 0 1.08732951531465e-08
or O 0 1.9736292600214256e-08
more O 0 1.0937499794749783e-09
years O 0 4.5041440022153267e-10
was O 0 9.658257527078717e-10
associated O 0 6.218080911279955e-11
with O 0 7.198637519412188e-12
a O 0 4.860221114455499e-10
60 O 0 1.5768727434917196e-09
percent O 0 1.1792385521403048e-06
reduction O 0 3.2723299625558866e-09
in O 0 1.8494324960371955e-09
risk O 0 9.869030748177465e-08
. O 0 3.311403773409438e-08

Oral O 0 1.6178291843971238e-05
- O 0 4.56881844002055e-06
contraceptive O 0 1.0269583981425967e-05
use O 0 4.488291693860447e-08
protected O 0 7.418626410071738e-06
against O 0 0.00015413099026773125
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
both O 0 1.9463970712951806e-10
for O 0 2.1471659519822772e-11
carriers O 0 2.0327846350642886e-10
of O 0 2.077103419817483e-11
the O 0 1.0544685125069009e-09
BRCA1 O 0 3.0143339699861826e-06
mutation O 0 1.704233625332563e-07
( O 0 7.567823034904109e-10
odds O 0 2.886550376501873e-08
ratio O 0 2.312216196287409e-09
, O 0 1.2019066297774827e-10
0 O 0 1.257400572551859e-10
. O 0 2.3901431181472255e-11
5 O 0 1.3254047859234674e-10
; O 0 7.115711492255983e-11
95 O 0 3.4161589113068658e-09
percent O 0 6.414251856767805e-06
confidence O 0 6.211627212593385e-09
interval O 0 2.325181991391645e-10
, O 0 8.812908736111069e-12
0 O 0 8.743726229165638e-12
. O 0 3.9723502265331945e-12
3 O 0 7.490487397010526e-11
to O 0 1.8628065756587375e-10
0 O 0 1.5471808556544175e-10
. O 0 8.138759804987572e-11
9 O 0 2.4065818227114733e-09
) O 0 3.40761065198425e-11
and O 0 2.7050365419833966e-11
for O 0 1.8492013476034685e-11
carriers O 0 1.8271460733298994e-10
of O 0 7.968834793425916e-12
the O 0 2.029926227109513e-09
BRCA2 O 0 2.344424501643516e-05
mutation O 0 8.702382103820128e-08
( O 0 1.7929886741985257e-10
odds O 0 1.6661998003542067e-08
ratio O 0 2.509221497248859e-09
, O 0 1.3866775783188956e-10
0 O 0 9.666564770860475e-11
. O 0 2.194331175098263e-11
4 O 0 1.3507858720451793e-10
; O 0 8.75077163509097e-11
95 O 0 3.263485259807908e-09
percent O 0 9.308726475865114e-06
confidence O 0 1.42709932759999e-08
interval O 0 2.3611043675764165e-10
, O 0 1.0303393555011198e-11
0 O 0 1.3410300647720419e-11
. O 0 7.705134273672254e-12
2 O 0 1.544901290229106e-10
to O 0 1.8548329538958797e-10
1 O 0 2.2732955795579102e-10
. O 0 7.907895172021284e-11
1 O 0 6.785434991662953e-10
) O 0 8.602283885217332e-10
. O 0 6.217660164509198e-09

CONCLUSIONS O 0 4.526014163275249e-05
Oral O 0 3.200269929948263e-06
- O 0 3.513956698952825e-06
contraceptive O 0 7.273709798027994e-06
use O 0 2.0771935282937193e-08
may O 0 2.3318728281651602e-08
reduce O 0 1.3193930392674247e-08
the O 0 3.1616909090814715e-09
risk O 0 2.0608185877790675e-06
of O 0 1.5025100310595008e-06
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 3.03879432728138e-09
women O 0 6.582918654629566e-10
with O 0 4.604547645947754e-11
pathogenic O 0 6.426688958782734e-09
mutations O 0 6.334191482437745e-08
in O 0 8.610454016455549e-11
the O 0 1.258812054594216e-09
BRCA1 O 0 3.469895091257058e-05
or O 0 7.190491487563122e-06
BRCA2 O 0 0.0026809906121343374
gene O 0 0.00023369422706309706

A O 0 1.7516404682282882e-07
Japanese O 0 2.859796310872298e-08
family O 0 7.640271526554443e-09
with O 0 1.078793765429964e-08
adrenoleukodystrophy B-Disease 1 0.9999998807907104
with O 0 3.005047322091059e-09
a O 0 6.982854294790286e-09
codon O 0 6.408110948541434e-07
291 O 0 3.514028890094778e-08
deletion O 0 4.998802296540816e-07
: O 0 7.891505782176012e-10
a O 0 7.000667268108884e-10
clinical O 0 5.765870891849545e-09
, O 0 4.693029853619635e-10
biochemical O 0 2.26937295622065e-08
, O 0 1.481187839047493e-09
pathological O 0 1.492150090598443e-06
, O 0 4.369591799502359e-09
and O 0 1.5008195575205718e-08
genetic O 0 4.057552814629162e-06
report O 0 4.380811787996208e-06
. O 0 4.142370357840264e-08

We O 0 1.881008415693941e-06
report O 0 3.32310250428236e-08
a O 0 3.5924827002098425e-10
Japanese O 0 4.68837058065219e-09
family O 0 1.2130962900869235e-08
with O 0 3.2697303709028347e-07
adrenoleukodystrophy B-Disease 1 1.0
( O 0 3.2058393117040396e-05
ALD B-Disease 1 1.0
) O 0 1.5881977954990134e-09
with O 0 4.426858185579974e-11
a O 0 8.001481699437818e-10
three O 0 3.349247323924942e-09
base O 0 2.350716732379965e-09
pair O 0 3.0021613639519273e-08
deletion O 0 5.100404791846813e-07
( O 0 6.102656158191166e-10
delGAG O 0 6.285149822815583e-08
291 O 0 4.224536276353774e-09
) O 0 2.1205617817265932e-10
in O 0 3.97341493041381e-10
the O 0 1.1334068261703578e-07
ALD B-Disease 1 1.0
gene O 0 6.881130502733868e-06
. O 0 7.98599870677208e-08

A O 0 1.1938351462958963e-07
variety O 0 5.3370463604096585e-09
of O 0 2.7598318075305883e-10
phenotypes O 0 4.0295537928614067e-07
were O 0 7.271816038212364e-09
observed O 0 7.817815728117239e-09
within O 0 6.220504111809078e-10
this O 0 3.380114244055932e-10
family O 0 1.7425124454462093e-08
. O 0 7.231928123019316e-08

While O 0 3.6743497844327067e-07
the O 0 3.5339629000930017e-09
proband O 0 7.517156973335659e-06
( O 0 2.540282828533691e-08
patient O 0 8.258665218363603e-08
1 O 0 5.067935404667878e-09
) O 0 1.1942610234072504e-09
was O 0 1.702345464593691e-08
classified O 0 9.037194814709437e-08
as O 0 8.210266910779751e-10
having O 0 2.1924623228031237e-10
a O 0 3.895029437872566e-11
rare O 0 7.818300173934034e-11
intermediate O 0 4.832031219592636e-09
type O 0 2.350976968656937e-09
of O 0 2.513929342473631e-10
adult O 0 2.9552799674092967e-07
cerebral O 0 2.3262695322046056e-05
and O 0 4.7029899974404543e-07
cerebello O 0 0.009978576563298702
- O 0 0.02879355102777481
brain O 0 0.05686892941594124
stem O 0 6.107844114922045e-07
forms O 0 9.468875816764921e-08
, O 0 3.1298605929208634e-09
his O 0 7.5633565188582e-08
younger O 0 7.108273791800457e-08
brother O 0 1.903833464211857e-07
( O 0 7.067982643604864e-09
patient O 0 7.800110068956201e-08
2 O 0 6.353015447047028e-09
) O 0 4.153808852436214e-09
and O 0 5.16142222295457e-08
nephew O 0 8.277940651169047e-06
( O 0 3.085143163161774e-08
patient O 0 3.608962799717119e-07
3 O 0 3.881150956175361e-09
) O 0 1.7809717034467099e-09
had O 0 1.9604367196279782e-07
a O 0 3.305025018107699e-07
childhood O 0 2.2286229068413377e-05
ALD B-Disease 1 1.0
type O 0 1.0141126040252857e-05
. O 0 8.964011044554354e-08

Another O 0 3.3871895084303105e-06
nephew O 0 7.022071076789871e-05
( O 0 2.8104275884288654e-07
patient O 0 2.573921847215388e-06
4 O 0 8.49660608537306e-09
) O 0 5.145385228999544e-10
of O 0 6.287059067799916e-11
patient O 0 3.2721885645514703e-07
1 O 0 9.42990574515079e-09
was O 0 9.919266119595704e-08
classified O 0 1.8414753810702678e-07
as O 0 7.686446146237813e-09
having O 0 5.1077031493207414e-09
an O 0 3.094528244762529e-10
adolescent O 0 2.2336696048341764e-08
form O 0 2.0002444145461595e-08
. O 0 6.186338907809841e-08

The O 0 2.2998358772952088e-08
tau O 0 9.141891865738216e-08
level O 0 1.092770585131575e-08
in O 0 4.933153330277662e-10
the O 0 1.0482906098729927e-08
cerebrospinal O 0 2.5388515496160835e-05
fluid O 0 2.5660128812887706e-06
( O 0 2.998141894750006e-07
CSF O 1 0.7363682985305786
) O 0 2.848624003348732e-09
in O 0 5.738373110020234e-10
patient O 0 6.183872613974017e-08
1 O 0 1.9469252876547216e-09
was O 0 2.9283405922342354e-08
as O 0 2.8978450195005223e-10
high O 0 7.314239214295526e-10
as O 0 2.2696042267789096e-10
that O 0 5.7650727941505053e-11
of O 0 4.521106405919184e-11
patients O 0 1.0950260254105615e-08
with O 0 4.553216914615632e-09
Alzheimers B-Disease 1 0.9987230896949768
disease I-Disease 0 0.00020309981482569128
( O 0 9.120844635113201e-10
AD B-Disease 0 8.626640237707761e-07
) O 0 2.333839610457744e-08
. O 0 6.075647007719454e-08

His O 0 1.8408765072308597e-06
brain O 0 3.7239300581859425e-05
magnetic O 0 4.071224850576982e-07
resonance O 0 4.784783982358931e-07
image O 0 4.347615686128847e-06
( O 0 4.446251011813729e-08
MRI O 0 0.0002014308556681499
) O 0 2.0953628165898408e-08
showed O 0 1.3498325870386907e-06
abnormalities B-Disease 0 9.880916331894696e-05
in I-Disease 0 7.117285927282779e-11
the I-Disease 0 8.908778159621988e-10
bilateral I-Disease 0 4.0587147509540955e-07
cerebellar I-Disease 0 0.011104034259915352
hemispheres I-Disease 0 0.13659721612930298
and O 0 3.2683990980331146e-07
brain O 0 2.499577203707304e-05
stem O 0 1.9634508419130725e-07
, O 0 4.823173860302177e-09
but O 0 3.785911140141707e-09
not O 0 1.2174581343060709e-09
in O 0 1.0222769158962919e-10
the O 0 3.1035203296170266e-09
cerebral O 0 1.2436760243872413e-06
white O 0 3.326260511471446e-08
matter O 0 5.057921637074969e-09
, O 0 1.833989488053689e-10
where O 0 1.1071531191841899e-10
marked O 0 1.6981610562183391e-09
reductions O 0 4.603061753982729e-08
of O 0 2.684190543444931e-11
the O 0 3.5713123569536265e-09
cerebral O 0 1.8807860442393576e-06
blood O 0 5.678435854861164e-07
flow O 0 1.4274049817686318e-06
and O 0 2.25288090405229e-08
oxygen O 0 6.967474597274759e-09
metabolism O 0 4.709479739517519e-08
were O 0 2.6537855246644426e-10
clearly O 0 2.371421947700014e-10
demonstrated O 0 2.788982586543476e-11
by O 0 1.2069553689819656e-11
positron O 0 1.0469262434753546e-07
emission O 0 1.6022501370116515e-07
tomography O 0 3.219903010176495e-05
( O 0 1.793708825914564e-08
PET O 0 1.2854120541305747e-05
) O 0 4.1926863758590116e-08
. O 0 6.296032495356485e-08

In O 0 2.1695316831937816e-07
patients O 0 3.3665037335595116e-07
2 O 0 5.848353801241046e-09
and O 0 1.1398240129523174e-09
3 O 0 3.6164438110830588e-09
, O 0 3.351469657353334e-10
the O 0 3.9230654835797907e-10
autopsy O 0 7.564267434645444e-06
findings O 0 5.583308748668969e-08
showed O 0 3.1434371550176365e-08
massive O 0 1.9656948069268765e-08
demyelination B-Disease 1 0.9999992847442627
of I-Disease 0 4.5305870166600926e-10
the I-Disease 0 4.546569787322596e-09
cerebral I-Disease 0 1.916409473778913e-06
white I-Disease 0 1.3153777622676444e-08
matter I-Disease 0 4.430568412150393e-10
with O 0 1.6122223348014053e-11
sparing O 0 5.067749553333556e-10
of O 0 1.888617907896961e-11
the O 0 5.908346034644296e-10
U O 0 0.0004171153123024851
- O 0 1.0393917364126537e-05
fibers O 0 3.430746801313944e-05
, O 0 2.7136781710623836e-10
compatible O 0 2.0186519122944446e-09
with O 0 4.311782875188186e-11
the O 0 2.537403898106305e-10
findings O 0 9.800483979915953e-09
of O 0 1.2508397650989878e-09
childhood O 0 3.6430383261176758e-06
ALD B-Disease 1 1.0
. O 0 4.584057933243457e-07

Oleic O 0 0.02168208919465542
and O 0 9.371597116114572e-07
erucic O 0 5.056836744188331e-05
acids O 0 5.639240043819882e-07
( O 0 4.107232776107139e-09
Lorenzos O 0 1.5616749351465842e-06
Oil O 0 4.309561631998804e-07
) O 0 4.801381514596414e-10
were O 0 1.7023533971372018e-10
administered O 0 5.905278349649379e-11
to O 0 1.086725598398175e-09
patients O 0 1.8657579647918254e-10
1 O 0 1.23072815827463e-10
and O 0 2.565890833139406e-09
4 O 0 7.82918618824624e-09
, O 0 2.9602365003711384e-09
but O 0 1.207483779630536e-09
sufficient O 0 1.7355054893197774e-10
effectiveness O 0 5.811455761062234e-10
was O 0 3.6049701002127676e-09
not O 0 1.0413550022292384e-09
obtained O 0 1.3205410098748871e-08
. O 0 2.6484938686621717e-08

The O 0 1.4165749462335953e-07
findings O 0 8.6538676669079e-08
in O 0 3.07641995211938e-10
this O 0 2.4671495402195376e-10
family O 0 3.2813423089805838e-09
suggest O 0 4.978081058482076e-09
that O 0 2.0028881331235482e-10
delGAG291 O 0 1.8666426626623434e-08
is O 0 6.787994472068348e-11
part O 0 6.490666337732875e-11
of O 0 9.844158474492382e-12
the O 0 4.250576279840601e-10
cause O 0 5.8229643329354985e-09
of O 0 1.2255582659825848e-10
Japanese O 0 3.192537576524046e-07
ALD B-Disease 1 0.9999996423721313
with O 0 1.2799458160017707e-09
phenotypic O 0 3.0274341611402633e-07
variations O 0 8.555393833376002e-07
. O 0 6.63242971654654e-08

Moreover O 0 3.3453213745815447e-06
, O 0 5.697152971606556e-09
although O 0 1.5807866127204306e-10
the O 0 2.932628792584602e-11
scale O 0 2.545699429035153e-09
of O 0 3.0624086599928546e-11
the O 0 7.931524326210138e-10
study O 0 5.884054354865498e-10
is O 0 2.8917768180036774e-10
limited O 0 4.701308231602752e-10
, O 0 3.935161363433082e-10
there O 0 1.467363036633529e-11
is O 0 1.57408842904605e-11
a O 0 1.5583551116193917e-10
possibility O 0 1.7385437534045423e-10
that O 0 6.828184545559779e-11
PET O 0 1.2106396241051698e-07
can O 0 1.064094323766085e-08
detect O 0 2.1255350191040634e-07
an O 0 7.193401985183812e-10
insidious B-Disease 0 3.989038305007853e-06
lesion I-Disease 0 0.0014468622393906116
which O 0 6.128495932955502e-09
is O 0 1.77542536228259e-10
undetectable O 0 4.869762371129127e-09
by O 0 1.768071106189595e-11
computed O 0 7.840143467774396e-08
tomogram O 0 6.637088517891243e-06
( O 0 2.5658322133637057e-09
CT O 1 0.8923755884170532
) O 0 1.1042834424657144e-09
or O 0 9.537223455424737e-09
MRI O 0 7.4747790677065495e-06
analysis O 0 3.0957398866604535e-09
, O 0 5.864335128613618e-10
and O 0 3.9017383768324976e-10
that O 0 6.261294260845318e-11
the O 0 9.262440120449966e-11
higher O 0 5.521637813643565e-09
level O 0 2.5501789568949107e-10
of O 0 1.3139389749838859e-11
tau O 0 2.725948355930541e-09
reflects O 0 9.927850763702395e-10
the O 0 6.020037940368539e-11
process O 0 5.802052172043659e-10
of O 0 1.7261266027635003e-10
neuronal B-Disease 0 6.664067041128874e-05
degeneration I-Disease 1 0.8660590648651123
in O 0 7.924226110844756e-07
ALD B-Disease 1 1.0
. O 0 6.418582643163973e-07

Lorenzos O 0 0.0009983868803828955
Oil O 0 6.249105354072526e-05
should O 0 3.8829448101296293e-08
be O 0 1.240970243232553e-10
given O 0 3.354256108978326e-11
in O 0 1.3221142063091218e-11
the O 0 1.2682271899322473e-10
early O 0 8.28832824595338e-09
stage O 0 3.542089643815416e-08
. O 0 5.990615226103557e-10
. O 0 7.281003799874952e-09

Nonsense O 0 3.13552918669302e-05
mutation O 0 1.514723408035934e-06
in O 0 5.330412999882128e-09
exon O 0 1.954751951416256e-07
4 O 0 5.2415303208874775e-09
of O 0 6.663752882829499e-11
human O 0 3.118567071247469e-10
complement O 0 4.854062929382508e-09
C9 O 0 9.473808404436568e-08
gene O 0 1.036238117535504e-07
is O 0 1.125951207270326e-10
the O 0 6.757340520469057e-11
major O 0 1.4445846741040214e-09
cause O 0 3.2149063411424095e-09
of O 0 4.336707729035716e-11
Japanese O 0 3.635242507016301e-08
complement B-Disease 0 4.5585679231407994e-07
C9 I-Disease 0 0.0002735448069870472
deficiency I-Disease 0 0.0007768631912767887
. O 0 4.4442671764954866e-08

Deficiency B-Disease 1 0.9987744688987732
of I-Disease 0 5.048572226939996e-09
the I-Disease 0 1.3577555746380199e-09
ninth I-Disease 0 6.582121159226517e-08
component I-Disease 0 1.378172775901021e-08
of I-Disease 0 1.1795950327631033e-10
human I-Disease 0 3.9498848636299044e-10
complement I-Disease 0 7.594823436818388e-09
( O 0 1.1992599135979276e-09
C9 O 0 6.879530189962679e-08
) O 0 2.1421436846580377e-10
is O 0 1.53091168214603e-11
the O 0 1.0999539820644166e-11
most O 0 1.0365569513837158e-10
common O 0 4.7885269083280946e-08
complement B-Disease 1 0.9999998807907104
deficiency I-Disease 1 1.0
in O 0 2.506742591279476e-10
Japan O 0 1.4017247806918931e-08
but O 0 1.4308837448240297e-10
is O 0 1.500900272122241e-11
rare O 0 2.3404425966710996e-11
in O 0 5.001440928076306e-11
other O 0 2.710584812160022e-10
countries O 0 1.0327545485466771e-09
. O 0 9.497668429503392e-09

We O 0 1.0800557674883748e-06
studied O 0 2.326462045232347e-08
the O 0 3.254637948035821e-10
molecular O 0 7.348460062672757e-09
basis O 0 3.6196872166271987e-09
of O 0 4.5141118620861675e-10
C9 B-Disease 0 0.0002058028185274452
deficiency I-Disease 0 0.00024335997295565903
in O 0 7.058020140560117e-11
four O 0 6.203217384204152e-10
Japanese O 0 4.749447946039709e-09
C9 B-Disease 0 3.951339294872014e-06
- I-Disease 0 0.0004417029849719256
deficient I-Disease 0 0.04117453470826149
patients O 0 8.214147783291992e-06
who O 0 1.3060258652330958e-07
had O 0 9.286930435337126e-06
suffered O 0 0.03278292343020439
from O 0 1.5140113873712835e-06
meningococcal B-Disease 1 0.9999998807907104
meningitis I-Disease 1 0.9999994039535522
. O 0 2.735716861934634e-07

Direct O 0 6.649661941082741e-07
sequencing O 0 1.2905114772365778e-06
of O 0 7.78007702706418e-09
amplified O 0 1.7169533350624988e-07
C9 O 0 6.152848754936713e-07
cDNA O 0 1.427391254082977e-07
and O 0 1.6360643950719123e-09
DNA O 0 1.780211889013117e-08
revealed O 0 1.3517949426500309e-08
a O 0 5.675566683294164e-10
nonsense O 0 6.62025589903692e-09
substitution O 0 3.415082105995282e-10
( O 0 8.136912671430352e-11
CGA O 0 2.2534058530254697e-07
- O 0 2.5050010776794807e-07
- O 0 6.010386641719379e-07
> O 0 6.433360955071521e-09
TGA O 0 1.483683149672288e-07
) O 0 1.0738697431289523e-10
at O 0 3.945939408556143e-10
codon O 0 5.183923956764147e-09
95 O 0 2.3212780309034287e-10
in O 0 1.3230375128792105e-11
exon O 0 6.493026116771716e-09
4 O 0 5.919084111738471e-10
in O 0 5.182960310934348e-11
the O 0 1.2683649963651789e-10
four O 0 7.64629248806159e-09
C9 B-Disease 0 1.873626752058044e-05
- I-Disease 0 0.0006648698472417891
deficient I-Disease 0 0.000280496955383569
individuals O 0 8.013994801103763e-09
. O 0 1.9521245064879622e-08

An O 0 6.540135188970453e-08
allele O 0 2.096787738992134e-06
- O 0 2.2848877279102453e-07
specific O 0 9.111233545411324e-09
polymerase O 0 8.493611858284567e-08
chain O 0 2.7043088834943774e-07
reaction O 0 2.2938153598772715e-09
system O 0 2.6848884226993164e-10
designed O 0 2.5000482239967425e-10
to O 0 1.6325979457221251e-09
detect O 0 3.41996155839297e-08
exclusively O 0 3.893196875992544e-10
only O 0 1.5235310235617305e-10
one O 0 3.520282329527724e-11
of O 0 2.4987822141303573e-12
the O 0 7.544010555138314e-11
normal O 0 1.5862157809465316e-08
and O 0 4.5006146032200434e-10
mutant O 0 5.4299085228137756e-09
alleles O 0 1.0271641315284796e-08
indicated O 0 1.2789220704689797e-07
that O 0 9.051241700586132e-11
all O 0 2.5533316780346205e-11
the O 0 4.339844109080282e-11
four O 0 3.7911718209215906e-09
patients O 0 8.068391510462902e-10
were O 0 2.559426628967465e-11
homozygous O 0 2.9614888319429156e-10
for O 0 4.5679454142855125e-12
the O 0 1.1165897199905128e-11
mutation O 0 8.997851907999177e-10
in O 0 4.5225899414358395e-11
exon O 0 2.1785043102795498e-08
4 O 0 1.2728716747290036e-08
and O 0 9.910255949208135e-10
that O 0 8.646264954004224e-11
the O 0 1.2144261984925464e-10
parents O 0 1.9700543973932838e-10
of O 0 2.5731318117894197e-11
patient O 0 1.1930413990057787e-08
2 O 0 2.9583737681804223e-09
were O 0 3.129568160176177e-09
heterozygous O 0 4.430691191714686e-08
. O 0 2.0556031543605968e-08

The O 0 1.0809007910950186e-08
common O 0 4.926244745462327e-09
mutation O 0 5.567442684650814e-08
at O 0 4.039292900159808e-09
codon O 0 5.950036907620415e-08
95 O 0 1.6057853935436128e-09
in O 0 6.263480706314439e-11
exon O 0 2.9303295789873118e-08
4 O 0 3.3914314911953625e-08
might O 0 2.3206563781741352e-08
be O 0 6.992153522844546e-10
responsible O 0 2.027341405863581e-09
for O 0 5.991321327947219e-11
most O 0 2.755124739461934e-10
Japanese O 0 5.205199116176118e-08
C9 B-Disease 0 2.6849229470826685e-05
deficiency I-Disease 0 1.2806964150513522e-05
. O 0 6.886757275559319e-10
. O 0 1.3648914887198771e-08

BRCA1 O 0 0.00010613607446430251
required O 0 1.0093398827848432e-07
for O 0 4.442584633501667e-10
transcription O 0 1.0786871484924632e-07
- O 0 1.188570422527846e-05
coupled O 0 6.110197432462883e-07
repair O 0 4.229076239425922e-06
of O 0 2.7280377956628854e-10
oxidative O 0 2.7094140264694033e-08
DNA O 0 2.559502263466129e-06
damage O 0 1.6285037418128923e-05
. O 0 9.45234717164567e-08

The O 0 1.838355638028588e-05
breast B-Disease 1 0.9999949932098389
and I-Disease 1 0.9999697208404541
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
susceptibility O 0 4.167241058894433e-05
gene O 0 1.0991367389578954e-06
BRCA1 O 0 2.796108674374409e-06
encodes O 0 3.180828116455814e-07
a O 0 4.802778263979235e-08
zinc O 0 1.9543582311598584e-05
finger O 0 2.310747731826268e-05
protein O 0 8.320105138182043e-08
of O 0 1.4264421588361387e-10
unknown O 0 1.3786617181210659e-08
function O 0 5.85844937006641e-08
. O 0 5.6493924205369694e-08

Association O 0 9.380828203120473e-08
of O 0 2.885947592012883e-10
the O 0 2.487861028299676e-10
BRCA1 O 0 6.370186866888616e-08
protein O 0 7.0409242880487e-09
with O 0 5.107922418368105e-11
the O 0 9.444458409779699e-11
DNA O 0 1.690254514130629e-08
repair O 0 9.359791874885559e-08
protein O 0 3.942127069223034e-09
Rad51 O 0 2.932791005605395e-07
and O 0 6.583245060198806e-10
changes O 0 8.81550249465235e-11
in O 0 3.711334191358606e-12
the O 0 4.084742093179994e-12
phosphorylation O 0 2.0581904236482984e-10
and O 0 9.701313086196706e-10
cellular O 0 5.121165269628136e-09
localization O 0 1.3474669158242136e-09
of O 0 3.2110345198760326e-12
the O 0 3.501171574882278e-11
protein O 0 1.3730949710577534e-09
after O 0 1.3893574069001602e-09
exposure O 0 1.4233036971234014e-09
to O 0 2.300153956191764e-10
DNA O 0 4.266289010956825e-08
- O 0 8.122486292450048e-07
damaging O 0 7.169984428401222e-07
agents O 0 4.780767781653594e-09
are O 0 3.743113458076763e-11
consistent O 0 1.7282845987676154e-10
with O 0 6.014078991756211e-12
a O 0 1.6332574181987525e-10
role O 0 4.035925482703817e-10
for O 0 1.5933580843618955e-10
BRCA1 O 0 8.805751861018507e-08
in O 0 1.523601467212643e-09
DNA O 0 9.69937673289678e-07
repair O 0 2.6140538466279395e-05
. O 0 8.603539214391276e-08

Here O 0 7.730902211733337e-07
, O 0 6.097109039870929e-09
it O 0 4.693611610484538e-10
is O 0 6.491892440285696e-11
shown O 0 1.4175378926228888e-10
that O 0 4.6964925004555624e-11
mouse O 0 1.8186641526085623e-08
embryonic O 0 7.647476962802102e-08
stem O 0 2.9763859288323147e-07
cells O 0 8.051732720559812e-07
deficient B-Disease 0 3.19716741614684e-06
in I-Disease 0 3.798856784698046e-10
BRCA1 I-Disease 0 1.6278294197036303e-06
are O 0 1.8589032535487604e-09
defective O 0 2.748577685451892e-07
in O 0 1.5659022689629154e-10
the O 0 2.412624267034147e-10
ability O 0 8.206357371420836e-09
to O 0 6.861570756022672e-10
carry O 0 3.133880932537636e-09
out O 0 1.4847235663140168e-09
transcription O 0 2.1939788652503012e-08
- O 0 3.4738945942081045e-07
coupled O 0 6.302171584593452e-08
repair O 0 5.424879532256455e-07
of O 0 2.8961527620552374e-11
oxidative O 0 1.058516829743894e-09
DNA O 0 3.3473273219897237e-07
damage O 0 1.9001380451300065e-06
, O 0 3.862923758646275e-09
and O 0 3.1034432801391176e-09
are O 0 1.370371371933743e-09
hypersensitive O 0 1.7005286281346343e-06
to O 0 1.630090906701298e-08
ionizing O 0 2.554919547037571e-07
radiation O 0 5.511549829861906e-07
and O 0 1.8898593800997787e-09
hydrogen O 0 1.3642173612993247e-08
peroxide O 0 7.837980433578196e-07
. O 0 1.9828584996162135e-08

These O 0 4.3008984107473225e-07
results O 0 1.5400065649373573e-06
suggest O 0 1.4507180345901816e-08
that O 0 2.094789341988701e-10
BRCA1 O 0 1.1555177792388349e-07
participates O 0 1.0695169194718801e-08
, O 0 2.787696740114143e-10
directly O 0 8.980397536717533e-10
or O 0 2.5835124262130194e-08
indirectly O 0 6.079391567936909e-08
, O 0 1.4096218636794333e-10
in O 0 3.981424218091334e-11
transcription O 0 4.5401417736457006e-08
- O 0 2.350096110603772e-06
coupled O 0 2.605517011033953e-07
repair O 0 3.1420549930771813e-06
of O 0 5.364176464128789e-11
oxidative O 0 2.4706541257302206e-09
DNA O 0 5.110259735374711e-07
damage O 0 1.3195764267948107e-06
. O 0 4.2647569920006845e-09
. O 0 2.1888293844085638e-08

Truncation O 0 0.00015777289809193462
mutations O 0 5.440115637611598e-05
in O 0 3.747417931521113e-09
the O 0 1.3693628453381734e-09
transactivation O 0 3.3089020234911004e-06
region O 0 5.421140940597979e-07
of O 0 8.222145742031728e-10
PAX6 O 0 2.8791275781259174e-06
result O 0 7.285379410859605e-09
in O 0 2.9776764387534627e-10
dominant O 0 9.921004675561562e-07
- O 0 7.404596544802189e-06
negative O 0 1.6326739569194615e-06
mutants O 0 8.250868859249749e-07
. O 0 2.2769777174858064e-08

PAX6 O 0 9.246193803846836e-05
is O 0 6.855948697648273e-09
a O 0 7.15264514283831e-10
transcription O 0 4.147657328701371e-09
factor O 0 5.26045706994438e-10
with O 0 2.2416643194467234e-11
two O 0 2.0265594757873373e-10
DNA O 0 5.0168306842124366e-08
- O 0 4.164187714650325e-07
binding O 0 3.6101948097666536e-08
domains O 0 1.210429090292564e-08
( O 0 2.1044767317679458e-10
paired O 0 4.893246696724418e-08
box O 0 2.476445217780565e-07
and O 0 1.989145514968982e-09
homeobox O 0 1.0711562303811206e-08
) O 0 1.0510083081616273e-10
and O 0 3.437981149767566e-11
a O 0 5.065980968055328e-10
proline O 0 5.526292170543456e-07
- O 0 1.9201601730856055e-07
serine O 0 6.340833351714537e-07
- O 0 7.266411330419942e-07
threonine O 0 1.2689572940871585e-05
( O 0 1.7215178171881007e-09
PST O 0 1.8842564486476476e-06
) O 0 7.48203776712586e-10
- O 0 6.221115000926147e-08
rich O 0 3.3629859785833105e-08
transactivation O 0 5.692317245120648e-06
domain O 0 3.8885781350472826e-07
. O 0 5.6979601481543796e-08

PAX6 O 0 0.008163056336343288
regulates O 0 0.0004225154989399016
eye O 0 0.07154164463281631
development O 0 8.747459645519484e-09
in O 0 7.947439928379652e-10
animals O 0 1.6589403184497087e-09
ranging O 0 2.318673031354024e-09
from O 0 3.7199843205826255e-10
jellyfish O 0 6.7813625825863255e-09
to O 0 1.1274560174356907e-09
Drosophila O 0 2.8989355360664604e-09
to O 0 1.653033709914098e-09
humans O 0 6.626522441877114e-09
. O 0 1.8684200853158472e-08

Heterozygous O 0 0.00015494557737838477
mutations O 0 0.00010767373169073835
in O 0 5.058143237590684e-09
the O 0 9.58454204891268e-10
human O 0 1.7880888991683719e-09
PAX6 O 0 1.7459612990933238e-06
gene O 0 3.7541164488175127e-07
result O 0 3.849743190897925e-09
in O 0 3.30570015805165e-11
various O 0 1.0296307556556528e-10
phenotypes O 0 1.344069602282616e-07
, O 0 2.0376142995104374e-09
including O 0 4.6345447479723134e-09
aniridia B-Disease 1 1.0
, O 0 1.3561481864599045e-05
Peters B-Disease 1 1.0
anomaly I-Disease 1 0.9999996423721313
, O 0 7.701196835796509e-08
autosomal B-Disease 1 0.9208360910415649
dominant I-Disease 0 0.005255156196653843
keratitis I-Disease 1 0.9983202815055847
, O 0 1.5357372262769786e-07
and O 0 1.1075052697151477e-07
familial B-Disease 0 0.14948448538780212
foveal I-Disease 1 0.9972400665283203
dysplasia I-Disease 1 0.9999537467956543
. O 0 3.4150966712331865e-06

It O 0 2.1772794411845098e-07
is O 0 1.6105212718997564e-09
believed O 0 1.6786970702398207e-09
that O 0 5.065640268364646e-11
the O 0 5.969522792748094e-11
mutated O 0 5.1135643275301845e-08
allele O 0 1.0878672895842101e-07
of O 0 4.0504391507489856e-10
PAX6 O 0 1.7150155144918244e-06
produces O 0 3.306531226598963e-08
an O 0 9.41801567289069e-11
inactive O 0 9.09146091743196e-09
protein O 0 1.630914958639096e-08
and O 0 1.0719291765326489e-07
aniridia B-Disease 1 1.0
is O 0 5.2552174167885823e-08
caused O 0 1.8103683885328792e-08
due O 0 5.5948294885865835e-09
to O 0 6.840874977598332e-09
genetic O 0 7.498087484236748e-07
haploinsufficiency O 0 3.8073212635936216e-05
. O 0 8.720226674086007e-08

However O 0 1.8723841321843793e-07
, O 0 3.9240383165051185e-10
several O 0 6.445218664330454e-11
truncation O 0 4.247820868386043e-07
mutations O 0 3.1755769214214524e-06
have O 0 5.207092534931235e-09
been O 0 5.402355229833233e-10
found O 0 9.64829660610178e-10
to O 0 7.305887006481271e-10
occur O 0 1.4243296819760332e-10
in O 0 1.4813868881580206e-11
the O 0 2.9908020504620936e-10
C O 0 5.893966772418935e-07
- O 0 2.5152274929496343e-07
terminal O 0 2.456697984598577e-06
half O 0 3.682572113916649e-08
of O 0 1.1501794655588427e-10
PAX6 O 0 2.1433440622331545e-07
in O 0 4.868422887049917e-10
patients O 0 3.989014007999003e-09
with O 0 2.2626281404036774e-10
Aniridia B-Disease 1 0.9999998807907104
resulting O 0 8.857309552467996e-09
in O 0 3.535132256371476e-11
mutant O 0 9.571150538789652e-10
proteins O 0 3.981562857191534e-10
that O 0 8.810292079219906e-11
retain O 0 1.9748935820018687e-09
the O 0 1.2140110097758061e-11
DNA O 0 6.386499329380513e-09
- O 0 6.123672591229479e-08
binding O 0 1.3080521554797997e-08
domains O 0 1.6208334230327637e-08
but O 0 6.327185442245309e-09
have O 0 1.3410904609045815e-09
lost O 0 8.868065037859196e-08
most O 0 1.2041960310849031e-11
of O 0 5.123258154521304e-12
the O 0 3.8864528262294584e-10
transactivation O 0 9.187425007439742e-07
domain O 0 6.808776475963896e-08
. O 0 2.0468158723474517e-08

It O 0 8.16030592432071e-07
is O 0 3.322587538434618e-09
not O 0 4.027128908123956e-10
clear O 0 8.103802628944834e-10
whether O 0 1.2076743771682885e-10
such O 0 2.3660623807431058e-11
mutants O 0 3.766761125234552e-08
really O 0 2.258301634583404e-08
behave O 0 8.738004098063357e-09
as O 0 5.895037236136602e-11
loss O 0 3.2386691106722765e-09
- O 0 6.710864308701048e-09
of O 0 1.707527175209833e-10
- O 0 1.1718466907950642e-07
function O 0 1.4587006269550784e-08
mutants O 0 5.594053931190501e-08
as O 0 1.1566919644323548e-09
predicted O 0 4.000246889290793e-08
by O 0 5.561366367423659e-10
haploinsufficiency O 0 1.942540166055551e-06
. O 0 3.597114428544046e-08

Contrary O 0 1.6606622921244707e-06
to O 0 7.716234762256136e-09
this O 0 2.2151859513375172e-10
theory O 0 6.098885840799539e-10
, O 0 7.204688512452151e-10
our O 0 3.641743351323612e-09
data O 0 5.089151855486307e-08
showed O 0 7.324336248615282e-09
that O 0 1.8178153426973154e-11
these O 0 5.7569608802321426e-12
mutants O 0 2.699277024120761e-09
are O 0 1.1397929128298401e-10
dominant O 0 3.3915025454689385e-08
- O 0 1.5957326127136184e-07
negative O 0 2.8093657178374087e-08
in O 0 1.5241966022649933e-10
transient O 0 3.9115910510645335e-09
transfection O 0 8.312300536772455e-08
assays O 0 9.047971261111343e-09
when O 0 1.113959591236835e-09
they O 0 3.907256740376397e-10
are O 0 3.438276052758482e-11
coexpressed O 0 2.9122043443408074e-08
with O 0 5.5687194439046905e-11
wild O 0 2.115659292201144e-08
- O 0 2.1063117401354248e-06
type O 0 2.4774158191576134e-07
PAX6 O 0 2.0731185941258445e-05
. O 0 8.315932120694924e-08

We O 0 6.341734888337669e-07
found O 0 4.104428796836146e-09
that O 0 2.657294349839301e-11
the O 0 3.02704250554342e-11
dominant O 0 2.4771773610154924e-07
- O 0 4.799197995453142e-06
negative O 0 3.399463253117574e-07
effects O 0 3.6401480940639885e-08
result O 0 5.152662740925962e-10
from O 0 1.7527566203989764e-11
the O 0 1.2321837994377915e-11
enhanced O 0 6.021132481492941e-10
DNA O 0 4.337589398772934e-09
binding O 0 1.3879033478048086e-09
ability O 0 1.0564433772231041e-09
of O 0 5.440342620843808e-11
these O 0 3.3994979053986185e-10
mutants O 0 1.4581310381345247e-07
. O 0 2.0158864799668663e-08

Kinetic O 0 1.1519346116983797e-06
studies O 0 4.3959598627907326e-08
of O 0 7.210448904615419e-10
binding O 0 5.241762934815597e-08
and O 0 1.7704055110812078e-08
dissociation O 0 5.841333106104685e-08
revealed O 0 1.136833063242193e-07
that O 0 4.437230444187534e-11
various O 0 1.9189960384635718e-11
truncation O 0 8.463322842544585e-08
mutants O 0 3.120914726650881e-08
have O 0 2.631040108003191e-10
3 O 0 2.8483454483918536e-10
- O 0 7.742122498655135e-09
5 O 0 8.76675176897379e-09
- O 0 4.378028251039723e-08
fold O 0 2.239817860072435e-07
higher O 0 5.853517670573183e-10
affinity O 0 1.3451527391961093e-10
to O 0 3.8489902237648366e-11
various O 0 2.6272864092624637e-12
DNA O 0 1.1279593925550557e-09
- O 0 1.853507791693687e-09
binding O 0 4.592305979933542e-10
sites O 0 9.704275161226406e-10
when O 0 1.8563300896445867e-10
compared O 0 1.9860056654774638e-10
with O 0 7.600652746075909e-12
the O 0 7.10929440317365e-11
wild O 0 2.466615711682607e-08
- O 0 2.0386728465382475e-06
type O 0 1.748631177633797e-07
PAX6 O 0 1.7804324670578353e-05
. O 0 8.907512949463126e-08

These O 0 1.8006679169957351e-07
results O 0 8.054899325316e-08
provide O 0 1.3321108105479595e-10
a O 0 1.4661047376129943e-10
new O 0 5.60881285860404e-10
insight O 0 5.807359038101367e-09
into O 0 2.9922514466207417e-10
the O 0 4.6612068371754134e-11
role O 0 2.6955868093203605e-10
of O 0 4.680699924874965e-11
mutant O 0 1.3862453407398334e-08
PAX6 O 0 1.3628060742121306e-06
in O 0 2.176199487280428e-08
causing O 0 2.70783384621609e-05
aniridia B-Disease 1 0.9999997615814209
. O 0 1.3319394476241087e-08
. O 0 2.534296683620596e-08

Reversal O 0 0.0005899609532207251
of O 0 7.970838851178996e-07
severe O 0 0.05925401300191879
hypertrophic B-Disease 1 0.9996621608734131
cardiomyopathy I-Disease 1 1.0
and O 0 3.860094238916645e-06
excellent O 0 1.1613193464654614e-06
neuropsychologic O 0 1.5098317817319185e-05
outcome O 0 1.3727715497680038e-07
in O 0 6.853487222180377e-10
very B-Disease 0 6.314177625199591e-09
- I-Disease 0 3.1265624329535058e-06
long I-Disease 0 8.878336075213156e-07
- I-Disease 0 5.55740189156495e-06
chain I-Disease 0 8.625565897091292e-06
acyl I-Disease 0 7.845154925689712e-08
- I-Disease 0 1.5287699284272094e-07
coenzyme I-Disease 0 3.837985218524409e-08
A I-Disease 0 5.931499202915802e-08
dehydrogenase I-Disease 0 0.00010818914597621188
deficiency I-Disease 0 0.0030194458086043596
. O 0 3.356347377803104e-08

Very B-Disease 0 9.841742212302051e-07
- I-Disease 0 4.061881099914899e-06
long I-Disease 0 4.117483172194625e-07
- I-Disease 0 3.2200525765802013e-06
chain I-Disease 0 2.9288655696291244e-06
acyl I-Disease 0 9.162472736079508e-08
- I-Disease 0 6.380876271805391e-08
coenzyme I-Disease 0 8.927971251182498e-09
A I-Disease 0 3.468975995346568e-09
dehydrogenase I-Disease 0 1.4192956143688207e-07
( I-Disease 0 1.0325541310862718e-08
VLCAD I-Disease 0 0.00026552227791398764
) I-Disease 0 2.48287733484176e-07
deficiency I-Disease 0 2.1054052922409028e-05
is O 0 1.7873957869340984e-10
a O 0 5.0108512894553314e-09
disorder O 0 8.857498869474512e-06
of O 0 2.2080011430336555e-11
fatty O 0 2.327454637907067e-07
acid O 0 9.669178524518429e-08
beta O 0 2.6610349479483375e-09
oxidation O 0 5.375222933423629e-09
that O 0 3.717175456330324e-10
reportedly O 0 4.051447533015562e-08
has O 0 5.177123174604503e-10
high O 0 9.937474176879846e-10
rates O 0 3.2490589774170076e-08
of O 0 6.008077368946374e-10
morbidity O 0 0.008258090354502201
and O 0 6.8398003350012e-07
mortality O 0 6.167610081320163e-06
. O 0 5.835553551492012e-08

We O 0 4.99682414556446e-07
describe O 0 1.2326158760345152e-08
the O 0 2.0524472399419125e-10
outcome O 0 1.2964396223225094e-09
of O 0 3.838343705375724e-12
a O 0 2.443420465958468e-10
5 O 0 2.016458555686995e-09
- O 0 4.7133976721625004e-08
year O 0 3.778274049182073e-08
- O 0 2.3584836128520692e-07
old O 0 1.8962333570016199e-06
girl O 0 6.095505887060426e-05
with O 0 2.725316221585672e-07
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
who O 0 2.2989368630987883e-08
was O 0 1.78828674091136e-09
first O 0 9.389359290068455e-10
seen O 0 8.389708483491631e-09
at O 0 2.577462021591259e-09
5 O 0 8.767349068961039e-10
months O 0 1.7422192577498663e-09
of O 0 1.9179312651940172e-11
age O 0 1.5336135694710151e-09
with O 0 3.0442958376397655e-08
severe O 0 0.0002819235669448972
hypertrophic B-Disease 0 0.27136683464050293
cardiomyopathy I-Disease 1 1.0
, O 0 9.246502304449677e-05
hepatomegaly B-Disease 1 1.0
, O 0 1.5249506759573705e-05
encephalopathy B-Disease 0 0.37068983912467957
, O 0 1.3979920332474194e-08
and O 0 6.634491711565715e-08
hypotonia B-Disease 0 0.0002874739293474704
. O 0 1.7022357212681527e-07

Biochemical O 0 0.000664780440274626
studies O 0 1.4641405869042501e-05
indicated O 0 0.050965722650289536
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
caused O 0 1.5482841035918682e-06
by O 0 1.9539032891646713e-10
a O 0 3.265483883296838e-09
stable O 0 3.05928074340045e-06
yet O 0 2.1738431499329636e-08
inactive O 0 6.129679519517595e-08
enzyme O 0 1.367826598652755e-07
. O 0 2.2202728544584716e-08

Molecular O 0 3.220553026039852e-06
genetic O 0 1.7955421753867995e-06
analysis O 0 5.385867751783735e-08
of O 0 1.9283101782008316e-09
her O 0 1.7435735344406567e-06
VLCAD O 0 0.000155877394718118
gene O 0 6.88920636093826e-07
revealed O 0 1.8706758453390648e-07
a O 0 3.4851914687550334e-09
T1372C O 0 1.6393831003824744e-07
( O 0 2.4617874405663542e-09
F458L O 0 5.552150739163153e-08
) O 0 2.3521700143191993e-09
missense O 0 2.2657325189356925e-06
mutation O 0 1.5792322756169597e-06
and O 0 1.3510474516920112e-08
a O 0 7.13114189920816e-08
1668 O 0 1.1706459190463647e-05
ACAG O 0 0.0006869607605040073
1669 O 0 2.2597616862185532e-06
splice O 0 0.0006080321036279202
site O 0 3.8156322261784226e-06
mutation O 0 9.577324817655608e-06
. O 0 6.613581859937767e-08

After O 0 3.405751840546145e-07
initial O 0 3.973850937200041e-08
treatment O 0 1.2548166949954975e-08
with O 0 1.8931126111176866e-10
intravenous O 0 5.610712960901765e-08
glucose O 0 4.211612576909829e-06
and O 0 6.208428438014835e-09
carnitine O 0 9.583836657611755e-08
, O 0 1.4835911388288991e-09
the O 0 5.111784329159264e-10
patient O 0 5.464592689463643e-08
has O 0 1.9576186505165794e-10
thrived O 0 1.5818611975859653e-09
on O 0 7.569873061719079e-10
a O 0 1.202661636945379e-09
low O 0 2.364198437021514e-08
- O 0 6.268604124670674e-07
fat O 0 4.179188181296922e-06
diet O 0 6.210075120804959e-09
supplemented O 0 7.113339917097505e-10
with O 0 4.552630494814025e-11
medium O 0 1.3679746224681821e-08
- O 0 4.734544916118466e-07
chain O 0 7.093718522810377e-06
triglyceride O 0 1.2528385013865773e-06
oil O 0 5.847263082614518e-07
and O 0 3.3598814841440117e-09
carnitine O 0 1.2956023809351791e-08
and O 0 3.2200719868313854e-10
avoidance O 0 1.430685969694423e-08
of O 0 8.468918344384235e-10
fasting O 0 8.766318160269293e-07
. O 0 4.64168650182728e-08

Her O 0 0.0008298975881189108
ventricular O 0 0.015110489912331104
hypertrophy O 0 0.0017838248750194907
resolved O 0 3.627378873716225e-06
significantly O 0 1.3106848939514748e-07
over O 0 1.992068954237425e-09
1 O 0 5.729255736497407e-09
year O 0 9.839779657738745e-09
, O 0 1.4636299949799536e-09
and O 0 1.8985566896390083e-08
cognitively O 0 2.073805660529615e-07
, O 0 1.0134788563931352e-09
she O 0 2.3129496540263972e-08
is O 0 1.8200668402967857e-11
in O 0 2.7429534338319073e-11
the O 0 4.786659402178373e-10
superior O 0 5.3161095081577514e-08
range O 0 5.805774971889832e-09
for O 0 4.3225334422913875e-09
age O 0 1.1699345492388602e-08
. O 0 2.8636391036229725e-08

Clinical O 0 2.623681393743027e-05
recognition O 0 1.0026344625657657e-06
of O 0 1.0767749927254044e-06
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
is O 0 4.318981172701797e-09
important O 0 4.915092777224572e-10
because O 0 1.2563918794228357e-09
it O 0 1.6328844942847809e-09
is O 0 1.7107709693320317e-10
one O 0 8.081694341521839e-11
of O 0 5.140043772555725e-12
the O 0 3.1046731852057974e-10
few O 0 5.188939500300194e-09
directly O 0 3.147637244182988e-07
treatable O 0 6.942405889276415e-05
causes O 0 9.3942169598904e-09
of O 0 1.982936925770673e-09
cardiomyopathy B-Disease 1 1.0
in O 0 2.3167383744748804e-07
children O 0 3.672415971323062e-07
. O 0 9.743561513175791e-09
. O 0 7.76761055476527e-08

Cloning O 0 3.6410025927580136e-07
of O 0 6.105310146331533e-10
a O 0 1.6072377873044275e-09
novel O 0 4.185916502308373e-09
member O 0 1.441556984893566e-09
of O 0 1.1703546118346786e-11
the O 0 5.936156011188132e-10
low O 0 1.2535923588075093e-07
- O 0 5.402795068221167e-06
density O 0 9.031128911374253e-08
lipoprotein O 0 3.6758706301043276e-07
receptor O 0 2.6877039260853053e-08
family O 0 1.7376213179431943e-07
. O 0 1.605388746384051e-07

A O 0 1.6715672757072753e-07
gene O 0 1.8435524395954417e-07
encoding O 0 9.624356778203946e-08
a O 0 5.7167679479164235e-09
novel O 0 2.2546991829131002e-08
transmembrane O 0 6.766636317934172e-08
protein O 0 8.911913340625688e-08
was O 0 5.120784241086085e-09
identified O 0 6.01275473854912e-10
by O 0 9.0201466088069e-12
DNA O 0 7.879893959561457e-10
sequence O 0 5.400964120383378e-10
analysis O 0 1.8787135735998106e-10
within O 0 2.055980385939904e-11
the O 0 9.604561590492722e-10
insulin B-Disease 0 0.027950553223490715
- I-Disease 1 0.9990291595458984
dependent I-Disease 1 0.9999920129776001
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
( O 0 2.824006344326335e-07
IDDM B-Disease 0 8.606669143773615e-05
) O 0 3.2398863591964755e-09
locus O 0 2.2147197853428224e-07
IDDM4 O 0 4.265267125447281e-05
on O 0 3.833581558865262e-07
chromosome O 0 0.00013695757661480457
11q13 O 0 1.0968405149469618e-05
. O 0 1.2183721764813527e-07

Based O 0 4.0601821638119873e-07
on O 0 6.482077452574231e-08
its O 0 2.3153859274316346e-08
chromosomal O 0 0.0009623601217754185
position O 0 3.0580877137253992e-06
, O 0 4.329007707859489e-10
this O 0 2.0531628480702224e-11
gene O 0 8.561558684228032e-10
is O 0 2.2871244828581716e-11
a O 0 1.6049578333010572e-10
candidate O 0 1.9552461871796822e-09
for O 0 6.043542749578634e-11
conferring O 0 1.7438424038118683e-08
susceptibility O 0 1.4440131053561345e-05
to O 0 4.494520908338018e-06
diabetes B-Disease 0 0.028108390048146248
. O 0 3.1269300393432786e-07

The O 0 3.234479351021946e-08
gene O 0 2.727971093463566e-07
, O 0 2.497771101062085e-09
termed O 0 1.1917227027424815e-07
low O 0 8.529815431757015e-08
- O 0 1.6910629483390949e-06
density O 0 8.362408721040993e-08
lipoprotein O 0 1.898010424383756e-07
receptor O 0 3.767125278386629e-09
related O 0 4.191452962487574e-09
protein O 0 1.1784854869745232e-08
5 O 0 3.1681741674560726e-09
( O 0 3.1992389293300505e-10
LRP5 O 0 4.160242212947196e-07
) O 0 5.64121145629759e-11
, O 0 6.13419341363719e-12
encodes O 0 1.6171199102021916e-10
a O 0 1.464735138734241e-10
protein O 0 1.553850381696975e-09
of O 0 4.49825211801258e-11
1615 O 0 9.795475541807264e-09
amino O 0 5.147145376582785e-09
acids O 0 2.391486120245645e-09
that O 0 4.314207845135254e-12
contains O 0 1.982968043240385e-12
conserved O 0 5.164979208216458e-11
modules O 0 3.4047473174148024e-10
which O 0 6.396379259587803e-11
are O 0 4.674657362591095e-12
characteristic O 0 5.0214471469800515e-11
of O 0 4.149858841978604e-12
the O 0 2.1581585130103775e-10
low O 0 8.544160579049276e-08
- O 0 1.7013494471029844e-06
density O 0 1.8010148039593332e-07
lipoprotein O 0 1.8986997929459903e-06
( O 0 2.4732155878837148e-08
LDL O 0 5.837596290803049e-06
) O 0 1.6026887594833283e-09
receptor O 0 1.066308263908411e-09
family O 0 1.5519674434472108e-08
. O 0 3.947072002574714e-08

These O 0 2.8641744975743677e-08
modules O 0 1.309949748673489e-08
include O 0 3.5053229763271077e-10
a O 0 9.47849909671561e-10
putative O 0 2.328357417979987e-08
signal O 0 1.1738551464191005e-08
peptide O 0 1.6152558179882703e-09
for O 0 2.36001374692707e-11
protein O 0 6.864581680865456e-10
export O 0 7.296003801116058e-09
, O 0 2.517537844859419e-10
four O 0 1.086356671287092e-09
epidermal O 0 2.1584493481441314e-07
growth O 0 1.0261991434390438e-07
factor O 0 2.9943652002373256e-09
( O 0 1.2359652190596648e-09
EGF O 0 8.264274242719694e-08
) O 0 1.433542506923402e-09
repeats O 0 2.051614416131997e-07
with O 0 5.843675543459881e-11
associated O 0 1.7101519089735007e-09
spacer O 0 6.024222898304288e-07
domains O 0 1.0691624652281462e-07
, O 0 4.890750027186641e-10
three O 0 1.3815645294457113e-09
LDL O 0 3.2080158689495875e-06
- O 0 7.871367415646091e-07
receptor O 0 6.138978214664803e-09
( O 0 2.09324468869454e-09
LDLR O 0 6.9760531005158555e-06
) O 0 1.2868537346832909e-09
repeats O 0 9.47127546169213e-07
, O 0 4.983034818106802e-11
a O 0 1.191914206222222e-10
single O 0 1.0760462743064636e-08
transmembrane O 0 3.4360307932246315e-09
spanning O 0 4.767846117914587e-09
domain O 0 2.103756457927375e-08
, O 0 1.268975591273147e-09
and O 0 1.4529594194456763e-10
a O 0 1.1031865421173848e-09
cytoplasmic O 0 4.5230800083118083e-07
domain O 0 9.23630523175234e-07
. O 0 6.95081894264149e-08

The O 0 9.37138189271991e-09
encoded O 0 3.488192135137069e-08
protein O 0 3.7693194343546566e-08
has O 0 3.9870193258018105e-10
a O 0 1.2004219840378028e-10
unique O 0 1.7618743963776495e-10
organization O 0 3.6908803791035893e-10
of O 0 1.7431557586267132e-10
EGF O 0 1.491633696559802e-07
and O 0 1.7140779462465616e-08
LDLR O 0 9.168709766527172e-06
repeats O 0 2.5280937734351028e-06
; O 0 2.288932376970365e-10
therefore O 0 3.5447689228362833e-10
, O 0 1.174731978359489e-10
LRP5 O 0 1.240650476574956e-06
likely O 0 1.2153142936455197e-09
represents O 0 2.7905575419873152e-11
a O 0 7.560792270044914e-11
new O 0 7.275599567257984e-10
category O 0 8.599991829782994e-09
of O 0 7.945299279610296e-11
the O 0 8.320942157524769e-09
LDLR O 0 5.4957046813797206e-05
family O 0 5.1325795169532284e-08
. O 0 4.2256669274820524e-08

Both O 0 8.529473660701115e-08
human O 0 1.2022883133511186e-08
and O 0 5.93192606146431e-09
mouse O 0 4.308443806166906e-07
LRP5 O 0 4.7682871809229255e-05
cDNAs O 0 2.241866013719118e-06
have O 0 4.215135351870458e-09
been O 0 7.418674008441428e-10
isolated O 0 6.994998358322846e-09
and O 0 9.25204010626679e-11
the O 0 7.773242119424317e-12
encoded O 0 5.128855673497412e-10
mature O 0 4.1352457569310275e-10
proteins O 0 2.8479040306561565e-11
are O 0 1.9108985227500597e-11
95 O 0 1.5850828982699738e-10
% O 0 1.819054351592797e-10
identical O 0 1.6782497169742783e-08
, O 0 1.6400165669949729e-09
indicating O 0 2.1181667975156415e-08
a O 0 1.2744452160262654e-09
high O 0 4.380172669016247e-09
degree O 0 3.4875451415672387e-09
of O 0 7.019409359321216e-11
evolutionary O 0 1.3504386497942278e-09
conservation O 0 1.2266135884786422e-09
. O 0 1.5382833895571935e-09
. O 0 1.4844466988961358e-08

The O 0 7.393959577939313e-08
APC B-Disease 0 7.935599910524616e-07
variants O 0 4.578300050184225e-08
I1307K O 0 6.831333365653336e-08
and O 0 6.016241949069467e-10
E1317Q O 0 2.3256545134131557e-08
are O 0 1.1487439888213657e-09
associated O 0 4.3097423940707813e-07
with O 1 0.9978085160255432
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 1.9073276007475215e-06
but O 0 1.3149387356747866e-08
not O 0 2.994154035818042e-09
always O 0 9.178819371236102e-10
with O 0 5.913461387230257e-11
a O 0 3.7110778894344776e-09
family O 0 2.1400550664907314e-08
history O 0 2.1303421249285748e-08
. O 0 9.968331937670882e-08

Classical O 0 0.43797725439071655
familial B-Disease 1 1.0
adenomatous I-Disease 1 0.9999997615814209
polyposis I-Disease 1 1.0
( O 0 0.00039712846046313643
FAP B-Disease 0 7.448607902915683e-06
) O 0 2.0809251211062474e-08
is O 0 5.105587064235806e-10
a O 0 2.740958349178868e-09
high O 0 3.2837751859915443e-06
- O 1 0.9998219609260559
penetrance O 1 0.9999535083770752
autosomal B-Disease 1 0.9999996423721313
dominant I-Disease 0 0.2370823621749878
disease I-Disease 0 0.10401991009712219
that O 0 3.2574387631711943e-10
predisposes O 0 3.259206948769133e-08
to O 0 4.889696425536272e-10
hundreds O 0 1.845829877833438e-10
or O 0 3.972780771022144e-09
thousands O 0 3.8368046517689436e-09
of O 0 2.651974909895216e-06
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 0.9937325119972229
carcinoma I-Disease 1 1.0
and O 0 1.5300403219953296e-06
that O 0 3.6069374154124034e-09
results O 0 7.276022984115116e-08
from O 0 2.4059287895283887e-10
truncating O 0 1.5283762877515983e-07
mutations O 0 9.188215699396096e-08
in O 0 6.29429494636291e-11
the O 0 3.8133760038583375e-10
APC B-Disease 0 2.2188254433785914e-07
gene O 0 2.7879318054147006e-07
. O 0 3.622396249625126e-08

A O 0 1.4741797826900438e-07
variant O 0 2.0727866285596974e-06
of O 0 6.563526611103043e-09
FAP B-Disease 0 4.23951451011817e-06
is O 0 4.783835265698144e-07
attenuated B-Disease 0 0.21582061052322388
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 0.999998927116394
coli I-Disease 1 1.0
, O 0 1.7294905774178915e-07
which O 0 2.9551479041600714e-09
results O 0 1.252242185501018e-07
from O 0 1.1697978141711474e-09
germ O 0 7.484194611606654e-06
- O 0 3.595723228499992e-06
line O 0 1.5337920558522455e-05
mutations O 0 5.281574999571603e-08
in O 0 3.925174421604005e-11
the O 0 5.6652241925414515e-11
5 O 0 2.909682050855622e-09
and O 0 1.6033187000275007e-09
3 O 0 1.2960267303796513e-09
regions O 0 1.2884902034215884e-08
of O 0 5.0455639666324714e-11
the O 0 2.919248842658817e-09
APC B-Disease 0 2.2238459962409252e-07
gene O 0 4.2141245160109975e-08
. O 0 1.6262028168512188e-08

Attenuated B-Disease 1 0.9999604225158691
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 0.9999998807907104
coli I-Disease 1 1.0
patients O 1 0.9437298774719238
have O 0 1.1276398481641081e-07
" O 0 1.342253312941466e-07
multiple O 0 0.00010654787183739245
" O 1 0.9999016523361206
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
( O 0 2.341563458685414e-06
typically O 0 6.05975714051965e-08
fewer O 0 1.173273123100671e-08
than O 0 2.456757852709046e-10
100 O 0 1.1268427163591e-10
) O 0 1.4157761074606867e-10
without O 0 2.0636858888423149e-10
the O 0 5.541153091925821e-10
florid O 0 4.267988060746575e-06
phenotype O 0 7.41334758913581e-07
of O 0 4.621707738738934e-10
classical O 0 4.29671658253028e-08
FAP B-Disease 0 1.1079526984758559e-06
. O 0 3.349153132603533e-08

Another O 0 4.4907153551321244e-07
group O 0 1.1260365084808655e-07
of O 0 3.1652372389778805e-10
patients O 0 9.77703340510061e-09
with O 0 2.9084212815888577e-10
multiple O 0 2.5092192572628846e-06
adenomas B-Disease 1 0.8253945708274841
has O 0 2.591997656509193e-07
no O 0 2.78619394222801e-09
mutations O 0 8.180353283648856e-09
in O 0 3.9175829247284355e-11
the O 0 1.5889393967238874e-10
APC B-Disease 0 1.2809844740502285e-08
gene O 0 4.909904038896684e-09
, O 0 1.5965796740236016e-10
and O 0 3.644889390308492e-10
their O 0 8.982458332695842e-09
phenotype O 0 1.3625501651404193e-06
probably O 0 9.563895986275384e-08
results O 0 4.076546744613552e-08
from O 0 5.5577265012374255e-11
variation O 0 2.424924705479725e-09
at O 0 4.655577701129232e-09
a O 0 1.093282797626216e-09
locus O 0 2.60912429439486e-08
, O 0 1.6078234299499172e-09
or O 0 2.5589848018370276e-09
loci O 0 4.804626474452789e-09
, O 0 3.866135744878818e-10
elsewhere O 0 3.906208245751941e-09
in O 0 1.345565880939148e-10
the O 0 1.423664852673312e-09
genome O 0 1.4631930866926268e-07
. O 0 8.75958505730523e-08

Recently O 0 1.7060992831829935e-05
, O 0 6.553681597409877e-09
however O 0 9.169090486871312e-10
, O 0 7.855580075322166e-11
a O 0 4.5932255221536877e-10
missense O 0 2.8117923989157134e-07
variant O 0 3.9285137631850375e-07
of O 0 9.771398135072218e-10
APC B-Disease 0 3.8009414993211976e-07
( O 0 1.1378906705772351e-09
I1307K O 0 2.8554579145634307e-08
) O 0 6.179858846877551e-10
was O 0 4.740722925333785e-09
described O 0 1.6905083999319004e-09
that O 0 3.590021682708944e-11
confers O 0 3.053265140717798e-10
an O 0 3.86244855543616e-11
increased O 0 1.908737701228347e-08
risk O 0 2.7578764274949208e-05
of O 0 0.003605997422710061
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 1.0071744327433407e-07
including O 0 3.9979164423442626e-10
multiple O 0 1.8139253370463848e-06
adenomas B-Disease 0 0.11971047520637512
, O 0 4.906779338398337e-08
in O 0 6.874359304021027e-09
Ashkenazim O 0 8.266772783827037e-05
. O 0 2.352059453869515e-07

We O 0 3.976732386945514e-06
have O 0 2.0265875644298603e-09
studied O 0 8.558962982796459e-10
a O 0 1.4254221414322643e-10
set O 0 1.283767314674833e-09
of O 0 1.6783144318743837e-11
164 O 0 4.246745177738376e-09
patients O 0 6.661599716295541e-09
with O 0 3.09145620214224e-09
multiple O 1 0.9999707937240601
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 0 0.01892469823360443
/ I-Disease 1 0.999975323677063
or I-Disease 1 0.9994451403617859
carcinoma I-Disease 1 1.0
and O 0 1.4960257885832107e-06
analyzed O 0 1.357779183308594e-06
codons O 0 6.937805665074848e-06
1263 O 0 9.042917099577608e-07
- O 0 2.885713684008806e-06
1377 O 0 1.1089242661910248e-06
( O 0 4.277074250325086e-09
exon O 0 3.155168997182045e-07
15G O 0 2.4793752118057455e-07
) O 0 2.055765696562517e-10
of O 0 8.610515946083641e-12
the O 0 8.696809938868455e-11
APC B-Disease 0 1.1933598997870831e-08
gene O 0 2.341369098601831e-09
for O 0 1.3506749885205949e-10
germ O 0 6.263405225581664e-07
- O 0 1.6105732356663793e-06
line O 0 8.858174624037929e-06
variants O 0 7.560326480415824e-07
. O 0 2.6677192010993167e-08

Three O 0 5.012555561734189e-07
patients O 0 2.767990849861235e-07
with O 0 2.22883711487043e-10
the O 0 4.782005347259144e-10
I1307K O 0 5.361842170259479e-08
allele O 0 4.5438886786541843e-07
were O 0 2.1487219115101652e-08
detected O 0 1.052958040759222e-07
, O 0 5.086096821482755e-11
each O 0 3.5709157852892304e-10
of O 0 6.595599622016834e-10
Ashkenazi O 0 4.0064533095574006e-05
descent O 0 1.824707396735903e-05
. O 0 2.6331670710533217e-07

Four O 0 3.3469871141278418e-06
patients O 0 4.649325092032086e-06
had O 0 8.55142801015063e-09
a O 0 2.754364292201217e-09
germ O 0 4.194629127596272e-06
- O 0 4.191342213744065e-06
line O 0 7.5676948654290754e-06
E1317Q O 0 5.9065264679247775e-08
missense O 0 1.4439716267133917e-07
variant O 0 4.778582152198396e-08
of O 0 1.8376521138119273e-10
APC O 0 4.765902517078757e-08
that O 0 1.464134508077919e-10
was O 0 2.4387145636239893e-09
not O 0 2.2858000214842633e-10
present O 0 9.430436986868074e-11
in O 0 8.926293038058475e-11
controls O 0 5.634772719531611e-07
; O 0 4.983420343052103e-09
one O 0 1.12973141952466e-09
of O 0 1.3113826864696865e-11
these O 0 3.3639513397076826e-10
individuals O 0 4.650284324281273e-11
had O 0 2.4587619051885667e-08
an O 0 7.51796819242756e-11
unusually O 0 5.337623676382464e-10
large O 0 1.0518184934138475e-10
number O 0 3.4198943676955196e-09
of O 0 4.254339658338324e-10
metaplastic B-Disease 0 4.1423863876843825e-05
polyps I-Disease 0 4.476170033740345e-06
of I-Disease 0 1.5012675824710442e-10
the I-Disease 0 5.979385875320986e-09
colorectum I-Disease 0 1.8337977962801233e-05
. O 0 5.344994491451871e-08

There O 0 1.576588459784034e-07
is O 0 1.1542083955262683e-09
increasing O 0 4.502649364468425e-10
evidence O 0 6.09758243896863e-10
that O 0 2.4420646060896445e-10
there O 0 1.8325978234923213e-10
exist O 0 2.24361729195266e-09
germ O 0 3.838410407297488e-07
- O 0 2.0600390371328103e-07
line O 0 9.673694876255468e-07
variants O 0 3.6093392719038775e-09
of O 0 6.11069831887856e-12
the O 0 8.562126008193616e-11
APC B-Disease 0 3.730729503104158e-09
gene O 0 8.075027313481087e-10
that O 0 1.9896407438269037e-11
predispose O 0 1.508990710163971e-09
to O 0 1.567100338384364e-10
the O 0 3.4449453706342226e-11
development O 0 4.3746933853228143e-10
of O 0 4.9152166781141204e-09
multiple O 1 0.999991774559021
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 0.9899156093597412
carcinoma I-Disease 1 1.0
, O 0 8.036423082558031e-08
but O 0 3.0327840239152692e-09
without O 0 4.3543810224200286e-10
the O 0 1.835172291908549e-10
florid O 0 2.9537686714320444e-06
phenotype O 0 4.555999453259574e-07
of O 0 1.0970213626393388e-10
classical O 0 4.282592502846683e-09
FAP B-Disease 0 1.6767939925443898e-08
, O 0 3.886608257452906e-10
and O 0 7.717727845690803e-11
possibly O 0 2.9088539910127054e-10
with O 0 2.094592554957586e-11
importance O 0 1.024382001446611e-08
for O 1 0.6307582855224609
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
risk O 0 2.6351819997216808e-06
in O 0 1.5218870608180168e-10
the O 0 3.6254202417929093e-10
general O 0 9.79775038878472e-10
population O 0 2.6351279491798607e-10
. O 0 9.91498327884699e-10
. O 0 1.7414725661524244e-08

Genomic O 0 8.531874300388154e-06
structure O 0 7.804410273593021e-08
of O 0 7.204345453537542e-10
the O 0 1.5401395714320643e-08
human O 0 9.92121385934297e-06
congenital B-Disease 1 1.0
chloride I-Disease 1 0.9999914169311523
diarrhea I-Disease 1 1.0
( O 0 1.0875451152969617e-06
CLD B-Disease 0 0.001713738078251481
) O 0 3.591684816228735e-08
gene O 0 1.3558706086769234e-06
. O 0 6.668670238241248e-08

Congenital B-Disease 1 1.0
chloride I-Disease 1 0.9999991655349731
diarrhea I-Disease 1 1.0
( O 0 0.00018488342175260186
CLD B-Disease 1 0.6181960105895996
) O 0 2.6885146553468076e-07
is O 0 2.492792638975061e-09
caused O 0 1.2264246507243115e-08
by O 0 1.1531603449910222e-10
mutations O 0 1.2024035811464273e-07
in O 0 5.896274440919669e-11
a O 0 5.4244092551059e-10
gene O 0 3.1311817139112463e-08
which O 0 9.44529232604907e-10
encodes O 0 4.997691149810635e-08
an O 0 5.063674368699367e-09
intestinal O 0 5.78025992581388e-06
anion O 0 1.9344120971709344e-07
transporter O 0 2.432579276501201e-05
. O 0 1.3929647479926643e-07

We O 0 5.319476258591749e-05
report O 0 3.0859322919241094e-07
here O 0 5.143265813245534e-10
the O 0 2.8830904677534797e-11
complete O 0 9.145231794072117e-10
genomic O 0 8.729541534080454e-09
organization O 0 2.6214724835327274e-10
of O 0 1.8755904815370705e-11
the O 0 2.4792873309920083e-10
human O 0 3.5909912821097123e-09
CLD B-Disease 0 2.3821016839065123e-06
gene O 0 5.1466273021105735e-08
which O 0 7.445522531845938e-10
spans O 0 1.6527572199720453e-08
approximately O 0 6.224364579310304e-09
39kb O 0 2.8297206426941557e-06
, O 0 2.534537024700967e-09
and O 0 1.051704723309399e-09
comprises O 0 1.2620648970340653e-09
21 O 0 1.1386207532382286e-08
exons O 0 9.674211014498724e-07
. O 0 5.069823316716793e-08

All O 0 3.9484885405727255e-07
exon O 0 2.9236387490527704e-05
/ O 0 0.00017196492990478873
intron O 0 0.00011743321374524385
boundaries O 0 4.606825712016871e-07
conform O 0 2.1992721030983375e-06
to O 0 3.4247966684830544e-09
the O 0 8.333756462697295e-10
GT O 0 1.218937450175872e-05
/ O 0 0.00995017308741808
AG O 1 0.9999905824661255
rule O 0 1.4692841432406567e-07
. O 0 1.61476076954159e-08

An O 0 1.2978481400693909e-08
analysis O 0 5.242570377816946e-09
of O 0 1.0611968942475514e-10
the O 0 9.058707117759468e-10
putative O 0 1.0341708645000836e-07
promoter O 0 3.5301320622238563e-07
region O 0 4.07510079014628e-08
sequence O 0 1.1540944200305603e-08
shows O 0 2.58751509107924e-09
a O 0 5.821407245143462e-10
putative O 0 3.891842226266817e-08
TATA O 0 5.838286597281694e-06
box O 0 4.5084419753038674e-07
and O 0 7.80522579901799e-09
predicts O 0 1.4106244350386987e-07
multiple O 0 2.2265054244741123e-09
transcription O 0 1.8729192419186802e-08
factor O 0 5.168551808765187e-09
binding O 0 3.8964174109423766e-08
sites O 0 2.504843621409236e-07
. O 0 1.1079341533104525e-07

The O 0 2.0978822234951622e-08
genomic O 0 4.467154326448508e-07
structure O 0 9.826617741737209e-08
was O 0 2.2736273308510135e-08
determined O 0 1.5695330590759227e-09
using O 0 1.6144786896266083e-10
DNA O 0 6.94318424976359e-09
from O 0 4.8980389188990614e-11
several O 0 1.5091790664389926e-11
sources O 0 1.059837564931776e-10
including O 0 1.0256649696227527e-11
multiple O 0 1.1256638954293408e-09
large O 0 3.968948281141138e-09
- O 0 2.559134372859262e-05
insert O 0 5.419072476797737e-05
libaries O 0 1.3763610695605166e-06
and O 0 2.7975455285655926e-10
genomic O 0 4.797026331715415e-09
DNA O 0 1.1520297249489886e-07
from O 0 5.7936513364609254e-09
Finnish O 0 8.246538345701993e-05
CLD B-Disease 0 0.011091197840869427
patients O 0 2.7974235763394972e-06
and O 0 2.452905434324748e-09
controls O 0 3.825174189842073e-06
. O 0 2.364104290109026e-07

Exon O 0 2.8644628400797956e-05
- O 0 1.7263907921005739e-06
specific O 0 1.789505610361175e-08
primers O 0 3.7514678297156934e-07
developed O 0 3.452823138516692e-09
in O 0 1.2118994696663776e-10
this O 0 9.783870241752979e-11
study O 0 1.9245247062649184e-10
will O 0 1.3331358239554447e-09
facilitate O 0 4.945127085598244e-10
mutation O 0 3.166108486496455e-09
screening O 0 4.1221124291723754e-09
studies O 0 3.6948530346414543e-10
of O 0 5.735262958994625e-11
patients O 0 5.422777782371213e-09
with O 0 1.0172296338595288e-10
the O 0 1.2490809275789161e-08
disease O 0 3.083564297412522e-05
. O 0 2.3818232719463595e-08

Genomic O 0 1.9693407011800446e-05
sequencing O 0 7.173048288677819e-07
of O 0 3.3744278482572554e-09
a O 0 5.756313825600046e-08
BAC O 0 0.000296529324259609
clone O 0 0.00015566707588732243
H O 1 0.9999998807907104
_ O 0 2.6383947471231295e-08
RG364P16 O 0 3.015159322217187e-08
revealed O 0 3.818066929284214e-08
the O 0 2.85761102281068e-11
presence O 0 7.782102739994912e-11
of O 0 6.398889664666063e-12
another O 0 1.8085201392015193e-10
, O 0 2.7022002691001745e-11
highly O 0 1.6051529896921046e-11
homologous O 0 1.3989828739902066e-10
gene O 0 8.44193659421677e-10
3 O 0 2.755576600232956e-10
of O 0 3.048311603137677e-11
the O 0 1.0462964938895425e-09
CLD B-Disease 0 2.267548325107782e-06
gene O 0 1.6711107164724126e-08
, O 0 2.3874914198418473e-11
with O 0 5.29994060791128e-12
a O 0 3.898835074234164e-11
similar O 0 6.220488707464611e-11
genomic O 0 1.0413653939167489e-08
structure O 0 3.868440856535926e-08
, O 0 1.6929220247874355e-09
recently O 0 4.839985123794577e-08
identified O 0 2.746873661862992e-08
as O 0 1.2979166630344707e-09
the O 0 3.4359612754997215e-07
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
gene O 0 1.3750109246757347e-06
( O 0 7.411323110773083e-09
PDS B-Disease 0 1.4118026228970848e-05
) O 0 1.559066431511269e-09
. O 0 1.111328029601566e-09
. O 0 1.7736740076657043e-08

The O 0 1.4861811337141262e-07
APCI1307K O 0 7.195564830908552e-05
allele O 0 0.0001660395646467805
and O 0 1.6131019719978212e-06
cancer B-Disease 0 4.798860027221963e-05
risk O 0 1.1300620883503143e-07
in O 0 8.754177244219008e-11
a O 0 1.5741800085677937e-09
community O 0 8.335696022321315e-10
- O 0 6.493598334600392e-07
based O 0 1.616339062593397e-07
study O 0 7.293690096332739e-10
of O 0 2.890177819292461e-10
Ashkenazi O 0 1.9129490738123422e-06
Jews O 0 4.5359957567825404e-08
. O 0 2.650131136761047e-08

Mutations O 0 0.0003171294229105115
in O 0 2.3710265750764847e-08
APC O 0 2.9443524454109138e-06
are O 0 5.502398536805231e-09
classically O 0 1.4849842955300119e-06
associated O 0 2.9606442240037723e-06
with O 0 7.821500912541524e-05
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 0 4.539327710517682e-05
FAP B-Disease 0 2.060507995338412e-06
) O 0 6.375922456669514e-09
, O 0 1.826076373445673e-10
a O 0 2.8154474307484634e-09
highly O 0 7.313415153475944e-07
penetrant O 1 0.9998680353164673
autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 0 8.698803526385745e-07
by O 0 1.6917051093301438e-09
multiple O 0 2.793920793919824e-05
intestinal O 1 0.86866295337677
polyps B-Disease 1 0.5519053936004639
and O 0 3.398165659973529e-08
, O 0 6.586384770912446e-10
without O 0 1.0466777444761988e-09
surgical O 0 1.0438694886261146e-07
intervention O 0 3.2450236941983235e-10
, O 0 4.3752584888423485e-11
the O 0 1.3020966249666088e-10
development O 0 4.361750072234827e-08
of O 0 0.0005197461578063667
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 3.5205765414048074e-08
CRC B-Disease 0 9.42170481721405e-06
) O 0 7.690404757454417e-09
. O 0 4.3829246010318457e-08

APC B-Disease 0 4.418725075083785e-05
is O 0 3.141075666235338e-08
a O 0 4.553679744390138e-08
tumour O 1 1.0
- O 0 7.913843546702992e-06
suppressor O 0 6.536282057822973e-07
gene O 0 6.628445703427133e-07
, O 0 5.683106207854394e-10
and O 0 3.590400199371402e-10
somatic O 0 3.086508826299905e-08
loss O 0 5.323445861904474e-07
occurs O 0 1.853395481532516e-08
in O 0 5.9105722982621955e-08
tumours B-Disease 1 1.0
. O 0 6.480062211267068e-07

The O 0 1.3640956808558258e-07
germline O 0 1.2240512660355307e-05
T O 0 5.326519840309629e-06
- O 0 1.6501309119121288e-07
to O 0 8.877842461174623e-09
- O 0 1.0860406973733916e-07
A O 0 5.2918906590093684e-08
transversion O 0 1.7337215751922486e-07
responsible O 0 3.345429488987861e-09
for O 0 1.8931909859243312e-11
the O 0 1.2091264101066201e-10
APC O 0 5.910107070405957e-09
I1307K O 0 2.54073229122298e-09
allele O 0 2.2087067730325316e-09
converts O 0 7.98760557696454e-10
the O 0 5.3712204822753407e-11
wild O 0 9.925332777882545e-10
- O 0 6.832933330258584e-09
type O 0 1.2586056641339383e-09
sequence O 0 3.614905930149348e-09
to O 0 2.0453359006467053e-09
a O 0 2.2133130883617014e-08
homopolymer O 0 0.0002674106217455119
tract O 0 6.967873923713341e-05
( O 0 1.7695649390248036e-08
A8 O 0 0.00021618344180751592
) O 0 1.7861356838011488e-09
that O 0 1.1208387690198052e-10
is O 0 1.924793435748029e-09
genetically O 0 5.999934273859253e-06
unstable O 0 0.0013114440953359008
and O 0 1.3077833216357249e-07
prone O 0 4.989527951693162e-06
to O 0 1.1753382267443158e-08
somatic O 0 3.6175913464830955e-07
mutation O 0 1.7493812265456654e-06
. O 0 5.118453216823582e-08

The O 0 7.671641100159832e-08
I1307K O 0 1.3538445955418865e-06
allele O 0 3.232023573218612e-06
was O 0 8.446244947890591e-08
found O 0 6.187552248348993e-09
in O 0 7.491762765710064e-10
6 O 0 2.864786274869857e-08
. O 0 3.015947314111145e-08

1 O 0 3.258971332797955e-07
% O 0 1.7290084031174047e-08
of O 0 9.337584039315061e-10
unselected O 0 6.47855767965666e-06
Ashkenazi O 0 1.2300637536100112e-05
Jews O 0 4.597507441417292e-08
and O 0 4.0838599169035206e-09
higher O 0 3.724899277912641e-09
proportions O 0 1.9871064793619553e-08
of O 0 2.289692324630721e-10
Ashkenazim O 0 1.8049005348075298e-06
with O 0 3.621344557558359e-09
family O 0 2.5981691464949108e-08
or O 0 4.152290671299852e-07
personal O 0 1.3382960162289237e-07
histories O 0 6.685251605631493e-07
of O 0 3.642285140159629e-09
CRC B-Disease 0 4.5946122554596514e-05
( O 0 3.078417298851832e-09
ref O 0 7.446125209753518e-07
. O 0 4.2575865055738404e-10
2 O 0 2.6345916559478155e-09
) O 0 1.6267324154384255e-09
. O 0 2.2035658631125443e-08

To O 0 2.5254908564420475e-07
evaluate O 0 1.3687635203041282e-07
the O 0 5.212336673388052e-10
role O 0 9.25859389155903e-10
of O 0 1.3012649291432865e-10
I1307K O 0 2.9135989620954206e-08
in O 0 2.4113877561404706e-09
cancer B-Disease 0 2.828674610100279e-07
, O 0 1.3241496787941287e-09
we O 0 6.258602081032905e-09
genotyped O 0 1.2156191075973766e-07
5 O 0 2.7871400742895958e-09
, O 0 7.978561145094432e-10
081 O 0 1.9183261201760615e-07
Ashkenazi O 0 4.534871038686106e-07
volunteers O 0 1.217546286014226e-09
in O 0 7.813082819607686e-11
a O 0 6.249318840190199e-10
community O 0 2.0117603138913864e-09
survey O 0 8.49068015895682e-08
. O 0 1.823015871593725e-08

Risk O 0 5.764378511230461e-05
of O 0 1.0854438237117847e-08
developing O 0 2.631521965668071e-05
colorectal B-Disease 1 1.0
, I-Disease 0 2.553887043177383e-06
breast I-Disease 0 0.005302931182086468
and I-Disease 0 4.887016302745906e-07
other I-Disease 0 2.1920087078797224e-08
cancers I-Disease 0 0.0008781072101555765
were O 0 3.757366418000174e-09
compared O 0 2.8122271178432356e-09
between O 0 1.360853096876724e-10
genotyped O 0 5.758168981628842e-07
I1307K O 0 2.0753956775365623e-08
carriers O 0 4.0715328886165025e-09
and O 0 3.166976403345956e-10
non O 0 3.951032390148157e-09
- O 0 4.161440472216782e-07
carriers O 0 9.53775511902677e-08
and O 0 1.3420524691554192e-09
their O 0 1.4974075313034518e-09
first O 0 1.2718766484454136e-08
- O 0 7.788407856423873e-07
degree O 0 6.54366658636718e-08
relatives O 0 1.798265429897583e-07
. O 0 3.475143017794835e-08

Sperm O 0 7.152628768380964e-06
DNA O 0 1.222994114868925e-06
analysis O 0 2.7753648268458164e-08
in O 0 3.153079131124059e-09
a O 0 6.570593313881545e-07
Friedreich B-Disease 1 0.9999769926071167
ataxia I-Disease 1 0.9999904632568359
premutation O 0 0.0007245798478834331
carrier O 0 3.333302629471291e-06
suggests O 0 4.325562130702565e-08
both O 0 6.162649834884348e-10
meiotic O 0 2.0636689157527144e-07
and O 0 1.5784855644795925e-09
mitotic O 0 2.6524169527419872e-08
expansion O 0 1.908820435048142e-09
in O 0 1.505390812006624e-10
the O 0 9.631656583408699e-10
FRDA B-Disease 0 8.32392652228009e-06
gene O 0 4.860513627136243e-07
. O 0 3.129092362996744e-08

Friedreich B-Disease 1 0.9999972581863403
ataxia I-Disease 1 0.9999997615814209
is O 0 3.9944779928191565e-06
usually O 0 6.81073828445733e-08
caused O 0 8.09489364428373e-09
by O 0 2.3937062401668818e-11
an O 0 5.245315640167725e-11
expansion O 0 1.0695816454742157e-09
of O 0 2.760627004771976e-10
a O 0 8.124239769813357e-08
GAA O 0 1.3027475688431878e-05
trinucleotide O 0 1.1625011211435776e-05
repeat O 0 5.220032903707761e-07
in O 0 1.8733747886301444e-10
intron O 0 1.9074609269864595e-07
1 O 0 9.41699607182045e-10
of O 0 3.812625215537935e-11
the O 0 1.094421997471784e-09
FRDA B-Disease 0 6.095727258070838e-06
gene O 0 2.636350586726621e-07
. O 0 1.7846824462708355e-08

Occasionally O 0 1.553352558403276e-05
, O 0 9.921325094808253e-09
a O 0 2.4392587949506606e-09
fully O 0 9.005822754204473e-09
expanded O 0 1.0010794415649116e-09
allele O 0 7.522382361457858e-08
has O 0 3.870239684289345e-09
been O 0 5.465451979880243e-10
found O 0 1.0040701603486468e-09
to O 0 1.3163508061353468e-09
arise O 0 8.721233180075671e-10
from O 0 3.9188458034189466e-11
a O 0 5.329251484553765e-10
premutation O 0 1.628916663776181e-07
of O 0 4.087277044595439e-11
100 O 0 8.542506702013952e-10
or O 0 1.8270956303467756e-08
less O 0 3.3724671055779254e-08
triplet O 0 0.0008521517156623304
repeats O 0 0.00039008271414786577
. O 0 6.333659996471397e-08

We O 0 1.8800090401782654e-05
have O 0 5.163693916898637e-09
examined O 0 5.062728014593176e-09
the O 0 9.730922317929824e-11
sperm O 0 3.441212204080557e-09
DNA O 0 7.408030189282044e-09
of O 0 1.9934581763081383e-11
a O 0 2.3361543810551666e-09
premutation O 0 2.253785169159528e-06
carrier O 0 5.819420039188117e-07
. O 0 4.607435855064068e-08

This O 0 8.570994936007992e-08
mans O 0 2.822091119014658e-06
leucocyte O 0 4.133659786020871e-06
DNA O 0 8.558845934203418e-07
showed O 0 1.1451464132505862e-07
one O 0 5.673813086026769e-10
normal O 0 4.197821645846034e-09
allele O 0 4.227456429362064e-08
and O 0 1.7797220364101918e-09
one O 0 2.3190653564153507e-10
allele O 0 1.3162209988593077e-08
of O 0 6.874194963257807e-11
approximately O 0 2.235104767933649e-09
100 O 0 5.3603264049684185e-09
repeats O 0 7.563812687294558e-06
. O 0 4.4588368552922475e-08

His O 0 8.412639544985723e-07
sperm O 0 3.997507974418113e-06
showed O 0 1.6975944561181677e-07
an O 0 9.19274309452156e-11
expanded O 0 1.0265447381030413e-09
allele O 0 7.542453062114873e-08
in O 0 4.284934906895188e-10
a O 0 1.9605566059510693e-09
tight O 0 7.545647662254851e-08
range O 0 3.1229494545925718e-09
centering O 0 5.891244381217575e-09
on O 0 6.198158875037052e-09
a O 0 5.675686032269311e-10
size O 0 1.8204714402614286e-09
of O 0 4.1488579238802004e-10
approximately O 0 3.6393632996123415e-08
320 O 0 1.46468138950695e-07
trinucleotide O 0 5.801918814540841e-05
repeats O 0 2.8952821594430134e-05
. O 0 4.1096953395936e-08

His O 0 1.5511910532950424e-05
affected O 0 6.42098484604503e-06
son O 0 5.955684628133895e-06
has O 0 2.450858538338707e-08
repeat O 0 2.472989990565111e-07
sizes O 0 7.968086634946303e-09
of O 0 1.2123595183322067e-10
1040 O 0 1.0515712034475655e-07
and O 0 4.057802538426358e-09
540 O 0 1.0142957762582228e-07
. O 0 3.844124663032744e-08

These O 0 3.666151826564601e-08
data O 0 5.012756432165588e-08
suggest O 0 2.777666985309679e-09
that O 0 1.637392652020786e-11
expansion O 0 9.516026855393989e-11
occurs O 0 8.69921565338494e-11
in O 0 2.4422684360980718e-11
two O 0 2.813352051322937e-10
stages O 0 4.6458912272839825e-09
, O 0 4.0405526147146986e-11
the O 0 2.1483334208816096e-11
first O 0 1.5818009124757282e-09
during O 0 1.5630256811061116e-10
meiosis O 0 2.641125929070398e-10
followed O 0 1.0286786700230977e-10
by O 0 3.246865450112768e-12
a O 0 8.762379710702817e-11
second O 0 4.269738340667573e-09
mitotic O 0 4.182064117230766e-08
expansion O 0 2.7185558693076928e-08
. O 0 5.702537109186778e-08

We O 0 1.977904275918263e-06
also O 0 2.3610111643534992e-09
show O 0 6.6924572550419725e-09
that O 0 6.890958637040256e-11
in O 0 1.88105035020536e-11
all O 0 2.883816449528176e-11
informative O 0 4.7311119466542095e-09
carrier O 0 3.5131240139207875e-08
father O 0 1.4153751948242643e-08
to O 0 2.407458676856322e-09
affected O 0 4.474314696523152e-09
child O 0 2.0279223633679067e-08
transmissions O 0 1.1282405694146291e-06
, O 0 1.0680521050909775e-10
with O 0 1.7749877956330096e-11
the O 0 3.4022396011579303e-11
notable O 0 2.8816171671053326e-11
exception O 0 6.252677542395446e-11
of O 0 9.411403080472613e-12
the O 0 4.256003327540725e-10
premutation O 0 4.1044705767490086e-07
carrier O 0 1.0836359365384851e-08
, O 0 2.7338234107054937e-11
the O 0 1.0537738216742643e-11
expansion O 0 5.671844105492596e-10
size O 0 8.505069537534382e-09
decreases O 0 1.4876516729600553e-07
. O 0 3.3989873138295934e-09
. O 0 1.2984968655871398e-08

The O 0 4.7263615243764434e-08
R496H O 0 3.478035068837926e-07
mutation O 0 1.3419231947864318e-07
of O 0 4.728204494597321e-10
arylsulfatase O 0 1.5188401221166714e-06
A O 0 2.2522004883285263e-07
does O 0 5.259369117993629e-07
not O 0 1.3693967559902376e-07
cause O 0 5.416043222794542e-06
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 0.9999995231628418
. O 0 5.4170732255443e-07

Deficiency B-Disease 1 0.9994924068450928
of I-Disease 0 5.070207365065471e-09
arylsulfatase I-Disease 0 4.64190907223383e-06
A I-Disease 0 3.169608930875256e-07
( O 0 1.838909113871523e-08
ARSA O 0 6.161897908896208e-05
) O 0 3.8911278643638525e-09
enzyme O 0 2.084636179233712e-07
activity O 0 5.432780767478107e-07
causes O 0 7.006292435107753e-05
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
( O 0 1.9630966562544927e-05
MLD B-Disease 1 0.9999994039535522
) O 0 6.565820598325445e-08
. O 0 5.694993632232581e-08

A O 0 3.134567521101417e-07
number O 0 8.578481036636276e-09
of O 0 2.2029427171332827e-09
ARSA O 0 0.0004661943530663848
gene O 0 5.348714239516994e-06
mutations O 0 2.178568138333503e-05
responsible O 0 1.5273752751454595e-06
for O 0 2.773444691683835e-07
MLD B-Disease 1 1.0
have O 0 1.3159922218619613e-06
been O 0 2.3906530088879663e-08
identified O 0 1.1257423437882608e-07
. O 0 2.2433017221601403e-08

Recently O 0 2.66698702944268e-06
, O 0 1.5832195554565942e-09
the O 0 1.517122538707838e-10
R496H O 0 9.788677424182879e-09
mutation O 0 1.6582957229616113e-08
of O 0 2.1237715752686626e-10
ARSA O 0 2.4951021259767003e-05
was O 0 4.781305573686723e-09
proposed O 0 1.7846908673124773e-10
to O 0 1.275607619533048e-09
be O 0 4.3803041749335137e-10
a O 0 2.594087389340416e-09
cause O 0 7.995020467888025e-08
of O 0 9.469757422664316e-09
MLD B-Disease 1 1.0
( O 0 2.154290612566001e-08
Draghia O 0 3.6451338019105606e-06
et O 0 1.4868128346279263e-05
al O 0 7.636072041350417e-06
. O 0 1.2971526963667657e-08
, O 0 9.965605007877798e-10
1997 O 0 1.7914274508257222e-09
) O 0 8.130867090727634e-10
. O 0 8.248601801597033e-09

We O 0 1.673891233622271e-06
have O 0 1.2239119717705194e-09
investigated O 0 1.3597588610636535e-09
the O 0 4.3565387408683875e-11
R496H O 0 6.659274465192766e-09
mutation O 0 7.077655794773818e-09
and O 0 1.427511719942487e-10
found O 0 1.3346693195082082e-10
this O 0 2.16081423587422e-11
mutation O 0 1.1007169620214086e-09
at O 0 5.029348049134796e-10
a O 0 2.802271747981422e-10
relatively O 0 2.8041538535639177e-10
high O 0 5.522973189897584e-10
frequency O 0 4.754940885476344e-09
in O 0 1.7523363315952167e-10
an O 0 2.26082486065593e-10
African O 0 2.6064356228872043e-10
American O 0 6.467461566295185e-10
population O 0 9.268042583387981e-11
( O 0 8.202342971497245e-11
f O 0 5.131561309212884e-08
= O 0 7.523326850389367e-09
0 O 0 1.1541444466800499e-09
. O 0 2.1051471676969413e-10
09 O 0 1.3184263680798836e-09
, O 0 1.043378439202769e-10
n O 0 6.639429273036512e-08
= O 0 2.0075722773071902e-07
61 O 0 6.197901569748865e-08
subjects O 0 6.5323910725112455e-09
) O 0 4.142929110884097e-09
. O 0 1.876992605787109e-08

The O 0 1.0009046036429936e-07
ARSA O 0 1.6865575162228197e-05
enzyme O 0 1.9809085927136039e-07
activity O 0 7.351909303565662e-09
in O 0 2.3455382081039033e-10
subjects O 0 8.798558548406277e-10
with O 0 8.512075488908977e-10
and O 0 4.5586743269154795e-09
without O 0 2.6812035924805855e-10
the O 0 5.435405597831178e-11
R496H O 0 1.0072105816050225e-08
mutation O 0 1.5668897290765926e-08
was O 0 8.585012700734751e-09
determined O 0 5.981690254230898e-09
and O 0 1.3410187404971907e-09
found O 0 2.6531035146604154e-09
to O 0 2.749120930900517e-09
be O 0 2.442112512213157e-09
normal O 0 6.67405259946463e-08
. O 0 3.6872179975944164e-08

It O 0 8.966069344751304e-07
is O 0 4.137330478215517e-09
therefore O 0 1.5807632980369135e-09
concluded O 0 1.872339838726589e-09
that O 0 2.1174728637163298e-11
the O 0 4.995272598340428e-11
R496H O 0 1.4919830704229753e-08
mutation O 0 1.5761036920025617e-08
of O 0 3.403299586590691e-10
ARSA O 0 0.00012160460755694658
does O 0 1.5420420140799251e-07
not O 0 1.6370163002932259e-09
negatively O 0 7.043181149413158e-09
influence O 0 7.572183435833324e-10
the O 0 2.2913000663482563e-10
activity O 0 3.4186684594317285e-09
of O 0 1.8843478166719052e-10
ARSA O 0 0.000316425139317289
and O 0 8.868094703018414e-09
is O 0 2.2529302035056986e-10
not O 0 2.8517430084029627e-10
a O 0 2.7677562464134553e-09
cause O 0 1.316190179068144e-07
of O 0 6.016086473437099e-08
MLD B-Disease 1 0.9999995231628418

Down O 0 0.00012660189531743526
- O 0 3.6652122616942506e-06
regulation O 0 9.011324664243148e-08
of O 0 7.961838410786015e-10
transmembrane O 0 2.2584443115647446e-07
carbonic O 0 5.700199380953563e-06
anhydrases O 0 7.637893759238068e-06
in O 0 5.7561489796853493e-08
renal B-Disease 1 0.9996868371963501
cell I-Disease 1 0.9994537234306335
carcinoma I-Disease 1 1.0
cell O 0 0.07916206121444702
lines O 0 3.468670911388472e-05
by O 0 1.3478063110028415e-09
wild O 0 3.946225888284971e-07
- O 0 0.0005808031419292092
type O 0 0.00010876626038225368
von B-Disease 1 0.9998273849487305
Hippel I-Disease 1 0.999460756778717
- I-Disease 1 0.9758235812187195
Lindau I-Disease 1 0.9945828318595886
transgenes O 0 0.0047066002152860165
. O 0 9.595722758604097e-07

To O 0 7.720483949924528e-07
discover O 0 8.904341939341975e-07
genes O 0 1.0125368277158486e-07
involved O 0 1.9652000915471035e-08
in O 0 2.8052856038129903e-08
von B-Disease 1 0.9999212026596069
Hippel I-Disease 1 0.9999774694442749
- I-Disease 1 0.9999717473983765
Lindau I-Disease 1 0.999963641166687
( O 0 9.969403436116409e-07
VHL B-Disease 0 7.901023491285741e-05
) O 0 3.14402477386011e-08
- O 0 5.382086328609148e-06
mediated O 0 2.0514124116743915e-05
carcinogenesis O 0 6.818785186624154e-05
, O 0 8.193032030590075e-09
we O 0 3.9404510765450595e-09
used O 0 2.1562108543093927e-07
renal B-Disease 1 0.9994465708732605
cell I-Disease 1 0.9998328685760498
carcinoma I-Disease 1 1.0
cell O 1 0.971599817276001
lines O 0 0.0012224394595250487
stably O 0 0.00011516002268763259
transfected O 0 6.174413101689424e-06
with O 0 2.6597917202053623e-09
wild O 0 2.3826416395422712e-07
- O 0 1.7633878087508492e-05
type O 0 2.5747715426405193e-06
VHL O 0 0.00041684263851493597
- O 0 3.0430755941779353e-05
expressing O 0 3.0270530260168016e-07
transgenes O 0 2.3559894543723203e-05
. O 0 1.0649982584709505e-07

Large O 0 5.511455825057965e-08
- O 0 5.999168593007198e-07
scale O 0 4.7886185683410076e-08
RNA O 0 7.766885090632059e-08
differential O 0 2.4622583083555583e-08
display O 0 4.175821022300852e-09
technology O 0 1.9457224720298427e-09
applied O 0 6.507007155320821e-10
to O 0 9.893088570578357e-10
these O 0 2.9617357177880166e-11
cell O 0 1.268497555884096e-07
lines O 0 7.477581220882712e-06
identified O 0 4.6986144752736436e-08
several O 0 1.585019338001814e-10
differentially O 0 2.260809850440637e-08
expressed O 0 4.158069374926576e-11
genes O 0 5.168569461311279e-10
, O 0 3.093334616233179e-11
including O 0 1.1185424114712461e-11
an O 0 1.6020278159611934e-10
alpha O 0 3.613963173165757e-08
carbonic O 0 5.524901212083932e-07
anhydrase O 0 2.37686350601507e-07
gene O 0 5.563281746390203e-08
, O 0 1.0031474539928809e-09
termed O 0 4.374731474854343e-07
CA12 O 0 6.156424933578819e-05
. O 0 1.4060846353913803e-07

The O 0 3.892956002005121e-08
deduced O 0 7.507532728823207e-08
protein O 0 5.206973519022995e-09
sequence O 0 6.5798841930586605e-09
was O 0 1.4224407207663603e-09
classified O 0 2.015351219242234e-09
as O 0 7.253399270101824e-11
a O 0 2.1982995979108466e-10
one O 0 4.209463444482253e-09
- O 0 1.1764408554881811e-05
pass O 0 9.79860942607047e-06
transmembrane O 0 1.4206812011252623e-06
CA O 0 1.615265318832826e-05
possessing O 0 1.751736533606163e-08
an O 0 2.504161877858735e-10
apparently O 0 1.7193038104323932e-08
intact O 0 2.417558819800547e-09
catalytic O 0 3.078699073455482e-09
domain O 0 7.095335430307159e-09
in O 0 3.5926675523434426e-10
the O 0 9.359677477505102e-10
extracellular O 0 5.323151341940502e-08
CA O 0 0.0001366643118672073
module O 0 1.5434560509675066e-06
. O 0 4.874253534126183e-08

Reintroduced O 0 1.308537321165204e-05
wild O 0 3.0040146157261916e-06
- O 0 0.00010403936903458089
type O 0 1.2010962109343382e-06
VHL B-Disease 0 3.563806239981204e-05
strongly O 0 5.068759989512728e-08
inhibited O 0 1.548566963549547e-08
the O 0 1.5089611504759404e-10
overexpression O 0 9.91517623560867e-09
of O 0 1.3469722733028267e-11
the O 0 8.19704096266527e-11
CA12 O 0 1.439524908164458e-07
gene O 0 5.2565081176680906e-09
in O 0 7.594976036973122e-11
the O 0 2.449455083208818e-09
parental O 0 2.38627617363818e-05
renal B-Disease 1 0.9999804496765137
cell I-Disease 1 0.9999812841415405
carcinoma I-Disease 1 1.0
cell O 1 0.990081250667572
lines O 0 0.04612203687429428
. O 0 8.657472108097863e-07

Similar O 0 6.972794608373079e-07
results O 0 3.8894263525435235e-06
were O 0 3.6693750260496927e-09
obtained O 0 1.8641013177500554e-09
with O 0 9.236105769083736e-10
CA9 O 0 2.307207068952266e-05
, O 0 4.728719082969235e-10
encoding O 0 3.460517206121949e-09
another O 0 2.2132244481554153e-08
transmembrane O 0 6.430161647585919e-08
CA O 0 3.2686314170859987e-06
with O 0 5.1835136877231847e-11
an O 0 2.768895390747872e-10
intact O 0 3.448500862646142e-08
catalytic O 0 9.137167467088148e-08
domain O 0 3.81759434731066e-07
. O 0 1.4467561015862884e-07

Although O 0 3.1739102723804535e-07
both O 0 3.719446750594102e-09
domains O 0 8.536892082133818e-09
of O 0 3.235049450545091e-10
the O 0 9.218242835729029e-10
VHL B-Disease 0 6.947312840566156e-07
protein O 0 3.378731605607754e-08
contribute O 0 2.2340691518962785e-09
to O 0 3.2038188768623854e-10
regulation O 0 5.813839409896104e-10
of O 0 4.568218026079762e-11
CA12 O 0 6.471638585026085e-07
expression O 0 6.978989053330054e-10
, O 0 3.8724731754591346e-11
the O 0 4.012888285553906e-11
elongin O 0 6.647335482057315e-08
binding O 0 5.658448376522074e-09
domain O 0 1.476461175542454e-08
alone O 0 2.2506310415337794e-07
could O 0 1.0579263687304774e-07
effectively O 0 1.7120660800173937e-07
regulate O 0 7.313966534638894e-07
CA9 O 0 0.00017886450223159045
expression O 0 6.26127928171627e-07
. O 0 6.439710631411799e-08

We O 0 1.1279834325250704e-05
mapped O 0 1.799901292542927e-05
CA12 O 0 0.00023497623624280095
and O 0 1.0686201790122141e-07
CA9 O 0 3.349429607624188e-05
loci O 0 6.614300787077809e-07
to O 0 5.6191840513974967e-08
chromosome O 0 5.6012672757788096e-06
bands O 0 1.5987639301329182e-07
15q22 O 0 1.1370719903425197e-06
and O 0 1.9905508352735524e-08
17q21 O 0 8.952748089541274e-07
. O 0 5.5522356490200764e-08

2 O 0 1.2762382084474666e-06
respectively O 0 2.2026115402695723e-06
, O 0 7.046540240196464e-09
regions O 0 1.1548406746442197e-06
prone O 0 2.6184896341874264e-05
to O 0 2.3615664090925748e-08
amplification O 0 1.0219800827826475e-07
in O 0 5.459627749893059e-10
some O 0 9.44089695309458e-10
human O 0 2.988843661455576e-08
cancers B-Disease 0 0.0003404513990972191
. O 0 9.599405359494995e-08

Additional O 0 8.618535218829493e-08
experiments O 0 6.447896083727755e-08
are O 0 6.882279746101005e-10
needed O 0 1.6405327096791211e-09
to O 0 2.7961052917468976e-10
define O 0 2.332356530132529e-09
the O 0 2.502548168692442e-10
role O 0 6.210986835952781e-09
of O 0 1.5346055537435177e-09
CA O 0 0.00011279189493507147
IX O 0 1.5177396335275262e-06
and O 0 8.978742016552133e-07
CA O 0 1.154593610408483e-05
XII O 0 3.451297203582726e-08
enzymes O 0 3.4721732156128837e-09
in O 0 2.9712583088370437e-11
the O 0 3.4010200905543186e-11
regulation O 0 6.814019348766465e-10
of O 0 2.78819519555773e-11
pH O 0 1.692209394832389e-08
in O 0 3.660675235162003e-11
the O 0 9.066550982206323e-11
extracellular O 0 1.4461781772112658e-09
microenvironment O 0 1.5841196443489025e-07
and O 0 2.5236301937070493e-09
its O 0 4.974066492025031e-09
potential O 0 1.623090883917655e-09
impact O 0 1.8754922059827095e-09
on O 0 2.545910149365227e-07
cancer B-Disease 0 7.641556294402108e-07
cell O 0 2.8089291390642757e-06
growth O 0 1.0763714044514927e-06
. O 0 4.1300317832337896e-08

A O 0 7.596348439165013e-08
gene O 0 5.881322451273263e-08
encoding O 0 3.204879561735652e-08
a O 0 3.70277741801317e-09
transmembrane O 0 2.5147999238583907e-08
protein O 0 1.7134503593752015e-08
is O 0 1.7847114064384328e-10
mutated O 0 1.6268177205347456e-07
in O 0 2.4784323482407444e-09
patients O 0 2.561336259532254e-06
with O 0 9.916436283674557e-06
diabetes B-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 0 0.1702086478471756
optic B-Disease 1 1.0
atrophy I-Disease 1 0.9999858140945435
( O 0 0.0006758833769708872
Wolfram B-Disease 1 1.0
syndrome I-Disease 1 1.0
) O 0 1.850157218541426e-07
. O 0 6.764106785794866e-08

Wolfram B-Disease 1 0.9999998807907104
syndrome I-Disease 1 1.0
( O 0 0.00012613614671863616
WFS B-Disease 0 0.009396543726325035
; O 0 1.0851291563085397e-06
OMIM O 0 0.0012482776073738933
222300 O 0 3.0674257232021773e-06
) O 0 3.836080342267678e-09
is O 0 5.549350423628141e-10
an O 0 1.0846180842349895e-08
autosomal B-Disease 1 0.9999998807907104
recessive I-Disease 1 0.9999998807907104
neurodegenerative I-Disease 1 0.9999997615814209
disorder I-Disease 1 0.9999586343765259
defined O 0 6.690915199669689e-08
by O 0 4.1061026800903733e-10
young O 0 1.4845090490211987e-08
- O 0 6.122554623289034e-05
onset O 0 0.00032379128970205784
non O 0 2.54079404840013e-05
- O 0 0.041502077132463455
immune O 0 0.006406422238796949
insulin B-Disease 1 0.9904588460922241
- I-Disease 1 0.9993483424186707
dependent I-Disease 1 0.9999936819076538
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 0 5.340091229300015e-05
progressive O 0 0.00046312090125866234
optic B-Disease 1 0.9999799728393555
atrophy I-Disease 0 0.12973041832447052
. O 0 5.356200745154638e-07

Linkage O 0 5.134639286552556e-05
to O 0 1.613930038502076e-07
markers O 0 1.7360075617034454e-06
on O 0 2.3387960936815944e-06
chromosome O 0 0.07513564079999924
4p O 1 0.8602809309959412
was O 0 8.229672857851256e-06
confirmed O 0 5.167875087863649e-07
in O 0 5.4761768036870606e-11
five O 0 1.0044378662144027e-09
families O 0 2.292625644884083e-09
. O 0 1.0946271444822742e-08

On O 0 1.380072518486486e-07
the O 0 7.114466238355988e-10
basis O 0 2.5817965543240007e-09
of O 0 2.6559274224347007e-10
meiotic O 0 4.037927283206955e-06
recombinants O 0 0.0006007427582517266
and O 0 1.2090708878531586e-06
disease O 0 8.307804091600701e-05
- O 0 1.4216625459084753e-06
associated O 0 3.871818705647456e-07
haplotypes O 0 6.53672032058239e-06
, O 0 1.6203997033059636e-09
the O 0 1.3159466849543833e-09
WFS B-Disease 0 4.204870037938235e-06
gene O 0 8.939016282738521e-08
was O 0 1.190783249782612e-09
localized O 0 1.3891832573165175e-08
to O 0 1.5500614125585344e-09
a O 0 1.335788724077247e-08
BAC O 0 0.0003517956065479666
/ O 0 2.190701889048796e-05
P1 O 0 8.036258805077523e-06
contig O 0 4.5865158426749986e-07
of O 0 6.757585463423865e-11
less O 0 4.2875106243123184e-10
than O 0 2.685472122454513e-10
250 O 0 1.3384557906448435e-09
kb O 0 2.947549546661321e-06
. O 0 4.632779848634527e-08

Mutations O 0 0.00011621696467045695
in O 0 4.2954031442832274e-09
a O 0 2.337785742767551e-09
novel O 0 1.6042065453802934e-08
gene O 0 3.08146240968199e-07
( O 0 5.0993418376776845e-09
WFS1 O 0 3.3175788303196896e-06
) O 0 1.3139621335422902e-10
encoding O 0 1.604765764717797e-09
a O 0 3.2391739290815735e-10
putative O 0 9.913531329175385e-09
transmembrane O 0 3.2958760165513468e-09
protein O 0 1.399000382207305e-08
were O 0 2.8146401875872584e-10
found O 0 2.855405911716957e-10
in O 0 6.124598050938346e-11
all O 0 2.50282489178133e-10
affected O 0 1.2363424728434325e-09
individuals O 0 2.6793208277031688e-11
in O 0 8.324092803935201e-11
six O 0 1.1523677123648213e-08
WFS B-Disease 0 1.417081875842996e-06
families O 0 7.681545954874025e-10
, O 0 1.432606949736126e-10
and O 0 3.650859337067658e-10
these O 0 7.173626970224944e-11
mutations O 0 2.5141716264442948e-08
were O 0 2.3772459001314417e-10
associated O 0 1.9421954322584867e-10
with O 0 1.5345784365461412e-10
the O 0 1.5103074346711765e-08
disease O 0 1.6621057511656545e-05
phenotype O 0 3.6044607440999243e-06
. O 0 6.62157191300139e-08

WFS1 O 0 0.00034501170739531517
appears O 0 5.795510560346884e-07
to O 0 2.7327002882771012e-09
function O 0 3.611026144767493e-09
in O 0 4.1818845608609934e-10
survival O 0 7.558683989827841e-08
of O 0 1.4877163390103476e-10
islet O 0 9.64371702139033e-06
beta O 0 6.394192837433366e-07
- O 0 2.0292864064686e-06
cells O 0 5.868446919521375e-07
and O 0 3.6114946588838848e-09
neurons O 0 3.236101875359054e-08
. O 0 5.064425545597828e-10
. O 0 8.474852819517764e-09

Stable O 0 3.23241256410256e-05
interaction O 0 1.042265562745115e-08
between O 0 6.592832946239469e-10
the O 0 2.1563151264558655e-10
products O 0 3.202136156232882e-08
of O 0 5.3373357816743905e-11
the O 0 1.668759241901796e-09
BRCA1 O 0 6.069038136047311e-06
and O 0 6.151417153432703e-08
BRCA2 O 0 1.584215715411119e-05
tumor B-Disease 0 8.338150792042143e-07
suppressor O 0 1.2712150976312842e-07
genes O 0 7.439822269361684e-08
in O 0 1.4104077905585655e-09
mitotic O 0 3.968734290538123e-06
and O 0 1.039674941694102e-07
meiotic O 0 1.1002316568919923e-05
cells O 0 8.280972906504758e-06
. O 0 1.055618454870455e-07

BRCA1 O 0 0.019147636368870735
and O 0 1.934038891704404e-06
BRCA2 O 0 0.00024016198585741222
account O 0 3.666858674478135e-07
for O 0 3.5312389123909327e-10
most O 0 8.093865855318683e-11
cases O 0 1.287216444545436e-10
of O 0 4.056792402007403e-11
familial O 0 2.0693855731224176e-06
, O 0 1.3090231121282159e-08
early O 0 1.2769793045208644e-07
onset O 0 7.216169251478277e-06
breast B-Disease 0 0.007332382258027792
and I-Disease 0 0.0001040375791490078
/ I-Disease 1 0.9999998807907104
or I-Disease 1 0.9999998807907104
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 6.065197233340314e-10
encode O 0 7.587829919941669e-09
products O 0 4.1918389115380705e-07
that O 0 8.904543769006068e-11
each O 0 4.1690145780037824e-10
interact O 0 1.9272439200079816e-09
with O 0 3.924756908357807e-10
hRAD51 O 0 4.143297701375559e-06
. O 0 5.02413683989289e-08

Results O 0 8.021403482416645e-05
presented O 0 3.840079543238062e-08
here O 0 1.3037946278160462e-09
show O 0 1.0560530228076459e-08
that O 0 4.431404965199448e-10
BRCA1 O 0 4.246188893830549e-07
and O 0 1.1398332055989613e-08
BRCA2 O 0 3.980211658927146e-06
coexist O 0 1.089270824650157e-07
in O 0 3.0409483958715455e-11
a O 0 2.747295446692277e-10
biochemical O 0 5.305551997736302e-09
complex O 0 1.2688109451985952e-09
and O 0 8.095109471639717e-09
colocalize O 0 2.928416051872773e-06
in O 0 1.1364851282280597e-09
subnuclear O 0 7.240760737659002e-07
foci O 0 6.006650465906205e-08
in O 0 9.324604977045681e-11
somatic O 0 1.9401895645643208e-09
cells O 0 1.8321731687365173e-08
and O 0 1.2288142725580542e-10
on O 0 8.396524031617503e-10
the O 0 5.592626362016517e-11
axial O 0 6.628683824061454e-09
elements O 0 3.086678024288858e-09
of O 0 1.6099829802662668e-10
developing O 0 1.385742987025651e-08
synaptonemal O 0 8.823798225421342e-07
complexes O 0 5.13166931170872e-08
. O 0 4.962034694244721e-08

Like O 0 1.5890036593191326e-06
BRCA1 O 0 0.0001680413115536794
and O 0 3.867036184601602e-07
RAD51 O 0 0.0001404743525199592
, O 0 7.16571975090119e-08
BRCA2 O 0 1.3991349987918511e-05
relocates O 0 1.8139011217499501e-06
to O 0 2.0659090438357453e-08
PCNA O 0 4.192621418042108e-06
+ O 0 4.943462883488792e-08
replication O 0 3.004756621294291e-08
sites O 0 6.528990237342214e-09
following O 0 1.2141720961977853e-09
exposure O 0 1.2972887653006637e-08
of O 0 7.590472000940096e-11
S O 0 1.6086522009572946e-05
phase O 0 6.466663204918177e-09
cells O 0 8.714220456340627e-09
to O 0 2.3630837286958695e-09
hydroxyurea O 0 3.1706338177173166e-07
or O 0 4.040997936272106e-08
UV O 0 2.635342752910219e-06
irradiation O 0 3.8270354707492515e-07
. O 0 2.7305601335569918e-08

Thus O 0 1.0491856983207981e-06
, O 0 8.738870960200984e-09
BRCA1 O 0 1.75638717792026e-06
and O 0 4.5359005440559486e-08
BRCA2 O 0 4.90314960188698e-06
participate O 0 1.3895701478361389e-08
, O 0 6.132632179856046e-10
together O 0 9.45468259239135e-10
, O 0 5.4307006808196334e-11
in O 0 1.1467026113376466e-11
a O 0 5.002321334934834e-10
pathway O 0 3.35313354860034e-09
( O 0 1.0476269629577928e-08
s O 0 5.512285861186683e-05
) O 0 5.124562996172699e-10
associated O 0 3.80375814179601e-10
with O 0 1.2994190792814386e-11
the O 0 5.2268991218573646e-11
activation O 0 3.3666794352349427e-10
of O 0 1.1102336931745338e-11
double O 0 9.11866067099254e-08
- O 0 3.1065419534570538e-06
strand O 0 0.005003137048333883
break O 0 0.00019115350733045489
repair O 0 3.893196117132902e-05
and O 0 1.3871392923192616e-08
/ O 0 1.542999712000892e-06
or O 0 1.3419148459092867e-08
homologous O 0 5.6665296455093994e-08
recombination O 0 9.95478472987088e-08
. O 0 5.892483301295215e-08

Dysfunction O 0 0.02037692256271839
of O 0 3.3459015558179317e-09
this O 0 5.32269950337394e-10
pathway O 0 1.6168009153716412e-08
may O 0 4.2935707256219757e-07
be O 0 3.7631020521899927e-10
a O 0 3.008544247062872e-10
general O 0 2.2414091416234072e-10
phenomenon O 0 6.073845315590631e-10
in O 0 4.912615453322999e-11
the O 0 4.898673827691269e-11
majority O 0 1.0550815776610989e-10
of O 0 4.9541187124857444e-12
cases O 0 3.418392513498958e-10
of O 0 2.7267788027529605e-10
hereditary B-Disease 1 0.9636042714118958
breast I-Disease 1 0.9981746673583984
and I-Disease 0 0.06505529582500458
/ I-Disease 1 1.0
or I-Disease 1 0.9999998807907104
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 3.856842845095798e-09
. O 0 1.3176276070225867e-08

A O 0 1.1999543403362622e-07
novel O 0 8.812287433102028e-08
Arg362Ser O 0 1.729382915982569e-06
mutation O 0 6.260634677346388e-08
in O 0 2.8617852532164534e-10
the O 0 9.441508685981148e-10
sterol O 0 1.2467719443520764e-06
27 O 0 1.7648233097133925e-07
- O 0 3.788420315231633e-07
hydroxylase O 0 4.3655309127643704e-06
gene O 0 3.2257003113045357e-07
( O 0 7.481781305607171e-10
CYP27 O 0 1.3576936908066273e-06
) O 0 3.814613069863526e-10
: O 0 5.272769720843229e-11
its O 0 8.255696126724388e-10
effects O 0 2.856099134973533e-09
on O 0 3.759982991624611e-09
pre O 0 1.0458584398520543e-07
- O 0 1.1301866997825982e-08
mRNA O 0 8.744707180596833e-09
splicing O 0 6.951760411766372e-08
and O 0 7.445863370314498e-10
enzyme O 0 1.1948995570776333e-08
activity O 0 2.392911113702212e-08
. O 0 1.3482595484504145e-08

A O 0 2.8463830403779866e-07
novel O 0 1.1655672693677843e-07
C O 0 1.7685698594505084e-06
to O 0 6.63005872425515e-10
A O 0 2.0637853648253213e-09
mutation O 0 6.392214757511283e-09
in O 0 7.615327118903892e-11
the O 0 6.642678629376064e-10
sterol O 0 7.56271333557379e-07
27 O 0 7.590410433522266e-08
- O 0 2.734955160121899e-07
hydroxylase O 0 3.8128678170323838e-06
gene O 0 2.821233522354305e-07
( O 0 1.7510275451826374e-09
CYP27 O 0 1.7437215547033702e-06
) O 0 2.416561950546736e-10
was O 0 3.6437494688179584e-10
identified O 0 4.89878859699644e-10
by O 0 1.1062069663059226e-11
sequencing O 0 6.131348762039579e-09
amplified O 0 1.951506511943535e-08
CYP27 O 0 2.0623625118787459e-07
gene O 0 8.257384997989448e-09
products O 0 1.362943002902739e-08
from O 0 4.5317430363844835e-11
a O 0 2.450618596938625e-09
patient O 0 3.6079785559195443e-07
with O 0 7.439141569420826e-08
cerebrotendinous B-Disease 1 1.0
xanthomatosis I-Disease 1 1.0
( O 0 7.024535619848393e-08
CTX B-Disease 0 4.597557199303992e-05
) O 0 2.737511373140933e-08
. O 0 6.996134516157326e-08

The O 0 3.246773161436067e-08
mutation O 0 4.032906133488723e-07
changed O 0 1.2220884748614935e-08
the O 0 2.2654307596514656e-10
adrenodoxin O 0 3.9972949394950774e-08
cofactor O 0 8.318022715059215e-09
binding O 0 3.659366365482697e-09
residue O 0 1.7038363608889995e-08
362Arg O 0 6.802493857094305e-08
to O 0 2.1417159157266497e-09
362Ser O 0 1.999859904344703e-07
( O 0 1.2696170781367755e-09
CGT O 0 5.782089829153847e-07
362Arg O 0 6.865359836183416e-08
to O 0 3.291817263217922e-09
AGT O 0 9.641809128879686e-07
362Ser O 0 9.488528007750574e-08
) O 0 4.898676464470952e-10
, O 0 2.538377008587389e-10
and O 0 1.249227943311837e-09
was O 0 6.927881912588418e-08
responsible O 0 5.665935631782304e-08
for O 0 9.780950271931488e-09
deficiency O 0 4.7442898676308687e-07
in O 0 8.111360194629214e-11
the O 0 6.915795713879902e-10
sterol O 0 1.4665475873698597e-06
27 O 0 9.350460317136822e-08
- O 0 5.4177768049612496e-08
hydroxylase O 0 6.923621072019159e-07
activity O 0 2.0507080478182615e-08
, O 0 3.3620850548032877e-10
as O 0 7.732876144972423e-11
confirmed O 0 7.796919776481559e-10
by O 0 2.315783198883481e-12
expression O 0 2.0921889221092727e-11
of O 0 5.569056500676073e-12
mutant O 0 5.323247398436592e-10
cDNA O 0 6.198265456447416e-09
into O 0 7.2599943834461556e-09
COS O 0 0.0001405154907843098
- O 0 1.433603955547369e-07
1 O 0 9.117839816497053e-09
cells O 0 1.5105038642104773e-07
. O 0 1.9268478368417163e-08

Quantitative O 0 2.3579757453262573e-06
analysis O 0 1.4982060747570358e-07
showed O 0 4.6849226720269144e-08
that O 0 3.191363145971238e-11
the O 0 3.8103641769593466e-11
expression O 0 2.4452434521649025e-10
of O 0 3.49659329268448e-11
CYP27 O 0 4.2526725252400865e-08
gene O 0 1.9282659913244515e-09
mRNA O 0 3.335311804519847e-09
in O 0 1.4169376783002008e-10
the O 0 3.86947751618294e-10
patient O 0 2.2433402691035553e-08
represented O 0 1.0418576001924862e-09
52 O 0 2.8964167952949538e-08
. O 0 1.1228811658270388e-08

5 O 0 8.327041314259986e-07
% O 0 5.219216703267193e-08
of O 0 1.2792228387681348e-10
the O 0 3.035909301729589e-09
normal O 0 7.593058626298443e-07
level O 0 6.971997379423556e-08
. O 0 6.215753955984837e-08

As O 0 2.7049168238590937e-08
the O 0 1.0439064057621295e-09
mutation O 0 2.594816272960543e-08
occurred O 0 6.7308487672335104e-09
at O 0 8.430705578099662e-10
the O 0 4.8719316775303056e-11
penultimate O 0 3.1217837204167154e-08
nucleotide O 0 5.198419916752073e-09
of O 0 7.382055383642339e-11
exon O 0 1.41594487246266e-08
6 O 0 1.034085039819388e-09
( O 0 3.7758404042298466e-11
- O 0 6.677080666150914e-09
2 O 0 6.199459168243493e-09
position O 0 6.834875776462468e-09
of O 0 1.884095310322742e-11
exon O 0 3.669950743301342e-08
6 O 0 5.1499533526566665e-09
- O 0 1.4373932799571776e-07
intron O 0 7.921575161162764e-06
6 O 0 1.4186536390070614e-08
splice O 0 5.088239731776412e-07
site O 0 1.4112103485786065e-08
) O 0 4.331979219784898e-11
of O 0 1.0067034011962406e-12
the O 0 1.8271452059681614e-11
gene O 0 3.6620264598496988e-09
, O 0 2.964568868168982e-10
we O 0 3.725522668140968e-10
hypothesized O 0 4.476207460246684e-10
that O 0 2.885026766097365e-11
the O 0 1.4292880767818872e-10
mutation O 0 1.0831135455191543e-07
may O 0 4.7424620674973994e-08
partially O 0 1.0175394749012412e-07
affect O 0 1.8303594195856476e-09
the O 0 3.894138136950609e-11
normal O 0 2.1679706918575903e-09
splicing O 0 1.0819135809470026e-08
efficiency O 0 1.8545827096261291e-09
in O 0 2.0588264426635305e-10
exon O 0 1.0449472398477155e-07
6 O 0 1.2364091972472124e-08
and O 0 6.717186806781683e-10
cause O 0 2.2488602646753009e-10
alternative O 0 2.3134721915951673e-10
splicing O 0 2.51838550013872e-08
elsewhere O 0 1.314542998898105e-07
, O 0 7.494178055900136e-10
which O 0 4.4785386510426406e-10
resulted O 0 1.1836073232629474e-09
in O 0 5.033522487707387e-10
decreased O 0 7.695549584241235e-07
transcript O 0 5.8272116802982055e-06
in O 0 7.420768444177384e-10
the O 0 3.2622717860419925e-09
patient O 0 1.3330887327356322e-07
. O 0 1.4403841674948126e-08

Transfection O 0 0.00011977890244452283
of O 0 1.0380555970357364e-08
constructed O 0 2.659940179228215e-08
minigenes O 0 6.7865935307054315e-06
, O 0 1.4141440241033365e-09
with O 0 1.642495028875146e-10
or O 0 2.130252596543869e-08
without O 0 1.0903505875958786e-09
the O 0 1.2120682235661207e-10
mutation O 0 6.249273987180004e-09
, O 0 1.0429406643863715e-10
into O 0 4.544765896952185e-09
COS O 0 0.02399221993982792
- O 0 3.4285247352272563e-07
1 O 0 9.220796570730272e-09
cells O 0 1.3777943230763867e-08
confirmed O 0 1.556010253978002e-08
that O 0 4.900896095200169e-12
the O 0 1.8093920459150148e-11
mutant O 0 4.620987148484801e-09
minigene O 0 1.007602691061038e-06
was O 0 1.1683847667143255e-08
responsible O 0 1.2886762768005156e-09
for O 0 1.4597477740463383e-11
a O 0 1.6606205299751764e-10
mRNA O 0 6.512884009879372e-09
species O 0 2.2760245077524388e-10
alternatively O 0 9.577383330849898e-09
spliced O 0 4.5148408389650285e-05
at O 0 8.160670361689881e-09
an O 0 3.387840008528542e-10
activated O 0 3.6251055490765793e-08
cryptic O 0 1.9843800203034334e-07
5 O 0 9.160053271450863e-10
splice O 0 5.541327823266329e-07
site O 0 4.6436433365215635e-08
88 O 0 6.999349100311747e-09
bp O 0 2.5701788786136603e-07
upstream O 0 1.2232312052162797e-08
from O 0 8.096012055203161e-11
the O 0 2.5243741125224872e-11
3 O 0 8.868259460115269e-10
end O 0 3.241697354994244e-09
of O 0 1.0903127012351632e-10
exon O 0 8.513090676842694e-08
6 O 0 1.2304806062957141e-08
. O 0 1.3706595858309356e-08

Our O 0 1.199763687509403e-06
data O 0 2.16740161818052e-07
suggest O 0 9.799362210571871e-09
that O 0 5.361813770754509e-11
the O 0 2.4057164246804597e-11
C O 0 1.0313987885979259e-08
to O 0 1.1481059852824771e-10
A O 0 1.1252475617951063e-09
mutation O 0 2.743170801622341e-09
at O 0 3.050116270664205e-10
the O 0 2.8992809888994664e-11
penultimate O 0 1.3039868740349903e-08
nucleotide O 0 2.0166353031925155e-09
of O 0 9.25620084052392e-12
exon O 0 4.0477998730636955e-09
6 O 0 1.635607899119762e-10
of O 0 2.2323193640816363e-12
the O 0 9.835417202896934e-11
CYP27 O 0 4.6871750214450003e-07
gene O 0 9.966084846269041e-09
not O 0 2.565551937561139e-10
only O 0 7.248392858150154e-11
causes O 0 4.752345184044771e-10
the O 0 2.6230342342614676e-09
deficiency B-Disease 0 8.616280524620379e-07
in I-Disease 0 2.2953711847906177e-11
the I-Disease 0 5.265626823458547e-10
sterol I-Disease 0 4.9881299446497e-07
27 I-Disease 0 3.61153773553724e-08
- I-Disease 0 6.894952520042352e-08
hydroxylase I-Disease 0 2.0304189547459828e-06
activity I-Disease 0 5.785305745575897e-08
, O 0 7.724949013798721e-10
but O 0 3.578470297860292e-10
also O 0 1.3156781220047264e-09
partially O 0 5.622700882668141e-08
leads O 0 2.740336402240473e-09
to O 0 1.0826473051395169e-10
alternative O 0 7.726599360324826e-10
pre O 0 1.2157229001275027e-08
- O 0 3.471007925526237e-09
mRNA O 0 2.1430277552525467e-09
splicing O 0 1.2855052133886602e-08
of O 0 6.026793647473383e-11
the O 0 3.1201435879424366e-10
gene O 0 9.244891430171265e-08
. O 0 1.49159600226767e-08

To O 0 1.3825031146552647e-06
our O 0 2.1445456965807352e-08
knowledge O 0 1.06914721520468e-09
, O 0 8.461470413223537e-11
this O 0 1.3003040484627082e-11
is O 0 2.7242978706265575e-11
the O 0 4.3908668367897974e-11
first O 0 1.3981760638159813e-08
report O 0 3.6610856568586314e-08
regarding O 0 2.7044805284148765e-10
effects O 0 2.3621913314286758e-09
on O 0 4.101321948724035e-09
pre O 0 4.967953159962235e-08
- O 0 1.1770291408197409e-09
mRNA O 0 8.541105600556875e-10
splicing O 0 1.5365474448358896e-09
of O 0 6.459134008901524e-12
a O 0 1.1881304273764215e-10
mutation O 0 1.0227396707307435e-09
at O 0 5.015917126094394e-10
the O 0 1.4346769605655396e-10
- O 0 2.121771984775478e-07
2 O 0 5.347044051973171e-08
position O 0 1.0995844235139884e-08
of O 0 6.758896393954661e-12
a O 0 7.036356497458485e-10
5 O 0 4.574954193259373e-09
splice O 0 1.2886868717032485e-05
site O 0 6.18383808159706e-07
. O 0 3.610394472275402e-08

ATM O 0 0.0005047596641816199
germline O 0 0.0002613068791106343
mutations O 0 0.00017519544053357095
in O 0 5.689120285978788e-08
classical O 0 0.0020862105302512646
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
patients O 1 0.999488353729248
in O 0 9.50855727488431e-10
the O 0 1.456789688880633e-09
Dutch O 0 4.589378022501478e-06
population O 0 1.49650034586557e-08
. O 0 2.4412335264401008e-08

Germline O 0 0.001655373489484191
mutations O 0 9.043495811056346e-05
in O 0 5.4177120567544534e-09
the O 0 3.54474893882184e-10
ATM O 0 1.603003624950361e-06
gene O 0 5.2625797053451606e-08
are O 0 1.8418770675321383e-10
responsible O 0 3.1040057191233927e-09
for O 0 2.9289144443112036e-09
the O 0 0.001046223216690123
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 0.014183616265654564
A B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
) O 0 9.407830248164828e-08
. O 0 4.28326458745687e-08

In O 0 2.4669739673299773e-07
our O 0 2.3996527431791037e-08
study O 0 2.483424799137879e-09
, O 0 1.694010487440778e-09
we O 0 3.824712102584726e-09
have O 0 2.291837691847931e-10
determined O 0 6.078991199309769e-10
the O 0 5.033203021032051e-11
ATM O 0 2.523295279388549e-07
mutation O 0 3.3860134696084287e-09
spectrum O 0 5.923059265278141e-10
in O 0 1.4208619003586165e-10
19 O 0 5.940315794816797e-09
classical O 0 2.03250358765672e-08
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 2.9254711080284324e-06
, O 0 6.608449898415358e-12
including O 0 1.260970494687541e-12
some O 0 1.0304003310313004e-11
immigrant O 0 1.42113099066421e-09
populations O 0 2.8893691883524752e-09
, O 0 6.859372514433915e-10
as O 0 3.3253375053554635e-10
well O 0 1.6994207430176544e-10
as O 0 2.6320640111876514e-10
12 O 0 1.8418137848197347e-10
of O 0 2.3118479353101407e-11
Dutch O 0 1.9663778516587627e-07
ethnic O 0 3.979851115332167e-08
origin O 0 3.7454260137792517e-08
. O 0 5.289720661494357e-08

Both O 0 1.535549110087686e-08
the O 0 1.0804322991830873e-09
protein O 0 5.783019396687905e-09
truncation O 0 5.381646701607679e-07
test O 0 2.7527532253657228e-08
( O 0 4.73165118197727e-10
PTT O 0 8.528918442607392e-07
) O 0 1.526393039741336e-10
and O 0 2.364754052297524e-11
the O 0 1.5958359633749808e-11
restriction O 0 2.818766331458278e-10
endonuclease O 0 2.5109414991675294e-08
fingerprinting O 0 8.04941606702414e-08
( O 0 4.882101389824811e-10
REF O 0 2.4850234581208497e-07
) O 0 2.989922198715078e-11
method O 0 4.1251937976660713e-10
were O 0 2.5123908509172566e-10
used O 0 3.2185429321707204e-10
and O 0 8.600823386828438e-10
compared O 0 5.879342568348989e-10
for O 0 6.0948910848845905e-12
their O 0 3.798246439590258e-11
detection O 0 2.139869254014215e-10
efficiency O 0 2.6000801511827376e-10
, O 0 4.2718030501820436e-11
identifying O 0 2.1205990297090693e-09
76 O 0 1.1213866502046699e-09
% O 0 1.279564371126085e-10
and O 0 2.6766663885346986e-10
60 O 0 3.5284111743472124e-10
% O 0 1.581733632960436e-10
of O 0 8.375530304027823e-12
the O 0 7.706111859739906e-10
mutations O 0 4.242019713274203e-07
, O 0 1.4409660131775581e-09
respectively O 0 1.0469801736689988e-07
. O 0 2.351830197255822e-08

Most O 0 2.0370508480027638e-07
patients O 0 2.048210035354714e-06
were O 0 2.8483739811235864e-09
found O 0 1.9124317685026426e-09
to O 0 1.6389190005128285e-09
be O 0 1.6372941891162895e-09
compound O 0 5.756445276006161e-08
heterozygote O 0 4.333549895818578e-06
. O 0 7.603755847185312e-08

Seventeen O 0 7.31907130102627e-06
mutations O 0 1.2943599358550273e-05
were O 0 1.5948343090599337e-08
distinct O 0 1.6307774020063448e-09
, O 0 2.883895067196107e-10
of O 0 2.048054781322861e-11
which O 0 7.584010752736958e-09
10 O 0 1.0765080382668657e-08
were O 0 7.261684142889635e-09
not O 0 1.2296523799193437e-08
reported O 0 1.0709396747188293e-06
previously O 0 1.2555138084735518e-07
. O 0 3.420241867502227e-08

Mutations O 0 0.00032774361898191273
are O 0 6.2448415327764906e-09
small O 0 2.6032322963942534e-09
deletions O 0 3.0448234156210674e-06
or O 0 1.4198793678588117e-06
point O 0 4.81524875795003e-06
mutations O 0 1.650063131819479e-05
frequently O 0 2.975488655465597e-07
affecting O 0 3.7137002095732896e-07
splice O 0 0.0006783236167393625
sites O 0 1.4732995623489842e-05
. O 0 3.648291340141441e-07

Moreover O 0 3.045049879801809e-06
, O 0 3.785838753600501e-09
a O 0 3.642848023233114e-09
16 O 0 3.5042834412024604e-08
. O 0 1.246596159631963e-08

7 O 0 5.377468824008247e-06
- O 0 3.971157184423646e-06
kb O 0 4.616162641468691e-06
genomic O 0 2.0027341918193997e-07
deletion O 0 5.502715794136748e-07
of O 0 5.282907097892142e-11
the O 0 1.8896889608654988e-10
3 O 0 3.6089191635113593e-09
end O 0 2.8138795737930877e-09
of O 0 3.427771304645444e-12
the O 0 2.4153901101442443e-11
gene O 0 2.5279034421288316e-09
, O 0 6.453595990940642e-11
most O 0 1.0818995005434928e-11
likely O 0 4.721094626347622e-10
a O 0 9.964915698157384e-11
result O 0 1.4991329011504462e-10
of O 0 1.7157950407686862e-12
recombination O 0 2.1144549999796425e-10
between O 0 1.264980342696731e-10
two O 0 3.1034728120715727e-09
LINE O 0 2.612062598927878e-05
elements O 0 2.2834099056012747e-08
, O 0 2.4870130399534673e-09
was O 0 1.855089415414568e-08
identified O 0 7.147851022182294e-08
. O 0 1.3983254554261748e-08

The O 0 3.609526899595039e-08
most O 0 1.9163097775276583e-09
frequently O 0 1.035678476313251e-08
found O 0 2.7172066818792473e-09
mutation O 0 9.133940714889377e-09
, O 0 1.3885355365506058e-10
identified O 0 1.3918958208236631e-09
in O 0 2.419060091130021e-11
three O 0 4.6098047601361714e-10
unrelated O 0 2.7517594869408413e-09
Turkish O 0 3.302321545106679e-07
A B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
individuals O 0 2.0606711004234057e-08
, O 0 8.370491522136092e-10
was O 0 1.7304367716519664e-08
previously O 0 9.608542406169818e-09
described O 0 1.609931632451378e-09
to O 0 2.3537574667109595e-10
be O 0 6.71165067966939e-11
a O 0 4.2418857315595915e-10
Turkish O 0 3.7769160599054885e-07
A B-Disease 1 1.0
- I-Disease 1 0.9999992847442627
T I-Disease 1 1.0
founder O 0 1.2365031807348714e-06
mutation O 0 3.388794311831589e-07
. O 0 1.1579376568704447e-08

The O 0 9.398626765744211e-09
presence O 0 3.754300426095369e-09
of O 0 5.200655878168092e-11
a O 0 8.45882808242493e-10
founder O 0 1.4357103950146666e-08
mutation O 0 1.4655470614854949e-08
among O 0 3.6916528861619113e-11
relatively O 0 3.718159460874837e-11
small O 0 4.532192676709457e-11
ethnic O 0 1.673289240500253e-08
population O 0 8.284214980669447e-10
groups O 0 2.4901433345880797e-11
in O 0 9.273452838964857e-11
Western O 0 2.023402068118685e-08
Europe O 0 1.4251470474846428e-06
could O 0 2.2407061095464087e-08
indicate O 0 5.14926323802456e-10
a O 0 8.746550012039833e-11
high O 0 7.536996027290854e-10
carrier O 0 1.9968329212360914e-08
frequency O 0 1.321400233678105e-08
in O 0 2.1675641836971238e-10
such O 0 1.0438919867405971e-10
communities O 0 1.1198183713645449e-08
. O 0 8.397268658200119e-08

In O 0 3.791228380123357e-07
patients O 0 6.36987181223958e-07
of O 0 1.502728635971451e-10
Dutch O 0 1.0161706995859277e-06
ethnic O 0 1.4387861568820881e-08
origin O 0 1.1035806934955872e-08
, O 0 4.651104390518412e-09
however O 0 9.558452918057014e-10
, O 0 1.5829650090726233e-10
no O 0 1.6649083500741568e-10
significant O 0 6.72397693080029e-11
founder O 0 3.006534043947795e-08
effect O 0 3.081467525589687e-08
could O 0 7.415454916781528e-08
be O 0 1.7809581587258094e-09
identified O 0 2.9993056926969075e-08
. O 0 2.08549053581919e-08

The O 0 4.1429785824220744e-08
observed O 0 9.96536613229182e-08
genetic O 0 1.821945829760807e-07
heterogeneity O 0 8.086208680424534e-08
including O 0 3.4766645118367023e-10
the O 0 1.7763840398643538e-10
relative O 0 1.278350092448477e-09
high O 0 4.904849415510171e-09
percentage O 0 1.0834111208168906e-07
of O 0 2.0306337167319555e-10
splice O 0 0.0015064806211739779
- O 0 1.463871194573585e-05
site O 0 7.79295078245923e-06
mutations O 0 2.2164906113175675e-05
had O 0 4.5388951264158095e-08
no O 0 5.448174689171026e-10
reflection O 0 4.894697425150696e-10
on O 0 5.72145886224007e-09
the O 0 2.1941115591062044e-09
phenotype O 0 1.544862357150123e-06
. O 0 2.7320604445435492e-08

All O 0 1.5984863921403303e-07
patients O 0 2.954705280444614e-07
manifested O 0 3.8521321243933926e-08
classical O 0 6.061999613393709e-08
A B-Disease 1 0.9999997615814209
- I-Disease 1 0.999998927116394
T I-Disease 1 1.0
and O 0 1.6747131681427163e-08
increased O 0 1.0053924359709754e-09
cellular O 0 2.7405834046589916e-08
radioresistant O 0 7.853074635022494e-08
DNA O 0 6.941518648773126e-08
synthesis O 0 6.281051412315719e-08
. O 0 3.0961668784357244e-08

Determination O 0 4.524279120232677e-07
of O 0 2.6809887643253205e-10
the O 0 1.176952146852983e-10
genomic O 0 8.462995637614767e-09
structure O 0 2.6911803896467745e-09
of O 0 3.7484505083229536e-11
the O 0 2.827101330815651e-10
COL4A4 O 0 7.597911917400779e-07
gene O 0 9.389380828395133e-09
and O 0 1.0394970301197404e-10
of O 0 2.6214612078301336e-11
novel O 0 3.338235501360032e-07
mutations O 0 0.011641022749245167
causing O 0 0.039044339209795
autosomal B-Disease 1 0.9999992847442627
recessive I-Disease 1 0.9999998807907104
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 1.11378367364523e-05

Autosomal B-Disease 1 0.9999998807907104
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
is O 0 4.5482283894671127e-07
a O 0 1.215665434983748e-07
progressive O 0 0.0004857064632233232
hematuric B-Disease 1 0.9976551532745361
glomerulonephritis I-Disease 1 1.0
characterized O 0 9.932933608070016e-06
by O 0 4.463498015638834e-09
glomerular B-Disease 0 0.0013115005567669868
basement I-Disease 0 0.01872817985713482
membrane I-Disease 0 0.0002972598886117339
abnormalities I-Disease 1 0.999974250793457
and O 0 1.1026465074337466e-08
associated O 0 7.024331782901072e-09
with O 0 7.546633873367625e-10
mutations O 0 1.657844137525899e-07
in O 0 3.4798225412302486e-10
either O 0 2.8724942424673827e-09
the O 0 9.890730456874053e-10
COL4A3 O 0 1.57264312292682e-05
or O 0 4.12035161545532e-09
the O 0 1.2640155588883317e-10
COL4A4 O 0 2.320559531199251e-07
gene O 0 6.746671221691258e-09
, O 0 3.618454841314289e-11
which O 0 7.34301335014731e-12
encode O 0 9.597310723918895e-10
the O 0 4.632297878615077e-10
alpha3 O 0 2.0823781596845947e-06
and O 0 4.323745361745068e-09
alpha4 O 0 9.721786682348466e-07
type O 0 4.0509068099936485e-08
IV O 0 1.2091173630324192e-05
collagen O 0 2.015207883232506e-06
chains O 0 1.4386893781193066e-05
, O 0 3.894765843170944e-09
respectively O 0 1.6555027571030223e-07
. O 0 3.849260465926818e-08

To O 0 1.0453619125883051e-07
date O 0 6.851101375104918e-08
, O 0 4.736147585227002e-10
mutation O 0 1.8987984518048506e-09
screening O 0 2.0661130584187504e-09
in O 0 1.0287767859828989e-10
the O 0 1.9273715956558135e-10
two O 0 1.7473109625854022e-09
genes O 0 2.403857912725016e-08
has O 0 1.869439536505979e-08
been O 0 3.015911298476226e-09
hampered O 0 2.9510939469901132e-08
by O 0 1.8585752728506044e-11
the O 0 2.262834190858154e-11
lack O 0 6.62818411267807e-11
of O 0 1.2219653240663764e-11
genomic O 0 1.2569869589640348e-08
structure O 0 6.118617079664546e-08
information O 0 1.1782274356164635e-07
. O 0 7.651664191143936e-08

We O 0 1.0092172487929929e-05
report O 0 1.1331139404546775e-07
here O 0 9.34919919259869e-11
the O 0 1.3609770428690826e-11
complete O 0 4.864441072172099e-10
characterization O 0 4.004153009162792e-09
of O 0 8.54955602841434e-12
the O 0 1.496216345264756e-10
48 O 0 2.1253854232128333e-09
exons O 0 4.9866528684106015e-09
of O 0 8.472900332734401e-12
the O 0 9.978000370391982e-11
COL4A4 O 0 2.354014156935591e-07
gene O 0 2.8201982971154393e-09
, O 0 1.756746137449028e-11
a O 0 5.5328918530106463e-11
comprehensive O 0 9.071831064133562e-10
gene O 0 2.3279266514464325e-08
screen O 0 1.7552100644024904e-06
, O 0 3.742889109759062e-09
and O 0 9.272413947769564e-10
the O 0 1.6261390844984902e-10
subsequent O 0 3.5282091137567306e-10
detection O 0 1.0817767792659083e-09
of O 0 1.7970893870233873e-11
10 O 0 3.0357802383029764e-10
novel O 0 2.2557433698722207e-09
mutations O 0 1.6024121407554048e-07
in O 0 6.441793209965851e-10
eight O 0 3.955211980155582e-07
patients O 0 9.263076776733215e-07
diagnosed O 0 4.201730916975066e-05
with O 0 1.0470441225152172e-07
autosomal B-Disease 1 0.9999998807907104
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 1.0593721526674926e-05

Furthermore O 0 4.279065706214169e-06
, O 0 2.6802041475093574e-08
we O 0 3.636530632178392e-09
identified O 0 1.147607453511057e-09
a O 0 3.744315135723042e-10
glycine O 0 3.3720937153702835e-08
to O 0 5.503886235658229e-10
alanine O 0 1.8762767339808306e-08
substitution O 0 1.0799008354211992e-09
in O 0 6.424709375618676e-11
the O 0 2.2274049271686636e-10
collagenous O 0 4.5501894874178106e-07
domain O 0 7.168861060335985e-09
that O 0 2.64306104780232e-10
is O 0 1.2914536107189178e-10
apparently O 0 8.7780955837502e-09
silent O 0 7.84830533895331e-10
in O 0 1.7593817028260794e-11
the O 0 7.940451074439636e-11
heterozygous O 0 1.1044693160044972e-08
carriers O 0 2.2881085914860932e-09
, O 0 2.501770179907936e-10
in O 0 5.918372458779686e-10
11 O 0 3.100977608028188e-08
. O 0 3.554420402451797e-08

5 O 0 1.93676001458698e-07
% O 0 7.64999708025016e-09
of O 0 1.5690294896675283e-10
all O 0 8.952418806273954e-10
control O 0 1.6348430165180616e-07
individuals O 0 1.1995734405800818e-09
, O 0 1.2016917461110665e-09
and O 0 3.7651139983552184e-09
in O 0 3.8896266763011056e-10
one O 0 5.132126723594865e-09
control O 0 1.3128261144856879e-08
individual O 0 2.0580254167512635e-10
homozygous O 0 6.198395130496692e-09
for O 0 3.963754324765034e-11
this O 0 2.7332499111243358e-11
glycine O 0 7.338655461097687e-09
substitution O 0 9.027836256336741e-09
. O 0 5.490028875954067e-09

There O 0 1.6206482769121067e-06
has O 0 2.2065814064831102e-08
been O 0 1.891211631743772e-09
no O 0 5.832743177336397e-10
previous O 0 6.825934817378254e-10
finding O 0 1.1308949610100427e-10
of O 0 1.6873005813725084e-12
a O 0 6.609651020950125e-11
glycine O 0 3.698464645651711e-09
substitution O 0 1.3440550061805112e-10
that O 0 5.4022699508271543e-11
is O 0 4.655066956904541e-11
not O 0 1.9036891507617781e-10
associated O 0 1.9387051686248213e-10
with O 0 6.419858394890454e-11
any O 0 3.993094299659106e-09
obvious O 0 4.008669396426967e-09
phenotype O 0 8.591322853135352e-08
in O 0 8.727789602147595e-10
homozygous O 0 4.1658441318759287e-07
individuals O 0 3.3715006342305287e-09
. O 0 2.1865178112534522e-08

Founder O 0 5.308495383360423e-05
BRCA1 O 0 0.0008616511477157474
and O 0 2.985653111409192e-07
BRCA2 O 0 3.0726270779268816e-05
mutations O 0 3.068359092139872e-06
in O 0 2.2499211382864814e-09
French O 0 2.584348294476513e-06
Canadian O 0 1.8908496713265777e-05
breast B-Disease 1 0.9999716281890869
and I-Disease 1 0.9998358488082886
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
families O 0 1.7134316010469774e-07
. O 0 7.06449512222207e-08

We O 0 7.789235496602487e-06
have O 0 1.3795133924077163e-09
identified O 0 2.5333382058789766e-09
four O 0 3.584946506318687e-10
mutations O 0 4.010283216615562e-09
in O 0 9.003164533338825e-12
each O 0 1.694074325264694e-10
of O 0 4.1378473564224194e-11
the O 0 5.07622885947967e-08
breast B-Disease 0 0.004053976386785507
cancer I-Disease 0 5.409035657066852e-05
- O 0 3.846079380309675e-06
susceptibility O 0 4.06061462854268e-06
genes O 0 1.6217863674228283e-07
, O 0 1.8372500187879837e-09
BRCA1 O 0 1.4526667655445635e-06
and O 0 1.694386320139074e-08
BRCA2 O 0 4.78463834951981e-06
, O 0 4.778540896310801e-10
in O 0 1.1435166008544329e-10
French O 0 6.667518732683675e-07
Canadian O 0 1.009834477372351e-06
breast B-Disease 0 0.0019407959189265966
cancer I-Disease 0 0.0005621133022941649
and O 0 4.422051279107109e-05
breast B-Disease 1 0.9999997615814209
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 1.6108607781006867e-07
from O 0 3.928955294441039e-08
Quebec O 0 9.698963367554825e-06
. O 0 2.6099436922777386e-07

To O 0 5.948044758952165e-07
identify O 0 3.837824635866127e-07
founder O 0 3.699606452300941e-07
effects O 0 1.1736042324628215e-06
, O 0 8.619286617772559e-09
we O 0 5.849625228648847e-09
examined O 0 6.344527125889954e-09
independently O 0 6.163572408013351e-08
ascertained O 0 5.213634608480788e-07
French O 0 3.0400951800402254e-07
Canadian O 0 1.827897300188397e-08
cancer B-Disease 0 4.0995722372372256e-08
families O 0 5.895060134486485e-11
for O 0 2.056713827025547e-11
the O 0 7.141408991939713e-11
distribution O 0 1.7607071356451343e-08
of O 0 6.310101746676011e-11
these O 0 4.5144563087795575e-10
eight O 0 2.2088428863753506e-08
mutations O 0 2.941457353244914e-07
. O 0 9.091876584932379e-09

Mutations O 0 0.001261850818991661
were O 0 1.136288929615148e-07
found O 0 8.594202682843388e-09
in O 0 4.1190531541168696e-10
41 O 0 5.746229714276296e-09
of O 0 6.845122385579216e-11
97 O 0 8.9589491381048e-09
families O 0 4.36597602515576e-09
. O 0 6.086584392051009e-08

Six O 0 3.0485176694128313e-07
of O 0 9.416654123128865e-10
eight O 0 1.1557994561428586e-08
mutations O 0 4.3292229179314745e-07
were O 0 4.687583654572336e-09
observed O 0 6.7896586131155345e-09
at O 0 2.053099379395462e-08
least O 0 1.068868460407657e-08
twice O 0 4.554209738216741e-07
. O 0 6.501629457034142e-08

The O 0 2.0974025005671137e-07
BRCA1 O 0 7.894433110777754e-06
C4446T O 0 1.0524817071200232e-06
mutation O 0 9.504555578132567e-07
was O 0 4.573025957910204e-09
the O 0 2.8409162175502267e-11
most O 0 1.757885677300397e-11
common O 0 1.0530952498921664e-10
mutation O 0 5.308983475060813e-09
found O 0 2.380032837479007e-09
, O 0 5.803344957366896e-11
followed O 0 2.0253075605491944e-10
by O 0 4.169855433167058e-11
the O 0 1.4341385856653233e-09
BRCA2 O 0 4.275354149285704e-05
8765delAG O 0 3.7422955756483134e-06
mutation O 0 9.32273906073533e-07
. O 0 3.942377446719547e-08

Together O 0 8.542487535123655e-07
, O 0 4.978613077355476e-09
these O 0 1.3683229549421583e-10
mutations O 0 1.9967108855212246e-08
were O 0 5.9222909909451e-10
found O 0 2.8979499355763494e-10
in O 0 8.490148861728386e-11
28 O 0 2.6333306646364463e-09
of O 0 1.930777586423016e-11
41 O 0 5.247021928056483e-09
families O 0 5.040052403204598e-11
identified O 0 2.162503776048652e-08
to O 0 9.064518913248776e-09
have O 0 1.4855903174293417e-09
a O 0 6.29149221609282e-09
mutation O 0 5.946638452769548e-07
. O 0 2.5042027118615806e-08

The O 0 1.2185093112293544e-07
odds O 0 7.084491358000378e-07
of O 0 3.0155070107618087e-10
detection O 0 5.650100831644522e-09
of O 0 6.675494879093691e-11
any O 0 3.178031726669417e-10
of O 0 5.213537587756001e-11
the O 0 1.1363204821535078e-09
four O 0 2.5504199641090963e-08
BRCA1 O 0 3.56957525582402e-06
mutations O 0 6.516452799587569e-07
was O 0 1.8737125628831564e-08
18 O 0 9.08665853671664e-09
. O 0 7.972357884966641e-09

7x O 0 0.0007611378678120673
greater O 0 2.5045139295798435e-07
if O 0 2.3151917716290882e-08
one O 0 1.0756003865353136e-09
or O 0 2.215263084082153e-09
more O 0 2.389569930816293e-10
cases O 0 1.1173221459159777e-08
of O 0 2.3227769361255923e-06
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
were O 0 1.6869363150817662e-07
also O 0 6.668935181863844e-09
present O 0 5.594325558355706e-10
in O 0 1.246459324644178e-10
the O 0 1.0570561093103947e-09
family O 0 8.013509500415239e-08
. O 0 1.3162554068912868e-07

The O 0 5.991089579993059e-08
odds O 0 5.199216275286744e-07
of O 0 2.0181044335654263e-10
detection O 0 6.525704421278533e-09
of O 0 4.272210710198898e-11
any O 0 2.428992840197708e-10
of O 0 1.660046405893567e-11
the O 0 9.316769578049389e-10
four O 0 6.263369556336329e-08
BRCA2 O 0 4.229340629535727e-05
mutations O 0 6.720556484651752e-07
was O 0 4.171545775477625e-09
5 O 0 2.2360981954960835e-09
. O 0 1.1415825618144027e-08

3x O 0 0.0009874652605503798
greater O 0 1.6835981853091653e-07
if O 0 9.405606249401899e-08
there O 0 5.221431620405781e-10
were O 0 8.558571074068766e-10
at O 0 1.309084840528385e-09
least O 0 2.458449832598575e-10
five O 0 7.232101029153171e-10
cases O 0 2.9087762754009816e-10
of O 0 5.671627612002794e-10
breast B-Disease 0 0.00033087804331444204
cancer I-Disease 0 1.0750209185061976e-05
in O 0 1.4339115450567874e-09
the O 0 8.476356505582316e-09
family O 0 5.132090450388205e-07
. O 0 2.3482895983306662e-07

Interestingly O 0 2.734234840318095e-06
, O 0 2.691113554220692e-09
the O 0 1.4431794648217533e-10
presence O 0 3.1056623939207384e-10
of O 0 8.396615347461278e-11
a O 0 8.477798729700226e-08
breast B-Disease 0 0.00013330989168025553
cancer I-Disease 0 1.9702590634551598e-06
case O 0 3.7055185586609696e-09
< O 0 9.85161108246757e-09
36 O 0 1.8433970794262677e-08
years O 0 4.390559305011976e-10
of O 0 2.047590048903647e-11
age O 0 3.6794109981030942e-09
was O 0 8.761435132953466e-09
strongly O 0 4.6448433987933413e-10
predictive O 0 5.166127525768616e-09
of O 0 2.0255111823908045e-11
the O 0 9.961741848085737e-11
presence O 0 1.1488815454541168e-10
of O 0 1.2760761197716519e-11
any O 0 2.0758728069836252e-10
of O 0 1.8638398116554988e-11
the O 0 5.76428460519196e-10
eight O 0 1.9967757225458627e-08
mutations O 0 1.618260796476534e-07
screened O 0 9.488416594649607e-07
. O 0 3.9525566819520463e-08

Carriers O 0 8.132896027746028e-07
of O 0 2.998490344907623e-10
the O 0 1.0670340999663352e-10
same O 0 4.885650217723025e-10
mutation O 0 8.840702392376443e-09
, O 0 1.765904922290673e-10
from O 0 4.7317934293023e-11
different O 0 2.8492243286937224e-11
families O 0 1.6546512771054012e-10
, O 0 1.056779455610446e-10
shared O 0 2.826314182691192e-10
similar O 0 5.198040331499953e-10
haplotypes O 0 2.62846526766225e-07
, O 0 8.528863171264334e-10
indicating O 0 3.3505314078752235e-09
that O 0 1.8196399248493478e-11
the O 0 1.357143217251e-11
mutant O 0 9.753002849777204e-10
alleles O 0 3.6222493893234287e-09
were O 0 2.335851290169444e-09
likely O 0 2.0638679654183534e-09
to O 0 3.112962665419161e-10
be O 0 3.282348559618953e-10
identical O 0 1.3631250794787775e-08
by O 0 4.1761771818471516e-10
descent O 0 6.723390129081963e-07
for O 0 5.134013769669821e-10
a O 0 2.4745496762790253e-09
mutation O 0 1.5989035873076318e-08
in O 0 1.183378811608904e-10
the O 0 8.660810957294984e-10
founder O 0 3.0294731345748005e-07
population O 0 2.9199840323457238e-09
. O 0 3.071421872391511e-08

The O 0 3.780996404856296e-09
identification O 0 1.2880920330360368e-08
of O 0 1.3654237462912278e-10
common O 0 7.284421066344748e-09
BRCA1 O 0 1.2132407391618472e-05
and O 0 1.0885812429251018e-07
BRCA2 O 0 4.4636741222348064e-05
mutations O 0 1.1681328260237933e-06
will O 0 7.871647778046054e-10
facilitate O 0 8.005129337185224e-10
carrier O 0 4.766600003591748e-09
detection O 0 5.247782208783747e-09
in O 0 3.918287083681804e-10
French O 0 7.469752745237201e-07
Canadian O 0 1.2060697827109834e-06
breast B-Disease 0 0.0032923829276114702
cancer I-Disease 0 0.03096866048872471
and O 0 5.90953350183554e-05
breast B-Disease 1 0.9999997615814209
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 4.458472062651708e-07
. O 0 7.423223991054329e-08

Are O 0 6.04932949954673e-07
Dp71 O 0 8.652298856759444e-05
and O 0 1.4346323951031081e-07
Dp140 O 0 2.3069369490258396e-06
brain O 0 9.305016646976583e-06
dystrophin O 0 1.1306275382594322e-06
isoforms O 0 1.2538075111478975e-07
related O 0 1.805103266860897e-08
to O 0 1.937117843908709e-08
cognitive B-Disease 0 2.290401425852906e-06
impairment I-Disease 0 0.00036896177334710956
in O 0 8.39084819403979e-08
Duchenne B-Disease 1 0.9982761144638062
muscular I-Disease 0 0.004999181255698204
dystrophy I-Disease 0 0.3003416359424591
? O 0 2.3403546947520226e-05

Molecular O 0 1.1800901802416774e-06
study O 0 6.633492688479237e-08
and O 0 2.4119410468870228e-08
neuropsychological O 0 1.9924165428619744e-07
analysis O 0 2.9640103704764442e-09
were O 0 6.329933799342768e-10
performed O 0 6.734354407456067e-09
concurrently O 0 7.4619181944513e-09
on O 0 3.8546971836694865e-08
49 O 0 6.267510457291792e-07
patients O 0 1.0150928098084933e-08
with O 0 5.24848298155689e-09
Duchenne B-Disease 1 0.5673695206642151
muscular I-Disease 0 0.0006655583274550736
dystrophy I-Disease 0 0.03010721690952778
( O 0 1.776452222657099e-06
DMD B-Disease 1 1.0
) O 0 5.1258975730661405e-08
in O 0 7.041942029495374e-10
order O 0 1.7816749187105074e-09
to O 0 3.9858352174348965e-09
find O 0 9.099679343371747e-10
a O 0 1.3268768028762423e-10
molecular O 0 5.07326181065082e-10
explanation O 0 7.619790909352275e-10
for O 0 4.3795585213946e-11
the O 0 5.587021401076697e-10
cognitive B-Disease 0 1.0054872490172784e-07
impairment I-Disease 0 6.329855182229949e-07
observed O 0 5.3580575531952945e-09
in O 0 1.7840996457962888e-09
most O 0 1.926003250218855e-07
DMD B-Disease 1 1.0
patients O 0 2.6065756173920818e-05
. O 0 1.3228754980332269e-08

Complete O 0 7.91169156855176e-07
analysis O 0 2.804445742299322e-08
of O 0 1.3475615068259117e-10
the O 0 5.194303875910578e-10
dystrophin O 0 4.346353321693641e-08
gene O 0 6.069774372008396e-08
was O 0 7.303898374999562e-09
performed O 0 7.493753173548612e-09
to O 0 1.4264638081851189e-10
define O 0 2.237284135730988e-09
the O 0 1.1480710132572014e-10
localization O 0 5.5602975557178524e-09
of O 0 2.412342200996953e-11
deletions O 0 2.251648680839935e-07
and O 0 7.680188041092606e-09
duplications O 0 6.652306865362334e-07
in O 0 7.952565272972834e-10
relation O 0 6.62843069321184e-09
to O 0 5.826553017840297e-09
the O 0 2.755362382700355e-09
different O 0 1.2819039341138705e-07
DMD B-Disease 1 0.9999998807907104
promoters O 0 7.0000451160012744e-06
. O 0 4.884276449956815e-08

Qualitative O 0 2.884305104089435e-06
analysis O 0 1.2863782927752254e-08
of O 0 1.1381007247734942e-10
the O 0 5.092651855775898e-10
Dp71 O 0 1.9830986275337636e-06
transcript O 0 7.578447821288137e-06
and O 0 5.379979794994938e-10
testing O 0 1.1178839104397653e-10
for O 0 1.88944931749091e-12
the O 0 2.9402892880864284e-12
specific O 0 2.3488230457835435e-11
first O 0 6.858050793923098e-10
exon O 0 9.561594183082889e-09
of O 0 5.211379938696581e-11
Dp140 O 0 4.755387905674979e-08
were O 0 4.683061938237643e-09
also O 0 8.741267154555032e-10
carried O 0 1.1513307640598214e-08
out O 0 4.4126263532007215e-08
. O 0 1.1103455044292332e-08

Neuropsychological O 0 0.0005185098270885646
analysis O 0 4.4386169406607223e-07
assessed O 0 1.0736331432781299e-06
verbal O 0 1.5307758758353884e-06
and O 0 2.955560951534153e-08
visuospatial O 0 7.489270956284599e-06
intelligence O 0 1.527400002032664e-07
, O 0 5.169498162871378e-09
verbal O 0 1.0394092697652013e-07
memory O 0 2.849384088676743e-07
, O 0 9.90066251205235e-09
and O 0 2.686499378512508e-08
reading O 0 4.3021452711400343e-07
skills O 0 5.790626644852637e-08
. O 0 4.5834021022983507e-08

Comparison O 0 8.968934253061889e-07
of O 0 7.255022138608069e-10
molecular O 0 1.6577644146309467e-08
and O 0 3.813618310033462e-09
psychometric O 0 1.2192938925181807e-07
findings O 0 1.4781377899453219e-08
demonstrated O 0 3.743386711718699e-10
that O 0 3.112314225783841e-11
deletions O 0 2.0123637867186517e-08
and O 0 2.7866191576464416e-09
duplications O 0 7.120988243514148e-07
that O 0 1.6445992345737181e-09
were O 0 2.7696084314854374e-10
localized O 0 5.7286655419375165e-09
in O 0 1.7408896546555752e-10
the O 0 5.379374168335005e-10
distal O 0 3.5283653687656624e-06
part O 0 5.433358651885101e-09
of O 0 2.938238888305911e-11
the O 0 1.6961369808665694e-10
gene O 0 2.933438736363314e-08
seemed O 0 8.09521782940692e-09
to O 0 4.0063052875183303e-10
be O 0 1.4021564465060976e-10
preferentially O 0 6.381555284207252e-09
associated O 0 3.1717113380125284e-09
with O 0 6.023857856973791e-09
cognitive B-Disease 0 1.7778215806174558e-06
impairment I-Disease 0 1.674639861448668e-05
. O 0 4.860160984776485e-08

Two O 0 1.0259975624649087e-07
altered O 0 5.176297690923093e-06
Dp71 O 0 1.059162059391383e-05
transcripts O 0 8.579946779718739e-07
and O 0 6.890291670558213e-10
two O 0 8.997298045487767e-11
deleted O 0 1.489682688315952e-08
Dp140 O 0 2.0228454467030588e-09
DNA O 0 1.785563474854257e-09
sequences O 0 8.619940317089458e-10
were O 0 2.8846983135544235e-10
found O 0 2.949160915477478e-10
in O 0 1.296980578491258e-10
four O 0 9.042208759524328e-09
patients O 0 1.0255392979274802e-08
with O 0 7.593940587469206e-09
severe O 0 0.00023111101472750306
cerebral B-Disease 0 0.0011206271592527628
dysfunction I-Disease 0 0.0015593040734529495
. O 0 3.7880840864090715e-07

These O 0 3.192930364548374e-07
findings O 0 1.0007556738855783e-07
suggest O 0 6.933590146473989e-09
that O 0 3.069484597051364e-11
some O 0 3.976898671487206e-12
sequences O 0 5.7260595570651773e-11
located O 0 5.76917902339602e-10
in O 0 1.958552348080289e-10
the O 0 5.862881291562871e-10
distal O 0 4.059577918269497e-07
part O 0 1.5478722747985785e-09
of O 0 2.7978749525536806e-11
the O 0 5.0029577702837e-11
gene O 0 1.4404555770397565e-08
and O 0 3.543472848477336e-09
, O 0 3.3317733988402765e-11
in O 0 8.092056538733239e-12
particular O 0 1.28303950797104e-10
, O 0 6.492242299316331e-10
some O 0 5.789957957524905e-10
DMD B-Disease 1 0.999998927116394
isoforms O 0 3.6146783344293e-09
expressed O 0 1.1490830509330863e-10
in O 0 3.955325997284653e-11
the O 0 1.2235805701976687e-09
brain O 0 5.950804188614711e-05
may O 0 1.1291167538729496e-06
be O 0 6.3462785027113e-10
related O 0 5.035951655685267e-10
to O 0 4.402914033363459e-09
the O 0 5.4518469738695785e-09
cognitive B-Disease 0 5.626916390610859e-07
impairment I-Disease 0 1.2643213267438114e-06
associated O 0 9.328491756832591e-09
with O 0 4.3416221728875826e-08
DMD B-Disease 1 1.0
. O 0 1.5138121511881764e-07
. O 0 6.091207183089864e-08

I1307K O 0 3.9733695302857086e-05
APC O 0 1.0574281986919232e-05
and O 0 2.074505189852971e-08
hMLH1 O 0 1.780694844910613e-07
mutations O 0 1.056101766039319e-07
in O 0 1.0841082892509846e-10
a O 0 7.196763740502377e-10
non O 0 1.7891574444206526e-08
- O 0 4.501932693301569e-08
Jewish O 0 2.2633555474271816e-08
family O 0 2.6560416088727834e-08
with O 0 2.0401198952413324e-08
hereditary B-Disease 1 0.9609208106994629
non I-Disease 1 0.7702990770339966
- I-Disease 1 0.9999998807907104
polyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.0527649010327877e-06

We O 0 2.562249505899672e-07
describe O 0 4.284702725954048e-08
a O 0 3.764927480887081e-09
French O 0 4.774983040078951e-07
Canadian O 0 5.667004643328255e-07
hereditary B-Disease 1 0.968427836894989
non I-Disease 1 0.8979803919792175
- I-Disease 1 1.0
polyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 2.8351822038530372e-05
HNPCC B-Disease 1 0.8604620695114136
) O 0 3.180919065925991e-07
kindred O 0 8.84170804056339e-05
which O 0 7.028338799841549e-09
carries O 0 9.77602621077267e-09
a O 0 1.2104491853293098e-09
novel O 0 1.8885236485743917e-08
truncating O 0 9.515779311186634e-06
mutation O 0 1.3991491414344637e-06
in O 0 3.7356997495407995e-09
hMLH1 O 0 5.6801163736963645e-06
. O 0 9.36947301966029e-08

Interestingly O 0 5.504523869603872e-06
, O 0 1.0177914511189101e-08
the O 0 8.774977966474751e-10
I1307K O 0 4.9892530995521156e-08
APC O 0 3.369631329519507e-08
polymorphism O 0 6.889651515962214e-09
, O 0 1.4493529987280596e-10
associated O 0 3.46241035842354e-10
with O 0 2.667165273362304e-11
an O 0 4.667329855934099e-10
increased O 0 1.530377460312593e-07
risk O 0 6.960827886359766e-05
of O 0 0.00016770820366218686
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 4.493645278103031e-08
is O 0 1.0769121150389083e-09
also O 0 3.6146918791502003e-09
present O 0 3.656908664773084e-10
in O 0 7.917434069470985e-11
this O 0 1.0735323741073444e-09
family O 0 4.000322917363519e-08
. O 0 5.760377419505858e-08

The O 0 5.8643294664761925e-08
I1307K O 0 6.216571932782244e-07
polymorphism O 0 5.620609044854064e-07
has O 0 2.8865448697956708e-08
previously O 0 2.617058925125093e-08
only O 0 7.500569609852903e-10
been O 0 5.082395060362899e-10
identified O 0 1.7828477583137214e-09
in O 0 3.361833381121393e-11
individuals O 0 5.3937243560397974e-11
of O 0 1.4044182483630152e-10
self O 0 1.996864966713474e-06
- O 0 0.0032852489966899157
reported O 0 0.010974094271659851
Ashkenazi O 0 7.184863534348551e-06
Jewish O 0 3.96400210433967e-08
origins O 0 3.3799472021200927e-07
. O 0 9.680915269427715e-08

In O 0 1.7772331162291266e-08
addition O 0 1.87325421840967e-09
, O 0 3.6769257083513196e-10
in O 0 1.2213857703002873e-10
this O 0 1.9132918860353954e-10
family O 0 8.149377173083394e-09
, O 0 4.427478828006315e-09
there O 0 4.3287437523353844e-10
appears O 0 1.4278235482834134e-08
to O 0 6.216391401636656e-09
be O 0 1.7618921877016192e-09
no O 0 3.318950392294795e-10
relationship O 0 2.0576447490316951e-10
between O 0 2.371945348467186e-11
the O 0 6.284361919739467e-11
I1307K O 0 5.080691867220821e-09
polymorphism O 0 1.5370721362373274e-09
and O 0 2.3443216812246703e-10
the O 0 7.274847391158801e-11
presence O 0 3.443797469415699e-10
or O 0 1.9888203084406086e-08
absence O 0 1.6317573958701814e-09
of O 0 1.065714044790056e-10
cancer B-Disease 0 7.244906186087974e-08
. O 0 1.06444486558388e-09
. O 0 2.7023794757496944e-08

Identification O 0 3.144340041671967e-07
of O 0 4.88302287493525e-10
a O 0 1.2829839413086574e-09
novel O 0 6.41467545747787e-09
mutation O 0 5.2576133668935654e-08
of O 0 1.501336277520693e-10
the O 0 7.641608457120697e-10
CPO O 0 2.3587346731801517e-05
gene O 0 2.8584916655916004e-09
in O 0 1.6142592471068973e-11
a O 0 1.3134416887439215e-09
Japanese O 0 1.0644458825481706e-07
hereditary B-Disease 0 2.6467108909855597e-05
coproporphyria I-Disease 0 9.511695679975674e-06
family O 0 1.5769433048262727e-07
. O 0 6.282824926984176e-08

Hereditary B-Disease 1 0.9999549388885498
coproporphyria I-Disease 1 0.6681482791900635
( O 0 9.344214959128294e-06
HCP B-Disease 0 0.0010289124911651015
) O 0 2.4175694335326625e-08
is O 0 8.430190434616236e-10
an O 0 7.714483274412487e-09
autosomal B-Disease 1 0.9999982118606567
dominant I-Disease 1 0.998026430606842
disease I-Disease 1 0.9334139823913574
characterized O 0 4.028315814252892e-08
by O 0 2.601940329860497e-10
a O 0 2.2678935351905238e-07
deficiency B-Disease 0 0.00043691438622772694
of I-Disease 0 9.218206753480729e-10
coproporphyrinogen I-Disease 0 6.50684887659736e-05
oxidase I-Disease 0 2.6830921342479996e-06
( O 0 7.965613235683122e-08
CPO O 0 0.0003865084145218134
) O 0 4.4737918925008557e-10
caused O 0 4.272457110321426e-10
by O 0 5.68954258706178e-12
a O 0 3.601642040163e-10
mutation O 0 8.6986604586059e-09
in O 0 1.600201637863563e-10
the O 0 2.015904776442312e-09
CPO O 0 0.00011136461398564279
gene O 0 1.9619423596850538e-07
. O 0 1.7684346431678932e-08

Only O 0 9.057229277686929e-08
11 O 0 7.119546729938975e-09
mutations O 0 3.121462199828784e-08
of O 0 4.694289401641072e-11
the O 0 2.147310385058887e-10
gene O 0 1.095981261300949e-07
have O 0 9.449766302793705e-09
been O 0 1.1017256440482015e-08
reported O 0 2.0792683699255576e-06
in O 0 3.828420247486974e-09
HCP B-Disease 0 0.0015018798876553774
patients O 0 2.132193230863777e-06
. O 0 1.6922415468911822e-08

We O 0 1.3004001630179118e-05
report O 0 5.784378842577098e-08
another O 0 1.0262354299683807e-09
mutation O 0 3.9952658958952725e-09
in O 0 4.421086413630704e-11
a O 0 9.629231856322917e-10
Japanese O 0 1.5012176390882814e-08
family O 0 8.432945008962633e-09
. O 0 5.0404544538196205e-08

Polymerase O 0 7.159159395087045e-06
chain O 0 3.434032350924099e-06
reaction O 0 6.021356568908232e-08
- O 0 1.239985181200609e-07
single O 0 2.1814313910795136e-08
strand O 0 9.556325721860048e-07
conformational O 0 1.7914079109004888e-08
polymorphism O 0 1.8921324951293172e-08
and O 0 2.465164461451508e-10
direct O 0 1.3353779193536752e-09
sequence O 0 8.369857695811334e-09
analyses O 0 1.255884551909503e-08
demonstrated O 0 4.475976811413318e-10
a O 0 2.2172233493655824e-10
C O 0 1.898172818926014e-08
to O 0 4.49016240855471e-10
T O 0 2.172781776721422e-08
substitution O 0 9.344438417491219e-11
in O 0 9.930568520277738e-12
exon O 0 2.4377191376601104e-09
1 O 0 9.078317264599178e-11
of O 0 2.7119367949218764e-12
the O 0 2.1384330417539843e-10
CPO O 0 7.289204404514749e-07
gene O 0 4.1151740348688293e-10
at O 0 9.829716207665484e-11
nucleotide O 0 3.345927090947498e-09
position O 0 2.28766481313869e-08
85 O 0 6.66977084673448e-10
, O 0 1.7732290635841252e-10
which O 0 2.8514818284364196e-10
lies O 0 5.746459752486999e-09
in O 0 4.512284990099147e-11
the O 0 1.3417471300680717e-10
putative O 0 1.4967630690421174e-08
presequence O 0 5.792891499822872e-08
for O 0 8.898363990095248e-11
targeting O 0 1.5716548062982838e-08
to O 0 1.260448900808342e-08
mitochondria O 0 2.1526687987716286e-07
. O 0 7.217693109851098e-08

This O 0 2.2242231167979298e-08
mutation O 0 1.2472982291455992e-07
changes O 0 3.028910899871562e-09
the O 0 1.3814294153036144e-10
codon O 0 9.806317535776543e-09
for O 0 3.944522486420965e-11
glutamine O 0 2.868995485627579e-09
to O 0 7.895897824461429e-11
a O 0 1.5372501882549017e-10
termination O 0 3.748089838495616e-09
codon O 0 2.9127320999577933e-08
at O 0 5.000012626155126e-10
amino O 0 3.730245889954631e-09
acid O 0 4.5911981771951105e-08
position O 0 1.5038885692320036e-08
29 O 0 3.7531421526182385e-08
. O 0 8.29854762685045e-09

MaeI O 0 3.660070797195658e-05
restriction O 0 7.668510448866073e-08
analysis O 0 1.4059687636347462e-08
showed O 0 2.3327848097665083e-08
two O 0 3.2318040604772946e-11
other O 0 2.3102124380169897e-11
carriers O 0 2.2904086960373604e-10
in O 0 6.647643546742188e-11
the O 0 8.74356864688508e-10
family O 0 8.664652284551266e-08
. O 0 1.2512417413290677e-07

The O 0 1.9268998130428372e-07
C O 0 0.0001939507492352277
- O 0 0.0013135167537257075
T O 0 0.0005724920192733407
mutation O 0 1.2505712732036045e-07
is O 0 1.39015202127446e-10
located O 0 3.5287880950640726e-10
within O 0 9.504345921396151e-11
a O 0 8.119026562170006e-10
recently O 0 7.096390586269763e-09
proposed O 0 6.819753095577141e-10
putative O 0 2.64940180905171e-09
alternative O 0 1.1904289776154542e-09
translation O 0 7.12432823846143e-09
initiation O 0 4.4297427947981305e-09
codon O 0 4.30325371780782e-07
( O 0 9.92826709733663e-10
TIC O 0 5.83676694532187e-07
- O 0 4.180293444733252e-08
1 O 0 1.5743722991956588e-09
) O 0 6.444370037606006e-11
, O 0 4.756822713503084e-11
supporting O 0 1.7548448805193573e-10
that O 0 1.0071576905801294e-10
TIC O 0 8.241292448474269e-08
- O 0 2.17260676116382e-09
1 O 0 1.3823230060605596e-10
is O 0 1.3663872117097853e-11
the O 0 2.2145766123693456e-11
real O 0 1.4660831437751654e-09
TIC O 0 5.315927253946029e-08
rather O 0 1.0445492387711752e-10
than O 0 5.080309090077506e-11
TIC O 0 2.4434417156271593e-08
- O 0 1.6490218079923125e-09
2 O 0 6.135498775705628e-10
. O 0 3.7120742590879274e-10
. O 0 4.60384086409249e-09

Human B-Disease 0 1.4921472484275e-06
complement I-Disease 0 1.6967298961390043e-06
factor I-Disease 0 1.2630797755264211e-05
H I-Disease 1 1.0
deficiency I-Disease 1 0.998205304145813
associated O 0 2.5393733267264906e-06
with O 0 3.859637672576355e-06
hemolytic B-Disease 1 0.9999997615814209
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 3.7133497698960127e-06

This O 0 1.0304690789553206e-07
study O 0 2.3840366125682522e-08
reports O 0 4.628805072570685e-08
on O 0 5.448531403828838e-09
six O 0 6.19544016089435e-09
cases O 0 1.0266211214471355e-09
of O 0 1.0728651300695446e-09
deficiency B-Disease 0 1.1047272892028559e-05
in I-Disease 0 8.164289383438827e-11
the I-Disease 0 1.5863714508679294e-10
human I-Disease 0 1.314039849154014e-10
complement I-Disease 0 2.199793680546236e-09
regulatory I-Disease 0 2.930115705623848e-09
protein I-Disease 0 7.55222462345273e-09
Factor I-Disease 0 1.0907236003276921e-08
H I-Disease 1 1.0
( O 0 2.3057257436676082e-08
FH O 0 2.866676550183911e-05
) O 0 4.42923128729511e-11
in O 0 7.559764446385397e-12
the O 0 2.0743795570155044e-11
context O 0 4.626249383576919e-10
of O 0 1.0654945675758754e-10
an O 0 4.0274139223583916e-07
acute B-Disease 1 0.7763381004333496
renal I-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 1.7772470073396107e-06

Five O 0 1.1080567929866447e-07
of O 0 2.8052560274716143e-10
the O 0 3.253868285924e-10
cases O 0 2.2191413151517736e-09
were O 0 4.274056664144155e-09
observed O 0 4.72998396006119e-09
in O 0 6.526658657968198e-10
children O 0 1.0218041524012733e-08
presenting O 0 4.348211177784833e-07
with O 0 3.126675437670201e-06
idiopathic O 1 0.9999990463256836
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.00023790595878381282
HUS B-Disease 1 0.9999974966049194
) O 0 2.082094169963966e-06
. O 0 3.671001422844711e-07

Two O 0 2.1068403910362576e-08
of O 0 4.427848088184305e-10
the O 0 7.182420214135732e-10
children O 0 7.643813582092207e-09
exhibited O 0 1.2743048394270318e-08
a O 0 3.784267121886842e-08
homozygous O 0 0.0002284709335071966
deficiency O 0 0.00018013892986346036
characterized O 0 6.998975621286263e-09
by O 0 7.895400999657909e-11
the O 0 4.60971677496147e-10
absence O 0 9.45143741049037e-10
of O 0 5.6972091974638595e-12
the O 0 2.8556386422184943e-11
150 O 0 8.284021385529527e-11
- O 0 8.731840139830638e-09
kD O 0 2.9561867620486737e-08
form O 0 1.2741625809997714e-10
of O 0 7.964321042941425e-12
Factor O 0 1.7353707360001636e-09
H O 1 1.0
and O 0 6.975475752568627e-10
the O 0 3.017502220314938e-11
presence O 0 9.223601743491017e-11
, O 0 3.978501555979008e-11
upon O 0 4.5925662578438775e-11
immunoblotting O 0 1.1274049249720974e-08
, O 0 1.6188349272194813e-11
of O 0 1.0276205884493517e-12
the O 0 5.926943658085548e-11
42 O 0 3.799670356130491e-09
- O 0 1.4144657001224914e-08
kD O 0 2.3673260329815093e-07
Factor O 0 8.951791308220436e-09
H O 1 0.9999929666519165
- O 0 6.05753580629198e-09
like O 0 1.7362669635367922e-10
protein O 0 4.443737045001228e-10
1 O 0 2.2591438442187695e-10
( O 0 1.0662284249951526e-10
FHL O 0 2.6925423668444637e-08
- O 0 6.205516545065848e-09
1 O 0 3.374883150719654e-10
) O 0 1.8225993630993642e-11
and O 0 1.4195508657444122e-10
other O 0 4.1440414988436203e-10
FH O 0 5.7944100262830034e-05
- O 0 1.64251865442111e-08
related O 0 2.578445235101867e-09
protein O 0 7.626308473618337e-09
( O 0 4.482897386637319e-10
FHR O 0 1.0097458016389282e-06
) O 0 3.5349589921906954e-10
bands O 0 1.6853549666961953e-08
. O 0 9.552516111455134e-09

Southern O 0 1.1866212844324764e-05
blot O 0 0.001013914356008172
and O 0 5.236444167167065e-09
PCR O 0 2.086684247615267e-08
analysis O 0 2.1291576834947534e-10
of O 0 5.865246222730436e-12
DNA O 0 2.1783328474356267e-09
of O 0 1.7679430835970678e-11
one O 0 1.9817838481372974e-09
patient O 0 1.476241617837104e-08
with O 0 1.020126982886893e-09
homozygous O 0 7.018296309979632e-05
deficiency O 0 0.0003880638687405735
ruled O 0 2.158156497955588e-08
out O 0 3.165347539635377e-09
the O 0 5.757424745289619e-11
presence O 0 6.56190518588673e-11
of O 0 2.943835930233063e-12
a O 0 6.580191252991696e-11
large O 0 1.8557035075250639e-10
deletion O 0 1.1982595538029273e-07
of O 0 1.253490228281251e-10
the O 0 2.3786894676192105e-09
FH O 0 8.763478035689332e-06
gene O 0 4.236591966133574e-09
as O 0 4.887101834327723e-11
the O 0 5.703975486381907e-11
underlying O 0 1.3147662514256808e-07
defect O 0 2.887950074637047e-07
for O 0 3.41685429949834e-10
the O 0 3.566862005754956e-08
deficiency O 0 8.916539809433743e-05
. O 0 6.777136718483234e-08

The O 0 1.4311335228001099e-08
other O 0 4.6908732453943e-10
four O 0 1.5876586711982554e-09
children O 0 6.241301919729381e-10
presented O 0 6.568094401693259e-10
with O 0 3.734282216782958e-09
heterozygous O 0 3.105804353253916e-05
deficiency O 0 0.00014962910790927708
and O 0 1.6331429542049136e-09
exhibited O 0 2.544141564086999e-09
a O 0 1.7028478627167942e-09
normal O 0 4.4142049659967597e-07
immunoblotting O 0 1.419195655216754e-06
pattern O 0 5.442260686550071e-08
of O 0 9.751392401891046e-12
proteins O 0 1.567354440679125e-10
of O 0 5.534738639623171e-11
the O 0 1.0082676915601496e-08
FH O 0 0.0021750552114099264
family O 0 7.200244311889037e-08
. O 0 3.363011913393166e-08

Factor B-Disease 0 0.002444137819111347
H I-Disease 1 1.0
deficiency I-Disease 1 0.9949085116386414
is O 0 2.4781914298444008e-09
the O 0 4.2197345617722704e-10
only O 0 1.7127126739069354e-07
complement B-Disease 1 0.9999992847442627
deficiency I-Disease 1 1.0
associated O 0 6.926890705472033e-08
with O 0 2.398970622152774e-08
HUS B-Disease 1 0.9999301433563232
. O 0 6.022585239406908e-07

These O 0 4.644476092607874e-08
observations O 0 6.090777304734729e-08
suggest O 0 4.892992233607174e-09
a O 0 4.274046672136933e-10
role O 0 2.613670391227174e-09
for O 0 1.7192012258249179e-09
FH O 0 0.004406423773616552
and O 0 3.133345103378815e-07
/ O 0 0.00012169554975116625
or O 0 1.3736531627728255e-06
FH O 0 5.5930609960341826e-05
receptors O 0 2.593938841499721e-09
in O 0 6.28033597349642e-11
the O 0 2.1992935250736423e-10
pathogenesis O 0 1.186055214930093e-06
of O 0 2.4090571759671775e-09
idiopathic O 0 0.00029123705462552607
HUS B-Disease 1 0.9998800754547119
. O 0 1.2454748343770916e-07
. O 0 7.298470450223249e-08

Further O 0 4.7478110332122014e-07
evidence O 0 3.0967202135911975e-09
for O 0 5.6507416801299115e-11
a O 0 1.8847216842754477e-10
major O 0 1.2481181643764216e-09
ancient O 0 6.961818144191056e-08
mutation O 0 0.001578135066665709
underlying O 0 0.0013519091298803687
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
from O 0 2.0557941127208323e-07
linkage O 0 6.592269073735224e-06
disequilibrium O 0 3.284523927504779e-06
studies O 0 4.064216074795013e-09
in O 0 2.563463330496063e-10
the O 0 4.0621758734538105e-10
Japanese O 0 2.970452683825897e-08
population O 0 4.946657305993085e-09
. O 0 1.61428648226547e-08

The O 0 0.00015019702550489455
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.6919482350349426
DM B-Disease 1 1.0
) O 0 1.1432619828610768e-07
mutation O 0 5.481837774823362e-07
is O 0 1.1944774058747498e-09
an O 0 1.3092545936288502e-09
unstable O 0 0.0005281188059598207
( O 0 1.7917189509830678e-08
CTG O 0 5.299964414007263e-06
) O 0 1.778761693493891e-09
n O 0 3.5526011288311565e-07
repeat O 0 3.437800842220895e-06
, O 0 3.998076592015565e-10
present O 0 7.057212453309702e-11
at O 0 1.3892666184123215e-10
a O 0 1.8839813042959008e-10
copy O 0 9.709041393080042e-08
number O 0 6.762100879242894e-10
of O 0 9.856501899385695e-12
5 O 0 1.2635420709727896e-08
- O 0 1.375682586512994e-06
37 O 0 1.3501012574579363e-07
repeats O 0 6.506020326924045e-07
on O 0 8.581213961633694e-09
normal O 0 2.8525727557848768e-08
chromosomes O 0 2.198813220388729e-08
but O 0 5.574471440006334e-10
amplified O 0 1.4635795908546356e-09
to O 0 1.3904277729182013e-10
50 O 0 1.5153930887912281e-10
- O 0 5.841241268456088e-09
3000 O 0 2.918836949916681e-09
copies O 0 1.922617371974411e-07
on O 0 7.590490895381663e-06
DM B-Disease 1 0.9999998807907104
chromosomes O 0 4.7280477701860946e-06
. O 0 4.203448256134834e-08

Previous O 0 1.0447121894685552e-05
findings O 0 1.5821552779016201e-07
in O 0 1.9067865064670286e-09
Caucasian O 0 1.907997102534864e-06
populations O 0 1.7745909630662027e-08
of O 0 7.610088670340076e-10
a O 0 2.2242563773033908e-06
DM B-Disease 1 1.0
founder O 0 5.076655611446768e-07
chromosome O 0 2.5401725451956736e-06
raise O 0 4.800412511940522e-09
a O 0 3.15901460545831e-09
question O 0 1.2583848407743403e-09
about O 0 8.198385720303847e-11
the O 0 4.8591800722030953e-11
molecular O 0 1.069459298896902e-09
events O 0 3.879535304118775e-10
involved O 0 6.714497291504529e-10
in O 0 5.606179409589629e-11
the O 0 2.404515753173797e-10
expansion O 0 2.9447514648950346e-08
mutation O 0 4.130134811930475e-07
. O 0 4.602271275189196e-08

To O 0 3.6243525869394944e-07
investigate O 0 6.155184451017703e-08
whether O 0 4.3473211697175884e-09
a O 0 1.278847694408114e-09
founder O 0 2.5496467159769054e-08
chromosome O 0 3.1084030069905566e-06
for O 0 3.4984781738245374e-09
the O 0 3.601137166242552e-08
DM B-Disease 1 1.0
mutation O 0 1.2279454608687956e-07
exists O 0 1.5278639464710864e-10
in O 0 5.517987108905054e-12
the O 0 2.5047578594561415e-11
Japanese O 0 3.4496436818187703e-09
population O 0 1.4215938148876006e-10
, O 0 2.1020898910428798e-10
we O 0 6.337738667205883e-10
genotyped O 0 9.341739826140838e-09
families O 0 3.397894812739999e-11
using O 0 4.212722393148738e-10
polymorphic O 0 3.134295525342168e-07
markers O 0 9.957782367564505e-07
near O 0 7.166675572989334e-07
the O 0 1.643120306482615e-08
( O 0 1.189900711295877e-08
CTG O 0 4.855277893511811e-06
) O 0 3.833761752503051e-09
n O 0 1.8877043430620688e-06
repeat O 0 2.3562792193843052e-05
region O 0 1.2324322824497358e-06
and O 0 1.661246251671855e-08
constructed O 0 8.348160918103531e-08
haplotypes O 0 1.1194274520676117e-05
. O 0 7.415582103931229e-08

Six O 0 1.9236591697335825e-07
different O 0 3.8833203319654785e-09
haplotypes O 0 1.4950644526834367e-06
were O 0 7.365779453039067e-08
found O 0 1.0170505504447647e-07
and O 0 9.574551995683578e-07
DM B-Disease 1 1.0
alleles O 0 9.063197126124578e-07
were O 0 9.483476226535004e-09
always O 0 1.1109047015622764e-08
haplotype O 0 1.6579737120991922e-06
A O 0 2.0677468626217888e-07
. O 0 1.0284427531814799e-07

To O 0 4.2434521674294956e-07
find O 0 9.747613383126463e-09
an O 0 7.697822934638054e-11
origin O 0 1.2460344978038052e-09
of O 0 6.820517761685352e-11
the O 0 1.3741638937858625e-09
( O 0 3.9784220362548695e-09
CTG O 0 1.4427179166887072e-06
) O 0 6.373122585223712e-10
n O 0 1.0644011894100913e-07
repeat O 0 2.5007523163367296e-07
mutation O 0 9.184358162883655e-09
and O 0 9.194974781578935e-10
to O 0 3.1320629423348123e-10
investigate O 0 3.0200600353857965e-10
the O 0 8.060170586521309e-12
mechanism O 0 2.6573195033297026e-11
of O 0 2.161501446579228e-12
the O 0 9.545180618131255e-12
expansion O 0 1.919425313134937e-10
mutation O 0 8.540633200659897e-10
in O 0 5.73075484636143e-12
the O 0 3.8623156756179e-11
Japanese O 0 1.6498084010052594e-09
population O 0 4.2818613238404524e-11
we O 0 3.066296938580848e-10
have O 0 1.8760807143913816e-11
studied O 0 7.662782214312713e-11
90 O 0 2.3543680893745034e-10
Japanese O 0 3.893579503255751e-08
DM B-Disease 1 0.9999997615814209
families O 0 2.448725111570127e-10
comprising O 0 4.3692788970206564e-11
190 O 0 5.823039272989661e-10
affected O 0 5.562663218938724e-09
and O 0 1.2235081836564632e-09
130 O 0 3.2176608044665045e-09
unaffected O 0 2.991245082739624e-07
members O 0 2.800814247194694e-09
. O 0 7.765163623218996e-09

The O 0 4.029984097542183e-07
results O 0 3.2091361390484963e-06
suggest O 0 6.8505894290638025e-09
that O 0 1.7718182823700523e-11
a O 0 5.140595935038128e-11
few O 0 6.900994359293477e-11
common O 0 4.066988065765109e-11
ancestral O 0 3.362554679142704e-09
mutations O 0 3.274835762567818e-07
in O 0 7.087321007848146e-11
both O 0 4.708899936645139e-10
Caucasian O 0 5.382273116083525e-07
and O 0 3.97270483176726e-09
Japanese O 0 1.586832110156422e-09
populations O 0 1.4536359616013073e-10
have O 0 2.087967125585788e-11
originated O 0 2.4115327790230623e-11
by O 0 2.248437547258675e-12
expansion O 0 4.535919556625245e-11
of O 0 3.286103810937191e-12
an O 0 2.6339409819886583e-11
ancestral O 0 6.278114472735297e-09
n O 0 2.0323891476436984e-06
= O 0 2.908080176666772e-08
5 O 0 2.4729973624459944e-09
repeat O 0 1.7481158920418238e-07
to O 0 2.8444648858538812e-09
n O 0 4.358357230671572e-08
= O 0 4.289404387236573e-08
19 O 0 1.7122840034744513e-08
- O 0 7.982678340567873e-08
37 O 0 1.1560640444940873e-08
copies O 0 2.0448695181585208e-07
. O 0 3.173752460838841e-08

These O 0 1.7028941812213816e-08
data O 0 1.9573816345541672e-08
support O 0 4.0220241026567294e-10
multistep O 0 1.8294564085863385e-08
models O 0 4.737839898183438e-09
of O 0 1.4207915399744309e-10
triplet O 0 2.6737978259916417e-05
repeat O 0 8.88202885107603e-06
expansion O 0 1.8104883148239992e-09
that O 0 1.463031917836588e-10
have O 0 7.227229925632628e-11
been O 0 2.8536024238023927e-11
proposed O 0 1.2992015796520207e-10
for O 0 3.087659572464929e-10
both O 0 4.2777620024025964e-07
DM B-Disease 1 1.0
and O 0 1.0491645525689819e-06
Friedreichs B-Disease 0 0.000523619179148227
ataxia I-Disease 0 0.05543900281190872
. O 0 2.128886622543291e-09
. O 0 1.361106338748641e-08

The O 0 2.5374209400297332e-08
molecular O 0 8.478688329205397e-08
basis O 0 7.683223657295457e-08
of O 0 1.774515681063349e-07
C6 B-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 6.283717990385185e-10
the O 0 1.571689167700896e-10
western O 0 5.602539765448e-09
Cape O 0 2.2390697296259532e-08
, O 0 6.506994387756038e-10
South O 0 1.2186940345770836e-09
Africa O 0 1.8194266093729539e-09
. O 0 4.054073521331247e-09

Deficiency B-Disease 1 0.9978300929069519
of I-Disease 0 3.868513065441448e-09
the I-Disease 0 1.286740936023989e-09
sixth I-Disease 0 1.2493005385749711e-07
component I-Disease 0 1.250043890621555e-08
of I-Disease 0 1.3483739125241812e-10
human I-Disease 0 5.735408259432972e-10
complement I-Disease 0 1.1838247715445505e-08
( O 0 2.4126529662993335e-09
C6 O 0 1.561752583256748e-06
) O 0 2.066274484846531e-09
has O 0 4.873981218622703e-09
been O 0 3.194192244038163e-09
reported O 0 1.8937181778255763e-07
in O 0 1.5599809638500162e-11
a O 0 1.0275863493447446e-10
number O 0 6.786155665183813e-11
of O 0 2.7566829027825257e-12
families O 0 2.4117029553960556e-11
from O 0 3.3635712270996265e-11
the O 0 2.890271633138042e-10
western O 0 7.95598342762105e-09
Cape O 0 2.5223997113243968e-08
, O 0 3.064157261256639e-10
South O 0 1.2218127620755581e-09
Africa O 0 1.405925154074339e-09
. O 0 2.830642387152693e-09

Meningococcal B-Disease 1 0.9896785020828247
disease I-Disease 1 0.5497711300849915
is O 0 4.523569518966042e-09
endemic O 0 5.922248913492467e-09
in O 0 3.612925791873778e-10
the O 0 4.689638122279405e-10
Cape O 0 1.2449808650671912e-07
and O 0 2.4565152134670143e-09
almost O 0 4.928658037250955e-10
all O 0 4.634681527448947e-11
pedigrees O 0 4.914373352704615e-09
of O 0 1.2353100764528335e-09
total O 0 6.797322566853836e-05
C6 B-Disease 1 1.0
deficiency I-Disease 1 1.0
( O 0 8.001851625749623e-09
C6Q0 O 0 1.3478164873959031e-05
) O 0 6.841328059614682e-10
have O 0 7.304437610322623e-10
been O 0 1.1612146799677703e-09
ascertained O 0 7.2510722759489e-08
because O 0 4.553944166207913e-10
of O 0 8.477903934434039e-10
recurrent O 0 0.027475550770759583
disease O 0 0.0013124713441357017
. O 0 1.1570064373245259e-07

We O 0 3.3819055715866853e-06
have O 0 2.503594886960059e-09
sequenced O 0 4.766356909158276e-08
the O 0 3.3906197294264473e-10
expressed O 0 3.222363764709968e-10
exons O 0 1.490666079462244e-08
of O 0 2.1257481885861296e-11
the O 0 1.0610146788936348e-10
C6 O 0 1.9973205311885067e-08
gene O 0 4.711480539043578e-09
from O 0 6.248624534466174e-11
selected O 0 4.121795960099206e-10
cases O 0 1.2302212026860104e-10
and O 0 3.3860894643744643e-10
have O 0 2.223559114611362e-10
found O 0 5.588417506530163e-10
three O 0 6.857671652760189e-10
molecular O 0 4.463227654127877e-08
defects O 0 0.0008842574316076934
leading O 0 4.646531692742428e-08
to O 0 5.417404835839079e-08
total O 0 1.0717775467128376e-06
deficiency O 0 6.4135178945434745e-06
879delG O 0 1.0048622556269038e-07
, O 0 4.178623280726157e-10
which O 0 1.2086191769622445e-10
is O 0 3.678487722758028e-11
the O 0 3.116299926442245e-11
common O 0 2.642175367384425e-09
defect O 0 3.663844694301588e-08
in O 0 2.9511795784920025e-11
the O 0 5.823381360459123e-11
Cape O 0 1.4036215745250047e-08
and O 0 8.26043733415105e-10
hitherto O 0 5.925005819307216e-09
unreported O 0 8.951500873877194e-09
, O 0 3.8680827985082544e-10
and O 0 5.754364762466935e-10
1195delC O 0 6.880658531827066e-08
and O 0 4.810054576864786e-09
1936delG O 0 6.790217810248578e-08
, O 0 4.925171381842119e-10
which O 0 1.792745812911889e-10
have O 0 4.1774517178794213e-10
been O 0 5.295155980356014e-10
previously O 0 3.568876394410836e-08
reported O 0 1.3925529174230178e-07
in O 0 3.0511152632195504e-11
African O 0 1.1384328202357352e-10
- O 0 9.185009730572347e-08
Americans O 0 2.077526239929739e-08
. O 0 9.79080549967648e-09

We O 0 3.0709468319400912e-06
also O 0 1.275466510186618e-09
show O 0 1.8658479206123957e-09
that O 0 1.3328369657950034e-11
the O 0 2.915306537842888e-11
879delG O 0 1.9468450318527175e-07
and O 0 5.22241982992e-09
1195delC O 0 6.080909315642202e-06
defects O 0 0.00011408821592340246
are O 0 5.315878293110643e-11
associated O 0 4.606262871131861e-10
with O 0 9.397618239148642e-10
characteristic O 0 7.28315717424266e-06
C6 O 0 0.03884390369057655
/ O 0 0.00035744431079365313
C7 O 0 3.867419309244724e-06
region O 0 7.064549123469988e-08
DNA O 0 8.503288739802883e-08
marker O 0 5.208993059113709e-08
haplotypes O 0 2.9531699397011835e-07
, O 0 4.1868966627056636e-10
although O 0 8.184745936556936e-11
small O 0 1.5457560231801892e-10
variations O 0 3.224451745609258e-07
were O 0 2.7742004249375896e-08
observed O 0 1.0640459890964848e-07
. O 0 3.557920180696783e-08

The O 0 8.207174317931276e-08
1936delG O 0 7.081295734678861e-06
defect O 0 2.018584382312838e-05
was O 0 1.0139955541887957e-08
observed O 0 2.9906039866745004e-09
only O 0 2.1439913733267701e-10
once O 0 7.19699744244906e-10
in O 0 6.410351416352711e-11
the O 0 1.363009149990546e-10
Cape O 0 5.445975226336941e-09
, O 0 2.467158977115247e-10
but O 0 1.1600984756166e-10
its O 0 7.329237217135187e-10
associated O 0 2.595666126481433e-09
haplotype O 0 6.223551736184163e-06
could O 0 1.0068015399156138e-06
be O 0 6.398179763777989e-09
deduced O 0 1.448028825734582e-07
. O 0 2.2448512382311492e-08

The O 0 8.178110277867745e-08
data O 0 1.1806322675056435e-07
from O 0 4.19173862287181e-10
the O 0 2.0056099836462948e-10
haplotypes O 0 3.272244555319048e-07
indicate O 0 2.6955484955237807e-08
that O 0 4.609872900074308e-11
these O 0 9.650183430132131e-12
three O 0 2.64405969341297e-10
molecular O 0 3.336185017133175e-08
defects O 0 0.0009615903254598379
account O 0 5.308601558340342e-08
for O 0 1.5347020321243576e-09
the O 0 1.9497209180485697e-08
defects O 0 0.0005119800916872919
in O 0 2.2661869603091134e-10
all O 0 1.2141899985440574e-10
the O 0 1.2232904966769098e-10
38 O 0 2.618445460456087e-09
unrelated O 0 1.7962825671347105e-09
C6Q0 O 0 2.668004754013964e-06
individuals O 0 7.468065610360952e-10
we O 0 8.391788597350569e-09
have O 0 4.1957542995518793e-10
studied O 0 6.550404108018881e-10
from O 0 1.5993106838863014e-10
the O 0 6.908544292194563e-10
Cape O 0 1.023064442051691e-07
. O 0 1.9433571196714183e-08

We O 0 4.142136276641395e-06
have O 0 4.9606034835392165e-09
also O 0 6.480390113416945e-10
observed O 0 1.462563847809406e-09
the O 0 1.2831130602464214e-10
879delG O 0 2.568240518030507e-07
defect O 0 5.609707187659296e-08
in O 0 1.1980157144098058e-10
two O 0 8.96670915295772e-09
Dutch O 0 0.32596325874328613
C6 B-Disease 1 1.0
- I-Disease 1 0.9999985694885254
deficient I-Disease 1 1.0
kindreds O 0 1.8750228264252655e-05
, O 0 7.91758825169353e-10
but O 0 4.1451148069526766e-11
the O 0 3.0925029897987955e-11
879delG O 0 4.90996292512591e-08
defect O 0 2.1586545884133557e-08
in O 0 2.76296416301669e-11
the O 0 1.6261948732054776e-10
Cape O 0 4.0867451644999164e-08
probably O 0 7.883058827928835e-08
did O 0 2.991923508943728e-08
not O 0 3.009376636775585e-10
come O 0 1.034358709794958e-10
from O 0 2.46990275454273e-11
The O 0 1.371249225279314e-10
Netherlands O 0 8.269051932074944e-08
. O 0 8.113082428096163e-10
. O 0 6.4691678680617315e-09

Complement B-Disease 1 0.9286128282546997
C7 I-Disease 1 1.0
deficiency I-Disease 1 1.0
: O 0 4.0920892274698417e-07
seven O 0 2.1265583072249683e-08
further O 0 4.746060877636182e-09
molecular O 0 5.047756985732121e-07
defects O 1 0.8158929347991943
and O 0 1.0550262885544726e-08
their O 0 1.437370844570296e-08
associated O 0 4.729075797627047e-08
marker O 0 4.314160378271481e-06
haplotypes O 0 6.900920561747625e-05
. O 0 1.3050797065261577e-07

Seven O 0 1.7466162205437286e-07
further O 0 9.037088410934757e-09
molecular O 0 2.8672024754428094e-08
bases O 0 4.4186487002662034e-07
of O 0 6.145852466943325e-07
C7 B-Disease 1 1.0
deficiency I-Disease 1 1.0
are O 0 2.6418037535336225e-08
described O 0 6.904177496380726e-08
. O 0 3.759905808919939e-08

All O 0 1.849758035632476e-08
these O 0 2.040386332113897e-10
new O 0 9.115818100369211e-10
molecular O 0 5.221287580070566e-08
defects O 0 4.5557466364698485e-05
involve O 0 1.8842984950140362e-09
single O 0 1.4061297015643959e-08
- O 0 7.617546060600944e-08
nucleotide O 0 5.862841945258879e-08
events O 0 1.2227593382263535e-09
, O 0 1.3126871811763863e-10
deletions O 0 2.9960922631744324e-08
and O 0 6.261416940489539e-10
substitutions O 0 4.63624250102157e-09
, O 0 2.5483738383402788e-11
some O 0 2.171700319575365e-12
of O 0 3.417411319206476e-12
which O 0 8.436882303897164e-10
alter O 0 1.4017535931998282e-06
splice O 0 1.7299675164395012e-05
sites O 0 1.1011483280753964e-07
, O 0 2.54548604416982e-09
and O 0 3.228763700846571e-09
others O 0 2.3355497091870348e-08
codons O 0 8.562054745198111e-07
. O 0 1.7567455046219038e-08

They O 0 2.3256639281044045e-07
are O 0 4.6106662932032805e-10
distributed O 0 3.4560762585122973e-10
along O 0 1.8117941591455633e-09
the O 0 9.213584895029214e-10
C7 O 0 3.106566452970583e-07
gene O 0 1.3268125265142316e-08
, O 0 8.368939569125544e-11
but O 0 2.0256771954274555e-11
predominantly O 0 2.7553282572201354e-11
towards O 0 1.4096325495760453e-10
the O 0 1.8289451897413045e-10
3 O 0 7.987106975804181e-09
end O 0 1.5522847718330013e-07
. O 0 1.9896209124681263e-08

All O 0 2.49758727477456e-07
were O 0 4.2867771554711e-09
found O 0 5.855717577496478e-10
in O 0 9.302683623424457e-11
compound O 0 9.049628602042503e-09
heterozygous O 0 2.7712238193089433e-07
individuals O 0 3.790564306882516e-09
. O 0 2.6178426537626365e-08

The O 0 5.765768378296343e-07
C6 O 0 0.0010946670081466436
/ O 0 0.0014163554878905416
C7 O 0 2.0581532226060517e-05
marker O 0 1.2896306316179107e-06
haplotypes O 0 4.604001787811285e-06
associated O 0 8.12994400689604e-08
with O 0 2.7608968444781112e-09
most O 0 2.846127244993113e-08
C7 B-Disease 0 0.38523009419441223
defects I-Disease 1 0.9916335344314575
are O 0 9.642029397127772e-09
tabulated O 0 1.1987526704615448e-06
. O 0 1.4049440499874777e-09
. O 0 1.0772311931361855e-08

A O 0 3.2233819524662977e-07
genome O 0 5.012464612264012e-07
- O 0 7.186852712948166e-07
wide O 0 2.822729072704533e-08
search O 0 2.9936931156271385e-08
for O 0 1.294339413426826e-09
chromosomal O 0 2.636457975313533e-05
loci O 0 7.724763690930558e-07
linked O 0 9.009462519316003e-05
to O 0 6.805562406952959e-07
mental O 0 1.3330317415238824e-05
health O 0 2.03847463353668e-08
wellness O 0 6.678369857127109e-08
in O 0 2.4159960698710847e-09
relatives O 0 2.840926072167349e-08
at O 0 1.0237828007575445e-07
high O 0 2.57249865853737e-07
risk O 0 5.272966973279836e-06
for O 0 1.2667253201925632e-07
bipolar B-Disease 1 0.9998008608818054
affective I-Disease 1 0.8384422659873962
disorder I-Disease 0 0.0383048914372921
among O 0 2.4002544396495296e-10
the O 0 2.719963698716299e-10
Old O 0 2.5616338916734094e-07
Order O 0 3.254759306514643e-08
Amish O 0 1.1838449154311093e-06
. O 0 7.260746315296274e-08

Bipolar B-Disease 1 0.999997615814209
affective I-Disease 1 0.9999769926071167
disorder I-Disease 1 0.9999696016311646
( O 0 1.077677370631136e-05
BPAD B-Disease 1 1.0
; O 0 0.000324565771734342
manic B-Disease 1 0.9999991655349731
- I-Disease 1 0.9999998807907104
depressive I-Disease 1 1.0
illness I-Disease 1 0.99993896484375
) O 0 3.4256915082409023e-09
is O 0 3.3115898911972863e-10
characterized O 0 3.1976974401715097e-09
by O 0 1.4855866536933604e-10
episodes O 0 8.62812328250584e-08
of O 0 2.405607657518516e-10
mania B-Disease 0 7.450825069099665e-05
and O 0 1.3837045287345973e-07
/ O 0 0.0005155609105713665
or O 0 1.805575493563083e-06
hypomania B-Disease 0 0.0007416171720251441
interspersed O 0 8.11123072708142e-07
with O 0 8.153323016735214e-10
periods O 0 1.6297052596314643e-08
of O 0 9.534890654805395e-10
depression B-Disease 0 4.652260656712315e-07
. O 0 1.4832071570936023e-08

Compelling O 0 1.1037564036087133e-06
evidence O 0 1.4117111923894754e-08
supports O 0 2.0093136043897175e-09
a O 0 5.220256449334215e-10
significant O 0 8.588594280212192e-10
genetic O 0 3.3289513368117696e-08
component O 0 1.427338958137625e-08
in O 0 1.6697040972069033e-10
the O 0 6.681026842869642e-10
susceptibility O 0 3.384088813618291e-07
to O 0 1.1521879628162424e-07
develop O 0 3.426534476602683e-06
BPAD B-Disease 1 0.9999998807907104
. O 0 6.020311502652476e-07

To O 0 5.255237738310825e-07
date O 0 3.5547193988350045e-07
, O 0 3.0719067289908253e-09
however O 0 5.524384838473395e-10
, O 0 1.4401958792209513e-10
linkage O 0 2.304718904611036e-08
studies O 0 8.221032188338029e-10
have O 0 9.614403717606024e-10
attempted O 0 9.469995632116479e-08
only O 0 5.070601716283818e-10
to O 0 5.434122596348345e-10
identify O 0 2.1765231394965667e-08
chromosomal O 0 6.613874575123191e-06
loci O 0 1.0664618343980692e-07
that O 0 1.0813234752049539e-08
cause O 0 3.4441427487763576e-08
or O 0 1.6673919134291282e-08
increase O 0 1.2002536742272696e-08
the O 0 4.606880210644704e-09
risk O 0 1.2187695119791897e-07
of O 0 7.242039745669615e-10
developing O 0 1.3059078582955408e-06
BPAD B-Disease 1 1.0
. O 0 6.324955279524147e-07

To O 0 2.957315530238702e-07
determine O 0 4.6368818118480704e-08
whether O 0 6.547284492341987e-09
there O 0 7.103022614529664e-10
could O 0 3.4360898570895415e-09
be O 0 1.201860694299839e-10
protective O 0 4.2473019545852253e-10
alleles O 0 2.683036459671939e-09
that O 0 1.5794544838687585e-10
prevent O 0 1.8064905127346265e-09
or O 0 1.5747064097126895e-08
reduce O 0 2.0786124821370322e-08
the O 0 4.2243411546571963e-10
risk O 0 8.372587956273492e-09
of O 0 6.055126539061817e-11
developing O 0 6.775456995455897e-08
BPAD B-Disease 1 1.0
, O 0 2.0127426392235748e-09
similar O 0 6.745969755028725e-11
to O 0 8.929669781387872e-10
what O 0 6.172080901922783e-11
is O 0 4.099237962962299e-11
observed O 0 5.986298123872302e-10
in O 0 6.112962913640274e-11
other O 0 2.8257241879714456e-08
genetic B-Disease 1 1.0
disorders I-Disease 1 1.0
, O 0 1.4142221838042701e-09
we O 0 2.2257071741194068e-09
used O 0 2.7578876071743252e-08
mental O 0 5.822117827847251e-07
health O 0 3.4495581946458742e-09
wellness O 0 5.362333155289889e-08
( O 0 2.0210328965930557e-09
absence O 0 8.101211257383056e-09
of O 0 3.226367228936766e-10
any O 0 7.801499464221706e-07
psychiatric B-Disease 0 0.0003238307835999876
disorder I-Disease 0 5.702260295947781e-06
) O 0 5.895060134486485e-11
as O 0 6.619251674555571e-11
the O 0 3.587983521402549e-10
phenotype O 0 5.832304168507108e-07
in O 0 2.1770534264220487e-09
our O 0 1.0907318603869953e-08
genome O 0 3.107354018538899e-08
- O 0 4.93324762373959e-07
wide O 0 6.154608911401738e-08
linkage O 0 6.687661766591191e-07
scan O 0 5.771799624199048e-05
of O 0 2.328718121114015e-11
several O 0 3.3230466989220275e-11
large O 0 3.9043365762658766e-10
multigeneration O 0 1.1683433740472537e-06
Old O 0 1.8267366286295328e-08
Order O 0 8.626618308582579e-10
Amish O 0 3.921146785046403e-08
pedigrees O 0 1.2114480796299176e-07
exhibiting O 0 3.812056803553787e-08
an O 0 3.3429403689666515e-10
extremely O 0 7.43398942404383e-09
high O 0 3.942648163501872e-08
incidence O 0 2.6086121579282917e-05
of O 0 2.6604303116073424e-07
BPAD B-Disease 1 1.0
. O 0 1.7937006759893848e-06

We O 0 9.1594902187353e-06
have O 0 1.1676828393092364e-08
found O 0 4.084062865672422e-09
strong O 0 4.6408496490180084e-10
evidence O 0 6.090826454308029e-11
for O 0 1.4166451865749163e-11
a O 0 2.7262744839440245e-10
locus O 0 4.3588809006678275e-08
on O 0 1.3382951919993502e-06
chromosome O 0 0.0003229644207749516
4p O 0 0.000709313724655658
at O 0 1.0522252580358327e-07
D4S2949 O 0 4.000109399271423e-08
( O 0 1.8442146421104866e-10
maximum O 0 6.249687989345887e-10
GENEHUNTER O 0 2.0801173832296627e-06
- O 0 1.6132389646372758e-07
PLUS O 0 6.797617402298783e-08
nonparametric O 0 8.45936867222008e-08
linkage O 0 1.9518639149396222e-08
score O 0 5.316593387760804e-09
= O 0 4.2044483450354164e-09
4 O 0 5.793051593983023e-10
. O 0 1.32097305316492e-10
05 O 0 3.2703519892152144e-09
, O 0 1.166257229678891e-10
P O 0 3.940464807783428e-07
= O 0 1.7694324894179658e-09
5 O 0 3.6613753695569073e-10
. O 0 6.527962892466377e-11
22 O 0 1.3620085614896027e-10
x O 0 7.62769047923939e-09
10 O 0 9.620054752801366e-10
( O 0 5.824524890174487e-11
- O 0 1.1847327563430099e-08
4 O 0 3.031523254648505e-09
) O 0 1.4152090610508594e-10
; O 0 1.2591669373840375e-10
SIBPAL O 0 1.6972398952930234e-07
Pempirical O 0 1.9601538170377353e-08
value O 0 2.425002421091449e-10
< O 0 1.6601929553328176e-10
3 O 0 1.634316848520001e-10
x O 0 1.857408626904089e-08
10 O 0 1.3102539053733153e-09
( O 0 7.246567929053427e-11
- O 0 4.809589526644231e-08
5 O 0 2.784452846071872e-08
) O 0 2.576462931891399e-10
) O 0 1.8019710723571336e-10
and O 0 5.025361460297972e-09
suggestive O 0 3.729365971594234e-07
evidence O 0 1.4417432525615226e-10
for O 0 1.060662061652673e-11
a O 0 5.13787346001493e-10
locus O 0 1.9352977176367858e-07
on O 0 2.6338948373449966e-05
chromosome O 1 0.8953761458396912
4q O 1 0.9999911785125732
at O 0 1.750922393739529e-07
D4S397 O 0 4.111326035172169e-08
( O 0 1.8373436105889596e-10
maximum O 0 1.8281438585177057e-09
GENEHUNTER O 0 1.125502421928104e-06
- O 0 1.0934172678389587e-07
PLUS O 0 8.10059646028094e-08
nonparametric O 0 1.9560236808047193e-07
linkage O 0 4.6369610373631076e-08
score O 0 2.4522938346649426e-08
= O 0 7.0066956681102965e-09
3 O 0 5.060563079695157e-10
. O 0 7.296288573321874e-11
29 O 0 1.1551839484980064e-09
, O 0 7.208342256426192e-11
P O 0 8.075679716057493e-07
= O 0 2.5614312892940916e-09
2 O 0 2.612707272753312e-10
. O 0 9.612308865536434e-11
57 O 0 4.2534470390265255e-10
x O 0 7.502148235971617e-09
10 O 0 6.495784465876397e-10
( O 0 7.31039950796486e-11
- O 0 1.3541716192833064e-08
3 O 0 5.056242979861736e-09
) O 0 9.234586706430292e-11
; O 0 1.363227586370641e-10
SIBPAL O 0 1.1802607247091146e-07
Pempirical O 0 8.987307786867405e-09
value O 0 1.7839048294110427e-10
< O 0 2.2031265700661606e-10
1 O 0 1.0758501034491275e-10
x O 0 1.9133413076133365e-08
10 O 0 2.4878006321671364e-09
( O 0 3.0448732424304126e-10
- O 0 6.832101462350693e-08
3 O 0 2.5322286489881662e-08
) O 0 3.959298444655701e-10
) O 0 4.655591190338981e-11
that O 0 1.1572916930324695e-10
are O 0 1.6385962031684187e-10
linked O 0 2.1129346805537352e-06
to O 0 1.959836254172842e-06
mental O 0 1.4232441571948584e-06
health O 0 8.756289915368143e-09
wellness O 0 1.201012196361262e-07
. O 0 3.262957903871211e-08

These O 0 7.208915064893517e-08
findings O 0 1.4371575218774524e-07
are O 0 6.876414437861911e-10
consistent O 0 5.969039484909899e-09
with O 0 3.23285218040148e-11
the O 0 3.2012028444716734e-11
hypothesis O 0 4.676516951462872e-10
that O 0 1.4159454858608811e-11
certain O 0 2.6327554719651758e-11
alleles O 0 4.39283986963801e-09
could O 0 9.94639215434745e-09
prevent O 0 6.458861001590321e-09
or O 0 2.061461223945571e-08
modify O 0 4.2525309140728496e-07
the O 0 5.422568505331071e-10
clinical O 0 1.0170055020353175e-08
manifestations O 0 1.710948716038274e-08
of O 0 1.8252243050298489e-09
BPAD B-Disease 1 1.0
and O 0 1.4001856563083948e-08
perhaps O 0 5.083985454845674e-10
other O 0 6.662040918925527e-10
related O 0 3.7819043541276187e-07
affective B-Disease 0 0.39095011353492737
disorders I-Disease 0 0.1309230774641037
. O 0 9.77388694423098e-08

Segregation O 0 0.0002772854932118207
distortion O 0 0.0055336738005280495
in O 0 4.948249625158496e-06
myotonic B-Disease 1 0.9999997615814209
dystrophy I-Disease 1 0.9999998807907104
. O 0 7.60953162171063e-06

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9999446868896484
DM B-Disease 1 1.0
) O 0 1.6054545994848013e-06
is O 0 1.886905964809671e-09
an O 0 1.002600447108648e-09
autosomal B-Disease 1 0.9994720816612244
dominant I-Disease 1 0.9535202980041504
disease I-Disease 1 0.9876729846000671
which O 0 1.8710759608353555e-09
, O 0 8.020592523472203e-11
in O 0 2.962775511039517e-11
the O 0 2.72503714038308e-10
typical O 0 2.5384958135532543e-08
pedigree O 0 9.753900940268068e-07
, O 0 3.5442485057934903e-10
shows O 0 4.1562636665659625e-10
a O 0 2.1639703917664121e-10
three O 0 7.341592334064728e-10
generation O 0 3.769173861911668e-09
anticipation O 0 1.109972735946485e-08
cascade O 0 9.841658084042137e-07
. O 0 5.7969479883013264e-08

This O 0 2.3543285010418913e-07
results O 0 2.832085783666116e-06
in O 0 2.3989478847852297e-08
infertility B-Disease 1 0.9258179664611816
and O 0 0.0015480400761589408
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 8.152177315423614e-07
CDM B-Disease 0 1.5100732753126067e-06
) O 0 6.941326957665694e-10
with O 0 7.514484867687798e-11
the O 0 8.893786818120475e-10
disappearance O 0 2.7970579594693845e-06
of O 0 2.8463116308330427e-08
DM B-Disease 1 1.0
in O 0 1.5107596951224878e-08
that O 0 1.9663988215512518e-09
pedigree O 0 6.986693392718735e-07
. O 0 3.724922592596158e-08

The O 0 1.0797077898416774e-08
concept O 0 6.190904233704941e-09
of O 0 5.982314643659947e-10
segregation O 0 3.305856566271359e-08
distortion O 0 8.012436296667147e-07
, O 0 6.529211060701812e-10
where O 0 9.55527740265083e-11
there O 0 1.2335076536584832e-11
is O 0 2.3610358459991154e-11
preferential O 0 2.031777635025378e-09
transmission O 0 1.0889400492430923e-08
of O 0 1.0270960297542597e-11
the O 0 3.571874393482055e-11
larger O 0 6.848926425995217e-10
allele O 0 8.530710005061337e-08
at O 0 1.1569633784347388e-07
the O 0 1.701398417708333e-07
DM B-Disease 1 1.0
locus O 0 4.0739203654993617e-07
, O 0 2.0548847068369014e-09
has O 0 5.652038281844796e-10
been O 0 4.62876514895072e-10
put O 0 3.0880147328105068e-09
forward O 0 2.718030911452729e-09
to O 0 4.1127257155437746e-10
explain O 0 1.0756209256612692e-09
partially O 0 2.365957740835256e-08
the O 0 2.6878294034915484e-10
maintenance O 0 2.6655063933844758e-08
of O 0 2.123108355789327e-09
DM B-Disease 1 1.0
in O 0 3.183675545415099e-09
the O 0 1.4111666279958968e-09
population O 0 5.160356586486614e-09
. O 0 2.6729855662210866e-08

In O 0 3.1565225100393945e-08
a O 0 2.167471357950035e-08
survey O 0 1.4491962474494358e-06
of O 0 3.497350631320728e-09
DM B-Disease 1 1.0
in O 0 6.068408708870265e-08
Northern O 0 5.023600806453032e-07
Ireland O 0 7.786373430462845e-07
, O 0 5.438166583715542e-10
59 O 0 1.6557949455986432e-09
pedigrees O 0 2.1255811333276142e-08
were O 0 8.078913538156485e-09
ascertained O 0 6.946624466763751e-07
. O 0 2.468893711693454e-08

Sibships O 0 5.0856495363404974e-05
where O 0 2.5997902497465475e-08
the O 0 3.0649405236005123e-10
status O 0 6.492564263993472e-10
of O 0 4.383160154275423e-11
all O 0 1.6870610464181368e-10
the O 0 1.4149229010662623e-10
members O 0 1.0576041431509253e-10
had O 0 5.1453388216771145e-09
been O 0 4.6232767614284853e-10
identified O 0 9.2827354691849e-09
were O 0 1.8754207076199236e-09
examined O 0 1.5112316953391769e-09
to O 0 5.821274018380507e-10
determine O 0 7.683949587722338e-10
the O 0 2.640793694830279e-10
transmission O 0 5.529471636123162e-08
of O 0 7.097222809449022e-11
the O 0 3.107063761831341e-08
DM B-Disease 1 1.0
expansion O 0 1.0637513092603967e-08
from O 0 1.6866886776156775e-09
affected O 0 7.9393087659696e-09
parents O 0 6.038486932702369e-10
to O 0 2.050167369205269e-09
their O 0 2.4632589301631924e-08
offspring O 0 3.17883888101278e-07
. O 0 4.053812929782907e-08

Where O 0 1.4670956716145156e-07
the O 0 1.2591368836467609e-08
transmitting O 0 9.294451592722908e-05
parent O 0 1.0561462659097742e-05
was O 0 1.405422409561652e-07
male O 0 2.4259669828552433e-08
, O 0 1.557241668947995e-09
58 O 0 2.3885018407554526e-08
. O 0 1.602549026813449e-08

3 O 0 8.140697360659033e-08
% O 0 2.8815430042072876e-09
of O 0 3.858737288031655e-11
the O 0 1.2639245206003125e-09
offspring O 0 3.2712867437112436e-07
were O 0 4.2075871675706367e-08
affected O 0 8.82978223870623e-09
, O 0 5.715848905296639e-10
and O 0 4.902135364304172e-10
in O 0 2.7301551644431932e-11
the O 0 5.3733621718787816e-11
case O 0 3.9959571762615553e-10
of O 0 7.548238943611008e-12
a O 0 1.2794552084471889e-09
female O 0 1.8641342691694263e-08
transmitting O 0 9.646900252846535e-06
parent O 0 8.355598879461468e-07
, O 0 7.146676139768715e-09
68 O 0 7.730542250783401e-08
. O 0 1.3867423653834976e-08

7 O 0 5.7436527640675195e-06
% O 0 1.795301045603992e-07
were O 0 4.820821430939759e-08
affected O 0 2.3489258182962658e-07
. O 0 5.464113073117005e-08

Studies O 0 3.670577939374198e-07
on O 0 1.734759358384963e-08
meiotic O 0 2.570794094935991e-06
drive O 0 2.1179421310080215e-06
in O 0 5.931170790063334e-07
DM B-Disease 1 1.0
have O 0 7.066866913874037e-08
shown O 0 9.726215388639048e-10
increased O 0 1.9255599892353814e-10
transmission O 0 8.579658761220799e-09
of O 0 6.527025881580828e-12
the O 0 4.415414908698345e-11
larger O 0 2.6581573053796603e-10
allele O 0 3.732653297561228e-08
at O 0 4.577924173077008e-08
the O 0 2.0990029270251398e-08
DM B-Disease 1 1.0
locus O 0 1.3618313232655055e-07
in O 0 2.4732191850063145e-09
non O 0 3.3081100809795316e-06
- O 0 0.49201634526252747
DM O 1 1.0
heterozygotes O 0 5.235925073066028e-06
for O 0 4.4387586939365065e-09
CTGn O 0 3.944652235077228e-06
. O 0 4.6284696963994065e-08

This O 0 3.397511250113894e-08
study O 0 4.545832599234245e-09
provides O 0 9.651278665145924e-10
further O 0 7.119841938241223e-10
evidence O 0 5.480442211158731e-10
that O 0 3.7668507202326396e-10
the O 0 4.526512498159718e-09
DM B-Disease 1 1.0
expansion O 0 1.5126106589491428e-08
tends O 0 2.7341352293319687e-08
to O 0 9.356535546345413e-10
be O 0 1.0598785182835968e-09
transmitted O 0 3.0580798693335964e-07
preferentially O 0 4.4675718413600407e-07
. O 0 4.8336747937582913e-08

Diagnosis O 1 0.9973925352096558
of O 0 4.780674771609483e-06
hemochromatosis B-Disease 1 0.9999998807907104
. O 0 1.1116656423837412e-05

If O 0 1.765139131748583e-05
untreated O 0 0.1839113086462021
, O 0 4.325773090840812e-07
hemochromatosis B-Disease 1 1.0
can O 0 0.0008989032357931137
cause O 0 1.6267638784484006e-05
serious O 0 1.1648904546746053e-05
illness O 0 3.351096893311478e-05
and O 0 3.1283089452216473e-09
early B-Disease 0 4.1767549419091665e-08
death I-Disease 0 8.176971277862322e-08
, O 0 2.9046640648289213e-09
but O 0 1.0987871723600051e-09
the O 0 7.761398190808677e-10
disease O 0 2.477137002188101e-07
is O 0 2.7147964432039373e-10
still O 0 1.1251622744623546e-08
substantially O 0 5.95875860653905e-07
under O 0 2.2121312781564484e-08
- O 1 0.834018349647522
diagnosed O 1 0.8906493782997131
. O 0 6.664194529548695e-08

The O 0 1.3315914593192701e-08
cornerstone O 0 3.660415259787442e-08
of O 0 1.4053104513411796e-10
screening O 0 4.542902942716864e-09
and O 0 2.2375734598512054e-10
case O 0 6.935461233092965e-11
detection O 0 5.641354050567315e-10
is O 0 4.942880132974281e-11
the O 0 2.4073229520915618e-11
measurement O 0 9.86452874940369e-09
of O 0 9.210417151184203e-11
serum O 0 6.398594099010779e-09
transferrin O 0 5.166278072010755e-08
saturation O 0 2.6739032321643208e-08
and O 0 4.825554400511578e-10
the O 0 8.171007759294469e-10
serum O 0 1.504204050206681e-08
ferritin O 0 2.2872289662245748e-07
level O 0 2.146821209692007e-08
. O 0 3.070426046747343e-08

Once O 0 2.12645431929559e-06
the O 0 7.934978896173561e-09
diagnosis O 0 2.567436058598105e-05
is O 0 1.7698104093355482e-09
suspected O 0 1.1581980743358145e-06
, O 0 8.306971999161306e-09
physicians O 0 2.0757113805558447e-09
must O 0 5.134669911477374e-10
use O 0 1.5464528546615952e-09
serum O 0 2.761856876531965e-08
ferritin O 0 6.168277195683913e-07
levels O 0 3.47627668872974e-08
and O 0 3.86622600601072e-09
hepatic O 0 2.5670198738225736e-05
iron O 0 1.16059918582323e-05
stores O 0 3.1294945074478164e-05
on O 0 1.5280906495718227e-07
liver O 0 1.6807933207019232e-05
biopsy O 0 0.00028360713622532785
specimens O 0 6.427865795188836e-09
to O 0 9.478521079131497e-09
assess O 0 1.8517954458729946e-07
patients O 0 6.586652556705985e-09
for O 0 7.46667571521753e-12
the O 0 8.509376536736113e-11
presence O 0 2.5909128176238028e-09
of O 0 1.6891192888834894e-09
iron B-Disease 0 0.0005697601591236889
overload I-Disease 0 0.00015834921214263886
. O 0 7.919287270397035e-08

Liver O 1 0.9998530149459839
biopsy O 1 0.9995623230934143
is O 0 1.2663141646385156e-08
also O 0 5.095002753030542e-10
used O 0 7.563378812136534e-10
to O 0 6.512196892849431e-10
establish O 0 1.0263920824371553e-09
the O 0 2.1910577518990948e-10
presence O 0 9.968836867102482e-10
or O 0 1.0938319583431166e-08
absence O 0 1.1094007934531191e-09
of O 0 6.84683282292653e-11
cirrhosis B-Disease 0 2.1911699150223285e-05
, O 0 3.186062969007253e-09
which O 0 9.730691807874337e-09
can O 0 1.1154376124977716e-06
affect O 0 3.3709159197314875e-06
prognosis O 0 6.815398228354752e-05
and O 0 7.68864527600499e-09
management O 0 1.7606710400741576e-07
. O 0 2.332130932813925e-08

A O 0 5.874528241633925e-08
DNA O 0 4.252238738899905e-07
- O 0 5.940726168773836e-07
based O 0 1.192172760511312e-07
test O 0 2.594839454417297e-09
for O 0 3.085597749530322e-11
the O 0 1.899097025470642e-11
HFE O 0 2.946852895036045e-08
gene O 0 2.8091498016635796e-09
is O 0 6.035617144961591e-11
commercially O 0 8.729355016612317e-10
available O 0 3.280990201748324e-10
, O 0 4.7562963984004725e-11
but O 0 3.620470589993374e-11
its O 0 1.3789418218390637e-10
place O 0 1.5645834627875388e-09
in O 0 9.593607852576014e-11
the O 0 6.925814366454119e-10
diagnosis O 0 1.0175177521887235e-05
of O 0 2.018120781599464e-09
hemochromatosis B-Disease 1 1.0
is O 0 1.6661590507283108e-07
still O 0 1.22121051049362e-07
being O 0 8.243914884076275e-09
evaluated O 0 4.394803099216915e-08
. O 0 1.2874830090936484e-08

Currently O 0 4.946976446262852e-07
, O 0 1.1103449271132604e-09
the O 0 4.579829918083256e-11
most O 0 2.7820279066559372e-11
useful O 0 1.529855686577264e-10
role O 0 2.434368262527187e-10
for O 0 2.0726087512912272e-10
this O 0 8.129481809948658e-11
test O 0 1.707491370517289e-10
is O 0 7.455121589505787e-12
in O 0 3.2499513063360963e-12
the O 0 2.6311189338379393e-11
detection O 0 6.043110900577631e-09
of O 0 2.0229997677034817e-09
hemochromatosis B-Disease 1 1.0
in O 0 5.348530507376381e-09
the O 0 2.687521594157971e-10
family O 0 2.4011439503368592e-09
members O 0 9.138496903648985e-11
of O 0 1.2676364298525034e-11
patients O 0 3.5681582688518176e-10
with O 0 6.3881703746271334e-12
a O 0 5.580335304955497e-09
proven O 0 2.885570360433576e-08
case O 0 3.8025976811795204e-10
of O 0 1.9071334789177996e-11
the O 0 8.983006338780797e-09
disease O 0 5.990912086417666e-06
. O 0 2.122741094012781e-08

It O 0 4.503916528619811e-08
is O 0 1.7387170592186862e-09
crucial O 0 5.0712838373101476e-08
to O 0 1.2353234524198342e-06
diagnose O 1 0.9998534917831421
hemochromatosis B-Disease 1 1.0
before O 0 0.006113610230386257
hepatic B-Disease 1 0.9999924898147583
cirrhosis I-Disease 1 0.9999716281890869
develops O 0 0.0001902563526527956
because O 0 1.9783938398632017e-07
phlebotomy O 0 0.00019019629689864814
therapy O 0 9.653010238253046e-06
can O 0 6.540260528709041e-07
avert O 0 0.0006640288047492504
serious O 0 0.0020089985337108374
chronic O 1 0.9992976188659668
disease O 0 0.0754486694931984
and O 0 4.459151625724189e-08
can O 0 1.1386755716102925e-07
even O 0 6.286468590133154e-08
lead O 0 5.995387937218766e-07
to O 0 3.77509721261049e-08
normal O 0 4.888736384600634e-07
life O 0 8.28133153163435e-08
expectancy O 0 1.1887941298027727e-07
. O 0 9.318635862953784e-10
. O 0 1.1964983670509355e-08

Prevalence O 0 0.0008900028187781572
of O 0 8.006370677549057e-09
the O 0 2.7879960562415818e-09
I1307K O 0 2.1684188311610342e-07
APC B-Disease 0 5.6508259405063654e-08
gene O 0 8.617906388508345e-09
variant O 0 3.1526958821359585e-08
in O 0 1.4852523377850702e-10
Israeli O 0 5.5447508806594215e-09
Jews O 0 1.280790806745813e-09
of O 0 3.672732257209432e-11
differing O 0 4.945657217092503e-09
ethnic O 0 4.236594008943939e-08
origin O 0 8.135776141671158e-08
and O 0 5.73278896354168e-07
risk O 0 1.551504828967154e-05
for O 0 0.00014538143295794725
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 5.988930524836178e-07

BACKGROUND O 0 6.240404036361724e-05
& O 0 6.211550498846918e-06
AIMS O 0 2.411038053651282e-07
Israeli O 0 3.7628328897199026e-08
Jews O 0 1.150820883033532e-09
of O 0 4.4391521708542214e-11
European O 0 8.166352927219123e-09
birth O 0 2.8555831477206084e-08
, O 0 3.1506262043734523e-09
i O 0 3.547471294496063e-08
. O 0 4.605742176533312e-11
e O 0 6.7440466544610445e-09
. O 0 5.305627465146401e-11
, O 0 1.615399758403413e-10
Ashkenazim O 0 3.511657098442811e-08
, O 0 1.8041033944538043e-10
have O 0 1.1909188912806457e-10
the O 0 1.408252714441005e-08
highest O 1 0.9996097683906555
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
incidence O 0 6.0101265262346715e-05
of O 0 2.385758257616999e-10
any O 0 7.284796321727072e-09
Israeli O 0 1.2407273288772558e-06
ethnic O 0 1.2633873893719283e-06
group O 0 4.486820671445457e-06
. O 0 5.4320558717790846e-08

The O 0 1.7935143148406496e-07
I1307K O 0 2.9264560907904524e-06
APC B-Disease 0 1.3566893812821945e-06
gene O 0 2.0945162759744562e-07
variant O 0 7.953359499879298e-07
was O 0 2.4165597523051474e-08
found O 0 6.9892238663271655e-09
in O 0 1.2979562979964498e-09
6 O 0 9.877108908540322e-08
. O 0 6.92800057322529e-08

1 O 0 1.22697272786354e-07
% O 0 6.5879461885742785e-09
of O 0 4.5759968730907374e-11
American O 0 1.2176020192100623e-09
Jews O 0 2.542026589225088e-09
, O 0 7.596891449246357e-10
28 O 0 6.557792087136249e-10
% O 0 6.981488998025753e-11
of O 0 4.123043920167824e-11
their O 0 5.802881423733197e-05
familial O 1 0.9999998807907104
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
cases O 0 3.7868123854423175e-06
, O 0 1.903661228652709e-09
but O 0 1.0472708256159535e-09
not O 0 2.6585020296288064e-10
in O 0 6.379114597665492e-11
non O 0 1.80611241518136e-08
- O 0 2.331126580656928e-07
Jews O 0 2.4691672706467216e-07
. O 0 1.091331611746682e-07

We O 0 8.178247981049935e-07
assessed O 0 1.2899833734536514e-07
the O 0 1.173265817833169e-09
I1307K O 0 2.0410158185768523e-07
prevalence O 0 2.428509162655246e-07
in O 0 3.0821639684930346e-10
Israeli O 0 1.5116762952516183e-08
Jews O 0 1.3922860642168189e-09
of O 0 2.850958358280309e-11
differing O 0 2.852097891192784e-09
ethnic O 0 2.4465753867275453e-08
origin O 0 4.5105448265303494e-08
and O 0 2.5490152211204986e-07
risk O 0 6.555886557180202e-06
for O 0 7.392698898911476e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 7.231154768305714e-07

METHODS O 0 4.325974884977768e-07
DNA O 0 1.4481861398962792e-07
samples O 0 1.3336757476167804e-08
from O 0 1.0007925044241972e-10
500 O 0 6.865154278390406e-11
unrelated O 0 3.204313758775612e-10
Jews O 0 3.765528722166067e-10
of O 0 2.3291578735151752e-11
European O 0 7.671828505806388e-09
or O 0 1.0052510823754801e-08
non O 0 8.623546321473441e-09
- O 0 4.6512223406125486e-08
European O 0 8.920464367179193e-09
origin O 0 1.1723464421464769e-09
, O 0 1.8222943987122875e-10
with O 0 1.796109441731808e-11
or O 0 1.0756824320168334e-09
without O 0 3.077030019671412e-10
a O 0 5.572525774155679e-10
personal O 0 4.2487485529818514e-08
and O 0 6.471305482591561e-07
/ O 0 0.0009116550791077316
or O 0 3.1822298751649214e-07
family O 0 2.832307188782579e-08
history O 0 2.2952553191402103e-09
of O 0 4.024433564175922e-10
neoplasia B-Disease 0 4.6369309529836755e-06
, O 0 6.051923406857895e-09
were O 0 1.2871876897690981e-09
examined O 0 1.3462416736942373e-09
for O 0 2.295730272550145e-11
the O 0 4.7316487533644036e-11
I1307K O 0 4.252281193828367e-09
variant O 0 8.138535179114115e-09
by O 0 6.477791913983566e-11
the O 0 2.439536628262573e-10
allele O 0 1.8760911757453869e-07
- O 0 2.935309169060929e-07
specific O 0 7.588583095241574e-09
oligonucleotide O 0 1.7846725768322358e-06
( O 0 4.263968289563991e-09
ASO O 0 1.1965917110501323e-06
) O 0 3.213457833162181e-10
method O 0 1.463680909807863e-08
. O 0 2.8496145887402236e-08

RESULTS O 0 0.0002297125174663961
In O 0 1.7687779019226468e-09
persons O 0 1.2488539091748407e-09
at O 0 4.7804116221072945e-09
average O 0 6.1365227566057e-07
risk O 0 1.1862083738378715e-05
for O 0 0.007602645084261894
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 1.3647249552661833e-08
I1307K O 0 1.1574169178629745e-07
was O 0 1.960288287250478e-08
found O 0 1.8242913846222564e-09
in O 0 3.4894598321955073e-10
5 O 0 1.5831115973696797e-08
. O 0 2.1739715805324522e-08

0 O 0 1.1854763215524144e-06
% O 0 3.625050482014558e-08
of O 0 1.89810209216823e-10
120 O 0 1.4073283649551627e-09
European O 0 1.296512053272636e-08
and O 0 4.312536105999243e-09
1 O 0 1.842001751128919e-08
. O 0 2.3861975506633826e-08

6 O 0 4.0857875660549325e-07
% O 0 8.932109274439881e-09
of O 0 7.964265358317846e-11
188 O 0 1.7779576699794575e-09
non O 0 6.0240994415039495e-09
- O 0 6.03706453716768e-08
European O 0 3.601741482839316e-08
Jews O 0 5.489505294775654e-09
( O 0 3.7871153435453664e-10
P O 0 1.977568672373309e-06
= O 0 4.773368811328282e-09
0 O 0 3.959207683923438e-10
. O 0 2.3464957754626425e-10
08 O 0 3.0810662909885878e-09
) O 0 5.292490889985402e-10
. O 0 5.808012293329057e-09

It O 0 2.7981096195617283e-07
occurred O 0 7.180933891959285e-08
in O 0 2.9701223702716106e-09
15 O 0 2.4719849278653783e-08
. O 0 2.382286723445759e-08

4 O 0 3.043001299829484e-07
% O 0 1.1602345750816312e-08
of O 0 2.2009929989685872e-10
52 O 0 4.3184723352851506e-08
Ashkenazi O 0 1.371448888676241e-06
Israelis O 0 1.1558653341126046e-06
with O 0 1.3957300204481271e-08
familial O 0 7.811990508344024e-05
cancer B-Disease 0 0.00010858500172616914
( O 0 2.0733461170152623e-08
P O 0 0.0005088162142783403
= O 0 3.065698308546416e-07
0 O 0 3.3106377639313678e-09
. O 0 4.67803351611451e-10
02 O 0 2.3228647894057985e-09
) O 0 8.031537934716226e-11
and O 0 3.269102766267906e-10
was O 0 1.960729711925069e-08
not O 0 7.262456191980959e-10
detected O 0 6.260655993628461e-09
in O 0 5.061892918711841e-11
51 O 0 7.621408393276852e-09
non O 0 2.145465138880809e-09
- O 0 7.0603700663696145e-09
European O 0 1.5249861817778765e-08
Jews O 0 2.0495651842367124e-09
at O 0 1.0051455667792197e-08
increased O 0 5.450935347539598e-08
cancer B-Disease 0 1.5932479300317937e-06
risk O 0 9.005396606198701e-08
. O 0 1.4720296093173602e-08

Colorectal B-Disease 1 0.9995930790901184
neoplasia I-Disease 0 0.0064896345138549805
occurred O 0 4.2560357542242855e-05
personally O 0 1.8431830540066585e-05
or O 0 6.817314357476789e-08
in O 0 1.0219420865098527e-09
the O 0 5.972498051676212e-10
families O 0 2.891275274752303e-10
of O 0 4.369354184019514e-11
13 O 0 8.923879968314452e-10
of O 0 2.2003872682252457e-11
20 O 0 1.1157712531684183e-09
Ashkenazi O 0 4.0811059420775564e-08
I1307K O 0 3.339959198100928e-09
carriers O 0 7.486648523347128e-10
, O 0 3.7050272572169973e-11
8 O 0 3.366628087420054e-10
of O 0 2.0272001091670155e-11
whom O 0 1.9965307274105726e-07
also O 0 3.971767270627424e-08
had O 0 5.7916871298857586e-08
a O 0 3.5404936760130568e-09
personal O 0 2.7915360689689805e-08
or O 0 1.3487897376762703e-07
family O 0 2.6849933831840644e-08
history O 0 6.3288632112801224e-09
of O 0 2.6584934254003656e-09
noncolonic O 0 0.0005049020401202142
neoplasia B-Disease 0 5.65284353797324e-05
. O 0 1.9368006576314656e-07

CONCLUSIONS O 0 1.3666228369402234e-05
The O 0 7.207977770207208e-09
I1307K O 0 5.096534323456581e-07
APC O 0 3.066037379539921e-07
variant O 0 2.478997203070321e-07
may O 0 2.2427114387824076e-08
represent O 0 3.829287165135753e-10
a O 0 2.909098240078123e-10
susceptibility O 0 2.9963381109610054e-08
gene O 0 2.2238417329845106e-07
for O 0 2.3458163411760324e-07
colorectal B-Disease 1 1.0
, I-Disease 0 6.266547813993384e-08
or I-Disease 0 3.555545902145241e-08
other I-Disease 0 2.844975144355999e-09
, I-Disease 0 1.0116117721281626e-08
cancers I-Disease 0 7.859299330448266e-06
in O 0 5.333654629069429e-10
Ashkenazi O 0 9.134751621786563e-07
Jews O 0 5.1929296418506965e-09
, O 0 1.4710354045988083e-09
and O 0 1.0493923507937097e-09
partially O 0 1.4612074039632716e-07
explains O 0 6.50672760116322e-08
the O 0 4.2359757368437556e-10
higher O 0 1.198571624172473e-07
incidence O 0 0.0015627167886123061
of O 0 0.045520201325416565
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 7.398174517447842e-09
European O 0 1.0961150564980926e-07
Israelis O 0 2.9857778827135917e-06
. O 0 2.6430537758415085e-08

Systematic O 0 2.2050221559766214e-06
analysis O 0 4.6935088704458394e-08
of O 0 1.412944206080624e-09
coproporphyrinogen O 0 1.3226431292423513e-05
oxidase O 0 9.565531399857718e-06
gene O 0 0.00018596899462863803
defects O 1 0.9699572324752808
in O 0 2.2728338322508534e-08
hereditary B-Disease 1 0.8627984523773193
coproporphyria I-Disease 0 0.041570995002985
and O 0 2.5044278118002694e-07
mutation O 0 1.2987169384359731e-06
update O 0 1.7060601749108173e-05
. O 0 5.967630301029203e-08

Hereditary B-Disease 1 0.9999685287475586
coproporphyria I-Disease 1 0.8746481537818909
( O 0 1.6595127817709e-05
HC B-Disease 0 0.21617630124092102
) O 0 3.531080849938917e-08
is O 0 2.7268167723804027e-09
an O 0 2.0912663600825e-08
acute O 0 0.014754709787666798
hepatic B-Disease 1 0.9999958276748657
porphyria I-Disease 1 0.9999996423721313
with O 0 1.3770201121587888e-06
autosomal O 1 0.9999847412109375
dominant O 0 0.01090622041374445
inheritance O 0 0.0024286690168082714
caused O 0 6.643585220444947e-05
by O 0 7.314061356566981e-09
deficient B-Disease 0 5.21339570696e-05
activity I-Disease 0 3.184205610295976e-08
of I-Disease 0 1.00637098654488e-09
coproporphyrinogen I-Disease 0 1.963216345757246e-05
III I-Disease 0 3.617795300669968e-06
oxidase I-Disease 0 9.815487373998621e-07
( O 0 1.9505092652138956e-08
CPO O 0 0.00015368206368293613
) O 0 4.824185939611425e-09
. O 0 1.3982160318448678e-08

Clinical O 0 4.174468631390482e-05
manifestations O 0 8.183740760614455e-07
of O 0 5.307715378322087e-10
the O 0 2.602140281027232e-09
disease O 0 7.884681508585345e-06
are O 0 4.3234626989629987e-10
characterized O 0 8.475304902333392e-09
by O 0 1.4337967479960412e-09
acute O 0 1.2335788142081583e-06
attacks O 0 3.0033183975319844e-06
of O 0 4.090473026963082e-08
neurological B-Disease 1 0.9776075482368469
dysfunction I-Disease 0 0.0008545666350983083
often O 0 2.116095032533849e-08
precipitated O 0 1.7648023487026876e-08
by O 0 7.966453191565748e-11
drugs O 0 2.708126389805443e-09
, O 0 1.6363879695724393e-10
fasting O 0 8.283527108687849e-08
, O 0 1.385369596818009e-09
cyclical O 0 1.0904117516474798e-05
hormonal O 0 1.9445030829956522e-06
changes O 0 4.4503214446933725e-09
, O 0 6.325528989492568e-10
or O 0 6.388243605215393e-07
infectious B-Disease 0 1.784141204552725e-05
diseases I-Disease 0 8.548350160708651e-05
. O 0 7.273762037129927e-08

Skin O 1 0.9999984502792358
photosensitivity O 1 0.9998025298118591
may O 0 0.0002207525831181556
also O 0 1.2268107418833551e-08
be O 0 2.3116428771174924e-09
present O 0 5.031317584780481e-09
. O 0 2.569972146204691e-08

The O 0 1.566429652655188e-08
seven O 0 9.397676414835132e-09
exons O 0 1.1388340936946406e-07
, O 0 2.019243938722326e-10
the O 0 1.818100392458888e-10
exon O 0 7.475945835722086e-07
/ O 0 1.3303102605277672e-05
intron O 0 1.1760167581087444e-05
boundaries O 0 1.395765139022842e-07
and O 0 9.320235694332268e-10
part O 0 1.1607779321076706e-10
of O 0 1.1560225866846796e-11
3 O 0 2.781392338668809e-10
noncoding O 0 5.693058025002529e-09
sequence O 0 8.429451026081836e-10
of O 0 1.0455892228422581e-11
the O 0 5.775013800501938e-10
CPO O 0 1.300436179008102e-05
gene O 0 6.830053411732706e-09
were O 0 4.978876200212312e-10
systematically O 0 2.364027196222196e-08
analyzed O 0 1.1006707767435842e-09
by O 0 5.696546099415167e-12
an O 0 1.7025473045273465e-11
exon O 0 4.2342030326381064e-08
- O 0 3.4253798020245085e-08
by O 0 2.861726633440753e-09
- O 0 1.9470508050289936e-06
exon O 0 2.4132419639499858e-05
denaturing O 0 3.9968101191334426e-05
gradient O 0 1.6134218867591699e-06
gel O 0 1.1072714187321253e-05
electrophoresis O 0 4.173844274646399e-07
( O 0 1.0767745584061572e-09
DGGE O 0 4.0929435840553197e-07
) O 0 1.574812918958557e-10
strategy O 0 8.102381543473314e-10
followed O 0 6.105761035657409e-11
by O 0 2.2011713198683003e-12
direct O 0 3.673133464054956e-10
sequencing O 0 1.4263101810740864e-08
in O 0 3.297269957069915e-10
seven O 0 3.036001894329843e-09
unrelated O 0 2.0615241069776857e-08
heterozygous O 0 2.5610719944779703e-07
HC B-Disease 0 4.964324034517631e-05
patients O 0 2.524961075778265e-07
from O 0 8.939075590852497e-10
France O 0 9.737653954289271e-07
, O 0 2.3326236497922537e-09
Holland O 0 1.773138137650676e-06
, O 0 1.565281793070028e-09
and O 0 1.5917307472079756e-09
Czech O 0 7.166299269556475e-07
Republic O 0 5.0646914218077654e-08
. O 0 2.6189114876729036e-08

Seven O 0 6.59496379284974e-07
novel O 0 1.3623470351831202e-07
mutations O 0 3.5062605547864223e-06
and O 0 7.269579938018467e-10
two O 0 2.0214134532903216e-10
new O 0 8.709081789071149e-10
polymorphisms O 0 1.5609736010446795e-06
were O 0 3.0601889022818796e-08
detected O 0 1.1687411642924417e-06
. O 0 1.2952069639027286e-08

Among O 0 7.139607305362006e-08
these O 0 2.2838837487881847e-09
mutations O 0 8.446389898608686e-08
two O 0 1.4030346884297273e-09
are O 0 1.241657332506918e-09
missense O 0 8.945988838604535e-07
( O 0 3.0459899047485806e-09
G197W O 0 4.773571760097184e-08
, O 0 1.1331583449347704e-09
W427R O 0 1.3211205462937414e-08
) O 0 2.8619598357870757e-10
, O 0 1.9074582191525025e-10
two O 0 8.525203876175169e-10
are O 0 1.426559759210022e-09
nonsense O 0 1.447476449811802e-07
( O 0 2.087952172269425e-10
Q306X O 0 5.5224598227709976e-09
, O 0 1.2199516397082277e-10
Q385X O 0 2.66058330922192e-09
) O 0 6.933741775183577e-11
, O 0 3.502153428369681e-11
two O 0 1.035489818890234e-10
are O 0 3.2385115422695065e-11
small O 0 1.782721054111036e-10
deletions O 0 8.819365007184388e-07
( O 0 1.502941437969696e-09
662de14bp O 0 9.002680378955574e-09
; O 0 1.923119302693621e-10
1168del3bp O 0 6.057202739384593e-08
removing O 0 2.7210391717602533e-09
a O 0 1.0022964680445057e-09
glycine O 0 4.720468993468785e-08
at O 0 8.981532850782514e-09
position O 0 7.160620540958007e-09
390 O 0 7.699882398348734e-10
) O 0 1.792195558625309e-10
, O 0 2.8954746933429476e-10
and O 0 4.0539482881740696e-10
one O 0 1.3449012736810317e-10
is O 0 1.7649612674142112e-11
a O 0 7.226223786016561e-11
splicing O 0 1.1545154166014981e-07
mutation O 0 4.181561408245216e-08
( O 0 4.926768437663043e-10
IVS1 O 0 1.2137313660787186e-06
- O 0 8.455126021544856e-08
15c O 0 6.796930307473303e-08
- O 0 1.5933483155095018e-07
- O 0 4.4061590642741066e-07
> O 0 6.123425322357434e-09
g O 0 9.521142629864698e-08
) O 0 4.931805658303645e-11
which O 0 3.648476659678934e-11
creates O 0 1.4865986219803062e-10
a O 0 9.813642259937083e-11
new O 0 2.2901856799872888e-10
acceptor O 0 6.772146843303517e-09
splice O 0 3.1896631753625115e-06
site O 0 3.0606358336626727e-07
. O 0 6.18860482859418e-08

The O 0 2.402226151332343e-08
pathological O 0 3.6085151577935903e-07
significance O 0 4.346649706832295e-09
of O 0 3.223283792652687e-11
the O 0 3.9012992836262583e-10
point O 0 5.951989123786916e-08
mutations O 0 3.302175954900122e-08
G197W O 0 1.7611942126904978e-08
, O 0 1.4024158223602257e-10
W427R O 0 5.181956641564511e-09
, O 0 2.280413219368782e-10
and O 0 8.153597935711687e-11
the O 0 5.1752747920463804e-11
in O 0 2.1868659660917444e-10
- O 0 2.423370801807323e-07
frame O 0 1.1270683444308816e-06
deletion O 0 2.040927256530267e-06
390delGly O 0 7.931456025289663e-08
were O 0 5.590069518390806e-10
assessed O 0 1.0299768815613675e-09
by O 0 3.2368566160734247e-11
their O 0 1.4765083600210005e-09
respective O 0 7.235112509107466e-09
expression O 0 4.3899225921073537e-10
in O 0 1.297222485679983e-11
a O 0 7.803372531478558e-11
prokaryotic O 0 3.2839264640927013e-10
system O 0 1.2862887144304835e-10
using O 0 9.081058127691222e-10
site O 0 1.1004282640669771e-07
- O 0 1.2376193581076222e-06
directed O 0 2.6554134890943715e-08
mutagenesis O 0 6.100792234065011e-06
. O 0 3.274211337611632e-07

These O 0 1.0141603468127869e-07
mutations O 0 1.5561163309030235e-06
resulted O 0 1.2782655822718425e-08
in O 0 3.113146962441249e-10
the O 0 2.927633968585752e-10
absence O 0 3.4539493487528716e-09
or O 0 9.590649385771144e-10
a O 0 1.738571064890948e-09
dramatic O 0 1.6570380978464527e-07
decrease O 0 1.0348136356697069e-06
of O 0 1.548273731444283e-09
CPO O 0 0.00032951062894426286
activity O 0 1.1168304325792633e-07
. O 0 1.854053088834462e-08

The O 0 1.8729622297541937e-08
two O 0 4.888859539420309e-09
polymorphisms O 0 1.6175384871530696e-06
were O 0 1.1430161706016406e-08
localized O 0 3.690658445520967e-08
in O 0 5.176482020807782e-10
noncoding O 0 6.908102534453064e-08
part O 0 6.917194039779417e-10
of O 0 1.5902392250244368e-11
the O 0 2.271907141582208e-11
gene O 0 3.3793662312930906e-10
1 O 0 8.541704149545026e-11
) O 0 1.346676763158694e-11
a O 0 4.304915313113611e-10
C O 0 3.536511030688416e-07
/ O 0 4.7042101414263016e-07
G O 0 7.343167141016238e-08
polymorphism O 0 2.155567946360293e-09
in O 0 1.7052260992134194e-10
the O 0 6.014280184984955e-10
promotor O 0 6.524971922772238e-07
region O 0 1.334745007852689e-07
, O 0 7.253914691141006e-10
142 O 0 1.1098706398371405e-09
bp O 0 9.542158352360275e-08
upstream O 0 4.155980004583171e-09
from O 0 6.03843780533353e-11
the O 0 8.57817376159753e-12
transcriptional O 0 2.6788471441108186e-10
initiation O 0 1.5588604018734742e-10
site O 0 3.46666095829562e-09
( O 0 3.835654016626222e-10
- O 0 6.922928719177435e-08
142C O 0 1.465430301550441e-07
/ O 0 2.2297328428066976e-07
G O 0 4.7534559399764476e-08
) O 0 3.4220768579951155e-11
, O 0 3.231810305481808e-11
and O 0 7.290182346686436e-11
2 O 0 3.4223593403659436e-10
) O 0 1.9505584647472318e-11
a O 0 1.6766484034480555e-10
6 O 0 1.125990412020883e-09
bp O 0 1.1810466560291388e-07
deletion O 0 4.741853576462063e-09
polymorphism O 0 4.428963029656785e-10
in O 0 2.3839102566980408e-11
the O 0 4.629089125907093e-11
3 O 0 5.594165131128648e-10
noncoding O 0 9.30379329133757e-09
part O 0 2.780984054151503e-10
of O 0 1.9816304847042332e-11
the O 0 1.195998078351579e-09
CPO O 0 6.179697265906725e-06
gene O 0 3.5456566571667736e-09
, O 0 6.638065097597234e-11
574 O 0 7.23058390939002e-10
bp O 0 4.0603286066698274e-08
downstream O 0 1.3395162312690445e-08
of O 0 8.484349507675848e-12
the O 0 1.3211141902669254e-10
last O 0 1.2966975049266694e-08
base O 0 4.736355196932607e-10
of O 0 4.844722713281957e-12
the O 0 1.1559592172361022e-10
normal O 0 4.673801612398165e-08
termination O 0 1.5372341621855412e-08
codon O 0 5.8433389682477355e-08
( O 0 3.8536937529976e-10
+ O 0 3.807609516570665e-08
574 O 0 3.345533272636203e-08
delATTCTT O 0 2.9664730050171784e-07
) O 0 3.9166678789115394e-09
. O 0 1.879080890887508e-08

Five O 0 4.851941071137844e-07
intragenic O 0 1.1860997801704798e-05
dimorphisms O 0 1.7113788999267854e-05
are O 0 6.632730364941608e-09
now O 0 2.24737783938167e-09
well O 0 7.288002423777584e-10
characterized O 0 1.001691085633638e-08
and O 0 1.5552410470576206e-09
the O 0 3.9795355899485685e-10
high O 0 3.573683793334226e-09
degree O 0 1.9790791228047055e-09
of O 0 1.648609165849635e-10
allelic O 0 8.583460697764167e-08
heterogeneity O 0 1.5806185160727182e-07
in O 0 4.423570842959634e-09
HC B-Disease 0 6.13325391896069e-05
is O 0 1.1325620441482442e-09
demonstrated O 0 1.551219985795882e-10
with O 0 1.0562005263448082e-11
seven O 0 1.3394127473809192e-10
new O 0 3.465831094340288e-11
different O 0 3.506905876804467e-11
mutations O 0 4.026731836859199e-09
making O 0 4.258813024460295e-10
a O 0 2.754861894160854e-10
total O 0 8.11261835487187e-10
of O 0 1.3733351955647066e-10
nineteen O 0 5.539467338167015e-07
CPO O 0 0.01106608472764492
gene B-Disease 0 2.434317320876289e-05
defects I-Disease 0 0.4617724120616913
reported O 0 8.986538887256756e-06
so O 0 4.050657587129081e-09
far O 0 1.9781545290697977e-09
. O 0 8.216110014558353e-10
. O 0 1.032784613386184e-08

Coincidence O 0 4.0793306652631145e-06
of O 0 2.375714958091635e-09
two O 0 6.950189868071277e-10
novel O 0 8.666598994011565e-09
arylsulfatase O 0 8.748796176405449e-07
A O 0 1.5278743603630573e-08
alleles O 0 5.870674968377898e-08
and O 0 5.211573839147832e-09
mutation O 0 1.0694438401515072e-07
459 O 0 3.987145191786112e-08
+ O 0 1.8934726142560976e-07
1G O 0 5.315122962201713e-06
> O 0 3.0839252929126815e-08
A O 0 5.968117111621041e-09
within O 0 4.949486376304435e-10
a O 0 4.039609091677221e-09
family O 0 2.935219640676223e-07
with O 0 5.786386736872373e-06
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 0.9999998807907104
: O 0 3.1567981562119485e-09
molecular O 0 3.949359506094652e-09
basis O 0 2.039519664265299e-09
of O 0 4.877884762777285e-10
phenotypic O 0 2.706044597289292e-06
heterogeneity O 0 1.8014503439189866e-05
. O 0 3.132490462576243e-07

In O 0 3.3031774648861756e-08
a O 0 2.8749442826381255e-09
family O 0 1.0922808435509523e-08
with O 0 3.987842944752629e-09
three O 0 4.783105111982877e-08
siblings O 0 1.508327329702297e-07
, O 0 1.722558207184477e-10
one O 0 1.0035010322706484e-10
developed O 0 6.650335282465392e-10
classical O 0 4.601683656346722e-08
late O 0 1.7070302419597283e-05
infantile O 1 0.996977686882019
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
( O 0 8.147598236973863e-06
MLD B-Disease 1 0.9999998807907104
) O 0 1.8489325626092068e-08
, O 0 1.234452762233218e-09
fatal O 0 5.642845735565061e-06
at O 0 3.470513831871358e-07
age O 0 9.697026293054023e-09
5 O 0 3.6164506944658115e-09
years O 0 6.453143575058107e-10
, O 0 1.067559304845922e-10
with O 0 9.662016742240098e-10
deficient O 0 7.377740985248238e-06
arylsulfatase O 0 1.1211957371415338e-06
A O 0 1.1325607829348883e-07
( O 0 3.5878420234780606e-09
ARSA O 0 3.103788912994787e-05
) O 0 6.143309194683866e-10
activity O 0 3.4508216284478976e-09
and O 0 1.179762287861763e-09
increased O 0 8.34155233775391e-09
galactosylsulfatide O 0 3.366209057276137e-05
( O 0 6.202939317745404e-08
GS O 1 0.9999991655349731
) O 0 1.136255978195777e-08
excretion O 0 2.997996091380628e-07
. O 0 2.5943609927026046e-08

The O 0 4.488617122433425e-08
two O 0 2.7903634958192924e-09
other O 0 5.043045980812622e-10
siblings O 0 9.929468802738484e-08
, O 0 2.3824036077257915e-09
apparently O 0 6.684307862769856e-08
healthy O 0 7.43902495159432e-09
at O 0 7.210641528310191e-10
12 O 0 5.506931577414775e-10
( O 0 7.122907819123725e-11
1 O 0 2.2738344540584876e-09
/ O 0 6.690743248327635e-07
2 O 0 4.232359795963703e-09
) O 0 1.8848043958907823e-10
and O 0 1.403861804583073e-09
15 O 0 1.1221354956347795e-09
years O 0 1.226475032645169e-10
, O 0 7.76496297816287e-11
respectively O 0 1.4456714048094454e-08
, O 0 6.68979982521023e-10
and O 0 1.727138654317173e-09
their O 0 8.598663114867122e-09
father O 0 5.483919807147686e-08
, O 0 1.4941381465405357e-09
apparently O 0 4.010988874370014e-08
healthy O 0 1.4228749289912912e-09
as O 0 2.126871595509172e-11
well O 0 1.347839062582068e-10
, O 0 3.34348854158506e-10
presented O 0 1.133009863707457e-08
ARSA O 0 0.00012196460738778114
and O 0 3.6212639997756924e-07
GS O 1 0.9999991655349731
values O 0 4.2417021006713185e-09
within O 0 1.0885069928745494e-10
the O 0 2.479391414400567e-10
range O 0 1.843544694679622e-08
of O 0 3.582277585678639e-08
MLD B-Disease 1 0.9999997615814209
patients O 0 3.775010782192112e-06
. O 0 1.3483880678677451e-08

Mutation O 0 8.334736776305363e-06
screening O 0 2.337127824603158e-07
and O 0 1.7677693753270773e-09
sequence O 0 4.371842887707089e-09
analysis O 0 4.009303999907843e-09
disclosed O 0 2.825768206093926e-07
the O 0 1.9580555232767693e-10
involvement O 0 1.4125561831335176e-09
of O 0 1.457082718370195e-11
three O 0 8.660084316325367e-10
different O 0 1.5251482299305508e-09
ARSA O 0 4.635081859305501e-05
mutations O 0 1.7747237279763795e-07
being O 0 1.7158786891346978e-10
the O 0 1.7830978013555487e-11
molecular O 0 8.118996031036829e-10
basis O 0 1.3239955798383107e-09
of O 0 2.653102459948542e-10
intrafamilial O 0 1.4116827514953911e-05
phenotypic O 0 4.811085545952665e-06
heterogeneity O 0 6.6387210608809255e-06
. O 0 2.4304392809426645e-07

The O 0 1.268994793690581e-07
late O 0 1.3927775626143557e-06
infantile O 0 0.003999105654656887
patient O 0 7.205370638985187e-05
inherited O 0 4.461128992261365e-05
from O 0 5.1051738836349614e-08
his O 0 8.522578553993299e-08
mother O 0 1.4972562212278717e-06
the O 0 1.448723585539824e-09
frequent O 0 6.898543603028884e-08
0 O 0 1.8562186454573748e-08
- O 0 8.329066645273997e-07
type O 0 1.9618413205080287e-07
mutation O 0 2.7156676196682383e-07
459 O 0 1.0028954555707514e-08
+ O 0 1.4206059439914043e-08
1G O 0 1.5102273209777195e-07
> O 0 2.9487967623254008e-09
A O 0 2.1772914138296073e-08
, O 0 1.8223091924340906e-09
and O 0 2.384394903742759e-09
from O 0 3.5795555408668633e-10
his O 0 6.988570611099476e-09
father O 0 9.026717151527919e-09
a O 0 4.906737238741243e-10
novel O 0 4.810917442199525e-09
, O 0 4.009240717195439e-10
single O 0 5.9509419614300896e-09
basepair O 0 3.552293037500931e-07
microdeletion O 0 2.353894501538889e-08
of O 0 8.88103045965094e-12
guanine O 0 8.676948604069423e-10
at O 0 1.2977774410671827e-10
nucleotide O 0 2.0355517271752888e-09
7 O 0 1.215552991595814e-09
in O 0 1.2367712409755427e-10
exon O 0 3.782059110335467e-08
1 O 0 5.4036459751216626e-09
( O 0 7.728603312884275e-10
7delG O 0 1.9129770123527123e-07
) O 0 3.4175338115005616e-09
. O 0 1.5395933417039487e-08

The O 0 1.3529871978334995e-07
two O 0 1.230181965183874e-07
clinically O 0 0.0008016759529709816
unaffected O 0 8.215996786020696e-06
siblings O 0 3.664083010335162e-07
carried O 0 8.033889997705046e-09
the O 0 1.0930304439327188e-09
maternal O 0 7.357860454249021e-08
mutation O 0 1.3947592947261e-07
459 O 0 2.7001691549344287e-08
+ O 0 6.320541956483794e-08
1G O 0 8.70234657668334e-07
> O 0 5.760396160070513e-09
A O 0 2.5543878123812647e-08
and O 0 5.315721640641868e-09
, O 0 1.6090374865829205e-10
on O 0 5.6504347867303295e-09
their O 0 1.956454998008894e-09
paternal O 0 4.496969907563653e-09
allele O 0 3.3042237390645823e-08
, O 0 1.3031847823086196e-10
a O 0 1.3807656407127666e-10
novel O 0 4.441214507266977e-09
cytosine O 0 6.190789036963906e-08
to O 0 5.745251496769299e-10
thymidine O 0 8.541618967683462e-08
transition O 0 1.0983582043877504e-08
at O 0 1.8193502260288597e-09
nucleotide O 0 1.0305080344608086e-08
2435 O 0 4.922922514083439e-08
in O 0 1.6142723269219061e-10
exon O 0 2.935974485751558e-08
8 O 0 4.1091365865497664e-09
, O 0 1.1625483214983134e-10
resulting O 0 2.297509821280741e-10
in O 0 1.8401379378585325e-11
substitution O 0 4.0886280472385295e-10
of O 0 5.543666914409329e-11
alanine O 0 5.757147505391913e-07
464 O 0 4.764775596299842e-08
by O 0 2.4120228037105562e-09
valine O 0 0.0009748330921866
( O 0 1.0140439599126694e-08
A464V O 0 2.6352347504143836e-07
) O 0 6.099365901235387e-09
. O 0 3.181340346714023e-08

The O 0 2.5106527345997165e-07
fathers O 0 1.2292524615986622e-06
genotype O 0 7.884245860623196e-06
thus O 0 9.302217307549654e-08
was O 0 4.476066450820326e-08
7delG O 0 2.82057112599432e-06
/ O 0 1.8266959159518592e-05
A464V O 0 1.8846930061044986e-06
. O 0 8.89101343659604e-08

Mutation O 0 3.6937570257578045e-05
A464V O 0 2.115222969223396e-06
was O 0 3.4106273005818366e-07
not O 0 1.0336531630628087e-09
found O 0 7.342376151520114e-10
in O 0 2.4931717801379705e-10
18 O 0 1.0296552943600545e-08
unrelated O 0 3.256970728671149e-07
MLD B-Disease 1 1.0
patients O 0 6.642571861448232e-06
and O 0 3.9701497644983874e-10
50 O 0 2.285055700212979e-09
controls O 0 1.888150472950656e-05
. O 0 6.020690648256277e-07

A464V O 0 1.1753036233130842e-05
, O 0 3.354005073674671e-08
although O 0 9.074206275272445e-09
clearly O 0 3.1776409059602884e-08
modifying O 0 2.0915381071517913e-07
ARSA O 0 0.0005939623224548995
and O 0 3.657356046460336e-06
GS O 1 1.0
levels O 0 9.126403455184118e-08
, O 0 2.798095088962782e-10
apparently O 0 6.433888533052823e-09
bears O 0 4.675564824196954e-09
little O 0 2.0599341676863503e-10
significance O 0 2.438657609182826e-10
for O 0 1.1743375716299909e-10
clinical O 0 1.900138713040178e-09
manifestation O 0 9.190210370491059e-09
of O 0 3.907758117094318e-09
MLD B-Disease 1 0.9999996423721313
, O 0 9.317520976992455e-09
mimicking O 0 4.120944083751965e-07
the O 0 3.642181223284524e-09
frequent O 0 1.0248040780425072e-06
ARSA O 0 0.002828155644237995
pseudodeficiency O 0 3.604057201300748e-05
allele O 0 1.4031756109034177e-05
. O 0 1.8207299490313744e-07

Our O 0 1.9176333807990886e-05
results O 0 1.227144025506277e-06
demonstrate O 0 1.9162731401678457e-09
that O 0 4.251822852130438e-11
in O 0 3.772154463788091e-11
certain O 0 7.140513180736718e-10
genetic O 0 1.5933011354718474e-06
conditions O 0 2.372536800976377e-05
MLD B-Disease 1 0.9999998807907104
- O 0 1.2147644156357273e-05
like O 0 2.0269369827019545e-07
ARSA O 0 0.0013858928577974439
and O 0 1.4510357004837715e-06
GS O 1 0.9999996423721313
values O 0 1.800227700243795e-08
need O 0 5.500811472991529e-10
not O 0 7.201772511677973e-11
be O 0 2.7920216486010396e-11
paralleled O 0 6.090066229091917e-09
by O 0 4.618816995538566e-10
clinical O 0 3.6071796216674556e-08
disease O 0 2.624129535888642e-07
, O 0 4.238883202778432e-11
a O 0 3.897327738311418e-10
finding O 0 1.5986344470420022e-09
with O 0 1.2445974251207303e-09
serious O 0 8.283811325782153e-08
diagnostic O 0 4.185336024420394e-07
and O 0 7.991754813474472e-09
prognostic O 0 2.733345354499761e-05
implications O 0 6.321276941889664e-07
. O 0 8.509373117249197e-08

Moreover O 0 7.541124887211481e-06
, O 0 5.967061156297859e-08
further O 0 3.4227674916564865e-08
ARSA O 0 0.00011627161438809708
alleles O 0 4.152445001182059e-07
functionally O 0 1.1227076583963935e-06
similar O 0 2.369831664239541e-09
to O 0 3.829661920917715e-09
A464V O 0 1.0525344151801619e-07
might O 0 1.972801300098581e-08
exist O 0 1.0169720621178158e-09
which O 0 3.090157574270336e-10
, O 0 5.432545038819292e-11
together O 0 9.664519184937603e-11
with O 0 6.978746053265539e-11
0 O 0 9.248274146500535e-09
- O 0 1.522917159491044e-06
type O 0 6.563716397067765e-07
mutations O 0 8.22607944428455e-06
, O 0 2.8513529315432606e-09
may O 0 5.649651058092786e-08
cause O 0 1.3906944040797953e-08
pathological O 0 8.155521413755196e-07
ARSA O 0 0.0007587015861645341
and O 0 3.382489239811548e-06
GS O 1 1.0
levels O 0 2.485374466232315e-07
, O 0 3.1005248368742855e-10
but O 0 3.665903414162841e-10
not O 0 3.575079399187331e-10
clinical O 0 5.138098835288929e-10
outbreak O 0 4.771600337072357e-10
of O 0 1.159505044062703e-11
the O 0 4.9835815474352785e-09
disease O 0 1.6764905694799381e-06
. O 0 1.044916375647631e-09
. O 0 1.8961102909997862e-08

Human O 0 0.0001319503498962149
MLH1 O 1 0.9944248199462891
deficiency O 1 0.9988553524017334
predisposes O 0 0.00010485186794539914
to O 0 1.2334011216807994e-06
hematological B-Disease 0 0.01711052842438221
malignancy I-Disease 1 0.6704865097999573
and O 0 4.634246977275325e-07
neurofibromatosis B-Disease 0 0.000496964028570801
type I-Disease 0 5.790654427073605e-07
1 I-Disease 0 1.2676896687935368e-07
. O 0 1.921636680890515e-07

Heterozygous O 0 0.0002983982558362186
germ O 0 0.0004944801912643015
- O 0 5.559491546591744e-05
line O 0 3.2057228963822126e-05
mutations O 0 4.7135731051639596e-07
in O 0 1.2006440286427278e-10
the O 0 1.833730528533195e-10
DNA O 0 9.284526925057435e-08
mismatch O 0 1.142975207812924e-07
repair O 0 5.373590283852536e-07
genes O 0 4.6854321311684544e-08
lead O 0 1.925547394421301e-06
to O 0 7.205037491075927e-06
hereditary B-Disease 1 0.9999992847442627
nonpolyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 2.5466731585765956e-06

The O 0 2.547063786551007e-07
disease O 0 0.00011892861948581412
susceptibility O 0 3.2652260415488854e-06
of O 0 1.3050260871949604e-09
individuals O 0 2.9756694885918478e-08
who O 0 1.9174808585376013e-06
constitutionally O 0 1.3479591871146113e-05
lack O 0 3.4056064635024086e-09
both O 0 3.3194377802026054e-10
wild O 0 4.444300927275435e-08
- O 0 3.9614060369785875e-06
type O 0 1.5966459443461645e-07
alleles O 0 8.4058420668498e-08
is O 0 3.5635012718415737e-09
unknown O 0 1.2353417844224168e-07
. O 0 5.58522579297005e-08

We O 0 6.810193553974386e-06
have O 0 4.6686676746787725e-09
identified O 0 4.934576747217534e-09
three O 0 5.72747183014144e-10
offspring O 0 1.1100278030085065e-08
in O 0 3.863747100041337e-10
a O 0 1.0495748483663192e-06
hereditary B-Disease 1 0.9999997615814209
nonpolyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 0 6.522037438116968e-06
who O 0 6.269321488616697e-07
developed O 0 7.398939771974256e-08
hematological B-Disease 0 0.00016690675693098456
malignancy I-Disease 0 4.2754396417876706e-05
at O 0 3.4704999762880107e-08
a O 0 5.8520024381891744e-09
very O 0 3.847218099650718e-09
early O 0 2.717254687922832e-08
age O 0 5.938061597987598e-09
, O 0 4.746248949416554e-10
and O 0 4.332462832934425e-09
at O 0 1.2674087557229541e-08
least O 0 1.711808889082178e-10
two O 0 7.865955109487288e-11
of O 0 1.2793636809671494e-11
them O 0 6.317522616150484e-10
displayed O 0 5.782897716244406e-09
signs O 0 2.9237527954251163e-08
of O 0 6.944051583746003e-11
neurofibromatosis B-Disease 0 1.3603142861029482e-06
type I-Disease 0 2.0831528502185392e-08
1 I-Disease 0 1.9177402776904273e-08
( O 0 3.1937230637879566e-09
NF1 B-Disease 0 5.435259936348302e-06
) O 0 7.761372877723716e-09
. O 0 1.919859293764148e-08

DNA O 0 7.026377488728031e-07
sequence O 0 3.27429177104932e-08
analysis O 0 8.303359777528385e-09
and O 0 3.2827743301488965e-10
allele O 0 4.2821454826480476e-08
- O 0 3.348623067722656e-08
specific O 0 1.932260573767053e-09
amplification O 0 2.5469637066066753e-08
in O 0 3.720793118056065e-10
two O 0 2.709014790269748e-09
siblings O 0 1.0624074064935485e-07
revealed O 0 8.414198759965075e-08
a O 0 1.1523259679790954e-08
homozygous O 0 1.5054877167131053e-06
MLH1 O 0 1.871303356892895e-05
mutation O 0 4.101043202808796e-07
( O 0 2.467489546020829e-09
C676T O 0 1.7792180528886092e-07
- O 0 3.853234829875873e-06
- O 0 3.730811658897437e-05
> O 0 2.2168921987031354e-07
Arg226Stop O 0 4.144222202739911e-06
) O 0 5.7632538741358985e-09
. O 0 9.541263779055953e-09

Thus O 0 3.0934694450479583e-07
, O 0 2.9375077925664073e-09
a O 0 4.68064165204396e-09
homozygous O 0 1.4556663927578484e-06
germ O 0 2.5084462322411127e-05
- O 0 7.449460827047005e-05
line O 0 0.00014891229511704296
MLH1 O 0 0.00019695708760991693
mutation O 0 2.835691020663944e-06
and O 0 8.535735673831368e-09
consequent O 0 1.902266717479506e-06
mismatch O 0 0.00011034106137230992
repair O 1 0.8882794976234436
deficiency O 1 0.9957987666130066
results O 0 1.1531105883477721e-06
in O 0 6.781902817110108e-10
a O 0 2.6958106857932762e-08
mutator O 0 0.0001741476880852133
phenotype O 0 8.124489977490157e-05
characterized O 0 1.8147250102629187e-07
by O 0 5.751722653712932e-09
leukemia B-Disease 0 0.03760313242673874
and O 0 5.791096100438153e-06
/ O 1 0.9999984502792358
or O 1 0.9999865293502808
lymphoma B-Disease 1 1.0
associated O 0 2.8914548693137476e-06
with O 0 4.363578831600989e-09
neurofibromatosis B-Disease 0 9.098980081034824e-05
type I-Disease 0 9.633134823161527e-08
1 I-Disease 0 1.1556187118344496e-08
. O 0 3.042981866485661e-09
. O 0 1.787547532217104e-08

Missense O 0 0.0017695919377729297
mutations O 0 0.000262521265540272
in O 0 5.589901874714087e-09
the O 0 2.4328689063324305e-10
most O 0 3.685679539344733e-11
ancient O 0 2.7808408353813263e-10
residues O 0 4.152986932126623e-08
of O 0 2.6090855170801674e-11
the O 0 2.2852855718902276e-10
PAX6 O 0 1.5372128245871863e-06
paired O 0 1.1824260326420699e-07
domain O 0 1.696682438989683e-08
underlie O 0 6.116773931807984e-08
a O 0 1.1253613596551304e-09
spectrum O 0 8.388364669542625e-09
of O 0 1.569712693161307e-09
human O 0 5.9619183048198465e-06
congenital B-Disease 1 0.9999998807907104
eye I-Disease 1 0.999998927116394
malformations I-Disease 1 0.9999847412109375
. O 0 5.221345418249257e-06

Mutations O 0 0.00032807933166623116
of O 0 5.810383729709656e-09
the O 0 2.2188659798416666e-09
human O 0 8.926302363931882e-09
PAX6 O 0 5.972521466901526e-05
gene O 0 0.00037624259130097926
underlie O 0 0.20358261466026306
aniridia B-Disease 1 1.0
( O 0 3.4467040677554905e-05
congenital B-Disease 1 0.9999995231628418
absence I-Disease 0 4.4362724338498083e-07
of I-Disease 0 2.3224872025551235e-10
the I-Disease 0 6.6690617472886515e-09
iris I-Disease 0 0.062134042382240295
) O 0 6.4351897144376835e-09
, O 0 1.4873219322808495e-10
a O 0 1.2815850602976298e-09
rare O 0 1.442352637326394e-08
dominant O 0 0.00043920899042859674
malformation B-Disease 0 0.057351332157850266
of I-Disease 0 1.1215128825625698e-09
the I-Disease 0 9.401893663607552e-08
eye I-Disease 1 0.8032890558242798
. O 0 1.5862117379583651e-06

The O 0 2.9354424668781576e-08
spectrum O 0 1.2552959560707677e-07
of O 0 2.1446182607576247e-09
PAX6 O 0 1.920990143844392e-05
mutations O 0 3.3276970498263836e-05
in O 0 1.1316722492438203e-07
aniridia B-Disease 1 1.0
patients O 0 1.5236380022543017e-05
is O 0 1.8193839490532326e-10
highly O 0 1.9966556186190587e-10
biased O 0 1.3741258442223625e-07
, O 0 1.7732020018979e-10
with O 0 2.4431442979810924e-11
92 O 0 9.27363463798514e-10
% O 0 9.811172013707292e-11
of O 0 1.7991472894829386e-11
all O 0 9.70835145608362e-09
reported O 0 4.587772309605498e-06
mutations O 0 3.443919922574423e-07
leading O 0 1.2604994381604229e-08
to O 0 1.1067678329368391e-08
premature O 0 3.131743397943865e-08
truncation O 0 6.339085700801661e-08
of O 0 2.5313699053564065e-11
the O 0 1.1378901987324497e-10
protein O 0 1.635073054728764e-08
( O 0 2.3092311396410992e-10
nonsense O 0 6.897922233406462e-09
, O 0 2.324741787962381e-11
splicing O 0 4.175534140671289e-09
, O 0 9.48395528777013e-11
insertions O 0 9.892244356990432e-09
and O 0 2.531589604615192e-09
deletions O 0 9.656259436496839e-08
) O 0 1.1151606305048745e-09
and O 0 1.2691909745399244e-09
just O 0 8.769778681028129e-09
2 O 0 3.130075532098431e-09
% O 0 1.1177132830386682e-10
leading O 0 1.293334467300511e-10
to O 0 1.741393487741938e-11
substitution O 0 1.764055915232099e-11
of O 0 8.207107411208059e-13
one O 0 7.22512119577523e-11
amino O 0 2.9968436066063475e-10
acid O 0 5.13811826419186e-10
by O 0 8.880946325562356e-12
another O 0 1.066428279017373e-09
( O 0 1.5187445745468153e-09
missense O 0 4.957414034834073e-07
) O 0 3.930707759280949e-09
. O 0 1.9424676978019306e-08

The O 0 1.3797192721654028e-08
extraordinary O 0 6.97466795429591e-09
conservation O 0 6.853356770974983e-10
of O 0 3.886954993981284e-11
the O 0 1.6988827011843455e-10
PAX6 O 0 8.683364427497509e-08
protein O 0 5.104937361721795e-09
at O 0 4.3763456747392127e-10
the O 0 2.3762202275290356e-11
amino O 0 1.7834327348253964e-09
acid O 0 7.350563269170607e-09
level O 0 1.9169410503394602e-10
amongst O 0 1.0588474541606274e-10
vertebrates O 0 1.110037839424649e-09
predicts O 0 3.1898775887384545e-07
that O 0 5.446584849799763e-10
pathological O 0 1.7263793949950923e-07
missense O 0 2.687020241864957e-06
mutations O 0 3.77289120478963e-06
should O 0 6.665577867437378e-09
in O 0 1.4497980593830562e-10
fact O 0 5.162549276960249e-10
be O 0 3.482119592668198e-10
common O 0 7.180064320877477e-10
even O 0 3.9350283032035804e-09
though O 0 1.2339889110535296e-09
they O 0 9.065310169198426e-10
are O 0 1.1976318547990417e-10
hardly O 0 4.929985752966104e-09
ever O 0 7.1780141830402044e-09
seen O 0 5.522757362541597e-08
in O 0 7.461093076699399e-09
aniridia B-Disease 1 1.0
patients O 0 7.655772265025007e-07
. O 0 8.606752643913751e-09

This O 0 1.5765945704515616e-07
indicates O 0 1.0151880047715167e-07
that O 0 1.6520558532295837e-10
there O 0 2.8883083424968703e-11
is O 0 3.0922434751667893e-11
a O 0 2.444479729746263e-09
heavy O 0 5.611388132820139e-06
ascertainment O 0 5.513450105354423e-06
bias O 0 2.853269904790068e-07
in O 0 1.0695627716827971e-10
the O 0 1.211749173224419e-10
selection O 0 5.074258235815421e-10
of O 0 2.350624729585693e-11
patients O 0 8.207339252663814e-10
for O 0 3.378114454832826e-11
PAX6 O 0 1.4013268412327307e-07
mutation O 0 2.595752057743539e-08
analysis O 0 2.3242430202685682e-09
and O 0 2.8035709864759895e-10
that O 0 9.972292436266628e-11
the O 0 1.139813132766676e-09
missing O 0 8.702670015736658e-07
PAX6 O 0 2.4936627596616745e-05
missense O 0 7.10267195245251e-05
mutations O 0 7.49604296288453e-05
frequently O 0 1.1448989880591398e-06
may O 0 8.914751106203767e-07
underlie O 0 2.2063832147978246e-06
phenotypes O 0 2.4275213945657015e-06
distinct O 0 1.781037894943438e-07
from O 0 8.009291718735767e-08
textbook O 0 3.399332854314707e-05
aniridia B-Disease 1 0.9999998807907104
. O 0 1.4238645462683053e-06

Here O 0 1.0068207529911888e-06
we O 0 2.7236577437861342e-08
present O 0 7.111196631548466e-10
four O 0 3.9563619047555676e-10
novel O 0 1.7302948407404983e-08
PAX6 O 0 1.4775968338653911e-05
missense O 0 2.1558298612944782e-05
mutations O 0 8.100832928903401e-06
, O 0 1.6079920728273578e-09
two O 0 3.5664640685162396e-10
in O 0 8.796092187957072e-10
association O 0 2.440127822023186e-10
with O 0 5.95075710929649e-10
atypical O 0 2.740782747423509e-06
phenotypes O 0 7.4272561505495105e-06
ectopia B-Disease 0 0.0002256182488054037
pupillae I-Disease 0 0.00022242357954382896
( O 0 2.6936159969181972e-08
displaced B-Disease 0 8.220920335588744e-07
pupils I-Disease 0 1.9310587049403694e-06
) O 0 1.5776443262893736e-07
and O 0 1.0036753337772097e-05
congenital B-Disease 1 0.999998927116394
nystagmus I-Disease 0 0.00053265510359779
( O 0 1.4128803016433267e-08
searching B-Disease 0 6.024906156198995e-07
gaze I-Disease 0 7.474808080587536e-05
) O 0 6.6856569169715385e-09
, O 0 1.4225139954859856e-09
and O 0 1.0529028759975745e-09
two O 0 1.1926585274935064e-09
in O 0 5.562109106627133e-10
association O 0 5.26523234734011e-11
with O 0 4.377679468925422e-11
more O 0 2.522807296401197e-09
recognizable O 0 4.992195317754522e-05
aniridia B-Disease 1 0.9999997615814209
phenotypes O 0 1.5275474652298726e-05
. O 0 6.76174636282667e-08

Strikingly O 0 9.00530576473102e-05
, O 0 4.589140800703717e-08
all O 0 5.798777569232527e-10
four O 0 4.343506387893825e-10
mutations O 0 2.5818474469474495e-08
are O 0 9.514847937319715e-11
located O 0 7.055950823620094e-10
within O 0 2.2404773869499905e-10
the O 0 3.8352446218858915e-10
PAX6 O 0 3.510498913783522e-07
paired O 0 3.719405938795717e-08
domain O 0 6.69732269642509e-09
and O 0 2.2227673035501994e-09
affect O 0 2.6881794568112127e-09
amino O 0 3.5587872648790153e-09
acids O 0 1.2216829325950584e-08
which O 0 1.6327590668385739e-10
are O 0 8.830206531251772e-12
highly O 0 1.2949630083525232e-11
conserved O 0 2.3118798542220986e-10
in O 0 1.666245891263074e-10
all O 0 9.078612167590094e-11
known O 0 9.981312998341707e-11
paired O 0 6.971090815710568e-09
domain O 0 4.147103549456688e-09
proteins O 0 3.723364949692609e-09
. O 0 1.9920395999406537e-08

Our O 0 3.980166184192058e-06
results O 0 2.4284398136842356e-07
support O 0 1.9480572710506294e-10
the O 0 4.113413776263286e-11
hypothesis O 0 6.456640222474164e-10
that O 0 1.9488997221595028e-11
the O 0 1.4354316346665286e-11
under O 0 2.185117711772655e-11
- O 0 1.5117246343621105e-09
representation O 0 1.1896436058478344e-09
of O 0 2.7495652976661233e-10
missense O 0 3.289790356575395e-06
mutations O 0 1.3961127933725948e-06
is O 0 6.482430148224694e-10
caused O 0 3.6212339793451065e-09
by O 0 3.1282418322398087e-10
ascertainment O 0 2.0755301193275955e-06
bias O 0 3.2718405691412045e-06
and O 0 4.4638808205377245e-09
suggest O 0 1.306092012320903e-09
that O 0 4.906042239127828e-11
a O 0 1.7821193132316893e-10
substantial O 0 1.5521885998737162e-09
burden O 0 9.42715505658498e-09
of O 0 3.101820189588267e-10
PAX6 B-Disease 0 0.00012281797535251826
- I-Disease 0 0.0006423355080187321
related I-Disease 0 1.7188343917950988e-05
disease I-Disease 0 0.08478830754756927
remains O 0 1.0262089489287973e-07
to O 0 9.433989589524572e-09
be O 0 3.0732838496305703e-09
uncovered O 0 1.3809875554215978e-07
. O 0 3.607350196332959e-09
. O 0 1.022492401858699e-08

The O 0 9.116816812593243e-08
chromosomal O 0 0.00012105181667720899
order O 0 1.9771105641552822e-08
of O 0 6.72931765866025e-10
genes O 0 6.000043839549107e-08
controlling O 0 4.0026311580732e-06
the O 0 1.912428215788964e-09
major O 0 4.4786605535307444e-09
histocompatibility O 0 2.215171335251398e-08
complex O 0 2.9960449676735834e-09
, O 0 9.517158172656082e-10
properdin O 0 1.1917419584506206e-07
factor O 0 2.604637838743429e-09
B O 0 4.5565815298687085e-07
, O 0 5.040307726744686e-09
and O 0 2.419516533791466e-07
deficiency B-Disease 0 2.420089913357515e-06
of I-Disease 0 1.2718577059589453e-11
the I-Disease 0 2.2569988933351937e-10
second I-Disease 0 2.6563558463976733e-08
component I-Disease 0 2.214688654689212e-09
of I-Disease 0 8.600753442777886e-11
complement I-Disease 0 2.239313268148635e-08
. O 0 1.8314638694505447e-08

The O 0 3.4485204025713756e-08
relationship O 0 1.751162059804301e-08
of O 0 5.198464228528543e-11
the O 0 6.325972384813028e-11
genes O 0 1.9315089527793816e-09
coding O 0 1.8685452118916146e-07
for O 0 1.6514140055434723e-09
HLA O 0 4.980885819350078e-07
to O 0 1.6630969934539053e-09
those O 0 9.638635722897249e-11
coding O 0 1.4309097906561874e-08
for O 0 1.881058503405697e-10
properdin O 0 9.05778207993535e-08
Factor O 0 1.353693157568614e-09
B O 0 6.130953522642812e-08
allotypes O 0 2.7643531552712375e-07
and O 0 1.3776358942507727e-09
for O 0 3.0579117016316104e-09
deficiency B-Disease 0 3.28986743625137e-07
of I-Disease 0 2.791700681389897e-12
the I-Disease 0 1.1501027213922654e-10
second I-Disease 0 1.8776479038251637e-08
component I-Disease 0 1.3255369024633978e-09
of I-Disease 0 1.3567135262460006e-11
complement I-Disease 0 2.5976820694495473e-09
( O 0 1.3682349697674567e-09
C2 O 0 6.254786200088347e-08
) O 0 1.7984276567961643e-10
was O 0 1.336147414932043e-09
studied O 0 4.370089845551206e-10
in O 0 5.364238220284534e-11
families O 0 1.0350830609295869e-10
of O 0 7.952880021200315e-11
patients O 0 3.362550060614922e-08
with O 0 3.146122695696363e-09
connective O 0 0.010381365194916725
tissue O 1 0.9353953003883362
disorders O 0 0.07135506719350815
. O 0 7.287175662895606e-08

Patients O 0 0.0028627640567719936
were O 0 6.968367927129293e-08
selected O 0 4.340204196040531e-09
because O 0 7.546662739166266e-10
they O 0 9.689146152069839e-10
were O 0 7.570464810591204e-10
heterozygous O 0 7.907345001001431e-09
or O 0 1.723664233566069e-08
homozygous O 0 2.673738435987616e-06
for O 0 4.044517481816001e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 2.8890957537441864e-07

12 O 0 1.9882709523244557e-07
families O 0 2.6576769673880563e-09
with O 0 7.390146272712173e-10
15 O 0 5.437287953213854e-09
matings O 0 1.4939499806132517e-06
informative O 0 1.666306843617349e-06
for O 0 1.2772617083101068e-05
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
were O 0 2.201549342828457e-08
found O 0 9.036260628647597e-09
. O 0 1.5329359115412444e-08

Of O 0 4.625486482723318e-08
57 O 0 1.3231635875854408e-07
informative O 0 5.32877919567909e-08
meioses O 0 2.3686568511038786e-06
, O 0 9.468741346552179e-10
two O 0 2.118629160996477e-10
crossovers O 0 4.897896488387232e-08
were O 0 1.1860615822811837e-09
noted O 0 1.0520597726326741e-09
between O 0 7.193566853302968e-10
the O 0 2.1808757537655765e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999994039535522
gene O 0 1.226174450863482e-08
and O 0 9.749984153373248e-11
the O 0 1.4696407979464254e-10
HLA O 0 3.3214441828022245e-06
- O 0 9.503017395218194e-08
B O 0 1.975715946400669e-08
gene O 0 7.622146247499018e-10
, O 0 4.577583104237171e-12
with O 0 1.221831988883204e-12
a O 0 1.1200090334340107e-11
recombinant O 0 1.2316063446871084e-10
fraction O 0 6.723044343459605e-10
of O 0 9.474553780419726e-11
0 O 0 1.223950008011343e-08
. O 0 3.3336725380195276e-08

035 O 0 0.007780002895742655
. O 0 1.0506491889827885e-05

A O 0 2.589326868474018e-06
lod O 0 0.003513185540214181
score O 0 4.657214560666034e-07
of O 0 2.8072844049376044e-10
13 O 0 4.124802277516437e-09
was O 0 1.0632923430620167e-09
calculated O 0 8.666433792825501e-09
for O 0 2.0891910423870286e-10
linkage O 0 4.273380909580737e-06
between O 0 1.6205469364649616e-05
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
and O 0 1.0173373254929174e-08
HLA O 0 4.787920033777482e-07
- O 0 2.9513529398172977e-08
B O 0 2.4129811038164917e-08
at O 0 1.4199949549542623e-10
a O 0 3.956925759274199e-11
maximum O 0 8.190117334327951e-11
likelihood O 0 1.775320446206763e-10
value O 0 5.991800805515979e-11
of O 0 1.9795857661430993e-12
the O 0 2.0945604625732805e-11
recombinant O 0 2.1062275534777797e-10
fraction O 0 4.3868592092266567e-10
of O 0 6.550713443909117e-11
0 O 0 1.1710285185984048e-08
. O 0 2.484852146267258e-08

04 O 0 0.0005982586299069226
. O 0 3.952190581912873e-06

18 O 0 2.0168286027910654e-06
families O 0 1.0230308156167212e-08
with O 0 1.7154933029672748e-09
21 O 0 1.738094468350937e-08
informative O 0 1.2108078095707242e-08
matings O 0 2.7036975325245294e-07
for O 0 6.743322567004384e-10
both O 0 3.2066677091435736e-10
properdin O 0 1.6970716387731954e-07
Factor O 0 4.090736194228839e-09
B O 0 4.130063047114163e-08
allotype O 0 1.9961213126862276e-07
and O 0 6.59454668650028e-09
HLA O 0 3.186373533026199e-06
- O 0 4.4186907643961604e-07
B O 0 8.931855290938984e-07
were O 0 3.9672829466042e-09
found O 0 4.346549786760079e-09
. O 0 8.55255422038681e-09

Of O 0 6.094089144426107e-08
72 O 0 5.637368758470984e-07
informative O 0 1.7567060695000691e-07
meioses O 0 2.421535100438632e-06
, O 0 2.454300096488282e-09
three O 0 1.1341378947093972e-09
recombinants O 0 1.378847969135677e-06
were O 0 4.629544303469402e-09
found O 0 4.814173504286146e-10
, O 0 9.08437561286668e-12
giving O 0 9.666044006872987e-12
a O 0 1.0772520028790034e-11
recombinant O 0 1.0509040859751906e-10
fraction O 0 7.894396247820623e-10
of O 0 1.0454541399251838e-10
0 O 0 2.4105061058321553e-08
. O 0 3.589082453459014e-08

042 O 0 0.0006597783649340272
. O 0 8.21499361336464e-06

A O 0 3.2199727684201207e-06
lod O 0 0.0013197138905525208
score O 0 1.8975616455918498e-07
of O 0 1.384470871279575e-10
16 O 0 1.3088201633593144e-09
between O 0 2.20996998478995e-10
HLA O 0 3.823266979452455e-06
- O 0 1.159476283874028e-07
B O 0 1.0911963954640669e-07
and O 0 8.593162292847012e-11
Factor O 0 2.414189126387356e-10
B O 0 5.000520886255799e-09
allotypes O 0 9.842502812773546e-09
was O 0 3.5580319246442116e-10
calculated O 0 1.6647979661499335e-09
at O 0 2.1880966483145414e-10
a O 0 9.721201621459841e-11
maximum O 0 8.629872511045633e-11
likelihood O 0 2.966921708313919e-10
value O 0 5.3132633709429555e-11
of O 0 3.3601708655101037e-12
the O 0 1.2576900458582951e-11
recombinant O 0 5.655615559208016e-11
fraction O 0 4.638955886093754e-10
of O 0 4.7493883825744376e-11
0 O 0 7.87118636935702e-09
. O 0 1.8115290600917433e-08

04 O 0 0.0005200479063205421
. O 0 2.1542593913181918e-06

A O 0 1.3423326095107768e-07
crossover O 0 1.4142747772893927e-07
was O 0 1.2893831069504813e-07
shown O 0 3.4319960207085387e-09
to O 0 5.193946939208161e-10
have O 0 9.242903664663515e-11
occurred O 0 2.115858876994281e-10
between O 0 8.124068258397177e-12
genes O 0 1.475592703581441e-10
for O 0 2.1214830239757454e-11
Factor O 0 1.3899663364735915e-10
B O 0 1.2205276789245545e-08
and O 0 1.1646239528317892e-09
HLA O 0 1.0678138551156735e-06
- O 0 1.411461454381424e-07
D O 0 2.7675051228470693e-07
, O 0 4.540134934671869e-11
in O 0 1.1941686355043668e-11
which O 0 4.132690856195609e-10
HLA O 0 1.938031175541255e-07
- O 0 4.9340243890583224e-08
D O 0 9.058922501026245e-08
segregared O 0 6.901780835733007e-08
with O 0 4.291928756838814e-10
HLA O 0 2.7744445674215967e-07
- O 0 1.0910981451672797e-08
A O 0 1.9080170332586022e-08
and O 0 4.115944918225978e-09
B O 0 7.332963747330723e-08
. O 0 7.279087999023659e-09

These O 0 6.213762304696502e-08
studies O 0 5.3571067581970055e-09
suggest O 0 2.3799693327219984e-09
that O 0 8.90290879212996e-12
the O 0 2.6500700505555086e-12
genes O 0 1.278310512997649e-10
for O 0 2.810674436248828e-11
Factor O 0 8.956979602459114e-10
B O 0 3.806704262387939e-05
and O 0 0.00010473356087459251
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
are O 0 1.0802649053065494e-10
located O 0 1.818755979154929e-10
outside O 0 4.842778400515613e-10
those O 0 1.6436764449512253e-10
for O 0 3.01257518930953e-10
HLA O 0 5.054563416706515e-07
, O 0 1.3554728173215125e-10
that O 0 1.719986653103689e-11
the O 0 1.1246112548157772e-11
order O 0 8.181577637600412e-11
of O 0 1.2167186529132845e-11
genese O 0 1.538496121611388e-07
is O 0 1.9466271650170341e-10
HLA O 0 4.241979212338265e-08
- O 0 1.3294945144792791e-09
A O 0 1.1240854469463102e-08
, O 0 1.1441361053021737e-10
- O 0 6.398777507854447e-09
B O 0 2.185283598521437e-08
, O 0 5.5128138165549956e-11
- O 0 5.045857509600182e-09
D O 0 2.1106290049033305e-08
, O 0 1.6908356659239843e-11
Factor O 0 8.641269644282801e-11
B O 0 2.7359035925655917e-08
allotype O 0 4.3292702684993856e-06
, O 0 2.925412445620168e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999998807907104
, O 0 2.475496023446322e-11
that O 0 6.467640659146845e-12
the O 0 8.681277051392211e-12
genes O 0 3.3082456774025104e-09
coding O 0 1.4965529771870933e-05
for O 0 8.98346297617536e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
and O 0 1.3479373173197473e-09
Factor O 0 7.791389200484389e-10
B O 0 1.6604131403141764e-08
allotypes O 0 3.8177901728886354e-08
are O 0 3.586873506544741e-11
approximately O 0 5.149260531855937e-11
3 O 0 4.3581865893926874e-10
- O 0 6.542840935708227e-09
- O 0 1.2683179839712011e-08
5 O 0 1.0353935486762111e-09
centimorgans O 0 9.389435007278735e-09
from O 0 4.339570716660468e-11
the O 0 3.004626061842153e-11
HLA O 0 6.05598984293465e-08
- O 0 1.6710078876158718e-09
A O 0 1.020812678831362e-08
and O 0 3.696856598622844e-09
HLA O 0 1.8968088966175856e-07
- O 0 1.4475614484865673e-08
B O 0 6.496841287173538e-09
loci O 0 7.459737272341727e-10
, O 0 7.262480894443257e-11
and O 0 4.944737674872357e-11
that O 0 1.6180013925892744e-11
the O 0 3.8914132333145446e-11
apparent O 0 5.980503647862179e-09
lack O 0 9.600874956161576e-11
of O 0 4.990298972662455e-12
recombinants O 0 1.6886176013031218e-08
between O 0 9.384962425251775e-12
the O 0 1.8990101158244954e-11
Factor O 0 2.644352237179959e-10
B O 0 6.463484680807596e-08
gene O 0 2.3471073973269085e-07
and O 0 1.3551346455642488e-05
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999997615814209
gene O 0 3.8055038231732397e-08
suggests O 0 1.39352684946914e-09
that O 0 2.298323857619078e-11
these O 0 5.332855684825333e-12
two O 0 1.0398539668221574e-10
genes O 0 5.878403541714761e-09
lie O 0 2.9799556955367734e-07
in O 0 6.031546373463925e-10
close O 0 9.457938432433366e-08
proximity O 0 1.560858287064093e-08
to O 0 5.0514454841277256e-08
one O 0 2.9903246545615048e-09
another O 0 1.746245459344209e-08
. O 0 2.028471790538333e-08

Distribution O 0 4.912974418402882e-07
of O 0 3.32508531819542e-09
emerin O 0 1.2459121535357554e-05
and O 0 1.1165871782736758e-08
lamins O 0 6.051943159945949e-07
in O 0 5.299602423569638e-10
the O 0 9.698464253915517e-10
heart O 0 5.274578711578215e-07
and O 0 6.0976210747298865e-09
implications O 0 3.990300090350729e-09
for O 0 4.2832626334643464e-09
Emery B-Disease 1 0.6198394894599915
- I-Disease 1 0.9886172413825989
Dreifuss I-Disease 1 0.9987261891365051
muscular I-Disease 0 0.0020324422512203455
dystrophy I-Disease 0 0.0014243784826248884
. O 0 1.361018604484343e-07

Emerin O 0 0.00020964027498848736
is O 0 1.3616905825131198e-08
a O 0 3.225525846417554e-09
nuclear O 0 8.56626769518698e-09
membrane O 0 3.0465940881185816e-09
protein O 0 1.6779136302602637e-08
which O 0 9.14104625326928e-10
is O 0 1.3937360987537062e-10
missing O 0 2.3280332328567965e-08
or O 0 9.70677760392391e-09
defective O 0 1.0629369171510916e-06
in O 0 3.715504570678263e-09
Emery B-Disease 1 0.9837132692337036
- I-Disease 1 0.9996601343154907
Dreifuss I-Disease 1 0.9999755620956421
muscular I-Disease 0 0.05146346613764763
dystrophy I-Disease 0 0.028685200959444046
( O 0 2.4957014943538525e-07
EDMD B-Disease 1 0.9999998807907104
) O 0 9.491424179941532e-08
. O 0 4.807745668244934e-08

It O 0 4.285904537937313e-07
is O 0 8.258751460488156e-10
one O 0 1.9601555101278478e-10
member O 0 6.079058090247003e-11
of O 0 4.590672460225154e-12
a O 0 4.899844419092858e-10
family O 0 5.84274539860985e-09
of O 0 3.937023207445378e-10
lamina O 0 1.0268075811836752e-06
- O 0 3.366099292634317e-07
associated O 0 2.1108062853159026e-08
proteins O 0 9.463992922675857e-10
which O 0 1.9860207922661743e-10
includes O 0 1.0149214801913331e-10
LAP1 O 0 5.86579460559733e-07
, O 0 5.776688016823073e-10
LAP2 O 0 1.0290377758792602e-06
and O 0 4.962344313241829e-09
lamin O 0 5.155863505024172e-07
B O 0 5.338789677011846e-08
receptor O 0 5.0518664806986635e-09
( O 0 7.910951005385414e-09
LBR O 0 7.186439688666724e-06
) O 0 8.566643394658513e-09
. O 0 3.6122333568755494e-08

A O 0 5.231964337326644e-07
panel O 0 6.73456241884196e-08
of O 0 2.2274558586499182e-10
16 O 0 2.0224442121019592e-09
monoclonal O 0 4.436304212873665e-09
antibodies O 0 8.89713369645051e-09
( O 0 1.3963018519191905e-09
mAbs O 0 4.939042597129628e-08
) O 0 1.4846158746806282e-09
has O 0 2.008800015218526e-09
been O 0 1.0167975350583447e-09
mapped O 0 8.187473810039592e-08
to O 0 1.3953114219589224e-09
six O 0 8.24319848491406e-11
specific O 0 1.3950359964431946e-11
sites O 0 5.447198248020868e-10
throughout O 0 1.3538112297872829e-10
the O 0 4.1440240128309824e-11
emerin O 0 6.535033403309853e-09
molecule O 0 2.1088203405739137e-10
using O 0 5.776997213935431e-10
phage O 0 3.179591478996713e-09
- O 0 1.6675247849207153e-09
displayed O 0 3.44500622473376e-10
peptide O 0 1.503680513437189e-10
libraries O 0 1.2933147608418238e-10
and O 0 3.8820224812496917e-10
has O 0 1.6567670846345806e-10
been O 0 7.957371567224314e-11
used O 0 1.5899701000243738e-10
to O 0 1.1042201597533108e-09
localize O 0 1.4983875189500395e-06
emerin O 0 1.2715537422991474e-06
in O 0 3.006622451007246e-10
human O 0 6.903788651868581e-10
and O 0 1.4020910654721774e-08
rabbit O 0 0.0005608123610727489
heart O 0 0.0001176012956420891
. O 0 1.3895521533413557e-07

Several O 0 7.990507810973213e-08
mAbs O 0 1.0529796554692439e-06
against O 0 1.6950092440737308e-09
different O 0 1.8682124736102423e-09
emerin O 0 9.163518370769452e-07
epitopes O 0 7.17374632586143e-07
did O 0 1.5597876767969865e-07
not O 0 1.2778796909529433e-09
recognize O 0 3.192365038984235e-09
intercalated O 0 3.4790013092589334e-09
discs O 0 1.8956167195938178e-06
in O 0 1.7052466105837993e-09
the O 0 1.2971940188677422e-09
heart O 0 2.486982339178212e-06
, O 0 3.2145812678407992e-09
though O 0 8.175030097312685e-10
they O 0 5.852836548747575e-10
recognized O 0 2.8783117556052673e-10
cardiomyocyte O 0 1.30952301446996e-07
nuclei O 0 1.448942565929201e-08
strongly O 0 7.642836585830537e-09
, O 0 1.780406932994083e-10
both O 0 9.779392573516787e-11
at O 0 1.4753851473869872e-09
the O 0 1.6221127774329602e-09
rim O 0 1.7803445189201739e-06
and O 0 5.590680363098954e-09
in O 0 2.4879226456775427e-10
intranuclear O 0 1.0495489277673187e-06
spots O 0 8.261947641585721e-07
or O 0 1.43574652611278e-07
channels O 0 3.611573220041464e-06
. O 0 8.362297165831478e-08

A O 0 2.1873640889680246e-06
polyclonal O 0 5.4521020501852036e-05
rabbit O 0 1.3044967090536375e-05
antiserum O 0 1.1107331374660134e-05
against O 0 2.4598737269343474e-08
emerin O 0 7.643016033398453e-06
did O 0 3.359095614996477e-07
recognize O 0 7.111783162372376e-09
both O 0 1.962830453727804e-10
nuclear O 0 3.3072740102113585e-09
membrane O 0 1.37608124894939e-09
and O 0 5.447218787146824e-10
intercalated O 0 1.468397514692299e-09
discs O 0 6.891769999128883e-07
but O 0 4.444381529467023e-10
, O 0 1.1026511301248654e-11
after O 0 1.8708350840723753e-11
affinity O 0 2.997471021393139e-11
purification O 0 8.658461447819121e-11
against O 0 6.264038766856661e-12
a O 0 8.555890024242174e-11
pure O 0 2.0832313651908407e-09
- O 0 2.500389939541492e-07
emerin O 0 6.234496368051623e-07
band O 0 8.396208173166997e-09
on O 0 4.391480512566659e-10
a O 0 2.703449131225e-10
western O 0 1.092355805809575e-08
blot O 0 0.00016378454165533185
, O 0 2.8029947252150578e-09
it O 0 4.7197916686059216e-09
stained O 0 1.5112992457488872e-07
only O 0 2.8776694915855217e-10
the O 0 1.1941009292470994e-10
nuclear O 0 1.068364952061529e-08
membrane O 0 1.2951995920218451e-08
. O 0 1.719310382952699e-08

These O 0 2.5024078809110506e-07
results O 0 3.424385113248718e-06
would O 0 4.0621856989275784e-09
not O 0 2.6132254693500556e-10
be O 0 2.6789800933180175e-10
expected O 0 9.734217876200546e-09
if O 0 7.811849500605206e-10
immunostaining O 0 4.694574329278112e-08
at O 0 9.255786692641266e-10
intercalated O 0 1.586187625690627e-09
discs O 0 1.842713686528441e-06
were O 0 1.1957933310213775e-08
due O 0 5.803447167274101e-10
to O 0 2.949864241763578e-10
a O 0 2.574271906752301e-10
product O 0 1.2358809975410168e-08
of O 0 4.3242583992741945e-12
the O 0 1.2880661814929084e-10
emerin O 0 8.156519015756203e-08
gene O 0 1.659282844457266e-08
and O 0 3.446374963189669e-09
, O 0 3.2163460783607434e-10
therefore O 0 7.375275945520343e-10
, O 0 1.979142266739231e-10
cast O 0 9.97393900803445e-09
some O 0 3.155964378720455e-11
doubt O 0 1.1808107269750678e-10
upon O 0 1.688595790971803e-11
the O 0 3.7009870862414473e-11
hypothesis O 0 2.255738928980122e-09
that O 0 1.4342917964427215e-09
cardiac B-Disease 0 4.14282112615183e-05
defects I-Disease 0 0.012988859787583351
in O 0 3.4650298630367615e-08
EDMD B-Disease 1 1.0
are O 0 9.128962830118326e-08
caused O 0 7.998647966189765e-09
by O 0 5.7207977938178445e-11
absence O 0 9.798011291195508e-10
of O 0 4.612405943293929e-11
emerin O 0 1.4727676216352847e-06
from O 0 1.02436392701577e-09
intercalated O 0 2.2873113181276494e-08
discs O 0 1.696322942734696e-05
. O 0 5.2275652251410065e-08

Although O 0 4.902065029455116e-07
emerin O 0 4.9512841542309616e-06
was O 0 9.90963755498342e-09
abundant O 0 7.479255548226149e-10
in O 0 7.952500463703771e-11
the O 0 2.10159667446419e-10
membranes O 0 5.921661827557045e-09
of O 0 9.134384221232139e-11
cardiomyocyte O 0 8.287286732411303e-07
nuclei O 0 3.462638176188193e-08
, O 0 1.6818217929426282e-09
it O 0 2.7110309552824674e-09
was O 0 8.32861157817888e-09
absent O 0 2.270445387253517e-09
from O 0 4.354378663196101e-11
many O 0 2.6374598685596773e-11
non O 0 8.621588776236422e-09
- O 0 3.4770101819958654e-07
myocyte O 0 1.4154259133647429e-06
cells O 0 1.0086143475973586e-07
in O 0 3.845543605773827e-10
the O 0 3.0492219860178693e-09
heart O 0 2.9334639748412883e-06
. O 0 1.0325231158958559e-07

This O 0 1.2209888211600628e-08
distribution O 0 5.39399724885925e-09
of O 0 2.2150423162337063e-10
emerin O 0 2.0467748527153162e-06
was O 0 5.056985497020605e-09
similar O 0 6.337674829381967e-11
to O 0 2.8495356074742517e-10
that O 0 2.700139417610714e-11
of O 0 7.82477121291647e-12
lamin O 0 3.876181509099297e-08
A O 0 1.8416294267353805e-08
, O 0 2.718402725143676e-10
a O 0 6.982904254826394e-10
candidate O 0 5.07536501714867e-09
gene O 0 2.353906847218923e-09
for O 0 5.391996224513029e-11
an O 0 4.3654413417471005e-10
autosomal O 0 0.0004368677327875048
form O 0 8.942014346757787e-07
of O 0 1.8916171029559337e-07
EDMD B-Disease 1 1.0
. O 0 1.1902840242328239e-06

In O 0 9.371402853730615e-08
contrast O 0 1.9909292348074814e-07
, O 0 2.924846320695451e-08
lamin O 0 7.238130638143048e-05
B1 O 0 2.635075361467898e-05
was O 0 3.999804576437782e-08
absent O 0 7.719237693493142e-09
from O 0 4.280695520275657e-10
cardiomyocyte O 0 1.7921841788393067e-07
nuclei O 0 2.6544512365944684e-08
, O 0 6.101736338415265e-10
showing O 0 1.9933320771770013e-08
that O 0 1.0031723229886325e-09
lamin O 0 1.5581181287416257e-06
B1 O 0 5.779183993581682e-07
is O 0 2.2731828919209107e-10
not O 0 4.102875331146727e-11
essential O 0 5.686507861812906e-11
for O 0 2.9244627552937885e-11
localization O 0 1.9772907755566393e-09
of O 0 5.8134150271449414e-11
emerin O 0 6.590047405552468e-07
to O 0 2.205726268300623e-09
the O 0 1.6405390379503615e-09
nuclear O 0 3.894983819918707e-07
lamina O 0 7.849298526707571e-07
. O 0 3.2961288809474354e-08

Lamin O 0 0.20967376232147217
B1 O 0 0.007454741280525923
is O 0 1.5404280873099196e-07
also O 0 2.4415268029542858e-08
almost O 0 1.7565712440159587e-08
completely O 0 1.2658222203754121e-06
absent O 0 1.6443750894268305e-07
from O 0 4.101181172444512e-09
skeletal O 0 3.7279935440892586e-06
muscle O 0 1.1483806474643643e-06
nuclei O 0 1.048047579388367e-06
. O 0 6.855598400079543e-08

In O 0 4.721585810329998e-06
EDMD B-Disease 1 0.9999998807907104
, O 0 1.2509167035545943e-08
the O 0 2.1106673353532557e-10
additional O 0 4.440746381728644e-10
absence O 0 1.3707190937850555e-09
of O 0 2.3463661569245176e-10
lamin O 0 1.5342573533416726e-05
B1 O 0 1.4315329281089362e-05
from O 0 9.133522382853698e-09
heart O 0 1.4562231172021711e-06
and O 0 2.129838172493237e-08
skeletal O 0 4.285784143576166e-06
muscle O 0 4.445751073944848e-07
nuclei O 0 3.912615298418132e-08
which O 0 2.638831153589649e-09
already O 0 1.3188746983416877e-08
lack O 0 5.562628691002658e-10
emerin O 0 4.5150119376557996e-07
may O 0 4.988593538257646e-09
offer O 0 2.9004770807361524e-10
an O 0 8.915552324184617e-12
alternative O 0 7.37834293662587e-10
explanation O 0 6.313270461966169e-10
of O 0 2.1209003303601648e-11
why O 0 1.246224567985621e-09
these O 0 8.395686923456935e-11
tissues O 0 1.578191444195909e-08
are O 0 2.346594307756078e-10
particularly O 0 2.626377171299765e-10
affected O 0 6.471031266386262e-09
. O 0 1.5827454902250793e-09
. O 0 1.9921763794172875e-08

Genetic O 0 1.968824290088378e-05
mapping O 0 7.169628588599153e-07
of O 0 7.924840783601894e-10
the O 0 4.47352110910515e-09
copper B-Disease 0 1.18512516564806e-05
toxicosis I-Disease 0 1.598566450411454e-05
locus O 0 8.802242490446588e-08
in O 0 2.388846676026901e-09
Bedlington O 0 3.7174565932218684e-06
terriers O 0 1.582453478476964e-05
to O 0 4.707889900146256e-08
dog O 0 2.98837016998732e-06
chromosome O 0 5.1795646868413314e-05
10 O 0 3.273848392382206e-08
, O 0 1.4334460007869865e-10
in O 0 4.5134725817908006e-11
a O 0 7.794158207730106e-09
region O 0 8.932452146837022e-06
syntenic O 0 0.00012683241220656782
to O 0 1.5778242712372048e-08
human O 0 2.4250865759967155e-09
chromosome O 0 3.3390489988960326e-05
region O 0 1.0458526048751082e-05
2p13 O 0 6.913170182087924e-06
- O 0 5.029515250498662e-06
p16 O 0 3.6799892768613063e-06
. O 0 8.790498640109945e-08

Abnormal O 1 0.9993547797203064
hepatic B-Disease 1 0.9998996257781982
copper I-Disease 0 0.0007892576977610588
accumulation I-Disease 0 2.3909278752398677e-06
is O 0 2.358414352698901e-09
recognized O 0 1.1887204554028585e-09
as O 0 2.9683782098999245e-09
an O 0 1.7546599906381743e-07
inherited B-Disease 1 1.0
disorder I-Disease 1 1.0
in O 0 3.974584217303345e-09
man O 0 7.688925620641385e-07
, O 0 1.0857663657048988e-09
mouse O 0 2.782975059290038e-07
, O 0 9.386569743696782e-09
rat O 0 0.00017591541109140962
and O 0 4.978957335310952e-08
dog O 0 3.872955494443886e-05
. O 0 9.886853291618536e-08

The O 0 1.9006508367169772e-08
major O 0 3.161011363772559e-08
cause O 0 3.260668179905224e-08
of O 0 8.134062312592505e-10
hepatic B-Disease 0 0.4689413905143738
copper I-Disease 0 0.00026459709624759853
accumulation I-Disease 0 1.076594230653427e-06
in O 0 1.483426936843557e-09
man O 0 8.177049437563255e-08
is O 0 1.820578132694095e-10
a O 0 1.00526009738644e-09
dysfunctional O 0 2.146543351955188e-07
ATP7B O 0 4.339521638030419e-06
gene O 0 4.1801902739280195e-07
, O 0 2.480115890435286e-09
causing O 0 5.476693331729621e-06
Wilson B-Disease 0 1.538147080282215e-05
disease I-Disease 0 3.177775215590373e-05
( O 0 2.0453175153534175e-08
WD B-Disease 0 0.0031161161605268717
) O 0 4.029022804274973e-08
. O 0 4.549200127712538e-08

Mutations O 0 0.00017205219774041325
in O 0 1.633875967854692e-08
the O 0 2.2903048346734067e-09
ATP7B O 0 1.134503872890491e-05
genes O 0 1.4649634749730467e-07
have O 0 8.616295232855009e-09
also O 0 1.6257120094564925e-09
been O 0 4.351690952031362e-10
demonstrated O 0 1.1895863460953393e-10
in O 0 3.1579152487415385e-11
mouse O 0 1.6837299199323752e-07
and O 0 4.9571912796864126e-08
rat O 0 0.00011913951311726123
. O 0 1.4521734215122706e-07

The O 0 8.417922714443193e-08
ATP7B O 0 1.1645882295852061e-05
gene O 0 1.0121195828105556e-06
has O 0 4.520920970918496e-09
been O 0 1.5723795598887591e-09
excluded O 0 8.286368924359522e-09
in O 0 3.366754791622739e-11
the O 0 5.022730495407579e-11
much O 0 2.806315457792863e-10
rarer O 0 3.357448719043532e-08
human O 0 7.552123371112884e-09
copper B-Disease 0 7.912211731309071e-05
overload I-Disease 0 0.00036078772973269224
disease O 0 9.784015855984762e-05
non B-Disease 0 1.072638866617126e-07
- I-Disease 0 4.611331405612873e-06
Indian I-Disease 0 1.5399140806948708e-07
childhood I-Disease 0 1.3410854080575518e-05
cirrhosis I-Disease 0 0.0276951864361763
, O 0 3.5825695743341157e-09
indicating O 0 2.051465770591676e-07
genetic O 0 2.292881845278316e-06
heterogeneity O 0 1.4193014976626728e-05
. O 0 3.4171549145867175e-07

By O 0 1.9338617818220882e-08
investigating O 0 4.966996414168534e-08
the O 0 1.7541631480710862e-09
common O 0 1.1840464964052444e-07
autosomal O 1 0.9926046133041382
recessive O 1 0.9983888864517212
copper B-Disease 0 0.004460218828171492
toxicosis I-Disease 1 0.5203406810760498
( O 0 1.907879294549275e-07
CT B-Disease 1 0.995262861251831
) O 0 6.2920681997979955e-09
in O 0 1.0600867961230165e-09
Bedlington O 0 1.6433605196652934e-05
terriers O 0 0.00028013187693431973
, O 0 4.3273939098753544e-08
we O 0 4.972918521417569e-09
have O 0 5.35885884278553e-11
identified O 0 1.722581244312238e-10
a O 0 6.626704740497757e-11
new O 0 6.242599770445167e-10
locus O 0 7.312892336130972e-08
involved O 0 1.1894173645998762e-08
in O 0 7.684484160108696e-08
progressive O 1 0.7109786868095398
liver B-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 1.2407447513851366e-07

We O 0 1.2032952554363874e-06
examined O 0 5.3792259535612175e-08
whether O 0 2.2170469904381207e-09
the O 0 5.388174351139696e-10
WD B-Disease 0 5.564497769228183e-05
gene O 0 1.6614592368568992e-07
ATP7B O 0 3.1718843729322543e-06
was O 0 3.20958815080985e-09
also O 0 6.921268419501914e-11
causative O 0 1.2187777453931403e-09
for O 0 6.208967368026563e-11
CT B-Disease 0 0.035619523376226425
by O 0 2.2342895589222422e-10
investigating O 0 4.662829677926084e-09
the O 0 1.3226907347174688e-09
chromosomal O 0 7.481103966711089e-05
co O 0 3.107395286860992e-06
- O 0 2.6489695414966263e-07
localization O 0 9.666080558190515e-08
of O 0 3.434528772494616e-10
ATP7B O 0 5.732467343477765e-06
and O 0 8.932974360220669e-10
C04107 O 0 1.7134822449804687e-09
, O 0 1.322520305074848e-11
using O 0 9.761930153118215e-11
fluorescence O 0 1.492901802180313e-09
in O 0 1.5126438990265e-10
situ O 0 1.880149191890723e-08
hybridization O 0 4.424051791573902e-09
( O 0 3.818514671127815e-10
FISH O 0 1.3006861365738587e-07
) O 0 4.3624468482050816e-09
. O 0 1.1976970526461628e-08

C04107 O 0 2.2481655832962133e-05
is O 0 1.3317158931158701e-08
an O 0 4.98691699046816e-10
anonymous O 0 4.57733904113411e-08
microsatellite O 0 3.1832209970161784e-06
marker O 0 6.373289579642005e-06
closely O 0 9.716050044517033e-07
linked O 0 1.8199005353380926e-05
to O 0 3.945590094645013e-07
CT B-Disease 1 0.9998406171798706
. O 0 3.031692870081315e-07

However O 0 8.363244319298246e-07
, O 0 2.184925129711246e-08
BAC O 0 1.0179137461818755e-05
clones O 0 1.536853574179986e-06
containing O 0 1.000165728015645e-08
ATP7B O 0 3.7914376207481837e-06
and O 0 9.693674751787285e-10
C04107 O 0 1.8962984071890787e-08
mapped O 0 2.3084064082468103e-07
to O 0 1.18292575734813e-09
the O 0 4.3700146279412877e-10
canine O 0 1.8539793700256268e-07
chromosome O 0 0.00012988175149075687
regions O 0 6.3651259551988915e-06
CFA22q11 O 0 8.060163963818923e-05
and O 0 2.3157305406584783e-08
CFA10q26 O 0 1.3510804137695231e-06
, O 0 4.59800281182865e-10
respectively O 0 1.0385507565047192e-08
, O 0 1.4223587585515673e-10
demonstrating O 0 7.953900316159945e-10
that O 0 6.147481967921919e-10
WD B-Disease 0 0.0001419823383912444
cannot O 0 5.825489424182706e-08
be O 0 2.286523886896319e-10
homologous O 0 7.098042154041195e-09
to O 0 4.036022005493578e-08
CT B-Disease 1 0.9927657842636108
. O 0 1.45147836860815e-07

The O 0 9.729340177955237e-08
copper O 0 5.59678539957531e-07
transport O 0 2.2791459386439783e-08
genes O 0 5.393588509150504e-08
CTR1 O 0 1.0918331099674106e-05
and O 0 2.0757321195219447e-08
CTR2 O 0 3.45480912073981e-05
were O 0 1.6800015600892948e-08
also O 0 1.4054774011285076e-09
excluded O 0 2.9727917905120194e-09
as O 0 8.7287670147429e-11
candidate O 0 6.466499558044347e-10
genes O 0 6.130293495054673e-10
for O 0 6.164624921645157e-10
CT B-Disease 1 0.9989155530929565
since O 0 1.0729396393571733e-07
they O 0 4.006376563836511e-09
both O 0 5.603905117723684e-10
mapped O 0 1.257102894669515e-06
to O 0 4.697145072896092e-08
canine O 0 2.6499621981201926e-06
chromosome O 0 0.00033588765654712915
region O 0 9.112263796851039e-05
CFA11q22 O 0 0.0007547803106717765
. O 0 3.7331020052988606e-07

2 O 0 2.8874867439299123e-06
- O 0 5.843826147611253e-05
22 O 0 7.329858817683998e-07
. O 0 1.1808078426156499e-07

5 O 0 8.587367119616829e-06
. O 0 1.3600912325273384e-06

A O 0 2.976124733322649e-07
transcribed O 0 1.0049099046227639e-06
sequence O 0 4.6868532166399746e-08
identified O 0 2.8785672512299243e-08
from O 0 4.862261149263247e-10
the O 0 2.085858569200738e-10
C04107 O 0 1.3140743249095976e-07
- O 0 1.0812084383360343e-07
containing O 0 1.8748993468875597e-08
BAC O 0 1.4050504432816524e-05
was O 0 1.5161692346055133e-08
found O 0 4.404423492587739e-10
to O 0 9.216954283131074e-11
be O 0 1.583048796216513e-11
homologous O 0 1.0687123408459342e-10
to O 0 1.5959433774526133e-10
a O 0 1.2632395129941187e-10
gene O 0 5.966034333226844e-09
expressed O 0 1.1169566660473862e-10
from O 0 4.3958024720236466e-11
human O 0 2.336429383298366e-10
chromosome O 0 2.0240408957761247e-06
2p13 O 0 2.9405933332782297e-07
- O 0 1.4665850756045984e-07
p16 O 0 3.5156176636519376e-08
, O 0 3.5413361132441423e-10
a O 0 8.870458811927051e-10
region O 0 1.0969328201326789e-07
devoid O 0 4.04653590635462e-08
of O 0 7.222213799229493e-11
any O 0 7.880135433069313e-10
positional O 0 2.465779118665523e-07
candidate O 0 1.9824639707621827e-07
genes O 0 2.2048193670798355e-07
. O 0 7.959128822676576e-08

Molecular O 0 5.215932219471142e-07
analysis O 0 2.5530189518008228e-08
of O 0 1.7563081544658132e-10
the O 0 3.065595277629285e-10
APC B-Disease 0 1.170921315463147e-08
gene O 0 2.168673685076783e-09
in O 0 5.5214537802994457e-11
205 O 0 4.143583254290206e-10
families O 0 3.2367405977673513e-10
: O 0 5.529550706206976e-10
extended O 0 1.778881220104722e-08
genotype O 0 6.073450094845612e-06
- O 0 1.9406404589972226e-06
phenotype O 0 4.638067821360892e-06
correlations O 0 7.115218636499776e-08
in O 0 5.084372922681268e-10
FAP B-Disease 0 2.721662228921673e-09
and O 0 3.286445560135576e-10
evidence O 0 6.023782861408478e-11
for O 0 5.6909971526963865e-12
the O 0 8.850405651406046e-12
role O 0 1.657405601651618e-10
of O 0 8.318946226326673e-12
APC B-Disease 0 5.3889377404914285e-09
amino O 0 6.492167914373681e-10
acid O 0 1.0703944397505438e-08
changes O 0 1.1926045040411282e-08
in O 0 4.444133537617745e-06
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
predisposition O 0 0.0008122854051180184
. O 0 2.2451943948453845e-07

BACKGROUND O 0 0.00012480180885177106
/ O 0 0.0001815890718717128
AIMS O 0 2.8777333227480995e-07
The O 0 3.490286726304248e-09
development O 0 1.9188123090430054e-08
of O 0 1.2530952517408878e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 8.192297507036983e-09
a O 0 9.67130930895621e-10
variable O 0 3.5858459312976265e-08
range O 0 2.2583231285011607e-08
of O 0 1.3209787708134968e-09
extracolonic O 0 0.0027567960787564516
manifestations O 0 5.126170799485408e-05
in O 0 3.0147909910738235e-06
familial B-Disease 1 1.0
adenomatous I-Disease 1 0.9999998807907104
polyposis I-Disease 1 1.0
( O 0 1.4572828149539419e-05
FAP B-Disease 0 9.335968798040994e-07
) O 0 8.270451878900076e-09
is O 0 4.491216010205079e-10
the O 0 1.5564896593822652e-10
result O 0 1.262074444952077e-09
of O 0 1.4035204422280234e-11
the O 0 1.9823129804308337e-09
dominant O 0 2.3932681870064698e-05
inheritance O 0 9.593376307748258e-05
of O 0 9.272266652260441e-06
adenomatous B-Disease 1 1.0
polyposis I-Disease 1 0.9999994039535522
coli I-Disease 1 1.0
( O 0 8.485901616950287e-07
APC B-Disease 0 3.4072893413394922e-06
) O 0 8.844091681226018e-09
gene O 0 1.4173359659253038e-06
mutations O 0 3.7829824577784166e-05
. O 0 1.227719508278824e-07

In O 0 7.26796471894886e-08
this O 0 1.9672579121277067e-09
study O 0 1.3006823396111145e-09
, O 0 1.9859373867614494e-10
direct O 0 8.606206303163333e-10
mutation O 0 1.1376677377938904e-08
analysis O 0 1.0025698049531684e-09
of O 0 3.754468264061117e-11
the O 0 7.142665348069954e-10
APC B-Disease 0 2.7295030236018647e-08
gene O 0 7.622294795339712e-09
was O 0 1.8033750048829233e-09
performed O 0 6.771681881900804e-09
to O 0 8.10244316085118e-10
determine O 0 1.556856510376292e-08
genotype O 0 4.733163677883567e-06
- O 0 3.664802989078453e-06
phenotype O 0 5.768326445831917e-06
correlations O 0 1.17158293733155e-07
for O 0 3.3373340202480506e-10
nine O 0 5.206427733384089e-09
extracolonic O 0 6.773511813662481e-07
manifestations O 0 1.2420511730226735e-08
and O 0 4.350446114465001e-10
to O 0 2.0055947180797062e-10
investigate O 0 8.336203949355081e-10
the O 0 1.3539300236509177e-10
incidence O 0 2.6005093189951367e-08
of O 0 9.414279772412826e-11
APC B-Disease 0 1.1011903922053534e-07
mutations O 0 2.0651526710935286e-08
in O 0 2.985273972466729e-10
non O 0 8.896057806850877e-06
- O 1 0.9999102354049683
FAP O 1 0.9999220371246338
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 7.387565688077302e-07

METHODS O 0 7.753865247650538e-07
The O 0 5.374853895290244e-09
APC B-Disease 0 2.6114400952792494e-07
gene O 0 6.607341163089586e-08
was O 0 4.351850879658059e-09
analysed O 0 9.51547463046154e-09
in O 0 9.742399942336277e-11
190 O 0 6.186557377496626e-10
unrelated O 0 2.218544459253735e-09
FAP B-Disease 0 6.95061785904727e-09
and O 0 4.737322201187055e-10
15 O 0 3.7036105293708488e-09
non O 0 6.76115359965479e-06
- O 1 0.9999011754989624
FAP O 1 0.9998645782470703
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 1.9989627162431134e-06
using O 0 4.77106620877521e-09
denaturing O 0 1.8931881641037762e-05
gradient O 0 4.554402039502747e-06
gel O 0 2.7424315703683533e-05
electrophoresis O 0 2.5635372935539635e-07
, O 0 2.4414220645141427e-10
the O 0 2.6705760866607697e-11
protein O 0 6.730601631588229e-10
truncation O 0 9.733516037613299e-08
test O 0 3.422164995825483e-09
, O 0 2.5914739104626605e-11
and O 0 5.922592971607799e-11
direct O 0 1.4822504335043618e-09
sequencing O 0 2.1209567080404668e-07
. O 0 4.2496399288438624e-08

RESULTS O 0 0.000283478235360235
Chain O 0 1.2947302820975892e-05
terminating O 0 3.4674344533414114e-06
signals O 0 1.1642567869785125e-06
were O 0 2.4626749528522396e-09
only O 0 1.6027308646915372e-10
identified O 0 5.9624962744919685e-09
in O 0 2.2921654851959516e-10
patients O 0 6.517205108913515e-10
belonging O 0 2.842283353121644e-10
to O 0 8.246882621243401e-10
the O 0 5.611563436147549e-10
FAP B-Disease 0 1.3299517043208198e-08
group O 0 1.2162332474474624e-08
( O 0 1.11102647915029e-10
105 O 0 1.8207596541586213e-09
patients O 0 6.327958157470448e-09
) O 0 6.686737830108314e-10
. O 0 2.7644919242675314e-08

Amino O 0 7.827642889424169e-07
acid O 0 5.812680683447979e-07
changes O 0 5.775060873958182e-09
were O 0 1.803019678003892e-10
identified O 0 8.00273292078657e-10
in O 0 1.0520813387149275e-10
four O 0 3.457765851422323e-09
patients O 0 2.4679884802480956e-09
, O 0 2.2391432458190863e-11
three O 0 8.808476864574644e-11
of O 0 2.6811716041796885e-11
whom O 0 1.571340035866342e-08
belonged O 0 4.737207071059402e-09
to O 0 4.815183252127042e-10
the O 0 1.7466868229565335e-10
non O 0 1.4895179312190976e-08
- O 0 8.842558827382163e-07
FAP O 0 7.552429792667681e-08
group O 0 3.3077189982577693e-06
of O 0 4.347877165855607e-06
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 2.1485522665898316e-05
. O 0 2.6195957403274406e-08

Genotype O 0 0.23017618060112
- O 0 0.0017416003393009305
phenotype O 0 0.0008344857487827539
correlations O 0 1.5958232324919663e-05
identified O 0 5.906993578719266e-07
significant O 0 8.946261509379383e-09
differences O 0 4.139337406172672e-08
in O 0 5.950995807246784e-10
the O 0 1.93176585838728e-10
nature O 0 1.0792295945805108e-09
of O 0 3.6894706040291325e-11
certain O 0 6.693679499569782e-10
extracolonic O 0 4.384205112728523e-06
manifestations O 0 2.2672010047131153e-08
in O 0 2.137438004368164e-10
FAP B-Disease 0 2.055732650774189e-08
patients O 0 7.566007376169637e-09
belonging O 0 9.152805180434598e-10
to O 0 4.371925932389331e-09
three O 0 1.2654353120922224e-08
mutation O 0 1.5077248463057913e-06
subgroups O 0 5.141185738466447e-06
. O 0 1.0631655555926045e-07

CONCLUSIONS O 0 2.2577587515115738e-05
Extended O 0 6.30990541594656e-07
genotype O 0 3.6906687455484644e-05
- O 0 1.6896226952667348e-05
phenotype O 0 3.932165782316588e-05
correlations O 0 7.945308766466042e-07
made O 0 1.1742717020979399e-08
in O 0 1.848719094477147e-10
this O 0 2.3291057971164264e-10
study O 0 5.065314279129041e-10
may O 0 2.853182401452159e-08
have O 0 2.0447381288146715e-10
the O 0 4.052368857143662e-11
potential O 0 1.81794787557088e-10
to O 0 3.622745436970831e-10
determine O 0 5.017218307479254e-10
the O 0 1.3186162231559884e-11
most O 0 9.182626881099054e-12
appropriate O 0 4.0582318755477687e-11
surveillance O 0 3.516709146111907e-09
and O 0 2.6859842128246214e-10
prophylactic O 0 9.358432251360682e-09
treatment O 0 1.800199433965588e-09
regimens O 0 1.7975163579819764e-09
for O 0 7.171876287292989e-11
those O 0 8.00480903784262e-10
patients O 0 1.787839987166251e-09
with O 0 1.6873411001760985e-10
mutations O 0 2.181107561227691e-07
associated O 0 8.882127922049676e-09
with O 0 1.127284576796228e-08
life O 0 6.8875515353283845e-06
threatening O 1 0.7503935694694519
conditions O 0 2.16529551835265e-05
. O 0 5.852886886259512e-08

This O 0 4.209786652609182e-08
study O 0 6.7456547014899115e-09
also O 0 7.592502182518501e-10
provided O 0 2.0805104861132406e-10
evidence O 0 1.4956656746445418e-10
for O 0 1.6212697850903623e-11
the O 0 8.82024522863567e-11
pathological O 0 1.0154165153153372e-07
nature O 0 4.64956823043039e-10
of O 0 2.804842642867289e-11
amino O 0 3.010135474212916e-09
acid O 0 7.4045556353041775e-09
changes O 0 2.607758176065289e-10
in O 0 2.8753307027007402e-11
APC O 0 5.2148352303049705e-09
associated O 0 2.572426438529618e-10
with O 0 1.757946045677361e-11
both O 0 2.0709491066472907e-10
FAP B-Disease 0 1.6209321884730343e-08
and O 0 6.648322337099444e-09
non O 0 1.3329249668458942e-05
- O 1 0.9999668598175049
FAP O 1 0.9998840093612671
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 5.143574162502773e-05
. O 0 2.5332609343564627e-09
. O 0 4.001803688424843e-08

Inherited B-Disease 1 0.9999959468841553
colorectal I-Disease 1 1.0
polyposis I-Disease 1 0.9999983310699463
and O 0 0.0066581773571670055
cancer B-Disease 0 0.14715372025966644
risk O 0 5.809061804029625e-06
of O 0 1.1533544119757266e-09
the O 0 6.8945551490173784e-09
APC O 0 4.7720427573949564e-06
I1307K O 0 9.166245718006394e-07
polymorphism O 0 1.0444067584103323e-06
. O 0 9.600869788073396e-08

Germ O 0 0.0006551554542966187
- O 0 6.893285171827301e-05
line O 0 1.1837436431960668e-05
and O 0 2.355263095665805e-09
somatic O 0 7.620409547826057e-08
truncating O 0 5.282230404191068e-07
mutations O 0 5.084330041427165e-07
of O 0 3.928642133832483e-11
the O 0 1.618489925414579e-10
APC B-Disease 0 2.846453028837459e-08
gene O 0 1.680309225093879e-08
are O 0 1.4906446910156745e-10
thought O 0 2.336929760815565e-09
to O 0 2.665008302926708e-08
initiate O 0 3.714927515829913e-05
colorectal B-Disease 1 1.0
tumor I-Disease 0 0.002808189485222101
formation O 0 1.5605926364514744e-06
in O 0 1.0151711649086792e-05
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
syndrome I-Disease 1 1.0
and O 0 0.0002155967813450843
sporadic O 1 0.9618308544158936
colorectal O 1 1.0
carcinogenesis O 0 0.4252875745296478
, O 0 9.811725476538413e-07
respectively O 0 5.652686013490893e-06
. O 0 9.984620419345447e-08

Recently O 0 5.974890427751234e-06
, O 0 1.0474590972364695e-08
an O 0 1.164768392847293e-09
isoleucine O 0 0.02792343683540821
- O 0 1.6410536773037165e-05
- O 0 1.921341936395038e-05
> O 0 3.8052789363973716e-08
lysine O 0 3.7172469546931097e-07
polymorphism O 0 2.4641797935487375e-08
at O 0 1.0695536900584557e-08
codon O 0 2.7903763566428097e-07
1307 O 0 3.640668921889301e-08
( O 0 3.4727609676821203e-10
I1307K O 0 5.232291044876547e-09
) O 0 3.012866692242433e-11
of O 0 4.401085398897386e-12
the O 0 1.3543897947609906e-10
APC B-Disease 0 4.121029917314445e-08
gene O 0 6.911038852308593e-09
has O 0 2.75030498375628e-10
been O 0 7.317779715521056e-11
identified O 0 4.2257430887815417e-10
in O 0 1.6579199818567147e-11
6 O 0 4.0875672291385e-10
% O 0 8.984075983153872e-11
- O 0 1.1963363633071822e-08
7 O 0 2.592852332838902e-08
% O 0 2.3101695556526636e-10
of O 0 9.841942365251821e-12
the O 0 5.881327647117018e-10
Ashkenazi O 0 2.3759592693295417e-07
Jewish O 0 1.634717428089516e-08
population O 0 8.831062103809018e-09
. O 0 2.0158941183012757e-08

To O 0 1.0808244041982107e-06
assess O 0 7.832593951206945e-07
the O 0 1.5571168798800272e-09
risk O 0 6.290532095221124e-09
of O 0 1.1373861054375656e-11
this O 0 1.0573217301690363e-10
common O 0 3.314371666007787e-09
APC B-Disease 0 1.0801880989674828e-07
allelic O 0 9.474512552287706e-08
variant O 0 2.341148046980379e-06
in O 0 2.645187748839817e-07
colorectal O 1 1.0
carcinogenesis O 0 0.002263730624690652
, O 0 3.2528916449336975e-07
we O 0 3.3202702809376206e-08
have O 0 1.771903734848479e-10
analyzed O 0 7.662537826469418e-10
a O 0 5.556115290072938e-11
large O 0 2.525463727032218e-10
cohort O 0 1.1884898398761834e-08
of O 0 1.1365843682886734e-10
unselected O 0 1.7009422208502656e-06
Ashkenazi O 0 1.0591616046440322e-06
Jewish O 0 1.183829301254491e-08
subjects O 0 1.0611331369148047e-08
with O 0 4.503158290702913e-09
adenomatous B-Disease 0 0.0001316744601354003
polyps I-Disease 0 0.010836577974259853
and O 0 2.08301059956284e-07
. O 0 8.836337315187848e-07
or O 1 0.999995231628418
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, I-Disease 0 3.0255562499803546e-09
for O 0 9.550484708631402e-11
the O 0 8.593559752689828e-10
APC O 0 6.745257792317716e-07
I1307K O 0 1.5630278937805997e-07
polymorphism O 0 2.1684768114482722e-07
. O 0 8.853378119511035e-08

The O 0 1.4737720732682646e-07
APC O 0 1.5754130799905397e-06
I1307K O 0 4.479679773794487e-07
allele O 0 7.509651709369791e-07
was O 0 8.150450092614392e-09
identified O 0 4.917983353891486e-09
in O 0 2.79700124172777e-10
48 O 0 2.4223592021144214e-09
( O 0 8.999906375706246e-11
10 O 0 1.4495657452151534e-10
. O 0 1.6942931432839536e-11
1 O 0 2.7259053347883366e-10
% O 0 1.564361834516248e-10
) O 0 3.9639964921622806e-11
of O 0 3.06170783170856e-11
476 O 0 1.1635609808990921e-08
patients O 0 5.141721715062886e-08
. O 0 6.564590648849844e-09

Compared O 0 3.1253218821802875e-06
with O 0 5.264522151549045e-10
the O 0 2.0470325434729375e-10
frequency O 0 2.095234918897404e-08
in O 0 3.0274652229600463e-10
two O 0 1.2017971062761035e-09
separate O 0 1.0792012616889224e-08
population O 0 4.4549139377458857e-10
control O 0 5.63707613920883e-09
groups O 0 4.202431458377731e-11
, O 0 7.453376110744259e-11
the O 0 9.212701435057369e-11
APC O 0 2.572380175536182e-08
I1307K O 0 3.4379974422904525e-09
allele O 0 8.97153373813353e-09
is O 0 9.970771430722891e-11
associated O 0 1.795651266567333e-10
with O 0 6.175825822962722e-11
an O 0 2.1430182628456862e-10
estimated O 0 5.158017657436176e-08
relative O 0 1.7399585772182036e-08
risk O 0 4.938110365060311e-08
of O 0 2.0558285629412865e-10
1 O 0 1.2256300863100478e-07
. O 0 9.095453634699879e-08

5 O 0 6.595001309506188e-07
- O 0 4.328973318479257e-06
1 O 0 2.026774836849654e-07
. O 0 8.13748357586519e-08

7 O 0 2.452789522067178e-05
for O 0 2.1761013613286195e-06
colorectal B-Disease 1 1.0
neoplasia I-Disease 0 0.0015935114352032542
( O 0 2.741752780366369e-07
both O 0 6.938381602594745e-08
P O 0 0.08706005662679672
= O 0 4.625037945515942e-06
. O 0 1.9835393771927556e-08
01 O 0 6.32824992408132e-08
) O 0 1.992441323039884e-09
. O 0 1.1499217578148091e-08

Furthermore O 0 1.5888491589066689e-06
, O 0 4.937457553921831e-09
compared O 0 8.228770553841969e-09
with O 0 2.947266042330199e-10
noncarriers O 0 1.4121279718892765e-06
, O 0 1.4735599407345035e-09
APC O 0 2.025842604780337e-08
I1307K O 0 1.1588236148440956e-08
carriers O 0 4.440757095380832e-09
had O 0 1.2775458468894385e-09
increased O 0 4.0468714490593527e-10
numbers O 0 2.9488531616550517e-09
of O 0 9.299956360564465e-10
adenomas B-Disease 1 0.8517537117004395
and O 0 0.35680925846099854
colorectal B-Disease 1 1.0
cancers I-Disease 1 0.9973951578140259
per O 0 6.433586804632796e-06
patient O 0 3.533874632921652e-06
( O 0 6.139329933319004e-09
P O 0 0.014302423223853111
= O 0 2.174176415792317e-06
. O 0 7.946398206115646e-09
03 O 0 6.767523874628978e-09
) O 0 5.880337883290565e-11
, O 0 4.954291490943952e-11
as O 0 5.406918662798077e-11
well O 0 2.5248469981420385e-10
as O 0 2.0886492535510115e-10
a O 0 1.7934479457082375e-09
younger O 0 9.311248660992533e-09
age O 0 1.3963123990379245e-09
at O 0 1.4904415479577438e-08
diagnosis O 0 3.053162799915299e-06
. O 0 5.95902029942863e-08

We O 0 3.4649158351385267e-06
conclude O 0 1.0242690962058987e-07
that O 0 2.614202465611726e-10
the O 0 1.1446993353203538e-10
APC O 0 3.334181286618332e-08
I1307K O 0 1.6746779962772962e-08
variant O 0 4.2331123495387146e-08
leads O 0 2.7142709413396915e-08
to O 0 7.635915011405814e-09
increased O 0 2.2008026689945837e-07
adenoma B-Disease 1 0.9999998807907104
formation O 0 1.3652851293954882e-07
and O 0 2.972831536496301e-09
directly O 0 9.718722493445853e-10
contributes O 0 2.6371205219533067e-09
to O 0 2.9981472859930136e-10
3 O 0 3.8228287202457523e-10
% O 0 3.4118918801340214e-10
- O 0 5.740040442958616e-09
4 O 0 6.965349186316416e-09
% O 0 1.6373902234079196e-10
of O 0 1.5782189791146983e-11
all O 0 1.2128603010808092e-08
Ashkenazi O 0 0.0010277384426444769
Jewish O 0 0.16463631391525269
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 3.573795197553409e-07

The O 0 2.0007252743425852e-08
estimated O 0 7.794830025886768e-08
relative O 0 3.084037203393564e-08
risk O 0 9.38589295174097e-08
for O 0 8.079294455676234e-10
carriers O 0 7.146773839394882e-08
may O 0 2.959944289671057e-08
justify O 0 4.044419910087527e-09
specific O 0 3.087635980225656e-10
clinical O 0 6.159852627973805e-10
screening O 0 8.896111070022528e-10
for O 0 2.559006652413931e-11
the O 0 5.714690873293016e-11
360 O 0 1.0451461918137284e-08
, O 0 7.57865228906418e-11
000 O 0 7.232814347446492e-11
Americans O 0 3.3081681838353916e-10
expected O 0 6.65206423278164e-09
to O 0 8.343903901142369e-10
harbor O 0 5.591717666675322e-08
this O 0 1.2096385004767285e-10
allele O 0 3.082237753915251e-08
, O 0 5.905450572996074e-10
and O 0 1.5937076658367744e-10
genetic O 0 1.151363115958759e-09
testing O 0 2.1216418899516754e-10
in O 0 2.696782250635743e-12
the O 0 1.9159313024985636e-11
setting O 0 2.3507031876590645e-09
of O 0 4.275919895935232e-11
long O 0 6.796836871103551e-09
- O 0 1.4660106444353005e-06
term O 0 4.626929523965373e-07
- O 0 7.014332936705614e-07
outcome O 0 4.4562614220922114e-07
studies O 0 1.1345164807607944e-09
may O 0 2.338344451402463e-08
impact O 0 5.226156840620888e-09
significantly O 0 4.375030766823329e-05
on O 1 0.9999890327453613
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
prevention O 0 4.112839491199338e-08
in O 0 1.2790128678386026e-10
this O 0 3.975249296406247e-10
population O 0 3.159605022062806e-09
. O 0 4.014417953612792e-08

Localization O 0 5.2209866225894075e-06
of O 0 5.3346136397181e-09
human O 0 4.544098430869781e-09
BRCA1 O 0 1.298771280744404e-06
and O 0 1.883875277997049e-08
its O 0 1.5025037214400072e-08
loss O 0 1.0687362816952373e-07
in O 0 9.548517532209644e-11
high O 0 3.698302331045511e-09
- O 0 6.134662271506386e-07
grade O 0 4.233377239870606e-06
, O 0 6.199825985930829e-09
non B-Disease 0 1.1972331321885576e-06
- I-Disease 0 0.03208265081048012
inherited I-Disease 1 0.980465292930603
breast I-Disease 1 0.9999849796295166
carcinomas I-Disease 1 1.0
. O 0 4.516176431934582e-06

Although O 0 5.827311611028563e-08
the O 0 7.925687328658171e-10
link O 0 3.4501521639640487e-08
between O 0 1.897900281377929e-09
the O 0 2.435434076630827e-08
BRCA1 O 0 0.003569650696590543
tumour B-Disease 1 1.0
- O 0 1.5058401004353072e-05
suppressor O 0 3.5884231692762114e-06
gene O 0 1.4613268831453752e-05
and O 0 9.158713396573148e-07
hereditary B-Disease 1 0.9999977350234985
breast I-Disease 1 1.0
and I-Disease 1 0.9999998807907104
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
is O 0 1.3360301753806425e-09
established O 0 9.547078405613973e-11
, O 0 9.110129317591031e-11
the O 0 8.547913765699633e-11
role O 0 1.4985104268561145e-09
, O 0 6.431308818832804e-10
if O 0 2.4227370110097013e-10
any O 0 7.772623517032784e-11
, O 0 2.7560271773086065e-11
of O 0 9.091169657360343e-12
BRCA1 O 0 3.282677880633855e-07
in O 0 1.657147308264939e-09
non B-Disease 0 2.1852413283340866e-06
- I-Disease 0 0.015150393359363079
familial I-Disease 1 0.985503613948822
cancers I-Disease 1 0.9999831914901733
is O 0 3.6136047043555664e-08
unclear O 0 1.8795654455061594e-07
. O 0 1.8304197269003453e-08

BRCA1 O 0 0.0032985445577651262
mutations O 0 0.00044941884698346257
are O 0 5.942933700708863e-09
rare O 0 3.0385971516722066e-09
in O 0 3.755059374555003e-09
sporadic B-Disease 0 4.025149246444926e-05
cancers I-Disease 1 0.7981955409049988
, O 0 2.2340488570193884e-08
but O 0 8.175595311854522e-09
loss O 0 3.259679459688414e-08
of O 0 6.529594226423185e-11
BRCA1 O 0 9.508644325251225e-07
resulting O 0 1.3388904207545238e-08
from O 0 1.8310124527687321e-09
reduced O 0 3.9802912965569703e-08
expression O 0 4.460008806717042e-09
or O 0 3.2768348035006056e-08
incorrect O 0 1.1288659607089357e-06
subcellular O 0 2.548835709603736e-06
localization O 0 1.6965051941042475e-07
is O 0 7.860769257739264e-10
postulated O 0 4.498573957789631e-09
to O 0 1.829169371525552e-09
be O 0 1.1053237491953638e-10
important O 0 2.7186190798555998e-11
in O 0 1.574626817824054e-10
non B-Disease 0 9.514186558590154e-07
- I-Disease 0 0.012718869373202324
familial I-Disease 1 0.9998582601547241
breast I-Disease 1 1.0
and I-Disease 1 0.9999977350234985
ovarian I-Disease 1 1.0
cancers I-Disease 1 1.0
. O 0 5.592495426753885e-07

Epigenetic O 0 0.0001279823190998286
loss O 0 0.012921773828566074
, O 0 4.67915342028391e-08
however O 0 4.455018132176747e-09
, O 0 5.677699421724469e-10
has O 0 2.0261314848113443e-09
not O 0 8.857271582840553e-10
received O 0 2.6189136970167226e-10
general O 0 1.428726581487183e-10
acceptance O 0 1.5221259808129162e-09
due O 0 2.362907869368769e-09
to O 0 8.622488834042485e-10
controversy O 0 2.401683296682222e-10
regarding O 0 3.283757432637202e-10
the O 0 5.7495674887775294e-11
subcellular O 0 1.4128107750366325e-07
localization O 0 6.12658155318968e-08
of O 0 1.1804368593715253e-10
BRCA1 O 0 7.328852547061615e-08
proteins O 0 3.4840215157316834e-09
, O 0 6.439753730269615e-10
reports O 0 8.568735054836907e-09
of O 0 8.407781415531446e-12
which O 0 1.2528382775656155e-09
have O 0 9.115348476029794e-10
ranged O 0 1.1291044765826541e-09
from O 0 7.080943470461065e-11
exclusively O 0 4.75190109483492e-10
nuclear O 0 1.120970249957054e-08
, O 0 3.248863678084746e-10
to O 0 7.3939526723521e-10
conditionally O 0 4.7029135430420865e-07
nuclear O 0 6.507966610058702e-09
, O 0 3.3931735893277803e-11
to O 0 1.0493318020055042e-10
the O 0 3.205157250718571e-10
ER O 0 1.8880620700656436e-05
/ O 0 1.2667691180467955e-06
golgi O 0 8.996795486382325e-08
, O 0 1.5864509705920682e-09
to O 0 8.683438967871382e-10
cytoplasmic O 0 2.8643384553106443e-08
invaginations O 0 6.644229415542213e-07
into O 0 3.7420826437539745e-09
the O 0 2.8379296690417277e-09
nucleus O 0 4.4365936702206454e-08
. O 0 2.0205751738444633e-08

In O 0 4.889944094088605e-08
an O 0 1.637703306300864e-09
attempt O 0 2.0252289800737344e-07
to O 0 1.1435093938416685e-07
resolve O 0 5.4196167553755004e-08
this O 0 1.281567851840748e-09
issue O 0 2.32528951649158e-09
, O 0 1.4077202736828553e-09
we O 0 1.2572027863200219e-08
have O 0 2.0875710049494955e-09
comprehensively O 0 8.913407327781897e-07
characterized O 0 4.635013262088705e-09
19 O 0 3.045751650887496e-09
anti O 0 9.383186672096144e-09
- O 0 8.111246074804512e-07
BRCA1 O 0 7.370982530119363e-06
antibodies O 0 1.9934314821057342e-07
. O 0 3.1943155676117385e-08

These O 0 3.6950961401771565e-08
reagents O 0 5.965661387108412e-08
detect O 0 2.735168891376816e-07
a O 0 1.9645394200296096e-09
220 O 0 1.0416037810045964e-08
- O 0 6.162891281746852e-07
kD O 0 9.426525480193959e-07
protein O 0 3.299449957694378e-08
localized O 0 3.269305537401124e-08
in O 0 1.5894212335165747e-10
discrete O 0 3.332845821546471e-08
nuclear O 0 1.2824443729186896e-07
foci O 0 2.1458596677348396e-07
in O 0 1.1293026513925497e-09
all O 0 3.4424837980218115e-10
epithelial O 0 1.5638681460927728e-08
cell O 0 5.139719633007189e-06
lines O 0 3.3474112569820136e-05
, O 0 5.151247761681077e-10
including O 0 1.4740757225961687e-11
those O 0 2.0672276390687472e-10
derived O 0 3.1281359724744107e-09
from O 0 8.288395036970542e-08
breast B-Disease 0 0.00010578867659205571
malignancies I-Disease 0 3.9531150832772255e-05
. O 0 2.541519563692418e-07

Immunohistochemical O 0 0.00012939384032506496
staining O 0 5.388247154769488e-05
of O 0 1.5036933476153536e-08
human O 0 6.213347347738818e-08
breast O 0 3.006829138030298e-05
specimens O 0 8.925523076186437e-08
also O 0 2.457552383816619e-08
revealed O 0 1.9071478618570836e-07
BRCA1 O 0 1.8990946273333975e-06
nuclear O 0 8.96720919740801e-08
foci O 0 5.658429245158914e-07
in O 0 5.80856607257374e-09
benign O 0 0.0006249147118069232
breast O 0 0.0002829630102496594
, O 0 2.026576773062061e-08
invasive B-Disease 0 0.0003670774167403579
lobular I-Disease 1 0.9971315860748291
cancers I-Disease 1 0.9999945163726807
and O 0 7.441843763444922e-07
low B-Disease 0 3.145754089928232e-05
- I-Disease 1 0.9914016127586365
grade I-Disease 1 0.9518865942955017
ductal I-Disease 1 0.9999431371688843
carcinomas I-Disease 1 1.0
. O 0 7.992053724592552e-06

Conversely O 0 2.8947162718395703e-05
, O 0 2.8611768954078798e-08
BRCA1 O 0 1.4227923657017527e-06
expression O 0 4.1341930767657686e-08
was O 0 3.612874266423205e-08
reduced O 0 1.1805596500380489e-08
or O 0 1.396547588683461e-08
undetectable O 0 6.685277043061433e-08
in O 0 4.724488508744962e-11
the O 0 3.949551449777822e-11
majority O 0 5.694191992922093e-11
of O 0 2.187298606126653e-11
high O 0 2.41067628081737e-08
- O 0 2.351424154767301e-05
grade O 0 4.616207297658548e-05
, O 0 1.4946382975722372e-07
ductal B-Disease 0 0.010819116607308388
carcinomas I-Disease 1 1.0
, O 0 1.4418711558050745e-08
suggesting O 0 9.56235979288067e-09
that O 0 2.0593292349158077e-10
absence O 0 4.4498271734028094e-10
of O 0 3.8022623244371445e-11
BRCA1 O 0 2.340924766031094e-06
may O 0 5.644340603794262e-07
contribute O 0 5.089350607612175e-10
to O 0 1.4472149867383877e-10
the O 0 1.0472023942442732e-10
pathogenesis O 0 1.1638629615617901e-08
of O 0 4.32195772226418e-12
a O 0 3.904314371805384e-10
significant O 0 1.3759815509217788e-09
percentage O 0 4.450357948826422e-07
of O 0 1.7425316745089958e-09
sporadic B-Disease 0 0.000561851542443037
breast I-Disease 0 0.36658161878585815
cancers I-Disease 0 0.26522818207740784
. O 0 1.8617500430195832e-08
. O 0 6.300681576476563e-08

